<SEC-DOCUMENT>0001558370-23-017664.txt : 20231106
<SEC-HEADER>0001558370-23-017664.hdr.sgml : 20231106
<ACCEPTANCE-DATETIME>20231106075052
ACCESSION NUMBER:		0001558370-23-017664
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		56
CONFORMED PERIOD OF REPORT:	20230930
FILED AS OF DATE:		20231106
DATE AS OF CHANGE:		20231106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		231378143

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>plx-20230930x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.4.0.13 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 11/6/2023 12:31:14 PM -->
      <!-- iXBRL Library version: 1.0.8630.22539 -->
      <!-- iXBRL Service Job ID: 76ee26cd-aa6d-4bc9-81d5-6b62d950dfad -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:plx="http://www.protalix.com/20230930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" xs:nil="true" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_79k0Fym550W0XRd-zx53gA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" xs:nil="true" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_xNypmcKgj0C0KYr8pGJEbg"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="dei:EntityCentralIndexKey" id="Tc_lim12hmlr0yO4bbBAxN6vQ_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="dei:CurrentFiscalYearEndDate" id="Tc_6_nxbeMHhkePJf8skc3bmg_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="dei:DocumentFiscalYearFocus" id="Tc_cs6Iw2Gn1ECTFQKhDW1-MA_4_1">2023</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="dei:DocumentFiscalPeriodFocus" id="Tc_TAxD6bvyU0i0MVQjYykgoQ_5_1">Q3</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="dei:AmendmentFlag" id="Tc_7YbUXHEyFkepLoLneQ38cQ_6_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="plx-20230930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_mfC9kUaxCUWkEdReEq0g8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtmEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MD0IJnJslU6DgpIpslYWHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nImxNodwz0S5hDYBFYIz4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_J6U7oUvVYE-mVxaE0p0afA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_U0vvCuWzP0ObL95ACk6iGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ljE3QYELHUKaEWcB1Rf2BA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jJqKna28f0aNpKm3h9LebQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DpbxB34Toka6ZMB06mjkFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZG9OKwFgA0KmxShrccpWnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_whHKsJQCKUCuIHXPg4Ju7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hThUOSh2DEu8b-5DZ4GtMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TvqjevVyaU2E1PYtpATXHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_qEv4_s2oRkuGKBh0bBdY8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RSrC8ujTNE-EKKHgIJyQfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mlxdQ7onNUCEQtHYpxTeEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6VRsvwfuMUqcCJm_5O_Dig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kSgL5r7c3k-B0VAIxyKmAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3RZ-bdtfs0CiBzoZ1x2umw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FCS-baPkIkmVTzMkLUh60g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uJvKLP-QfUi47f7FK9xAAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-2ASuQfAFkaEwmIK1OCojg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_28_2023_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_VafRBM-KXUKE9nl21SfoWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_27_2023_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_WfHmnalC9keIkorDt44VZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_F7acgBp0NEaoQj7JasNEtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_n9IBOPzcQEm-_TNOT65ZwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_15_2023_To_8_15_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_IPgkJRT2mUmlR7n5uxuhBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-15</xbrli:startDate><xbrli:endDate>2023-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_sVnDgezrHka5Dw8PspQs3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_ZO1PgNYXMEuC--7AWaeWEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_eB0Q82DpoUe8I_AVASAV5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_Lo8_JpbjYUCk7biQuAf2Cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_3i3mFrnEFE2XxVcL7eIj9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_nJExY4OnmUmt1WUuJLndIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_-Z5nFPVF50-Y_QNXqgvqxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_UWm8Okbu-EqlxDiNTSf2Zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_ZRFZeNwM3kOgwL_HZhzgeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_1lopoDCmBESgKQUfzzjJoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_tKo7RTZIJ0G9Lb7VY5FW9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_c26sRwH14EOOXdDcKHSfXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_54yhJyQsfUWr69wXcncDRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_isIRGT_PckWgKUstJZEmKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_FPM1y3Bjl0Gc-RAt1yp0Fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_iH38GCBvckuT-5RWJRmh4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_UZ9M3vS4pUmQfa--0rmbMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_nYCRV7igxEO8F_DL0WaJTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_r2IxwFzzbEK8WGh9RQOkuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_403rz0Wpzk6dQXNU5Z2R7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_8_2023_To_5_8_2023_LWrHj6ICi0aqDBWvUoRhNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-08</xbrli:startDate><xbrli:endDate>2023-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_TBP-Nxi6xkSucxKQEfEKFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtmEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_bcEsWzSIKk6tSkX7LMh0hQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_mvxv3O6LxEaaJFEPDGVkrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtmEquityOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Ky9hROQdhEKplEsRyyjknA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_smFmNjh_GkaF3ZVKa76X_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Pdy3Pw8g706hDOOxHjfOfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_U2kNPoY9pkW-TRdA8PGoWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_uB6aVsBg6EaCcs-hRuTW_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_bez3doxPHEy6nArxyu-5WA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_X09KFdeVa0mgHlIW0IelcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_tTdbaH9LGEq9pS4VzhrCSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_G4UyzvxD9UiRqqT-Li8wCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_h7Ke6bk0e0aU5lPXoIrMVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_kgA--Gd-2UWeFMP4kZXqwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_25_2023_edYzzPajLkGQMaRQZP-YaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_24_2023_9kwXDECmXUmLqJV4f95MAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-07-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_ABTzvay3O0OZCuw98-XbeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_10_2023_EgRr_kLVqEarxsyOSeb0Ng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_NdH__egkDk-gnw4KdsuuTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_WSd24FsHlEmdwHxFiK3fWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_7EmATnfMK0aTY5iMdjV79w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_3o-LEw18Kkyl1N3FcZEEcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_c1_YEps6pEOYi4wGlehl0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsWarrantsAnd2024NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_gylvzioUakSqiKwd3I9tug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsWarrantsAnd2024NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_cbS2-pmOL0Kpi-J5rXA22Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_LKZh0o6NGE2MzvbfP03xRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_ALka6XKZRUmdNKQ5DKH7HQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_QE-SblqY_067QtFhhF2IPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_86JU9iqNeUK_xkPVKBXLAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_Nmsn3P7UYUW6XcC0gH1dFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_wDkN_aLVuk6lqFu3E0NlpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_CbDm0MJU2kKR-xAL6zKx2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_sY47uYJaBUyZAjhmKmp6Ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_Xy3Mpk_8mkmNehLbu6bpWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_u97-niTANECYjZrKdF99Mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_SzhiOOTJqkimQ5q3bMRpYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_c_DS6CF9IUONf5DnuePWGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_I0f7iY_hoUWDw20FCFX8EQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_10_2023_To_5_10_2023_uEkJTuuYLE2tgKefXtN0Mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-10</xbrli:startDate><xbrli:endDate>2023-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_8_2023_To_5_8_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_aZyevVDxgUeUldAkpXak_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-08</xbrli:startDate><xbrli:endDate>2023-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hlJfBq7xHUuJTVElf5mZ9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WbDaBJULK0-Dh7pEyOjn7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4ubTKPzTYUaZJP68MFh1aA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_74hbg6s0YUGMZEgtc7zlCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EHdJ5Zm9dUSQMKgSd6xQEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PdQzi6Bi4kqkEATH0PHmyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bKsEqv1Q706_PDc9XAYvmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gbkRzHwbyku8_AQoT0Dllg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_15_2023_To_8_15_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_fMPAZxDZF0CjT3jIiJlVWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-15</xbrli:startDate><xbrli:endDate>2023-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_15_2023_To_10_15_2023_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_8Dni7RhDUkWYV5S6kg5TFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-15</xbrli:startDate><xbrli:endDate>2023-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_29_2023_To_9_29_2023_srt_TitleOfIndividualAxis_plx_NonExecutiveDirectorsOtherThanChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_Bq1ATcIXikWWLcA2fkgW1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:NonExecutiveDirectorsOtherThanChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-29</xbrli:startDate><xbrli:endDate>2023-09-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_14_2023_To_9_14_2023_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_hR8IXrLXFkKqN26E-oWJTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-14</xbrli:startDate><xbrli:endDate>2023-09-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_15_2023_To_8_15_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_yKs6Fnw-ukqovfuD-GaUEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-15</xbrli:startDate><xbrli:endDate>2023-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_15_2023_To_8_15_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_dHfFwQNMk0elAnvVrjK_Aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-15</xbrli:startDate><xbrli:endDate>2023-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_15_2023_To_8_15_2023_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member__6-TI0LU8kycGOjbjujtRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:OfficersAndOtherEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-15</xbrli:startDate><xbrli:endDate>2023-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_27_2023_To_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_z_3UoywC8ECDn2BmWvhnnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-27</xbrli:startDate><xbrli:endDate>2023-02-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_IZYUYcpDQ0W3wVn53D7jkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_FE-7EpG9IkW88m9UfwwG6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_eoOa9SWffEiVP049zeIqSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_4_2023_To_10_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_4Sfq-5ZsukC6Bl13MlMlcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-04</xbrli:startDate><xbrli:endDate>2023-10-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_etzFjnmIFkqSQ8Z9LeDedg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-23</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_DKlLQr64h0q6S5laUAGccw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-23</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3JKpw53nwkGDyDlVTy2Gxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-19</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_GHWT0ykNeEuO1RlIzpZFhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-19</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_21_2023_59uxaENwDEeis1uswurdAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2023_Qhp5my5CU0-pA3CT50IRVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_iN4jeRGThUGJ9_j3XbAknA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_ONDNURLUTUKjjQ_0xrpP0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_FillFinishAgreementMember_sD-xmdGPaE-ij5-ExlU3kQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:FillFinishAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-29</xbrli:startDate><xbrli:endDate>2022-08-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_IsSkHrMXCEC808Zd6VbjIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_-xsCF2uYFkqT5zfBjQzLVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_GERNj3wXEUWT0EvS1LtJJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-13</xbrli:startDate><xbrli:endDate>2021-05-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_jp1gAPcWdUq4GpRSn43eoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_rCjFnyR3fEa9cw5ekQ7pew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_WBsGH7Src0eGVZCrXqiz2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2023_ZRHeL0WBLUyknbdyhuAyuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_agreement_lKNqKU4rvUupTelfJQIVSg"><xbrli:measure>plx:agreement</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_dyUGGngOZEG007onwpOmGw"><xbrli:measure>plx:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_Y_P_CRw8WyjU2VbFabIi54IQ"><xbrli:measure>plx:Y</xbrli:measure></xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_3ak7Ebjw5kG6Kyjj5L8Eqg_10_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_9yhZrR-b-EGqxOFYn_g5Nw_19_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_GQwKI1DfuUWngKk4EwwxsA_33_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Xmtr-8UVh0W8zZUKbrcCNg_8_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_yK0f7kNti0uhUFBdgENL7A_25_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_UwQx0fb9LkSfPmBHKpezKQ_16_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_70Fh3FgfJ0i1a7pZPnjd4Q_11_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_b7Y7BJIK3UedTfkl07xmNQ_20_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_J0Q06cNZT0aJQvKE4KrnZg_6_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Bvi01VlUckODSjGL09xVuQ_23_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_xBU_amZ-LkuBgXXAAuDnEA_29_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_XGzOlH__60G7j3Mh5UicPQ_13_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_1eTA6uTMHkyR3m-Xxn97EQ_14_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_5JtCaCayY02Yie7S2mhEPw_30_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_xfcNdFkJBECaKEusvGlF7g_35_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_UnYL-Dklw0Oi5ZpVIu_wxw_22_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_zHYnQE3siUSd8cZtbB4jMQ_17_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_8wtWJciV8kmbYLH3-slgtA_6_6" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_c34c36I-G0S88s1ziCq9og_6_12" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_G0ODR8Y4jkmKMtpr632bPA_6_3" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_-7kbwyUL10qShnyaYOvqvg_6_9" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_vtrKcBIMm0S36Zv8et0UtA_7_6" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Wb3u-4rnKkun54FaHGKbGg_7_12" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_y6Oll5Og3kOBM7CsL9ePzg_7_3" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_T8ohq58km0y3V14t17cmZA_7_9" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_ohkn7emcLUW77GJO-hPiMA_8_6" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_LFDGdqGoaEmMTMxTxEiR8w_8_12" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_JDDF75sBRkyjOTbTIkA6qg_8_3" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_myGHGQWRZEKv8Cpthrqxyw_8_9" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:9.2pt;"><p style="border-bottom-style:none;font-family:'Times New Roman','Times','serif';font-size:1pt;padding-bottom:0pt;padding-top:1pt;text-align:right;border-top:3.0pt solid #000000;margin:0pt;"><b style="font-weight:bold;">Or</b></p><p style="border-bottom-style:none;border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:0pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a4f65b78_8c87_4934_a708_262f862e77d5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="dei:DocumentType" id="Narr_ZpFnWfF6cE6fwGvkJfBykg"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="dei:DocumentQuarterlyReport" id="Narr_PxlshRZarUGWC4rlaGSsLA"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-size:8pt;font-weight:bold;">For</b><span style="font-size:8pt;"> </span><b style="font-size:8pt;font-weight:bold;">the quarterly period ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="dei:DocumentPeriodEndDate" id="Narr_w4aayxutKUaa_dqFqjJaKA"><b style="font-size:8pt;font-weight:bold;">September&#160;30, 2023</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="dei:DocumentTransitionReport" id="Narr_y71JFQkYw0SeIHZZA9Ev8A"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">For the transition period from </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160; to</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="dei:EntityFileNumber" id="Narr_e7a2Z01ykE2UZ-bVELFYZw"><b style="font-size:8pt;font-weight:bold;">001-33357</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission file number)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="dei:EntityRegistrantName" id="Narr_UBL0kfTlyUeNlMe1UDV-rQ"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a1bb36ca_e2bf_4dc9_949a_f711226b91ef"></a><a id="Tc__4fikZuh0E2E6zm6PTPEWw_1_1"></a><a id="Tc_6Xkbb-BdDk6MDIftar5FIw_2_0"></a><a id="Tc_oIPzXUdD3k-zy3qYGybQpA_2_1"></a><a id="Tc_5llaftWbMkaQaihliOj3dA_4_0"></a><a id="Tc_QIhsQPPvWk-5t0F-bkgQWw_5_0"></a><a id="Tc_DIR-Gsu3x0qd1t5marxgJQ_5_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="dei:EntityIncorporationStateCountryCode" id="Tc_9hwcn1E8lEagnpaOJAz-RQ_1_0"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">&#160;</span><b style="font-size:8pt;font-weight:bold;">__</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="dei:EntityTaxIdentificationNumber" id="Narr_bptRBvqH1USQD5qs_NnVyw"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">65-0643773</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">__</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of incorporation or organization)&#160;</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)&#160;</b></p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="dei:EntityAddressAddressLine1" id="Narr_wexkwzhIgk2o3ck7sGbxaw"><b style="font-size:8pt;font-weight:bold;">2 University Plaza</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="dei:EntityAddressAddressLine2" id="Narr_Y2NYpVKtm0-1zi-Ylg5otg"><b style="font-size:8pt;font-weight:bold;">Suite 100</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="dei:EntityAddressCityOrTown" id="Narr_flN6S65QNEeBr77E6vkwQQ"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Hackensack</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">, </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="dei:EntityAddressStateOrProvince" id="Narr_3_UeUeHndEGhSl3qrUsSBA"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="dei:EntityAddressPostalZipCode" id="Tc_-3zbPnBDv0OjViqPVWk4kA_4_1"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">07601</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="dei:CityAreaCode" id="Narr_rzuwY_6Aiki3WeS3N3OoVw"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">201</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">)-</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="dei:LocalPhoneNumber" id="Narr_yBsYCQRfjkyh5wBLEeHfxA"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">696-9345</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name, former address and former fiscal&#160;year, if changed since last report)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_45e8230e_f727_4422_812c_a1e35f80e47e"></a><a id="Tc_2ANQTczrHkKKRtK38wzRyA_1_0"></a><a id="Tc_WkJRlE0RJk29lApSDQSFfg_1_2"></a><a id="Tc_YQqdaIykkUqcxvVc2AFyfw_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"></td></tr><tr><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="dei:Security12bTitle" id="Tc_Eqjs6imuyUK25zuvY77zLg_2_0"><span style="font-size:8pt;">Common stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="dei:TradingSymbol" id="Tc_BOL-1IYTtkyLjFzAiHlL3A_2_2"><span style="font-size:8pt;">PLX</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="dei:SecurityExchangeName" id="Tc_L-Jv3dR0KkSdFtUP4j2hMw_2_4"><span style="font-size:8pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="dei:EntityCurrentReportingStatus" id="Narr_3UfJ2hItykGYRvrVgqL8mA"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;&#160;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="dei:EntityInteractiveDataCurrent" id="Narr_qzGpodYTBkaj3you556Dqw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160; No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a975f266_f6c7_407d_aa80_42ce67244ae1"></a><a id="Tc_CokSU_2cGkWzTqackht8tw_1_0"></a><a id="Tc__copBMXQBEihd-Tv5o7aNQ_1_1"></a><a id="Tc_6H1IuKMLok-gkZCYV1R3EQ_1_2"></a><a id="Tc_-DqCjQCH_UGyLnH1h3NrKA_1_3"></a><a id="Tc_4qEDMcxnjkiipa5TGreezA_2_1"></a><a id="Tc_x2wkX2xnbEW38lu6QiZsvA_2_2"></a><a id="Tc_ZFnlOcSaIUOrJPmkrlWVOg_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90.1%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="dei:EntityFilerCategory" id="Tc_ZiGRgJgZME6ROfgwehHwJA_2_0"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#8999;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="dei:EntitySmallBusiness" id="Tc_IYwtrOjOPkG9Oz9EtioTpA_2_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="dei:EntityEmergingGrowthCompany" id="Tc_BVdYJOZXQEuGrYnejeyOYQ_3_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="dei:EntityShellCompany" id="Narr_0A1lwhLFgEmn2pUiUpo9PA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> &#160;&#160;No&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">On November&#160;1, 2023, approximately <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_11_1_2023_ZRHeL0WBLUyknbdyhuAyuw" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_4NzGzAX6FEqbBakMcGQg2Q">72,952,124</ix:nonFraction> shares of the Registrant&#8217;s common stock, $0.001 par value, were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_435df638_e4cb_446a_9af0_e95a4b1c75ab"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM 10-Q</b></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIFINANCIALINFORMATION_363674"><b style="font-style:normal;font-weight:bold;">PART I &#8211; FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-style:normal;font-weight:normal;">Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Balance Sheets (Unaudited) &#8211; As of September&#160;30, 2023 and December&#160;31, 2022</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Operations (Unaudited) &#8211; For the Three and Nine Months Ended September&#160;30, 2023 and 2022</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Changes in </span><span style="font-style:normal;font-weight:normal;">Stockholders&#8217; Equity (</span><span style="font-style:normal;font-weight:normal;">Capital Deficiency) (Unaudited) &#8211; For the Three and Nine Months Ended September&#160;30, 2023 and 2022</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#ffffff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Cash Flows (Unaudited) &#8211; For the Nine Months ended September&#160;30, 2023 and 2022</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#ffffff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"><span style="font-style:normal;font-weight:normal;">Notes to Condensed Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">17</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIIOTHERINFORMATION_770480"><b style="font-style:normal;font-weight:bold;">PART II &#8211; OTHER INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">36</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">36</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">36</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-style:normal;font-weight:normal;">Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">36</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">37</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">37</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-style:normal;font-weight:normal;">Exhibits</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">37</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_574709"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">39</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_98d0a83e_69eb_4204_9c1f_653faae89557"></a><a id="PARTIFINANCIALINFORMATION_363674"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PART&#160;I&#160;&#8211; FINANCIAL INFORMATION</p><a id="Item1FinancialStatements_969154"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Item&#160;1. Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_26ebb788_9b3d_4dbb_85f8_adaa92a7253b"></a><a id="Tc_y0YtnY_nE0OCtWMjr45eWg_1_2"></a><a id="Tc_39Nole1iyEuelOS3AYEUGw_1_5"></a><a id="Tc_Cc375SVeUU2jws9N2bBV7g_3_0"></a><a id="Tc_ivZQQ_6sjkmRi6JimIkCaw_5_0"></a><a id="Tc_UCfyVYz5J0aq8Z3UTpIAlQ_6_0"></a><a id="Tc_yXsn2VOz3k2sKJheulSBjw_6_2"></a><a id="Tc_Q0NiBnkkKEKFrO9zmhkhJg_6_5"></a><a id="Tc_25TIwKPgW0mX0uyApgYNqg_7_0"></a><a id="Tc_to3_seIp5kiU4jeqOtl6XQ_8_0"></a><a id="Tc_BzNWxr9PK0WX6w-crCdmYg_9_0"></a><a id="Tc_MKgBmAjHFkuZ7f0dH9XVGg_10_0"></a><a id="Tc_cK_c65BT1k2saqr5SRdapQ_11_0"></a><a id="Tc_1t7RbL_M_km6eHoj8_5fzw_11_2"></a><a id="Tc_M-XKfu1O8EyoXP0og-bkng_11_5"></a><a id="Tc_2l-qEl4rAUqVz6nMxQmF-Q_13_0"></a><a id="Tc_9k6YqUItFkeNEwblpisGDw_14_0"></a><a id="Tc_771m_Eq0KU-yQ8FiLhhbxA_14_2"></a><a id="Tc_l0BC-i4LdUOc9KXGL9ttpg_14_5"></a><a id="Tc_Bvk80noDnU-eWliPJ-ui4w_15_0"></a><a id="Tc_gSnTeHlEs06LlgXuHb744A_16_0"></a><a id="Tc_Qgvr6kjOQUCOZIlp_6GCow_16_6"></a><a id="Tc_ea5XOQFk40eSGrGVUGUJiA_17_0"></a><a id="Tc_M0psg-PTwUuGSG_2mOcsCQ_18_0"></a><a id="Tc_riD1Xa2RL02DkKrmmmJL2Q_18_2"></a><a id="Tc_VHnetPnnnUun0BagX5PRlQ_18_5"></a><a id="Tc_tj0JOdjiPEGf8AcMhx-TzA_20_0"></a><a id="Tc_sy8p3GZF-USKGjSxSsyJdg_22_0"></a><a id="Tc_roLuR107TkqtNLrAibJgZw_23_0"></a><a id="Tc_MaIJnxT9YkaGcqof_z0cig_24_0"></a><a id="Tc_HI4cNpphlUiS6L3uMSD7Rg_24_2"></a><a id="Tc_FHnYkDkZG0a_7GYBqzkIUg_24_5"></a><a id="Tc_p4y4Ng-1NEmwFmUVFG4Xnw_25_0"></a><a id="Tc_PbGuXV3RoUiJMbfGGplvxQ_26_0"></a><a id="Tc_aAzPSumQYkyVU0LRLxmrUQ_27_0"></a><a id="Tc_l2Jg3BUdF0Wr72Ki7z4hAQ_27_3"></a><a id="Tc_-XLaBaBz0ke3-ofnoUqY4w_28_0"></a><a id="Tc_G6ZIDpD2qkmcM1k2NKoApQ_28_6"></a><a id="Tc_rPeMIVhxkUC0W8qJnhinRA_29_0"></a><a id="Tc_m2O3C3ykt06_r9BMX-7Neg_29_2"></a><a id="Tc_wKMtVKWNgkuvrNc1K8nMRQ_29_5"></a><a id="Tc_eTzbKsqKuUKgahFT1qMVuw_31_0"></a><a id="Tc_GQ8ZAtTClEyox3Rn3-RsHw_32_0"></a><a id="Tc_JgJIB5WmikCbmbLDdMopnQ_32_5"></a><a id="Tc_alLrs8WDu029W5BB2xz2Kg_33_0"></a><a id="Tc_k3-fLwzp7Uu_qqidB-CSgg_33_2"></a><a id="Tc_J2Y3ZgNX5kCOrOugcJMjQg_34_0"></a><a id="Tc_k0lhQZdeLkWlM9R_pJUBiw_35_0"></a><a id="Tc_z2PScXxC20WKbML63gjv7Q_35_2"></a><a id="Tc_ctgXDKm_b0a1V-XB0KjvyQ_35_5"></a><a id="Tc_lbjRtQYIAUSuHrxE6jRIFQ_36_0"></a><a id="Tc_EPcvqgUGPEeSSEkW5qa_wg_36_2"></a><a id="Tc_2IqvDleIuEet0E8XloNW3A_36_5"></a><a id="Tc_8iWMutRs3kyIy0TetH0ZTQ_38_0"></a><a id="Tc_jj8bMhXV4keB6rzfdj-N-A_40_0"></a><a id="Tc_i-F3bRXZtEC79YUNTTB0SQ_41_0"></a><a id="Tc_sHenNkK4HEWG9BE2TbTkhw_41_2"></a><a id="Tc_ZiKZCYlPg0CQE_hmW-VoCg_41_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_2ykBFYDYY0Cj7RqZHL8XOw_6_3">20,408</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_4vvueeMnlUSeBCRN5y46Fg_6_6">17,111</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Short-term bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ShortTermBankDeposits" scale="3" id="Tc_C9nRA2sND0-0aNpLmu3Tug_7_3">20,567</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ShortTermBankDeposits" scale="3" id="Tc_IyXiNlfNnUetvA2t3y6QDw_7_6">5,069</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts receivable &#8211; Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_8m_B89z5V0KDNxul0let0Q_8_3">8,935</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_6blqH6z2LUqZwARX4RxTkQ_8_6">4,586</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_6OH4LcU3Sk-3rcOHufNfxQ_9_3">1,125</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_hWYLTKIUbUmOcDpri-9GYQ_9_6">1,310</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_MKRBUH2_SEW8dFImeooZZg_10_3">21,583</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_PQdRZPT8KESgfkA7Epw85g_10_6">16,804</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_l-qnNJgVoUSBCn-IV7DIiw_11_3">72,618</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_EthWUNrYG02eNDfOaNmo0g_11_6">44,880</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NON-CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Funds in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_-Dly0AwAOEObCccrBTZMnw_14_3">1,260</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_DNR9VkowU0GyYI2c9ZBWtw_14_6">1,267</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_v0jSl0chxkO-vdQE106SfA_15_3">4,684</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_AOX8OawzskWpC2DAN_VWww_15_6">4,553</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Deferred income tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="Tc_PdrWYQ2L20CxsVBEorLGQg_16_3">3,092</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_HWWbvjMDG0Se7B7l4Y_bIw_17_3">5,915</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc__qKeSUqhfkyuuE3-EOUOOA_17_6">5,087</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_Q_ucWSm6ukyPn5158R1Ufg_18_3">87,569</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_D7Yekxy0wUW4KAAbRdofdg_18_6">55,787</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#39; EQUITY (NET OF CAPITAL DEFICIENCY)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable and accruals:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_BRws_jzyb0S4ljWdwW_JCg_24_3">3,114</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_5tsyBIapXUy7EYQY8ZDtTQ_24_6">5,862</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_hbzUmCqYEEy2Gm0M34vNcA_25_3">18,740</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_AJ5Z2UgL3E-PErfQh7badQ_25_6">12,271</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_pFxWfUN1SkuPj8tkrGbjJQ_26_3">1,313</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_GOdbQ3DcqEKml7EY5nuWAw_26_6">1,118</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Contracts liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_y7nYbOVceUWce3-ViqSW3g_27_6">13,178</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="Tc_u50XKh0IxkWFJmdYdG5frQ_28_3">20,192</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_NGbR8NIoDEuSETS56q8boA_29_3">43,359</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_ozWhHhQJxUiE9l-f5x1oLw_29_6">32,429</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LONG TERM LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" id="Tc_1uqgtlemMk-mmzmcVTvXoQ_32_6">28,187</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_atigZGIHj0y9_MXha8aM3A_33_3">1,461</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc__lrQqySaLUmo1v1ggjfbVg_33_6">1,642</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_JjYJagKwD0OmbKg3OhPthA_34_3">4,502</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_nmWg4ugYT0-wDSNUUJb4hQ_34_6">4,169</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_cKLgcak4VkCOhLGzvioSpg_35_3">5,963</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_lHUuVvvLgEaKrz1Fb261-A_35_6">33,998</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_CjiTkpv1pkGfOLy4zejncw_36_3">49,322</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_nCZR-v2gakChsBSHHb0yBQ_36_6">66,427</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COMMITMENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">STOCKHOLDERS&#39; EQUITY (CAPITAL DEFICIENCY)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_DDCo6UdOGUeSBLdXOcXzHA_40_3">38,247</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_jeu12nV8UEydE6MaoVAx-A_40_6">10,640</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total liabilities and stockholders&#39; equity (net of capital deficiency)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_JFk7VA_SCkGH-TB-sUbaNQ_41_3">87,569</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_JFx0IpEpW0qmzFjGTT7QLw_41_6">55,787</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_651b6d04_41e2_4fb0_926f_949cc7faf75d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands, except share and per share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_245770eb_1795_4abb_94f5_de46e607fba1"></a><a id="Tc_DuT8fj-_kUah_k46obYZSg_1_2"></a><a id="Tc_Ss19UzIhEkqcx8yU5A899A_1_8"></a><a id="Tc_fGp7IhXegEy7NBnx3OFSAQ_2_2"></a><a id="Tc_LLVLT9dBrEWM2z7t_uLBMw_2_5"></a><a id="Tc_a6D5q5nTGUOZEOPCFSDb7g_2_8"></a><a id="Tc_aIj7BTjz70eyZnRZjrfNow_2_11"></a><a id="Tc_KJPpKioADki9bOmTASN3Qw_3_0"></a><a id="Tc_I3dAavHELEa8AV-7k54_Ag_3_2"></a><a id="Tc_iQYBTXu6iEawJjZ1DCXWyA_3_5"></a><a id="Tc_wK6YPTkLtUeyFe8dnCs79A_3_8"></a><a id="Tc_AV6vnIDgBkuECWe0jELc7w_3_11"></a><a id="Tc_5E6o3pfUUkS2tNpSc-z22Q_4_0"></a><a id="Tc_xvc-qkHiW0KMsM5L1rYQmQ_5_0"></a><a id="Tc_5Nb9oeDk60yhhLatZY1ayw_6_0"></a><a id="Tc_ggaWpaFO_kG6aoQ-Tml-Eg_7_0"></a><a id="Tc_j4I6V8iirUydeMkti9vvoQ_8_0"></a><a id="Tc_1jy1REULAk-X4y1YmImCiA_9_0"></a><a id="Tc_IsdZvL8aI0qrqjjPdu22cw_10_0"></a><a id="Tc_0TTbkzAv_0yjHFXMj4pzfQ_11_0"></a><a id="Tc_B1CUS2T7fEOhdy_idVag5g_12_0"></a><a id="Tc_v-WQelVHxE6L8t3EAqFbAg_13_0"></a><a id="Tc_MEXT0o4LEUerPVLD-gvpsg_14_0"></a><a id="Tc_sCXKX4xkbU217PBUKaQvQw_14_6"></a><a id="Tc_jLALcMfeDkyAZGiFhFVP7g_14_12"></a><a id="Tc_9LQXwfvABEOMOQOFnhjG5A_15_0"></a><a id="Tc_lXqahItr6Ui3o8hv2w-Wdw_15_2"></a><a id="Tc_JtL_F4db1EmtmA_adPrg5w_15_5"></a><a id="Tc_Y4ICBQYx4EW9lwj8jqHpNw_15_8"></a><a id="Tc_jhyjjTWdKU2g961inoQvXA_15_11"></a><a id="Tc_vJcqHTkEP0allHtHzMSIew_16_0"></a><a id="Tc_JQOVArnNcEKlblpOdT-ULg_17_0"></a><a id="Tc_tnJXeHr2y0OTAnMf80PGgQ_17_2"></a><a id="Tc_hb-t0dhiGEm0QRw1D711OQ_17_5"></a><a id="Tc_BQzpmjTt_kWfaUEKwDPY_A_17_8"></a><a id="Tc_OMQ-kwNLQE-xNPJfHWRZ8w_17_11"></a><a id="Tc_cC4XXo_QwE6ZlqtWnIrL6w_18_0"></a><a id="Tc_dqzWkaMqJEOrdsJcuvxgdQ_18_2"></a><a id="Tc_MiG7-IcW0k2jPks5-rN0wA_18_5"></a><a id="Tc_o9f4SmfrqkWUuuK2dlnXtw_18_8"></a><a id="Tc_-X4Jot17m0eHoJI-g-Z5iQ_18_11"></a><a id="Tc_I6o3vh1Na02kAPUrPWq4cg_19_0"></a><a id="Tc_diF8K8mKdUSADINSI_Yc0w_20_0"></a><a id="Tc_CmY2sawi3UGjCvm62wvy_A_21_0"></a><a id="Tc_NJ-ZsvJyaUyRKPspWfbkUA_22_0"></a><a id="Tc_dISGH51ZT0qQUUmS_H1nRQ_23_0"></a><a id="Tc_wVyZOj6jT0qmEcoANOt0VA_23_2"></a><a id="Tc__ohjcFW2z0OT8HvlDbTKQg_23_5"></a><a id="Tc_jR0LFFr_oU2WxgjLQudjng_23_8"></a><a id="Tc_f_jC2FeWMEOp-b1CC0Cpsw_23_11"></a><a id="Tc_TE-V0UOjCECWdzy3y_fNJA_24_0"></a><a id="Tc_BPVstSAr-UuWsADuD1jc-Q_24_2"></a><a id="Tc_TJpxh2d0ZkWVmjVdCOnokw_24_5"></a><a id="Tc_tf-SbQVZ9Eu9kazmAdS8BQ_24_8"></a><a id="Tc_FYYXm8jpFUKIAHWEt1iSag_24_11"></a><a id="Tc_T9RnY--4BUS5VN4Lgmlf1Q_25_0"></a><a id="Tc_K20puVWx3ESC_TRMgIH-BA_25_2"></a><a id="Tc_MsHaCbtVFEqmG1bOORRnWQ_25_5"></a><a id="Tc_wqKPUDA80k25wi2Tfa8vvA_25_8"></a><a id="Tc__dif9YK66k2yR_c_4PGx3w_25_11"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-1.7083359%;padding-left:0pt;padding-right:0pt;width:103.41%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:45.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM SELLING GOODS</b></p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_ZRFZeNwM3kOgwL_HZhzgeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_bkPXmefXuEibjQiEZoWjcA_3_3">30,309</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_r2IxwFzzbEK8WGh9RQOkuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_pIxvtS6LZUes6JQYgAQtEQ_3_6">21,222</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_Lo8_JpbjYUCk7biQuAf2Cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_vLjTt5XNGUC0NExGjiHqmw_3_9">10,168</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_isIRGT_PckWgKUstJZEmKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_8WTby3rt4EOvbWwvWMIuog_3_12">8,812</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM LICENSE AND R&amp;D SERVICES</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_1lopoDCmBESgKQUfzzjJoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_uDbIPMNj70GW20WBBZ17Iw_4_3">24,699</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_403rz0Wpzk6dQXNU5Z2R7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_MCeYHn4n0kavf-QBOhUjUg_4_6">17,799</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_3i3mFrnEFE2XxVcL7eIj9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_izVWE8fcH0qNEeFs30ErKw_4_9">177</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_FPM1y3Bjl0Gc-RAt1yp0Fw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_rpk0b4maj0eeNd56iFXorA_4_12">5,371</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL REVENUE</b></p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_-5uDFLQTIECA0c63b4m1Kg_5_3">55,008</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_qciJ_4R0HEK0Btde43MdUg_5_6">39,021</ix:nonFraction></p></td><td style="vertical-align:middle;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_N26z-awyA0Ollv4aZSFSGg_5_9">10,345</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_NET1dlW5xkSITkc0ZqafXw_5_12">14,183</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COST OF GOODS SOLD (1)</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_G0ODR8Y4jkmKMtpr632bPA_6_3">14,126</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_8wtWJciV8kmbYLH3-slgtA_6_6">17,195</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_-7kbwyUL10qShnyaYOvqvg_6_9">4,893</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_c34c36I-G0S88s1ziCq9og_6_12">7,074</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">RESEARCH AND DEVELOPMENT EXPENSES (2)</b></p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_y6Oll5Og3kOBM7CsL9ePzg_7_3">13,991</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_vtrKcBIMm0S36Zv8et0UtA_7_6">23,732</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_T8ohq58km0y3V14t17cmZA_7_9">3,669</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_Wb3u-4rnKkun54FaHGKbGg_7_12">7,386</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (3)</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_JDDF75sBRkyjOTbTIkA6qg_8_3">10,816</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_ohkn7emcLUW77GJO-hPiMA_8_6">8,613</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_myGHGQWRZEKv8Cpthrqxyw_8_9">3,670</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_LFDGdqGoaEmMTMxTxEiR8w_8_12">2,848</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">OPERATING INCOME (LOSS)</b></p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="Tc_ibHFDZ5hskqP9bA8KMo8lA_9_3">16,075</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_D-27XZ_2DEe_G3QD11YhVw_9_6">10,519</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_O6ufI-r1_Um_mVWb_qY27Q_9_9">1,887</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_sZVTuhY8gkK6xNUvqrxfvw_9_12">3,125</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_RWJw44NyR0qKrh_qKBYy6Q_10_3">2,406</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_r3F_3UfQYEuZmgz10bThJA_10_6">1,879</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_bg9LZkm_rUeyFb3QwmXADg_10_9">460</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_o6UHZ1vdZkqgVeJ3CPUHMA_10_12">639</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL INCOME</b></p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_RXONl4hfYk2ObVYDxL-VvQ_11_3">1,323</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_rDEFPKo-I0-uz8LnhIYLQw_11_6">1,211</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_xuIZVA0EhESMs9n3NV5nRg_11_9">628</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_DSKLidnI60eucOiC1LU9Cw_11_12">197</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL INCOME (EXPENSES), NET</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_MwfvH9US70Wwuz8kd79f9w_12_3">1,083</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_WzFZl7moP06BeP76Qe5xXw_12_6">668</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_OQCSqqUkxkqiEF5rTkQPow_12_9">168</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_Stth-RilaUGmClT3HyEh-A_12_12">442</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">INCOME (LOSS) BEFORE TAXES ON INCOME</b></p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="Tc_HOW3csPwEEmWfUaiEzb22Q_13_3">14,992</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_CndD8q-t7kiH1HMepnQj-A_13_6">11,187</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_SvLvsUAIjUmKWyDRIlc1Dw_13_9">1,719</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_ZAgw8_ol2E-31x5Xq8wYiw_13_12">3,567</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TAXES ON INCOME</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_wnkALPTav0ul7UySDGs4Mw_14_3">636</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_4td0wPqyP0WhnzaP3Upjrg_14_9">133</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET INCOME (LOSS) FOR THE PERIOD</b></p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_uua0KxnzZ0CEXmrKHABvew_15_3">14,356</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_hSyc2IPGEUKfPBzV_dI4KA_15_6">11,187</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_DyarZOSjvkuh_QYVAqCHNQ_15_9">1,852</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_80BADIf6lE29QeBL1YZBDw_15_12">3,567</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EARNINGS (LOSS) PER SHARE OF COMMON STOCK:</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BASIC</b></p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_VE_wjBhubUOmOGIL9RCPAA_17_3">0.22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_GXzedqLkR0yuinujo6eyhA_17_6">0.24</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg" contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_tcIalq7EYEylMJLta1Dqmg_17_9">0.03</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg" contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_d-onVhQFc0KqE1JEHtBHFg_17_12">0.07</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">DILUTED</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_k3ctnbG_FkSWV9wSrHzsFg_18_3">0.16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_ynYXQAGJC0-en-6mU2yk9Q_18_6">0.24</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg" contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_87mD3-06cEyDrT0l-A7NDw_18_9">0.04</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg" contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_yWMpeoT8fESx5QTvCf_43w_18_12">0.07</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK </b></p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">USED IN COMPUTING EARNINGS (LOSS) PER SHARE:</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BASIC</b></p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_88836MAH30WSJ6HwR20hLQ_21_3">65,811,506</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_EJzKW6sNaUSgvqTxgNNLRw_21_6">47,582,733</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_qTGAKch9EEywniE1goMfhg_21_9">72,281,681</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_hZYkntesxU-_dOni6gudhw_21_12">49,498,105</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">DILUTED</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_GnpiwWUZUkWR76IdMa-OFw_22_3">81,040,281</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_P1iFhxdNHk6v3gnjVqdJeA_22_6">47,582,733</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_P2jcjZ1BZUWCa1Jh_V-z0g_22_9">83,782,679</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_60r4bbq0dkOkN6Y4f1bpLA_22_12">49,498,105</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><ix:footnote xml:lang="en-US" id="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"><b style="font-size:8pt;font-weight:bold;">(1) Includes share-based compensation</b></ix:footnote></p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_Nmsn3P7UYUW6XcC0gH1dFw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_aNBMHY7EskGcS2Na-VKyww_23_3">299</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_SzhiOOTJqkimQ5q3bMRpYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_4C-eO2ELpE2-Cd5TPfc2DA_23_6">58</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_ALka6XKZRUmdNKQ5DKH7HQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_VTgwaxq8_0CappJBI9NjIA_23_9">195</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_sY47uYJaBUyZAjhmKmp6Ug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_UUplnK6KOkq9Ru4zV7_ZHg_23_12">36</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><ix:footnote xml:lang="en-US" id="_8530ca94_6c84_4f48_984f_7cc5a2959400"><b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</b></ix:footnote></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_86JU9iqNeUK_xkPVKBXLAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_qvxW8X5DL0CaLdzFflIEOQ_24_3">506</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_u97-niTANECYjZrKdF99Mw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_quwWFSbGYEug0PlB4BcKwA_24_6">275</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_LKZh0o6NGE2MzvbfP03xRg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_sOQN3ZK-U0iig1vu1IqHxA_24_9">182</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_CbDm0MJU2kKR-xAL6zKx2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_StRVhKVrBUyqDvPDioOXjg_24_12">114</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><ix:footnote xml:lang="en-US" id="_64475d15_2bf5_4e75_bed3_14deb6a39d55"><b style="font-size:8pt;font-weight:bold;">(3) Includes share-based compensation</b></ix:footnote></p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_QE-SblqY_067QtFhhF2IPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_nWwC0MMkc0aCPQt4dTDo3A_25_3">1,276</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_Xy3Mpk_8mkmNehLbu6bpWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_vObSNit_qUeZYZkSTYJSEg_25_6">1,213</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_cbS2-pmOL0Kpi-J5rXA22Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_TzWL1ozZVUuXQrPL9AtF7Q_25_9">720</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_wDkN_aLVuk6lqFu3E0NlpA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_BUV-PafmpE6_lr8al_b1uw_25_12">272</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_387649f5_56e7_498d_88bc_243e6db12cdc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">STOCKHOLDERS&#8217; EQUITY (CAPITAL DEFICIENCY)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands, except share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_51b0fa27_d06a_4470_84d5_013b9f213bd8"></a><a id="Tc_g7XAi-NgKkOGz5Xnq-OmRg_1_7"></a><a id="Tc_41ev72523k2B2vO3kMldpA_2_2"></a><a id="Tc_hzJwpng0A0qxCZelT1430w_2_4"></a><a id="Tc_uGzvXrzJxUW4MKJY0b0gUQ_2_7"></a><a id="Tc_8LUEw4-4sECwjsOdEp24dA_2_10"></a><a id="Tc_KFrNMo3x6UmO3JtWiOI9uA_3_2"></a><a id="Tc_AMPChzFe80mE5_LcHHFGoA_3_4"></a><a id="Tc_aJVufg5i9U6MPT6rxXi58g_3_7"></a><a id="Tc_9QN8GncVOU6Dy_v9ykxWKg_3_10"></a><a id="Tc_Zrkql30V8Ei2JjVmYeS0xA_3_13"></a><a id="Tc_D3aqt6VgBk-8Sk6m8iFHPw_4_2"></a><a id="Tc_JJQU0yRTmkS92dIGfGMbHQ_5_2"></a><a id="Tc_BMXTX9liN0aW1e9o8_A33A_5_4"></a><a id="Tc_m-ks3rMxaEurqmGPO2loPw_6_0"></a><a id="Tc_vjoKFUdQLUWmILdk529hBA_6_4"></a><a id="Tc_C33u2gQE80afD3EKyGTNIQ_6_7"></a><a id="Tc_GmhbNMe6g0ufueCmqrC7rQ_6_10"></a><a id="Tc_BD3BBixanUytYQSXIfHvCQ_6_13"></a><a id="Tc_AxqzQ1dceEGmjYdNb9UY2Q_7_0"></a><a id="Tc_C_8RupVGGkaCmxjvd0Mqvg_8_0"></a><a id="Tc_A1WE84VRAUWMo1zGNG7hhg_9_0"></a><a id="Tc_oXLpCnyGVUOsle0HpkVnhw_10_0"></a><a id="Tc_Js9KI1Udck2u-xjtoG70Qg_10_5"></a><a id="Tc_ngslp9E4o02f6av54xhHEQ_11_0"></a><a id="Tc_6XF0bJnJOkOQ7DonLOK5Ng_11_5"></a><a id="Tc_enXF1ycHu0amB72_t1mBZQ_12_0"></a><a id="Tc_HIUXNGRpaU6HR-PiJJ5p0g_13_0"></a><a id="Tc_YgoFvBXpWEK2p6NsLONSlA_13_4"></a><a id="Tc_Lc-uBS3uHUq5NKwqZ24eyA_13_7"></a><a id="Tc_-0wAIY4ENUynw8alGtB-tg_13_10"></a><a id="Tc_nYszntc040KZ9UBYL4AneA_13_13"></a><a id="Tc_BK6v7AzJAkW-aPN_bRg5_Q_14_0"></a><a id="Tc_dhnuQjUdZEGerLUkUZntxA_14_4"></a><a id="Tc_-ynx7vQZkUKdJpqmL_vvNQ_14_7"></a><a id="Tc_X1wm9OOjf0i3XzhkCWxeWg_14_10"></a><a id="Tc_wk27m49IsEa90mBSNrusWA_14_13"></a><a id="Tc_l8W-b4BaFUmG7DsdJBjf7Q_15_0"></a><a id="Tc_0MZoLEw3R0eMwsoNtpDgKg_16_0"></a><a id="Tc_ljjIUp-BHEWe8PTTShXG7g_17_0"></a><a id="Tc_1Wvew0tl2UmWEGheqo16ew_18_0"></a><a id="Tc_Ys8cUWiz70WRdDARNfP1Og_19_0"></a><a id="Tc_90Pfs3JHNU2QlULm2xGLug_20_0"></a><a id="Tc_NfiuT7vkZE-GLtJqyeaymg_20_5"></a><a id="Tc_TC-wwCkIVEOiwfvDSdKD4A_21_0"></a><a id="Tc_DfVGZhPMukqDOQKz8IySig_22_0"></a><a id="Tc_sYHfeXnBkkOMs15KAQSGsA_22_4"></a><a id="Tc_3qMUcZkm00O-_3L7oKI4NQ_22_7"></a><a id="Tc_TfvUR1vBCUyJDMTzDgXRNw_22_10"></a><a id="Tc_4oB5nk_SGEmydNCB8maZGQ_22_13"></a><a id="Tc_tRX9a0cmoUWjuRGMmfducQ_23_0"></a><a id="Tc_HHaHeVIxIUq3-uXVzHF_Cw_23_4"></a><a id="Tc_XYr09YBt20yvQ0S-9MrYNw_23_7"></a><a id="Tc_4PIjYRAdEUiwXtOBzMeFmQ_23_10"></a><a id="Tc_lPCOR81Pwki5rrM2GSh9Rg_23_13"></a><a id="Tc_FUKozm9fp0C6ChGaJgSrpA_24_0"></a><a id="Tc_DNyozFzVxUq0CkClMkyVPQ_25_0"></a><a id="Tc_iFJm5cfid0uBHuQbFgjztQ_26_0"></a><a id="Tc_roCHglLN_EOYF1dCrhCs1Q_27_0"></a><a id="Tc_R27du0dIQ0-h5tNksfAsbg_28_0"></a><a id="Tc_B7CyIoe-lkiRkBnMlRfzAg_29_0"></a><a id="Tc_E7V-sH_tME-Z6ozyX_mHSQ_29_4"></a><a id="Tc_xBnpGc0NC02k0RsvqIbYvA_29_7"></a><a id="Tc_ExrLECJ790mbo7CpqK8i6A_29_10"></a><a id="Tc_Ydhh0T_ppE6ib7FuMTNprQ_29_13"></a><a id="Tc_DMqYVMInn0WFo_I-M7heLg_30_0"></a><a id="Tc_1-eNnAYAp0O0EPnmMsAcgA_30_4"></a><a id="Tc_Y4UvB5TfYEGl5qNaYac6VA_30_7"></a><a id="Tc_cI8tAdZEOki9oKVRinNXxw_30_10"></a><a id="Tc_M9qDfsgkgEOC4J6HXbFQDw_30_13"></a><a id="Tc_JQawtb08NUaP8T0BAZU9XA_31_0"></a><a id="Tc_E0LNsrpdZUafOczL2pwtHw_32_0"></a><a id="Tc_JxLCuLVlUECNY3M8ZlNPiQ_33_0"></a><a id="Tc_i9Ja2oV_KEe2Z_2z8H1UdA_34_0"></a><a id="Tc_MkdCo0eP-EKRGkmZnd4eJA_35_0"></a><a id="Tc_UyPr0VSAB0yqgaag8_SlMQ_35_4"></a><a id="Tc_LwH6HXwG1UyKRNjqIe-MTg_35_7"></a><a id="Tc_DlXUDjB1dE6QlnSBEU3K4w_35_10"></a><a id="Tc_uWtkgpijskmNYK9E2kOWPg_35_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock (1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-2ASuQfAFkaEwmIK1OCojg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_J0Q06cNZT0aJQvKE4KrnZg_6_2">45,556,647</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-2ASuQfAFkaEwmIK1OCojg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_35s4mwejOkuxbATc6E_lPg_6_5">46</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mlxdQ7onNUCEQtHYpxTeEw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_U4bjFrxj-UaBT5DjPYWZNg_6_8">368,852</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RSrC8ujTNE-EKKHgIJyQfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_i-KyUgoPFUikcLYKrbDovg_6_11">374,934</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2021_WSd24FsHlEmdwHxFiK3fWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_no3FLywtk0yZZrY0k19pWA_6_14">6,036</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the nine-month period ended September&#160;30,&#160;2022:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WbDaBJULK0-Dh7pEyOjn7g" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Tc_Xmtr-8UVh0W8zZUKbrcCNg_8_2">3,841,479</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WbDaBJULK0-Dh7pEyOjn7g" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_LvcEcxjT4UeMFGeymTdmgQ_8_5">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gbkRzHwbyku8_AQoT0Dllg" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_FpTSStsomEupyKyGaH4WnQ_8_8">4,157</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_xeB_wNXVwEWwFrr9kIpPZA_8_14">4,161</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gbkRzHwbyku8_AQoT0Dllg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_BZJwvzWAREi4tmnXqGWW8A_9_8">592</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_e5xgTP8wTEilVk0lVT0_CA_9_14">592</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WbDaBJULK0-Dh7pEyOjn7g" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_3ak7Ebjw5kG6Kyjj5L8Eqg_10_2">759,482</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gbkRzHwbyku8_AQoT0Dllg" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_I7LAvUaQBkK23jCVLjmuOw_10_8">954</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_Z8Bz7x11a0OFJbV3nXQ3qA_10_14">954</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WbDaBJULK0-Dh7pEyOjn7g" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Tc_70Fh3FgfJ0i1a7pZPnjd4Q_11_2">1,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gbkRzHwbyku8_AQoT0Dllg" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_F26x8WeRPkGIOY6N2IgpLA_11_8">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_HtijywFhD0OfpPFozYJAow_11_14">2</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_U2kNPoY9pkW-TRdA8PGoWw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_3DyKCgbPCUOVY8UTEeLQBA_12_11">11,187</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_NIMHf3M2aECaMjeSv2WYWA_12_14">11,187</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FCS-baPkIkmVTzMkLUh60g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_XGzOlH__60G7j3Mh5UicPQ_13_2">50,158,608</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FCS-baPkIkmVTzMkLUh60g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_aBwuRKQFPUOf_heS0d6X8w_13_5">50</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_whHKsJQCKUCuIHXPg4Ju7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_0TWqUbcwhUm7hhuUo_X7zA_13_8">374,557</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZG9OKwFgA0KmxShrccpWnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_9vZm-_rbvEypHNB-i80mug_13_11">386,121</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2022_NdH__egkDk-gnw4KdsuuTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_upNsvEL-HEaqocD4Lwnakw_13_14">11,514</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3RZ-bdtfs0CiBzoZ1x2umw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_1eTA6uTMHkyR3m-Xxn97EQ_14_2">53,790,167</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3RZ-bdtfs0CiBzoZ1x2umw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_fP9tdGw5v0eerzTPJEF1Kg_14_5">54</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DpbxB34Toka6ZMB06mjkFw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_CBJGpSbQP0Sgg3lfqm4gfA_14_8">379,167</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jJqKna28f0aNpKm3h9LebQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_eelVxSZJtkW_B1F0RaSBWA_14_11">389,861</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_eObqsVs3EEm6SEgGzsrHhA_14_14">10,640</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the nine-month period ended September&#160;30,&#160;2023:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EHdJ5Zm9dUSQMKgSd6xQEQ" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Tc_UwQx0fb9LkSfPmBHKpezKQ_16_2">12,560,150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EHdJ5Zm9dUSQMKgSd6xQEQ" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_F0XKuP22REebgjnMSc4pzQ_16_5">13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PdQzi6Bi4kqkEATH0PHmyQ" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_D7_pNsjF90qa4tE3ox6wbA_16_8">23,941</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_cPCBqzzwTEKMA0ojPpz4ow_16_14">23,954</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Convertible notes conversions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EHdJ5Zm9dUSQMKgSd6xQEQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_zHYnQE3siUSd8cZtbB4jMQ_17_2">4,691,623</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EHdJ5Zm9dUSQMKgSd6xQEQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_cO6bR__IRU-bvMAoYnDczg_17_5">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PdQzi6Bi4kqkEATH0PHmyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_CJH7qSiYFU6x8x1itIalbw_17_8">7,778</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_giP-OWbc6UCQAi7g5ZHftw_17_14">7,783</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PdQzi6Bi4kqkEATH0PHmyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_3-M9PsR6OEa7fSG3BVAF-w_18_8">1,195</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_iIQR50Z9xUa_mMqkfVEzDA_18_14">1,195</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EHdJ5Zm9dUSQMKgSd6xQEQ" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_9yhZrR-b-EGqxOFYn_g5Nw_19_2">1,371,362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EHdJ5Zm9dUSQMKgSd6xQEQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_A-OywiQSm0SYADlahtz2Rg_19_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PdQzi6Bi4kqkEATH0PHmyQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_S9FmsJvGgEC8MI5XO3sJUw_19_8">886</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_6ouDkmIGiUCAN6nj2YvdVA_19_14">887</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EHdJ5Zm9dUSQMKgSd6xQEQ" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Tc_b7Y7BJIK3UedTfkl07xmNQ_20_2">538,822</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PdQzi6Bi4kqkEATH0PHmyQ" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_FnhUFhjo60WdAvXPeKRpOQ_20_8">712</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_earkpNbLQEWV0SKNpZsfqA_20_14">712</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net income for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_smFmNjh_GkaF3ZVKa76X_A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_rwe9wrnP_UmLLu7Q_Qnf0Q_21_11">14,356</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_SOMWVQXGWEqPJMn_qiDKEw_21_14">14,356</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6VRsvwfuMUqcCJm_5O_Dig" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_UnYL-Dklw0Oi5ZpVIu_wxw_22_2">72,952,124</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6VRsvwfuMUqcCJm_5O_Dig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_REaFJNl8YkKyEZeUOwtvUw_22_5">73</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nImxNodwz0S5hDYBFYIz4A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_MmlChRLf_0mzxj_YPlJvfQ_22_8">413,679</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MD0IJnJslU6DgpIpslYWHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_idWd9dITdU6O85KFl3JDzA_22_11">375,505</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_gt8BScB2fEiq7Iu4e7A9vQ_22_14">38,247</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uJvKLP-QfUi47f7FK9xAAQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_Bvi01VlUckODSjGL09xVuQ_23_2">48,712,952</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uJvKLP-QfUi47f7FK9xAAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_urvyISw19Ei6qHCMYZk3ZQ_23_5">49</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TvqjevVyaU2E1PYtpATXHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_TsLmszYby0C9TA1bVRPwvg_23_8">372,616</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hThUOSh2DEu8b-5DZ4GtMg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_qC0vCn4mTESY_Lf0wWMk8Q_23_11">382,554</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_6_30_2022_qEv4_s2oRkuGKBh0bBdY8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_gOzXNbH78E2mWZmVK2EcBA_23_14">9,889</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended September&#160;30,&#160;2022:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hlJfBq7xHUuJTVElf5mZ9Q" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Tc_yK0f7kNti0uhUFBdgENL7A_25_2">1,445,656</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hlJfBq7xHUuJTVElf5mZ9Q" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_pcWSisSGPUqqaF5R5OhJ6Q_25_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bKsEqv1Q706_PDc9XAYvmA" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_BQGCaYNgU0CYb28e1rJ8qQ_25_8">1,519</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_hycE_oRgNk-dEzFvv311oA_25_14">1,520</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bKsEqv1Q706_PDc9XAYvmA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_kEpLpHWqD06wb6hcaiv0-A_26_8">298</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_CLLgtBGNbEOq7Dj-ZAx79w_26_14">298</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bKsEqv1Q706_PDc9XAYvmA" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_YVpeLJWZuky7cOT2_0mEcA_27_8">124</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_ndFMKZBjEkSZRnJx2rGc4w_27_14">124</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Pdy3Pw8g706hDOOxHjfOfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_r7B1Tym6_kStcgHryYRK1A_28_11">3,567</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_IP3_GuLFX0Cie-UG04-qqg_28_14">3,567</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FCS-baPkIkmVTzMkLUh60g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_xBU_amZ-LkuBgXXAAuDnEA_29_2">50,158,608</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FCS-baPkIkmVTzMkLUh60g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_qSqcxtDrHkKfWEvkmPfmWg_29_5">50</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_whHKsJQCKUCuIHXPg4Ju7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_hE1P2g-NuEehQEzhTBAmzQ_29_8">374,557</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZG9OKwFgA0KmxShrccpWnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_7dBF6GM240uzNQrlBuQj7A_29_11">386,121</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2022_NdH__egkDk-gnw4KdsuuTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_wLc8Z-iY_EudddgDsODZkg_29_14">11,514</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kSgL5r7c3k-B0VAIxyKmAQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_5JtCaCayY02Yie7S2mhEPw_30_2">71,580,762</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kSgL5r7c3k-B0VAIxyKmAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_J0Gw3XqvY0OgZ6OaDq61Sg_30_5">72</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_U0vvCuWzP0ObL95ACk6iGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ZiDns9xcokqMkYVDz7qQuQ_30_8">412,582</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_J6U7oUvVYE-mVxaE0p0afA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_0UEUaHb3Q0uwua4AARLPag_30_11">373,653</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_6_30_2023_ljE3QYELHUKaEWcB1Rf2BA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_xMz58Y8KiUOJxdxv8TMbzA_30_14">39,001</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended September&#160;30,&#160;2023:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_74hbg6s0YUGMZEgtc7zlCQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_CqIIQgfw-k2mmHOByJTqkQ_32_8">383</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_HsCkhrXJeEy2fu3A2HhMXw_32_14">383</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4ubTKPzTYUaZJP68MFh1aA" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_GQwKI1DfuUWngKk4EwwxsA_33_2">1,371,362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4ubTKPzTYUaZJP68MFh1aA" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_tmeK12uDsUW-E0RJNtXvyg_33_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_74hbg6s0YUGMZEgtc7zlCQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_Mldx4XwReEKiqUooo-V2tQ_33_8">714</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_HCmkBA_NwUaon6zmV_ceyw_33_14">715</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Ky9hROQdhEKplEsRyyjknA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_gJ3Iug9Cz0qKn9iLHd9BGw_34_11">1,852</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_oRVv8wBuok6RTz3KL5f_4g_34_14">1,852</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6VRsvwfuMUqcCJm_5O_Dig" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_xfcNdFkJBECaKEusvGlF7g_35_2">72,952,124</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6VRsvwfuMUqcCJm_5O_Dig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_2FFhYJkWFkGIetyz_ajSEw_35_5">73</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nImxNodwz0S5hDYBFYIz4A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ypFLMrev30-EuSiUyyko2A_35_8">413,679</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MD0IJnJslU6DgpIpslYWHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_7H5TdEdB_UeQ2X9_jmW5Aw_35_11">375,505</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_4cSjhTe-KEWWpUpU3kX9YA_35_14">38,247</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">*Represents an amount equal to less than $1.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a2e03645_2643_4168_926d_13e04faf108a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(1)&#160;<ix:footnote xml:lang="en-US" id="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_OGXS2XbVUkCIfbX2ptcq9A"><ix:nonFraction unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_L4e8_3m_yUCGXoXAx7KX4Q">0.001</ix:nonFraction></ix:nonFraction> par value; Authorized &#8211; as of September&#160;30, 2023 and December&#160;31, 2022 &#8211; <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_grZI2TAWWkuMvo3WLpaE7A">185,000,000</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_Vf02-JriJ0ekFDrg3kEQ9A">144,000,000</ix:nonFraction> shares, respectively.</ix:footnote></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a3071650_01f8_4626_bba8_14472dcee9f8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_036b0258_18a7_4ba6_9dee_ce3a7dd27b55"></a><a id="Tc_9LCq6TFtQUycjG4okNZ3fA_1_2"></a><a id="Tc_IKuN3T78oUOCukiQQIpwgg_2_2"></a><a id="Tc_VCXV1QRDFUCYEC7fZuBGGg_2_5"></a><a id="Tc_MPKdlYF4aEukq79pVrlgTg_3_0"></a><a id="Tc_-PETkehirEOG_IP-wL0clA_4_0"></a><a id="Tc_xDlH5Y9KkkK2xYodSeeF_w_4_2"></a><a id="Tc_9V7aLUP_L0u-3GiGG9X4bA_4_5"></a><a id="Tc_-NDIwNEhPUylhNvtCsGnJA_5_0"></a><a id="Tc_rSkNEAmNL0aeS1QfEMQ3QQ_6_0"></a><a id="Tc_ui2F9bmBUkGn93JHTfPULw_7_0"></a><a id="Tc_5tJfpZFznkqO8X1Fb50ufA_8_0"></a><a id="Tc_lDaNI4xlPU2A5xI6IPORzw_9_0"></a><a id="Tc_T6vAhcnfHUqUbK6LAbVgNg_10_0"></a><a id="Tc_gcTL31O8hEG96kD5wz-h3A_10_6"></a><a id="Tc_3A0_qAsonUmJS_VnRPiw4g_11_0"></a><a id="Tc_sfx2_d4gr0yyRfutajHTIg_12_0"></a><a id="Tc_-1rXOXsIPkSk_3pgCA_wIw_12_6"></a><a id="Tc_6rePl4uTVEaMX95f0N2v_A_13_0"></a><a id="Tc_WOJs9AA_HEO-QVWBgU3ERQ_14_0"></a><a id="Tc_8y_AgjoX10Cq8FkmG5NS3g_15_0"></a><a id="Tc_NUwt7Q7_rUqJ2dAORYfJ_Q_16_0"></a><a id="Tc_h049cbUtekq22AKdEcp-2g_17_0"></a><a id="Tc_WG9PoXIEYUOQ1B7Nm37pXQ_18_0"></a><a id="Tc_vFpgZkvlyka3IVNrb5eB2g_19_0"></a><a id="Tc_AS2QKTCylkSIBu-5by2x0g_20_0"></a><a id="Tc_CNA6QmPjXECsA8F8xVYOXQ_20_2"></a><a id="Tc_huElnqd_Qkizd4kQcJ66kg_20_5"></a><a id="Tc_ZBoIZBwBjEyKkJoePIaQuQ_22_0"></a><a id="Tc_AOscqIrqUkOtRaqPCJTHUQ_23_0"></a><a id="Tc_XsHksNFJmkWjRPyZXodbUA_23_2"></a><a id="Tc_zOEW4NzwEUeYwtfBCG98lw_23_5"></a><a id="Tc_9YUr1-vpAUGSsTJJzSlx9w_24_0"></a><a id="Tc_mkL9v2EMIkaOvCpeb0xefg_25_0"></a><a id="Tc_Gry_wTMddU6_bkng0V54nw_26_0"></a><a id="Tc_Sy4ocLcPzUilWo4vgnVXGg_27_0"></a><a id="Tc_L0OLUgobZ0C3zTgLvA7r2g_27_2"></a><a id="Tc_nlqSYG8HxEKBHtxACDVUAA_27_5"></a><a id="Tc_iuv9g4Q350SaclubKeD59Q_29_0"></a><a id="Tc__yAd-ZcgiEeXCvln_Fbp6w_30_0"></a><a id="Tc_zuOVdnAzPky8LN5ODjCVpw_30_2"></a><a id="Tc_K1qBqwEUOkqjvY9SCiNIgw_30_5"></a><a id="Tc_X3Fm4P2kh0C_MQIJQ-U5Ow_31_0"></a><a id="Tc_Z_10ru0fEUeg-E0V6wyFVg_32_0"></a><a id="Tc_mHPkt1BzNEKLhP29ZzX32Q_32_2"></a><a id="Tc_PBALmSbH7EK4PblnwhJ2_g_32_5"></a><a id="Tc_rw7Ng71s0UCpVXQp2VDGVg_33_0"></a><a id="Tc_kKYFqxddT0uIkD6bWvBi3w_33_2"></a><a id="Tc_Vh6DCJAr-UWjAoctvJtmLQ_33_5"></a><a id="Tc_zC47oTha40C69JW4QhjoNg_34_0"></a><a id="Tc_XOpizvs0L0edy5jELZcSzg_35_0"></a><a id="Tc_IR5RUylamE6i4CdZnWMC6A_36_0"></a><a id="Tc_X4KsGuKZXUSEhMSt1EPD7g_36_2"></a><a id="Tc_OuG0L6v43UCuayFjCCtGuQ_36_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM OPERATING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="Tc_h_L9bTiiHEaPxk09coh3bA_4_3">14,356</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_hGnYxGnloUyTLcj79pP_lw_4_6">11,187</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Adjustments required to reconcile net income (loss) to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_3GYKW74_2UyS0xwDb_MqHA_6_3">2,081</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_ZXFrhoQupkuPq3uuLiEB-g_6_6">1,546</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_9sahu4Cc10mFigecvux4aQ_7_3">878</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc__gwDNQGNRk6Jt6wRI45-ng_7_6">811</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Financial income, net (mainly exchange differences)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="Tc_bGp8oClmfk6j6-x-lgfQXQ_8_3">511</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="Tc_c7UQfHza6EGFmqWay5_awg_8_6">1,083</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in accrued liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" sign="-" scale="3" id="Tc_268lZaPBBkKN_DQy-IbuyA_9_3">50</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" sign="-" scale="3" id="Tc_EkmnzPCICE2A4lH8nsHihQ_9_6">391</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in deferred tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_M9j0JtMNJ0iw_Dqol6ORdQ_10_3">3,092</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Loss (gain) on amounts funded in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" scale="3" id="Tc_ECfgfUt-hUmikVfduqVPGA_11_3">49</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" sign="-" scale="3" id="Tc_PYT5Pt_sFEOpMBdvNkpKYg_11_6">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gain on conversions of convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnDebtConversion" scale="3" id="Tc_8OD9BkaT3EulWRvhQst_lg_12_3">421</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amortization of debt issuance costs and debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_871zzaIuU0y8f-52y866pw_13_3">208</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_I_qv9YGjcUq9kccBtJasNg_13_6">224</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease in contracts liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_FXeM-aOlk06stbQlnEYzAg_15_3">13,178</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_qTqbDjE09EONqsfxoQyo9w_15_6">5,547</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase in accounts receivable-trade and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_YrWQvzihdkCBHMmul282YA_16_3">4,188</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_Zfnnncw9M0aFKjpAouAxVw_16_6">5,692</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Changes in operating lease right of use assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" sign="-" scale="3" id="Tc_SxDDrL3Aq0G2Gk86Af0YBg_17_3">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" scale="3" id="Tc_5AtoUuTO-Uq_GTbiULXFYw_17_6">30</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease (increase) in inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_9fbyMby1xkePenkc76R6Ng_18_3">4,779</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" sign="-" scale="3" id="Tc_u1Xrsvlm7EiCjBm6y8CKZQ_18_6">3,392</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase (decrease) in accounts payable and accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_OmJ3JIH0KUGyPYpD8GGfug_19_3">3,820</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="3" id="Tc_ryFZqzfrn0eHo8x1vBWp6w_19_6">4,438</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 13.5pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_5zvuRkC4CkGtBFEtIjpMUA_20_3">4,913</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_vKvyT6-xE0ixRYbc5SdTgQ_20_6">22,389</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM INVESTING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Investment in bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInBankDeposits" scale="3" id="Tc_0ZgjW9orZU2fZspHWsbsfA_23_3">20,420</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInBankDeposits" scale="3" id="Tc_ridz6eWHyUKYE9NIIScSrg_23_6">16,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from sale of short-term deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromSaleOfShortTermDeposits" scale="3" id="Tc_SyBX_UkOw0CoqXsoPPz8ZQ_24_3">5,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromSaleOfShortTermDeposits" scale="3" id="Tc_jqCrhOWvsEiLq6tqljhOQA_24_6">6,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_AVSnifNGAUST56VNakcqmg_25_3">899</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_HWGIfPkaCUaGO94D0nCgxQ_25_6">415</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amounts paid (funded) in respect of employee rights upon retirement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_MdGZwb2U6Ua8JR_tiLqkbA_26_3">50</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" sign="-" scale="3" id="Tc_YpmYhapJsEWTbLp-xcq74g_26_6">427</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_R3jBzLYOxkOq-Ausx6QO8Q_27_3">16,369</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_Tw47nGHztUO1N4iyKJWp8g_27_6">9,988</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM FINANCING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_vNFbsAikpEa8BrtGTwdhag_30_3">23,954</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_q_Hs48OCU0ecHEd1v-Kb2g_30_6">4,161</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_mnpH3xv7GU2F0ezKe50idQ_31_3">712</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_MnTjso8-JkCGxC1kSbjjJw_31_6">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_Vh4z3v1_N0eE4nf21c1ncw_32_3">24,666</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_YKUzwGVtTUq4Fv1bq_Vn0w_32_6">4,163</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" sign="-" scale="3" id="Tc_rsCP1423wEC4pJ2EeIo6Cw_33_3">87</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" sign="-" scale="3" id="Tc_AZyoh7NAaEWCZlCX3WTvkQ_33_6">51</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_tqvuCwmHo0WGQWpdVs5Bgg_34_3">3,297</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_uGNAyKYQrEu5iWER6Qljkg_34_6">28,265</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_m8-MRPTBKESqWZF19ZTlQw_35_3">17,111</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2021_WSd24FsHlEmdwHxFiK3fWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_QF4TmIiaikO_iGZ8lvOA2Q_35_6">38,985</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_sdwgUAfZRUmhLL9KEg_e8A_36_3">20,408</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2022_NdH__egkDk-gnw4KdsuuTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_o0EDyXRDgUOyMcHKLJnOag_36_6">10,720</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Continued)&#160;&#8211; 2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_46a503f9_bdde_4384_ae1e_7932ccc325a6"></a><a id="Tc_LZVegksOFEqcMHGRGxtnsg_1_2"></a><a id="Tc_lyfbL5oQ7U6XJElXwjRFLg_2_2"></a><a id="Tc_VFMS_CYldEe5M4Z-XirdUw_2_5"></a><a id="Tc_wvez79zp1kGTUQAAvESG0A_3_0"></a><a id="Tc_vayjjuwZaEa5sro-7WtpUw_4_0"></a><a id="Tc_8Y7_mQAKlUWEKr1Wi_EJrQ_4_2"></a><a id="Tc_DIIKTb8pMUmfUWIo1ie55Q_4_5"></a><a id="Tc_sgtZnZWaWE6U5_kUfqLszQ_5_0"></a><a id="Tc_YYTCZ4ZrjkC2RoNnWkobog_5_2"></a><a id="Tc_XFR0T0T92UqlIIMwuJozTg_5_5"></a><a id="Tc_G_AqnfBVOUOUv6Jba33hmw_6_0"></a><a id="Tc_GCfjoninck2vgA92r_4mgA_6_2"></a><a id="Tc_4PGQ2-fHXEG5qf1SFr7iEQ_6_5"></a><a id="Tc_iS2u1XJwxEqtIH5WMwGm4g_6_6"></a><a id="Tc_Ca_lPg5dJ0qqpKqJ11-DzQ_7_0"></a><a id="Tc_xCCOpQtQrEmmghLT_LsWgg_8_0"></a><a id="Tc_UDp-VFflCUOriFBwV2SL5A_8_2"></a><a id="Tc_Qf9nGuXyQk2MiBrB1unh0Q_8_5"></a><a id="Tc_QyXHfPSVn0emku9V_nMilg_9_0"></a><a id="Tc_46wm72R0Uka-ExE1H9uT2w_9_2"></a><a id="Tc_rLFtMRdOVkGQ8o364uJjYQ_9_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_W6jmPjiCW0KY4RRKFal4IA_4_3">253</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_uimbCBfijEilhaUv7sz8Pg_4_6">205</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease right of use assets obtained in exchange for new operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_eOp7k9eFdkSgwIvD2VH-EA_5_3">1,395</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_9HTBNbjIDUG2K4SbSOnIgg_5_6">396</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Convertible notes conversions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" id="Tc_2Mbz_Gitj0i5ctQ0PEnsYw_6_3">7,783</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_5uS7-1VejUeyG4XxA32Aeg_8_3">2,743</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_hl6PlX6GCUCTDQkbHHNEFg_8_6">2,198</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest received</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="plx:InterestReceivedNet" scale="3" id="Tc_S0rp3jEZW0SQL02A7oFPqA_9_3">303</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="plx:InterestReceivedNet" scale="3" id="Tc_nk7RaPMNwk--yoEZQEG_qw_9_6">136</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_0LHuygT7JUiPOYYUewHgSQ" continuedAt="Tb_0LHuygT7JUiPOYYUewHgSQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="plx:NatureOfOperationsPolicyTextBlock" id="Tb_-o45tTp75Ui0www99M_qdg" continuedAt="Tb_-o45tTp75Ui0www99M_qdg_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). The Company&#8217;s current focus is to facilitate the commercialization efforts of Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), the Company&#8217;s development and commercialization partner for pegunigalsidase alfa, or Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (which the Company referred to as PRX-102 during its development stage), for the treatment of Fabry disease, a rare, genetic lysosomal disorder. To date, the Company has successfully developed taliglucerase alfa (marketed under the name Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> except in Brazil where it is marketed as BioManguinhos alfataliglicerase), an enzyme replacement therapy for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s strategy is to develop proprietary recombinant proteins designed to address high, unmet needs in the rare disease space that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. Consistent with this strategy, the Company has a number of product candidates in varying stages of the clinical development process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On May&#160;5, 2023, the European Commission (&#8220;EC&#8221;) announced that it had approved the Marketing Authorization Application (&#8220;MAA&#8221;) for Elfabrio and on May&#160;9, 2023, the U.S.&#160;Food and Drug Administration (&#8220;FDA&#8221;) announced that it had approved the Biologics License Application (&#8220;BLA&#8221;) for Elfabrio, each for adult patients with Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. The European Medicines Agency (&#8220;EMA&#8221;) approval followed the February 2023 adoption of a positive opinion and recommendation of marketing authorization for Elfabrio by the EMA&#8217;s Committee for Medicinal Products for Human Use the (&#8220;CHMP&#8221;). Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with Enzyme Replacement Therapy (ERT) class labeling, and Warnings/Precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The Warnings/Precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In August and September of 2023, Elfabrio was approved in Great Britain and Switzerland, respectively, for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The Company has entered into <ix:nonFraction unitRef="Unit_Standard_agreement_lKNqKU4rvUupTelfJQIVSg" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="INF" format="ixt-sec:numwordsen" name="plx:NumberOfGlobalLicensingAndSupplyAgreements" scale="0" id="Narr_BPbFGo0yRkCDGUyp0wcJ7w">two</ix:nonFraction> exclusive global licensing and supply agreements for Elfabrio with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;). On October&#160;19, 2017, Protalix Ltd., the Company&#8217;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi Ex-US Agreement&#8221;), pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the Chiesi US Agreement, with respect to the commercialization of Elfabrio in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Elfabrio, an enzyme replacement therapy, or ERT, was the subject of a phase&#160;III clinical program studying the drug as a treatment of patients with Fabry disease, a rare, genetic lysosomal disorder. The phase&#160;III clinical program included three separate studies, which are referred to as the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which subjects that participated in our phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship of the two open-label extension studies was transferred to Chiesi, which is now administering the extension studies. Over time, and as Elfabrio is approved for marketing in different jurisdictions, </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_0LHuygT7JUiPOYYUewHgSQ_cont1" continuedAt="Tb_0LHuygT7JUiPOYYUewHgSQ_cont2"><ix:continuation id="Tb_-o45tTp75Ui0www99M_qdg_cont1" continuedAt="Tb_-o45tTp75Ui0www99M_qdg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">participants withdraw from the open-label extension studies. Some of the withdrawals<span style="text-decoration-line:line-through;text-decoration-style:solid;"> </span>transfer to a commercial setting, others withdraw for other reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The BLA for Elfabrio for the treatment of adult patients with Fabry disease was resubmitted to the FDA on November&#160;9, 2022. An initial BLA for Elfabrio was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, but resulted in a Complete Response Letter (&#8220;CRL&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The MAA was submitted to the EMA on February&#160;7, 2022, after the October&#160;8, 2021 meeting we held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The FDA publicly released the internal review documents for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161. These documents provide previously unavailable additional information regarding the basis for the FDA&#8217;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study (Study PB-102-F01/02) with confirmatory evidence provided by the <i style="font-style:italic;">BALANCE</i> study (also referred to as Study PB-102-F20). The FDA review team also concluded that the <i style="font-style:italic;">BALANCE</i> study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the <i style="font-style:italic;">BALANCE</i> study did not support a non-inferiority claim to the comparator product due to the lack of data to support a non-inferiority margin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has licensed the rights to commercialize taliglucerase alfa worldwide (other than Brazil) to Pfizer Inc. (&#8220;Pfizer&#8221;), and in Brazil to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;). Otherwise, except with respect to taliglucerase alfa and Elfabrio, the Company holds the worldwide commercialization rights to its other proprietary development candidates. In addition, the Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(1)</span>PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat severe gout; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(2)</span>PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</div><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On March&#160;21, 2023, the first patient was dosed in the Company&#8217;s phase&#160;I First-in-Human (&#8220;FIH&#8221;) clinical trial of PRX-115. As of September&#160;30, 2023, <ix:nonFraction unitRef="Unit_Standard_item_dyUGGngOZEG007onwpOmGw" contextRef="As_Of_3_21_2023_59uxaENwDEeis1uswurdAQ" decimals="INF" format="ixt:numdotdecimal" name="plx:NumberOfPatientsDosed" scale="0" id="Narr_HY07nkL-zk-MXaB_6kBcTA">32</ix:nonFraction> patients have been dosed in this trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;2021 Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell, from time to time through the Agent, shares of its common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg" contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_ABTzvay3O0OZCuw98-XbeQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_BzhCttsxX0W08dI9OJtzKg">0.001</ix:nonFraction> per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_FE-7EpG9IkW88m9UfwwG6w" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_eBVVMKPpikGhmbS8IOKcWA">20.0</ix:nonFraction>&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the 2021 Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). During the term of the sales agreement with BofA Securities, the Company sold a total of <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_mvxv3O6LxEaaJFEPDGVkrA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_jD4eYDzKPEW6F8nb1FRh6A">3,296,123</ix:nonFraction> shares of Common Stock for total gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_mvxv3O6LxEaaJFEPDGVkrA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_9-PDJWvxYEmUotkb0D--fA">13.8</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, the Company sold a total of <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_bcEsWzSIKk6tSkX7LMh0hQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_5Yl222-uy0Cn-x3KEjq13Q">13,980,060</ix:nonFraction> ATM Shares for total gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_bcEsWzSIKk6tSkX7LMh0hQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_P3EE_7wPwE6HhAJxCo4Ing">20.0</ix:nonFraction>&#160;million under the 2021 Sales Agreement, thereby completing the ATM program under said agreement.</p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_0LHuygT7JUiPOYYUewHgSQ_cont2" continuedAt="Tb_0LHuygT7JUiPOYYUewHgSQ_cont3"><ix:continuation id="Tb_-o45tTp75Ui0www99M_qdg_cont2" continuedAt="Tb_-o45tTp75Ui0www99M_qdg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#8220;2023 Sales Agreement&#8221;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_2_27_2023_To_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_z_3UoywC8ECDn2BmWvhnnw" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_fl84Zaa9nU2wujrUE3NU5A">20.0</ix:nonFraction>&#160;million. As of September&#160;30, 2023, shares of Common Stock for total gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_IZYUYcpDQ0W3wVn53D7jkQ" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_FEV3dBDXMkStUmpmiN_BpQ">6.4</ix:nonFraction>&#160;million remain available to be sold under the 2023 Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_I0f7iY_hoUWDw20FCFX8EQ" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNoncreditablePaymentReceivable" scale="6" id="Narr_JRpPKU2PfUmMavjgZxVAkg"><ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_c_DS6CF9IUONf5DnuePWGg" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNoncreditablePaymentReceivable" scale="6" id="Narr_fg_FgWo83EmbroF0qd8yQw">25.0</ix:nonFraction></ix:nonFraction>&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_WBsGH7Src0eGVZCrXqiz2A" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_gE-AujAEkkaGxYQ6AIyGWw">25.0</ix:nonFraction>&#160;million in pegunigalsidase alfa development costs and to receive additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_WBsGH7Src0eGVZCrXqiz2A" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_aawHMbp25ESpZAvMtjF4mg">320.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_rCjFnyR3fEa9cw5ekQ7pew" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_jL0dGnJ0j02kwmHbPhL1Hg">20.0</ix:nonFraction>&#160;million to cover development costs for pegunigalsidase alfa and to receive additional payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_rCjFnyR3fEa9cw5ekQ7pew" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_3YyC-cT5iUy5qGw1YrSyrQ">760.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements. In addition, following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_iN4jeRGThUGJ9_j3XbAknA" decimals="-5" format="ixt:numdotdecimal" name="plx:MilestonePaymentReceived" scale="6" id="Narr_J_N3VfrKFkWjFr-v8QSmbw">20.0</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. is required to manufacture all of the Elfabrio drug substance needed under the agreements, subject to certain exceptions, and Chiesi will purchase Elfabrio drug product from Protalix, subject to certain terms and conditions. The consideration for Protalix Ltd. is based on the drug product supplied to Chiesi and the average selling price of the drug product in the relevant territory multiplied by tiered payments as described in the relevant agreement. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments for drug product purchased from Protalix of <ix:nonFraction unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw" contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3JKpw53nwkGDyDlVTy2Gxw" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_FbZktYaQ706B1z6skG28ug">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw" contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_GHWT0ykNeEuO1RlIzpZFhg" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_LBWGsG0nS02ynHXJV8deqw">35</ix:nonFraction>%, depending on the amount of annual net sales outside of the United States, and under the Chiesi US Agreement, Chiesi is required to make tiered payments for drug product purchased from Protalix of <ix:nonFraction unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw" contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_etzFjnmIFkqSQ8Z9LeDedg" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_BRcufVO2tUadI8EDETHYZg">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw" contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_DKlLQr64h0q6S5laUAGccw" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_VZlAbnPoM0GYRv2fNp20eQ">40</ix:nonFraction>%, depending on the amount of annual net sales in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#8220;F/F Agreement&#8221;) and a Letter Agreement (the &#8220;Letter Agreement&#8221;), in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for PRX-102 and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide the Company with commercial fill/finish services for PRX-102, including to support the anticipated global launch of PRX-102. The F/F Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with the terms of the F/F Agreement and the term may be extended by mutual agreement for an additional period of&#160;<ix:nonNumeric contextRef="Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_FillFinishAgreementMember_sD-xmdGPaE-ij5-ExlU3kQ" format="ixt-sec:durwordsen" name="plx:ExtendedTermOfAgreement" id="Narr_Ctajezos-0Gy33CDwq-mag">seven years</ix:nonNumeric>&#160;upon mutual written agreement prior to expiration of the initial term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_jp1gAPcWdUq4GpRSn43eoQ" decimals="-5" format="ixt:numdotdecimal" name="plx:AgreementAmendmentPaymentReceivable" scale="6" id="Narr_7HN7MFaTa0WtPVcCIFWS-Q">10.0</ix:nonFraction>&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_GERNj3wXEUWT0EvS1LtJJA" decimals="-5" format="ixt:numdotdecimal" name="plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_pmtKhrRKpU6IIJsIaxoa5A">25.0</ix:nonFraction>&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for <ix:nonFraction unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw" contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_-xsCF2uYFkqT5zfBjQzLVw" decimals="2" format="ixt:numdotdecimal" name="plx:CollaborativeArrangementRevenuesExpensesSharingPercentage" scale="-2" id="Narr_4VXmwTLIHkekUvihR2wxpw">100</ix:nonFraction>% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement with Fiocruz (the &#8220;Brazil Agreement&#8221;) for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply </p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_0LHuygT7JUiPOYYUewHgSQ_cont3" continuedAt="Tb_0LHuygT7JUiPOYYUewHgSQ_cont4"><ix:continuation id="Tb_-o45tTp75Ui0www99M_qdg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to the product candidates. Under the terms of the Company&#8217;s outstanding <ix:nonFraction unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw" contextRef="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_ONDNURLUTUKjjQ_0xrpP0w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_A1I0iWOevEaCy0eqUqHorg">7.50</ix:nonFraction>% Senior Secured Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;)<span style="font-family:'28mugxoulnobhnx';">, </span>the Company is required to comply with certain<span style="color:#222222;background:#ffffff;"> </span>financial covenants, including the maintenance of a minimum cash balance of at least $<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_ONDNURLUTUKjjQ_0xrpP0w" decimals="-5" format="ixt:numdotdecimal" name="plx:MaintainOfMinimumCashBalance" scale="6" id="Narr_ICwgvzGix0-O3RcRDU_IcA">7.5</ix:nonFraction>&#160;million. As of September&#160;30, 2023, the Company is in<span style="background:#ffffff;"> compliance with all such covenants. </span>The Company believes that its cash and cash equivalents as of September&#160;30, 2023, are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_RlegqHN8xkeHe5dTWx_gRA" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2022 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2022.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="Tb_HFsrOjleAU2xinF68td5DA" continuedAt="Tb_HFsrOjleAU2xinF68td5DA_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Revenue recognition</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Revenues from selling products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery), at the net selling price, which reflects reserves for variable consideration, potential discounts and allowances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price is the consideration to which the Company expects to be entitled from the customer. The consideration promised in a contract with the Company&#8217;s customers may include fixed amounts and variable amounts. The Company estimates the variable consideration and includes it in the transaction price using the most likely outcome method, and only to the extent it is highly probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_0LHuygT7JUiPOYYUewHgSQ_cont4"><ix:continuation id="Tb_HFsrOjleAU2xinF68td5DA_cont1"><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenues from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified <ix:nonFraction unitRef="Unit_Standard_agreement_lKNqKU4rvUupTelfJQIVSg" contextRef="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_eoOa9SWffEiVP049zeIqSA" decimals="INF" format="ixt-sec:numwordsen" name="plx:RevenuePerformanceObligationNumber" scale="0" id="Narr_nQq2Rh8QoUSsmNWG7M6zMw">two</ix:nonFraction> performance obligations in the Chiesi Agreements as follows: (i)&#160;the license and research and development services and (ii)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The manufacturing was contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license, research and development services. Following the regulatory approvals for Elfabrio received in May 2023, the Company started recognizing revenue from manufacturing, see also revenue from selling products above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue. Following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_iN4jeRGThUGJ9_j3XbAknA" decimals="-5" format="ixt:numdotdecimal" name="plx:MilestonePaymentReceived" scale="6" id="Narr_XuN7DFGPd06u6sKZbJ7Nwg">20.0</ix:nonFraction>&#160;million (see also note 4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services was recognized over time using the cost-to-cost method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi is recognized over time using the cost-to-cost method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services was recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the services.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation><a id="Tc_D7_bCvz-P06WL-E35R9zHQ_1_2"></a><a id="Tc_ftlq_7efeUyLP7X5R7bT0A_1_5"></a><a id="Tc_4qD6UgbzkEmalum1qccT5Q_2_0"></a><a id="Tc_f7kZVw3c7EinNbzGoBzs9w_2_2"></a><a id="Tc_EYiy6XaY-E2ojYjleA05Tg_2_5"></a><a id="Tc_HVZPdRhrQUaCk3arQXT7aw_3_0"></a><a id="Tc_zZ5gHXVS1USTzf_BvTO2jw_3_2"></a><a id="Tc_ZmXNbyQKo0WOodtSlIhDFg_3_5"></a><a id="Tc_CThoku_ZRU6EEM4-TbMhqA_4_0"></a><a id="Tc_YEMwVDL18USusk1JRvRajw_5_0"></a><a id="Tc_Cq0_OtQZwECEtPSbiI44Cw_6_0"></a><a id="Tc_Kq10IjhyQU-pSHLSAtdw6Q_6_2"></a><a id="Tc_RSU206rJ5E68gnQwxNjezg_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_Jpcm8yTCkkqdd0RLi0JX4Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at September&#160;30, 2023 and December&#160;31, 2022 consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb_GdCkTKd880GcI55VBwBGDA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_30Pjrj068kO_qkyIsJ8EGQ_3_3">4,198</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_pW_aKbDRdkKScvqrbdTp4Q_3_6">3,508</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_TKIhhqbbRkiLc0oHumd2xA_4_3">9,116</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_iqV61xDeNk6a945z3F3pdQ_4_6">2,678</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_JIrRKoTdWkiBdWwAd9sFyg_5_3">8,269</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_tDMpT7mhhUOAychbtYG7bw_5_6">10,618</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_ng4uO8OeEkmVSyJb7rEySg_6_3">21,583</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_fRUp5v-MYkOVsPafqdtAZw_6_6">16,804</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_NP2USvyA9EatKNAI5J9ghg" continuedAt="Tb_NP2USvyA9EatKNAI5J9ghg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_6C6StIimhE6Frfa1IapRsg_1_5"></a><a id="Tc_dwZ-LWK3NE65pi0ySVgZEA_2_0"></a><a id="Tc_AqxCCUxnm0-wR1lk9xaYLw_3_0"></a><a id="Tc_y6YQEw21w06gCorHLRqbJQ_4_0"></a><a id="Tc_6hGWceyc4kCEpQwZa_2BoA_4_6"></a><a id="Tc_ive6NqogUUyO2wngyDRRkA_5_0"></a><a id="Tc_UvwrQRI1E0GfLU00pa4RBA_5_6"></a><a id="Tc_9rv3-812Z0S41H5_iB9KwQ_6_0"></a><a id="Tc_HZU_gE63N0aDmPUotP6aDw_6_6"></a><ix:continuation id="Tb_NP2USvyA9EatKNAI5J9ghg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">Based on a Level 3 measurement, as of September&#160;30, 2023, the fair value of the $<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_kgA--Gd-2UWeFMP4kZXqwA" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="Narr_TnY_-SFdbESZEKHIRv746w">20.4</ix:nonFraction>&#160;million aggregate principal amount of the Company&#8217;s outstanding 2024 Notes is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_kgA--Gd-2UWeFMP4kZXqwA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="Narr__L3MZoch7E2EkZZrT4AkMQ">24.5</ix:nonFraction>&#160;million. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used: </p><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_IsSkHrMXCEC808Zd6VbjIQ" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_EUdlsbm8Y0OiA2eMvR07RQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg" contextRef="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_uB6aVsBg6EaCcs-hRuTW_A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_Ix7qqpwHNE6ArUbPsr7GFQ_2_5">1.66</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_P_CRw8WyjU2VbFabIi54IQ" contextRef="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_tTdbaH9LGEq9pS4VzhrCSw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_M5DGdhXbfUebMCfrB0Qp9Q_3_5">0.93</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw" contextRef="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_bez3doxPHEy6nArxyu-5WA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_CMz7LUJ_1UCsG_m-9fVkwg_4_5">5.34</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw" contextRef="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_X09KFdeVa0mgHlIW0IelcQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_2XdPeY5fr0y9GXtOWRrl3A_5_5">62.84</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw" contextRef="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_G4UyzvxD9UiRqqT-Li8wCA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_9hYrT8X4ZE6Bjn9083lG_g_6_5">12.49</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_zTLSXdLkRkGHupKbJjtfXg_1_2"></a><a id="Tc_k3S94wT7UUeUdevo8ivpiw_1_8"></a><a id="Tc_EqKzi1rzd0OL1Gaj58AaSw_2_0"></a><a id="Tc_GwIA3oTPRk6tHeipoiP51Q_2_2"></a><a id="Tc_H7u46qOF-kCiKVERbv5jvg_2_5"></a><a id="Tc_WT1FQAbRSUGYf2YSi5JnMw_2_8"></a><a id="Tc_SaRbAMjqbECzNMZ9Lo0ufw_2_11"></a><a id="Tc_JT0JWzSFckSIGS2j1a_uHA_3_0"></a><a id="Tc_zODa-sEahU6mXBoGyq_FjQ_3_2"></a><a id="Tc_FaLH6hXBWU2AcAo79mnNqg_3_5"></a><a id="Tc_38ixcZqzGE-J27-QUYDHXA_3_8"></a><a id="Tc_iBX_21WQNUeNkHSC3vd6Kw_3_11"></a><a id="Tc_A_MdP7NlUk2IYvc9xKoW_w_4_0"></a><a id="Tc_BhwjyoSqMkyepVzkF8445w_4_2"></a><a id="Tc_Ki2wssyB6kOEE261HvgnEA_4_5"></a><a id="Tc_U-2KVDkK_EKGO1jFGoiLlQ_4_8"></a><a id="Tc_GjDSjNq7xUq3HR5X4_2hdg_4_11"></a><a id="Tc_7bnBlQmmfk-dCaDyc3A8rw_5_0"></a><a id="Tc_VIeVzT2TvEuhRYfOq3okMg_5_2"></a><a id="Tc_9UuFYggPW0CjA53Ma1zrbA_5_5"></a><a id="Tc_FoSUfbbCWkqDZeMxO3t36w_5_8"></a><a id="Tc_J5wyEvIm4kqNIXB17r_Cow_5_11"></a><a id="Tc_kNlJEyEjxkGhNyceKmCXrQ_6_0"></a><a id="Tc__07QWddEZk2qy7U4DeyH-A_6_2"></a><a id="Tc_COAqz1P_nUSRbD0S7dXyTw_6_5"></a><a id="Tc_FB9lyQXNnEKG_QNzvU_BEw_6_8"></a><a id="Tc_vjr5ZqsFck-fFl_uJ4X29g_6_11"></a><a id="Tc_WNyB5eHS40CNx2I4XMvOCg_7_0"></a><a id="Tc_8Z68RVnCAk-Y-2GHFn_r1w_7_2"></a><a id="Tc_-a38c83fa0qlUIzKZ4Kw-Q_7_5"></a><a id="Tc_k-vGawCz7kmgKGETlPVfkQ_7_8"></a><a id="Tc_xMpRcIuYt0axxAV532ZQQg_7_11"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="plx:RevenueDisclosureTextBlock" id="Tb_tXB_CAklzUqDf54ruIJc4w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">NOTE&#160;4&#160;&#8211; REVENUES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="Tb_gCQZKczj-EWNQaqHKSu4VQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_sVnDgezrHka5Dw8PspQs3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_0A3xcGB9A0moGME3M1EGVw_3_3">2,304</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_tKo7RTZIJ0G9Lb7VY5FW9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_wlxHhHivz0KOeE_VAf6bjg_3_6">4,541</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_nJExY4OnmUmt1WUuJLndIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_eZe8q4cbMUSa2xTQmzWMLg_3_9">7,972</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_iH38GCBvckuT-5RWJRmh4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_yX9rb1lMR0CVck3eX_QQpA_3_12">11,279</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_eB0Q82DpoUe8I_AVASAV5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_yF9zO5dljU29010NJxxj3g_4_3">2,320</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_54yhJyQsfUWr69wXcncDRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_cvKD_JVKg0ORlhb5i5lDHQ_4_6">1,708</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_UWm8Okbu-EqlxDiNTSf2Zg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_myoC_KTvNk2l72U86a2DQw_4_9">5,120</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_nYCRV7igxEO8F_DL0WaJTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_9mFzwE1EOUiqjwQhN8iGXA_4_12">7,162</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_ZO1PgNYXMEuC--7AWaeWEQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_aod4aOXFEUOVY94NYe3c8A_5_3">5,544</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_c26sRwH14EOOXdDcKHSfXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_LFYEjG-J8E6scpBuWz7lUw_5_6">2,563</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_-Z5nFPVF50-Y_QNXqgvqxg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_SmmxSZBX6U2M6o6Pq9yazQ_5_9">17,217</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_UZ9M3vS4pUmQfa--0rmbMg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_AsBJMVUz80qaxcjLwjRCVA_5_12">2,781</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_Lo8_JpbjYUCk7biQuAf2Cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_byrBSPcDdUuuG9_iziMWng_6_3">10,168</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_isIRGT_PckWgKUstJZEmKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_bNfrnuDhLUqjp7woTXweow_6_6">8,812</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_ZRFZeNwM3kOgwL_HZhzgeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_vGpZzAZBKUO8Kst0rTD8kA_6_9">30,309</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_r2IxwFzzbEK8WGh9RQOkuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_5aBgsEtzakGsvsCSY8cDJQ_6_12">21,222</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_3i3mFrnEFE2XxVcL7eIj9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_nrBK5BVeZki4gvMTopoukg_7_3">177</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_FPM1y3Bjl0Gc-RAt1yp0Fw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_YBvGLjAE-0mUzo4Rax8nAA_7_6">5,371</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_1lopoDCmBESgKQUfzzjJoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_GAHH9qIPQkqkoTcyBC1gRA_7_9">24,699</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_403rz0Wpzk6dQXNU5Z2R7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_yzp0jOFASUaV0w2t68NDww_7_12">17,799</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_NBGPSGpc_UOCCkwkuibhqQ" continuedAt="Tb_NBGPSGpc_UOCCkwkuibhqQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; STOCK TRANSACTIONS</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;">Authorized Capital</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">On June&#160;28, 2023, the Company held its 2023 Annual Meeting of Stockholders, which was adjourned and reconvened on July&#160;13, 2023 (the &#8220;Annual Meeting&#8221;). At the Annual Meeting, the Company&#8217;s stockholders, among other matters, approved an amendment to the Company&#8217;s Certificate of Incorporation, as amended, to increase the number of shares of Common Stock authorized for issuance from <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="As_Of_7_24_2023_9kwXDECmXUmLqJV4f95MAw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_cSaJe3XCL0iXDwv4IgloXA">144,000,000</ix:nonFraction> to <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="As_Of_7_25_2023_edYzzPajLkGQMaRQZP-YaA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_hXCHF1w8bUqBua6YXXMbuQ">185,000,000</ix:nonFraction> (the &#8220;Charter Amendment&#8221;). The Charter Amendment was filed with the Secretary of State of the State of Delaware on July&#160;25, 2023.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_NBGPSGpc_UOCCkwkuibhqQ_cont1" continuedAt="Tb_NBGPSGpc_UOCCkwkuibhqQ_cont2"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;">At-the-Market (ATM) Offering</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">During the nine months ended September&#160;30, 2023, the Company sold, in the aggregate, <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_TBP-Nxi6xkSucxKQEfEKFA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_V3z3EWQhHkC-hTfBz71r6w">12,560,150</ix:nonFraction> shares of Common Stock under the 2023 Sales Agreement. The Company generated aggregate gross proceeds equal to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_TBP-Nxi6xkSucxKQEfEKFA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_cXpKDKZwZkyixmGzy330Fw">24.9</ix:nonFraction>&#160;million in connection with such sales. All such sales were completed during the quarters ended March&#160;31, 2023 and June&#160;30, 2023. <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_mfC9kUaxCUWkEdReEq0g8g" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_5jQm3oD3Fk-paHce4yRUcQ">No</ix:nonFraction> sales were completed during the three-months ended September&#160;30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;">(c)</b></span><b style="font-weight:bold;background:#ffffff;">Exercise of Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">On May&#160;8, 2023, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_5_8_2023_To_5_8_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_aZyevVDxgUeUldAkpXak_A" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Narr_CpyWGwzdM0aGySefqBYPqw">301,810</ix:nonFraction> shares of Common Stock in connection with the cash exercise of a warrant issued on March&#160;18, 2020, as part of the Company&#8217;s private placement of Common Stock and warrants. The Company generated net proceeds equal to $<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_5_8_2023_To_5_8_2023_LWrHj6ICi0aqDBWvUoRhNQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="6" id="Narr_-pT0noy5X0mURxa5LrHDbw">0.7</ix:nonFraction>&#160;million from the exercise of the warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">On May&#160;10, 2023, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_5_10_2023_To_5_10_2023_uEkJTuuYLE2tgKefXtN0Mg" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Narr_tus0EOuDYEelJ9uBLorz0Q">237,012</ix:nonFraction> shares of Common Stock in connection with the cashless exercise of a warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="As_Of_5_10_2023_EgRr_kLVqEarxsyOSeb0Ng" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_wZ5BUnLBOkaWmdAAwvYqJQ">845,000</ix:nonFraction> shares of Common Stock issued on March&#160;18, 2020, as part of the Company&#8217;s private placement of Common Stock and warrants. The Company did not generate any proceeds from the cashless exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;"><ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg" decimals="INF" format="ixt-sec:numwordsen" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Narr_2TleHd53xk-AyRKt5x6xQw">No</ix:nonFraction> warrants were exercised during the three months ended September&#160;30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;">(d)</b></span><b style="font-weight:bold;background:#ffffff;">Conversion of 2024 Notes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">During the nine months ended September&#160;30, 2023, the Company issued, in the aggregate, <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_IsSkHrMXCEC808Zd6VbjIQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="Narr_x3Jn4tjUb0Orl3R6m6hhVQ">4,691,623</ix:nonFraction> shares of Common Stock in connection with the conversions of 2024 Notes. In connection with such conversions, during the nine months ended September&#160;30, 2023, the Company paid to the converting holders $<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_IsSkHrMXCEC808Zd6VbjIQ" decimals="-5" format="ixt:numdotdecimal" name="plx:PaymentsToDebtHoldersOnConversion" scale="6" id="Narr_BVPeA3vrp0OfmdJg3At2tw">0.9</ix:nonFraction>&#160;million representing cash payments due to accrued but unpaid interest, make-whole interest payments and payments in lieu of fractional shares. As a result of the conversions, the total principal amount of the 2024 Notes decreased by approximately $<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_IsSkHrMXCEC808Zd6VbjIQ" decimals="-5" format="ixt:numdotdecimal" name="plx:DebtConversionDecreaseInPrincipalAmount" scale="6" id="Narr_ajmio51OUkyv5xJpC5dJDA">8.3</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;"><ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_h7Ke6bk0e0aU5lPXoIrMVA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="Narr_YH0NSp1OqECNNqElwXmxig">No</ix:nonFraction> 2024 Notes were converted during the three months ended September&#160;30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(e)</b></span><b style="font-weight:bold;">Stock based compensation</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On June&#160;28, 2023, at the Annual Meeting, the Company&#8217;s stockholders, among other matters, adopted amendments to the Company&#8217;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#8220;Plan&#8221;) to increase the number of shares of Common Stock available under Plan from </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="As_Of_6_27_2023_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_WfHmnalC9keIkorDt44VZg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_-v-RLvbezEehBIU8VW1MMQ">8,475,171</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="As_Of_6_28_2023_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_VafRBM-KXUKE9nl21SfoWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_olkQbyxRDkqjnYdZwommdw">12,475,171</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares and to amend certain other terms of the Plan.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On August&#160;15, 2023, the Company granted, with the approval of the Company&#8217;s compensation committee, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_8_15_2023_To_8_15_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_fMPAZxDZF0CjT3jIiJlVWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_VDJgeFMmlkuwmzUpyNKC6g">1,371,362</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of restricted Common Stock, in the aggregate, to certain of the Company&#8217;s officers under the Plan. Of such grants, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_8_15_2023_To_8_15_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_IPgkJRT2mUmlR7n5uxuhBQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_6A3XaJ-qU0upF7iJyHmAtQ">200,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of restricted Common Stock vested upon grant, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_8_15_2023_To_8_15_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_yKs6Fnw-ukqovfuD-GaUEw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_H0xkdG2Djk6BTd9I9FECMA">600,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of restricted Common Stock vest over a </span><ix:nonNumeric contextRef="Duration_8_15_2023_To_8_15_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_yKs6Fnw-ukqovfuD-GaUEw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_uhWbUe_S_0GEE5jBJXWUUw"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two-year</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> period in </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_item_dyUGGngOZEG007onwpOmGw" contextRef="Duration_8_15_2023_To_8_15_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_yKs6Fnw-ukqovfuD-GaUEw" decimals="INF" format="ixt-sec:numwordsen" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements" scale="0" id="Narr_tVftvRyu9Umd-LRY2pL8SQ">eight</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;equal quarterly increments and the remaining </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_8_15_2023_To_8_15_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_dHfFwQNMk0elAnvVrjK_Aw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_QSBRnYjnBUKu3vpZX31yLw">571,362</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of restricted Common Stock vest over a </span><ix:nonNumeric contextRef="Duration_8_15_2023_To_8_15_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_dHfFwQNMk0elAnvVrjK_Aw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_HOPWrCxFzEyJBgs1O3cXGQ"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three-year</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> period in </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_item_dyUGGngOZEG007onwpOmGw" contextRef="Duration_8_15_2023_To_8_15_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_dHfFwQNMk0elAnvVrjK_Aw" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements" scale="0" id="Narr_oA7V78vnmUqEhU1pe2OhcQ">12</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;equal quarterly increments. The Company estimated the fair value of the restricted stock on the date of grant to be approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_8_15_2023_To_8_15_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_fMPAZxDZF0CjT3jIiJlVWg" decimals="-5" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant" scale="6" id="Narr_iOI2nOX7y0Sknt536iWChA">2.7</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">On August&#160;15, 2023, the Company granted, with the approval of the Company&#8217;s compensation committee, <ix:nonNumeric contextRef="Duration_8_15_2023_To_8_15_2023_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member__6-TI0LU8kycGOjbjujtRw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_01eOZXisHEWZnRFWzx0U2A">10-year</ix:nonNumeric> options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_8_15_2023_To_8_15_2023_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member__6-TI0LU8kycGOjbjujtRw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_uH504OlqlEyT3sxDs50krQ">1,056,315</ix:nonFraction> shares of Common Stock, in the aggregate, to certain of the Company&#8217;s officers and other employees under the Plan. The options have an exercise price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg" contextRef="Duration_8_15_2023_To_8_15_2023_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member__6-TI0LU8kycGOjbjujtRw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_Lwf959kMNUC3KTsfoAXfZA">1.99</ix:nonFraction> per share and vest over a <ix:nonNumeric contextRef="Duration_8_15_2023_To_8_15_2023_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member__6-TI0LU8kycGOjbjujtRw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_3ap6OD14y02-Q4D1A285Pg">three-year</ix:nonNumeric> period in <ix:nonFraction unitRef="Unit_Standard_item_dyUGGngOZEG007onwpOmGw" contextRef="Duration_8_15_2023_To_8_15_2023_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member__6-TI0LU8kycGOjbjujtRw" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements" scale="0" id="Narr_LhhOjSuXGEmNTWJK4ZLpYg">12</ix:nonFraction>&#160;equal quarterly increments. Vesting of the options granted to executive officers is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the aggregate fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_8_15_2023_To_8_15_2023_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member__6-TI0LU8kycGOjbjujtRw" decimals="-5" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant" scale="6" id="Narr_A7WWa1yR_kKKY75350_TTA">1.5</ix:nonFraction>&#160;million. </p></td></tr></table></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_1wahBza72UygwyJA2_L1jw_1_0"></a><a id="Tc_ufzuTSOsWEuuRldEKS2iDg_2_0"></a><a id="Tc_ajRopAIjW0SOEjxz-ndD9w_3_0"></a><a id="Tc_Dz-JSoRyV0C4e46JFPXiEA_3_3"></a><a id="Tc_n4qlGCWt2E6ENovU0v2M9A_4_0"></a><a id="Tc_QQuQBIFg60m1F8_epBfMAA_4_3"></a><a id="Tc_owmxSpVjMUS2o7s25EcxDg_5_0"></a><a id="Tc_asRoGC2FAUi41OhUmJP-yQ_5_3"></a><a id="Tc_25kwCxqXQ02necMkQ_PYEQ_6_0"></a><ix:continuation id="Tb_NBGPSGpc_UOCCkwkuibhqQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 108pt;">On September&#160;14, 2023, the Company granted, with the approval of the Company&#8217;s compensation committee, <ix:nonNumeric contextRef="Duration_9_14_2023_To_9_14_2023_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_hR8IXrLXFkKqN26E-oWJTg" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_ly_ciIdI9EyELBLzU6zksg">10-year</ix:nonNumeric> options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_9_14_2023_To_9_14_2023_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_hR8IXrLXFkKqN26E-oWJTg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_vQTomEGbK0i02qa0xBMDjA">85,715</ix:nonFraction> shares of Common Stock, in the aggregate, to the new Chairman of the Company&#8217;s Board of Directors under the Plan. The options have an exercise price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg" contextRef="Duration_9_14_2023_To_9_14_2023_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_hR8IXrLXFkKqN26E-oWJTg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_fu-GpIOnokKs5b6dvwhS2w">1.75</ix:nonFraction> per share and vest over a <ix:nonNumeric contextRef="Duration_9_14_2023_To_9_14_2023_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_hR8IXrLXFkKqN26E-oWJTg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_4Cp3GAeXbEGeozmQ69w70A">three-year</ix:nonNumeric> period in <ix:nonFraction unitRef="Unit_Standard_item_dyUGGngOZEG007onwpOmGw" contextRef="Duration_9_14_2023_To_9_14_2023_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_hR8IXrLXFkKqN26E-oWJTg" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements" scale="0" id="Narr_VuABQEWHOkC9u0QPyuBYig">12</ix:nonFraction>&#160;equal quarterly increments. Vesting of the options is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the aggregate fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_9_14_2023_To_9_14_2023_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_hR8IXrLXFkKqN26E-oWJTg" decimals="-5" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant" scale="6" id="Narr_dBFZfW6EfkexMQ0hnjaAbg">0.1</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 108pt;">On September&#160;29, 2023, the Company granted, with the approval of the Company&#8217;s compensation committee, <ix:nonNumeric contextRef="Duration_9_29_2023_To_9_29_2023_srt_TitleOfIndividualAxis_plx_NonExecutiveDirectorsOtherThanChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_Bq1ATcIXikWWLcA2fkgW1Q" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_RyasA4daR0en530R8HrwSA">10-year</ix:nonNumeric> options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_9_29_2023_To_9_29_2023_srt_TitleOfIndividualAxis_plx_NonExecutiveDirectorsOtherThanChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_Bq1ATcIXikWWLcA2fkgW1Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_ohljFngQ6UiVkWJ3ImhuGQ">308,380</ix:nonFraction> shares of Common Stock, in the aggregate, to the non-executive directors of the Company&#8217;s Board of Directors, other than the Chairman, under the Plan. The options have an exercise price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg" contextRef="Duration_9_29_2023_To_9_29_2023_srt_TitleOfIndividualAxis_plx_NonExecutiveDirectorsOtherThanChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_Bq1ATcIXikWWLcA2fkgW1Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_9_Y1_xdwj0SdTRk7RUYuGA">1.66</ix:nonFraction> per share and vest over a <ix:nonNumeric contextRef="Duration_9_29_2023_To_9_29_2023_srt_TitleOfIndividualAxis_plx_NonExecutiveDirectorsOtherThanChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_Bq1ATcIXikWWLcA2fkgW1Q" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_BFjenqRABEKOOOPHf3CQNQ">three-year</ix:nonNumeric> period in <ix:nonFraction unitRef="Unit_Standard_item_dyUGGngOZEG007onwpOmGw" contextRef="Duration_9_29_2023_To_9_29_2023_srt_TitleOfIndividualAxis_plx_NonExecutiveDirectorsOtherThanChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_Bq1ATcIXikWWLcA2fkgW1Q" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements" scale="0" id="Narr_QTzI_Zx83k2Vci6CoHxKfA">12</ix:nonFraction>&#160;equal quarterly increments. Vesting of the options is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the aggregate fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_9_29_2023_To_9_29_2023_srt_TitleOfIndividualAxis_plx_NonExecutiveDirectorsOtherThanChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_Bq1ATcIXikWWLcA2fkgW1Q" decimals="-5" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant" scale="6" id="Narr_PopcxVCJOEWdZGIcQqJMOA">0.4</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 108pt;"><span style="background:#ffffff;">The fair value of each option granted during the three-month period ended September&#160;30, 2023 is estimated at the date of grant using the Black-Scholes option-pricing model. The following weighted average assumptions were applied in determining the fair value of the options described in this Note&#160;5(e)(3) on their respective grant dates:</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_1qUgChpJWkmJaywcyqoDYw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Weighted average grants date fair value (USD)</p></td><td style="vertical-align:bottom;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_F7acgBp0NEaoQj7JasNEtg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_L9UOE5pXlkqbAZens8zAdw_1_2">1.34</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Exercise price (USD)</p></td><td style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg" contextRef="As_Of_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_n9IBOPzcQEm-_TNOT65ZwQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Tc_DlcIQ0gAyUqZZ3cgj8R-3Q_2_2">1.91</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_F7acgBp0NEaoQj7JasNEtg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_Kes3hrwrBEee_x5agdNO8Q_3_2">4.40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_F7acgBp0NEaoQj7JasNEtg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_2NydLLgeA0208YywzRykGg_4_2">79.40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_F7acgBp0NEaoQj7JasNEtg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_Xh-UeIXOSE-9QyW2nkQtyA_5_2">0</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected life (Years)</p></td><td style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_F7acgBp0NEaoQj7JasNEtg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_Ww33gYu8C0a9qQPArzaEpA_6_2"> 5.75</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="us-gaap:EarningsPerShareTextBlock" id="Tb_Gb4nUA7FFkOqDAZ0pkPsMQ" continuedAt="Tb_Gb4nUA7FFkOqDAZ0pkPsMQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; EARNINGS (LOSS) PER SHARE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Basic earnings (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of Common Stock outstanding during each period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Diluted earnings per share is calculated by dividing the net income by the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#8220;if-converted&#8221; method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9d6e618e_db3f_4f9f_bf4b_001e1f565bb3"></a><a id="Tc_otVQHIY5V0aJZHRLxTNPpw_1_3"></a><a id="Tc_XKNA8oCIu0Gg8z7VLQy-xA_1_9"></a><a id="Tc_mT70Sn1vjEib3iItsISyOA_2_0"></a><a id="Tc_ldOtABNZFUS8iWZwIPAi7Q_2_3"></a><a id="Tc_Id3wf4m0cE26pIOoSbSBLQ_2_6"></a><a id="Tc_8pHlRSZCTEeiioAOtZN9Eg_2_9"></a><a id="Tc_54gmYEbTvEeFitNP1VwJAA_2_12"></a><a id="Tc_V117c9oBCkCqPMp_ttznwA_3_0"></a><a id="Tc_OTgwKPs78ku-2FxLwOnfjw_4_0"></a><a id="Tc_RQP3EJuZz0-tvQAZt0CJ2g_4_2"></a><a id="Tc_nYuTjKCfK0-5vhN1HPzYiQ_4_5"></a><a id="Tc_aJs9__7Ti0WMKwF1Fdy8fQ_4_8"></a><a id="Tc_NIkgqCX-iEC6CmLArqkbOw_4_11"></a><a id="Tc_o6z56yIo20iMCEog9zm1Gw_5_0"></a><a id="Tc_4m54FV3rZkytm1h3gP336w_6_0"></a><a id="Tc_2AvE8KNV9UimRf_9bXk2Xw_6_2"></a><a id="Tc_tjVybOSOtUGh9L6xtS8nOw_6_6"></a><a id="Tc_rCghL2QoKU2JCSIaPxkjmQ_6_8"></a><a id="Tc_mvl0YO7XskyPIgNawUDjhg_6_12"></a><a id="Tc_A5VQjaNjD0WFp_2reF_Scw_7_0"></a><a id="Tc_zL3XJe3nt0CVJ0AUW8KR6Q_7_2"></a><a id="Tc_91wAnGPAbE2AbnrRd_PJZw_7_5"></a><a id="Tc_kF1mxpQDL06MkAMq2zJXdQ_7_8"></a><a id="Tc_Sl8oOZfNkEqIEGLHGaD6_w_7_11"></a><a id="Tc_maaDe4UqqUKdPThL4xcGuQ_8_0"></a><a id="Tc_0dZl9Niy-0S8a5sk5dAMyA_9_0"></a><a id="Tc_ETfYLbeRA0S9GxvnTYTa6w_10_0"></a><a id="Tc_0vcZsb-3JESiXys3uVMI6g_10_6"></a><a id="Tc_-AynGaqByUKbCT-tmgzwJA_10_12"></a><a id="Tc_kpmjz-vLG0mUqZPbUc-_mQ_11_0"></a><a id="Tc_YUck1hmRA0yhvUi3sX61HQ_11_3"></a><a id="Tc_-32GSSXPoUeOBahdj9MxsQ_11_6"></a><a id="Tc_zB7d-vEe2UuGzQEC8zXJvg_11_12"></a><a id="Tc_jbdadIs5skKS4T51GtZkhQ_12_0"></a><ix:continuation id="Tb_Gb4nUA7FFkOqDAZ0pkPsMQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Basic and diluted net earnings (loss) per share attributable to common stockholders were calculated as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_lO56xroqA0KP4RLvYbWGeg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:29.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(In&#160;thousands,&#160;except&#160;share&#160;data)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_q9ViZB5T80CftMJMH0SBUA_4_3">1,852</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_izvHNV5vMUuk1JFoiCGgYQ_4_6">3,567</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_ZbsOCAmFR0ewDjDpQZ-R6w_4_9">14,356</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_0jFIzkXizUORZaTWdUWTTw_4_12">11,187</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Add:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financial expenses of 2024 Notes*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DilutiveSecurities" sign="-" scale="3" id="Tc_xvqlqRK4I0uqP0htPPsG7A_6_3">1,766</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DilutiveSecurities" sign="-" scale="3" id="Tc_b1IAf62yDU23p_yCDd16HQ_6_9">1,610</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net income (loss) for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_-HGYh6gqb0KzSbPYiKAL3g_7_3">3,618</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_Pd32DO4k1kGfiiCDlok7KQ_7_6">3,567</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="Tc_JkgILYQrwUWiLyX53-NoxA_7_9">12,746</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_-bR-rl07n0uyAL_k3EDWDg_7_12">11,187</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares of Common Stock outstanding for basic calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_9J_QAB3F6Em8Y2migqHapQ_9_3">72,281,681</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_7uXqG6ogZ0uL-fJEIkyBtA_9_6">49,498,105</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_BFl-FqOWCEmG5PZNlfIhsw_9_9">65,811,506</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_v9NmF0MmmEi70Rz5Rn2uGQ_9_12">47,582,733</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average dilutive effect of 2024 Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="0" id="Tc_JxE4BShAhkaBMCPwldlEBQ_10_3">11,500,998</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="0" id="Tc_LY9PwIsDKkWqjDq3xhXZRw_10_9">13,981,660</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average dilutive effect of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="Tc_2NcZYlB3SkiOAej-hvgtCw_11_9">1,247,115</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares of Common Stock outstanding for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_F_gr67VSVE2udycTl4uALQ_12_3">83,782,679</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_KWfFtnhRDU2irafuq_X_TQ_12_6">49,498,105</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_LRBkAwPl40enZLrLwkVJeQ_12_9">81,040,281</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_txr5qlmml0OSJ1RMP4HQ1A_12_12">47,582,733</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 10pt 54pt;">* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the period and inclusion of make-whole interest payments that will be incurred upon conversion.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Diluted earnings (loss) per share do not include <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_7EmATnfMK0aTY5iMdjV79w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_6fPkzvvsdUqFqU1vSHmWvg">19,429,910</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_3o-LEw18Kkyl1N3FcZEEcQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_U85CfE2We0uFXV-6_27SVg">18,399,260</ix:nonFraction> shares of Common Stock underlying outstanding stock options and warrants of the Company for the three and nine months ended September&#160;30, 2023, respectively, because the effect would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Diluted earnings (loss) per share do not include <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_c1_YEps6pEOYi4wGlehl0Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_QRcvyvcEiE6Q4fQwuL9eVw">33,922,624</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_gylvzioUakSqiKwd3I9tug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_Fz1OD9jbFEyqYgUtCqbW3Q">33,295,154</ix:nonFraction> shares of Common Stock underlying outstanding stock options, warrants and the 2024 Notes for the three and nine months ended September&#160;30, 2022, respectively, because the effect would be anti-dilutive.</p></ix:continuation><a id="Tc_5dYUGDwFU0eTzX0XQtH5nw_1_2"></a><a id="Tc_tALE8py4R0yz7hiWZgIU_w_1_5"></a><a id="Tc_2sVWV80xfUmaM1DnfeWivg_2_0"></a><a id="Tc_b2iB4aC0CkeS4GHPbM1Pxw_2_2"></a><a id="Tc_ycXJBS0pqkSsJ4yLupIkng_2_5"></a><a id="Tc_pkr18aEgTUuLliz4_CdAJw_3_0"></a><a id="Tc_i6h_wes4xUCpuPd23iswnw_3_2"></a><a id="Tc__DcGMuIHGkOkUUEiN-qCrw_3_5"></a><a id="Tc_cUlL0jOtwEqWxdO5WRcCjw_4_0"></a><a id="Tc_KvEHxMOgqkeT2Lxu41Rphw_5_0"></a><a id="Tc_5MVgZyGvTE6Ef_M1Nm4VFw_5_2"></a><a id="Tc_jLlwNks1VE2COVWhoku1zg_5_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_m8_Mfv_erUaiHI4p2moL1Q" continuedAt="Tb_m8_Mfv_erUaiHI4p2moL1Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 7 &#8211; TAXES ON INCOME</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s taxes on income:</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_DMTK64XJjU6I1WvGvCXtMA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_F0x2LiEvH0ydmUCUsH9yiw_3_3">95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_8HyMpj0XuEK45nPhfsyaZw_3_6">3,728</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="Tc_dKQvw0c-YkeYCmAgmME8JA_4_3">38</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_MMfJi-GKOESaij2Bdq7PVw_4_6">3,092</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_DrJQmC76DUKmrFhh4a8mzQ_5_3">133</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_8xqaOvlHBEizwW1a7psdbg_5_6">636</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company had an effective tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_miufEYLb7E2Gjp_juFgMTw">4</ix:nonFraction>% for the nine months ended September&#160;30, 2023, compared to an effective tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw" contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_USexgcvYlUeVC6R_b2Zx2w">0</ix:nonFraction>% for the nine months ended September&#160;30, 2022. For the nine months ended September&#160;30, 2023, the difference between the Company&#8217;s effective tax rate and the U.S.&#160;federal statutory rate of <ix:nonFraction unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw" contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_F4QXr__5oUSD694JJo303Q">21</ix:nonFraction>% was the result of the provision for current taxes on income mainly derived from U.S. taxable GILTI income mainly in respect of milestone payments and Section&#160;174 of the U.S.&#160;Tax Cuts and Jobs Act, which was enacted in December 2017 (the &#8220;TCJA&#8221;), partially offset by the release of the valuation allowance on net operating losses (NOLs) in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Following the regulatory approvals for Elfabrio in May 2023, the receipt of the $<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_5_31_2023_Qhp5my5CU0-pA3CT50IRVw" decimals="-5" format="ixt:numdotdecimal" name="plx:MilestonePaymentToRegulatoryApprovals" scale="6" id="Narr_iDyUBQPXXkmqBrD1KITbMw">20.0</ix:nonFraction>&#160;million milestone payment and the launch of Elfabrio in the United States, the Company released valuation allowance previously recorded on deferred tax assets in respect of its NOLs in the United States resulting in a net tax benefit of $<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="Narr_LNO4RHzIeUq7vOUcy9wF2A">3.1</ix:nonFraction>&#160;million. The Company concluded that, based upon the preponderance of positive evidence over negative evidence and the anticipated ability to use the deferred tax assets, it was more likely than not that these deferred tax assets would be realizable due to forecasted profits. The Company considered the following: (i)&#160;cumulative profits for tax over the previous 12 quarters in its U.S. operations; (ii)&#160;the impact of </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_m8_Mfv_erUaiHI4p2moL1Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Section&#160;174 of the TCJA which requires the Company to capitalize and amortize its research and development expenses over 15 years; and (iii) its forecasted profits in the United States following the regulatory approvals of Elfabrio.</p></ix:continuation><a id="Tc_1MRP2yN-hU-B1CycFkOYvw_1_2"></a><a id="Tc_0uljdfYT-EW7ef_l5Y_FIQ_1_5"></a><a id="Tc_-TCRZiU66kK17suxyEHzwA_2_0"></a><a id="Tc_1-FMDnSpKU6h_Scj7YiP7w_2_2"></a><a id="Tc_xIYEXCMoRk-nNrafLrEWgg_2_5"></a><a id="Tc_U3zIGFCk8U-1XoHulJgLcw_3_0"></a><a id="Tc__6vLDfVHOkm7wDBP7bjqCQ_4_0"></a><a id="Tc_6m1lTZcicEazPYbqWkRuMQ_4_2"></a><a id="Tc_tSspwRUXI06xLZ7x4b32HA_4_5"></a><a id="Tc_caIldkK2r0yXC50lbHNspw_5_0"></a><a id="Tc_nvfviGx-PkCQg5MmhLNLfg_6_0"></a><a id="Tc_UNd6JqrjnEWtN-QEIR0x9w_7_0"></a><a id="Tc_XNAM4l13fUSy4POpl8eJYA_8_0"></a><a id="Tc_LscPYsVdGkCH0G6KIOS3ZQ_9_0"></a><a id="Tc_h0FaRD_lTEO6jl5GZMR2pg_10_0"></a><a id="Tc_g9BWKIqhskiXamLUN985Dw_10_6"></a><a id="Tc_GQfqIuU_2E2Tk9GVkn3Mmw_11_0"></a><a id="Tc_25LLRCJ-iU2FldoUhFaSuw_12_2"></a><a id="Tc_F325Lmc4FE2x9CY5r44uyg_12_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="Tb_h0OZ6P5AF0qSzt2GBfeKWw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 8 &#8211; </b><b style="font-weight:bold;background:#ffffff;">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">Balance sheets:</b></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="plx:SupplementaryBalanceSheetsInformationTableTextBlock" id="Tb_0DIj7WFHHUyrSY7QQzfdTQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_vm6jQw2Tc0mELJz7dMGJQw_4_3">1,239</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_5KnRVTwEsUmgILN-XEk2fA_4_6">1,216</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest Payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="3" id="Tc_Zf7vD-bRqUKEDDBXxuGkJQ_5_3">123</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="3" id="Tc_kOmreecsTkev10Mdpz29wQ_5_6">719</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedVacationCurrent" scale="3" id="Tc_oyGkpDZhUUmJonry3mhegQ_6_3">1,471</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedVacationCurrent" scale="3" id="Tc_-dKofppgSkCcjUWVPpPwIQ_6_6">1,404</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_SKNi1zQ2hU6fAWb5BR9g2w_7_3">9,249</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_r0RFVHZcgUKqo-Z7XRW5cQ_7_6">7,478</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="Tc_mAU9MyrxAUWI6AdFXMS_qw_8_3">332</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="Tc_vt41thqyPk2HEytHaw1vMg_8_6">781</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="Tc_RWERPmXhTkGStmK0susRcw_9_3">3,257</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="Tc_k7FNdnM6I0WSUi2ZfShdTA_9_6">530</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reserve for deductions from revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ReserveForDeductionsFromRevenueCurrent" scale="3" id="Tc_tPsJp1hSVkePldqPxmg0Og_10_3">2,816</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent" scale="3" id="Tc_BVqnVllCW0eXxM6Gvf9oKA_11_3">253</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent" scale="3" id="Tc_cQb5TGiFLkatqnPoqtooPA_11_6">143</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_zITyN_3P-UW3eXbV8VJFLg_12_3">18,740</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_GycKLvvrSUCmKcjQxeBGHg_12_6">12,271</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug" name="us-gaap:SubsequentEventsTextBlock" id="Tb_cll6vfPrGUibToooafizcg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 9 &#8211; SUBSEQUENT EVENTS</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">On October&#160;4, 2023 the Company collected approximately $<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_10_4_2023_To_10_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_4Sfq-5ZsukC6Bl13MlMlcw" decimals="-5" format="ixt:numdotdecimal" name="plx:ProceedsFromSaleOfProducts" scale="6" id="Narr_Irsi69UX_ECKTts5OXJedw">6.4</ix:nonFraction>&#160;million from sales to Chiesi<span style="background:#ffffff;">.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">On October&#160;15, 2023, the Company granted, with the approval of the Company&#8217;s compensation committee, <ix:nonNumeric contextRef="Duration_10_15_2023_To_10_15_2023_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_8Dni7RhDUkWYV5S6kg5TFg" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_GFpf3Pl4dkqTCy1DhGrrcg">10-year</ix:nonNumeric> options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg" contextRef="Duration_10_15_2023_To_10_15_2023_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_8Dni7RhDUkWYV5S6kg5TFg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_Rtqm2hUnRk-hnA01NLlWMA">250,000</ix:nonFraction> shares of Common Stock to a new officer of the Company under the Plan. The options have an exercise price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg" contextRef="Duration_10_15_2023_To_10_15_2023_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_8Dni7RhDUkWYV5S6kg5TFg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_spC05Pmfl0ODXHG0DGyJgw">1.48</ix:nonFraction> per share and vest over a <ix:nonNumeric contextRef="Duration_10_15_2023_To_10_15_2023_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_8Dni7RhDUkWYV5S6kg5TFg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_7sm6n3l5LkCmiUUJzZMjSQ">three-year</ix:nonNumeric> period in <ix:nonFraction unitRef="Unit_Standard_item_dyUGGngOZEG007onwpOmGw" contextRef="Duration_10_15_2023_To_10_15_2023_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_8Dni7RhDUkWYV5S6kg5TFg" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements" scale="0" id="Narr_tWWz6j_Y1EqSqTU51IhRFw">12</ix:nonFraction>&#160;equal quarterly increments. The Company estimated the aggregate fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw" contextRef="Duration_10_15_2023_To_10_15_2023_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_8Dni7RhDUkWYV5S6kg5TFg" decimals="-4" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOnDateOfGrant" scale="6" id="Narr_1mAj0T8rBE2cNOxFT_xt6w">0.26</ix:nonFraction>&#160;million.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">3)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Because the Company&#39;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;In October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets while simultaneously launching extensive rocket attacks on the Israeli population and industrial centers. At the same time, clashes between Israel and Hezbollah in Lebanon have increased. In response, Israel&#8217;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#8217;s defensive measures, may result in a greater regional conflict. It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on our business, operations and financial conditions. The ongoing conflict is rapidly evolving and developing, and could disrupt certain of our business and operations, among others.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_05682c41_000b_4b7c_88cc_a6c452f1508a"></a><a id="Item2ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">AND RISK FACTORS SUMMARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the consolidated financial statements and the related notes included elsewhere in this Form</i>&#160;<i style="font-style:italic;">10-Q and in our Annual Report on Form</i>&#160;<i style="font-style:italic;">10-K for the year ended December</i>&#160;<i style="font-style:italic;">31, 2022. Some of the information contained in this discussion and analysis, particularly with respect to our plans and strategy for our business and related financing, includes forward-looking statements within the meanings of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including statements regarding expectations, beliefs, intentions or strategies for the future. When used in this report, the terms &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and words or phrases of similar import, as they relate to our company or our management, are intended to identify forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance, and we undertake no obligation to update or revise, nor do we have a policy of updating or revising, any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as may be required under applicable law. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements as a result of several factors </i><i style="font-style:italic;background:#ffffff;">including those set forth under &#8220;Risk Factors&#8221; in our Quarterly Report on Form</i><span style="background:#ffffff;">&#160;</span><i style="font-style:italic;background:#ffffff;">10-Q for the quarter ended June</i><span style="background:#ffffff;">&#160;</span><i style="font-style:italic;background:#ffffff;">30, 2023 and in this Quarterly Report on Form</i><span style="background:#ffffff;">&#160;</span><i style="font-style:italic;background:#ffffff;">10-Q</i><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Examples of the risks and uncertainties include, but are not limited to, the following:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the commercialization of Elfabrio, our approved product for the treatment of adult patients with Fabry disease;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to Elfabrio&#8217;s market acceptance, competition, reimbursement and regulatory actions, including as a result of the boxed warning contained in the FDA approval received for the product;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to our commercialization partner&#8217;s ability to obtain and maintain reimbursement for Elfabrio, and the extent to which patient assistance programs and co-pay programs are utilized;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the possible disruption of our operations due to the war declared by Israel&#8217;s security cabinet against the Hamas terrorist organization located in the Gaza Strip, the military campaign against the Hezbollah and other terrorist activities and armed conflict, including as a result of the disruption of the operations of certain regulatory authorities and of certain of our suppliers, collaborative partners, licensees, clinical trial sites, distributors and customers; </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the likelihood that the FDA, EMA or other applicable health regulatory authorities will approve an alternative dosing regimen for Elfabrio;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the regulatory approval and commercial success of our other product and product candidates, if approved;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability to satisfactorily demonstrate non-inferiority to approved therapies; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; inability to monitor patients adequately during or after treatment; and/or lack of sufficient funding to finance our clinical trials;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>delays in the approval or potential rejection of any applications we file with the FDA, EMA or other health regulatory authorities for our other product candidates, and other risks relating to the review process;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks associated with the novel coronavirus disease, or COVID-19, outbreak and variants, which may adversely impact our business, preclinical studies and clinical trials;</div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks associated with global conditions and developments such as supply chain challenges, the inflationary environment and tight labor market, and instability in the banking industry, which may adversely impact our business, operations and ability to raise additional financing if and as required and on terms acceptable to us;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to any transactions we may effect in the public or private equity markets to raise capital to finance future research and development activities, general and administrative expenses and working capital;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our evaluation and pursuit of strategic partnerships;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that the results of our clinical trials will not support the applicable claims of safety or efficacy and that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our ability to manage our relationship with our collaborators, distributors or partners, including, but not limited to, Pfizer and Chiesi;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the amount and sufficiency of our cash and cash equivalents;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our ability to make scheduled payments of the principal of, to pay interest on or to refinance our outstanding notes or any other indebtedness;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to changes to interim, topline or preliminary data from clinical trials that we announce or publish;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to the compliance by Fiocruz with its purchase obligations under our supply and technology transfer agreement, which may have a material adverse effect on us and may also result in the termination of such agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risk of significant lawsuits, including stockholder litigation, which is common in the life sciences sector;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>our dependence on performance by third-party providers of services and supplies, including without limitation, clinical trial services;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the inherent risks and uncertainties in developing drug platforms and products of the type we are developing;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the impact of development of competing therapies and/or technologies by other companies;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to our supply of drug products to Pfizer;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>potential product liability risks, and risks of securing adequate levels of related insurance coverage;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the possibility of infringing a third-party&#8217;s patents or other intellectual property rights and the uncertainty of obtaining patents covering our products and processes and successfully enforcing our intellectual property rights against third-parties; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Given these uncertainties, you should not place undue reliance on these forward-looking statements. Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results or preliminary findings for such clinical trials. Even if favorable testing data is generated from clinical trials of a drug product, the FDA or foreign regulatory authorities may not accept or approve a marketing application filed by a pharmaceutical or biotechnology company for the drug product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Recent Company Developments</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.3pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On August&#160;15, 2023, Chiesi announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) had granted marketing authorization for Elfabrio in Great Britain for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease.</div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:229.64pt;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.3pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On September&#160;11, 2023, Swissmedic, the national authorization and supervisory authority for drugs and medical products in Switzerland, announced the approval of Elfabrio in Switzerland for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 4.3pt 0pt 0pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On September&#160;12, 2023, we announced the appointment of Eliot Richard Forster, Ph.D. as Chairman of our Board of Directors effective as of September&#160;14, 2023. Zeev Bronfeld, the former Chairman of Protalix&#8217;s Board retired from our company for personal reasons, effective as of the same date.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">ProCellEx: Our Proprietary Protein Expression System</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">ProCellEx is our proprietary platform used to produce and manufacture recombinant proteins through plant cell-based expressions in suspension. ProCellEx consists of a comprehensive set of proprietary technologies and capabilities, including the use of advanced genetic engineering and plant cell culture technology, enabling us to produce complex, proprietary, and biologically equivalent proteins for a variety of human diseases. Our protein expression system facilitates the creation and selection of high-expressing, genetically-stable cell lines capable of expressing recombinant proteins.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our ProCellEx technology allows for many unique advantages, including: biologic optimization; an ability to handle complex protein expressions; flexible manufacturing with improvements through efficiencies, enhancements and/or rapid horizontal scale-ups; a simplified production process; elimination of the risk of viral contaminations from mammalian components; and intellectual property advantages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression, and with the recent approval of Elfabrio, we now have two FDA approved proteins produced through our platform. Our ProCellEx platform uses flexible polyethylene disposable bioreactors and is optimized for plant cell cultures. As opposed to the large stainless-steel bioreactors commonly used for recombinant protein production, our ProCellEx bioreactors are easy to use and maintain and allow for the major advantage of rapid horizontal scale-up.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Plant Cell Production Advantages</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-size:12pt;"><img src="plx-20230930x10q005.jpg" alt="Graphic" style="display:inline-block;height:229.64pt;width:540pt;" /></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:226.51pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">ProCellEx</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><b style="font-weight:bold;">: Protalix&#8217;s Differentiated Plant Cell Protein Expression Platform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="plx-20230930x10q006.jpg" alt="Graphic" style="display:inline-block;height:226.46pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:540pt;" /></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Products and Product Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="plx-20230930x10q007.jpg" alt="Graphic" style="display:inline-block;height:170.54pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:540pt;" /></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Elfabrio (PRX-102) for the Treatment of Fabry Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On May&#160;5, 2023, the EC announced that it had approved the MAA for Elfabrio and on May&#160;9, 2023, the FDA announced that it had approved the BLA for Elfabrio, each for adult patients with Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. The EMA approval followed the February 2023 adoption of a positive opinion and recommendation of marketing authorization for Elfabrio by the CHMP. Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with ERT class labeling, and Warnings/Precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The Warnings/Precautions for MPGN alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In August and September of 2023, Elfabrio was approved in Great Britain and Switzerland, respectively, for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elfabrio, an ERT, is our proprietary, plant cell culture expressed enzyme, and a chemically modified stabilized<span style="letter-spacing:-0.15pt;"> version of, the recombinant &#945;-Galactosidase-A protein, a </span>lysosomal enzyme<span style="letter-spacing:-0.15pt;">. </span>Fabry disease is a serious life-threatening rare genetic disorder. Fabry patients lack or have low levels of &#945;-galactosidase-A resulting in the progressive accumulation of abnormal deposits of a fatty substance called globotriaosylceramide, or Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>, in blood vessel walls throughout their body. The ultimate consequences of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> deposition range from episodes of pain and impaired peripheral sensation to end-organ failure, particularly of the kidneys, but also of the heart and the cerebrovascular system. Fabry disease occurs in one person per 40,000 to 60,000 males.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The global market for Fabry disease, that includes Sanofi&#8217;s Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, Shire&#8217;s (acquired by Takeda Pharmaceutical Company Limited) Replagal<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, and Amicus Therapeutics&#8217; Galafold<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, among others, was approximately $2.0&#160;billion in 2022, is forecasted to be approximately $2.0&#160;billion in 2023 and is forecasted to grow at a CAGR of approximately 10% from 2022-2029.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">In preclinical studies, PRX-102 showed significantly longer half-life due to higher enzyme stability, enhanced activity in Fabry disease affected organs leading to reduction of the accumulated substrate and reduced immunogenicity, which together can potentially lead to improved efficacy through increased substrate clearance and significantly lower formation of anti-drug antibodies, or ADAs. In 2015, we completed a phase&#160;I/II clinical trial of PRX-102 (NCT01678898), which was a worldwide, multi-center, open-label, dose ranging study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and efficacy parameters of PRX-102 in adult patients with Fabry disease. Our phase&#160;III clinical program, which has now been completed, included the following three separate studies:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 36pt;">The <i style="font-style:italic;">BALANCE</i> study (PB-102-F20, NCT02795676), a pivotal 24-month, randomized, double blind, active control study of PRX-102 in adult Fabry patients with deteriorating renal function that was designed to evaluate the safety and efficacy of 1&#160;mg/kg of PRX-102 administered every two weeks compared to agalsidase beta; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 36pt;">The <i style="font-style:italic;">BRIDGE</i> study (PB-102-F30, NCT03018730), a 12-month open-label, single arm switch-over study evaluating the safety and efficacy of PRX-102, 1&#160;mg/kg infused every two weeks, in up to 22 Fabry patients previously treated with agalsidase alfa for at least two years and on a stable dose for at least six months; and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 36pt;">The <i style="font-style:italic;">BRIGHT</i> study (PB-102-F50, NCT03180840), a multicenter, multinational open-label, switch-over study designed to evaluate the safety, efficacy and pharmacokinetics of treatment with 2&#160;mg/kg of PRX-102 administered every four weeks for 52 weeks (a total of 14&#160;infusions). The 2&#160;mg/kg every four weeks dosage was not approved by the EMA, FDA or any other jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">Patients who completed the <i style="font-style:italic;">BALANCE</i>, <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies, and the extension of the phase&#160;I/II study, were offered the opportunity to continue PRX-102 treatment in one of two long-term open-label extension studies. Overall, 126 subjects who participated in our PRX-102 clinical program initially opted, with the advice of the treating physician, to enroll in one of our long-term, open label, extension studies of PRX-102: 97 patients in the 1&#160;mg/kg every two weeks extension study (PB-102-F60, NCT03566017) (10 subjects who completed an extension study from the phase I/II study, 18 subjects who completed the <i style="font-style:italic;">BRIDGE</i> study, 69 subjects who completed the <i style="font-style:italic;">BALANCE</i> study); and 29 subjects who completed the <i style="font-style:italic;">BRIGHT</i> study in the 2&#160;mg/kg every four weeks extension study (PB-102-F51, NCT03614234). Two of the subjects in the PB-102-F51 study are being treated with 1&#160;mg/kg every two weeks. As of March&#160;1, 2023, sponsorship of the two extension studies was transferred to Chiesi, and Chiesi is now administering the open-label extension studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">Over time, and as Elfabrio is approved for marketing in different jurisdictions, participants withdraw from the open-label extension studies. Some of the withdrawals<span style="text-decoration-line:line-through;text-decoration-style:solid;"> </span>transfer to a commercial setting, others withdraw for other reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">A BLA for Elfabrio for the treatment of adult patients with Fabry disease was first submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, but resulted in a CRL. The BLA was resubmitted to the FDA on November&#160;9, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">The MAA was submitted to the EMA on February&#160;7, 2022, after the October&#160;8, 2021 meeting we held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The FDA publicly released the internal review documents for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161. These documents provide previously unavailable additional information regarding the basis for the FDA&#8217;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study (Study PB-102-F01/02) with confirmatory evidence provided by the <i style="font-style:italic;">BALANCE</i> study (also referred to as Study PB-102-F20). The FDA review team also concluded that the <i style="font-style:italic;">BALANCE</i> study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks (two years). </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">However, the FDA also determined that the results from the <i style="font-style:italic;">BALANCE</i> study did not support a non-inferiority claim to the comparator product due to the lack of data to support a non-inferiority margin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In February 2020, we, together with Chiesi, announced an agreement with the FDA for the Initial Pediatric Study Plan (iPSP) for PRX-102, which is intended to be initiated post-marketing approval. The joint announcement was made after completion of discussions with the FDA and receipt of confirmation from the FDA in an official &#8220;Agreement Letter&#8221; which outlines an agreed-upon approach to evaluate the safety and efficacy of PRX-102 in pediatric Fabry patients in a clinical trial to be performed by Chiesi with our collaborative efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Chiesi, together with Protalix, participated in an Oral Explanation at a meeting of the EMA&#8217;s Committee for Orphan Medicinal Products (COMP) held on March&#160;21, 2023, as part of the Orphan Drug Designation maintenance process. Following the meeting, Chiesi formally withdrew the application for Orphan Drug Designation for PRX-102. The EC first granted Orphan Drug Designation for <span style="font-family:'Times-Roman';">PRX-102</span> for the treatment of Fabry disease in December 2017.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase III BALANCE Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Clinical Study Report for the <i style="font-style:italic;">BALANCE</i> study was completed in July 2022. The final analysis confirmed the positive topline results (announced in April 2022) and favorable tolerability profile. A total of 78 patients who were previously treated with agalsidase beta for at least one year with an eGFR slope at screening worse than -2&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year were enrolled in the study. Patients were randomized on a 2:1 ratio for switching to PRX-102 or continuing on agalsidase beta. A total of 77 patients were treated; 52 with PRX-102 and 25 with agalsidase beta. Approximately 40% of the enrolled patients were female.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The primary endpoint of the <i style="font-style:italic;">BALANCE</i> study is the comparison in the annualized rate of decline of eGFR slope between the agalsidase beta and PRX-102 treatment arms. eGFR is considered a reliable and accepted test to measure kidney function and stage of kidney disease. Additional parameters evaluated include: cardiac assessment, lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> (a biomarker for monitoring Fabry patients during therapy), pain, quality of life, immunogenicity, Fabry Clinical Events, pharmacokinetics and other parameters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">Based on the original primary analysis (random intercept random slope (RIRS)), the estimated mean eGFR slopes were                        -2.4&#160;mL/min/1.73 m</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> /year and -2.3 mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> /year in the PRX-102 and agalsidase beta arms, respectively, and the treatment difference was -0.1 (95% CI: -2.2, 2.1) mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> /year. Based on the ANCOVA adjusted for continuous baseline proteinuria, the estimated mean eGFR slopes were -2.0 and -3.1 mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> /year in the PRX-102 and agalsidase beta arms, respectively, and the treatment difference was 1.1 (95% CI: -0.8, 3.1) mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> /year. Based on quantile regression model, the median of the eGFR slope in the PRX-102 arm was -2.514&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year (95% CI:-3.788, -1.240) and -2.155&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year (95% CI:-3.805, -0.505) in the agalsidase beta arm, demonstrating a large overlap in the confidence intervals of the two arms. The difference in medians (95% confidence interval) is -0.359&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year (-2.444, 1.726). Additional sensitivity and supportive analyses investigated mean eGFR slopes using other statistical models. These models yielded results similar to the primary analysis and confirming the comparability between the treatment arms. These results supported the robustness of the methodology used for comparisons of treatment effects in the <i style="font-style:italic;">BALANCE</i> study.<span style="white-space:pre-wrap;"> The results of the analyses on eGFR slopes were further supported by the analysis of change from baseline in the average eGFR at the last two visits (100 and 104 weeks). The estimated mean changes were     -3.0 and -3.8 mL/min/1.73 m</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> in the PRX102 and agalsidase beta arms, respectively. The difference in mean change (PRX-102 &#8211; agalsidase beta) was 0.8 (95% CI: -3.0, 4.6) mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> or annualized change of 0.4 (95% CI: -1.5, 2.3) mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The study population (ITT analysis set) was composed of 47 males (61.0%) and 30 females (39.0%), with a mean (range) age of 44.3 (18-60) years. The mean duration of prior treatment with agalsidase beta was approximately six years. At baseline, mean (SD) eGFR was 73.69&#160;ml/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> (20.32) and median eGFR was 74.51&#160;ml/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>; mean (SD) eGFR slope was -8.10&#160;mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year (5.92) and median eGFR slope was -7.25&#160;ml/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A comparable efficacy response was also observed across biomarkers and functional systems relevant to Fabry disease, as demonstrated via secondary endpoints, where in some cases the trend was in favor of PRX-102 and in some in favor of agalsidase beta, but the actual difference between the two arms is always clinically small, supporting the comparability of the two treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Key secondary endpoints included Urine protein creatinine ratio (UPCR) as indicator of proteinuria, plasma levels of lyso&#8211;Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>, imaging marker of cardiac remodeling (Left Ventricular Mass Index, LVMI, by cardiac MRI), disease severity (by Mainz Severity Score Index, MSSI), pain severity (Short Form Brief Pain Inventory, BPI) and quality of life (EQ-5D-5L). Both treatments showed either a stabilization of clinical parameters (e.g., for eGFR, eGFR slope and UPCR) or prevention of further progression of Fabry disease (e.g., LVMI, MSSI).</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><i style="font-style:italic;">Secondary measures of kidney function</i>. In addition to eGFR levels and slope, the proportion of patients categorized as having severe proteinuria (UPCR &#8805; 1 gr/gr) in the PRX-102 arm remained stable during the study (at baseline, 7/52 [13.5%] and </div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;">6/45 [13.3%] 24-month), while in the agalsidase beta arm, the proportion increased slightly with 3/25 (12.0%) and 4/24 (16.7%), respectively. Mean (SE) UPCR data (post-hoc analysis) for the entire study population remained stable throughout the study with a slight advantage for PRX-102 at 24-months compared to agalsidase beta (Table&#160;1).</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><i style="font-style:italic;">Biomarkers of Fabry disease</i>. Mean (SE) and median (range) plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> change from baseline to 24 months of treatment in the PRX-102 arm were 3.30 (1.38) and 1.15 (-32.2 to 32.7) nM for PRX-102, and -8.74 (4.85) and -1.50 (-102.3 to 2.4)&#160;nM for agalsidase beta. As expected, a gender difference was noted, with female Fabry patients exhibiting lower values at baseline and no remarkable changes during the study. Overall, the absolute changes of the Fabry biomarkers were minor in both treatment arms and were considered not clinically significant since there was no indication of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> re-accumulation nor of disease progression.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><i style="font-style:italic;">Measures of cardiac disease</i>. LVMi was centrally evaluated based on cardiac MRI. An increase in LVMi is indicative of progressing cardiomyopathy, hence preventing an increase in LVMI represents a therapeutic goal in Fabry patients. In the <i style="font-style:italic;">BALANCE </i>study, the change from baseline in both treatment arms was analyzed by absence/presence of hypertrophy at baseline (defined as a LVMI above 91&#160;g/m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> for males and LVMI above 77&#160;g/m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> for females at baseline) and by gender (Kawel-Boehm 2015). Similar results were achieved in the two treatment arms after 24 months, with a slight reduction in the mean (SE) LVMi values in the PRX-102 arm -4.238 (5.731) and a small increase in the agalsidase beta arm 2.417 (9.620) for patients with hypertrophy at baseline. Small differences were observed also in those patients without hypertrophy at baseline in both treatment arms.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><i style="font-style:italic;">Measures of systemic disease burden (MSSI)</i>. Further evidence of the stabilization of the disease is provided by the MSSI overall scores, which remained stable throughout the <i style="font-style:italic;">BALANCE</i> study in both arms, with the baseline score in both groups at the low end of the moderate range (means of 23.18&#160;points in the PRX-102 arm and 25.16&#160;points in the agalsidase beta arm), that slightly decreased (improvement by -2.1&#160;points) in the PRX-102 arm and slightly increased in the agalsidase beta arm (+2.0&#160;points). In this case, the CI of the difference in mean changes did not contain 0, suggesting a difference between the two arms in favor of PRX-102.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><i style="font-style:italic;">Patient reported outcomes</i>. With regards to the patient-reported outcomes (BPI and EQ-5D-5L), the two treatments showed very similar results, with the majority of patients reporting an improvement or no change in both groups, for each domain.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">For an overview of primary and secondary endpoints collected in the <i style="font-style:italic;">BALANCE</i> study, please refer to the Table&#160;1 below.</p><a id="_Ref124326188"></a><a id="_Toc124351688"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Table&#160;</b><b style="font-weight:bold;">1</b><b style="font-weight:bold;">: Summary Table of Comparison of Treatment Benefit Data in the </b><span style="font-style:italic;font-weight:bold;">BALANCE</span><b style="font-weight:bold;"> Study, (Mean (SE) [median]), Efficacy Population</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:89.86%;"><tr style="height:11.95pt;"><td style="vertical-align:top;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Parameter</b></p></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:25.02%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PRX-102 (N = 52)</b></p></td><td colspan="2" style="vertical-align:top;width:25.94%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Agalsidase beta (N = 25)</b></p></td></tr><tr style="height:13.7pt;"><td rowspan="4" style="vertical-align:top;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">eGFR </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(ml/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>)</p></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">n</b></p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">n</b></p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Baseline</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">52</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">73.46 (2.80) [73.45]</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">25</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">74.16 (4.19) [74.85]</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Month 24</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">47</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">70.53 (3.19) [69.35]</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">24</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">72.05 (4.69) [74.48]</p></td></tr><tr style="height:11.95pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change from Baseline </p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">47</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-3.60 (1.58) [-2.39]</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">24</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-1.97 (1.51) [-3.20]</p></td></tr><tr style="height:1pt;"><td rowspan="2" style="vertical-align:top;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">eGFR slope (ml/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/yr)</p></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Baseline</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">52</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-8.03 (0.92) [-6.70]<br />Range: -30.5; 6.3</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">25</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-8.25 (0.85) [-7.84]<br />Range: -20.3; -2.8</p></td></tr><tr style="height:1pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Month 24</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">51</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-2.38 (1.25) [-2.51] <br />Q1; Q3: -4.8; 0.8</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">25</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-2.31 (0.71) [-2.16]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Q1; Q3: -4.6; -0.5</p></td></tr><tr style="height:25.35pt;"><td style="vertical-align:top;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reaching kidney therapeutic goal<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">a</sup></p></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Month 24</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">52</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">41 patients (80.4%)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">25</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">20 patients (80.0%)</p></td></tr><tr style="height:14.4pt;"><td rowspan="3" style="vertical-align:top;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">UPCR</p></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Baseline</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">52</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.441 (0.084)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">25</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.284 (0.097)</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Month 24</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">45</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.480 (0.118)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">24</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.489 (0.162)</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change from Baseline </p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">45</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.088 (0.067)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">24</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.197 (0.085)</p></td></tr><tr style="height:14.4pt;"><td rowspan="3" style="vertical-align:top;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> (nM)</p></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Baseline</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">52</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">26.22 (3.78) [15.20]</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">25</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.14 (7.08) [17.60]</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Month 24</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">46</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">29.22 (4.48) [18.80]</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">22</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">19.65 (3.60) [15.30]</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change from Baseline </p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">46</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.30 (1.38) [1.15]</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">22</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-8.74 (4.85) [-1.50]</p></td></tr><tr style="height:11.95pt;"><td rowspan="3" style="vertical-align:top;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LVMI (g/m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>)</p></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Baseline</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">40</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">75.97 (5.13)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">22</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">82.22 (6.34)</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Month 24</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">35</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">71.56 (5.20)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">20</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">82.43 (8.39)</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change from Baseline </p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">28</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-0.64 (2.69)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">19</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.29 (3.73)</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:89.86%;"><tr style="height:11.95pt;"><td rowspan="3" style="vertical-align:top;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">MSSI (overall score)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">a</sup></p></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Baseline</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">49</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">23.18 (1.42)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">25</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">25.16 (2.14)</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Month 24</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">46</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">22.11 (1.80)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">23</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">27.09 (2.30)</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change from Baseline </p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">44</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-2.07 (0.77)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">23</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2.04 (1.10)</p></td></tr><tr style="height:11.95pt;"><td rowspan="3" style="vertical-align:top;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BPI (score for pain at its worst)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">b</sup></p></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Baseline</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">52</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.5 (0.4)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">25</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2.6 (0.6)</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Month 24</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">45</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.3 (0.5)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">22</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #aeabab;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.0 (0.7)</p></td></tr><tr style="height:14.4pt;"><td style="display:none;vertical-align:middle;width:26.79%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"></td><td style="vertical-align:top;width:22.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change from Baseline </p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">45</p></td><td style="vertical-align:top;width:20.39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-0.1 (0.5)</p></td><td style="vertical-align:top;width:4.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">22</p></td><td style="vertical-align:top;width:21.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #aeabab;margin:0pt;padding:0pt 5.02pt 0pt 5.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.6 (0.6)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;">BPI=brief pain inventory; eGFR=estimated glomerular filtration rate; lyso-Gb<sub style="font-size:6pt;vertical-align:sub;">3</sub>=globotriaosylsphingosine; LVMI=Left Ventricular Mass Index; MSSI=Mainz Severity Score Index; UPCR=Urine Protein Creatinine Ratio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">a </sup>Wanner 2018; <sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">b </sup>Higher scores indicate higher symptom severity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Forty-seven (90.4%) patients in the PRX-102 arm experienced at least one treatment-emergent adverse event (TEAE) compared to 24 (96.0%) in the agalsidase beta arm. The number of events adjusted to 100 years of exposure is 572.36 events for the PRX-102 arm and 816.85 events for the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Treatment-related adverse events were reported for 21 (40.4%) patients in the PRX-102 arm compared to 11 (44.0%) in the agalsidase beta arm. The number of treatment-related events adjusted to 100 years of exposure is 42.85 events for the PRX-102 arm and 152.91 events for the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Usage of infusion pre-medication was tapered down during the study, if possible, for all patients. At baseline, 21 (40.4%) patients in the PRX-102 arm used infusion premedication compared to 16 (64.0%) in the agalsidase beta arm. At the end of the study, only three out of 47 (6.4%) patients in the PRX-102 arm used infusion premedication compared to three out of 24 (12.5%) in the agalsidase beta arm. Even with this reduction in use of premedication, there were fewer reported infusion-related reactions with PRX-102: 11 (21.2%) patients in the PRX-102 arm experienced a total of 13 events compared to six (24.0%) patients experiencing a total of 51 events in the agalsidase beta arm. The number of infusion-related reactions adjusted to 100 infusions is 0.5 for the PRX-102 arm and 3.9 for the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Assessment of immunogenicity, that is, the existence and development of anti PRX-102 antibodies or anti-agalsidase beta antibodies, in the study indicated that for the PRX-102 arm, 18 (34.6%) patients were ADA positive at baseline, of which 17 (94.4%) had neutralizing antibody activity. For the agalsidase beta arm, eight (32.0%) patients were ADA positive at baseline, of which seven (87.5%) had neutralizing antibody activity. Only a small number of patients showed treatment-emergent ADA. At the end of the two-year study, 11 (23.4%) patients who received PRX-102 were ADA positive, of which seven (63.6%) had neutralizing antibody activity, while in the agalsidase beta arm six (26.1%) were ADA-positive and all six (100%) had neutralizing antibody activity. There was little change in the percentage of patients who were ADA positive, with a trend of reduction observed in the PRX-102 arm and stability in the agalsidase beta arm. The proportion of patients with neutralizing ADA decreased in the PRX-102 arm while it remained stable in the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Out of the 78 randomized patients, six patients discontinued the study: out of the five (9.4%) from the PRX-102 arm, one patient withdrew consent prior to the first infusion, two discontinued due to personal reasons, and two due to adverse events (one due to an unrelated adverse event and one due to a treatment related adverse event); one (4%) patient from the agalsidase beta arm discontinued for personal reasons. There were no deaths in this study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Considering that in the trial, patients in the PRX-102 arm were exposed for the first time to the novel enzyme, tolerability data appear favorable for PRX-102 and in line with what was observed in the previous clinical studies of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Of the patients who completed the trial from both the PRX-102 and agalsidase beta treatment arms, 69 have opted, with the advice of the treating physician, to receive PRX-102 1&#160;mg/kg every two weeks in the long-term open-label extension study which is now sponsored by Chiesi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The results of the direct, blinded comparison of PRX-102 to agalsidase beta, for the primary efficacy renal endpoints (i.e., eGFR change, eGFR slope) and for the main secondary endpoints (e.g., urine protein to creatinine ratio [UPCR] LVMI, MSSI, BPI) strongly suggest comparability in treatment effects between the two treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">At the same time a potentially favorable safety profile was identified based on lower rates of IRR, lower ADA positivity, and less premedication use in the PRX-102 arm compared to agalsidase beta. Overall, a positive benefit-risk balance was confirmed.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;III BRIDGE Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The <i style="font-style:italic;">BRIDGE</i> study was completed in December 2019. In the study, patients were screened and evaluated over three months while continuing agalsidase alfa treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Final results of the data generated in the <i style="font-style:italic;">BRIDGE</i> study showed substantial improvement in renal function as measured by mean annualized eGFR slope in both male and female patients. Twenty of 22 patients completed the 12-month treatment duration. Eighteen of the patients who completed the study opted to roll over to a long-term extension study and continue to be treated with PRX-102. In the study, the mean annualized eGFR slope of the study participants improved from -5.90&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year while on agalsidase alfa to -1.19&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year on PRX-102 in all patients. Male patients improved from -6.36&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -1.73&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year and female patients improved from -5.03&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -0.21&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year. Following the switch to PRX-102, there was a decrease in patients with progressing or fast progressing kidney disease which is consistent with the therapeutic goals for Fabry disease, as identified by Christoph Wanner, et. al., in 2019, and most patients achieved a stable status post-switch.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-102 was well-tolerated in the <i style="font-style:italic;">BRIDGE</i> study, with all adverse events being transient in nature without sequelae. Of the 22 patients enrolled in the <i style="font-style:italic;">BRIDGE</i> study, the majority of TEAEs were mild or moderate in severity, with two patients (9.1%) withdrawing from the therapy due to hypersensitivity reaction that was resolved. The most common moderate TEAEs were nasopharyngitis, headache and dyspnea.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">An immunogenicity assessment indicated that four out of 20 patients (20%) developed persistent ADAs over the course of the study, of which two had neutralizing activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">Baseline characteristics of the 20 patients who completed the study, ranging from ages 28 to 60 years, were as follows: mean eGFR 75.87&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> in males, and 86.14&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> in females and plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> were 51.81&#160;nM and 13.81&#160;nM in males and females, respectively. While lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels remain slightly high, particularly within the male cohort, continuous reduction in lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels was observed of 19.55&#160;nM (32.35%) in males and 4.57&#160;nM (29.81%) in females.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">Of the patients who completed the trial, 18 have opted, with the advice of the treating physician, to continue receiving PRX-102 1&#160;mg/kg every two weeks in a long-term open-label extension study which now sponsored by Chiesi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;III BRIGHT Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The <i style="font-style:italic;">BRIGHT</i> study, which studied the 2&#160;mg/kg every four weeks dosage, was completed in June 2020. This dosage was not approved by the EMA or the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Enrollment in the study included 30 adult patients (24 males and 6 females) with mean (SD) age of 40.5 (11.3) years, ranging from 19 to 58 years previously treated with a commercially available ERT (agalsidase beta or agalsidase alfa), for at least three years and on a stable dose administered every two weeks. To determine eligibility for participation in the study, candidates were screened to identify and select Fabry patients with clinically stable kidney disease. The most common Fabry disease symptoms at baseline were acroparesthesia, heat intolerance, angiokeratomas and hypohydrosis. Patients who matched the criteria were enrolled in the study and switched from their current treatment of IV infusions every two weeks to 2&#160;mg/kg of PRX-102 every four weeks for 12&#160;months. Patients participating in the study were evaluated, among other disease parameters, to determine if their kidney disease had not further deteriorated while being treated with the four-week dosing regimen as measured by eGFR and for lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>levels as a Fabry biomarker, as well as other parameters. In addition, participating patients were evaluated to assess the safety and tolerability of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We announced final results from the <i style="font-style:italic;">BRIGHT</i> study in March 2022. The results indicate that 2&#160;mg/kg of PRX-102 administered by intravenous infusion every four weeks was well tolerated, and Fabry disease assessed by eGFR slope and plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> was stable throughout PRX-102 treatment in adult Fabry patients. None of the patients without ADAs at screening developed treatment-induced ADAs following the switch to PRX-102 treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">All 30 patients received at least one dose of PRX-102, and 29 patients completed the one-year study. Of these 29 patients, 28 received the intended regimen of 2&#160;mg/kg every four weeks throughout the entire study, while one patient was switched to 1&#160;mg/kg PRX-102 every two weeks per protocol at the 11th infusion. One patient withdrew from the study after the first infusion due to a traffic accident.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">First infusions of PRX-102 were administered under controlled conditions at the investigation site. Based on the protocol-specified criteria, patients were able to receive their PRX-102 infusions at a home care setup once the applicable Investigator and Sponsor </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Medical Monitor agreed that it was safe to do so. Safety and efficacy exploratory endpoints were assessed throughout the 52-week study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Overall, 33 of 183 total TEAEs reported in nine (30.0%) of the patients were considered treatment related; all were mild or moderate in severity and the majority were resolved at the end of the study. There were no serious or severe treatment-related TEAEs and no TEAEs led to death or study withdrawal. Of the treatment-related TEAEs, 27 were infusion-related reactions (IRRs) and the remainder were single events of diarrhea, erythema, fatigue, influenza-like illness, increases urine protein/creatinine ratio, and urine positive for white blood cells. The 27 IRRs were reported in five (16.7%) patients, all male. All IRRs occurred during the infusion or within two hours post-infusion; no events were recorded between two and 24 hours post-infusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Study outcome measures show that plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> concentrations remained stable during the study with a mean change (&#177;SE) of 3.01&#160;nM (0.94) from baseline (19.36 nM &#177;3.35) to Week&#160;52 (22.23 &#177;3.60 nM). Mean absolute eGFR values were stable during the 52-week treatment period, with a mean change from baseline of -1.27&#160;mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> (1.39). Mean (SE) eGFR slope, at the end of the study, for the overall population, was -2.92&#160;(1.05) mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year indicating stability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Following a survey of participants using the Quality of Life EQ-5D-5L questionnaire, responses indicate that patient perception of their own health remained high and stable throughout the 52-week study duration, with overall health mean (SE) scores of 78.3 (3.1) and 82.1 (2.9) at baseline and Week 52, respectively, in a 0 to 100 scale. Using the short-form Brief Pain Inventory, or questionnaire, approximately 75% of study participants had an improvement or no change in average pain severity at Week 52 (compared to baseline). The short-form BPI interference items also remained stable during the study. Pain-related results indicate that there was no increase and/or relapse in pain. No Fabry clinical events were reported during the study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Phase I/II Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Sixteen adult, na&#239;ve Fabry patients (9 male and 7 female) completed our phase&#160;I/II clinical trial of PRX-102, each in one of three dosing groups, 0.2&#160;mg/kg, 1&#160;mg/kg and 2&#160;mg/kg. Each patient received IV&#160;infusions of PRX-102 every two weeks for 12 weeks, with efficacy follow-up after six-month and twelve-month periods. A majority of the patients who completed the trial opted to continue receiving PRX-102 in an open-label, 60-month extension study under which all patients were switched to receive 1&#160;mg/kg of the drug, the selected dose for our <i style="font-style:italic;">BALANCE</i> and <i style="font-style:italic;">BRIDGE</i> studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The adult symptomatic, ERT-na&#239;ve Fabry disease patients enrolled in the phase&#160;I/II study were evaluated for Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels in kidney biopsies and for plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> concentration by the quantitative BLISS methodology. Biopsies were available from 14 patients. The outcome of &#8805;&#160;50% reduction in the average number of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions per kidney PTC from baseline to Month 6 was demonstrated in 11 of 14 (78.6%) of the patients treated with PRX-102. The overall results demonstrate that PRX-102 reaches the affected tissue and reduces kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions burden and lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>in the circulation. A high correlation was found between the two Fabry disease biomarkers, reduction of kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>inclusions and the reduction of plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> over six months of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Data was recorded at 24&#160;months from 11 patients who completed 12&#160;months of the long-term open-label extension trial that succeeded the phase&#160;I/II study. Patients who did not continue in the extension trial included: female patients who became or planned to become pregnant and therefore were unable to continue in accordance with the study protocol; and patients who relocated to a location where treatment was not available under the clinical study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">Results show that lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels decreased approximately 90% from baseline. Renal function remained stable with mean eGFR levels of 108.02 and 107.20 at baseline and 24&#160;months, respectively, with a modest annual eGFR slope of -2.1. An improvement across all the gastrointestinal symptoms evaluated, including severity and frequency of abdominal pain and frequency of diarrhea, was noted. Cardiac parameters, including LVM, LVMI and EF, remained stable with no cardiac fibrosis development detected. In conclusion, an improvement of over 40% in disease severity was shown as measured by the Mainz Severity Score Index, or MSSI, a score compiling the different elements of the disease severity including neurological, renal and cardiovascular parameters. In addition, an improvement was noted in each of the individual parameters of the MSSI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The majority of adverse events were mild-to-moderate in severity, and transient in nature. During the first 12 months of treatment, only three of 16 patients (less than 19%) formed ADAs of which two of these patients (less than 13%) had neutralizing antibodies. Importantly, however, the ADAs turned negative for all three of these patients following 12&#160;months of treatment. The ADA positivity effect had no observed impact on the safety, efficacy or continuous biomarker reduction of PRX-102.</p><a id="_DV_M79"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Commercialization Agreements with Chiesi Farmaceutici</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have entered into two exclusive global licensing and supply agreements for PRX-102 for the treatment of Fabry disease with Chiesi. The agreements have significant revenue potential for Protalix. Under the agreements, Protalix&#160;Ltd. has received $50.0&#160;million </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">in upfront payments and development cost reimbursements of $45.0&#160;million, and is entitled to approximately $1.0&#160;billion in potential milestone payments as well as additional payments as consideration for drug product supply. The additional payments for drug product supplied are based on the average selling price of the drug product in the relevant territory multiplied by tiered payments, as detailed below. During the quarter ended June&#160;30, 2023, we received net proceeds of $20.0&#160;million representing a milestone payment earned upon the FDA&#8217;s approval of Elfabrio for adult Fabry patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into the Chiesi Ex-US Agreement pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize PRX-102. Under the Chiesi Ex-US Agreement, Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of the agreement, and Protalix&#160;Ltd. was entitled to additional payments of up to $25.0&#160;million in development costs in the aggregate, capped at $10.0&#160;million per&#160;year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $320.0&#160;million in regulatory and commercial milestone payments. Protalix&#160;Ltd. agreed to manufacture all of the PRX-102 needed for all purposes under the agreement, subject to certain exceptions, and Chiesi will purchase PRX-102 from Protalix&#160;Ltd., subject to certain terms and conditions. Chiesi is required to make tiered payments for drug product purchased from Protalix based on the average selling price of the drug product in the relevant territory multiplied by 15% to 35%, depending on the amount of annual net sales outside of the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On July&#160;23, 2018, Protalix&#160;Ltd. entered into the Chiesi US Agreement with respect to the development and commercialization of PRX-102 in the United States. Protalix&#160;Ltd. received an upfront, non-refundable, non-creditable payment of $25.0&#160;million from Chiesi and was entitled to additional payments of up to a maximum of $20.0&#160;million to cover development costs for PRX-102, capped at $7.5&#160;million per&#160;year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Chiesi agreed to make tiered payments for drug product purchased from Protalix based on the average selling price of the drug product in the United States multiplied by 15% to 40%, subject to certain terms and conditions, depending on the amount of annual net sales in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">On May&#160;13, 2021, we signed a binding term sheet with Chiesi amending the Chiesi Agreements in order to provide our company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to us before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. We received the payment in June&#160;2021. We also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">On August&#160;29, 2022, we entered into the F/F Agreement and the Letter Agreement with Chiesi. Under the F/F Agreement, we agreed to supply Chiesi with drug substance for PRX-102 and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide us with commercial fill/finish services for PRX-102, including to support the anticipated global launch of PRX-102. The F/F Agreement will expire December&#160;31, 2025, unless terminated earlier in accordance with its terms and may be extended by mutual agreement in writing for an additional period of seven years. The Letter Agreement changed our obligations and those of Chiesi under the License Agreements with respect to, among other things, the evaluation, selection and establishment of an initial alternate source of commercial fill/finish services for PRX-102. In addition, the Letter Agreement amended certain provisions of the License Agreements to reflect the appointment of Chiesi as a supplier to our company of commercial fill/finish services and the potential establishment of an initial alternate source of commercial fill/finish services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">As of March&#160;1, 2023, sponsorship of the two extension studies was transferred to Chiesi, and Chiesi is now administering the extension studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Elelyso</span><sup style="font-size:7.5pt;font-style:italic;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-style:italic;font-weight:bold;"> for the Treatment of Gaucher Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elelyso (taliglucerase alfa), our first commercial product, was approved by the FDA in 2012 for injection as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type&#160;1 Gaucher disease. In August 2014, the FDA approved Elelyso for injection for pediatric patients. Elelyso is the first plant cell derived recombinant protein to be approved by the FDA for the treatment of Gaucher disease and is now approved in over 20 markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gaucher disease, also known as glucocerebrosidase, or GCD, deficiency, is a rare genetic autosomal recessive disorder and one of the most common Lysosomal Storage Disorders, or LSDs, in the world. It is one of a group of disorders that affect specific enzymes that normally break down fatty substances for reuse in the cells. If the enzymes are missing or do not work properly, the substances can build up and become toxic. Gaucher disease occurs when a lipid called glucosylceramide accumulates in the cells of the bone marrow, lungs, spleen and liver, and sometimes the brain. Gaucher disease symptoms can include fatigue, anemia, easy bruising and bleeding, severe bone pain and easily broken bones, and distended stomach due to an enlarged spleen and thrombocytopenia. Epidemiology of Gaucher disease varies; recent literature provides that prevalence of Gaucher disease ranges from 0.70 to 1.75 per 100,000 in the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">general population. In people of Ashkenazi Jewish heritage, estimates of occurrence vary from approximately 1 in 400 to 1 in 850 people.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The global market for Gaucher disease, that includes Sanofi&#8217;s Cerezyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, Shire&#8217;s Vpriv<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and Sanofi&#8217;s Cerdelga<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, among others, was $1.6&#160;billion in 2022, is forecasted to be approximately $1.4&#160;billion in 2023 and is forecasted to grow at a CAGR of approximately 1.6% from 2023-2029.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Commercialization Agreements for Elelyso</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have licensed to Pfizer the global rights to Elelyso in all markets excluding Brazil. Pfizer retains 100% of revenue and reimburses 100% of direct costs.<span style="font-family:'Times-Roman';"> </span>We manufacture drug substance for Pfizer, subject to certain terms and conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">For the first 10-year period after the execution of the October 2015 Amended Pfizer Agreement, we have agreed to sell drug substance to Pfizer for the production of Elelyso, and Pfizer maintains the right to extend the supply period for up to two additional 30-month periods subject to certain terms and conditions. In a subsequent amendment, we agreed that after the completion of the first 10-year supply period, the supply term would automatically extend for a five-year period (i.e., until October 2030).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We maintain distribution rights to Elelyso in Brazil through a supply and technology transfer agreement with Fiocruz, an arm of the Brazilian MoH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Uricase (PRX-115)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-115 is our plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme under development for the potential treatment of severe gout. We use ProCellEx to express an optimized recombinant uricase enzyme under development for the potential treatment of severe gout which we are designing to lower uric acid levels while having low immunogenicity and increased half-life in the circulation. Pre-clinical data demonstrates stable PK profile and long half-life, low immunogenic risk and high specific activity which supports the potential of PRX-115 to be a safe and effective treatment for severe gout. Results from the one-month multiple dosing toxicity studies in two species demonstrate that PRX-115 is well tolerated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On March&#160;21, 2023, the first patient was dosed in our phase&#160;I First in Human (FIH) clinical trial of PRX-115, a double-blind, placebo-controlled trial designed to evaluate the safety, pharmacokinetics, pharmacodynamics (reduction of uric acid) and immunogenicity of PRX-115 in patients with elevated uric acid levels (&gt;6.0&#160;mg/dL). The trial is a single ascending dose (SAD) study with up to seven cohorts, and patients are to be randomized 3:1 to receive a single intravenous (IV) dose of PRX-115 or a placebo. The study is being conducted at New Zealand Clinical Research (NZCR) under the New Zealand Medicines and Medical Devices Safety Authority (MedSafe) and the Health and Disability Ethics Committee (HDEC) guidelines, and is expected to enroll up to 56 patients with no previous exposure to PEGylated uricase. As of September&#160;30, 2023, 32 patients have been dosed in this trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Gout is the most common inflammatory arthritis in the<span style="direction:rtl;"> </span>United States, affecting<span style="direction:rtl;"> </span>an estimated 9.2&#160;million<span style="direction:rtl;"> </span>adults. Gout is caused by factors that elevate serum uric acid, or sUA, levels, which may include diet or genetic predisposition and environmental factors leading to hyperuricemia and tissue deposition of monosodium urate crystals, tophi, in joints and soft tissues, causing acute and chronic inflammation, and is characterized by recurrent flares. Gout leads to substantial morbidity by causing severe pain, reduced quality of life, decreased physical function, increased healthcare costs, and lost economic productivity. Furthermore, gout is strongly associated with metabolic syndrome, and may contribute to myocardial infarction, type&#160;2 diabetes mellitus, chronic kidney disease, or CKD, and premature mortality.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Severe gout is generally described as a state of gout in which there is a presence of monosodium urate crystals with any of the following: frequent recurrent gout flares, chronic gouty arthritis, subcutaneous tophi or disease elements of gout seen via imaging. It is estimated that approximately 2% of the gout patient population is considered to have chronic refractory disease, and we believe the incidence of severe gout is higher.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Currently available urate-lowering therapies, or ULTs, can be effective in treating gout. However, we believe that new effective, safe therapies are needed to treat severe gout and chronic refractory gout regardless of treatment history. One treatment option may be a therapeutic use of the uricase enzyme which converts uric acid to allantoin, which is easily eliminated through urine. The uricase enzyme does not exist naturally in humans. To date, two variants of recombinant uricases are approved for marketing: (i)&#160;Krystexxa<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegloticase) for treatment of chronic gout refractory to conventional therapy (gout patients who have contraindication/failure of other lowering uric acid treatments) and (ii)&#160;Elitek<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, indicated for the treatment of tumor lysis syndrome but not gout. Both have a black box warning for anaphylaxis and other major side-effects. In particular, 89% of patients treated with Krystexxa developed an immunogenic response associated with a failure to maintain normalization of serum uric acid levels over a 6-month therapy cycle. In addition, a phase&#160;IV study demonstrates that co-treatment with Krystexxa and methotrexate prolongs efficacy and increases </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">tolerability in patients with refractory gout. Krystexxa is no longer marketed in the European Union. The EC withdrew the marketing authorization for Krystexxa in 2016 at the request of the marketing authorization holder which notified the EC of its decision not to market the product in the European Union for commercial reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">PRX-119</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-119 is our plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases. NETs, Neutrophil extracellular traps, are web-like structures, released by activated neutrophils that trap and kill a variety of microorganisms. NETs are composed of DNA, histones, antimicrobial and pro-inflammatory proteins. Excessive formation or ineffective clearance of NETs can cause different pathological effects. NETs formation has been observed in various autoimmune, inflammatory and fibrotic conditions, diverse forms of thrombosis, cancer and metastasis. According to scientific literature, animal studies have demonstrated that DNase treatment reduces NETs toxicity. Our proprietary modified DNase&#160;I design for long and customized systemically circulating in the bloodstream, may potentially enable effective treatment of acute and chronic conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual Property</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A key element of our overall strategy is to establish a broad portfolio of patents to protect our proprietary technology, proprietary product and product candidates and their methods of use. As of September&#160;30, 2023, we hold a broad portfolio of over 85 patents in Europe, the United States, Israel and additional countries worldwide, as well as over 45 pending patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Scientific Presentations and Publications</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On August&#160;21, 2023, an article disclosing six-year results from our Phase&#160;I/II clinical trial of pegunigalsidase alfa was accepted for publication by Genetics in Medicine. The article entitled &#8220;Long-term safety and efficacy of pegunigalsidase alfa: A multicenter 6-year study in adult patients with Fabry disease,&#8221; was authored by Dr.&#160;Derralynn Hughes of University College London&#160;in&#160;London, UK, a principal investigator in our clinical trials of PRX-102, and was made available online on August&#160;24, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Yael Hayon, Ph.D., our Vice President, Research &amp; Development, gave a presentation at the Next Generation Protein Therapeutics Summit on September&#160;20, 2023.The summit was held at the Boston Convention and Exhibition Center, Boston MA, on September&#160;18 through 20, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On October&#160;21, 2023, an article entitled &#8220;Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open&#8209;label study,&#8221; was published online. The article was authored by Ales Linhart, MD,&#160;Charles University,&#160;Praha, Czech Republic, a principal investigator in our clinical trials of PRX-102, and others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research &amp; Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We continuously work on the further development of our ProCellEx plant cell expression technology and bioreactor system. In addition, we are working on the development of new products, each in different initial stages of development, for specific products for which there are unmet needs in terms of efficacy and safety. Our development strategy focuses on the utilization of different modification approaches and development improvements, customized for each protein product, in all stages of expression and development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our significant accounting policies are more fully described in Note&#160;1 to our consolidated financial statements appearing in this Quarterly Report. There have been no material changes to our critical accounting policies since we filed our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The discussion and analysis of our financial condition and results of operations is based on our financial statements, which we prepared in accordance with U.S.&#160;generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to the assessment of sales reserves and valuation allowances. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Three months ended September&#160;30, 2023 compared to the three months ended September&#160;30, 2022</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from Selling Goods</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from selling goods of $10.2&#160;million during the three months ended September&#160;30, 2023, an increase of $1.4&#160;million, or 16%, compared to revenues of $8.8&#160;million for the three months ended September&#160;30, 2022. The increase resulted primarily from an increase of $3.0&#160;million in sales to Chiesi, following the approvals by the FDA and the EMA of Elfabrio, and of $0.6&#160;million in sales to Brazil, partially offset by a $2.2&#160;million decrease in sales to Pfizer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from License and R&amp;D Services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from license and R&amp;D services of $0.2&#160;million for the three months ended September&#160;30, 2023, a decrease of $5.2&#160;million, or 96%, compared to revenues of $5.4&#160;million for the three months ended September&#160;30, 2022. Revenues from license and R&amp;D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements. As of March&#160;1, 2023, sponsorship of the extension studies was transferred to Chiesi, and Chiesi is now administering all open-label extension studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Cost of Goods Sold</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold was $4.9&#160;million for the three months ended September&#160;30, 2023, a decrease of $2.2&#160;million, or 31%, from cost of goods sold of $7.1&#160;million for the three months ended September&#160;30, 2022. <span style="background:#ffffff;">The decrease in cost of goods sold was primarily the result of the decrease in sales to Pfizer, partially offset by an increase in sales of </span>Elfabrio <span style="background:#ffffff;">to Chiesi and of </span>Elelyso <span style="background:#ffffff;">to Brazil.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">For the three months ended September&#160;30, 2023, our total research and development expenses were approximately $3.7&#160;million comprised of approximately $1.0&#160;million of subcontractor-related expenses, approximately $1.9&#160;million of salary and related expenses, approximately $0.2&#160;million of materials-related expenses and approximately $0.6&#160;million of other expenses. For the three months ended September&#160;30, 2022, our total research and development expenses were approximately $7.4&#160;million comprised of approximately $4.9 million in subcontractor-related expenses, approximately $1.7&#160;million of salary and related expenses, approximately $0.2&#160;million of materials-related expenses and approximately $0.6&#160;million of other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">Total decrease in research and developments expenses for the three months ended September&#160;30, 2023 was $3.7&#160;million, or 50%, compared to the three months ended September&#160;30, 2022. The decrease in research and development expenses primarily resulted from the completion of our Fabry clinical program and the regulatory processes related to the BLA and MAA review of Elfabrio by the applicable regulatory agencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">We expect research and development expenses to continue to be our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Selling, General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses were $3.7&#160;million for the three months ended September&#160;30, 2023, an increase of $0.9&#160;million, or 32%, compared to $2.8&#160;million for the three months ended September&#160;30, 2022. The increase resulted primarily from an increase of approximately $0.6&#160;million in salary and related expenses due to one-time cash bonuses and an increase in share-based compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Financial Income, Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Financial income, net were $0.2&#160;million for the three months ended September&#160;30, 2023, compared to financial expenses, net of $0.4&#160;million for the three months ended September&#160;30, 2022. The change resulted primarily from an increase of $0.3&#160;million in interest income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Income taxes</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In the three months ended September&#160;30, 2023, we recorded income taxes of approximately $0.1&#160;million which were primarily the result of the provision for current taxes in respect of Section&#160;174 of the TCJA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Nine months ended September&#160;30, 2023 compared to the nine months ended September&#160;30, 2022</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from Selling Goods</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from selling goods of $30.3&#160;million during the nine months ended September&#160;30, 2023, an increase of $9.1&#160;million, or 43%, compared to revenues of $21.2&#160;million for the nine months ended September&#160;30, 2022. The increase resulted primarily from an increase of $14.4&#160;million in sales <span style="background:#ffffff;">to Chiesi, </span>following the approvals by the FDA and the EMA of Elfabrio<span style="background:#ffffff;">, which was </span>partially offset by a decrease of $3.3&#160;million in sales to Pfizer of $2.0&#160;million in sales to Brazil, resulting from timing differences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from License and R&amp;D Services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from license and R&amp;D services of $24.7<span style="direction:rtl;">&#160;</span>million for the nine months ended September&#160;30, 2023, an increase of $6.9&#160;million, or 39%, compared to revenues of $17.8&#160;million for the nine months ended September&#160;30, 2022. The increase resulted from the $20.0&#160;million regulatory milestone payment from Chiesi in connection with the FDA approval of Elfabrio which was partially offset by a decrease of $13.1&#160;million in revenues recognized in connection with the Chiesi Agreements. Revenues from license and R&amp;D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Cost of Goods Sold</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold was $14.1&#160;million for the nine months ended September&#160;30, 2023, a decrease of $3.1&#160;million, or 18%, from cost of goods sold of $17.2&#160;million for the nine months ended September&#160;30, 2022. <span style="background:#ffffff;">The decrease in cost of goods sold was primarily the result of a decrease in sales of goods to Brazil and to Pfizer which was partially offset by an increase in sales of Elfabrio to Chiesi. Sales to Chiesi included certain drug substance costs which had already been recognized as research and development expenses as it was produced as part of research and development activities. Accordingly, the related cost of goods sold does not include the costs of such drug substance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">For the nine months ended September&#160;30, 2023, our total research and development expenses were approximately $14.0&#160;million comprised of approximately $6.2&#160;million in subcontractor-related expenses, approximately $5.5&#160;million of salary and related expenses, approximately $0.5&#160;million of materials-related expenses and approximately $1.8&#160;million of other expenses. For the nine months ended September&#160;30, 2022, our total research and development expenses were approximately $23.7&#160;million comprised of approximately $15.1&#160;million in subcontractor-related expenses, approximately $5.4&#160;million of salary and related expenses, approximately $1.2&#160;million of materials-related expenses and approximately $2.0&#160;million of other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">Total decrease in research and developments expenses was $9.7&#160;million, or 41%, for the nine months ended September&#160;30, 2023 compared to the nine months ended September&#160;30, 2022. The decrease in research and development expenses primarily resulted from the completion of our Fabry clinical program and of the regulatory processes related to the BLA and MAA review of Elfabrio by the applicable regulatory agencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 21.6pt 12pt 0pt;">We expect research and development expenses to continue to be our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Selling, General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses were $10.8&#160;million for the nine months ended September&#160;30, 2023, an increase of $2.2&#160;million, or 26%, compared to $8.6&#160;million for the nine months ended September&#160;30, 2022. The increase resulted primarily from an increase of approximately $1.5&#160;million in salary and related expenses due to one-time cash bonuses and increase in share-based compensation, an increase of $0.2&#160;million in professional fees and of $0.3 million in travel, conferences and employee training expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Financial Expenses, Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financial expenses, net were $1.1&#160;million for the nine months ended September&#160;30, 2023, an increase of $0.4&#160;million, or 57%, compared to $0.7&#160;million for the nine months ended September&#160;30, 2022. The increase was primarily due to a decrease of $0.6&#160;million </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">in income related to exchange rates as well as an increase in our convertible notes related expenses of $0.5&#160;million net of a gain recognized due to conversions of a portion of the 2024 Notes of $0.4&#160;million and a $0.3&#160;million increase in interest income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Income taxes</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In the nine months ended September&#160;30, 2023, we recorded income taxes of approximately $0.6&#160;million which were primarily the result of the provision for current taxes in respect of Section&#160;174 of the TCJA. Section 174 eliminated the option to immediately deduct research and development expenses in the year incurred and requires us to capitalize and amortize these expenditures over 15&#160;years (for out of U.S.-based research and development). In addition, during the nine months ended September&#160;30, 2023, we released a valuation allowance related to deferred tax assets of the U.S. jurisdiction that resulted in a net benefit to tax expense of $3.1&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">Our sources of liquidity includes our cash and cash equivalents balance. At September&#160;30, 2023, we had $41.0&#160;million in cash, cash equivalents and short term bank deposits. We have primarily financed our operations through equity and debt financings, business collaborations, and grants funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">During the year ended December&#160;31, 2022, we raised gross proceeds equal to approximately $8.7&#160;million from the sale of 7,473,038 shares of our common stock under our ATM program. During the six months ended June&#160;30, 2023, we raised gross proceeds equal to approximately $24.9&#160;million from sales of common stock under our ATM program through the sale of 12,560,150 shares of our common stock of which 4,347,668 shares were sold; we did not sell any common stock under our ATM program during the three-months ended September&#160;30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">On August&#160;25, 2021, we completed exchanges, or the Exchanges, of a substantial majority of our then outstanding 7.50% Senior Secured Convertible Notes due 2021, or the 2021 Notes, with institutional note holders of a substantial majority of the 2021 Notes. The Exchanges involved the exchange of an aggregate of $54.65&#160;million principal amount of our 2021 Notes for an aggregate of $28.75&#160;million principal amount of newly issued 7.50% Senior Secured Convertible Notes due 2024, or the 2024 Notes, $25.90&#160;million in cash, and approximately $1.1&#160;million in cash representing accrued and unpaid interest through the closing date. The initial conversion rate for the 2024 Notes is 563.2216 shares of our common stock for each $1,000 principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $1.7755 per share of common Stock, subject to adjustment in certain circumstances. This initial conversion price represents a premium of approximately 32.5% relative to the closing price of the common stock on the NYSE American on August&#160;13, 2021. After giving effect to the Exchanges, $3.27&#160;million aggregate principal amount of the 2021 Notes remained outstanding. On November&#160;15, 2021, all of the then outstanding 2021 Notes&#160;matured and were paid in full. As a result of the conversion of 2024 Notes during the nine months ended September&#160;30, 2023, the total principal amount of our remaining 2024 Notes outstanding decreased by approximately $8.3&#160;million. As of September&#160;30, 2023, the total principal amount of our 2024 Notes outstanding was $20.42&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The 2024 Notes were issued pursuant to the Indenture dated as of August&#160;24, 2021 between us, the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent, or the 2024 Indenture. Interest on the Notes are payable semi-annually at a rate of 7.50% per annum. The 2024 Notes will mature on September&#160;1, 2024, unless earlier purchased, converted, exchanged or redeemed, and are guaranteed by our subsidiaries. The 2024 Notes are secured by perfected liens on all of our assets, including those of our subsidiaries. <span style="font-family:'28mugxoulnobhnx';">Under the terms of the 2024 Indenture, we are required to comply with </span><span style="color:#222222;">certain covenants, including the requirement to </span>maintain a minimum cash balance of at least $7.5&#160;million. Failure to comply with such covenants may result in an event of default under the 2024 Indenture and, accordingly, may result in the acceleration of the payment of the notes or in additional interest payments. As of September&#160;30, 2023, we were in compliance with all covenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We believe that our cash, cash equivalents and short term bank deposits as of September&#160;30, 2023 are sufficient to satisfy our capital needs for at least 12&#160;months from the date that these financial statements are issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Cash Flows</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash used in operations was $4.9&#160;million for the nine months ended September&#160;30, 2023. The net income for the nine months ended September&#160;30, 2023 of $14.4&#160;million was decreased by a $13.2&#160;million decrease in contracts liability, a $3.1&#160;million increase in deferred tax assets, a $4.8&#160;million increase in inventories, a $4.2&#160;million increase in accounts receivable-trade and other assets and a $0.5&#160;million financial income-net (mainly currency exchange differences). The net income was increased by a $3.8&#160;million increase in accounts payable and accruals, $2.1&#160;million in share-based compensation and $0.9&#160;million in depreciation. Net cash used in investing activities for the nine months ended September&#160;30, 2023 was $16.4&#160;million and consisted primarily of net investment in bank deposits. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Net cash provided by financing activities was $24.7&#160;million resulting primarily from the sale of common stock under our ATM program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Net cash used in operations was $22.4&#160;million for the nine months ended September&#160;30, 2022. The net loss for the nine months ended September&#160;30, 2022 of $11.2&#160;million was increased by a $5.5&#160;million decrease in contracts liability, a $4.4&#160;million decrease in accounts payable and accruals, a $5.7&#160;million increase in accounts receivable and other assets and an increase of $1.1&#160;million in financial income, net (mainly exchange differences), and was partially offset by a $3.4&#160;million decrease in inventories and a $1.5&#160;million in share-based compensation. Net cash used in investing activities for the nine months ended September&#160;30, 2022 was $10.0&#160;million and consisted primarily of net investment in bank deposits. Net cash provided by financing activities was $4.2&#160;million resulting mainly from the sale of common stock under our ATM program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As a result of our significant research and development expenditures and the lack of significant revenue from sales of taliglucerase alfa, we have generated operating losses from our continuing operations since our inception. Our outstanding <span style="font-family:'28mugxoulnobhnx';">2024 Notes are </span>secured by a perfected lien on all of our assets<span style="font-family:'28mugxoulnobhnx';">. Under the terms of the 2024 Indenture, we are required to comply with </span><span style="color:#222222;background:#ffffff;">certain covenants, including the requirement to </span>maintain a minimum cash balance of at least $7.5&#160;million. Failure to comply with such covenants may result in an event of default under the 2024 Indenture and, accordingly, may result in the acceleration of the payment of the notes or in additional interest payments. As of September&#160;30, 2023, we were in compliance with all covenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the nine months ended September&#160;30, 2023, we issued, in the aggregate, 538,822 shares of our common stock in connection with cash and cashless exercises of our outstanding warrants to purchase shares of our common stock at an exercise price equal to $2.36 per share which were initially issued on March&#160;18, 2020 as part of our private placement of common stock and warrants, or the 2020 Warrants. In connection with the exercises, we generated net proceeds equal to $0.7&#160;million and retired 2020 Warrants to purchase 1,146,810 shares of common stock. As of September&#160;30, 2023, 2020 Warrants to purchase 13,439,712 shares were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, during the nine months ended September&#160;30, 2023, we issued, in the aggregate, 4,691,623 shares of our common stock in connection with a number of conversions of 2024 Notes. In connection with such conversions, during the nine months ended September&#160;30, 2023, we paid to the converting holders $0.9&#160;million representing cash payments due to accrued but unpaid interest, make-whole interest payments and payments in lieu of fractional shares. As a result of the conversion of 2024 Notes during the nine months ended September 30, 2023, the total principal amount of our remaining 2024 Notes outstanding decreased by approximately $8.3&#160;million. As of September&#160;30, 2023, the total principal amount of our 2024 Notes outstanding was $20.42&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Future Funding Requirements </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect to continue to incur expenditures in the near future as we increase our research and developments efforts with respect to our product candidates. We cannot anticipate the costs or the timing of the occurrence of such costs. We also expect to increase the revenues generated from the sales of our approved drug products. To the extent we need to obtain additional financing in excess of such anticipated revenues, it may be more difficult for us to do so given the volatility of the price of our common stock. Our material cash needs for the next 24&#160;months will include, among other expenses, (i)&#160;costs of preclinical and clinical trials, (ii)&#160;employee salaries, (iii)&#160;payments for rent and operation of our manufacturing facilities, (iv)&#160;fees to our consultants and legal advisors, patent advisors and fees for service providers in connection with our research and development efforts, (v)&#160;payments of principal and interest on our outstanding 2024 Notes and (vi) tax payments. We believe that the funds currently available to us are sufficient to satisfy our capital needs for at least 12&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As discussed above, we may be required to raise additional capital to develop our product candidates and continue research and development activities. Our ability to raise capital, and the amounts of necessary capital, will depend on many other factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the duration and cost of discovery and preclinical development and laboratory testing and clinical trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Chiesi&#8217;s progress in commercializing Elfabrio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our progress in commercializing BioManguinhos alfataliglicerase in Brazil;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights; and </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with any litigation claims.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect to finance our future cash needs through sales of our approved drug products (Elelyso and Elfabrio), corporate collaborations, licensing or similar arrangements, public or private equity offerings and/or debt financings. We currently do not have any commitments for future external funding, except with respect to milestone payments and royalties that may become payable under the Chiesi Agreements. As of September&#160;30, 2023, shares of our common stock for total gross proceeds of approximately $6.4&#160;million remain available to be sold under our 2023&#160;Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Effects of Currency Fluctuations </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Currency fluctuations could affect us through increased or decreased acquisition costs for certain goods and services and salaries expenses. We do not believe currency fluctuations have had a material effect on our results of operations during the three and nine months ended September&#160;30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have no off-balance sheet arrangements as of each of September&#160;30, 2023 and December&#160;31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_319fd400_0e9a_41a2_b887_3f67da46a826"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Quantitative and Qualitative Disclosures about Market Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Currency Exchange Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The currency of the primary economic environment in which our operations are conducted is the U.S.&#160;dollar. Most of our revenues and more than 50% of our expenses and capital expenditures are and were incurred in dollars, and a significant source of our financing has been provided in U.S.&#160;dollars. Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are remeasured using the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at historical exchange rates. Revenue and expense items are remeasured at the average rate of exchange in effect during the period in which they occur. Foreign currency translation gains or losses are recognized in the statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Approximately 43% of our costs, including salaries, expenses and office expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S.&#160;dollar cost of our operations in Israel. If the U.S.&#160;dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations in Israel. A revaluation of 1% of the NIS will affect our loss before tax by less than 1%. The exchange rate of the U.S.&#160;dollar to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:17.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Average rate for period</p></td><td style="vertical-align:bottom;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.745</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.402</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.643</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.315</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.360</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rate at period-end</p></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.824</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.543</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.824</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.543</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.519</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, we have not engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rate of the U.S.&#160;dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due to the impact of inflation in Israel.</p><a id="_bdc8fdc2_2098_4d3a_9c7c_75f3b92d9c2d"></a><a id="Item4ControlsandProcedures_865226"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form&#160;10-Q. The evaluation was conducted under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly Report on Form&#160;10-Q, is recorded, processed, summarized and reported within the time periods specified in the Commission&#8217;s rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Based on the evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form&#160;10-Q, our disclosure controls and procedures were effective to provide reasonable </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the Commission, and that material information relating to our company and our consolidated subsidiary is made known to management, including the Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are being prepared.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Inherent Limitations on Effectiveness of Controls</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company have been detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Changes in Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter ended September&#160;30, 2023 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_9fac17b7_49fb_4ed7_a173_ed1f8c5502b9"></a><a id="PARTIIOTHERINFORMATION_770480"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART II &#8211; OTHER INFORMATION</b></p><a id="Item1LegalProceedings_676392"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1.  Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are not involved in any material legal proceedings.</p><a id="_df3a1b35_6440_45ff_96cb_6b2f20ae8106"></a><a id="Item1ARiskFactors_983377"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1A.  Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 18pt 10pt 0pt;">Except as set forth below, there have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2022 and in our Quarterly Reports on Form 10-Q for the <span style="background:#ffffff;">three-month periods ended March&#160;31, 2023 and June&#160;30, 2023.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Significant parts of our operations are located in Israel and, therefore, our results may be adversely affected by political, economic and military conditions in Israel.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Our executive office and operations are located in the State of Israel. Accordingly, economic, geopolitical and military conditions in Israel directly affect our business. Any armed conflicts, political instability, terrorism, cyberattacks or any other hostilities involving Israel or the interruption or curtailment of trade between Israel and its present trading partners could affect adversely our operations. In October 2023, terrorists from the Hamas&#160;organization infiltrated Israel&#8217;s southern border from the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets while simultaneously launching extensive rocket attacks on the Israeli population and industrial centers. At the same time, clashes between Israel and Hezbollah in Lebanon have increased. In response, Israel&#8217;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. The attacks by Hamas and Hezbollah, and Israel&#8217;s defensive measures, may result in a greater regional conflict. To date, our operations have not been adversely affected by this situation. Hostilities have not taken place where our facilities are located and we do not anticipate any disruption to the supply of Elfabrio or Elelyso. However, our facilities are in range of rockets that were fired from Lebanon into Israel during a 2006 war with the Hezbollah in Lebanon, and suffered minimal damages during one of the rocket attacks. Our insurance policies do not cover damages incurred in connection with these conflicts or for any resulting disruption in our operations. The Israeli government, as a matter of law, provides coverage for the reinstatement value of direct damages that are caused by terrorist attacks or acts of war; however, the government may cease providing such coverage or the coverage might not be enough to cover potential damages. If our facilities are damaged as a result of hostile action, our operations may be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Ongoing and revived hostilities or other Israeli political or economic factors, could prevent or delay future shipments of our products, harm our operations and product development and cause any future sales to decrease. In the event that hostilities disrupt the ongoing operation of our facilities or the airports and seaports on which we depend to import and export our supplies, materials, drug substance and other products, our operations may be materially adverse affected. It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on our business, operations and financial conditions. The ongoing conflict is rapidly evolving and developing, and could disrupt certain of our business and operations, among others</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Our operations may be disrupted by the obligations of our personnel to perform military service which could have a material adverse effect on our business.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">Many of our male employees in Israel, including members of senior management, are obligated to perform up to one&#160;month (in some cases more) of annual military reserve duty until they reach the age of 45 and, in the event of a military conflict, could be called to active duty. To date, we have not suffered any disruptions to our operations from the absence of employees in connection with the recent military action. However, we continue to face the risk that our operations could be disrupted by the absence of a significant number of our employees related to military service or the absence for extended periods of military service of one or more of our key employees. Any such disruption may have a material adverse effect on our business, results of operations and financial condition.</p><a id="_29073e87_79b4_446f_a5cd_caad49b82788"></a><a id="Item2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Unregistered Sales of Equity Securities and Use of Proceeds</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">None.</p><a id="_1e8a5414_7d41_4389_8cad_7f073a833b96"></a><a id="Item3DefaultsUponSeniorSecurities_505234"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Defaults Upon Senior Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">None.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ca1eb5c8_d6b0_45ca_a031_18fa14fbfc19"></a><a id="Item4MineSafetyDisclosure_204781"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Mine Safety Disclosure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Not applicable.</p><a id="_50c083fb_89d2_4969_b86f_d9fd2fcddf11"></a><a id="Item5OtherInformation_679200"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">5.  Other Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">During the quarter ended September&#160;30, 2023, none of our directors or officers adopted or terminated a Rule&#160;</span>10b5-1 <span style="background:#ffffff;">trading arrangement or&#160;</span>non-Rule<span style="background:#ffffff;">&#160;</span>10b5-1<span style="background:#ffffff;">&#160;trading arrangement (as such terms are defined in Item 408 of Regulation&#160;</span>S-K).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;">.</p><a id="_eb1108c7_b9a0_4858_a062_31e8a074aa95"></a><a id="Item6Exhibits_829552"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">6.  Exhibits</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:13.5pt;"><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:41.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Number</b></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File Number</b></p></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed or Furnished Herewith</b></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:22.5pt;"><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">July&#160;1, 2016</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.3</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">October&#160;17, 2018</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.4</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465919074602/tm1926620d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">December&#160;19, 2019</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.5</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837022013560/plx-20220630xex3d5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.5</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">August&#160;15, 2022</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.6</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837023013483/plx-20230630xex3d6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fifth Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.6</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">August&#160;7, 2023</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.7</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Bylaws of the Company</span></a> </p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.2</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.1&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Agreement/Notice</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">July&#160;18, 2012</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837023002102/plx-20221231xex4d7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Capital Stock</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.7</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">February&#160;27, 2023</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.3</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/tm2012488d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">March&#160;12, 2020</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.4&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Executives)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.8</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.5</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Standard)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.9</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.6</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/plx-20210824xex4d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Indenture, dated as of August&#160;24, 2021, between Protalix BioTherapeutics, Inc., the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;26, 2021</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.7</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/plx-20210824xex4d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Exchange Note (2024)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.3</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;26, 2021</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">10.1&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837023013483/plx-20230630xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Amended and Restated Pro BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;7, 2023</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20230930xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20230930xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20230930xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20230930xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer</span></a> </p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.INS</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">XBRL Instance Document - <span style="color:#333333;background:#ffffff;">the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.SCH</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Schema Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.CAL</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.DEF</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.LAB</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">101.PRE</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">104</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">COVER PAGE INTERACTIVE DATA FILE (formatted as Inline XBRL and contained in Exhibit 101).</p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="8" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;">&#8224;&#160;&#160;&#160;&#160;&#160;Management contracts or compensation plans or arrangements in which directors or executive officers are eligible to participate.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9438b124_4742_4daa_b0be_345ad592ed83"></a><a id="SIGNATURES_574709"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.9pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:12pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROTALIX BIOTHERAPEUTICS, INC.</p></td></tr><tr style="height:10.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant)</p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:10.8pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;6, 2023</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr style="height:20.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr style="height:17.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;6, 2023</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eyal Rubin</p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer, Treasurer and Secretary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:458.2pt;"></span><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>plx-20230930xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.4.105.0--><!--Created on: 11/6/2023 12:31:13 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT&#160;31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 10pt 0pt;">I, Dror Bashan, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 24.45pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:98.94%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;6, 2023</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>plx-20230930xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.4.105.0--><!--Created on: 11/6/2023 12:31:14 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT&#160;31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 10pt 0pt;">I, Eyal Rubin, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 24.45pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;6, 2023</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sr. Vice President &amp; Chief Financial Officer,</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasurer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>plx-20230930xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.4.105.0--><!--Created on: 11/6/2023 12:31:14 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT&#160;32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2023 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Dror Bashan, President and Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.5pt;">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;6, 2023</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>plx-20230930xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.4.105.0--><!--Created on: 11/6/2023 12:31:14 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT&#160;32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2023 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Eyal Rubin, Senior Vice President and Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;6, 2023</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>plx-20230930x10q005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20230930x10q005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ',!#@# 2(  A$! Q$!_\0
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M_P"%'U*?=!_Q$7+O^?,__)?_ )(_1NBOSD_X:#^(O_0VW_YK_A1_PT'\1?\
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M+O\ GS/_ ,E_^2/T;HK\Y/\ AH/XB_\ 0VW_ .:_X4?\-!_$7_H;;_\ -?\
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M3_AH/XB_]#;?_FO^%'_#0?Q%_P"AMO\ \U_PH^I3[H/^(BY=_P ^9_\ DO\
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M@ Q3QR _W6!KYLU+PUK?AV-9=0L(A"0#YF]?3)Z^E/U#1&TR&TDU1ETLW?\
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MQ'JSQASY5OF)3QD9SSUKYG\:^$KSP-XHU#0[XJUQ9R%"Z]&'9A]17UZ/VIO
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MZBDK6<J$,(/(EB/S'JV'%0^+?BE\$?$-U>>)K[2KK6-;N(0GV257 W*#C^(
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M;J:$2),(W9/,C.5;!QD>QK[*T3]ICP1X?TY9D\0ZWJ$*0"-=,O8%D<,.G[S
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M4_V:?&_C?Q_K.N:9;V3V%Y*KQ-)=!6("*O([<@URO_#'WQ%_Y]=/_P# Q?\
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M\*/^&/OB+_SZZ?\ ^!B_X5]XT4?7*GD'_$/\H[S_ / E_P#(GP=_PQ]\1?\
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M\*/^&/OB+_SZZ?\ ^!B_X5]XT4?7*GD'_$/\H[S_ / E_P#(GP=_PQ]\1?\
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MYRM^G^78OU?]:+_@_P!;]%J_Q@T/1H[.:4RR6UQIC:J9HP"(X045<\]79PH
MZD'TKE?'WQEO=/\ !WB".*QN_"_B6#3?[1LDNQ%+YD.]5+K@LI(+ %3R-PXY
MJEI'[.DH\+>,=%U?4;>YCU(K::6ZQLXM;&-VD@B=6^\0\C[@."-H[56N/V?;
MW4='UR---\*^'+NZTTZ= FC6HVR$NK-++,8ED7[@ C7@9))8XPM'_7K;]$_Z
M:I:6_KM?]?ZT?7S?&6&SAO94TB_U.PTA8TU74[?8([>0QJ[ *2&? 8$[0<9J
M.;XZ6HOM?6UT#4[W3M"EC2^U*'R_*1'B20.H+;G 5QD 9&/<5G7'PG\16.G^
M)=#TF\TS^Q/$<GGW4]UO%Q9NT21S>6H4K*&V9&YDVDG[U<SX<\$^)[G6OB;X
M9TU;*T\.WEY!:F\O1(LZ)]BA1GB 4K+D#')7!!Y/0/=OTO\ /2_RUT)6B5^_
MX=/GW.RUWX]V6D7?B);?0=2U.RT".WGOKVV,?EK%-'YBNH+ O@=0!FK2_'+2
M[7^V%U;3KW2)M/M(+](9]C-<PS.4B*;2?F9QMVG!!(K+N?@K>K8_$2SM+RV2
M#Q#9VEI9>86)B$,'E9DX[]>,U!XW^ \WC?5=7EN;NT%I=Z'9:?$DD9DQ/;W!
MF#.AP&C)V@C//-&E_+_@/]1]$^O_  5_P?N-C5_CC9^&](UNXUG1+_3M0TJW
MANY-,9HY)9())!&KH58J?FX(SD8K/\7?&R^TWPQXT%IH%U9>)-$TS^T8K2\>
M)E>)@P67(?& 5.5R&XQBL2^_9_O=3\.>)8(=/\,>&KW4[:WM(8-'ML1 1SK*
MSR3>4LA+;0 F-JX[DYKIO%_PEOO$VN^,+M+ZW@@UOPXNBQ;@Q:.0&0[V&,;?
MG'0YX-3+;3S_ "T_0J%N97VNOTO^OW??WOA?4+K5O#FFWE[;-:7<]NDDD+,K
M%6(!/*DC\JU*S/#-O?6?A_3[?4EMTOH8$CE%K(SQ9 Q\I95)''<"M.M)VYG8
MRA?E5]PHHHJ"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .?4_Z;/\ ]=&H
MH7_C]G_ZZ-10!\^?\%'&V_LXR?\ 86MOY25\X_L$70^SZDAX#1G_ -"-?2O_
M  40TV;5?V=Y((&B5_[5MFS-*L8P!)W8@9]J^8OV&K9]/?4(9BGF"-L^6X<?
M>]1Q7E*$GC^:VG*>HYQ6 Y;Z\QT;WXU7PCXDM2<RZ5J,CJOHI8UC:?K!M;?2
MG!P?LK\CKP]='X!T>X&M^,;:]M"L5]<O&I)'S#YN1^E<+>12:>EA#*C(4M[A
M3D8Y#G_"O#J4IJM3Q%M7H_D_\CT(5(\DJ5_/\%<]#_:7N1?WL-HJ[D^Q0W>0
M/1@#^AKYM\>WZ)K'@NUB8H+B_974''_+2O>?B;J:MXT\.17+;HKW28HF'UKY
MA^(-PUO\1/"$'41:K(N[UQ**]G$14ZUWO=+[CS\/+DIV]3T"YU;5K'XDWMA:
MW4L4LDV44_,"!'GH?<5].Z'\0[;6_A;K\-]+$+I;;ROW1(&[RQTS[BODSQSK
M3-X[ANX,QRPRSQF1#R2%!_K6N=:&G-J^D--MCN(4G5F.,=S_ .A5Y\\'R>T5
M'=M-_@=*JQK1A&IT3/L?]G2?1#\/[DII$]W<SJ+*8@@NL6-W/_ B?SKPWXG^
M'X=-\27D#6,L0B;C>GS;>V:T_P!G+XH:SHO@%9=.EMQ<F\,!FN5\U0N0.F1T
MQWKZA\?>%[;QUHEB7AT^6[DB#F\!*,[8Y& .GMFO;E"557OKH>(K1E9]#Y/T
MK2(C;JS1,ZD K\N,#%8/B_PS?7+P/IB/&5)+[#M.,5[==_#Z:V 6*[L"J<;1
M<+S^9KS[Q%;SQ7OV2*]6VFB8[O*.\-D<<@FE&,H[H)),\8U7P!>7^K6&I7\4
MTEW8$FWE+_<SU^M='\-O">C>(_'5O:^(M0^PZ8 6N)I"1D#J ?4]*Z35!>P6
M[>=?AQZ;,'^5<H)XXKR::&TDN$BCS)(N,#C)^IJ)S:U:'&/F?8W@SX6?!?1K
MQ]9\-EKZ[@C8F*WN7F8C'/R$\\5\X_M.ZMX%UK6K3_A&(=4BUR:$9E5FC6V8
M'(,B9'!'\Z[#X+^(;O0+ZXU"#$%F86SYZC.2/N8QQT_6O#O$NM0WWB+7=7U"
M,QSF:1O*B(&[$7*CZ=?PK>%6,HI-?(EIWN:WPP\,I%KNNP-,TK0LB@$\ XYQ
MZ<YKU3XRE%T*PA)P1 M<Q\'$_MKQ3XG9;1K58C'E7'))+9)J[\9[W?-80@Y
M@(_(UHM82;,W\22/---U6/37 >S-Y;I(LK1L^U'*O'@'@\9QGVS7J'B#Q!YN
MC>$0BAY)M0N/ND]44@G\3G\Z\HL65=-;>ORF[0LW<*&0D?Y]*V+:_D70/ARZ
MG>&NM0()/4[R*\Z3_=RCY'HTE[T7YFM'K#C5/G+?.RGGW\NN^^)M]N^-$5R6
MS';0$C:,D,X1$_,N?RKQQ]6-QJ5GG'^JMNG^T4KMOC#XP7X??$W3-2=E>6^O
M[<&%^@MXPH8GUR6/_?->=@>5TYN6R:9ZF*E/VD%'=IH] ;QA;6%[XHGNXC(U
MS>M#'\N=K[;<9]NAYKQC1M0G;4XOEW21E(\[L?=&T?RKH=0UD7R7TP95$FKR
M@KZ8D1<?DM<!HVI>1K-H0V2]Z(S^;5ABZ[>*C'HG^EPPM-*A*7D'C76'M? G
MB D[1?:[<$#V#9_Q_*M;X^R!?V?_  CCC)M>_P#TRKSSXP7[V.@>'8"P6&YE
MN[IE/4DN"#^3BNS_ &@Y/+^ _@\$YRUMC/;]U77337M8OI#]0DT_8R765_P/
M$_"2_:M>N8CRIBA8CU N$8_H*WOAY*NI?%JS;DI+)*>>>"&K"\$7T&FR>(;V
MX4LZ:;LA [R-*H7\LY_"MCX1R_9/&J7[1[A;VDT@SP Q4JI_[Z=?SKS:4;.F
MK=3MK5-*K^1FZNP&O>(/+/R+&=OT\Y?\:N>&YF:+PRO4"2^'YJE9.H3)_:/B
M!@RDF+'!Z?OXZM>'7*2:  W2XN>GNL=7%-3NO/\ ,4ZGN_=^1WVGZCL_9_U^
M7=R)9!]/WZ"HY_$+S_LX0.6)/VY0#]'K$CN2/V9]?D!&//D!/_;RE9/VW_C&
MRS7/)U$#]6_PKU/9VDI?W3SHU;QM_?.!@U!O['O!NX>?)_[YK]EOV+CN_9:^
M'!]=,'_H;U^*D$A.DR#^](Q^M?M5^Q7_ ,FL?#?_ +!8_P#0WHP$;5I/R#'U
M.>DO4]EDZ5C:E]QOH:V9.E8VI?<;Z&O?/"-32/\ D&P?0_S-7*IZ1_R#8/H?
MYFKE !16+K'C30?#^L:9I6I:M:66I:FQ2RM9I0LD[#J%'>MJCS **\G^,/QD
MOOA;XL\)VXT^*[T._,SZG-M8S6T2!?WJX.,*6!;(/&?2M.X^*T6G?$#5=.O9
M[.'PY9Z'#JHO<$N2\K+US@J0!@ 9R>IH6NOK^&H/3\/Q=CT6BN;\,^/])\57
MLUE;?:K6_BC$S6E_;/;RF,G <*X!*D]Q63XG^+>B:!K.J:$9KD:O8V0O9FCT
M^6XBMHF#E9)-F!M^1N-P/;(S0]-QI7.ZHK@H/C%H,<=C%)<W&HW,EG;W<\VG
MZ?*T<*2CY'D W&(-@D!B3@=36=X?^,4<_B;Q=INK^3&NGZW%I6FQV<+M-<!K
M:&4EER<D&1LD   #/K3L[N/];I?FR;Z7_K:_Z'IU%97B3Q/IWA/3#?ZE,88-
MZQH%4N\CL<*BJ.68GH!7G'Q$^/-OH/@FZU+0K>>?5H[Z#3GM;O3YF>TDE9=K
M30@J^,'(&5W' !YI>A1ZY16%)XCBT/3=';6;@"XOI8K42QVSQ(TS@X!0LQC!
M(QAF."0,YK$UGXGZ59>(['3(]3C@D.H-83QR6,DOFR"V:<QI(&4(0H#%B&'!
M7 )R#^OR_P U]XNG]?UT.XHK@-.^-_AC5M&AU.U;4)+6YE$%I_H$H>\<ACMA
M7;F0@(Q.WIBLS4_C/'=:SX&@T)8Y;76=;FTF_2]@DCGMREM-*5"DJ4?=&OW@
M>">.]-*[L'2_]:?\,>I45@^*_&NF>#DM/M[3R7%Y(8K:TM(&GGG8#<P1%!)P
M 2?05DS_ !=\/Q6]D\9OKN>[B:9;.VL99+A(U.&9XPNY #QDCK2 [2BN$NOC
M5X7@GLX+>XNM3GN[(ZA!%IUI)<,\(;:6 4'H>HZBJ#_&S3[GQCX3TO3;::_T
MO7;*>\74HH7*1A"H&3C 'S'<3]W SUH_K\_\F&W]?UW/2J*XS0_BWX=\0ZK;
M6%K+=*]W$\]G-/:R1PW:*,LT+L,. "#QVK'TS]H7P?K$6GR6<FI3+J4;26!7
M39O],V_>6+Y?G8=P.: /2Z*\_P#^%OZ'=MHUY;:JB:?>0W<S026,K3-]G'[P
M;MP\ID((*LI)/ Q5CPY\9?"_BB>SCM+FXB2]M#?6D]W:R017$(4,S1LP ; (
MSCI1_7Y_Y,#N**X&+XU>'KM6%LM_*\EI)>6>ZRE1;Z-5W$P,5Q)P0?ESP:Q/
M!OQTL?$&A^&=7U2XCT)-2T>34Y[*ZLI5("A"SI,6 "#?@94[\@@BCO\ UW_R
M8?U^7^9ZS17"GXS^&8K'4+JZFN]/2QM3>R1WMG)#(\ ('FHK#+KR.16AX:^)
M>B>*M7?3+1[J&]%N+N.*\M7@,T)./,CW ;USCD>HH ZJBO(O%/QLE\/_ !6O
M- F0V&@Z/I U;4KR;2YIVE5F8 1R*ZJ@ 7[Q5]QRH (-=(/C'X?:SLYUCU-Y
M+P,]O:+ITQN)8U"DRB/;N\OYE^;&.:%JK_UV_1@]'9_UI?\ 5'<T5P=_\;/"
MMD^EHES=7\NIVDM[:Q6%I).\D43*LAPH."I89!YZ^E3>'/C%X8\5:CIUGI]U
M.YU*-Y+*>6VDCAN=@RZH[ !F4=5ZC!]*=K_U_78-CMJ*Y+Q9\3]#\&ZU9:1?
MF[EU.]MIKNWM;.TDG>2.(J)" @/3>OX9]*J>'_C-X6\3W^G6MC=SG^T8Y'LY
MYK:2.&X*#+JCL "RC)*]1@^E):[?U_5@>FYW%%<38?&#PUJ.K6EA'/<HUZ9!
M9W,MK(EO=&-2SK%(1M<A58X!Z UF6?[07A"_:Q$$NH2'4%D-CC3IO],*??2'
MY?G8<DJ.< T >DT5P4OQM\+);Z/)'/=W,NK>>MI;6]G)),[P_P"M0H!D,OH>
M>#3M!^-?A7Q)?:;:V5U<DZA(]O;RS6DD<33H"7A+L !( K?*>>#3M<-M3NZ*
MXP_%SPX-;ATWS[G,UW]@CO/LLGV5KC./*$V-N_(QC/7BN7\&_&<ZM< :W?:?
MI@%WJL9A6TDP\%I)M\SS3)M3"\MD'.>-N*2U_K^NXVK?UZ_Y'K=%<'%\:_##
M07TTLM[9QVEA)J9-U92Q>=;(,M+%N7]X,?W<]15WPQ\4] \6ZG#86,MRMQ/;
M"\MOM5K)"MS"<?/&6 #CD9QZT[/;^OZT?W"\_P"OZU7WG7T5ROBCXE:+X1OU
MLKPW<]UY7VB2*RM)+@PQ9QYC[ =JY[GTJOK?Q:\.:#>2V]Q<7$GD1)-=36]K
M)+%:QN,JTS*,1@CGYNU+<#LJ*X#7OCCX3\.:CJ-I>75R3IR0R7D\-I))#;QR
MKN1W=00%(/7-/E^-GA6UL=7N[JYN;*+2H8[FX%S:21N87;:DJ*1ET)_B'% '
M>45Q^F_%;P[J,>H.]Q-I_P!AM_M<JZC;O;MY':50X&Y#TR*K+\9O#*V=_<W,
MUW8+9VIOG2]LY(7DMP0#+&K %UY'(SUH>@;G<T5Q>D_%WPUJ]S<P"YGLGAL_
M[0_T^V>W$MMG!E0N!O49&2/4>M,@^,?AJ2SO[F6:ZLDL[1K]EO+22%Y+<=98
MU8 NO(Y7/44/3<%KL=O17FVH?';08](U:XL8KV>^M--?5(+2:SEB:[A'&^/*
M_.N2H)&<9%/TOXW:-<:1I4]U;Z@NH7=A'J$]G;V$TCVT3Y >0!250D-@GKBG
M;^OO_P F']?E_FCT:BH[>=+J".:)MT<BAU.,9!&14E( HHHH **** "BBB@
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MJ7O-W_JW+_\ (H\,\$_"3Q!X<\7^'=0NHH7BBTK5ENVBF!6&XNKF.9(E!Y(
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MP]\1?%?[7J%UIX\--%HATZTM[FX24W$S2QREF,18"+]TH&?F.YB5&,&O\0/
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M_5_D>4:?8M C2%XY(W"8:-LC()./6DA0YF4<EK4\?5A52R<VPG;8Q4F%5;'
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MF!8 =3]![5X7X(\->(O#FE_#R230;UI[:QU:R,,EN^V&667,*R@#,:,%^\<
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M&VF5G"KGMGN1CTS6KH'CC2=?\%VOBB.[BATF:V^U-.[C9$H'S;FZ?+@@_2O
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MJBV>NZG;7'C*QOY)=6MDAD,<<,BM.UND,?DJ&V\L,G@G'%$5S-)Z:KY7Y?\
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MKB2-8D)4N< F6,9Q^-<2=)2C8WG&HHMZ&??>=<:OJK)!)(0=HVJ3GGM^5/\
M[#U66SM5%A.C"&0YD78!EFQR<"G:]/)_:FKA9'P)!CYCQR?\*R;IY?L%NS.Y
M)ADR"Q.?F>M4Z:EK?^F9RYFA/BEG3_V>-/CNH5??>0*463@']YW'TK2NAI6K
M_ _PEK,MHTEA;2"RG@L9-DB2X8JS$@C! -87QADV?L^^'H2>MY /_')35[X<
MWWV#X?7.BS6_VBWU;35EB!;A)HQD,!Z_-C\:^B>L-.QXBT:;[LQY9?#!M(/(
MM]7A_=@C?-$W4^RU^S/['_E_\,S?#SRMPB_LQ=N_&<;VZXK\3I5"VMMV_P!'
M4GZ\U^V'['8Q^S%\.?\ L%)_Z$U<>#ES5I:=#JQ*M")ZY)TK&U+[C?0ULR=*
MQM2^XWT->R>::FD?\@V#Z'^9JY5/2/\ D&P?0_S-7* "BHWGBBD1'D1'<X56
M8 M]!WJ2@ HKE]>\;KH?C/PYX?-F9CK(G(N/,V^5Y:AONXYSGU%4=;^)4>C^
M)=6T=X;.W^P:?!?&\U"]^SP'S)3'M9MC;<;>O.20,#K1O;S [:BN>U?XA>&?
M#]ZMGJGB#3-.O"@D\BYNT1]IZ'!(.*Y[0_C9X?U'Q7XAT"_O++1[W3-273K=
M+F]0/>EH8Y0R*<$?ZS;CGIUYQ0M79?ULOU!Z:L]"HKBO"_Q0L?$/BGQ)H4RQ
M:?=:3J8TV 27 +7K?9HYRR+@$8$F,#/W<YKIAKNG-#?RK>V[QZ>[1W;+("(&
M"ABK_P!TA6!P>Q%'2_E?Y?TPZV^1?HKA/"?QI\*>*O!$/BH:O9Z?I<DC0M)=
M74:B-P?NL<X#8P<9Z$5:UKXDV6G:MX/M;-(]3M?$=U);17D$XV1A(7EWC .X
M'9CJ.M.SO8/Z^X[&BL33/''A[6KR\M-/US3[VZLP3<PP7*.\('7< >,>]4X/
MB=X0NM/N[^'Q/I,ME:%1<7"7D9CB+9VAFS@9P<?0T@.F(# @C(/!!KG-(^''
MAK0=5.I6&CV]M>Y9EE4$["V=Q4$X7.3T ZTYOB+X632[34F\1:6NGWC,EO=&
M[3RYF52S!6S@D*K$@=@:Q/%/QM\)^%]*T+47U>SN[+6;^.PMKB"ZC,>6.&<M
MG&U>^,]11L_/;[PZ?C]QWM%4-7U[3= TU]0U._MK"Q0 M<W,HCC&>GS$XKA?
MB%\=- \%Z+H=[:7VF:G)K5\EC9&74%@MV)R6=Y0K[44#DA6Y*COFCK;Y?>'F
M>DT5E:MXETWPUI*:AKFH6>DV^%#S7%P%B#'L';&?;@9]*I77Q$\+6.G6E_<>
M(M+@LKM6>WN)+M DJKRQ4YP<9&<=* 6IT5%<]IOQ#\+ZQ?6ME8>(=,O+N[C\
MVW@@NT=Y4_O* <D?2I$\=>')/$']A+KNG-K//_$O%RGG\=?DSF@#=HKS#P7\
M;D\8:[I6FC1VM3?OJ*>8;G?L^R3F(\;1G=C/MTYKM=?\::!X4DMX]9UJPTI[
M@[85O+A(C(?;<1FCHGW#JUV-JBO/XOC1H$'CC7?#FJ7MEH\FGM;+!-=7B+]K
M,R;P%4XZ=.ISFNDUOQSX=\-7=O:ZMKFGZ;<W&/*BNKE(VDSTP">: -RBN>UC
MXA^%_#]XUIJ?B'3-/NE"$PW-VD;@/G8<$Y^;!QZX-2ZYXX\.^&7MTU?7-/TQ
M[A2T2W=RD9D Y)&3R* -RBL'4/'OAO28["2]U[3K6/4 &M&FND47 /0ID_,#
M[4[5_'/AWP_?6MGJ>N:?87=T 8(+FY1'E!.!M!.3S0!N45E>(M<30=/CNFEL
M8U>:.(-?W7V>,[V"X#;6RQSPN.3@9&<U2B^(OA:?58M,C\1:6^HRR/#':K=H
M9&=20RA<Y)!!!'M1N'F=%16?K7B'2_#=JESJVH6NFV[R")9;N58U9SG"@D]3
M@\>U9K_$7PM'HD>LMXBTM=)DE$*7QNT\EI#G"A\XSP>* .BK/U+0-.UB[TZZ
MO;2*YN-.F-Q:22#)AD*,A9?0[68?B:S)?B1X4AEL8I/$>EI)?*'M5:[0&=3T
M*<\CZ56\>?$O0OA_I=W/J&HV4=]':RW,%A-=+%)<;%+;5SSSC&<&DWRJ[&ES
M:(ZRBN;\.>/-*U_08M1:\M;61;&&_N[=KA2UHDD>\&0\8&,\D#.,T_4OB%X7
MT=;!K[Q#IEFM^JO:&>[1!.K8VE,GY@<C!'K5--/E>Y*::NCH:*\[_P"%V:#<
M^(M;T.TOM,6_TFYM;>;[?J"P(_G,J_*0')8%@ I W,0N1G-=5)XU\/Q:\NB/
MK5@NL-]VP-R@F/\ P#.:6Z3[C[HVJ*YY?B'X7?5TTI?$.F'4WE:!;07:>:9%
M^\@7.=P].M:^IZI9Z+8S7NH74-E9PKNDGN'"(@]23P*.EPZV+5%<ZOQ$\+/H
M1UM?$6F-I ;8;X7:>2&]-V<9]JEG\=^'+;2[74I=>TZ/3[K(@NFND$<N 2=K
M9P> 3QZ4; ;M%84?CSPW+X?.NIKVG-HH)7^T!=(8,@X(WYQG-<?H'QSTKQ#J
M6L1Q3:7;Z=IVIFP%[/J8 NE%LDYDA 0AB ^"NX8"DY[4=UVU_+_,.ESTVBN!
M\"?&'1OB)INAZAI-UI_V;4A-F&:^47*&/DJL:J0Q (+?,-H(ZUOZ?X_\,ZM)
M?)9:_IMV]BK/=+#=(Q@4=2^#P!CO3:MN&YOT5@:1X_\ #7B"\FM-,U_3=0N8
M8Q-)#;722,B$9W$ ].1S4N@^-?#_ (IGN(='UJPU2:V.)H[2X21H_P#> /%(
M#:HK,\1ZPN@:+<W[R6<2P@$OJ%S]GA'('S2;6V_D:SI?B/X6MM0CT^?Q'I4-
M^\OD"V:\0.9< [ ,YS\PXZ\BC?0#I**Q-1\<>'M(UBWTF^US3[34[C'E6<]R
MB2R9Z84G)K&\'?%#3O%,US;S^3I=VNIW.F6UO+< O=-#RS(, GY020,X H6N
MW]?U<'IO_7]6.THK#N_''AVPT^XOKG7-/@LK:8VTUQ)<HJ1RCJC$G 8>G6N6
M\*_&.Q\69E@.FVUK_:\VEI+<:D ;@1QE]\("$2,0,[,C"ACNXP1:_P!?UW!Z
M;_U_5CT6BN?T7X@>&/$E\++2O$&F:E=F+SQ!:W22.8_[V <X]Z2T^(7AB_U@
M:3;>(=,GU,R-"+..[1I2X4L5V@YR "<>@- '0T5Q/C/QSJVB^*M$\/Z)HUEJ
ME]J<,]QOO]1>SBC6+9GE(922=X[#I7/:K\=&\,I/;ZYHT-EJEIJ=E874<-_Y
MELB7+8699FC4D 9)5D4\>G-"UMY_YV_,'I?^O,]7HK*\/>*M&\6VCW6BZK9Z
MM;(VQI;.=955O0E2<&J^H^.O#FD:S!I%[KNG6FJ3D+%9S7*+*Y/0!2<G-'D!
MNT5ST_Q$\+6VK?V7-XBTR+4O/^S?9'NT$OFX!V;<YW88''7D5D?$[XNZ%\,=
M#U"ZN[RSFU.VMC<1:4]VL4TX'90<G\<&@=M;'<45Q_CSXH:/\.O#=CK.L2I;
MP7<\,"*\JIAI"!G+$<*"2?85J7/CCP[9:G::=<:YI\&H7:A[>UDN4$DJGH54
MG)!H_P"&)OI?YFY17-W?Q)\)V&J/IMSXETJWU!)OL[6LMY&LBR;0VPJ3D-M9
M3CT(J2V^('AB\TN[U*#Q!IDVGV<GE7-TETACA?CY7;.%/(X/K0,Z"BL;2/&>
M@:_:W5SIFLV%_;VI(GEM[A'6(C^\0>/QJO:_$/PO>Z/=ZK;^(=,FTRT.+B\2
M[0Q0G_:;.!^- '0T5S,_Q-\(VVDPZI+XFTF/39G:..[:\C$3L#@@-G!(/!K)
MU'XT^%M,\;Z3X:FU.U$VHZ?-J4=T;F,1"-&0 9SR6#EAVPC>E'6W];7_ "#^
MOT.\HK(D\7Z'$MDSZO8H+V![FU)N%'GQ(H9W3GYE ()(X (JA!\3?"-SH\^K
M1>)M)DTR!Q'+>)>1F)&(R 6S@$@@XH Z:BJNF:I9ZU8Q7MA=0WMI,-T<\#AT
M<>H(X-6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH Y]?^/V?_ *Z-10O_ !^S_P#71J* /!_^"B-E%??LR:RLJ!A'<PRJ
M3_"P#$'_ #ZU^;O[*NF3SZQ-*;:5H2[!7"G!.1WK]#/^"F5]/9?LPW0A<IY^
MJVL+X[J0Y(_05^=?[*TVSQ#>$D[1GC/3I7F2?^UI>1Z$8_[))^9[K^U2-/MY
M=.>.8G4'MA#-;[<;!G<K$^XKR3PC$LM[X:60?(URWY9KM_VD;NVO=8L98I?,
MFG@1G49^7:-HR:Y#P2"]YX; P#&\S<_B:\6M+FS%KM;\T=U%<N#3]3UOXA_$
M.:#2V&G7!9GLI9HY23\H4[>!7B_@$OK?BK7(YB6:>U#NW;/!Z5TD&S5?AG=:
MBRF2>VAN8NN/E9B0*P_@XTC:]K<C!5$<"D!1_L]Z^CFF\73;?<\>G_ G9' >
M.&+^(KY4*96:9<X]-O-9_@@&34K%&0,6%P#Q]:MZ\YN-9O9F(!::5C^(6NE\
M.^%XX_$$$R,LEFMH]R6C8'&0,CZYSQ7)1O.I/U-JEH0@_(WO"MG% JV>%DD
MB#IGG[ISCTKZ1\ S+'!'MB X .!7AOPOTZ&_DCU$ " R- D97!V@\$GN>O-?
M2WA6QMXH56)!FO64>AYU^IW-K=DP+A><5Y5K'@>%_%&N:FTUQ.;^+RG@FD+1
M*.,[5Z#I7K"XB@&1C KF]1D0RN<=>M6KK8B6I5\+Z0FCZ!!;VP\F&,86-3P!
M7)>.=(_M198I1OC<88'H:[RWN5%J%' %<[K<B.3WK"2&F?(GQ'\)W'A2>YE"
MO/!>%81*G/DIZ-D\^V*X2:]DMO#]^TD,D1C>(0(!_>)4,?1<<U]7>+M%MM3M
M98I8]R2*58@\@5\N^/\ 2)=!9-#MI97:>=&:61,>9$@9@H/?'!_"B.S3'J>T
M_ :XD_LK5K,R":.T(575<+R"<>_UK9OW)\KY2#]B1L^O2N/_ &;;\SP^,8FY
M,%R$SG/&S-=IJ)#01$=1;1+GVVBLE'E@TS23YI71YL(X+CXFV:7,<<T(EC=E
M.00%RQ.1["I?B?X@L-2;0H+67$@L#=&!F^<;P&+'OU)I]M;*WB7Q'=]9K>Q9
M8@.N]EV#_P!"KB/''E6/QE$+QB6./1O("@XSMPHY_P" UY=E/#U;];GHQTJ0
M\CL_AQK>HZ9XHMH[&Y,*3W%O%*HZ,IX(_*OI+X+?#O3O"$/B#Q4;B&YUGQ#(
M%F(/,<:X 3'U7/XU\V> #I=WXOTX0&ZMIEGB>2.10Z$JA/##! X[UU?PH\=Z
MQK7QZU[3)]3_ .)-I=LZ6]C@C:657W'CD\FM<K7LZ5GKJ+'OFJ:::%3XK.]S
MXP,C-\S;L<]MS8KS;4!ML8 PSMG&/^^#7?\ Q!D,GB:W8L&W6P<D>IW&N O<
M26T0/_/53_XZU?'Y@_\ ::GS_)'TN!_@P^1[WX5^$WA/Q!X=T)=2@+W)M]TD
MD?4M(=V?P4H/^ U:_;-^QZ;X5\(Z=#&9 L[1PRL>45$ Q^.?TK!^&_BGS=/T
MR+>RR(?()';R]H'_ ([M_7TJY^V=-_HG@J(GDO/*?Q _QKZ=.F\$Y4U;1'C1
MY_KD5-WU9\S0=+X'_GXMO_09JTK)]E_<-G&(8S_Y&CK+@.3?$\#[1;_^@S5<
MBEP][QT@3G_MJE?.1^->A[<E>+]3J/&,-LQDU&V;_7OY$R8QME3(/YJ4;_@5
M<K?MMTRWY_Y8R$?]]M6WJ-V7TG7(&&0FHPNI]-T<@;\]B_E6#J>/[*M0.]N_
M_H;?XUW2?-)-=D<"5HM,I?&Z(P?!'PX"P_X_(>/^V<M/L+S^S=%\"/C"MF-C
MZ@H@_K3/CP,?!SP\!SF[B Y[^7)5#796'AWP;$@.](]WL/ECKZ>3M"_H>%&S
M:7J5]9MFL]1N;3!_=C8H]LG%?M;^R C1_LR_#I6&UAI2 @]N6K\9O'UW%;^)
M;]H 1/M0LY[':.E?LO\ L=G=^S%\.2>3_92?^A-7+A%:O41O7;=*!ZY)TK&U
M+[C?0ULR=*QM2^XWT->P>>:FD?\ (-@^A_F:N53TC_D&P?0_S-7* /._'OP4
MTGX@^//"/BN]O]0MKWPW,9K>"VFVQ2D]G'^&,CCI7HE%%"T5@>KN>4?%+P5_
MPE_Q,\!?:=.N;S2K?[8UQ+"9$2(F,!=SH1MR>F3S7 _$WX7W&FWGCB'P]H>H
M2VUWHU@D7EB:X\V5;LLRJ6+$D+@D \#FOI6BA:-/L#UO\OP/ESXF[O#/@GXC
M:3J^BZAJE]JNL1WMI>PV32P&)O($8:8 K&T6TIL8AC@%0<U>U;P1JLWA7XU-
M'H=V][J6KVLMD5M6,ERB6]J T?&6 8/R.A!]*]NN?AGX9O-<?5YM)B>^DD$S
MMO<(\@QAVCSL9A@?,1G@5T]$=%YVM]W+_P#(@][^=_S_ ,SYKNO#6K:+:?$[
MQ*VGW%M>Z7XAM]:T]YXRGVE([&W60(3C<& D3(XR"*]?^$VCW&F_#^RDO4V:
MIJ7F:E> ]?/G8R,/PW!1[**Z/7?#NG>);:.WU.V%U!'()1&SL%+#ID C(]CD
M5HJH4    < "C>/+Y)?<DOQLON%U3]?SO^%W]Y\Y>#-/U+P]:^ -4U/0M8>R
M\._VE8ZA:IILTLT$\C*8YTB52TR;0R[X@WW^/XL4-1^'_B;48-!:RTR]T];W
MQ%J]];1&(J=/@FM)5B,@'^JW,<X.,%\=>*^G:*'KO_6MW^/X:%7_ *^37ZGS
M3X.\):U=W7A2VF7Q&]SX>LKF.YCN]+CLK>W+0-&8UE$0^U!VP0(V(^4,Q! !
MM6>@ZKX?^%_PKAET?4;*&QG,FH3V6F275[8MY4@0K JLWS,Q4L$)4-GC.1]&
M44V[W?I^K_4E*VGR/ECPCX+UR3Q+X8FNM!UC[)%XZO-0+:E:DLD#64NR9^,*
M"Y'/9B!P>*V;WPWK&FQZE=G1=1>UM?B#!J9CM[221S:C :6.-06=<G)V ]SV
M-?1U%"T::Z6_#E_^10W[R:?6_P"/-_\ ),\U^*EA=GQ!X%\1+I]UJFCZ-?2S
MWUI:P--,@>!TCF$(!9RC$?*H+#=D XKSJ\\+:UJ?B'2=:M=%U"WTN\\=6NHQ
M6TEJZ20VZV\B//)&1NB#-S\X!Y&0":^CZ*(OEDGV=_Q3_3^M!-737=-?>FOU
M_K6_GGQBTJTO+31;V=-=AN-/NS-;:CH%H;N6S<QLF]H5#,ZD,5^5&QGG YK@
M?#VD>(M8\:?#O4-5T60V]E>ZHXO/[--J3&T2B*::+ \EW.[A@ISV'2OH&BE'
MW7<;U/G72?!.IZ?IWA$0:'=6\L7CR[O9]EJRE(&>XQ*W'"$%?F/!!%88T;7[
MO4/"D+:/X@BU"R\7?;;ZSATQXK"SB:63,BS%<3!@P)96;&X[MO0?4U%$?=MY
M6_"W^02]Z_G?\>;_ .2/G+X1^$M;TOQKX9N+S1[ZU@AEU\R236[HJ"2\+1Y)
M'&Y>1ZCD5V'B%9/#'Q7UG5]6T/4=>T?5=(AL[5+#37O<2([EX6"@A ^Y3N?:
MG'+#%>NT4=(KM_P?\PW;??\ SN?/'B?P=J&H1?&Z>+P[=QR:GHUI%81&UR\I
M6U8>5'MR&*M@80D BL/XCZ+K]YIGC2P;2-?^V7VAVL%A!I.FO(M_MMQN,UQM
M*HR.67RV93CH&+5]1T4GK_7J-.S3[?\  _R/GQ?"&IW.I?$"XFT6ZD:[\%V-
MG;R2VK$RRB*??$I(Y8$KE1SDC-8TT-SX*\+^)I/$6B:GJJZKX2LK>W6*Q>?[
M.T5NZRP3$ ^3\QW[I-JG)YR,5].5S6N_#?PWXEU3^T=2TN.XO"@C>3S'02J.
MBN%(#@9/# ]:)^_==_\ @_YA#W;/M_\ :_\ R)\\Z?X9US3HUOICKHTW6O"N
MG65I'I6DI?@LD3B2V?,;F#)<-O;:AW<G*UN:OX6O/"$,!TZV\2)XHDT:TLY$
MDTO^U+#4S$&V13.B%8RI<@L_E#G(S@U]&QQI#&L:*$10%55& !Z"G5<G=M]W
M_G_F1%623Z+_ "_R7]6/+OC+I6JZY\-])ABTZ2;4!J.G2S6MG&9/+VSQL^ N
M?E7!Y[ 5Y_/X*U9?A9K,$>AW8U&3QM]N2-;5O-:+[<I$P&,E=F3NZ;?:OI&B
MDG9W\[_C%_\ MH[:)?ULU^IY'^T==6]CHW@V>ZL9=2@C\46#-:PQ>:[_ '_N
MI_$>^!R<5QGB/PMJ?BC61K=IH=^FCZAXPTB[BM)[*2*41PH5EN9(64-&I./O
M@'"@GK7O^L:!I^OBS&H6J70L[E+R#?G]W,F=KCW&36A2A[NO]Z__ *3_ /(C
MEK]UO_2O\SPCQ%IUWHTOQ+TF[\/:EJ]YXF;=IDUI8O/#,IA"+&\J@I#L8$_O
M2HYR"36-K>AZMX0\.^.=)UK0M4\4W^M:)#!92V%@]VD[I:B-H6=01'AP6!D*
M@[N"3Q7TA14VO%Q[JWR12=I*79W^>G^1\QVNFZSX0T;Q5!<>'-:N[G7/"5I;
M6$=EI\LP:>.T:-XI&52(F!(_UA7/;)XK8\$V5UX$NFE\1^&M6U>UU3P]IUK;
MP6NE279#QQ;9+:0 $1?,<YEV)R<L,''T)16CE=M]_P#@_P"9FE9)=O\ @?Y'
MS7\1/#^L7>M>)+>W\/ZIF]UC0+ZW$5D\D8ABN(O-^= 4!3!R-W !/3FK&I^'
M-7?PKK7@M=$U%O$][XC_ +0M]66S<VJQ&Z65;DW.-BE(QMV%M_& I%?1E%"=
MK>O_ ,C_ /(K\1M7_KU_S9\W:CX*U?\ X07Q0D6AW?V^;QY#?1!+5O->$7<)
M\Y>,E0H8[AQ@&O3?C9H]_J6BZ'=6=K-J$&F:Q;7]Y96\?FR30(QW;4ZN5R&V
MC).W@$X%>B45*TC%+I9_<DO_ &T;U;;ZW_%O_,\6UZ]34O%OAWQ?9^%]930=
M/NI_MF[1Y([F61XPJW(MMOGMM(*Y,8;G(!'-<W;>#=6O_%.D:O\ V%>0:1?>
M,I-4@LYK8AK:#[+L\Z6/'[K?(I?#8(W#(#$BOHVBFO==UT_S3_0'JK?ULU^I
M\YIX:UC1?'>OZY-HVH3:':>+S?O;6]F\K31-91)Y\48&Z0+)G.P$Y!X)%8WA
M?PWJVH?$V75[?PMJNE:9<>,YKY/M-B\.83IZ)YY!'RJ[@]<<G!P<@?4M%3%6
M279)?^D__(H;=[^=_P ;_P#R1\JV'@SQ)K?A;P-H]II6IZ=J6G:7K&FW,EU:
M2PI!.T>$^=EVE6R-KJ2IYP>#6_KVF7_B_2?#EGH_AO5=,N- TF\AO_M.GR6X
M7=:M&+:)F4"?<Y!S$67Y<YSC/T713E[R:?7_ (/^;_K=IV:?;_@?Y'SV?!%W
M]C^$=O)X?OGM;31+VUU&"U@\MX@]HH\MB=H0LP( 8CYJT/AU?WGAK7@R1:S=
M>$M.TF43W.NZ#);7FG[&0I!&_EAKA2-Y.P.!L!W<C/NE175K%>VTMO.@EAE4
MHZ-T8'J#5.3<G+O?\;_YD)))1?0\]^-D$WBSX,ZPNCV\^HR7EO&]O%!"S22
MLI&$QGISC%>;:KX)U:3X>_&&)-#NVO\ 4-566T46K&6X58H-K)QE@"&P1T(-
M?1L,*6\211($C10JJHP !T I]+9NW7_-/]!W>E^AXIX;67P?XB\6V>O^&M4U
MV;6=1AO+%[;3&N8IHO*C55>4_NXC&RMQ*R>JYS7(V'AW6O#GBG0O$=WH>J/I
MNF^+=6GN5MK*2:=89X'CCE6)%+NA8@$H#C.>F2/IFBA-K7RM^7^0K:6_K9_Y
MGS/X0TS6=*UZQ\6:EX=UD:-;^(-5FEL?[/>2YB$Z*(;H0 %W VLOR*2!)G&
M<9ND>%=9O)]#NH/"^J:;;'QKJ-]Y$UD\;10/9SJLK+CY59F&">[ =>*^JJ*G
MI;RM^7^13=[^=W]]_P#,^;O#?@;6;;PO\$[:'2KK3;NRM[Z.\D^RLALR]G*H
M,O'RY<K][&3BJ^@W,</BCX(:#+H%_:ZOI#W,%W>3V31PAELY Y24C;*';YMR
M%AZD'BOI=T61&1U#*PP5(R"*YSP_\-_#?A:^^V:7I4=K<!2B-O=Q$IZJ@8D(
M#Z* *OFO)R?77\_\R6O=MY6.2^(7@^\\3?%?P?+')JEE8V]C>B:^TUVB\MB8
MMJLX! S@\'KCVK)^*'PN@M?#FDV^FV-[K5Q<>)=,N;^:?=<S2QI.N6D./NJO
MX 5[1126G+Y._P"-QO6_FK?A8\W\&Z/>V/QB\>WDEE-;V%W#8F&=HBL<S*CA
MMIQAB. <>U>1?%;1M>U.#QS8PZ1KYU*XUB"ZM;32],<VL\"-$1<-<;2KMA3E
M VX;0 O<_4M%):-/M_FG^@/5/S_RL?-_B;P7JUQX3^,/DZ'=R7M_X@M[BSV6
MK&2X15MOGCXRP!5^1TP?>H?BGI.I6/ASXJZ/<>&=7\1:AXAECNM+ELM.DN(W
MC$,2",R*"(S&R.=K$$YRN<FOI:BA:)+R2^Y+_)#3L[^=_P _\SS7XNZ?>W'P
MYT[[-8W5[+:7EC<2P6L+2S!$D0N1&H+,0 > "?:O+/$7A#7Y-6\=Z?.WB-_^
M$DU*.\L$L=*22*>$Q1! ]RT3?9C$5(*R%2-N5!S7T[10M&WW_P"!_DOQ)2LD
MNWZ7_P V?-.I?#_5)]$^+L,NA75S-J'B&PDMR]JSM=1);V@+J=OSJ"LG(X!#
M>]5_C#HUUIEW\6;Z?2K@Z1<:7HBQ?N2(KETDE#HA.%9@"H(SQD9KZ>JAKFA6
M'B33)=/U.U2\LI<%X9,X;!!'3W IWT2[6_!)?H-=?ZZW/G[QSX7UGXF2ZYJO
MA?2=1TBR&@P6#)=69LYKZ5;@2>6L4H4D1HK*&8;6\W"DC-9/BGPAK/BO2O%V
MI6MOXDU42Z)!INW4-)%@9W$X<1I;")'D,:[OWGW</A=W)'U*JA%"J, # %+1
MMMY_C>_YL7_ _"W^2_K;Q+XA6=_:>.M)D_L_5;;35T*2V@O-#TUKJ:6=G&ZV
M=E5O(3 1@S!5)!RPV@5P?A'P?XALM,\$P7>AZK#))X7U?1V\ZV=S;W,LT+1)
M,5!\L%8V^=L)QUY&?JFBETMZ_CS?_)/\/.]+3;R_"W^2_JUOELV>LZY/\/K*
M'PSKL)T7PUJEC?2W.FS1)'<-;QHL89E ?)4X9<JW8DYQM:CX-US3/"GP?U"&
M+4].M-!M674(=/TX75S:R/;A4E-L59GVG<I"J7'F9 P#7T515.3=WU?^<G_[
M<2DE9=%?\DOT/.O@GH5WH^@ZI/=#4574-1ENXAJ<:0RE6Q\WDJB^4&()V$9&
M><'BO1:**38!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[I/[U?[O,IJS:\VON=CZG%Q$P)$B$#J0PJ'4;UK&SGFCMY+V6)-XMH&02/[
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M ,N>,4/2_E_]M_\ (_B$=4GW_P#M?_DOP/KEYXX_OR*O^\P%97_"5Z:?%/\
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M?18S+;V\2D*QNNK=!Q6IXZL_MGQ>U2'(7S($!8]OEK*M$^SV4;AE<BXR0.V
M:\#$Q?UB[VU_]*1Z-+^ K>1Z#X#@EN+V-I@/^/2X4E>G"X%><OXPA^'/B7_A
M'Y8@USK @D7!)V OC''?BO<OAO%_;?@^75C;"$7&F2+D# 5N5_I7AWBWPM<Z
MK\<?"$?]GF8)8VLCW6W.P*,GG\*^PA1C>,I;GS?M79Q07PT"R^*]_);1W<FH
MVGF@VTN#$"R#)/?!]*V_@S%>^.Y5?4].GCEMVD\MS:F**.($;57(_E3[KX>:
MKXO^).H:G8316L'VGS9)YU)\QL *H [ "OJ/PCI7D:9 DP1IE4!V5=H8^PK9
MRYMC-=R?P9X?:)$+J0  !FO6-&L2B*. /:N<T>V ('2NVTZ$+&!CBFE83=R&
MZA X!.:QI+4>;D\FN@NP,D;<$BLN2+G^M5<13G7]V1P,5E36JN>.E;4T7R^_
MK58P9S6;0T8K6 'ICWJ"2P!4Y K>>V![57DMQSZU+07.;O\ 2(-2TR>RF7<K
MJ1GZBO(-:^#TUOY@@U&]=\C:6D)^6O=IK?CC@UCW=O('R>E0T4CY$\0Z%J'A
MSQUX=>!9);BTNA* [X).Y>??I73:]IW@6V\57WB2_OIY8[6U8O8^7L985R6W
M>@SGIZ5Z-<?"Z:X\<'Q!<:G),D3EHK9UR%''&?3(S7S7\2-3FT[Q9X_V,J/'
MHGF)N&0<.1S[4G!3CRM%*3B[H]%GO=1\3ZKI&JF-+BQDOH3;M:L'BC@'W  .
M0,8ZT_X/6\1^-'Q1GDX+&&%?J<'^E>,? GQ-+8>(='LC*\B:C*)$C;=\G[S&
M5]N#@>U>U>$]=FT#Q!XWNDD202^(["T.$!P) P(YZ=*YZ=%TI-ON=,JJFK6\
MB#XD1#_A)4R?^6:+GV*M_C7"+8-=HD$:&222>-451R20P _,UZ%\18R/$X1L
M_P (_0UJ?##0K31M+OO&6KK_ *+IC_Z'&_2>XP=H'J!D5\AB*3JXJ4>FOZ'T
MM"?L\/%K>R,CXM7,GP\\+:#\.(BGVB<KJFK2(V<RL<)&/8!1^0]:B_:8NI[6
M_P#!TMO*T4R12LCH<$'"<BN#\6ZK>>)/%<6IWS^9=W3>;(Q]3*_ ] ,8_"NW
M_:4;??>$5SR+>8_^@UZ*J)T*O)LDK>AAR<M:DI;MML\AT^:<0_:UE=+K^T78
M2JQW!EC0YS]374:#-]EN;YY+AGU"2ZMQ<2DY^]YAV_7@Y/O6!HJ#^R()<X/]
MI7'/TB@_QI]D9(=/UN1@5D6]M&#>^V<C^5>?";C)2\CJJ14ERE;4+96N-9P"
M0;I""1CC$E9^JIMMH@.GV;G_ +ZK9U*Y%S<:E<A01/+$YQVR'_Q-96M ?9UV
M?,!;@9_X$*UO[VGD8RVMZC_VA+,0^#/""@$;G?(_[9K_ (U:N=+^U?$KP]&1
M\D%BLK?\!)(_4"G_ !X26\\.^#(T7?F608R.!LBK>OH!9^.[ZZ.$2ST-F#-P
M,\FOJ+727H> MOO//;[4C<ZEJ,Z2DF2Z\P+CJ3TK]IOV1F9OV;? )?[W]G#.
M?]]J_$>/ L&F"Y(;?NS["OVW_9%.?V;/ )_ZA_\ [.U<&"=ZU1G7BE:$3UB3
MI6-J7W&^AK9DZ5C:E]QOH:]L\PU-(_Y!L'T/\S5RJ>D?\@V#Z'^9JY0 4444
M %%<YXD^(?A[PCK.BZ5J^I)97^LRF"PA>-SYSCMD @?\"(J?5?&^B:)XCTG0
M;V_2#5]5#FSM2C%I0@RQR 0,>Y%&X;&Y6-XI\+VWB[3/[/O)[F*S9@9HK>0(
M)U[H_!RI[@8K8)P,U7T[4(M4LHKJ%9DBD!*BX@>%QSCE' 8=.X% $T4201)'
M&H5$ 55'0 =!3ZIS:Q96^J6VFR7427]RCRPVY;YW1,;F ]!N&3[BK,L@BC=V
M#%5!8[5+'\ .3]!1YA;H/HJ"RO(]0M(;F)95CE4,HFB>)P#ZHX#*?8@&IZ "
MBBB@ HI"<#-9OA[Q)IOBK3OM^E7(N[3S'A\P*R_.C%6&& /!!% &G115&XUR
MQM=16PDN4^W- ]RMLN6D:-2 S!1R1D@?4T 7J*@LKN._M(;F(2K'*@=1-$T3
M@'^\C@,I]B 14] !1110 4444 (1D$=*I:)H]MX?TFUTZS4I;6Z!$#')/J2>
MY)R2?>KU% !115/2=8LM=L5O-/N8[RU9G19HFW*2K%6 /LRD?A0!<HHHH **
M** "BBJ5QK-C::G9Z=-=11W]XLCV]NS?/(J8WD#T&Y<GW'K0!2M_".GVOB^\
M\2H)/[3N[2*RD)?Y/+C9F7 ]<N>:VJ*0D $DX H#K<6BJ>E:O9:Y9)>:?<QW
MEJY95FB;<I*DJ<'V((_"KE !116=XB\0Z?X3T*_UG5KD6>F6$+7%S<%681QJ
M,LV%!)P/04!OHC1HJI<ZI;VNEOJ#>;+;+%YW^CP/*[+C/RH@+,<=@"?:K*.)
M$5AD!AD;@0?R/2@5[ZCJ*S-/\2:;JFKZGI=K="6_TTQB[A"L#$77<G)&#D<\
M$UIT#"BBB@ HHHH Q+GPCI]UXPLO$KB3^T[.SEL8B'^3RY&1FR.YRB\UMUF:
MOXDTW0KO3+:^NA;SZE<?9;1"K'S9=I;;P#CA2<G XK3HZ6_KO^H=?Z]/T"BF
MR.(T9SDA1D[02?R')K&TGQEI.M:O-I5K<2?VE!;17DMK-;R0R)%(65&8.HQD
MHW'7CD4 ;=%8FO\ C/2?"\%W/JL\MG;6B1R2W#VTIB =]B@.%*L=W5021D$@
M BI9/%6EP2PQ3W!M9)[O[#"MU$\)GFVEML>\#?PK'*Y& >>#0!K4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/KWBZ:?2[G35U#35ABGNHRJAB_W.1R17WKJ%@ V-N<U\Z_M$^$_&/B2&73M
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MP7UZ77;V]US5=4:6YAGOWE1Y!;R^9MB+%8_+8[?D"]<')JUI'C745^&WPO\
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MS D2I"=HP1PVU<@].,UV6B^//$$WB6V\%7&H-)KUIK,QN[HPH#+IP!EB;&W
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M^?X<W_R+!*[MUT_'E_\ DD?4E4[_ %FPTIH5O;ZVLVFW>6+B94+[5+-MR><
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MRL&)"X4G)R5('J0?2M*O+?A1I9^('@3P?XJ\0W4NHZV]C"\DHVI&[JS-N"*
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M9.W#?+GC%1R?![PK+IJ6;6=V=ES]L6\_M.Z^V";;LW_:O-\[.WY?O]..E'_
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M=;_BV_U7J>1^&_B!XQ_X1SPKXHO?$DE\FH^(9=(FTMK.W2 P?:I8E;<J"3S
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MZ 7D_P#\731^S]X"!S_87/\ U^3_ /Q=>B44[L+(\_7X"^!4.1H0SZ_:IO\
MXNIU^"?@Q  NC8QZ7,W_ ,77<T47861Q)^#'@XG/]D'_ ,"IO_BZ8WP3\&-U
MT;_R:F_^+KN:*+A9'"_\*1\% Y_L;G_KZF_^+KK])TJUT/3H+"RB\FU@79''
MN+;1]22:MT4@L,<55GBW U<(S3&3.:!F?#</9DKM+H3TSTI7UH+_ ,L'_,58
M>W!YP/RJNUH#V'Y4 ,_M\?\ /N_YBD_X2 ?\^[_F*4V(]!^5)]B'H/RH /\
MA(!_S[O^8H_X2 ?\^[_F*/L0]!^5'V(>@_*@ _X2 ?\ /N_YBC_A(!_S[O\
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M'Y4?8AZ#\J #_A(!_P ^[_F*/^$@'_/N_P"8H^Q#T'Y4HL0>P_*@!RZX&/\
MJ'_,5(=2:1<)&5)[D]*C6S /0?E4Z6^,<#\J ([>'!YS15Q$ [44 2T44F:
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M\T9H ;L]J4+BES1F@ QBBEHH C+XIAE'K5.:Z"CK^E4I-0"D\_I0!KF8#O\
MK1YX_P FL(ZD,]?TIO\ ::^OZ4 ;_GC_ "://'^36!_::^OZ4?VFOK^E &_Y
MX_R://'^36!_::^OZ4?VFOK^E &_YX_R://'^36!_::^OZ4?VFOK^E &_P">
M/\FCSQ_DU@?VFOK^E']IKZ_I0!O^>/\ )H\\?Y-8']IKZ_I1_::^OZ4 ;_GC
M_)H\\?Y-8']IKZ_I1_::^OZ4 ;_GC_)H\\?Y-8']IKZ_I1_::^OZ4 ;_ )X_
MR://'^36!_::^OZ4?VFOK^E &_YX_P FCSQ_DU@?VFOK^E']IKZ_I0!O^>/\
MFCSQ_DU@?VFOK^E']IKZ_I0!O^>/\FCSQ_DU@?VFOK^E']IKZ_I0!O\ GC_)
MH\\?Y-8']IKZ_I1_::^OZ4 ;_GC_ "://'^36!_::^OZ4?VFOK^E &_YX_R:
M//'^36!_::^OZ4?VFOK^E &_YX_R://'^36!_::^OZ4?VFOK^E &_P">/\FC
MSQ_DU@?VFOK^E']IKZ_I0!O^>/\ )H\\?Y-8']IKZ_I1_::^OZ4 ;_GC_)H\
M\?Y-8']IKZ_I1_::^OZ4 ;_GC_)H\\?Y-8']IKZ_I1_::^OZ4 ;_ )X_R://
M'^36!_::^OZ4?VFOK^E &_YX_P FCSQ_DU@?VFOK^E']IKZ_I0!O^>/\FCSQ
M_DU@?VFOK^E']IKZ_I0!O^>/\FCSQ_DU@?VFOK^E']IKZ_I0!O\ GC_)H\\?
MY-8']IKZ_I1_::^OZ4 ;_GC_ "://'^36!_::^OZ4?VFOK^E &_YX_R://'^
M36!_::^OZ4?VFOK^E &_YX_R://'^36!_::^OZ4?VFOK^E &_P">/\FCSQ_D
MU@?VFOK^E']IKZ_I0!O^>/\ )H\\?Y-8']IKZ_I1_::^OZ4 ;_GC_)H$X/\
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M ;_GC_)H\\?Y-8']IKZ_I1_::^OZ4 ;_ )X_R://'^36!_::^OZ4?VFOK^E
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M_IK,HH T_P#A)=6_Z"-S_P!_31_PDNK?]!&Y_P"_IK,HH T_^$EU;_H(W/\
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M^$EU;_H(W/\ W]-'_"2ZM_T$;G_OZ:S** -/_A)=6_Z"-S_W]-'_  DNK?\
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ME&);F3.U6=4' )/+$ < ]35VZ\(ZG::=+?&.">TB($DMK=13B// W;&./QH
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M75O^@C<_]_36910!I_\ "2ZM_P!!&Y_[^FC_ (275O\ H(W/_?TUF44 :?\
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M&<Y)&<UQP\0:B$T]/MDNVP)-J,_ZK)R<?C4EEXIU73DD6WO7C620RL, _/\
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M"R+:69CBMF\Y5*JY )X)&,>]27-VM]XXU+17M;4:;]BE_<K"HPRP%PP.,@Y
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /7OV?C_ *7JG^ZO]:*3]G__ (_-3_W5_K10!2^,>CW^H>)+>2ULKBY0
M6X!:*)F .3QD"N"_X1G6/^@5>_\ @._^%?8WAW_CS?\ WZU: /B3_A&=8_Z!
M5[_X#O\ X4?\(SK'_0*O?_ =_P#"OMNB@#XD_P"$9UC_ *!5[_X#O_A1_P (
MSK'_ $"KW_P'?_"OMNB@#XD_X1G6/^@5>_\ @._^%'_",ZQ_T"KW_P !W_PK
M[;HH ^)/^$9UC_H%7O\ X#O_ (4?\(SK'_0*O?\ P'?_  K[;HH ^)/^$9UC
M_H%7O_@._P#A1_PC.L?] J]_\!W_ ,*^VZ* /B3_ (1G6/\ H%7O_@._^%'_
M  C.L?\ 0*O?_ =_\*^VZ* /B3_A&=8_Z!5[_P" [_X4?\(SK'_0*O?_  '?
M_"OMNB@#XD_X1G6/^@5>_P#@._\ A1_PC.L?] J]_P# =_\ "OMNB@#XD_X1
MG6/^@5>_^ [_ .%'_",ZQ_T"KW_P'?\ PK[;HH ^)/\ A&=8_P"@5>_^ [_X
M4?\ ",ZQ_P! J]_\!W_PK[;HH ^)/^$9UC_H%7O_ (#O_A1_PC.L?] J]_\
M =_\*^VZ* /B3_A&=8_Z!5[_ . [_P"%'_",ZQ_T"KW_ ,!W_P *^VZ* /B3
M_A&=8_Z!5[_X#O\ X4?\(SK'_0*O?_ =_P#"OMNB@#XD_P"$9UC_ *!5[_X#
MO_A1_P (SK'_ $"KW_P'?_"OMNB@#XD_X1G6/^@5>_\ @._^%'_",ZQ_T"KW
M_P !W_PK[;HH ^)/^$9UC_H%7O\ X#O_ (4?\(SK'_0*O?\ P'?_  K[;HH
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M?\(SK'_0*O?_  '?_"OMNB@#XD_X1G6/^@5>_P#@._\ A1_PC.L?] J]_P#
M=_\ "OMNB@#S+X8V\MKX/TR*:-XI53#(ZD$?4&NQ?_5_A45S_P A&;_?_I4K
M_P"K_"@#S7XQ6<]]X4FBMH)+B4S1G9$A9L9]!7A7_",ZQ_T"KW_P'?\ PKZX
MTC_D+?\  3_*NCH ^)/^$9UC_H%7O_@._P#A1_PC.L?] J]_\!W_ ,*^VZ*
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M&=8_Z!5[_P" [_X4?\(SK'_0*O?_  '?_"OMNB@#XD_X1G6/^@5>_P#@._\
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M#XD_X1G6/^@5>_\ @._^%'_",ZQ_T"KW_P !W_PK[;HH ^)/^$9UC_H%7O\
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MQN+&&YB)E WJP<?,,C(/&.>M:DGP?T[_ (5]H?A*&[GALM)EMY8I< NWE.&
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M_"HKG_D(S?[_ /2I7_U?X4 0:1_R%O\ @)_E71USFD?\A;_@)_E71T %%%%
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MSB<@0V+3!8\\D[B<;STXZ<=*5D.\F;/A[Q'%KB2/')!*@<J/L\PF"X./F9>
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M!P5%7*SDK>?Y?YF:NEKY?FOT,*Q_:A@U%=:O(/#5P-(T2S2ZU&YDNE$L;MN
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MMJ7A;5#9SKI2SP7%C(!M&JWKNK#'9'5F'8,">#5)7<5WM\KJ_P" GHI/M?\
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MP5D#R%AN(*JP)."<US?P\^%=YKS2#Q)X5O;E+'PC=PV::CI\BI%<"]E,2HK
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M0,9'<4F[*_S&E=V^1Z_17A'@W]I0WOPHN_$FJZ6\U]I=OI[7BV[!%FDN0G*
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M[QSY385?3DC(KI/!G[0-CX_\4/IFB:;]JM8Y4CDE:]B2Y0-&L@E-LQ#F(A@
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MYT:]>T;3)KMKS4UA1UC#6Y52T989#-Q@=*CT#]G71M%?7O-U"YO8];TM=.O
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MTZ:_NB+:8-!Y:H=J!HQYF2Y&0>WO6MHWAOP]X=T^^\-W?BV?4KS6X2@&HWL
MN&B*; (8T1$  SR$R3RQ8U'XB^&/ACQ=HFB6D^K3I;6UI)IUE-;7,69 X3)!
M*D.P\H'&,=<@BD]]/+];_C8%LK_TM/\ @E#_ (:4\'FVCF0:C+EKA98XK0NU
MOY'E>:9-I(  FC/4]:LW?[0OA.Q6!9C?K<374EJ+4VI\X,B)(Q*YZ;)8V&,D
MAAQUK!T#X.>!8[K688?%MSJEZT=S'?!KVUWPB<0+(2D<:B/_ (]4P, #+<=
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M+^[15VO&(V/*DE9(R!R5(SBO=*IJUB$[A1112*"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R=<
M^_;_ %-%&N??M_J:* %\/#%F_P#O5JUFZ$NVU;_>K2H **** "N>\5> M#\:
MM:-K-F;LVI8PXE=-N<9^Z1GH.M=#10!QEU\'_"=[8V]G-I9:"W^T&$?:)08S
M/)YDA#!L@E^0<Y7MBJLWP/\ "%REJLUC=S_9V9MTNHW+--E@Y\XF3,PW '$F
M[I7>T4;.X>0BJ%4 #  P *6BB@ HHHH *XCXD_%.W^&MSX>AGT35]8.LWJV2
M-I=MYHMR<?/+R-J\^_>NWHHZH KSWXR)K\^FZ/%H4LTBM?!K[3[*]6SO+VV"
M-N2"4D;6!VL<%20I 85Z%6'XK\%Z1XTMK:'5;=Y#;2^?;SP3/#-!)@C='(A#
M*<$C((X-)C1XYX/^)U[I/C/1?#,%QJ$D6H:L]K<Z;XDB=[[3HQ:/,%6<R-YH
M9DR&;=QD>AJI>?'GQH]O<W4-GI6G:9;7M_;OJEQIUS=6_P"XF*)')Y4@,.5&
M3*0P'9.U>H3?!3PI/:K'):W;W"W*W@U ZA<?;1*JE0WVC?YGW25^]T.*JI\
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MRI[T?94]Z -7^U[/_GNM']KV?_/=:ROLJ>]'V5/>@#5_M>S_ .>ZT?VO9_\
M/=:ROLJ>]'V5/>@#5_M>S_Y[K1_:]G_SW6LK[*GO1]E3WH U?[7L_P#GNM']
MKV?_ #W6LK[*GO1]E3WH U?[7L_^>ZT?VO9_\]UK*^RI[T?94]Z -7^U[/\
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M_P#GNM']KV?_ #W6LK[*GO1]E3WH U?[7L_^>ZT?VO9_\]UK*^RI[T?94]Z
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DU&V;I*IK)6U0>M31VZ#UH GN)5NI%V\JN>314L,0'%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>plx-20230930x10q006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20230930x10q006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '%!#@# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBBB@ HHHH **** "BBB@ HHHH X[Q]\1X?!5QI>GP6$VL:YJKLEEIUNP4OM
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M-?U>\U.]UG2/!%GJ=A;)<RQQM=!K@QRF-& 8L(TX(P=W3I6:?N\[[7^5F_\
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MWC30;RS77]<TBZTZQM?L\<6FZ?Y4MR1@"29V)(8 =$P"2<CI7H]%).W]>O\
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M)Z\R]?Q3_-(\R\+?#WQ]I5G#8W?BC28K6TM6M[>6QTM?.E;;A'E,FX9''"@
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M\JIC,14^*;+M[K6H:E.9KJ]N+B4]7DD+$TW3YY&U"US(Q_>KU8^HJI5C3O\
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M=3I]RB7JH#DVSM&%G'O$7X.>E<)H'[7VFWTG@DW^CWMK;^(8+R1V2SNGFC>
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M78Z1P$[8S&/FRH!^4YKZ)\0^!=#\5ZCIE_JE@+F\TUV>UF$CQM&6^\,J1D'
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M#%)\F]CRQ .,GDXKJM!^#G@[PSJ-E?Z;HR6UU9/*]L_GRL(3("'VJS$ ')X
MQ6WX;\(Z1X0AO8M'LDL8[V[DOKA49CYD\AR[G)/)/IQ6KE=OS3^]M/\ !71#
M6UNC7W6E^;:?R/B+4?B?XSNM"\0?$[_A9MWIVM:9K#V5OX(#K]EDC63:(VA/
M+,P[U4UWQOXNU_Q+\9]1?XL:OX3D\+W$-YIVA+=*$<F!6,95N2F[(VKQG-?7
MUW^S[\.K_P <IXQN/".GR^)%;>+YE;.[^\5SM)]R,UYOX?\ V0]!U'XD^.O$
MGCK2-(\0PZMJT>HZ4 TAEMU6)5(DX4=5SMRPK*/1;:/Y.\=N[T;U-)M-\R77
M\/>T\DM%H>(^!3K7B'X]7?BK4?%NK6&I7/@Y-3-CYX1'=EQY(7^X#\P [U6\
M.>(_'GQ"E^%NC6_Q"U_05OO!%QJ5Y<65R=\TJ3R ,<Y&[  W=<"OLO6?@MX)
M\0>);'Q!?^'K6?6+& VMO=@NC1Q$8*X4@$8XY%-T?X)>"- NM+N-/T"&VFTO
M3WTNS=99#Y-JS%FC&6Y!))R<GWJG9JR5M[?^3V_]*C]Q*NFF]=%_[9_\B_O/
MD;P!X\^(R+\)?%NH^/M3U*/6=<.@W6DR[1;/""1YC #YI#C[QJ+6_'NH7'P4
MUG4-1^(_B;0M;B\7ZK8Z7!H]Z(YKT^?MCA);HB #Z U]?6GP4\$V.G:+80:!
M#'::->&_L(A+)B"?.=X^;)//0Y%8/B#]EGX5^*K&.SU7P?:WEM'=3WRQO/,
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MH *L:=_R$+7_ *ZK_,57JQIW_(0M?^NJ_P Q2>PUN?K7X?\ ^0#IO_7M%_Z
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MP6LT,.N^%929H=Q4^5)#D!T8J#\V1E>G->VT5<I.>KWNW\VK"24=MK6_%O\
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M.T8&3FNBNM N?"_C;QCX>U_X*ZI\0=;U_6HK_2M<6,16HB^0KYEX/GM]A7.
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M_$S1];\8^*/B5K%AX<U@6NJ^";9+9&T^56:3J8@I7.\=UZCTK&?X*ZCHNM_
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ML[3PCJ^E>$(+(I_:'B?PW;Z5J E# +&'A;$R8!.<#IUKZ[JI)))KJ3%MMI]
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MY+^U/_R)VG?]?7]*]:\/_P#(!TW_ *]HO_0!7DO[4_\ R)VG?]?7]*^)PO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>E,KZ ^8"BBB@04444 %%%% !1110 445-9V<^H7,=M:PR7%Q(P5(HE+,Q]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7C'Q!_
M:5TKX??$%= NK5KBT2-3<W,)RT3GG&.XQBO2O''BRU\#>%-2UR\(\FSA:0+G
M!=OX5'N3@?C7YN:YK-UXAUB\U*]D,MU=2M-(Y[L3DUUT*2J7<MCQ<QQDL,HQ
MI_$_R/TG\+^+]'\9:<E]H]_#>V[#K&V2OL1V-;-?F7X4\9ZUX)U)+_1=0FL+
MA3SY9^5_9E/!'UKZI^%?[7&FZ[Y6G^+(ETJ].%%[%DP2'U8=4_4?2BIAY1UC
MJA87-*=;W:GNO\#MOBQ^SCX2^*\3S7-J-.U;'R:A:@*^?]H=&'UKXG^+/[./
MBOX53/-<6QU'2<_+?VJEEQ_M#^$U^D]G>0:A;1W%K-'<02#<DL3!E8>H(IUQ
M;Q74+PS1I-$XVM'(H96'H0>M;8?&U</INNQMBLOHXKWMI=T?D!17WI\8?V--
M \8B?4?"SIX?U<Y8V^,VLQ^G5#[C(]J^,O'?PU\1_#;5&L=?TR6R?)"2XS%*
M/56'!_G7TM#%TL0O=>O8^1Q.!K85^^KKOT.8HHHKM//"BBB@ H ).!R:['X=
M_"3Q1\4=0%KH&F/.@.)+J3Y((O=G_H,GVK[2^#_[('AKP$L-_KVWQ%K(PW[U
M,6\1_P!E#][ZM^0KAQ&,I8?23N^QZ.%P%;%.\59=V?+WPB_9@\5_%%XKIX3H
M^BD\WMRI!8?["]37VQ\*_@#X3^%%JITZR6YU$C$FH7(#2M]/0>PKT=$6)%1%
M"(HP%48 %17%W%:H6D8 "OF<1C:N(T>B['U^%R^CAM4KR[LF)Q6=JFNVNF1,
MTLJ+M'<US.J>-Y+V<V6DVLE[<YQB/HON3T I^F> #=SB\UV7[7,3D6J$^4GU
M_O?I7 >F0V^O:OXEN -+BVVH/S7$@PGX>M7H/$EUI,ZV^K1^2Q.%D_A;Z&NJ
MBB2"-8XT6.-1A548 'L*9=V<%]"T-Q$DT3=5<9% "6U[#=KNC=6'L:DEB2>-
MHY$5T88*L,@UREQX7N]#=KC1Y#+'U-G*W_H+?T/YU;TGQ=%<R"WN8WM;D<-'
M*,$4 >?_ !!_9RTGQ%YMYHA72K\Y8Q@?NG/T[?A7SEXK\#ZSX+O6MM5LW@.?
MEDQE''J#7W<DBR#*G(JIJVC6.NV3VFH6L5W;OUCE7(_#T/O7IT,?4I:3U1Y&
M)RVG6]Z'NO\  _/ZBOH7XA_LR,GF7OA6;<.2=/N&Y'^X_P#0_G7@NIZ3>:+>
M/:W]M+:7"'#1RJ5-?04:].NKP9\Q7PU7#NU1?Y%2BBBN@Y0HHHH *55+L%4%
MF/  [UU_@;X5:_X]G7[#:F&SS\UY."L8^G]X_2OI?X?_  ,T#P0D<\L8U34@
M,FXN%!53_LKT'XY-<-?%TZ&CU?8]'#8&KB-4K+N>&?#[]G_6_%WEW5^K:5IK
M8(>0?O''^RO]:^DO!GPXT/P+:B/3;11,1A[AQF1_J:ZBBOGJ^+J5]&[+L?48
M?!4L/K%7?<*9+*D$;/(X1%Y+,< 5ROBWXEZ1X55HVD^V7HZ6\)S@_P"T>@_G
M7B7BOXA:OXL=EN)O(M.UM"<+^/K7&=Y[WI'C?2==U>?3K*X$TT*[BR_=;UP>
M^*WZ^5/"VNR^&]=M+^,D>6_SCU4]17U+9W4=]:PW$3!HY5#J1Z&@":BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HJ*ZN8K*VEN)Y%BAB4N\CG 4#J37D4O[4_@V&^"R6VMII1D\H:X=/
M;[!G./\ 69R>?:M(4YU':"N95*L*2O-V/8J*9#-'<PI+$ZR1NH974Y!!Z$4^
MLS1.^J"BJNJ:G;:+IMS?W<GE6MO&9)'P3A0,G@55\,>([+Q=H-GK&G,SV5VG
MF1,Z[25R1G'X4[-J_07,DU&^O]?YFI1112*"BJ&NZNF@Z1=Z@]O<7:6\9D,%
MI'YDKX[*O<T[1=476])M+]+>XM4N(Q((;J/9*F>S+V/M3L[7%=7L7:***0PH
MKEM1^(NF:9X]TWPC+%<G4[^W:YB=$4Q!5.#D[L@_A5WQEXUTCP#H<NK:U="U
MM$(084L\CGHJJ.23Z57++33?;\B>:.JOMO\ F;E%>9>#?V@O#?C'7XM%-GK&
MA:E.-UO!K5D;<SCU3DY_2NH\&^/]-\<S:S%I\=S&VE79LI_M"*H+@9)7!.1]
M<5<J4X?$O/\ 0SA6IS^&5^GX7_(Z6BBBLC8***P]>\61:!JNCV$FGZA=OJ4K
M1)-:0>9% 0,YE;(V@]CS32;=D)M15V;E%%%(845S'BWX@Z;X,U/0;"^CN7FU
MFZ%I;F!%95<]VRPP/IFHOB;\2M*^%'AAM=UB*ZFLUE6$K9HKON;..&91CCUJ
MU"3M9;[$.<5>[VU?H=917F_B3X^^%_"_P[TWQG="\ETK4-GD101HTQW=BI8#
MCOS7;>&]?MO%.@:?K%FLB6M] EQ$LP <*PR,@$C/XU4J4XIN2T3M\^Q$:U.;
M2B[MJ_R[FE117+>,/B+IG@C5- L+^*YDFUJY-K;&!%95< '+Y88'/;-1&+DU
M%;LTE)03E+9'4T5Q5S\5]*T_0M?U>_LM3TZRT:0QS-=VVPS8[Q#/S ]CQ53P
M5\9;#QS=:?#:>'_$-BE[$\T=Q?V'E1*JD?>;<<9SD>HJU2FTVE_5K_D9NM33
M2;W_ ,[?F>@4445D;!16#J7C?2M*\4Z9X=GE?^U=11Y((E0D%4&6)/04OA;Q
M;%XJ.IB+3M1T_P"P7;V;?VA;^5YI7'SQ\G<ASPW>JY96O;3_ (-OS(YXWY;Z
M_P!,W:***DL**** "BBB@ HHHH **** "BBB@ HHI&8(I9CA0,DGM0!\O_MG
M>./+M=+\+02<RG[7<@'^$<(#]3D_\!KY2KN/C3XL;QG\2M;U#<3$LQ@B![(G
M&/SR?QKAZ]JE'D@D?G^-K>WKRETV04445L<1WGPY^-/B;X:7*_V=>&>R)R]E
M<$M$WX=C[BOKGX7_ +1WAKXAK%:S2C2=7(P;6X; <_[#=Z^"J56*,&4E6!R"
M.HKGJ48U->IZ6&Q];#:)WCV9^I@((!!R#W%97B7PKI/C#2Y=/UBPAU"TD&&C
MF0'\O2OC#X6_M0^(_ K0V6JDZ]HXP-DS8FC'^R_?Z'/U%?6W@'XJ^'/B39+/
MH]\K3;<O:386:/ZK_49%>=.E.D[_ (GU6'QM'%KE6_9_UJ?+_P 8/V);FR\_
M4O \INH?O'2YV^<?[C=_H:^5]5TB]T.^EL]0M9;.ZB8J\4RE6!'L:_7>N(^(
M_P &_"GQ4L_*U[35DG PE[!A)T^CXY^AR*]3#YG*'NU=5WZGG8K*(5/>H:/M
MT_X!^8F@^'=3\4:E%8:38S7]Y*=J10(6)-?6?P@_8D$9AU+QS,&/##2[=N/^
M!M_05])_#_X6^&OACIHL_#^FQVN1B2X8;II?]Y^I^G3VKJR0.O%+$9E.I[M+
M1?B5A<IITK2K>\_P_P""4=$T'3O#>G16.F6<-C:1 *D4*!0!5R258ERS #WK
M+UCQ)::1"[RRJ-HS@M7)C4-<\:2A;"$6=@?O7<V>1_LCO_*O&;;U9[Z22LC7
M\0>.[+3%,<<GFSD[51.2365;^&M8\53+<:E/)861Y$"G$C#W]*Z/P_X,T_0#
MYJ(;F\/WKF;E_P /0?2MZD,I:5HUGHEL(+.!84'7 Y)]2>]7:** "BBB@ K-
MU?0+/6XP+B/YU^[*G#K]#6E10!Q+6^K>$]SEWU"Q'.]1ET'N*WM(\36>JQJ8
MY5+'MWK8KG]6\'VUY+]IM&^PWHY$D8^5O]Y>] &^"",CD5S_ (N\!:+XVLS!
MJEFDQQ\LP&'3W!K-B\0ZAX?D6#6+<(A.%N8SF-OQ[?C74V>HP7J!HW5@?0U4
M9.+O%V9,HQFN62NCY9^(7[.VL>&?-N](+:MIZY8JH_>H/<=_J*\CDC>%RCJ4
M=3@JPP17Z&5Q/B[X.^%_&ETES?6)AN0P9IK5A&TGLW&#GUZ^]>S0S%K2JK^9
MX&(RI2]Z@[>3/C_PWX3U7Q;?+::79R74A/)4?*ON3VKZ(^'O[-FGZ1Y5YXA9
M=0NAR+9?]4I]_6O7-"\.Z;X9L5L]+LXK.W7^&-<$^Y/4GW-:585\?.II#1?B
M=&&RVG2]ZI[S_ BMK6&SA2&")(8D&%1!@ 5+5>^O[?3;9[BZF2WA7DO(<"O*
M/&'QN"[[;08\GH;N4<?\!7^I_*O+/9/2/$'BG3?#%L9K^Y6/^[&#EF^@KQGQ
M?\8=1UO?;Z?FPM#QD']XP]SVKA+_ %"YU2Y>XNYY+B9NKR-DU7H 5W:1BS$L
MQZDGDTE%% !7OGP5U_\ M/PVUC(V9;-MHS_</2O Z[GX/:W_ &5XPAA9L17B
MF$_4_=_7% 'T/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFR!%5Y(@SD#&X^IKB/H"CH_PZB%Q]MUF7^T+HG<(C_JT_#O79(BQJ%50JC@
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M?H1D5/7(?"C4O[1\#Z>2?GA!A/\ P$D#],5U] !1145S.MK;RS,"5C4L0.N
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M:W.F6F?M%P24$7^\& (_+FE*E.-[K1?\,.-:G*R35WTZ]SJJ*Y+P=\6?"/Q
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M7]$>_45Q4/QG\%W'B0:!'KT#:P;@VOV01R;_ #?[OW<?CT]ZC;XW^!5\4?\
M".GQ+9C5]_E_9\MC=TV[\;<YXQFH5*H]HO[BW6I*]Y+33?J=S17(>,OBWX0^
M']S!;^(-=MM.GGY2-PSL1ZD*#@>YJ?Q%\3_"OA/0K;6=5URUM-,N@#!<;BXE
M'^R%!)_ 5*A)I-+<IU()M.2NM7Z'445RI^*?A,>$SXF_MVT_L,=;S<=N?3&,
MY]L9I/"OQ5\)>-M+N]1T77;:]L[0$W$@RGE#&<L& ('!YQ3=.:3;3TW\@56F
MVDI+7;7?T.KHKB_"7QF\%>.M5DTW0O$%MJ%]&"3 H=&..N-P&[\,UVE*4)0=
MI*PXSC-7@[A1114%A1110 4444 %%%% !1110 4444 %%8/CKQE9?#[PGJ/B
M#4(;B>SL4#O%:*K2ME@H"AB!G)'4BN1TWXZ6<VJZ/9ZOX7\0^%TUB18+&[U>
M*W$,TK#*IF*>0@D=,@#WH6KL@>BN_P"K;GIE%<Y%\2/"4\=S)'XIT62.V4/.
MZ:A"1$IZ%CN^4'U-75\7:$^AMK*ZUIS:.HW'4!=1FW ]?,SM_6CS#R-:BN&\
M-?&?PIXKU;6[*QU.'9I4\5M)>231BVG>1 Z"*0,0^0P].<UU;ZYIL<]U ^H6
MJ36L8EN(VF4-"ASAG&?E'!Y/H:-E<.MB]16);>./#EYH\VK0:_I<^E0DB2^C
MO8V@0]PSAMH_$U(GB_0I-$.LIK6G-HZC)U 7<9MP/^NF=OZT; :]%4='US3O
M$-DEYI6H6NIV;\+<6<RRQGZ,I(J"/Q9HDNMMHR:SI[ZNJ[CIZW2&X ]?+SNQ
M^%'6P>9JT5C67C3P_J5[=6=IKNF75W: FXMX+R-Y(0.N]0<KCWJHOQ*\(N9@
MOBK1&,,7G2 :C"=D><;V^;A<GJ>* .DHK!N/'OABUT^WOY_$>DPV-PI>&YDO
MHEBE4=2K%L$#VK-U/XJZ!IVN^$]+2=K]_$TLL-A<V)26 F.)I6+.&Z;4.",\
MT[/8/,["BL:T\:>'[^^N[*VUW3+F\M 3<6\5Y&TD('7>H.5Q[U8C\2:3*; )
MJEDYO\FT"W"'[3@9/E\_/@<\9I :-%96M>*]$\-M NKZQ8:6TYQ$+VZ2$R'T
M7<1G\*YR'XR>%IO&X\+KJ$8NGL8[^*\,L?V69'E,2HDF[YG+ \ 4+5V0/1-O
M^M;?F=Q15.YUG3[.:2*>^MH)8XO/=))E5ECZ;R">%]^E4+?QOX<N]'FU>#7]
M+FTJ$[9+Z.]C:!#Z,X;:/Q- &W16,?&?A\:)_;)UW31I'_00^V1_9_\ OYG;
M^M2:?XKT35WMEL=8L+UKI&E@6WNDD,R*0&9,$[@"0"1TR*/(#5HKD9OBEH47
MC^U\'K,TVJSVTMSOA*-%$L9PRN=V5;VQ4LWQ1\(QVFISQ>)-)N_[-A>>ZBMK
MZ)WB5>NX!N.F.<<TFTES/;_(=G>W4ZFBN*\-?&+PEXC\%Z9XG_MS3]/TS4!^
MZ>]O(HP&_N$EL;O;-;^J^+=#T*RM[S4M9T_3[6X($,]U=)&DI(R K,0&)]JJ
M2Y;I]"4[ZHUJ*Y;X>?$;2/B9X77Q!I/G)I[221!KE54Y0X)X8C'OFKNF>.O#
M6M7IL]/\0Z5?W83S3!;7L4D@3^]M5B<>]+;09N45SD?Q(\)31W4D?BC17CM5
MWSNNH0D0KG&7.[Y1GN:QO&'QL\)>#=.T*^N-7L[FTUJ]6QM)[:ZB:-F()+;M
MV-HQ@D9P2!WH[+^M0_K[MSO**QYO&&@V^K0Z7+K>G1:G. T5D]W&)I >A5,Y
M/X"J"?$;0HY=22_O[;2%LKHVC27]W BR.(U<E<2'& XX;:W&<8P2 =/16(WC
M?PZNB#66U_2QI!.!J!O(_LY/_73=M_6KMMKVF7FE#5+?4;2?3"AD^VQSJT.T
M=6W@XQ[YH O451CUS39KF"WCU"U>>>(S11+,I:2,=749R5]QQ7#>-_CWX5\!
MVM[<ZA=(]M;&W7SXKJW*2M+(8P%'F;OE*L6RH& <$X.#K8-ST>BO/](^.O@W
M5O$&J:.VL6UA=6#PQE[VXBBCN#(I9?))?Y^!Z5WX((!!R#WIV%<6BBBD,***
M* "BBB@ HHHH *^1OVU]7,GB+0-,!RL5LTY'H68C^2BOKFOAK]K?43=_%^ZM
M^?\ 1;:&/GW0-_[-75AE>H>/FLN7#-=VCQ:BBBO6/B@HHHH **** "BBB@ K
M]*/AG_R3WP[_ ->,/_H(K\UZ_2CX9_\ )/?#O_7C#_Z"*X,7LCZ+)OCGZ(=X
M^_Y%R\_ZYFD^''_(DZ3_ -<12^/O^1<O/^N9I/AQ_P B3I/_ %Q%><?5G2T4
M44 %%%% !1110 4444 %%%% !1110 4444 <M\0?^0=IW_7]'_Z"]=':?ZA/
MH*YSX@_\@[3O^OZ/_P!!>NCM/]0GT% '-_%'_D0M7_ZYK_Z&M?--?2WQ1_Y$
M+5_^N:_^AK7S30 4444 %%%% !1110 4444 >V_ 2],FC:A:DY\N<.!Z J/\
M#7J=>)_ .XV:KJD/]^)&_(G_ !KVR@ JMJ3W$>GW+6D23W0C8Q1R'"LV. 3Z
M9JS12>HUH?"^O7>B30SSZ7H6N>#_ (H_:2!I>FI+]G:3=UZ;<$<UZMXDNI?#
M/Q@^&>M^*+*1S/ISVES-';&0"Y90%W8'7)Z]N:^DJ*]+ZWM[NU^O=6LNR^\\
MKZC\7O;VZ=I*5WW>ENFA\X_"+PHVH:/\69(+0#5KC6;V.WF>/#]/EVD_7]:\
MC^&?A+[=X@\)Z)<:AXH?7M/U!9I].6S18+(H^3(9#C*_0YYK[JHI4\8Z;;2Z
M+\%;^OS"I@8U(I-]9/\ \"=^_P#78^%?BS>:AK6I>/K":SNM*O4O6E2PL-,+
M?:8P>)I9L="/Z5Z?X(T.VUKX\:1)>V:W<$?@^$JTT>Y0_"GKWP37TW12^M?N
M_9J/1K[U8KZG>HZCEN[_ /DW,?%EAX8M[?\ 9QMYTTT+??\ "2 ^8(OWF!.0
M.<9Q@"NX\2VTS>/_ (J,(G(?P:54[3\QP>![U]-T42Q3G>ZWO^*2_0M81)Q:
M>UNG9M_J?*UAHRZC+\ X;NS\^%+,&1)(\J"(QU'^-8_C+P=JFJP_'#3M!LI5
M8W=A,MO;)M\Q%^9PH[\ G K[!HIO&/FYDN_XR4OTL0L$N7E;[?A'E_X)\>?"
M+PS%XF\67%YHVK^)=4N+;2I;=[B_M$MX8G9<"+L2<]Q7*>(M7TJ#X%0^#G\-
MWB>+M-U!#=S&S;$9\WF0R8YW [<9[U]W45:QOOJ3CHK/?LV^VVIE_9_[MP4M
M7=;=&DN^^FYP?Q3C9_@YKJ*I9SII 4#)/RBO.OA%^SAX.G\*^&=<O;:^N[WR
M([@P75V[PB3J#Y9XX-?0-%<D*\J<9*#M=W_,[9X:%1Q<U=137WV_R/"?!_AZ
MWO?VDO'MQ<6:2>796RPO+'D*=O\ "37FLNIZ=X,TCXA>$_$OAR\O_%6M7MP]
MA(MFTOVI7&(MKXXVFOL"BM(XBUDUI9+?M8S>&W<7KS.6W?I;J?)GV";X5>+/
M ^K>-]-N=2TZ/0UL2Z0FX\B?'W2H!YK%TG2Y]?\ @W\8UTK1[BU6?4XIX+(Q
M%7"!PQPOT!.*^S:*T>,;UMK^'Q<VWJ91P*BU:6B\M?AY=_34^6(/'$'Q)^*?
M@)](LK^."WTZ: W%S;M$OF;<$ D<X/>L_P"'OB#P_P"$]"/@OQ)X+O-;\6C6
M'E^S"S),I+_+,)2,  <]>U?6]%+ZS%:*.GKYM[_,/JDK7<]?33:VUSYNM+BU
M\-_'3QO9WFGRP3:OIJO8L+<E<A/F&X# KC;#3+NT^#?PIUJ[TVXU'0='O[F;
M4[..,L0ID<)(4[A3D_C7V'12CBN5*RU7+_Y+=?J6\(I<UY:/FZ?S6_R/E(2Q
M>-]7\?>*O#6EW%AX:DT-[8N]N81=3 =D('2G7_ANVT[P#\#I;33EAN1J<!ED
MCBP_S*2VXXSR?6OJNBFL5RM<JT377M?_ #)E@^=/FEJU+IWMLO*QY-^U%;->
M?!S5H51G+R1#:@).-XIG@']G3P;X;N-*UN.WO;N_BB22/[==O,D;E1EE5N :
M]<HKGA6G3@X1=KN_X6.F>'A4J*<U>RM^)X!\&?#:77B/XK7/V51?OJCI!/)'
M\R_*<;2??TKRJ.YM$^$TGPVD\-7K?$5KUOG^R-DN9MPG\W'3;[U]J45O'$\L
MKM:>[U_EV^_JC"6$O&R>MY=+_%OIY=&?*][=V?PK^*NKW_CK2;G4[+4=+AM[
M6X2U-PK. -R< X/:L?XM:0TJ?#[Q!#INK^"/"<%M/&8K*W$LM@S.2"4&>'!%
M?8%%-8IIQE;5?=:S6W?7^M27@DXRAS:/RUOH]^VFWXGQWIW@NR'P7U6]E@\4
MW^G7>II=)=/#&L\6W_EN(QU7OC%6_AA<S^)9_'21:9/XFT.?2PDFJ16/V*[G
M<<>5SC<0.?P]Z^N:*<L7S*2:W_R2_3I84<$HN#4MO+?5OOY];_>?&WPDO7C^
M)?A6QT2*ZUV&T9H[A=5TSR9]-C[_ +W&#C]:^R:**QKU_;M.UK&^&P_U=-7O
M?^OZ_(****Y3L"BBB@ HHHH **** "BBB@ HHHH \Q_:7AEN/@AXHC@)$S0Q
MA2J[B#YJ<X[UF:1\(-6UU?"^H^*O%TVO6ND>5?6FGQV$=JBSJGR,Q4DMMST/
M>O8:*FVC7?\  ;=TEZ_C;_(^'_A]X:T[0/A/\(]=U/2UC\/P:E=2ZW,T.0,N
MWE/-QR@.[KP,U<OHK:Y\;S>)[6UD;X0KXDM+BX*1G[(X6"8-.%Z&(2F$D]/E
MSVK[4HK3FM+F\_U3_304O>3OUO\ K_F?">JC1]5G^(FL^%;,_P#".V_BO3+]
MY;>(B,Q+"GF2J,?<R<Y'&#5_XD:J?B'XD^*&J^&A<:IHS6VB/<26B-BYM([L
MM<!,?>'E[LX]Z^W:*4?=Y;=/\DM?+1: _>NWU_S;^_7<^//BKJ'A+Q$^AZIX
M&DAT_P /6NJ1OK^K6FF^=:?ZL"-F!PCA.C>G>EO/"_ABY\&:[JI\?7EUI\VM
M65W'JD&AA=,@N(\X8HOR-$> YZ# S7V%12VV]?R?Z:!VOZ?G_F>(_LW:U)K&
MG^*T@L-+^RQWQ$&M:+&8[;4B4!,BJ> 0?E.WC(KROPP^@0>#=?\ #FHV#S?%
MM]0U-[!!;L]XD[I)Y,^X#(CVE1N/RBOL*BE-<UUW5ORU\MAQ?+]]_P ]^^Y\
M7&;0]8\,?#[2_"-F\?BK28)/[:CBB*SVL8A(F6YXSDMV;J:3P)X%TOR_V;-^
MD19FEOS=EHN9!]GF<"3U&Y5.#W K[2HK7G]YRMN[_GMY:D<MH\O2S7_!]3X+
MTRZ\/>&_'?A7_A*H$B\/V7BC7%B2=/W,"ASL)'0(/RJS)H^K7GC+0[GPU#-:
MZ;J&OZU+X>)0JBAM)D59$'9#+DCM7V%X@^'FG^(_&/AWQ)<SW,=[H?F_9XXF
M41OY@ ;>"I)Z<8(KJ:S7\-1?9K\M?70MOWW)==?S_P SXL^$VFZ)-#X-&H^,
MI%UC1E:2^T2VT-$N(B%(E2ZD4[MIYY;K6G^SC81Z1\7VO]9TZ\M-(UF&Y?P2
MMV2R6T'F;IT _@9^'4'^$&OL"BM.?WN?U_'^OS74AQO'E]/P_K4^9OBA=Z#H
M/Q;\87/CR!'TV_T-(=%DN8]Z,P4^9''Z.6YQUKQ[X;> I/'UE'I]C%)!=+X
MAN=-E<$&*YBU"22'GU#*OYFOKWQO\*&\9:G)=P^+_$?A]9X/LUU:Z9<1&"XC
M]"DL<@0]MT>UO>MF+P-;:9X&B\+Z%>W?AVU@MUMK>ZL?+:>!1W4RHZDGG)93
MU/?FL8IQC=;K;[IJ_P N:_RZ&CLY6Z.U_O@_QY;/^D?*5W>:Y\7/@YX@\?OI
M]VCW=S:6DEHJGS!96[ 3@ <D,P+5O>,=7^'VK>)/"FN>&]/27P;8:Q')XBO;
M.U861/V65;=I#C:P1B W]TLN>U?3GA+PO8^#/#MCHVG*PM+2,1H9""[>K,0!
MDGJ36O6K:3]W:]_R_P K^KN9I::]FOO_ %6Q\7ZQ8:!K&J>)-?M=5E\.>#SK
M5O<:1J!L3/ILDZQ@2.Z$;1$6S\QXS1-JUUH_@)?B;IVB62/X,\02LUWH:,D&
ML6,T:)/)&I_VBA..,Q'%?:%<SXZ\#Q^/;"VL+K5+ZRT])UEN;6S\H)>*I!$4
MI=&;9D D(5)Z$XR*A7BK+R_"VOW*WH7HW>7G^NGX[]]3Y:L].OO"OC/0-:N]
M(DU74K[POJ&J7EFJD^=+*Q<H<?6N?@U2T\5?$7X?2::VE7$4NA:G;7%EHMD5
MAMY&MU98))",NX(^ZW(VY[U]T11K#&D:*%1 %51T %/HDE*ZZ:I?/F_27X>8
MDWN]^O\ Y+^J_$^#_#4EM%/X+O+WQ%9^&_#4>@-9+=7&FQW5O%>!SYL3A\!)
M"._7M76>&-+T'P)XF\-WGBN_NM:\"RZ'=PZ7?ZQ8F&-;I[IG=!&>%W(5$?JJ
M\5]B454GS-OU_'F_^2T)2LN7T_"W^6OS/ ?V6TMT_9UE^R026UH9+TPQ2J0R
MIN;'!KQ'X;W'ASQ!\*OA5I7@^VV^,[/4I+F^\B,B>& ";SGE;_GFV5 SP>,=
M*^YKRU6^LY[=R0DR-&Q7J 1CBL+X=^!;'X:>#-+\,Z;-<7%CIZ-'%)=,K2L"
MQ;YBH ZL>@%2_>;?^'\+_P# OW*7NQMZ_C_6A\D^#/#6F^'OAY\*==U32UC\
M.P:G<S:U.T/RKDMY;S<?<#X// I^MPZ9<:OJ?B>QLUC\ 'QKI\]I=21?Z-@6
MK)/-'D8$9DV#(X)%?:U%7S>]S>=_QB_T%;2WDU]Z?^9\/R:-!?:CXRTCQ1XS
M?1-5O]7::UM+?14N+VYA8@PO;29WD8_N]*L+X>74_C):6E_:O>VI^(<[2>?&
M<2 :3;X9ATZC\Z^V**5-\EO2WW.+_P#;?Q\AS]Z_G?\ %-?J?%FI:/I-KK/C
M#[?K#>%;72_%QFTZ::Q\_3XW,9XF4C:J'U/&<5[1\!BOC7X7^(M.N-&T^PT^
M>]N[6.YTQ66UU&-QS<1JW0,68<<94XKVNBH2]QP?9+\$K_AZ:C;;DI+H[_BW
M^I^?VGW?BW2+E/%RV-[)?>$9?^$3A@13B<3;D+X[@,T9S[5TWQ"\!Q>$I/%V
MD&V^U0:5HGAL23/'O!*7,AFD/'^\Q/N:^VZ*T4FK=[I_K^+;?SMT%I=]MOQ7
MY))'QOJ.A:1KUA^T#JT%C!>?\2N$V-RL6<#[.Y!C...0.E?4GPUEEN/AUX6E
MN&9YWTJU:1G^\6,2Y)]\UTE%).R:]/PO^=Q-7:?:_P"/+^5OQ"BBBI&%%%%
M!1110 4444 %?G_^TI<?:/C-XA;!&UT3GV11_2OT K\^?VBO^2Q^)/\ KN/_
M $$5V87XV>#G'\"/K^C/-Z***]0^0"BBB@ HHHH **** "OTH^&?_)/?#O\
MUXP_^@BOS7K]*/AG_P D]\._]>,/_H(K@Q>R/HLF^.?HAWC[_D7+S_KF:3X<
M?\B3I/\ UQ%+X^_Y%R\_ZYFD^''_ ").D_\ 7$5YQ]6=+1110 45XY=?M!7<
MWQ"\3^%-&\(W.LS^'I(([N>.Z"#]['O4A=A[9[]JL7?[04#:-I]QIN@7=]J=
MS>M8/I<L@AEAE49(8X- 'K=%>=^%?C%!K.NOHFL:3<^'-7%NUVD-TX9)8EQN
M97P,[<C(QWK+'QGUG7Y99?"/@U_$&DQ.4.H3W_V19,=3&IC;</Q% 'K%%>9'
MXTM=^$[G4],\/7-[J=E/Y-]I#S"*6V^4L6)VG(XX..<U)X ^,,WC+PS<>(+[
M0)-#TI+;[5%/+<B02IC/]T8H ])HKB?A1\4;/XK>''U6VM)=/:.8Q26MP<NG
MRJRD\#AD96'UK:\)^*8O%=C=W,,+0K;W<MH0S9R8VP3T[T ;E%>=6/QCMKS2
MSJ7]F3+81ZG<Z9<3*^[R3%(4WD8^Z2I^GO6YX9\?V?B*^N+$Q_9;Z$Y$3/N$
MB=G4X&0:#/VD5+EOJ=317,WWC>&'Q+:Z):6YOKR3YI]CX6W3LS'!Y/85TU!2
MDI7MT.6^(/\ R#M._P"OZ/\ ]!>NCM/]0GT%<Y\0?^0=IW_7]'_Z"]=':?ZA
M/H*"CF_BC_R(6K_]<U_]#6OFFOI;XH_\B%J__7-?_0UKYIH **** "BBB@ H
MHHH **** /1/@;*5\7RQXX:V8_D1_C7OE?/_ ,#_ /D=6_Z]9/YK7T!0 445
M0U^YO;/0]0GTVW6[U"*!WMX'.%DD"DJI/8$X%3)\J<GT&ES-(OT5\O> /BGX
M@U>YT"27X@2+XLN98UU7PAXET^.PMHLC]XEJX@$C,I^[F60$=>M;UG^T1J=O
MXD30-/T&Y\0ZGJ.NWNF6POM0B@CA\F$2?>2WXCZ]0S#GEN!6G*]OZZ?YDWTO
M_77_ "9]!T5\_:)^U+J%_;66H7_@@Z9I#:PV@WER=4$CP7BNR$(@B'F1[E(W
M94_[-2Z;^T_J$^GS:]?>!Y+#PA;ZN='N-5&I"25'\T1+*(?*&8]S+D[P1GH<
M4DN9I+^MO\U]XWHFWT_X/^3^X]\HKY6TCX\>+/)N0;F75-1.IZ]#:1O)!;V_
MEVTA$2R8@9CM7&"I4G'.<\0_#'X]Z]X<T'1M=^(6K:A=Q7NB:AKDJI-:- L4
M+1A55$M8G#?,0H,AQW+9&$M5S=+7_!O\DRG%WY>MVON=OS/J^BO =+_:WT>.
M<QZ]::=9>;927]K_ &1K46I,RIC*2A57RI.1Q\PY^]4>D?%_QQKGQL\ :5J&
MA_\ ",^'M9TZ]O# ETEW]I"QAHM[&)6C=<Y*J2.>IQ32;:7]=?\ )F;DDK_U
MT_S1]!45XWX]^/6J^%O&FO>'])\(+KC:+IL>JW-S)J8ME\ILY"CRGRPP<#H?
M45#X/_:*O/$FL:':WG@^;3X/$&ESZGHS1WRS37(B56:-XRBB-B&X^=@>Y%)>
M\KK^M_\ )_<4]'9_UM_FOO/:J*\(N_VB]1L/$*:!KGARWT>YO]/N+RSDT_6X
M[N=/+4DK+&80(V_[[7/K69H/[2FOZE$]CI'@Y]>ET_0+?7+R]O\ 5TMV:-P^
M5^2WVM)\G "JIR?NXY.E^G_#_P"3'9_U\O\ -'T517S?IO[0VJ7OQ(EU>2&*
M'X??\(M%K(#W0$J!F/SE/*^\3\NTOCC.><5:LOVOM/,9:^TS34>ZTVZU+38=
M-UV*]DE$$+3&*=50&!RBDC[XX(SQRY+EO?I>_P K_P"3$O>=EUM^*3_5'T-1
M7BG@_P#:&U/7+_PW%J_@QM'M_$ED]YI30ZDMS+*57<8Y$,:!"01CYF'TJM<?
MM)W^A^*]+T7Q!X4M=-;5;>[FLQ:ZVEU<*T$32E)XA&/+)53RK. >*)+D^+S_
M  O?\F"][;^KGNE%>%>$/VF+O65\*7NN>$?[!T3Q-&[:?>+J0N)-RKN(DC\I
M=H(Z$,?H*M:7^T7>76@S^++SP;<6O@(07-Q%KD5\DDFR$D9E@*KL#D$+M9^V
M0,T-.-[] 7O6MU/:Z*\6^'W[2EEXP\5Z7H5[9Z99SZM$\U@=-UJ/4&PHR5G5
M47RFQV^8>]2?$;]I"U^&\/CK[;H4UQ<>&H[*:&WCN/GU!+AF12GRG;M9'R/F
M^[0]+7_K6P+WM$>RT5X7XU_: Q<6%OHUK<M&TM@9+NVNHD&^X8;86#PR<;3D
MD8/H17FFB_'/XHG4O"J26MO=S:AXMU336LH[Q"MS%%%(5B9S;@Q+&54[E!+
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MVO;\_P#(^M**\1^&O[2S>)O$%QH7C7PE=?#?5EM&U"!-4O8I89K8=7\T;0I
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MOAGPWX"OVTB+PIH6IQWPUB&=VNKN**4RPQ& H%C.[;N?>V0O"C/!]E7WTO\
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M+J%XX8E7J0ID(WGV7)KQ_P 6_M'^*9M4UFZ\,Z'+=:&/"4>M6<KRPH8V<O\
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MOB-\.=?TK5-*@T/4A#H#:5/;7%[)$/--U-*KAA&>%$@XQSDCC&:TE\5UY_\
MM]O_ &TQBO=:?:/YPO\ ^W'HG@_X\Z)XVURQTW3[6YW76G2:AYD@ $>QMK1L
M.H8&N(MOVCK[6_&WA::TTB:T\)7EAJ=S>2SRQ!E-M,(V?[V<+M)QWWC'0U'X
M?^!?BSX=:IHNKZ&VF:U?BPN+/4(KR=[9 \K[S)&0KY /&TCD=Q6;HO[.GBFS
MT#PQI]^^FW30V6L:=J1BN'C"I>3^8LL7R'<0 ,H<=>O'(]-5Y_?[UOE\.O\
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MME>>)#.J&:1=21Y+H2R0_9BGS ,6(E#;=H'!ZU,=7&/73_VS_.7];G1OI?\
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M#CS+FY<(B9(49)X&20/QKXWO+_7+7P/X\\=#Q3X@;6=(\2O%8Q'59_LL40E
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M_P#H+UT=I_J$^@KG/B""=/T['/\ IT?_ *"U=':_ZA/H* .;^*/_ "(6K_\
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M))&VU?NJY1AO4>C9%;T/PE\)VWBNV\1P:/';ZM;:=_9,,L,CHD=KG(B6,,$
M]]N?>FK6L_/\I:_>U=;*P;?<OSC_ )/7?4XO]D_QUK/C_P"#]I>Z_=MJ&J6M
MW/8RW;##3>6^T,?<U['7/>!O &@_#?16TGP[8_V?I[3R7!B\YY<R.<L<NQ/)
M[9Q70U<VI.Z(@G%684445!9E^)O"^E>,M$N='UNQBU+3+D!9K:<91P#GG\16
M1XM^%?A'QWX=M]"\0>'[+5M(M@HAM;F/<L8487'<8 K;U_7].\+:/=:KJUY%
M8:=:H9)KF9L(BCN:\NOOVM/A?%X UWQ=I_B>VUC3='3,Z6BMYA<G"(%8 Y9B
M #TR>M2VK._34I)W5O0ZW4/@QX'U3P=;>%+OPOIT_AVVQY.G-%^[CQW'>H-/
M^!?@#2O#VK:%:>%-.@T?5MOVZR6+]W/@8&X9[#TKFK/]K#X9?\*_T+Q=J?BB
MSTC3M73]RLV]F$@X=,!<G:P()QCBJ7C+]K#P?X,\5>$;.ZN;=_#GB"QN;]?$
M/VG$,*1+N^YM)8MTP"#GL:TDG=J7H_SU^[\"([)KIJO^!]YV?ACX%^ /!C3M
MHGA/3=.,]L+.7R8N'A'1"#U'-2^$O@MX%\"0:C#H'A;3=+BU$%;M(81B8'J&
MSG@^E9DOQV\-7UAX6U'0M4TW5]-U^[^R07)NGCR<9PJB-B6_V6V_6N<T?]I>
MRU65TDTVWT[;XG'AI?ME\RF5R,[TVQ-ECV0X'^T*5FVX]=OQ7ZR7WAHE?IO^
M#_2+^X[7P=\%/ OP_74!X=\+:=I(U $77D1?ZT'J#G/'M5/PU^SY\./!^NVV
MM:+X/TS3=5MI))8;JWC*NC2+M<@Y[@D5R'A/]LCX:>*M:\0:>NM+9#2;Q;/S
MIT?$Y8X#KA>%+9'/IVKL?'_QL\.> [/7E>Z2^UG2=*;5FTJ,E7DBZ)\VT@;F
M(4?7I0FTE)=M/2U_R*Y7=P??7UV_X!TFK>!]!UW6K;5[_2X+K4K:%[>&YD!W
MI&_WU'L:RK3X/^#+"VT.WM_#MG%!H=PUUIJ*IQ:RMG+ISU.X_G6'J_[1WP^\
M+:UIVA>(O$MCHOB&\CC<:9*[.Z,X&%+*N!U[XJ_XQ^/7P^\ :[8:-XA\5Z?I
M>IWVW[/;RN26!. 20"%!SU8BA*S27?\ 'R^9-^9:]OP_X8MS?!SP5<332R>'
M+)Y)M0_M61BIRUU_SU//WJENOA+X/O8O$<4_A^SEC\1%#JRLI_TPJ,+OYYQ7
M"3?M7^"?^%E:[X(@O8WU?2K1KAGE9DBD=02T88*V-HZG'TS78^"/B_X>\:'3
M;2+4;1=9O-.&J"R@D>1?L^[;O61D3<,\= ?:DM8W6WZ?U'[D-NTM=_Z_67WO
MN,\2_ OP!XPU"TOM:\)Z;J5W:0BW@FGBRR1XP%^F/6KV@?";P?X6U&RO])\/
MV=A>65D=.MYHE(:*W+;C&.?N[N:XG5OVI?!.FSBXCU:QNM%6PGOGO%EE$I$3
M%6"1&+##(QNWCZ&K?PE_:;\"_%^QT9M*U5(=2U7S_(TV4-YF8L%USM"Y"LK$
M9_B[TTF[V_K=?Y_TPE[N_I^7_ -ZX^!O@&[\(GPO-X5TZ70#*T_V!X\Q^8QR
MS#G())]:XWXU?LXV_CCX01>"?!TMEX5M[:XCN(K4V^ZTF"Y_=RJ!DJ>,D<\5
MZCX9\::)XR_M#^Q=0CU 6%R]G<F-6 CE4X9<D#./;(K;J6N9:];/_(I2:=^J
MO_P3P'X _LUW7P]A\27/C&;1M7O]<2.WFM-+M#%9) B[50(W/0<UWND_L_?#
MG0O#NK:%I_A#3+32-5Q]NM8XB%N,$$;N<]0#7H-%6VW^1$5R[=[_ #.6OOA?
MX4U/4;._NM#M9[RSM&L+>9U.Z.!AAHQST(K,UWX$_#_Q-X=TO0=5\)Z;?:1I
M8Q96LT65@'HISG'XUWE%3_7]?>_O&<VOPX\,)>:3=+HEHMQI,+06+JF/L\;#
M#*HZ $5YS\1_V?;:]^'>N^$/ >E:%X>L_$<Q?5IIUD!Y8$R(J@@OP>N!TKVJ
MBDUS;_UU'%N+370QO!WA>T\%^%=*T&Q4+::?;I;Q@#'"C%<U>_ ;P!J.H75[
M<^%K*:YNI1/,S!L-(&#!]N<!LJ#D#/%=]15-N4N=[DI*,>5;'+/\+_"CZ+?Z
M0VAVITV_G-S<VQ4[992<ESSUS5'Q%\$O WBW4I;_ %?PU97UW*$$DD@8;]I!
M4L 0"1@<D9XKMZ*0S,UKPSI7B/1)='U.P@OM+E3RWM9TW(R],8KD],^ ?P\T
M;PQ+X=L?"6FVNB2SI<R6<<9"/(IRK'G)(/3FN_HHZW#I8Y36/A5X1\07MU>:
MCH-I=W-U9'3II9%.7MS_ ,LSS]VE?X6>$I)=$E?0;-GT2V:STXLA/V:%E"LB
M\]"H Y]*ZJBC^OS_ ,W][#^OR_R7W(\]T;]GSX<>';F.XTSP?IEE<1R/,DL,
M6U@S@ACG/<$\5HP_!_P9;Z#HNBQ^';)-*T6X^U:=:A3LMI<D[UYZY9C^-=C1
M3N_Z\MON$U?<XJ_^"O@75/&,/BN[\+:;/XBA.4U!X<R ^OH3[TW5/@CX#UOQ
MC#XKOO"NFW/B*(@IJ+P_O 1T/H3[FNWHI+2UN@WK>_4X'Q9\!/AYXZUF35M?
M\(Z9JFI21&%KF>++LAXP2#5'XW?"23XC_!C4O VB26NE":&&"V,X;RHDC92%
MX!.,+BO3**5M+=!IVES=3SSP'\"O!G@/3IDL/#FFVM]?6JV^HW%O%@W.% ;/
ML?PK>B^&WA>'P6GA%-$M/^$:2+R%TPIF$)Z 'ZUTM%5)\U[DQ7+:W0XO1/@Q
MX'\-^%;[PUIGAC3K+0KY2ES8Q1828$8(;N:SM2_9X^&VKZ!I6B7O@W2[G2M*
MS]BMI(LK!DDD+SG&23CWKT6BD]=_ZMM]P]OZ[[G)W?PH\(7TL,D_A^R=X;&3
M38SLQMMG&'B '\)%+'\*O"447AR--!M%3PX,:2H4_P"AC:%^3GC@ 5U=%.[W
M_KK_ )O[V'E_7;\D@HHHI %%%% !7G7[0'AP^)_A3K=NB!YH8_M$8_VE_P#K
M9KT6H;RUCOK.>VE&Z*9&C8>H(P:J+Y6F9U(*I!P?5'Y;T5O>//#TGA3QCJ^D
MR)L-M<NJK_LYROZ$5@U[J=U<_-Y1<6XOH%%%%,0444H4L0 "2> !WH 2K.GZ
M==:K=QVMG;R7-Q(=J11*69C[ 5ZS\+OV9_$?CYHKN^4Z)I#<F:9?WCC_ &5_
MJ?UKZX^'?PB\-_#.S$>D6*_:B,27LP#32?5NP]A@5S5*\8:+5GK87+:M?WI>
M[$^?/A;^R'=Z@8=0\82FRM^&&GQ']ZW^\?X?IUKZNTW3X-)T^WLK5/+MK>,1
MQH.R@8 JS52]U6RTUX4N[RWM7F;9$LTJH7;T7)Y/TKS9U)5'[Q]9A\+2PT;4
MU\Q-5L%U*RE@;HZXKDK.ZU3P<$MY(!>::O"[.'C'MZUW-1S6Z3J5=0161UE7
M2M:L]9A,EK,LF.&7HRGT([5>KDM4\%(LYO-/DDM+P<B2)L?@?4>QHLO%MUIL
MJV^M6Y7L+N-?E/\ O#M^% '6T5'!<1742RPR+)&PR&4Y!J2@ HHHH **** "
MBBB@ HHJ"[O8+&(R3R+&@[GO0!/6=J>N6NE_+(^^8CY84Y8_A63-K&H:WF/3
MXGM8"<&XD'SGZ#M5O2_"]M8.97#2SMRTDC%F/XF@"DL.H>(IHY+J-+>U1PZ0
M]3D=R?QKIT78@'I2JH08 P*ANKZVL55KFXBMU8A5,KA03Z#/>@#.\7:))XB\
M-WVG12+%).@"LW0$$'^E?-WB+PGJ?A>Y\J_MFC!/RR#E&^AKZH!R*@OK"VU*
MV>WNH([B%QADD4,#0!\CT5[#XO\ @BOSW.@R%>YM)3D?\!;_ !KR?4--NM*N
M6@NX'MY5ZJXQ0!6HHHH **** "E1"[JH&23@ 4E=/\-M%.N>,-/B*YBC<32>
MF%YP?KC% 'T1X=TP:-H5A98P8(40_4#G]:T:** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .#^./A^V\4?"[
M7=-N]%O_ !!!-#\UAI;HMS)@Y&S<0"01G'>OE3P;X2\?>+?AU\4-!'@O6;/P
M_/X?F@TV+Q-I<-MJ,EWMPB*4^^O<'UQ7W/14<NDEW5BU*SB^SO\ J?#MYJ/C
MN?P)X"T:#X0ZVNB-HKV%S;Q:7$M[#>+E-SE^(HVQOW'KN]:Y+P[X"\8>"KCX
M,ZIJ'PPU[Q1!X?M=5&HZ6++>\18_(!O 4GNH_BQQ7Z'T5LYMS<^K;?Y_Y_D9
M**4%#HE8^$O!7PC\8P3>&=<?PEJ.CV6I^.9M:31OLYWZ9:LN%\U1Q'TZ'UJ\
M/AEXM^W:8W_"-:IM3XJ1:FQ^R/A;0+S.>/\ 5_[72OM^BE&7)*+72WX<G_R"
M^\J5Y)I];_CS_P#R;^X^.=+^%-]>ZM\>?"U_X/O=-AU:[EU33-=^RA+5U !1
M$D_O KG Z9KD_A+X:\4?%?PS#XAO],NI+OQ'XATW3+J54,BV]A8$22,S= KO
M&5YZD@5]M^*O"UCXRT.XTG46NUL[@;9/L5Y+:R$>GF1,K 'N,\TOA7PKI7@C
MP_9:)HEFEAI=FGEPV\>2%'7J>22<DD\FE3?):_112_[=Z_-))]T.H^>_FV_O
M7Z/5=F?&/[2.D_$/QIKWC+P^/AUJM] DT,NDZKI%E'Y+VZE<F27&]WZ_(O/Y
M58U7PQXA\"^,?%/]I?"'4?B7;^+M.L8K"80!X[5DBV/%<,?FA7<<D_7TK[<H
MJ8KECR_?Y@W>7-_7<^-]7\#:_H/QB\6./A[=O;Z[X4BMK>\TNV\^VM;A(L.A
MDQG)/ [G%4/&OPX\?>'O@7\+O$'A#0+U_&^EV$FC7=@('$Z6]S&\;%U R/+?
MRWYZ8S7VO13>JL_+[DY:?-2:?D):24ET5OPBK_+E3]3Y"O?@1J'ASQYX4TC3
MM#N;[2++P3=6$MT8"T)N6R=K-C&YB<X-<->Z;K7@3]EOP?XQ_P"$1U#PSXH^
M'&J9FM[ZW%O)>1R$Q2,O=D82KR>NROO:N3\=_"[P]\2OL"^(K>YO[:SE$R68
MO9XK:1@P93+"CA)<%00'#8[4Y-RT?5K_ -*<O_;FK DE:ZV5O7W4OTW.9_9H
M\#R^ _@[H5I=J1J=U&;Z]9N6,\IWOD_4UZE3418T5% 55& !T IU5.7-)M*Q
M$4XQ2;NPHHHJ"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#XZ_;'\%'2_%5AXAACQ!J$?DRL.
M@D7I^)&?^^:^=J_1#XX?#_\ X6/\.]2TR)0;Z-?M%H?^FJ\@?CROXU^>,D;1
M.R."K*<$'J#7K8>?-"W8^*S2A[*OSK:6O^8VBM;PYX5U;Q=J*6.D6$U_<N<;
M8ER!]3T'XU]1?"W]D*STXPZAXPE6_N!\PT^$D1+_ +QZM^@^M:SJQI[G'A\)
M5Q+M!:=^A\^?#SX0>)?B7=B/2;)A:@XDO9AMA3ZMW/L.:^N/A=^S3X<\ B*[
MO476=6&#YTZ_NT/^RO\ 4UZS8:?;:59Q6MG;Q6MM$-J0PH%51Z "IR0 23@#
MO7FU*\IZ+1'U>&RZEA_>E[T@50BA5  '  [5#>WMOIUK+<W4\=O;Q*6>65@J
MJ!U))KPGXY?MF>!O@S'-9QW \0^( "%T^Q<%4;_IH_(4?3)K\[_C;^U'XY^.
M5T\>KZBUEHVXF/2+$F. #MN&<N?=B:YCUC[+^.__  4*\.^#?M&D^!8T\1ZL
MN4-\3_HD3>Q_C/TX]Z^"?'OQB\7_ !*U_P#MC7M<NKJ\5MT6V0HD/H$ Z8KC
M** /J_X$?M^^*?AY]GTOQ:C^)]#7""4G%U"OL3PWT.*_03X7?&CPA\8M'&H>
M%]8AO@ /-M\[9H3Z.AY'XU^)E:OACQ7K'@O6(-5T+4KG2M1A.4N+60HP]LCJ
M/:@#]UJJWFGPWL92100?:OA;X$?\%&@_V?2/B7:@-PBZY9)C\98QQ]2N/H:^
MW?#/BO1_&6DPZGHFHV^IV,HRDUNX8?CZ'V- &!-X=U#P_*UQI-R54G+6[\HW
MX=JT]*\96UU,MK>#[#>'C9)]UC_LFNA(##!&163JWAJRU9")8$8XZD4 :W6E
MKBX_[9\*#;&#J%@I_P!5(WSH/]EOZ&NBTGQ!9ZPN(9-LP^]"_#K^% &E1110
M 4C,$4EB !U)K,U+7X+ F*,&YN>T,9Y_$]JS?[-O]?96U!O+MNHMHR0I^OK0
M!-=^)Q<,\&EH+J8<&7_EFI^O>F6?AR6XG6YU"<W$O7!^Z/H*V;+3;>PC"0Q*
M@'H*M4 1Q0K"H51@"EDE2&-GD8(BC)9C@ 5YY\1OCMX:^'<;Q37 U#4P/ELK
M9@2#_M'HO\_:OE'XD_'/Q+\1WDAN+DV.EGI8VQ*H1_M'JWX\4 ?0?Q,_:BT3
MPOYMEH&W6M17*F5#^XC/^]_%^%?+OC#XBZ_XYU$W>JZA+*P.4C0E4C_W17-4
M4 >P_#3]I37_  48K/4BVLZ6N!LE;][&/]EN_P!#7U5X#^*'A_XBV8FTF]1Y
M@,R6KG;*GU7^M?GI5G3M2N](O8KNQN9;2ZB.Y)H7*LI]B* /TOK)U_PMIOB6
MV,-_;++Z..&7Z&OFWX9_M97-IY-AXNA^UQ#"C4(% D'^^O0_48_&OI7P_P")
M=+\4V"7NE7L5[;N,[HFSCZCJ* /%_%_P<U#1=]QII.H6@YV@?O%_#O\ A7G;
MHT;%64JPX((P17U_7*>+?AOI'BM6DDB^S7AZ7,(PQ^OK0!\U45U/BOX<:OX5
M=GEB^TVF>+B$9'XCM7+4 %>S_ C0?*M;S5G7F0^3&?8<G^E>/V%E+J-[#:PJ
M6EE<(H'J:^I_#FCQZ!HEI81C AC /N>] &E1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUZ_110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'P!_P %(_A7K:7>F^.+:ZNKO0B%
MM;JV+EH[63^!PO0!LXSZX'>OA.OW7\3^&M.\8^'M0T35[9+S3;Z%H)X7'#*P
MP?Q]Z_'O]HKX$:G\!?'USH]R'GTN4F33[UEP)HL\9[;AT(H \LHHHH ****
M"BBB@ HHHH **** "BBB@"2VN9K.=)[>5X)D.Y)(V*LI]01TK[#_ &7/VV_&
M.G>)M%\(^)/^*BTZ]G2UBN96Q<09.!S_ !#V-?'%=U\"_P#DL7@__L)0_P#H
M5 '[8UY[\:OB=)\+?"\=_!:"[N9Y/)C#-A5..IKT*O!/VP?^1&TS_K\_]EH
M^9O&GQ#U[Q]?M=:Q?//S\D*G$:>P6N;HHH **** "BBB@ HHHH **** "BBB
M@ HHHH 5':-PR,58'(93@BOMG]FF/Q+)X&%WK]Y+/!.P-E'.,NL8[Y]#VKYV
M^ WPCE^)/B-9[J,KH=DP:X<CB0]HQ_7V^M?<5M;QVEO'!"@CBC4(B*,  =!0
M!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM=?E:WYWT-6[\7Z%8:U!H]SK-A;ZM/CRK&6Y19Y,]-J$Y/X"M>O@_P <>.=
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M!+F/EH+A1B:W?'#HW4']#T/%?F#^T+^R3XK^!=]+=")]8\-,Q\G4H$SL'82
M?=/OTH \*HHHH **** "BBB@ HHHH *[KX%_\EB\'_\ 82A_]"KA:[KX%_\
M)8O!_P#V$H?_ $*@#]L:\$_;!_Y$;3/^OS_V6O>Z\$_;!_Y$;3/^OS_V6@#Y
M"HHHH **** "BBB@ HHHH ***.M !78?#7X7ZQ\3=96TTZ(I;(1]HNW'[N)?
M<]S[=:[+X1?LZZMX\EBO]5632]$R#N88DG'HH[#WK[!\->&--\(Z3#INE6J6
MEK$,!4')/J3W/O0!D_#OX;Z1\-M$2PTR+,C &>Y8?/,V.I]O;M75T44 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_(\6\2?LUQ:WXGUC5+7Q3J&E6NL1>7?6<$*-YIQC(<\@>P_.M71/@7'H^H>
MKMM:DG;PI%<0HIMPOVD2J5Y^;Y<9]\UZI10L14244]O\FOR;0?5J3DY6U?KW
M3_-(XWXF?#F/XCV.F6TE\U@+*]CO RQ;]Y4YV]1C/K78D94CU&*6BL7)N/(]
MO\_^&-U"*DY]79?=?_-G!>!_A'9>$/!%_P"&;BZ;5+.]EFDE9XQ&<2,21C)Z
M9ZUR&C_LT+9ZAID>I>+M2UCPWI<XN;'0YXU6.)U.5RX.6 YX(KVRBM57J*3D
MGJ_Z_IF4L/2FDI+:_P"._P GVV/FB/X1^(O%'QA\?7%MJVK^$;:X\M([V&US
M%=)_$HW8!^H/%=QJ7[-^E'PYX=LM%U:\T+5M"+M::O"H>3<_^L+*3@[J]?HJ
MWB*EHI.UK?@K?TMC-86G>3DK\S?XN_\ 3W/)+CX "]^']QX=O/$U_?7=U=QW
MEQJ=TOF,[JV<*F["CV!K>^*/PJ7XD:%I5G'J\^C7VEW4=W:WT$0=DD0$ [21
MGKZUWM%9^VJ73OL[_/3_ "1K["GRN-M&K?(^;?B?X#OOB7\4O"ND'1=69-'*
M_P!H^(+B#R[:ZAZE58'#'/:OH'7-*?5=!OM.MKC[ ]Q;O DZIN\K*XR!D9Q]
M:T:*)U7.$8/97_'<5.BJ<Y5%N[?<MCSSPQ\#_#?A_P $1>'IK&TU%Q"T<E_-
M:)YLC'J^>2#^-<A!^S$=/T;P_%IWB^]T[6=$,L=KJT-NN_R';<8F0M@X).#G
MOTKW*BJ^L54W*^^OY_YLEX:BXJ/+HM/R_P E\]3R_P"'?P,MO UOXGAN=8GU
MU=><O.UW$ PRN#D@_-^E-^'GP!TCP#X&USPT+R:_CU=I//NF7RY A4*J#D_=
M'3ZUZE14RK5)73>]D_EL5&A3BXM+:[7SW^\\(T+]EUM'NO#LTGC*^O4T*[6X
MLK>2U18T0'[F <D_[1/X5UEE\%H;/2/'5B-5=AXIN))W?R /L^Y0N -WS8Q[
M5Z7153Q%2=U)_P!73_-"AAJ5.W*MO7LU^39Y)J'P",J^#Y=/\2W.EZAX=@^S
M)=16ZMY\9^\"I/RY_&N>U7]E"'4!XAM8/%^H6>CZO<F].GI A5)R02S-G+CC
M[O':O?**I8FJG=/\NKO^>OET)>$HM6Y>W?HK?EIY]3Y;^,'A?Q%X4^(.CZGH
M^E^(Y+9;!+.ZU/PU +B6Y"C&QHCPG^]DUK_"SX!S:U\(;S3/$45WHEY=ZQ)J
M]DS$&YM"<"-F_P!K Y!]:^C:*OZU-4^1;]_G?\S+ZG#VG.WIVZ;6_(\IT/X$
MR6VE:S!K?B_6-=O]2B$)O3(8#"H^[L53@$>O>JW@W]GZ30O&5EXCUSQ7>^)[
MO3XS%9+/;I#Y(/!R5)+G'<UZ_167UBI=N^_IZ?+Y&WU6E9)K;S?KKW^84445
MSG4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5]0TZUU:
MRFM+VWCNK692LD,RAE8>A!JQ10!\2_M!?\$\;'7VN=;^',R:=?MF1]&N&Q#*
M>O[M_P" ^QXYZBO@KQCX'U[X?ZW-I'B+2KK2-0B)!ANHRA89QN4]&7T(R#7[
MGURGQ!^%OA?XI:0VG>)M&MM4MR#M:9 7C/JK=5/N* /P_HK[B^,/_!-O4-/\
MZ_\ A]JGV^');^S-0;;(!Z*XZ_0\^]?'WC#X>^)/ %^UGXAT6\TF=3C%Q&0#
M]#T- '/4444 %%%% !7=? O_ )+%X/\ ^PE#_P"A5PM=U\"_^2Q>#_\ L)0_
M^A4 ?MC7@G[8/_(C:9_U^?\ LM>]UX)^V#_R(VF?]?G_ ++0!\A4444 %%%%
M !1110 45O>%_ FO>,KI8-(TV>[)/+JI"#W+=*^@_ /[(D4?E77BJ\,IZFQM
M3A?HS=3^&* /GKPCX)UKQSJ0LM%L);V7C>R#Y(QZLW0#ZU]4_"O]F'2_"AAU
M#Q R:MJ:X80@?N8C_P"S&O8M"\/:;X9L$LM+LH;&U3I' @4?7CO6C0 U$6-%
M5%"JHP% P *=110 4444 %%%% !1110 4444 %5=5O3IVF7=V$\PP1-)M)QG
M SBK59GB?_D7-4_Z]I/_ $$U,G:+:+@KR29X-IG[2?C>Z\)0^+[CX<1KX4/S
M27UOJR22*F[:6$> W!]<5[>_CC0[3P]9ZU?ZI::5IUU&DD<U_.L*_,,@98@9
MYKYO^!GP&C\>_"?0KO4_%WB%M)N-S2:%'=8LR Y^7;CH<9K:^*5IX;T'XR>'
M$\;6T9\#VVEM#9B[C,EK',,#YQ@CH!C/>O9KTJ+JNC#1IO:^R6VKU?H>!AJU
M=4%7J.Z:6]MVUKHM%K=W/9O&'CH:-X3AUO1CIVK132QK')+J,4$#JQQN$K':
M?89YJ_J?CGP_X?\ LD>LZYIFDW%RH:.*[O(XR^?[NXC=U[5\F3Q1#X9^,9M&
MBD@\'R^(X&TI&4JFS<,E >BYZ59^-=AH,'CJ^O;S4;".ZDTN.-K'Q%I^^*4;
M>#;2CE6Z],&LUAHW47^6OPIV_$V>+FDY)+[]/B:NON[GUSJNOZ9H6GF^U+4;
M73[(8)N;J98XQGI\S$"BUU[3;W2_[3M]0M9].VE_M<<RM%M'4[P<8_&OC3Q[
M+=ZYX+^%EQ<11^%_#ZP/&_\ :5NU[;0,#@%TDR2I &-V::OA^[@^ _BZ33=6
MDUS1)=5MI)Q8:>;2+RE<>:8E!QM(V] .E/ZDK:RL[V_\FY=>GGN3]?;DK0NN
M6_G\/-I?7RVW/I"[^-FGS?$'PYX?T9['6['5HY&;4+2\618BI(VC;D'IZBI/
MC=\9;3X/Z#;7)B@OM4O)UAMK&6Z6#?D\NS'HH[MT&1FO$M#N? %U\?\ P+)X
M$M[:*W^R.+AK.+RXRWOP,MZFNW_:XT33]0T?P=-<V4%Q,=>MK??)&&/EN3N3
M)_A.!D=\4O8052E!IV;UOONT5'$5)4JTTU>*NK:KX4_Z\ST_2?B+I\7A32-6
M\37VE>'9K^)9!%+J4319(SA)<[7'N*V[_P 5:+I5O:7%[J]C:07;!+>6>Y1%
MF8C("$GYB1Z5\W>*+7P;X>^-&KQ?$"QMH_#R:7!%HD=S!NMHU"X947& V>E<
M2^AOJO@/P)I]]!+_ &#>>-@MC;W(.39MG"X/\)YIQPL*K33LG;TU>WJNI,L7
M.BG%V;BGZZ*]]MGT/LW3=;L-;TT7^F7MOJ-FP.R>UE62-L=<,I(KQ+0OCA\1
M_&/]H3^'?AK:ZGIUK>2V?VEM;CA+,C8/RN ?3\Z]GTO0=.\-:+_9^E64&GV,
M2MLM[= B+GDX X%?-?P-^%5]XMTW6]4@\<>)-!B37;I38:9=>7 V'!R5QU.<
M&L:$:3<W+96M>_?R-L1.LE3C'=WO:W;S/:M%^)5W?_$JY\)7>EI:26^GQWDD
MPGWD,PY3&,<>N:Z?3_&&@ZMJD^FV.M:?>:C!_K;2"Z1Y8_\ >0'(_&O"O%D5
M\?C1XXCTTNU__P (T@B*_>+;?YUXQ\(] BN?%?@<V_B:SCUR&\\R6PLM#"7<
M>"?,6XF!!(*[AEL]:VIX:%:*E>VB[];_ (:&57%SH/EMS:^2V4?35W/MA?&W
MAU[*\O%UW36M+)_+N9Q=Q[(&_NNV<*?8US.M_$Z?3->U2VM[73[S3K70Y-7B
MN$U*,S2E>B^2,OL(_P"6F,=J^=/B'?Z>_P 7[[5;6SNI_ ":A"NN/"?]'ENE
M/WL=P#UKN/&4\%S\:O%,ULRO;R> )VC9/NE2W&/;%9_5THJ7=-^EHW_X*\K&
MRQ+E-P[-+UO*W_ ?G<];^'?Q8TCQOH>C3S7MA8:SJ-NMP-)^UJTP!'93AB/?
M%&@?$AM9^)7B;PO)9);PZ-!#.+OS<F3?G.5QQC'K7R5IQ\&W?PQ\&6GARU2/
MXB&]A8O#"5N3\WSL7QDICISBN]^($.K3>)?C5'I8D;4#I%D"(<[BN?WF/^ [
MJWJX:$9RMHO>W\FM?37\#FI8N<X1OJ_=V\[W3\]#Z;T;Q;H?B.:>'2M9L-3E
M@.V5+.Y25HSZ,%)Q^-<W\7OBC#\*_#UM>FRDU._O;I+*SLXV"^;*V< L>@XZ
MU\U_ +0[9_B;X;N-,\3V-Y<0VQ:XM=+T06VU,?,D\BXRWUS7M?[3=SH:>$=.
MMO$FB7>I:/<7JK)?6<FU]/;!Q-T)Q@M6%3#QI5H0O=/Y=?,VI8J=:A.=K-+3
MKTOT[?TB[\//C/J/B#QC/X3\4^&V\,>(%@^TQ0K<K<1RQXSD.O?':N]B\9Z!
M-K;:-'KFG/JZ\M8+=1F<?5,[OTKYE^'?BC4K+X@-X>\(>,+[QSX=FT^5GGO
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M0?!=/%]_H?VC69[-KRWTFQA>)I<J"B .S')/\6<$<XHULWV_X/\ DPZI=_\
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MGM4>F?M#Z%K.B6.IV6B^([B/4,-90)IC>;=)MW%XQGE0.I)%-73YNO\ G?\
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MTQ;&,(.IKV[P9X[T3X@:,VJ:'=M=6B2O!()89(98I%.&1XY%5T8=U8 U\X^
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MP3\%M,@L]%;5?$FFZ/#%'I*W$<?FW"Q*NSS&;8!NZG., XS7=T4-WBXK2_\
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M:2$+$N]G=W8E5 !^52 ,\"M.5IM?U>Z5OQ1.ZO\ ULW?_P E9];45\X_LO\
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M:J^FC4;&YTNSDB &_;(KP;W9MO4;3EAV%8EU\8-5U30;)I==T#Q$PU_2K?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
40 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>plx-20230930x10q007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20230930x10q007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %6!#@# 2(  A$! Q$!_\0
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M&1^N![T=;!YE^BBD)P"3T% "T50T;7=/\0V9NM-NX[VW#M&9(CD;AP1^%7Z
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MI72_3_@%/6]NO_!.-_9Q_P"2?3?]A*Y_]#KU*J6DZ+8:#:FVTZTALK<N9#%
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M_6B_4MOWVU_6K_(^>+;Q9JW@WP?XTTE;&Y\*W,(&H:=!*ZL\4;$!@",C /\
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MYKHI^5NHR"",UT#?&BQ:#2)8+":Y%[927TJQOEK=$'((QR<\=J3T6O\ 6_\
MDPZ_UY?YGHU%>=^#OB[_ ,)/8WM_<Z.=.TZVA:?[4M]#< J!G!53N4^Q%9A^
M+]]K,"6L>@7FC-K$,B:-J$\B,L\NPE,J.4SQC-#NM 5F>KT5XGX!TS68/%I<
M17**UR6)>WDB\J#+Y29V4"5B-N"I;G\S[93MI<76P4444AA1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %>>?%.39/IP]FKT.O /VJ/%E_X530I+
M%D5I2X;>H- &KI\G/%=-8N645\EP_&_Q+!]V2W_[\BKL7[0WBV'[LMM_WX%
M'U[!]VK2]!7R O[2GC%1@2VO_?A:D_X:;\9_\];3_P !UH ^O**^0_\ AIOQ
MG_SUM/\ P'6C_AIOQG_SUM/_  '6@#Z\HKY#_P"&F_&?_/6T_P# =:/^&F_&
M?_/6T_\  =: /KRBOD/_ (:;\9_\];3_ ,!UH_X:;\9_\];3_P !UH ^O**^
M0_\ AIOQG_SUM/\ P'6C_AIOQG_SUM/_  '6@#Z\HKY#_P"&F_&?_/6T_P#
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MKRBOD/\ X:;\9_\ /6T_\!UH_P"&F_&?_/6T_P# =: /KRBOD/\ X:;\9_\
M/6T_\!UH_P"&F_&?_/6T_P# =: /KRBOD/\ X:;\9_\ /6T_\!UH_P"&F_&?
M_/6T_P# =: /KRBOD/\ X:;\9_\ /6T_\!UH_P"&F_&?_/6T_P# =: /KRBO
MD/\ X:;\9_\ /6T_\!UH_P"&F_&?_/6T_P# =: /KRBOD/\ X:;\9_\ /6T_
M\!UH_P"&F_&?_/6T_P# =: /KRBOD/\ X:;\9_\ /6T_\!UH_P"&F_&?_/6T
M_P# =: /KRMC3/\ CU'U-?%?_#3?C/\ YZVG_@.M6(?VJ/&\";%EL\=>;=:
M/M>BOBO_ (:N\=?\];+_ ,!EH_X:N\=?\];+_P !EH ^U**^*_\ AJ[QU_SU
MLO\ P&6C_AJ[QU_SULO_  &6@#[4HKXK_P"&KO'7_/6R_P# 9:/^&KO'7_/6
MR_\  9: /M2BOBO_ (:N\=?\];+_ ,!EH_X:N\=?\];+_P !EH ^U**^*_\
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MKRBOD/\ X:;\9_\ /6T_\!UH_P"&F_&?_/6T_P# =: /KRBOD/\ X:;\9_\
M/6T_\!UH_P"&F_&?_/6T_P# =: /KRBOD/\ X:;\9_\ /6T_\!UH_P"&F_&?
M_/6T_P# =: /KRBOD/\ X:;\9_\ /6T_\!UH_P"&F_&?_/6T_P# =: /KRBO
MD/\ X:;\9_\ /6T_\!UH_P"&F_&?_/6T_P# =: /KRBOD/\ X:;\9_\ /6T_
M\!UH_P"&F_&?_/6T_P# =: /KRBOD/\ X:;\9_\ /6T_\!UH_P"&F_&?_/6T
M_P# =: /KRBOD/\ X:;\9_\ /6T_\!UH_P"&F_&?_/6T_P# =: /KRBOD/\
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MCE5+' &3@#K1INHV^KV%O>VD@FMIT$D;CNIZ4 6:*** "BBB@ HHHH ****
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M74[76].\66VCV%OICVSVRE9)@V"#&L+<,')Z].]6)_&VES_$&XFDU>&33O\
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MCQ2_\&Z]I5Q;P7NBZA:3W#;88Y[5T:0^B@CD_2FWGA#7=/OH+*ZT:_M[R?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW_OS0!^?U%?H#_PI/P)_T*NF_P#?FC_A2?@3_H5=-_[\T ?G]17Z _\ "D_
MG_0JZ;_WYH_X4GX$_P"A5TW_ +\T ?G]17Z _P#"D_ G_0JZ;_WYH_X4GX$_
MZ%73?^_- 'Y_45]UWOP<\$I<NJ^&=/ '815#_P *?\%?]"UI_P#WZH ^&J*^
MY?\ A3_@K_H6M/\ ^_5'_"G_  5_T+6G_P#?J@#X:HK[E_X4_P""O^A:T_\
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M/_"D_ G_ $*NF_\ ?FC_ (4GX$_Z%73?^_- 'Y_45^@#_!3P($8CPMIN<?\
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M?^ DO_Q-']K0?\\[K_P$E_\ B:NT4 4O[6@_YYW7_@)+_P#$T?VM!_SSNO\
MP$E_^)J[10!2_M:#_GG=?^ DO_Q-']K0?\\[K_P$E_\ B:NT4 4O[6@_YYW7
M_@)+_P#$T?VM!_SSNO\ P$E_^)J[10!2_M:#_GG=?^ DO_Q-']K0?\\[K_P$
ME_\ B:NT4 4O[6@_YYW7_@)+_P#$T?VM!_SSNO\ P$E_^)J[10!2_M:#_GG=
M?^ DO_Q-']K0?\\[K_P$E_\ B:NT4 4O[6@_YYW7_@)+_P#$T?VM!_SSNO\
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M-']K0?\ /.Z_\!)?_B:NT4 4O[6@_P">=U_X"2__ !-']K0?\\[K_P !)?\
MXFKM% %+^UH/^>=U_P" DO\ \31_:T'_ #SNO_ 27_XFKM% %+^UH/\ GG=?
M^ DO_P 31_:T'_/.Z_\  27_ .)J[10!2_M:#_GG=?\ @)+_ /$T?VM!_P \
M[K_P$E_^)J[10!2_M:#_ )YW7_@)+_\ $T?VM!_SSNO_  $E_P#B:NT4 4O[
M6@_YYW7_ ("2_P#Q-']K0?\ /.Z_\!)?_B:NT4 4)-6@*-\EST/_ "ZR_P#Q
M-8?V^+^[-_WX?_"NID_U;?0USU %?[?%_=F_[\/_ (4?;XO[LW_?A_\ "K%%
M %?[?%_=F_[\/_A1]OB_NS?]^'_PJQ10!7^WQ?W9O^_#_P"%'V^+^[-_WX?_
M  JQ10!7^WQ?W9O^_#_X4?;XO[LW_?A_\*L44 5_M\7]V;_OP_\ A1]OB_NS
M?]^'_P *L44 5_M\7]V;_OP_^%'V^+^[-_WX?_"K%% %?[?%_=F_[\/_ (4?
M;XO[LW_?A_\ "K%% %?[?%_=F_[\/_A1]OB_NS?]^'_PJQ10!7^WQ?W9O^_#
M_P"%'V^+^[-_WX?_  JQ10!7^WQ?W9O^_#_X4?;XO[LW_?A_\*L44 .TN[26
M_B4+*"<_>B91T/<BBIM/_P"/R/\ '^5% &W7.^/_ !E#X \*7NN7%M+>16H!
M,$) =LG&!GBNBKSC]H6QGU'X2:Y;V]O/=RNBXBMD+R,-PS@#G-'5?(XL;4G1
MPM6I3^*,9->J3L0:+\8M4U(2RWG@'7=)L8[9[DWEUY?EX5=V.#U/:JUW^T+I
M<-AX4DM]+N[V]\1+O@L8G021)W9B3CO^/:O-_!R^%;6"Z@TC1?',>KSZ9/ #
MJD-P;8,8CG[Q('(XXIOA;X<QWFN?!NXO_#\DCPV$_P!L>:W8>6T:;H@YQ\I#
M<C/>NYTZ:GJM/^!)]_)'PL,SS&I0BJ512D]+Z.UYTH](+92;LT^^MK'TH-9L
M'NGM4O;=[M 2UNLJF08_V<YK \#_ !'TWQO9S30XLI8[N:T%O/(OF.8VP6 !
MY%?.]E8WFI_$70M7@\'7N@:E!KA74I8;-EC,3,P7,N27R,$D?*/RK,TSPT\L
M<UE;>$=8B\82>()9[75S Z1)#YN2=YX QGC'-1"BG:[W_P"!^%G]QU5.(,0J
MEX4_=3DNOO*VGV;J5[JUK7TN?5>O>+K'1M-O;B.2*_N;9&?[%#.@E<CJH!/!
M^M6+7Q%:/H]E?WDD>F+<QJX2ZE52I(SMSG!/TKYX'PX6XT+XL:K<Z+--KC7$
MT=G,T+[W4HN?+'<$^E1ZWH<=C=^'KSQAX7U3Q'X=_P"$?@M[:UM+=I?LUR!\
MV^,$$$C^+M6:IJV_;\4W9?EZG9+.,5%N<J:2UMJ[*T^6\GRW75Z7T^]>R^-_
MBUIO@N]AM'B^U3R%!_K5C7+YV*&;@L=I( ]*ZO0]9@U_38KR!71')4I(,,C
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M-_\ 0>T[_P "4_QH_P"$]\-_]![3O_ E/\:_*^BCZBOY@_XB57_Z!5_X$_\
M(_5#_A/?#?\ T'M._P# E/\ &C_A/?#?_0>T[_P)3_&OROHH^HK^8/\ B)5?
M_H%7_@3_ ,C]4/\ A/?#?_0>T[_P)3_&C_A/?#?_ $'M._\  E/\:_*^BCZB
MOY@_XB57_P"@5?\ @3_R/U0_X3WPW_T'M._\"4_QH_X3WPW_ -![3O\ P)3_
M !K\KZ*/J*_F#_B)5?\ Z!5_X$_\C]4/^$]\-_\ 0>T[_P "4_QH_P"$]\-_
M]![3O_ E/\:_*^BCZBOY@_XB57_Z!5_X$_\ (_5#_A/?#?\ T'M._P# E/\
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M\:_*^BCZBOY@_P"(E5_^@5?^!/\ R/U0_P"$]\-_]![3O_ E/\:/^$]\-_\
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MEC#;HRQ/).U@,^U>B5A)6?\ 774][#5UB:2J15M_DT[-?)IH****DZ0HHHH
M**** "OAK_@HY_R&O!G_ %PG_P#0EK[EKX:_X*.?\AKP9_UPG_\ 0EKIP_\
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M%4OS[URW@;QW)X-^(-CXIEMCJ,MM.\[0&7R_,+!@?FP<?>]#32J.3UTM^/\
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MHX %4*ZX<W*N;<^%Q'LO;3]A\%W;TOIV"BBBK.<**** "BBB@ HHHH ****
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M7Z%44?7:G9!_Q#O*/YY_>O\ Y$_/7_ADCXE?] >#_P "D_QH_P"&2/B5_P!
M>#_P*3_&OT*HH^NU.R#_ (AWE'\\_O7_ ,B?GK_PR1\2O^@/!_X%)_C1_P ,
MD?$K_H#P?^!2?XU^A5%'UVIV0?\ $.\H_GG]Z_\ D3\]?^&2/B5_T!X/_ I/
M\:/^&2/B5_T!X/\ P*3_ !K]"J*/KM3L@_XAWE'\\_O7_P B?GK_ ,,D?$K_
M * \'_@4G^-'_#)'Q*_Z \'_ (%)_C7Z%44?7:G9!_Q#O*/YY_>O_D3\]?\
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MR1\2O^@/!_X%)_C1_P ,D?$K_H#P?^!2?XU^A5%'UVIV0?\ $.\H_GG]Z_\
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MKXA_] J'_P "4_QH_P"&6OB'_P! J'_P)3_&OO"BCZ[4[(/^(=Y1_//[U_\
M(GP?_P ,M?$/_H%0_P#@2G^-'_#+7Q#_ .@5#_X$I_C7WA11]=J=D'_$.\H_
MGG]Z_P#D3X/_ .&6OB'_ - J'_P)3_&C_AEKXA_] J'_ ,"4_P :^\**/KM3
ML@_XAWE'\\_O7_R)\'_\,M?$/_H%0_\ @2G^-'_#+7Q#_P"@5#_X$I_C7WA1
M1]=J=D'_ !#O*/YY_>O_ )$^#_\ AEKXA_\ 0*A_\"4_QH_X9:^(?_0*A_\
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MJ[10!2^QW/\ S_R_]^T_PH^QW/\ S_R_]^T_PJ[10!2^QW/_ #_R_P#?M/\
M"C['<_\ /_+_ -^T_P *NT4 4OL=S_S_ ,O_ '[3_"C['<_\_P#+_P!^T_PJ
M[10!2^QW/_/_ "_]^T_PH^QW/_/_ "_]^T_PJ[10!2^QW/\ S_R_]^T_PH^Q
MW/\ S_R_]^T_PJ[10!2^QW/_ #_R_P#?M/\ "C['<_\ /_+_ -^T_P *NT4
M4OL=S_S_ ,O_ '[3_"C['<_\_P#+_P!^T_PJ[10!2^QW/_/_ "_]^T_PKS/X
MPVTJRZ8'N7E)W8+*HQ^0KUFO,OC"NZXTSZ-0!PFG0L"O[P_D*Z[2H&^7]Z?R
M%<[IRC<.:ZO35  .: ->WB;_ )ZG\A5](FR/WA_(57MN5J\H [T ,\IO^>K?
MD*9]GF_Y^G_[Y7_"K&:* *_V>;_GZ?\ [Y7_  H^SS?\_3_]\K_A5BB@"O\
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M7^SS?\_3_P#?*_X4?9YO^?I_^^5_PJQ10!7^SS?\_3_]\K_A1]GF_P"?I_\
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MO^?I_P#OE?\ "K%% %?[/-_S]/\ ]\K_ (4?9YO^?I_^^5_PJQ10!7^SS?\
M/T__ 'RO^%'V>;_GZ?\ [Y7_  JQ10!7^SS?\_3_ /?*_P"%'V>;_GZ?_OE?
M\*L44 5_L\W_ #]/_P!\K_A1]GF_Y^G_ .^5_P *L44 5_L\W_/T_P#WRO\
MA1]GF_Y^G_[Y7_"K%% %?[/-_P _3_\ ?*_X4?9YO^?I_P#OE?\ "K%% #M+
MAE2_B+7#..?E*J,\'T%%3:?_ ,?D?X_RHH VZ**X_P"+'B>^\'>!K_5=.,8N
MX2FPRKN7E@#Q1UL3*2A%R?0["BN!\2>--1TK7? MK"T0AU>1ENMR9) BW?+Z
M<USVO?'[2=0\*ZW=:#<W-G<6"!C>7>GN\"$2JA'!^8_-T![YK3DD]OZZ&+KT
MUN[?\-<]?HK@-:^-7AOPQ?6^GZA<7$EUY,<EQ);VS/' ' (,A'W >O-2^)OC
M+X=\*7\-M>_;F215?[5!:.\"ANA:3H.M+DEM8/K%*S;DM#NJ*X.Z^-7ANW\0
M_P!CH;Z[N RJ\MK:/+#&6&0&8#CJ*?K_ ,9O#/AO7CI-Y/<><A43SQ6[/#;E
MNGF..%ZCK0H2=M-QNO25VY+0[FBN3^)WC%O!/@V[U.W"271*0VRMRID=@J_4
M9.:\Z\3>._&,7CNXT"T\0Z'HR6FFQ74DNI0#$LAX8*=P[CI1&+E_7S%4KQIZ
M/7;\=$>XT5\^W'QE\4ZMH7@]K.[TS1KO5;FXMI[R\CW6Y\L<.,D8!Q^M;_A+
MQIXOUK4?$_ALZKI.IZM9V:7-GJMA%FWWMTC<9//'KZU3I2BFWY_@91Q=.322
M>MOQ/8Z*\:^'/Q4\1?$CQ):6$-JFG0Z3$5UXRQY+7 )41Q\\#*DY_P *]!\?
M>*KCPEX?FO+33I]3O""L4$*Y^;!.6/8"IG%PW_K_ (<VIUHU8N4=E_7X=?,Z
M2BO%I_C)KEI\'++7TTTWVMW=O)*6ACQ!!MZL_L/3O1\2/BQKGA[P3X,N=.>)
M-5UK8TTGV5IPJ"+<Y6->3R1TJG3DG;SL9?6J=N;RO\O\]3VFBO'/#GQ2U/['
MX-OKS5++5K'5KR2PN9;>W,)CE(_=@J3E2"""#ZU['4R@X;FU*M&JKQ_JX444
M5!L%%%% !1110 4444 %%%% !7S'^V%\4-3^'NH^'([""WF%Q%*S>>I.""!Q
M@U].5\:?M]KNU?PE_P!<)O\ T(5M12E-)G#C9RIT'*#LSS.T_:>\2IC%CIW_
M 'PW^-;EE^U5XGCQ_H&G'_@#?_%5X_X*\)S^+-2DMHIDMHH('N9YY 2L<:CD
MX')ZCCWK9U?PM!I6F6>HV6K6^JV=P[Q9C!22-UQD,AY P1@]*[_9TV[6/F/K
M>+Y>?G=OD>N1_M9>*5'&GZ;_ -\/_P#%5.G[6_BL 8T_3?\ OA__ (JO$!9S
MJZ1M!*KL,JI0Y(]A3U@D*J1&Y#':"%."?3ZUI[*EV.7Z_BK_ !L]N_X:Y\6_
M] _3/^^&_P#BJ?\ \-<^*/\ H&Z;_P!\O_C7B1LKA9EA-O*)FZ1E#N/X=:N)
MX7UF2;RETB^:78)/+%LY;:>C8QT]Z/94NQ2QN+?VV>P_\-<^*/\ H&Z;_P!\
MO_C1_P -<^*/^@;IO_?+_P"->*VNF75YJ,5A%"YNY)!$L)&&W$XQBNUE^%]G
M!JS:-)XHL$UM1AK9D81+)CE#+]W/:DZ5);HN.+QD]IO\#M?^&N?%'_0-TW_O
ME_\ &C_AKGQ1_P! W3?^^7_QKQR+P]J=P;C[/87%TL#%9)+>)I%4CKD@$56&
MG796!A;3%;ABD)$9Q(P."%]3GC I^QIOH2\;BUO-GMG_  USXH_Z!NF_]\O_
M (T?\-<^*/\ H&Z;_P!\O_C7E>K^!-:T+P]8:U>V;PV-Z[QQLRD,K(<$,"/E
MYZ9ZUS]"I4GL@EC<7'XIM'NG_#7/BC_H&Z;_ -\O_C1_PUSXH_Z!NF_]\O\
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MA^@_] 33O_ 2/_"K7]I?].MS_P!^Z/[2_P"G6Y_[]T78^6/8J_\ "'Z#_P!
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MM+_IUN?^_=']I?\ 3K<_]^Z+L.5=AO\ 8&F?] VT_P"_"_X4?V!IG_0.M/\
MOPO^%._M+_IUN?\ OW1_:7_3K<_]^Z+L.5=AO]@Z9_T#K3_OPO\ A1_8.F?]
M ZT_[\+_ (4[^TO^G6Y_[]T?VE_TZW/_ '[HNPY5V$_L+3?^@?:?]^%_PH_L
M+3?^@?:_]^%_PI?[2_Z=;G_OW1_:7_3K<_\ ?NB[#E78/[$T[_GPM?\ ORO^
M%)_8>G?] ^U_[\K_ (4O]I?].MS_ -^Z/[2_Z=;G_OW1=ARKL']B:=_SX6O_
M 'Y7_"C^Q=/_ .?"V_[\K_A1_:7_ $ZW/_?NC^TO^G6Y_P"_=%QV78231[ 1
MM_H-MT/_ "R7_"L+^S[7_GVA_P"_8K=DU+*-_HMST/\ RSK"^V?],)O^^*+A
M9=A?L%M_S[Q?]\"C[!;?\^\7_? I/MG_ $PF_P"^*/MG_3";_OBBX6787[#;
M?\^\7_? H^PVW_/O%_WP*3[9_P!,)O\ OBC[9_TPF_[XHN%D.^Q6_P#SPB_[
MX%'V*W_YX1?]\"F_;/\ IA-_WQ1]L_Z83?\ ?%%PLAWV.W_YX1_]\"E^R0?\
M\8_^^!3/MG_3";_OBC[9_P!,)O\ OBB["R'_ &6'_GC'_P!\BC[+#_SQC_[Y
M%,^V?],)O^^*/MG_ $PF_P"^*+A9$GV:'_GDG_?(H^SQ?\\T_P"^14?VS_IA
M-_WQ1]L_Z83?]\47"R)?(B_YYI_WR*/)C_YYK^51?;/^F$W_ 'Q1]L_Z83?]
M\47"R)?)C_YYK^5'DQC^!?RJ+[9_TPF_[XH^V?\ 3";_ +XHN%D3[%'\(_*C
M:/05!]L_Z83?]\4?;/\ IA-_WQ2"R)\#T%&!Z5!]L_Z83?\ ?%'VS_IA-_WQ
M0%C0T_\ X_(_Q_E14.EW/F7\2^5*N<\LN!T-% SH:**P_&GB8>#_  ]<ZJ;<
MW8AV_N@^S.3CK@_RII.320I-13D]D;E%0VMP+BTAG(V"1 ^">F1GK56P\0Z5
MJK3K9:G9WC6_^N$$Z.8_][!X_&BSU\A<R=O,T**R[/Q5HNHW$,%IK%A=3S*7
MCBAN4=G7U4 Y(X/(]*)_%.BVUQ)!-J]A%/&P5XGN4#*3P 03D$]J?+*]K"YX
MVO<U**HZWJ\.@Z/>:C<']S;1-*V#UP.GXUC>!/&Z>--&EO)+1M,N()6BGM97
MW-$1R,G Z@@].]-0DXN2V0.<5)1;U9T]%8%WX\\/6FCWFJ?VQ93V5IQ-);SK
M)M/9?E)Y/853@^(-I?7ND"R-K<:??PM,;IKZ)&B"C./+)RWOCIWIJG-]/ZW)
M=6"Z_P!;'5T5F6?B?1M1N4M[35K&ZN)%WI%#<H[LOJ #DCWI)?%.BPW$EO)J
M]A'/&ZQ/$UR@97;[JD9R">P[U/++:Q7/&U[FI16+XN\30^$M#FU&6,SE2J1P
MJ<&1V.%4'GJ3533?&+7WC"ZT"2R\F6WM([II?-W#+'!7&!T]<_A34)27,EH*
M52,7RMZ_YG2T5SGCOQ@O@K1/MHLWU"X>010VD;;6E8]LX/8$]*J7OQ$MK/PO
MI.OBW,FG7DL,<SA\?9E<XW'CG#8!''6G&G*232W=OF*56$&U)[*_R.NHK$\9
M>)/^$2\-7VK_ &;[7]F3?Y(?9O\ ;.#C\JYK1?B=J$VI:=;:[X8GT&'4<"TN
M?M:7$<C$9"G:!MR/6G&G*:<D*=:$)*,G^?\ 2/0**\\T7XQ6>LZ?XDE6R,5W
MHN]FMC+GS57.&#;>,X]#BNALO'6DMHFEZAJ-_9Z0;^!9HX;NZ1#R < MC.,^
ME-TIQW7]/42K4Y;/O^&C.BHK-U'Q)I&D-"M_JEE9--S$+BX2,R?[N2,_A3]0
MU[3-)$)OM1M+(3'$1N)UC\P_[.3S^%9\K[&O-'N7Z*R/%7B!?#/AN^U?R?M2
MVL1E\L/MW_C@X_*K.AZG_;6C65^(_)%S"DWE[MVW<,XSWHY7;FZ"YES<O4O4
M445)84444 %<]XJ3>T'T-=#7EOQE^)MIX N=-CNK.:Z-RC,IB8#&".N:N$)5
M'RQ6IG4J1I1YINR-I$[<5;B&*\R\&_&*'QMJ4UEINDS&XB@>XVRRJN\+CY5P
M#R<C%367QKM[S3A>)I,R1_;X].*R2@,)7#$$C'  4Y[^U;/#54[.)SK&4&N9
M2T^?0]03[HI:\[U;XU:)HEU<VEQ<VQN[:5H984:?*L&PPR8<<'/>I[GXP:-:
MZ1#J;7-JUK,S)$5:?+LHY !A&.HZXJ?85=/=W*^M4%?WEH=[17C9_:8TG_H$
M7?\ WVM:V@_'&#Q*]RMAHEPXMHO.F>:ZAA2-,@;BSLHZD=ZT^JUK7Y3-8[#M
M\JGK\STZBO--8^-4>A6<%W=:).;2=BD=Q;7<%Q&S#JNZ-F&?;-4])_: L]<O
M!:V6B7D]P59@GFQKP!D\D@=*%A:S5U'3Y#>,H)\KEK\SU>BO'3^TKI"D@Z3>
M9''WUJ:Z_:*L+%U2YT+4;=W02*LN%)4C(89[$=#3^IU_Y1?7L/\ S_F>N45X
M[_PTMI'_ $";S_OM:NZO\?+30KB.&^T.\@EDB695\V-LHPRIX)ZT?4Z_\H?7
ML.U?G_,]5HKQS_AI?2/^@3>?]]K1_P -+Z1_T";S_OM:?U.O_*+Z_AOYSV.B
MO'/^&E](_P"@3>?]]K1_PTOI'_0)O/\ OM:/J=?^4/K^&_G/8Z*\<_X:7TC_
M *!-Y_WVM,E_:8TQ5'EZ/=.V>C2JO]#1]3Q'\H?7\-_/^9[-17BG_#3=E_T
MI_\ P('_ ,36YH7QQM]>MWEBTIXRC;2K3C(_\=H>"KK>/Y"6/PTG93_!_P"1
MZ?17!_\ "TU_Z!I_[_\ _P!C3E^**M_S#3_W_P#_ +&I^J5OY?R-/KE#^;\&
M=U5_2/\ 6R?2O-_^%GK_ - X_P#?[_[&K%G\65M68_V66R,?Z_'_ ++1]4K?
MR_D'URA_-^#/5**\U_X7,G_0(/\ X$?_ &-._P"%QK_T"3_X$?\ V-'U2M_+
M^0?7*'\WX,](HKS?_A<:_P#0)/\ X$?_ &-'_"XU_P"@2?\ P(_^QI_5*_\
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MX2\?\^A_[^?_ %J/J]3L'UBGW.BHKGAXM!_Y=3_W\_\ K4O_  EH_P"?4_\
M?S_ZU'L*G8?MZ?<Z"BL'_A*A_P ^Q_[[_P#K4X>)@1_Q['_OO_ZU+V%3L'MZ
M?<W**Q/^$F'_ #[G_OO_ .M2CQ(#_P NY_[[_P#K4>QJ=@]O3[FU16,/$8)Q
M]G_\?_\ K4Y=?W'_ %'_ (__ /6I>QGV'[:'<UZ*RO[=_P"F'_CW_P!:E&N
M_P#+'_Q[_P"M1[&?8/;0[FI16:NL[O\ EC_X]_\ 6I?[7_Z9?^/?_6H]C/L'
MM8=S1K8TS_CU'U-<PNJAA_JO_'JNVOB06\03[/NYSG?C^E+V<^P_:0[G2T5@
M_P#"4C_GV/\ WW_]:G#Q,#C_ $8_]]__ %J7LY=A^TCW-RBL0>)0?^7<_P#?
M?_UJ7_A)!_S[G_OO_P"M1[.78.>/<VJ*Q?\ A)!_S[G_ +[_ /K4[_A(!_SP
M/_??_P!:CDEV'SQ[FQ160-?!_P"6!_[Z_P#K4O\ ;X_YX'_OK_ZU'LY=@YX]
MS6HK+&M@_P#+'_Q[_P"M3_[7_P"F7_CW_P!:ER2'S(T:*SO[7_Z9?^/?_6H&
MK _\LO\ Q[_ZU'*PYD:-%9_]K#_GD?\ OJE&J@G_ %?_ (]1RL.9%^BJ7]I?
M],_UIPO\C.S]:7*PYD6Z*J?;_P#8_6D.H8_@_6CE:"Z+4G^K;Z&N>K6:_P!R
MD;.HQUJC]D_V_P!*5F.Z*]%6/LG^W^E'V3_;_2BS"Z*]%6OL/^W^E*+#/\?Z
M468714HJY_9__33]*/[/_P"FGZ468713HJY_9_\ TT_2C^S_ /II^E%F%T4Z
M*NKINX?ZS_QVE_LO_II_X[18+HHT5>_LO_II_P".THTLD_ZW_P =HL%T4**T
M?[(_Z:_^._\ UZ/[(_Z:_P#CO_UZ0S.HK0.D$?\ +7_QW_Z]']D_]-?_ !W_
M .O0!GT5H#2<_P#+7_QW_P"O2_V1_P!-?_'?_KT 9U%:/]D?]-?_ !W_ .O1
M_9'_ $U_\=_^O0!6T_\ X_(_Q_E15F*S^R7</S[MV>V.U% &E7&_%VPNM3\!
M:C;V5M+>7#;2L,"%G;# \ 5V5%5&7+)270F4>>+B^IY7?>(=5\:>$[WP_:>&
M]<TB\DLBB7-];B.(D 97=N[\BL/PSX9N;OQ)I5SIWA.X\+Q:;8SP7TDD2Q_:
MV9-JJ,?ZSGG<?\*]PHKH]O9-15K_ *JQR_5KN+E*]O3HT_T/GW1/AY=:7X;^
M'\\&AR6NKQZ@7OYUM]LR)N;F1L9"XQUXKFIA9KI?V7^QDEU6'7!YFMH482YD
M^Z'!W$^J]!7U/7,K\-?#":W_ &N-&MAJ._?YV#][UQG&?PKIAC/><IKK?\;V
M]#DG@;04:;Z6U]+7]3*^*6EZGXETW3M!TX2P+?3C[3>+%O2&-?F^8=.3C@]:
MX?7O 'BS2SKNGQ:C-KIUZP(:Z2U6!8Y8L81@IVC>F5SQGBO<Z*Y85Y4URI:?
MU_DON.R>'C4ES-N^G]?G]YX=_P (O%XA\/ZW%8?#^30IO[+\CS+E?+,LHY 6
M(?*QR,^8>:;#X?OKF;PE):^'KS3HK;3+B&>)K;R]LFS&2!T+'GGDU[G15_69
M:Z?B^S7ZF:PD5;7\%W3_ $/!-(^'USI5CX"N+719+34(YI&O[A+?;(@*G!D;
M&<?6N2MULO[)T>U714;5+?Q!&LNM(487&92=JN#N?MD=!BOJBN9@^&GABVUS
M^V(M&MDU$/Y@F /#>H&< _A6\,9[S<UY_C?[C"I@;Q2IOR_"U_7^KF)\9XF_
ML+2KGGR+;4[>689.-F['/MDBLG5=2U#PK\5=1U5?#NKZO97-A%"DFG6_F#<"
M2<DD"O3M1TVVU>QFL[R%9[:9=KQMT85-#$L$21H-J(H51G. .E<D*JA'E:OO
M^-O\CLJ47.?,G;;\&_\ ,\JUFRU_XF>(M+FLA?\ A.VT^$SK-?V2NQE;C&QC
MM) ]^,USNO:-JGACX;>*?"]\9;T?:8/L%Z8O*2<RR*=J@< AL\ ]Z]ZJGJ&D
M6>JM:F[@6?[-,MQ#N)PL@SAL=\9/6M(8CE:5O=5OP=]S.>&YKRO[WX;6VV.8
M^)>F7EY\-=1LK:&6]O#;JHCB4L[D8S@=ZY5)-5\>R^&=/_X1W4]'M=,DCFN;
MK48A$#L7&$&3G)KUVBLX5N5;:WN:3H*;6ME:WR/GV[^'VM+X0U;4;"PGBUE;
MJYC-N8R&N;:0D$ =3V(IWB#0=9O=)TW29?"+7(.BI##>1V,4DT<^SE9)) 3&
M%/8#/7'7CZ HK7ZU+JOZL9/!QO=/^KW_ . ?/>M^%;F'2_#MTOAW5KO5TTJ"
MV</ID-Y;Y4?==)/F0@]2,<5#XZ\%^)K_ %'3+R[TQ_)DT]+=K?3-,AO%MW[J
M$<@(.G(/%?15%4L7).]N_P")#P,6K<SV7X6_R//=6\/7T'P8GTA5N;V^6Q\M
M4:,"5CQP54L,_0FNJ\'6TMGX4TB">-HIH[2-'C<8*D*,@BMBBN651R33ZNYU
MPHJ#BUT5OR_R"BBBLC<**** "OFO]K;_ )"7A[_KE)_,5]*5\V_M:_\ (1\/
M_P#7*3^8KOP/\>)YN8_[M+Y?F>6?#B__ ++NM:F$_P!FE&F2^5)G'SAD(Q[\
M5VE_K>EZKX1T[4X)8X;^\UVUFO;4$#9(D<@=P/[K94Y[$UY JY-.KZ*=!3GS
MMVV/DJ==PAR6[GH7Q$CO;O4]<G73].6R>[EE2[A"^:R>82&R#DY'7CO6-J=S
M$_PZT2 .OG)>7#,@;E00N":Y:BJC1:C%7V8Y5G)MVW1[1K5[;ZWX3GBN]033
MK5;6'9]FNHY[.0C PL3*'C?KG;Z&L3P'>:&+#Q>8;&[BM1H["6*2^1GE/FI]
MUO* 7\FKS*BLXX>T7&^Y;Q+<HS:V/8]!30+_ $'PU&D;0>'WU-S?07DPDD$X
M3Y,L H*$>P^M;=E:V-MJ%K++IQL;W?<"*8V-O8[H_+;Y=D<A+#T;'XUX#12E
MA^:]I;_U_7D5#%<MKQV_K^O/4][TS0],?2UMCHEK=6)TF2X_M-(X=GG!20"Q
M0R%P?]L#_9I]S'9:Q/)>W-M!=7G]C6HTT0Z?!/N; $Y6([5D9>.&)V@\#M7@
M-%)X9MWYOZ_K3T*6+25N7^M/+ROZL]MO=(T]GU9]*T>W_P"$C6SMRMG<VT!&
M2Q$DBP!G56QM^7MSP*Y#XTAE\5VJN(UD73[=76+&U6"\@8XXK@:*TA1<9*3=
M_P"OR,JF(4XN*C:_]?>%%%%=1QA1110 4444 %=1X U'[+JQMV.$G7'XCI7+
MU;TKS/[3M?)_UGF+C'UJ6KJQ47:29[+3X^AI@S@9ZT^/H:XSTQ]%%%  .M2]
MZB'6I>]4AA1113*"BBB@!1UIU-'6G5+*0J?>%2'I4:?>%2'I4,3W#TIPZ4WT
MIPZ4Y;@A:***1H2+]T4Y?O"FK]T4Y?O"@9)1WHH[TGL4/HHHK(4=R1?NBI!T
M%1K]T5(.@I/8T6X4Y/O4VG)]ZLS4E3[PJ2HT^\*DH <M+Z4BTOI292)!TJ4=
M!40Z5*.@J&,6G#I3:<.E"&AR?>J9.M0I]ZIDZU#W+Z#Z<.E-IPZ4ACX^II],
MCZFGT#6Y(G2G#K34Z4X=:R-!U2CH/I452CH/I2>Q2%'6G4T=:=4(M"CK4M1#
MK4M#&.'2B@=**8$P[5+40[5+63-%L%*M)2K0#'4J_>%)2K]X4")*D'W14=2#
M[HI,H4]*:>M./2FGK4R*ZA4HZ5%4HZ5 PHHHH EI1UI*4=: '4444 %%%% #
MTZ4ZFITIU2P"E7[PI*5?O"D-;DM%%%2:"-TIM.;I3: %'6G4T=:=0 4444 5
MI_\ CZMOJW\J*)_^/JV^K?RHH LUS/Q&\0R^&/"%]>P';<X$<)/9V. ?UKIJ
MY;XF:%-XB\&W]K;)YERH$T2 <LRG( _*KA;G7-M<B?-R/EWMH>:^+O$-QIGB
MO3M-U/QG>Z!9_P!F)*T\0!,DO?/!JC?^-];_ .$*\.SWVO7.F6\^JO;OJJ)M
MDDM@#B0C']*],TCPE_:7B&R\37)V[].2W:QN(,,K<$DYZ?3%7_%G@Q?$UYH$
MHF2WBTN\%T8C%N$@ QMZC'ZUZ'M:<7&,EZ_>_+_@'E^QJR4I1?33?LO/_@G"
M>!=4O];U[4]+T[Q/?:_HTECO&JR)L:WGW8"JV!GCG%0^!/%'B'Q7XK30[K4A
M"F@EQ>30R#=>D'"Y]O6NND^'=WINJZO<^']432;?4X2LMJ8-ZI-_SU3##!]J
MI:;\';?0)M$N])O?LNH661=3O'N^V*WWPXR.I_*E[2D[ONM-.NNK_+[GT'[*
MLK)='KKNM-%=W\]?-;,WO$WB>8Z1=?\ "./::GJ"95@MPI$ P<NP!SQCI7':
M9XK\32_!RUU&T O=4DAG::\G? A5=Q+X[GC %=_:>#](TM+XZ;IUM83WB,LL
ML$04MG/)QUZUG:%X';1OA^_AHW@E9K>:#[2(\#Y]W.W/;=ZUS*5-0:2ZK?YW
M.MPJ2J)MV5GM\K?/<\ZU?QGJZ^$_ [76LW&DV.H6IDO=8C3>XD"@JIX.-QJS
MI'Q&U.?POH.LRW;R+!J9T^ZRN!<(3M5B.QY!KJ[CX=ZE'X3T+2M.U]K"YTR,
M1F;R \4XQ@[HR<?3GBLK6? 1L=)\.^'+2.>[234!=WEX4XR#N9F(X&3@ 5V*
M=&3MI\7X7?EV\_D<+IUXJ^OP_C;U[Z[?,]0!R,TM(!@4M>4>R%%%% !1110
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M?^_/_P!E4]I\)GNF8?VFJX&?]1G_ -FH^M4?YOS#ZG7_ )?R. '6I>]>B?\
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M_P"^?_KTHT0@?ZX?]\__ %Z7MH=Q^QGV,Z/J:?6@NC%?^6H_[Y_^O2_V0?\
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MO_Q- %:BJ_V5_P#GYF_\=_PH^RO_ ,_,W_CO^%*PK(L457^RO_S\S?\ CO\
MA1]E?_GYF_\ '?\ "BP618HJO]E?_GYF_P#'?\*/LK_\_,W_ ([_ (4PL6**
MK_97_P"?F;_QW_"C[*__ #\S?^._X4#+%%5_LK_\_,W_ ([_ (4?97_Y^9O_
M !W_  H L457^RO_ ,_,W_CO^%'V5_\ GYF_\=_PH L457^RO_S\S?\ CO\
MA1]E?_GYF_\ '?\ "@"Q15?[*_\ S\S?^._X4?97_P"?F;_QW_"@"Q15?[*_
M_/S-_P"._P"%'V5_^?F;_P =_P * +%%5_LK_P#/S-_X[_A1]E?_ )^9O_'?
M\* +%%5_LK_\_,W_ ([_ (4?97_Y^9O_ !W_  H L5?TC_6R?2LC[*__ #\S
M?^._X5=TNR=Y'Q=SKQVV_P#Q- &]15+^SY/^?ZY_-/\ XFC^SY/^?ZY_-/\
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MKG\T_P#B:/[/D_Y_KG\T_P#B: +M%4O[/D_Y_KG\T_\ B:/[/D_Y_KG\T_\
MB: +M%4O[/D_Y_KG\T_^)H_L^3_G^N?S3_XF@"[15+^SY/\ G^N?S3_XFC^S
MY/\ G^N?S3_XF@"W)_JV^AKGJU9-/DV-_IUST/=/_B:POLK_ //S-_X[_A0!
M8HJO]E?_ )^9O_'?\*/LK_\ /S-_X[_A0!8HJO\ 97_Y^9O_ !W_  H^RO\
M\_,W_CO^% %BBJ_V5_\ GYF_\=_PH^RO_P _,W_CO^% %BBJ_P!E?_GYF_\
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M4^WJ***\T^K"BBB@ HHHH **** "BBB@ J_I'^MD^E4*OZ1_K9/I0!J4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8E__ ,?3U7JQ
M?_\ 'T]5Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *V-,_X]
M1]36/6QIG_'J/J: +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 -D_U;?0USU=#)_JV^AKGJ "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@"QI__'Y'^/\ *BC3_P#C\C_'^5% &W1110 4444
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &R?ZMOH:YZBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH L:?_P ?
*D?X_RHHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>plx-20230930.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.4.0.13 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/6/2023 12:31:26 PM-->
<!--Modified on: 11/6/2023 12:31:26 PM-->
<xsd:schema xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:currency="http://xbrl.sec.gov/currency/2022" targetNamespace="http://www.protalix.com/20230930" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:plx="http://www.protalix.com/20230930" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" id="StatementCondensedConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" id="DisclosureInventoriesScheduleOfInventoryDetails">
        <link:definition>40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1" id="DisclosureEarningsLossPerShareDetails1">
        <link:definition>40601 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)1</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails" id="DisclosureTaxesOnIncomeDetails">
        <link:definition>40701 - Disclosure - TAXES ON INCOME (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" id="DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails">
        <link:definition>40801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" id="StatementCondensedConsolidatedStatementsOfOperationsParenthetical">
        <link:definition>00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency">
        <link:definition>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical">
        <link:definition>00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" id="DisclosureFairValueMeasurementTables">
        <link:definition>30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" id="DisclosureSignificantAccountingPoliciesDetails">
        <link:definition>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" id="DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails">
        <link:definition>40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" id="DisclosureFairValueMeasurementAdditionalInformationDetails">
        <link:definition>40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesDetails" id="DisclosureRevenuesDetails">
        <link:definition>40401 - Disclosure - REVENUES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" id="DisclosureStockTransactionsDetails">
        <link:definition>40501 - Disclosure - STOCK TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails" id="DisclosureStockTransactionsStockBasedCompensationDetails">
        <link:definition>40502 - Disclosure - STOCK TRANSACTIONS - Stock based compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactionsScheduleOfWeightedAverageAssumptionsDetails" id="DisclosureStockTransactionsScheduleOfWeightedAverageAssumptionsDetails">
        <link:definition>40503 - Disclosure - STOCK TRANSACTIONS - Schedule of Weighted average assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" id="DisclosureEarningsLossPerShareDetails">
        <link:definition>40601 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>40901 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>10201 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" id="DisclosureFairValueMeasurement">
        <link:definition>10301 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenues" id="DisclosureRevenues">
        <link:definition>10401 - Disclosure - REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactions" id="DisclosureStockTransactions">
        <link:definition>10501 - Disclosure - STOCK TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShare" id="DisclosureEarningsLossPerShare">
        <link:definition>10601 - Disclosure - EARNINGS (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncome" id="DisclosureTaxesOnIncome">
        <link:definition>10701 - Disclosure - TAXES ON INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" id="DisclosureSupplementaryFinancialStatementInformation">
        <link:definition>10801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>10901 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" id="DisclosureInventoriesTables">
        <link:definition>30203 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" id="DisclosureRevenuesTables">
        <link:definition>30403 - Disclosure - REVENUES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactionsTables" id="DisclosureStockTransactionsTables">
        <link:definition>30501 - Disclosure - STOCK TRANSACTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareTables" id="DisclosureEarningsLossPerShareTables">
        <link:definition>30603 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTables" id="DisclosureTaxesOnIncomeTables">
        <link:definition>30703 - Disclosure - TAXES ON INCOME (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" id="DisclosureSupplementaryFinancialStatementInformationTables">
        <link:definition>30803 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20230930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20230930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20230930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20230930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
  <xsd:element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" name="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="ChangeInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ChangeInOperatingLeaseRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="plx_RevenueDisclosureTextBlock" name="RevenueDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="NatureOfOperationsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_NatureOfOperationsPolicyTextBlock" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
  <xsd:element name="AmendedPfizerAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_AmendedPfizerAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ChiesiUSAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiUSAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ChiesiExUSAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiExUSAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ProtalixBioTherapeuticsIncorporationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ProtalixBioTherapeuticsIncorporationMember" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
  <xsd:element id="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" name="CollaborativeArrangementRevenuesExpensesSharingPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" name="UpfrontNonrefundableNoncreditablePaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" name="AdditionalAmountsPayableToCoverDevelopmentCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element name="PaymentOnNetSalesPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_PaymentOnNetSalesPercentage" substitutionGroup="xbrli:item" />
  <xsd:element id="plx_PfizerMember" name="PfizerMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_EmployeeStockIncentivePlan2006Member" name="EmployeeStockIncentivePlan2006Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_MaintainOfMinimumCashBalance" name="MaintainOfMinimumCashBalance" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_SupplementalInformationAbstract" name="SupplementalInformationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_SupplementaryBalanceSheetsInformationTableTextBlock" name="SupplementaryBalanceSheetsInformationTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" name="AccountsPayablePropertyAndEquipmentSuppliersCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="plx_ChiesiMember" name="ChiesiMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" name="ChiesiUsAgreementAndChiesiExUsAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ShortTermBankDeposits" name="ShortTermBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_IncreaseDecreaseInBankDeposits" name="IncreaseDecreaseInBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_ChiesiAgreementsMember" name="ChiesiAgreementsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_MeasurementInputYieldMember" name="MeasurementInputYieldMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_AtmEquityOfferingSalesAgreementMember" name="AtmEquityOfferingSalesAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_SaleOfStockMaximumOfferingPrice" name="SaleOfStockMaximumOfferingPrice" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_AtMarketEquityOfferingMember" name="AtMarketEquityOfferingMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_InterestReceivedNet" name="InterestReceivedNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" name="AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_StockIssuedDuringPeriodSharesSalesAgreement" name="StockIssuedDuringPeriodSharesSalesAgreement" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_StockIssuedDuringPeriodValueSalesAgreement" name="StockIssuedDuringPeriodValueSalesAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_ProceedsFromSaleOfShortTermDeposits" name="ProceedsFromSaleOfShortTermDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_AgreementAmendmentPaymentReceivable" name="AgreementAmendmentPaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" name="ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_RevenuePerformanceObligationNumber" name="RevenuePerformanceObligationNumber" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" name="SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_StockIssuedDuringPeriodValueWarrantsExercises" name="StockIssuedDuringPeriodValueWarrantsExercises" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_StockIssuedDuringPeriodSharesWarrantsExercises" name="StockIssuedDuringPeriodSharesWarrantsExercises" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="ConvertibleNotesDue2021And2024Member" id="plx_ConvertibleNotesDue2021And2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ProceedsFromSaleOfProducts" id="plx_ProceedsFromSaleOfProducts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MilestonePaymentReceived" id="plx_MilestonePaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ExtendedTermOfAgreement" id="plx_ExtendedTermOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="GainLossOnDebtConversion" id="plx_GainLossOnDebtConversion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PaymentsToDebtHoldersOnConversion" id="plx_PaymentsToDebtHoldersOnConversion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DebtConversionDecreaseInPrincipalAmount" id="plx_DebtConversionDecreaseInPrincipalAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NumberOfGlobalLicensingAndSupplyAgreements" id="plx_NumberOfGlobalLicensingAndSupplyAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NumberOfPatientsDosed" id="plx_NumberOfPatientsDosed" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="OutstandingStockOptionsAndWarrantsMember" id="plx_OutstandingStockOptionsAndWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OutstandingStockOptionsWarrantsAnd2024NotesMember" id="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MilestonePaymentToRegulatoryApprovals" id="plx_MilestonePaymentToRegulatoryApprovals" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ReserveForDeductionsFromRevenueCurrent" id="plx_ReserveForDeductionsFromRevenueCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FillFinishAgreementMember" id="plx_FillFinishAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements" id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOnDateOfGrant" id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOnDateOfGrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant" id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OfficersAndOtherEmployeesMember" id="plx_OfficersAndOtherEmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NonExecutiveDirectorsOtherThanChairmanMember" id="plx_NonExecutiveDirectorsOtherThanChairmanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>plx-20230930_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.4.0.13 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/6/2023 12:31:26 PM-->
<!--Modified on: 11/6/2023 12:31:26 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureInventoriesScheduleOfInventoryDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureEarningsLossPerShareDetails1" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureTaxesOnIncomeDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" />
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638348706850887643" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638348706850887643" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638348706850887643" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638348706850887643" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638348706850887643" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_638348706850887643" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638348706850887643" xlink:to="plx_ShortTermBankDeposits_638348706850887643" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638348706850897637" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638348706850887643" xlink:to="us-gaap_AccountsReceivableNetCurrent_638348706850897637" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638348706850897637" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638348706850887643" xlink:to="us-gaap_OtherAssetsCurrent_638348706850897637" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638348706850897637" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638348706850887643" xlink:to="us-gaap_InventoryNet_638348706850897637" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638348706850897637" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638348706850897637" order="2" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638348706850897637" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638348706850897637" order="3" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_638348706850897637" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_638348706850897637" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638348706850897637" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638348706850897637" order="5" use="optional" weight="1" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638348706850897637" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_Liabilities_638348706850897637" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638348706850907636" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638348706850897637" xlink:to="us-gaap_LiabilitiesNoncurrent_638348706850907636" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_638348706850907636" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638348706850907636" xlink:to="us-gaap_ConvertibleDebtNoncurrent_638348706850907636" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638348706850907636" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638348706850907636" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638348706850907636" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638348706850907636" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638348706850907636" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638348706850907636" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638348706850907636" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638348706850897637" xlink:to="us-gaap_LiabilitiesCurrent_638348706850907636" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_638348706850907636" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638348706850907636" xlink:to="us-gaap_AccountsPayableTradeCurrent_638348706850907636" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_638348706850907636" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638348706850907636" xlink:to="us-gaap_AccountsPayableOtherCurrent_638348706850907636" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638348706850907636" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638348706850907636" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638348706850907636" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638348706850917636" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638348706850907636" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638348706850917636" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent_638348706850917636" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638348706850907636" xlink:to="us-gaap_ConvertibleDebtCurrent_638348706850917636" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638348706850917636" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_CommitmentsAndContingencies_638348706850917636" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638348706850917636" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_StockholdersEquity_638348706850917636" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637041422967477240" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638348706850917636" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637041422967477240" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638348706850917636" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638348706850917636" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638348706850917636" xlink:to="us-gaap_OperatingIncomeLoss_638348706850917636" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638348706850927642" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638348706850917636" xlink:to="us-gaap_Revenues_638348706850927642" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638348706850927642" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638348706850917636" xlink:to="us-gaap_CostOfRevenue_638348706850927642" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638348706850927642" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638348706850917636" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638348706850927642" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638348706850927642" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638348706850917636" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638348706850927642" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638348706850927642" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638348706850917636" xlink:to="us-gaap_NonoperatingIncomeExpense_638348706850927642" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638348706850927642" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638348706850927642" xlink:to="us-gaap_OtherNonoperatingExpense_638348706850927642" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638348706850927642" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638348706850927642" xlink:to="us-gaap_OtherNonoperatingIncome_638348706850927642" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638348706850927642" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637041422967477240" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638348706850927642" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638348706850937639" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638348706850937639" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638348706850937639" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638348706850937639" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638348706850937639" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638348706850937639" xlink:to="us-gaap_ProceedsFromWarrantExercises_638348706850937639" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638348706850937639" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638348706850937639" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638348706850937639" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638348706850937639" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638348706850937639" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638348706850937639" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638348706850937639" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638348706850937639" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638348706850937639" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638348706850937639" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638348706850937639" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_638348706850937639" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638348706850937639" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_638348706850937639" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_638348706850937639" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638348706850937639" xlink:to="plx_IncreaseDecreaseInBankDeposits_638348706850937639" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638348706850937639" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638348706850937639" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638348706850947647" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638348706850937639" xlink:to="us-gaap_ProfitLoss_638348706850947647" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638348706850947647" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638348706850937639" xlink:to="us-gaap_ShareBasedCompensation_638348706850947647" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638348706850947647" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638348706850937639" xlink:to="us-gaap_Depreciation_638348706850947647" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638348706850947647" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638348706850937639" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638348706850947647" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_638348706850947647" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638348706850937639" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_638348706850947647" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638348706850947647" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638348706850937639" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638348706850947647" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638348706850947647" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638348706850937639" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638348706850947647" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_GainLossOnDebtConversion" xlink:label="plx_GainLossOnDebtConversion_638348706850947647" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638348706850937639" xlink:to="plx_GainLossOnDebtConversion_638348706850947647" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638348706850957740" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638348706850937639" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638348706850957740" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638348706850957740" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638348706850937639" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638348706850957740" order="10" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_638348706850957740" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638348706850937639" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_638348706850957740" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638348706850957740" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638348706850937639" xlink:to="us-gaap_IncreaseDecreaseInInventories_638348706850957740" order="12" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638348706850957740" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638348706850937639" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638348706850957740" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638348706850957740" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638348706850937639" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638348706850957740" order="14" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" xlink:type="extended" xlink:title="40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_638348706850967652" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_638348706850967652" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_638348706850967652" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_638348706850967652" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_638348706850967652" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_638348706850967652" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1" xlink:type="extended" xlink:title="40601 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities_638348706850967652" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_DilutiveSecurities_638348706850967652" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638348706850967652" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLoss_638348706850967652" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638348706850967652" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638348706850967652" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_638348706850967652" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_638348706850967652" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638348706850977636" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638348706850977636" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - TAXES ON INCOME (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638348706850977636" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638348706850977636" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638348706850977636" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638348706850977636" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" xlink:type="extended" xlink:title="40801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637041422969008821" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638348706850977636" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638348706850977636" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_638348706850977636" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_InterestPayableCurrent_638348706850977636" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_638348706850977636" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_AccruedVacationCurrent_638348706850977636" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638348706850977636" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638348706850977636" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent_638348706850987642" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_AccruedRoyaltiesCurrent_638348706850987642" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638348706850987642" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638348706850987642" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_638348706850987642" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="us-gaap_TaxesPayableCurrent_638348706850987642" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ReserveForDeductionsFromRevenueCurrent" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_638348706850987642" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableCurrent_637041422969008821" xlink:to="plx_ReserveForDeductionsFromRevenueCurrent_638348706850987642" order="8" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>plx-20230930_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.4.0.13 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/6/2023 12:31:26 PM-->
<!--Modified on: 11/6/2023 12:31:26 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#StatementCondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureStockTransactionsStockBasedCompensationDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureStockTransactionsScheduleOfWeightedAverageAssumptionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsScheduleOfWeightedAverageAssumptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureEarningsLossPerShareDetails" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="plx-20230930.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_1" xlink:title="us-gaap_ShortTermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_1" xlink:title="us-gaap_ShortTermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShortTermDebtTypeAxis_1" xlink:to="us-gaap_ShortTermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShortTermDebtTypeAxis_1 To us-gaap_ShortTermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentRedemptionPeriodAxis_1 To us-gaap_DebtInstrumentRedemptionPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:title="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_1" xlink:title="us-gaap_ChangeInAccountingEstimateTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ChangeInAccountingEstimateByTypeAxis_1 To us-gaap_ChangeInAccountingEstimateTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_1" xlink:title="us-gaap_RetirementPlanTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_1" xlink:title="us-gaap_RetirementPlanTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RetirementPlanTypeAxis_1" xlink:to="us-gaap_RetirementPlanTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RetirementPlanTypeAxis_1 To us-gaap_RetirementPlanTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1 To us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_1" xlink:title="srt_ConsolidatedEntitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_1" xlink:title="srt_ConsolidatedEntitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidatedEntitiesAxis_1" xlink:to="srt_ConsolidatedEntitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidatedEntitiesAxis_1 To srt_ConsolidatedEntitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_1" xlink:title="srt_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MajorCustomersAxis_1" xlink:to="srt_NameOfMajorCustomerDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MajorCustomersAxis_1 To srt_NameOfMajorCustomerDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_AmendedPfizerAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiExUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_FillFinishAgreementMember" xlink:label="plx_FillFinishAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_FillFinishAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BR" xlink:label="country_BR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_AtMarketEquityOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_AtmEquityOfferingSalesAgreementMember" xlink:label="plx_AtmEquityOfferingSalesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_AtmEquityOfferingSalesAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_NumberOfGlobalLicensingAndSupplyAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_NumberOfPatientsDosed" xlink:label="plx_NumberOfPatientsDosed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_NumberOfPatientsDosed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SaleOfStockMaximumOfferingPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ExtendedTermOfAgreement" xlink:label="plx_ExtendedTermOfAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_ExtendedTermOfAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AgreementAmendmentPaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_MilestonePaymentReceived" xlink:label="plx_MilestonePaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MilestonePaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_PaymentOnNetSalesPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConvertibleDebtCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_RevenuePerformanceObligationNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MaintainOfMinimumCashBalance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="plx_MeasurementInputYieldMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - REVENUES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="plx_PfizerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BR" xlink:label="country_BR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_SegmentGeographicalDomain" xlink:to="plx_ChiesiMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - STOCK TRANSACTIONS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_AtmEquityOfferingSalesAgreementMember" xlink:label="plx_AtmEquityOfferingSalesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_AtmEquityOfferingSalesAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_EmployeeStockIncentivePlan2006Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_PaymentsToDebtHoldersOnConversion" xlink:label="plx_PaymentsToDebtHoldersOnConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_PaymentsToDebtHoldersOnConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_DebtConversionDecreaseInPrincipalAmount" xlink:label="plx_DebtConversionDecreaseInPrincipalAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_DebtConversionDecreaseInPrincipalAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails" xlink:type="extended" xlink:title="40502 - Disclosure - STOCK TRANSACTIONS - Stock based compensation (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_OfficersAndOtherEmployeesMember" xlink:label="plx_OfficersAndOtherEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_OfficersAndOtherEmployeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_NonExecutiveDirectorsOtherThanChairmanMember" xlink:label="plx_NonExecutiveDirectorsOtherThanChairmanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_NonExecutiveDirectorsOtherThanChairmanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_EmployeeStockIncentivePlan2006Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsScheduleOfWeightedAverageAssumptionsDetails" xlink:type="extended" xlink:title="40503 - Disclosure - STOCK TRANSACTIONS - Schedule of Weighted average assumptions (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" xlink:type="extended" xlink:title="40601 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_OutstandingStockOptionsAndWarrantsMember" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="plx_OutstandingStockOptionsAndWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" xlink:label="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_NetIncomeLossAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_DilutiveSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40901 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficerMember" xlink:label="srt_OfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_OfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_EmployeeStockIncentivePlan2006Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOnDateOfGrant" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOnDateOfGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOnDateOfGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ProceedsFromSaleOfProducts" xlink:label="plx_ProceedsFromSaleOfProducts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ProceedsFromSaleOfProducts" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>plx-20230930_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.4.0.13 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/6/2023 12:31:26 PM-->
<!--Modified on: 11/6/2023 12:31:26 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShortTermBankDeposits" xlink:to="plx_ShortTermBankDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term bank deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable - Trade</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Funds in respect of employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred Income Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred income tax asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY (NET OF CAPITAL DEFICIENCY)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals - other:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contracts liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Convertible Debt, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Convertible notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG TERM LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible Debt, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability for employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity (net of capital deficiency)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and R&amp;D Services</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">TOTAL REVENUE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">COST OF GOODS SOLD</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING INCOME (LOSS)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other Nonoperating Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">FINANCIAL EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other Nonoperating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">FINANCIAL INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">FINANCIAL INCOME (EXPENSES), NET</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">INCOME (LOSS) BEFORE TAXES ON INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">TAXES ON INCOME</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total taxes on income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET INCOME (LOSS) FOR THE PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss) for the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - BASIC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - DILUTED</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE- BASIC</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average shares of Common Stock outstanding for basic calculation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE- DILUTED</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average shares of Common Stock outstanding for diluted calculation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of goods sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, general and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (CAPITAL DEFICIENCY)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Value, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Convertible notes conversions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Convertible notes conversions (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation related to stock options</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Amount of recognized equity-based compensation during the period for restricted stock awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Value of shares issued during period for exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Number of shares issued during period for exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Exercise of warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net income (loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net income (loss) to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Financial income, net (mainly exchange differences)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Changes in accrued liability for employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Changes in deferred tax asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred taxes on income</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain (loss) on amounts funded in respect of employee rights upon retirement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Loss (gain) on amounts funded in respect of employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_GainLossOnDebtConversion" xlink:label="plx_GainLossOnDebtConversion" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnDebtConversion" xlink:to="plx_GainLossOnDebtConversion_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GainLossOnDebtConversion_lbl" xml:lang="en-US">The amount of gain (loss) on conversion of convertible debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GainLossOnDebtConversion_lbl" xml:lang="en-US">Gain (Loss) On Debt Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_GainLossOnDebtConversion_lbl" xml:lang="en-US">Gain on conversions of convertible notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt issuance costs and debt discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Decrease in contracts liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase in accounts receivable-trade and other assets</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amount of Net Change in Operating Lease Right Of use Assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Change in Operating Lease Right Of use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Changes in operating lease right of use assets, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Decrease (increase) in inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (decrease) in accounts payable and accruals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseDecreaseInBankDeposits" xlink:to="plx_IncreaseDecreaseInBankDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Amount of increase (decrease) in deposits held with banks.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Increase (Decrease) in Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Investment in bank deposits</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromSaleOfShortTermDeposits" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Amount of cash inflow from sale of short-term deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Proceeds from Sale of Short-term Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Proceeds from sale of short-term deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Amounts paid (funded) in respect of employee rights upon retirement, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock under the Sales Agreement, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Stock issuance proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease right of use assets obtained in exchange for new operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Convertible notes conversions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_InterestReceivedNet" xlink:to="plx_InterestReceivedNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Amount of cash received for interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest Received, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" xml:lang="en-US">REVENUES</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueDisclosureTextBlock" xlink:to="plx_RevenueDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure pertaining to revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">Revenue Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">REVENUES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">STOCK TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCK TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">TAXES ON INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">TAXES ON INCOME</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementalInformationAbstract" xlink:to="plx_SupplementalInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplementalInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NatureOfOperationsPolicyTextBlock" xlink:to="plx_NatureOfOperationsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">General</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">Represents the information pertaining to seven point five percentage senior secured convertible notes due 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">2024 Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of Company's Disaggregation of Revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Valuation Assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Basic and Diluted Net Earnings (Loss) Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of components of Income Tax Expense (Benefit)</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:to="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure for supplemental balance sheets information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">Supplementary Balance Sheets Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">Supplemental Information, Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="plx_SignificantAccountingPoliciesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AmendedPfizerAgreementMember" xlink:to="plx_AmendedPfizerAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiAgreementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUSAgreementMember" xlink:to="plx_ChiesiUSAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUSAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiExUSAgreementMember" xlink:to="plx_ChiesiExUSAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiExUSAgreementMember_lbl" xml:lang="en-US">Chiesi Ex-US Agreement</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_FillFinishAgreementMember" xlink:label="plx_FillFinishAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FillFinishAgreementMember" xlink:to="plx_FillFinishAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_FillFinishAgreementMember_lbl" xml:lang="en-US">Fill/Finish Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_FillFinishAgreementMember_lbl" xml:lang="en-US">Fill/Finish Agreement</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement and Chiesi Ex-US Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BR" xlink:label="country_BR" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BR" xlink:to="country_BR_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_BR_lbl" xml:lang="en-US">Brazil</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_ConvertibleNotesDue2021And2024Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Represents information pertaining to convertible notes due 2021 and 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Notes 2021 and 2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AtMarketEquityOfferingMember" xlink:to="plx_AtMarketEquityOfferingMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">Represents the information pertaining to At The Market equity offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">ATM Shares</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_AtmEquityOfferingSalesAgreementMember" xlink:label="plx_AtmEquityOfferingSalesAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AtmEquityOfferingSalesAgreementMember" xlink:to="plx_AtmEquityOfferingSalesAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AtmEquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">Represents information pertaining to ATM Equity Offering Sales Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AtmEquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">ATM Equity Offering Sales Agreement</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:to="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" xml:lang="en-US">Represents the number of global licensing and supply agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" xml:lang="en-US">Number Of Global Licensing And Supply Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" xml:lang="en-US">Number of global licensing and supply agreements</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_NumberOfPatientsDosed" xlink:label="plx_NumberOfPatientsDosed" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfPatientsDosed" xlink:to="plx_NumberOfPatientsDosed_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NumberOfPatientsDosed_lbl" xml:lang="en-US">Represents the number of patients that were dosed in the trial.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NumberOfPatientsDosed_lbl" xml:lang="en-US">Number Of Patients Dosed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_NumberOfPatientsDosed_lbl" xml:lang="en-US">Number of patients dosed</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">Upfront Nonrefundable Non creditable Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">Non-refundable Payment Receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SaleOfStockMaximumOfferingPrice" xlink:to="plx_SaleOfStockMaximumOfferingPrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale Of Stock Maximum Offering Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">The maximum amount payable to the entity to cover development costs under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">Additional Amounts Payable To Cover Development Costs</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ExtendedTermOfAgreement" xlink:label="plx_ExtendedTermOfAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExtendedTermOfAgreement" xlink:to="plx_ExtendedTermOfAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ExtendedTermOfAgreement_lbl" xml:lang="en-US">Extended term  of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ExtendedTermOfAgreement_lbl" xml:lang="en-US">Extended Term Of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ExtendedTermOfAgreement_lbl" xml:lang="en-US">Extended term of agreement</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AgreementAmendmentPaymentReceivable" xlink:to="plx_AgreementAmendmentPaymentReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">The total amount payable to entity for the achievement of regulatory and commercial milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_MilestonePaymentReceived" xlink:label="plx_MilestonePaymentReceived" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MilestonePaymentReceived" xlink:to="plx_MilestonePaymentReceived_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MilestonePaymentReceived_lbl" xml:lang="en-US">Amount of milestone payment received upon achievement of certain milestone.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MilestonePaymentReceived_lbl" xml:lang="en-US">Milestone Payment Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_MilestonePaymentReceived_lbl" xml:lang="en-US">Amount of milestone payment received</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PaymentOnNetSalesPercentage" xlink:to="plx_PaymentOnNetSalesPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Represents the payment as a percentage of future net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Payment On Net Sales Percentage</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative arrangement revenues and expense sharing percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative Arrangement Revenues Expenses Sharing Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative Arrangement Revenues and Expenses Sharing Percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenuePerformanceObligationNumber" xlink:to="plx_RevenuePerformanceObligationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenuePerformanceObligationNumber_lbl" xml:lang="en-US">Revenue, Performance Obligation, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenuePerformanceObligationNumber_lbl" xml:lang="en-US">Revenue, Performance Obligation, Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-term Debt, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Debt Instrument Carrying Amount</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaintainOfMinimumCashBalance" xlink:to="plx_MaintainOfMinimumCashBalance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MaintainOfMinimumCashBalance_lbl" xml:lang="en-US">Minimum cash balance required to be maintained under long term debt agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MaintainOfMinimumCashBalance_lbl" xml:lang="en-US">Maintain of Minimum Cash Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Raw materials</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Work in progress</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished goods (drug substance and drug product)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Share Price.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Risk free rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Volatility</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MeasurementInputYieldMember" xlink:to="plx_MeasurementInputYieldMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MeasurementInputYieldMember_lbl" xml:lang="en-US">Yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MeasurementInputYieldMember_lbl" xml:lang="en-US">Yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMeasurementInput" xlink:to="us-gaap_DebtInstrumentMeasurementInput_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMeasurementInput_lbl" xml:lang="en-US">Debt Instrument, Measurement Input</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Debt Instrument Fair Value</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerMember" xlink:to="plx_PfizerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Global except for Brazil</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Pfizer</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiMember" xlink:to="plx_ChiesiMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Global except Brazil and Italy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Chiesi</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeStockIncentivePlan2006Member" xlink:to="plx_EmployeeStockIncentivePlan2006Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_EmployeeStockIncentivePlan2006Member_lbl" xml:lang="en-US">It represent the employee stock incentive plan for the particular period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_EmployeeStockIncentivePlan2006Member_lbl" xml:lang="en-US">2006 Employee Stock Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants issued to purchase common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Converted instrument, shares issued</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_PaymentsToDebtHoldersOnConversion" xlink:label="plx_PaymentsToDebtHoldersOnConversion" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PaymentsToDebtHoldersOnConversion" xlink:to="plx_PaymentsToDebtHoldersOnConversion_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PaymentsToDebtHoldersOnConversion_lbl" xml:lang="en-US">The cash outflow to debt holders on conversion for accrued but unpaid interest, make-whole interest payments and payments in lieu of fractional shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PaymentsToDebtHoldersOnConversion_lbl" xml:lang="en-US">Payments To Debt Holders On Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PaymentsToDebtHoldersOnConversion_lbl" xml:lang="en-US">Paid to the converting holders</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_DebtConversionDecreaseInPrincipalAmount" xlink:label="plx_DebtConversionDecreaseInPrincipalAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtConversionDecreaseInPrincipalAmount" xlink:to="plx_DebtConversionDecreaseInPrincipalAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DebtConversionDecreaseInPrincipalAmount_lbl" xml:lang="en-US">The amount of decrease in the total principal amount of debt due to conversion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DebtConversionDecreaseInPrincipalAmount_lbl" xml:lang="en-US">Debt Conversion, Decrease In Principal Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_DebtConversionDecreaseInPrincipalAmount_lbl" xml:lang="en-US">Decrease in principal amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of shares authorized for issuance under share-based payment arrangement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Shares of restricted Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Upon grant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Over a two-year period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US">Over a three-year period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Relationship to Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_OfficersAndOtherEmployeesMember" xlink:label="plx_OfficersAndOtherEmployeesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OfficersAndOtherEmployeesMember" xlink:to="plx_OfficersAndOtherEmployeesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OfficersAndOtherEmployeesMember_lbl" xml:lang="en-US">Represents the member information pertaining to officers and other employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OfficersAndOtherEmployeesMember_lbl" xml:lang="en-US">Officers and Other Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_OfficersAndOtherEmployeesMember_lbl" xml:lang="en-US">Officers and other employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Chairman, Board of Directors</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_NonExecutiveDirectorsOtherThanChairmanMember" xlink:label="plx_NonExecutiveDirectorsOtherThanChairmanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NonExecutiveDirectorsOtherThanChairmanMember" xlink:to="plx_NonExecutiveDirectorsOtherThanChairmanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NonExecutiveDirectorsOtherThanChairmanMember_lbl" xml:lang="en-US">Represents the member information pertaining to non-executive directors other than Chairman.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NonExecutiveDirectorsOtherThanChairmanMember_lbl" xml:lang="en-US">Non-Executive Directors Other Than Chairman [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_NonExecutiveDirectorsOtherThanChairmanMember_lbl" xml:lang="en-US">Non-executive directors other than Chairman</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Represents the vesting of awards in number of quarterly increments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting, Number of Quarterly Increments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Vesting in number of quarterly increments</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant_lbl" xml:lang="en-US">The estimated grant date fair value of awards under share-based payment arrangement granted during the reporting period as calculated by applying the disclosed option pricing methodology.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Estimated Fair Value on Date of Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant_lbl" xml:lang="en-US">Estimated fair value on date of grant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Term of award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options to purchase shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average grants date fair value (USD)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price (USD)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life (Years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_OutstandingStockOptionsAndWarrantsMember" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OutstandingStockOptionsAndWarrantsMember" xlink:to="plx_OutstandingStockOptionsAndWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember_lbl" xml:lang="en-US">Outstanding stock options and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember_lbl" xml:lang="en-US">Outstanding Stock Options And Warrants</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" xlink:label="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" xlink:to="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_lbl" xml:lang="en-US">Outstanding stock options and warrants and 2024 notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_lbl" xml:lang="en-US">Outstanding Stock Options Warrants And 2024 Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Numerator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DilutiveSecurities" xlink:to="us-gaap_DilutiveSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DilutiveSecurities_lbl" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DilutiveSecurities_lbl" xml:lang="en-US">Financial expenses of 2024 Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net income (loss) for diluted calculation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Denominator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" xml:lang="en-US">Weighted average dilutive effect of 2024 Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US">Weighted average dilutive effect of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current taxes on income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory income tax rate</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_MilestonePaymentToRegulatoryApprovals" xlink:label="plx_MilestonePaymentToRegulatoryApprovals" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MilestonePaymentToRegulatoryApprovals" xlink:to="plx_MilestonePaymentToRegulatoryApprovals_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MilestonePaymentToRegulatoryApprovals_lbl" xml:lang="en-US">Amount of the milestone payments to regulatory approvals.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MilestonePaymentToRegulatoryApprovals_lbl" xml:lang="en-US">Milestone Payment To Regulatory Approvals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_MilestonePaymentToRegulatoryApprovals_lbl" xml:lang="en-US">Milestone Payments to regulatory approvals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance related to deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Payroll and related expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest Payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Accrued Vacation, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Provision for vacation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Accrued Royalties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Royalties payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Taxes Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Income tax payable</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ReserveForDeductionsFromRevenueCurrent" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ReserveForDeductionsFromRevenueCurrent" xlink:to="plx_ReserveForDeductionsFromRevenueCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of reserve for deductions from revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_lbl" xml:lang="en-US">Reserve For Deductions From Revenue Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_lbl" xml:lang="en-US">Reserve for deductions from revenue</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Accounts Payable, Property And Equipment Suppliers, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Property and equipment suppliers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable and accruals - other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficerMember" xlink:label="srt_OfficerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficerMember" xlink:to="srt_OfficerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OfficerMember_lbl" xml:lang="en-US">Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_OfficerMember_lbl" xml:lang="en-US">New officer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOnDateOfGrant" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOnDateOfGrant" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOnDateOfGrant" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOnDateOfGrant_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOnDateOfGrant_lbl" xml:lang="en-US">The estimated grant date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOnDateOfGrant_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Estimated Fair Value on Date of Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOnDateOfGrant_lbl" xml:lang="en-US">Estimated fair value on date of grant</label>
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ProceedsFromSaleOfProducts" xlink:label="plx_ProceedsFromSaleOfProducts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromSaleOfProducts" xlink:to="plx_ProceedsFromSaleOfProducts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromSaleOfProducts_lbl" xml:lang="en-US">The amount of proceeds from sale of products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromSaleOfProducts_lbl" xml:lang="en-US">Proceeds From Sale Of Products</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>plx-20230930_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.4.0.13 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/6/2023 12:31:26 PM-->
<!--Modified on: 11/6/2023 12:31:26 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#StatementCondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureInventories" roleURI="http://www.protalix.com/role/DisclosureInventories" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureFairValueMeasurement" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureRevenues" roleURI="http://www.protalix.com/role/DisclosureRevenues" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureStockTransactions" roleURI="http://www.protalix.com/role/DisclosureStockTransactions" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureEarningsLossPerShare" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShare" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureTaxesOnIncome" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncome" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureSupplementaryFinancialStatementInformation" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureSubsequentEvents" roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureInventoriesTables" roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureRevenuesTables" roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureStockTransactionsTables" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureEarningsLossPerShareTables" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureTaxesOnIncomeTables" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureSupplementaryFinancialStatementInformationTables" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureInventoriesScheduleOfInventoryDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureStockTransactionsStockBasedCompensationDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureStockTransactionsScheduleOfWeightedAverageAssumptionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsScheduleOfWeightedAverageAssumptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureEarningsLossPerShareDetails" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureTaxesOnIncomeDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20230930.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <presentationLink xlink:role="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638348706851437643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638348706851437643" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_638348706851437643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_638348706851437643" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638348706851437643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638348706851437643" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638348706851447646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638348706851447646" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638348706851447646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638348706851447646" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638348706851447646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638348706851447646" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638348706851447646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638348706851447646" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638348706851447646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638348706851447646" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638348706851447646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638348706851447646" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638348706851447646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638348706851447646" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638348706851447646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638348706851447646" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638348706851447646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638348706851447646" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638348706851447646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638348706851447646" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638348706851447646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638348706851447646" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638348706851447646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638348706851447646" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638348706851457640" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638348706851457640" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638348706851457640" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638348706851457640" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638348706851457640" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638348706851457640" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638348706851457640" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638348706851457640" order="19" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638348706851457640" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638348706851457640" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638348706851457640" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638348706851457640" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638348706851457640" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638348706851457640" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638348706851457640" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638348706851457640" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638348706851457640" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638348706851457640" order="24" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638348706851467643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638348706851467643" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638348706851467643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638348706851467643" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638348706851467643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638348706851467643" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638348706851467643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638348706851467643" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638348706851467643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638348706851467643" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638348706851467643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638348706851467643" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638348706851477638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_AssetsAbstract_638348706851477638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638348706851477638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638348706851477638" xlink:to="us-gaap_AssetsCurrentAbstract_638348706851477638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638348706851477638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638348706851477638" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638348706851477638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_638348706851477638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638348706851477638" xlink:to="plx_ShortTermBankDeposits_638348706851477638" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638348706851477638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638348706851477638" xlink:to="us-gaap_AccountsReceivableNetCurrent_638348706851477638" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638348706851477638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638348706851477638" xlink:to="us-gaap_OtherAssetsCurrent_638348706851477638" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638348706851477638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638348706851477638" xlink:to="us-gaap_InventoryNet_638348706851477638" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638348706851477638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638348706851477638" xlink:to="us-gaap_AssetsCurrent_638348706851477638" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_638348706851477638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638348706851477638" xlink:to="us-gaap_AssetsNoncurrentAbstract_638348706851477638" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638348706851477638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638348706851477638" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638348706851477638" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638348706851477638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638348706851477638" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638348706851477638" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_638348706851487641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638348706851477638" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_638348706851487641" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638348706851487641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638348706851477638" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638348706851487641" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638348706851487641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638348706851477638" xlink:to="us-gaap_Assets_638348706851487641" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638348706851487641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638348706851487641" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638348706851487641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638348706851487641" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638348706851487641" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638348706851487641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638348706851487641" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638348706851487641" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_638348706851487641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638348706851487641" xlink:to="us-gaap_AccountsPayableTradeCurrent_638348706851487641" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_638348706851487641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638348706851487641" xlink:to="us-gaap_AccountsPayableOtherCurrent_638348706851487641" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638348706851487641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638348706851487641" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638348706851487641" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638348706851487641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638348706851487641" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638348706851487641" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent_638348706851497642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638348706851487641" xlink:to="us-gaap_ConvertibleDebtCurrent_638348706851497642" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638348706851497642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638348706851487641" xlink:to="us-gaap_LiabilitiesCurrent_638348706851497642" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_638348706851497642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638348706851487641" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_638348706851497642" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_638348706851497642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638348706851497642" xlink:to="us-gaap_ConvertibleDebtNoncurrent_638348706851497642" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638348706851497642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638348706851497642" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638348706851497642" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638348706851497642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638348706851497642" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638348706851497642" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638348706851497642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638348706851487641" xlink:to="us-gaap_LiabilitiesNoncurrent_638348706851497642" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638348706851497642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638348706851487641" xlink:to="us-gaap_Liabilities_638348706851497642" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638348706851507651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638348706851487641" xlink:to="us-gaap_CommitmentsAndContingencies_638348706851507651" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638348706851507651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638348706851487641" xlink:to="us-gaap_StockholdersEquity_638348706851507651" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638348706851507651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638348706851487641" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638348706851507651" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract_637041422967477240" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638348706851507651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637041422967477240" xlink:to="us-gaap_StatementTable_638348706851507651" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638348706851507651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638348706851507651" xlink:to="srt_ProductOrServiceAxis_638348706851507651" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638348706851507651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638348706851507651" xlink:to="srt_ProductsAndServicesDomain_638348706851507651" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638348706851507651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638348706851507651" xlink:to="us-gaap_ProductMember_638348706851507651" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_638348706851507651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638348706851507651" xlink:to="us-gaap_LicenseAndServiceMember_638348706851507651" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638348706851517645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638348706851507651" xlink:to="us-gaap_StatementLineItems_638348706851517645" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638348706851517645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851517645" xlink:to="us-gaap_Revenues_638348706851517645" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638348706851517645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851517645" xlink:to="us-gaap_CostOfRevenue_638348706851517645" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638348706851517645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851517645" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638348706851517645" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638348706851517645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851517645" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638348706851517645" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638348706851517645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851517645" xlink:to="us-gaap_OperatingIncomeLoss_638348706851517645" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638348706851517645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851517645" xlink:to="us-gaap_OtherNonoperatingExpense_638348706851517645" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638348706851517645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851517645" xlink:to="us-gaap_OtherNonoperatingIncome_638348706851517645" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638348706851517645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851517645" xlink:to="us-gaap_NonoperatingIncomeExpense_638348706851517645" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638348706851517645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851517645" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638348706851517645" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638348706851517645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851517645" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638348706851517645" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638348706851527642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851517645" xlink:to="us-gaap_NetIncomeLoss_638348706851527642" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638348706851527642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851517645" xlink:to="us-gaap_EarningsPerShareBasic_638348706851527642" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638348706851527642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851517645" xlink:to="us-gaap_EarningsPerShareDiluted_638348706851527642" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638348706851527642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851517645" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638348706851527642" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638348706851527642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851517645" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638348706851527642" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_411762" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638348706851527642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_411762" xlink:to="us-gaap_StatementTable_638348706851527642" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638348706851527642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638348706851527642" xlink:to="us-gaap_IncomeStatementLocationAxis_638348706851527642" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638348706851527642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638348706851527642" xlink:to="us-gaap_IncomeStatementLocationDomain_638348706851527642" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember_638348706851537641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638348706851527642" xlink:to="us-gaap_CostOfSalesMember_638348706851537641" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638348706851537641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638348706851527642" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638348706851537641" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638348706851537641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638348706851527642" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638348706851537641" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638348706851537641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638348706851527642" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638348706851537641" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638348706851537641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638348706851537641" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638348706851537641" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638348706851537641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" xlink:to="us-gaap_StatementTable_638348706851537641" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638348706851537641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638348706851537641" xlink:to="us-gaap_StatementEquityComponentsAxis_638348706851537641" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638348706851537641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638348706851537641" xlink:to="us-gaap_CommonStockMember_638348706851537641" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638348706851537641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638348706851537641" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638348706851537641" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638348706851537641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638348706851537641" xlink:to="us-gaap_RetainedEarningsMember_638348706851537641" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638348706851537641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638348706851537641" xlink:to="us-gaap_EquityComponentDomain_638348706851537641" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638348706851547644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638348706851537641" xlink:to="us-gaap_StatementLineItems_638348706851547644" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638348706851547644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851547644" xlink:to="us-gaap_StockholdersEquity_638348706851547644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638348706851547644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851547644" xlink:to="us-gaap_SharesOutstanding_638348706851547644" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_638348706851547644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851547644" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_638348706851547644" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_638348706851547644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851547644" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_638348706851547644" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638348706851547644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851547644" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638348706851547644" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638348706851547644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851547644" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638348706851547644" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638348706851547644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851547644" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638348706851547644" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638348706851547644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851547644" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638348706851547644" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_638348706851547644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638348706851547644" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_638348706851547644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_638348706851547644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851547644" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises_638348706851547644" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_638348706851557644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises_638348706851547644" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises_638348706851557644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638348706851557644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851547644" xlink:to="us-gaap_NetIncomeLoss_638348706851557644" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638348706851557644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851547644" xlink:to="us-gaap_StockholdersEquity_638348706851557644" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638348706851557644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851547644" xlink:to="us-gaap_SharesOutstanding_638348706851557644" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" xlink:type="extended" xlink:title="00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638348706851557644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638348706851557644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638348706851557644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockSharesAuthorized_638348706851557644" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_746" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638348706851567647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638348706851567647" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638348706851567647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638348706851567647" xlink:to="us-gaap_ProfitLoss_638348706851567647" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638348706851567647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638348706851567647" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638348706851567647" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638348706851567647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638348706851567647" xlink:to="us-gaap_ShareBasedCompensation_638348706851567647" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638348706851567647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638348706851567647" xlink:to="us-gaap_Depreciation_638348706851567647" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638348706851567647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638348706851567647" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638348706851567647" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_638348706851667644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638348706851567647" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_638348706851667644" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638348706851667644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638348706851567647" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638348706851667644" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638348706851667644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638348706851567647" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638348706851667644" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_GainLossOnDebtConversion" xlink:label="plx_GainLossOnDebtConversion_638348706851667644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638348706851567647" xlink:to="plx_GainLossOnDebtConversion_638348706851667644" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638348706851667644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638348706851567647" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638348706851667644" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638348706851667644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638348706851567647" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638348706851667644" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638348706851667644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638348706851667644" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638348706851667644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638348706851677645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638348706851667644" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638348706851677645" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_638348706851677645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638348706851667644" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_638348706851677645" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638348706851677645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638348706851667644" xlink:to="us-gaap_IncreaseDecreaseInInventories_638348706851677645" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638348706851677645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638348706851667644" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638348706851677645" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638348706851677645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638348706851567647" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638348706851677645" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638348706851677645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638348706851677645" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_638348706851677645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638348706851677645" xlink:to="plx_IncreaseDecreaseInBankDeposits_638348706851677645" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_638348706851677645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638348706851677645" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_638348706851677645" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638348706851677645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638348706851677645" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638348706851677645" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638348706851677645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638348706851677645" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638348706851677645" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638348706851687643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638348706851677645" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638348706851687643" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638348706851687643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638348706851687643" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638348706851687643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638348706851687643" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638348706851687643" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638348706851687643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638348706851687643" xlink:to="us-gaap_ProceedsFromWarrantExercises_638348706851687643" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638348706851687643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638348706851687643" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638348706851687643" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638348706851687643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638348706851687643" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638348706851687643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638348706851687643" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638348706851687643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638348706851687643" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638348706851697646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638348706851697646" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638348706851697646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638348706851697646" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638348706851697646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638348706851697646" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638348706851697646" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638348706851697646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638348706851697646" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638348706851697646" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_638348706851697646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638348706851697646" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_638348706851697646" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638348706851697646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638348706851697646" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638348706851697646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638348706851697646" xlink:to="us-gaap_InterestPaidNet_638348706851697646" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet_638348706851697646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638348706851697646" xlink:to="plx_InterestReceivedNet_638348706851697646" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_802" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638348706851707639" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_802" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638348706851707639" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventories" xlink:type="extended" xlink:title="10201 - Disclosure - INVENTORIES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_638348706851707639" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8" xlink:to="us-gaap_InventoryDisclosureTextBlock_638348706851707639" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurement" xlink:type="extended" xlink:title="10301 - Disclosure - FAIR VALUE MEASUREMENT">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_23" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638348706851707639" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_23" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638348706851707639" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenues" xlink:type="extended" xlink:title="10401 - Disclosure - REVENUES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock_638348706851717640" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="plx_RevenueDisclosureTextBlock_638348706851717640" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactions" xlink:type="extended" xlink:title="10501 - Disclosure - STOCK TRANSACTIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638348706851717640" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638348706851717640" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShare" xlink:type="extended" xlink:title="10601 - Disclosure - EARNINGS (LOSS) PER SHARE">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638348706851717640" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638348706851717640" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncome" xlink:type="extended" xlink:title="10701 - Disclosure - TAXES ON INCOME">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422967633303" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638348706851717640" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422967633303" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638348706851717640" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" xlink:type="extended" xlink:title="10801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION">
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422967789587" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_638348706851717640" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422967789587" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_638348706851717640" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="10901 - Disclosure - SUBSEQUENT EVENTS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638348706851727647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1" xlink:to="us-gaap_SubsequentEventsTextBlock_638348706851727647" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock_638348706851727647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_NatureOfOperationsPolicyTextBlock_638348706851727647" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638348706851727647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638348706851727647" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_638348706851727647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_638348706851727647" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesTables" xlink:type="extended" xlink:title="30203 - Disclosure - INVENTORIES (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_101" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638348706851727647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_101" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638348706851727647" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_129" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638348706851727647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_129" xlink:to="us-gaap_StatementTable_638348706851727647" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638348706851737642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638348706851727647" xlink:to="us-gaap_DebtInstrumentAxis_638348706851737642" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638348706851737642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638348706851737642" xlink:to="us-gaap_DebtInstrumentNameDomain_638348706851737642" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638348706851737642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638348706851737642" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638348706851737642" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638348706851737642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638348706851727647" xlink:to="us-gaap_StatementLineItems_638348706851737642" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638348706851737642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851737642" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638348706851737642" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesTables" xlink:type="extended" xlink:title="30403 - Disclosure - REVENUES (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_638348706851737642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_638348706851737642" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsTables" xlink:type="extended" xlink:title="30501 - Disclosure - STOCK TRANSACTIONS (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638348706851737642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_3" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638348706851737642" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShareTables" xlink:type="extended" xlink:title="30603 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638348706851747642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638348706851747642" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeTables" xlink:type="extended" xlink:title="30703 - Disclosure - TAXES ON INCOME (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638348706851747642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638348706851747642" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" xlink:type="extended" xlink:title="30803 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)">
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422967854703" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_638348706851747642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422967854703" xlink:to="plx_SupplementaryBalanceSheetsInformationTableTextBlock_638348706851747642" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_177" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable_638348706851747642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_177" xlink:to="plx_SignificantAccountingPoliciesTable_638348706851747642" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638348706851747642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638348706851747642" xlink:to="us-gaap_TypeOfArrangementAxis_638348706851747642" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638348706851747642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638348706851747642" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638348706851747642" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember_638348706851747642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638348706851747642" xlink:to="plx_AmendedPfizerAgreementMember_638348706851747642" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_638348706851757638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638348706851747642" xlink:to="plx_ChiesiAgreementsMember_638348706851757638" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember_638348706851757638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiAgreementsMember_638348706851757638" xlink:to="plx_ChiesiUSAgreementMember_638348706851757638" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember_638348706851757638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiAgreementsMember_638348706851757638" xlink:to="plx_ChiesiExUSAgreementMember_638348706851757638" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_FillFinishAgreementMember" xlink:label="plx_FillFinishAgreementMember_638348706851757638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638348706851747642" xlink:to="plx_FillFinishAgreementMember_638348706851757638" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_638348706851757638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638348706851747642" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_638348706851757638" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638348706851757638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638348706851747642" xlink:to="dei_LegalEntityAxis_638348706851757638" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638348706851757638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638348706851757638" xlink:to="dei_EntityDomain_638348706851757638" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_638348706851757638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638348706851757638" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_638348706851757638" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638348706851757638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638348706851747642" xlink:to="srt_StatementGeographicalAxis_638348706851757638" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638348706851757638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638348706851757638" xlink:to="srt_SegmentGeographicalDomain_638348706851757638" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BR" xlink:label="country_BR_638348706851757638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638348706851757638" xlink:to="country_BR_638348706851757638" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638348706851757638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638348706851747642" xlink:to="srt_RangeAxis_638348706851757638" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638348706851757638" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638348706851757638" xlink:to="srt_RangeMember_638348706851757638" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638348706851767644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638348706851757638" xlink:to="srt_MinimumMember_638348706851767644" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638348706851767644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638348706851757638" xlink:to="srt_MaximumMember_638348706851767644" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638348706851767644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638348706851747642" xlink:to="us-gaap_DebtInstrumentAxis_638348706851767644" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638348706851767644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638348706851767644" xlink:to="us-gaap_DebtInstrumentNameDomain_638348706851767644" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_638348706851767644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638348706851767644" xlink:to="plx_ConvertibleNotesDue2021And2024Member_638348706851767644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638348706851767644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_638348706851767644" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638348706851767644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638348706851767644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638348706851747642" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638348706851767644" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638348706851767644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638348706851767644" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638348706851767644" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember_638348706851767644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638348706851767644" xlink:to="plx_AtMarketEquityOfferingMember_638348706851767644" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_AtmEquityOfferingSalesAgreementMember" xlink:label="plx_AtmEquityOfferingSalesAgreementMember_638348706851767644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638348706851767644" xlink:to="plx_AtmEquityOfferingSalesAgreementMember_638348706851767644" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems_638348706851777642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638348706851747642" xlink:to="plx_SignificantAccountingPoliciesLineItems_638348706851777642" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_638348706851777642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638348706851777642" xlink:to="plx_NumberOfGlobalLicensingAndSupplyAgreements_638348706851777642" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_NumberOfPatientsDosed" xlink:label="plx_NumberOfPatientsDosed_638348706851777642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638348706851777642" xlink:to="plx_NumberOfPatientsDosed_638348706851777642" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_638348706851777642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638348706851777642" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_638348706851777642" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638348706851777642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638348706851777642" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638348706851777642" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638348706851777642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638348706851777642" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638348706851777642" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice_638348706851777642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638348706851777642" xlink:to="plx_SaleOfStockMaximumOfferingPrice_638348706851777642" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638348706851777642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638348706851777642" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638348706851777642" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638348706851787645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638348706851777642" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638348706851787645" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_638348706851787645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638348706851777642" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_638348706851787645" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ExtendedTermOfAgreement" xlink:label="plx_ExtendedTermOfAgreement_638348706851787645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638348706851777642" xlink:to="plx_ExtendedTermOfAgreement_638348706851787645" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable_638348706851787645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638348706851777642" xlink:to="plx_AgreementAmendmentPaymentReceivable_638348706851787645" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_638348706851787645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638348706851777642" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_638348706851787645" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_638348706851787645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638348706851777642" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_638348706851787645" order="13" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_MilestonePaymentReceived" xlink:label="plx_MilestonePaymentReceived_638348706851787645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638348706851777642" xlink:to="plx_MilestonePaymentReceived_638348706851787645" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage_638348706851797641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638348706851777642" xlink:to="plx_PaymentOnNetSalesPercentage_638348706851797641" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_638348706851797641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638348706851777642" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_638348706851797641" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638348706851797641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638348706851777642" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638348706851797641" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent_638348706851797641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638348706851777642" xlink:to="us-gaap_ConvertibleDebtCurrent_638348706851797641" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber_638348706851797641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638348706851777642" xlink:to="plx_RevenuePerformanceObligationNumber_638348706851797641" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638348706851797641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638348706851777642" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638348706851797641" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance_638348706851807643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638348706851777642" xlink:to="plx_MaintainOfMinimumCashBalance_638348706851807643" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" xlink:type="extended" xlink:title="40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_261" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_638348706851807643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_638348706851807643" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_638348706851807643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_638348706851807643" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_638348706851807643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_638348706851807643" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638348706851807643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryNet_638348706851807643" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_566" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638348706851807643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_566" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638348706851807643" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638348706851807643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638348706851807643" xlink:to="us-gaap_DebtInstrumentAxis_638348706851807643" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638348706851817642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638348706851807643" xlink:to="us-gaap_DebtInstrumentNameDomain_638348706851817642" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_638348706851817642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638348706851817642" xlink:to="plx_ConvertibleNotesDue2021And2024Member_638348706851817642" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638348706851817642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_638348706851817642" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638348706851817642" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638348706851817642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638348706851807643" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638348706851817642" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638348706851817642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638348706851817642" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638348706851817642" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638348706851817642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638348706851817642" xlink:to="us-gaap_FairValueInputsLevel3Member_638348706851817642" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638348706851817642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638348706851807643" xlink:to="us-gaap_MeasurementInputTypeAxis_638348706851817642" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638348706851817642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638348706851817642" xlink:to="us-gaap_MeasurementInputTypeDomain_638348706851817642" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_638348706851817642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638348706851817642" xlink:to="us-gaap_MeasurementInputSharePriceMember_638348706851817642" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_638348706851817642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638348706851817642" xlink:to="us-gaap_MeasurementInputExpectedTermMember_638348706851817642" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_638348706851817642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638348706851817642" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_638348706851817642" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_638348706851817642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638348706851817642" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_638348706851817642" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember_638348706851817642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638348706851817642" xlink:to="plx_MeasurementInputYieldMember_638348706851817642" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638348706851827644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638348706851807643" xlink:to="us-gaap_StatementLineItems_638348706851827644" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput_638348706851827644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851827644" xlink:to="us-gaap_DebtInstrumentMeasurementInput_638348706851827644" order="1" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_584" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638348706851827644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_584" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638348706851827644" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638348706851827644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638348706851827644" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638348706851827644" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638348706851827644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638348706851827644" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638348706851827644" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638348706851827644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638348706851827644" xlink:to="us-gaap_FairValueInputsLevel3Member_638348706851827644" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638348706851827644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638348706851827644" xlink:to="us-gaap_DebtInstrumentAxis_638348706851827644" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638348706851827644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638348706851827644" xlink:to="us-gaap_DebtInstrumentNameDomain_638348706851827644" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638348706851827644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638348706851827644" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638348706851827644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638348706851827644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638348706851827644" xlink:to="us-gaap_StatementLineItems_638348706851827644" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638348706851837644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851827644" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638348706851837644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_638348706851837644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851827644" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_638348706851837644" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - REVENUES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638348706851837644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_StatementTable_638348706851837644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638348706851837644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638348706851837644" xlink:to="srt_ProductOrServiceAxis_638348706851837644" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638348706851837644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638348706851837644" xlink:to="srt_ProductsAndServicesDomain_638348706851837644" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638348706851837644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638348706851837644" xlink:to="us-gaap_ProductMember_638348706851837644" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_638348706851837644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638348706851837644" xlink:to="us-gaap_LicenseAndServiceMember_638348706851837644" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638348706851837644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638348706851837644" xlink:to="srt_StatementGeographicalAxis_638348706851837644" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638348706851837644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638348706851837644" xlink:to="srt_SegmentGeographicalDomain_638348706851837644" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember_638348706851837644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638348706851837644" xlink:to="plx_PfizerMember_638348706851837644" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BR" xlink:label="country_BR_638348706851837644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638348706851837644" xlink:to="country_BR_638348706851837644" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember_638348706851837644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638348706851837644" xlink:to="plx_ChiesiMember_638348706851837644" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638348706851847666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638348706851837644" xlink:to="us-gaap_StatementLineItems_638348706851847666" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638348706851847666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638348706851847666" xlink:to="us-gaap_Revenues_638348706851847666" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - STOCK TRANSACTIONS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638348706851847666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_1" xlink:to="us-gaap_ScheduleOfStockByClassTable_638348706851847666" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638348706851847666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638348706851847666" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638348706851847666" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638348706851847666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638348706851847666" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638348706851847666" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_AtmEquityOfferingSalesAgreementMember" xlink:label="plx_AtmEquityOfferingSalesAgreementMember_638348706851847666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638348706851847666" xlink:to="plx_AtmEquityOfferingSalesAgreementMember_638348706851847666" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_638348706851847666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638348706851847666" xlink:to="us-gaap_PrivatePlacementMember_638348706851847666" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638348706851847666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638348706851847666" xlink:to="us-gaap_DebtInstrumentAxis_638348706851847666" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638348706851847666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638348706851847666" xlink:to="us-gaap_DebtInstrumentNameDomain_638348706851847666" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638348706851847666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638348706851847666" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638348706851847666" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638348706851847666" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638348706851847666" xlink:to="us-gaap_PlanNameAxis_638348706851847666" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638348706851857649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638348706851847666" xlink:to="us-gaap_PlanNameDomain_638348706851857649" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member_638348706851857649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638348706851857649" xlink:to="plx_EmployeeStockIncentivePlan2006Member_638348706851857649" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638348706851857649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638348706851847666" xlink:to="us-gaap_ClassOfStockLineItems_638348706851857649" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638348706851857649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638348706851857649" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638348706851857649" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638348706851857649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638348706851857649" xlink:to="us-gaap_CommonStockSharesAuthorized_638348706851857649" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_638348706851857649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638348706851857649" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises_638348706851857649" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_638348706851857649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638348706851857649" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises_638348706851857649" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638348706851857649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638348706851857649" xlink:to="us-gaap_ProceedsFromWarrantExercises_638348706851857649" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638348706851857649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638348706851857649" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638348706851857649" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_638348706851857649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638348706851857649" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_638348706851857649" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_PaymentsToDebtHoldersOnConversion" xlink:label="plx_PaymentsToDebtHoldersOnConversion_638348706851857649" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638348706851857649" xlink:to="plx_PaymentsToDebtHoldersOnConversion_638348706851857649" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_DebtConversionDecreaseInPrincipalAmount" xlink:label="plx_DebtConversionDecreaseInPrincipalAmount_638348706851867647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638348706851857649" xlink:to="plx_DebtConversionDecreaseInPrincipalAmount_638348706851867647" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638348706851867647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638348706851857649" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638348706851867647" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638348706851867647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638348706851857649" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638348706851867647" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails" xlink:type="extended" xlink:title="40502 - Disclosure - STOCK TRANSACTIONS - Stock based compensation (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638348706851867647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_2" xlink:to="us-gaap_ScheduleOfStockByClassTable_638348706851867647" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638348706851867647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638348706851867647" xlink:to="us-gaap_PlanNameAxis_638348706851867647" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638348706851867647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638348706851867647" xlink:to="us-gaap_PlanNameDomain_638348706851867647" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member_638348706851867647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638348706851867647" xlink:to="plx_EmployeeStockIncentivePlan2006Member_638348706851867647" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638348706851867647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638348706851867647" xlink:to="us-gaap_AwardTypeAxis_638348706851867647" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638348706851867647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638348706851867647" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638348706851867647" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638348706851877643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638348706851867647" xlink:to="us-gaap_RestrictedStockMember_638348706851877643" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638348706851877643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638348706851867647" xlink:to="us-gaap_EmployeeStockOptionMember_638348706851877643" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638348706851877643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638348706851867647" xlink:to="us-gaap_VestingAxis_638348706851877643" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638348706851877643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638348706851877643" xlink:to="us-gaap_VestingDomain_638348706851877643" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638348706851877643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638348706851877643" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638348706851877643" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638348706851877643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638348706851877643" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638348706851877643" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_638348706851877643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638348706851877643" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_638348706851877643" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638348706851877643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638348706851867647" xlink:to="srt_TitleOfIndividualAxis_638348706851877643" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638348706851877643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638348706851877643" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638348706851877643" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_OfficersAndOtherEmployeesMember" xlink:label="plx_OfficersAndOtherEmployeesMember_638348706851877643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638348706851877643" xlink:to="plx_OfficersAndOtherEmployeesMember_638348706851877643" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember_638348706851877643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638348706851877643" xlink:to="srt_BoardOfDirectorsChairmanMember_638348706851877643" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_NonExecutiveDirectorsOtherThanChairmanMember" xlink:label="plx_NonExecutiveDirectorsOtherThanChairmanMember_638348706851887643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638348706851877643" xlink:to="plx_NonExecutiveDirectorsOtherThanChairmanMember_638348706851887643" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638348706851887643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638348706851867647" xlink:to="us-gaap_ClassOfStockLineItems_638348706851887643" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638348706851887643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638348706851887643" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638348706851887643" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638348706851887643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638348706851887643" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638348706851887643" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638348706851887643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638348706851887643" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638348706851887643" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements_638348706851887643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638348706851887643" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements_638348706851887643" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant_638348706851887643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638348706851887643" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant_638348706851887643" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638348706851887643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638348706851887643" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638348706851887643" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638348706851887643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638348706851887643" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638348706851887643" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638348706851887643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638348706851887643" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638348706851887643" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsScheduleOfWeightedAverageAssumptionsDetails" xlink:type="extended" xlink:title="40503 - Disclosure - STOCK TRANSACTIONS - Schedule of Weighted average assumptions (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638348706851897645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_4" xlink:to="us-gaap_ScheduleOfStockByClassTable_638348706851897645" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638348706851897645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638348706851897645" xlink:to="us-gaap_AwardTypeAxis_638348706851897645" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638348706851897645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638348706851897645" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638348706851897645" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638348706851897645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638348706851897645" xlink:to="us-gaap_EmployeeStockOptionMember_638348706851897645" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638348706851897645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638348706851897645" xlink:to="us-gaap_ClassOfStockLineItems_638348706851897645" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638348706851897645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638348706851897645" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638348706851897645" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_638348706851897645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638348706851897645" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_638348706851897645" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638348706851897645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638348706851897645" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638348706851897645" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638348706851897645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638348706851897645" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638348706851897645" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638348706851897645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638348706851897645" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638348706851897645" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638348706851907646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638348706851897645" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638348706851907646" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" xlink:type="extended" xlink:title="40601 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638348706851907646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_2" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638348706851907646" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638348706851907646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638348706851907646" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638348706851907646" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638348706851907646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638348706851907646" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638348706851907646" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_OutstandingStockOptionsAndWarrantsMember" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember_638348706851907646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638348706851907646" xlink:to="plx_OutstandingStockOptionsAndWarrantsMember_638348706851907646" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" xlink:label="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_638348706851907646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638348706851907646" xlink:to="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_638348706851907646" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638348706851907646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638348706851907646" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638348706851907646" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract_638348706851907646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638348706851907646" xlink:to="us-gaap_NetIncomeLossAbstract_638348706851907646" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638348706851907646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638348706851907646" xlink:to="us-gaap_NetIncomeLoss_638348706851907646" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities_638348706851907646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638348706851907646" xlink:to="us-gaap_DilutiveSecurities_638348706851907646" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638348706851917645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638348706851907646" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638348706851917645" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638348706851917645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638348706851907646" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638348706851917645" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638348706851917645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638348706851917645" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638348706851917645" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_638348706851917645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638348706851917645" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_638348706851917645" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638348706851917645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638348706851917645" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638348706851917645" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638348706851917645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638348706851917645" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638348706851917645" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638348706851917645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638348706851907646" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638348706851917645" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - TAXES ON INCOME (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638348706851917645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638348706851917645" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638348706851917645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638348706851917645" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638348706851917645" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638348706851917645" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638348706851927644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638348706851927644" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638348706851927644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638348706851927644" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_MilestonePaymentToRegulatoryApprovals" xlink:label="plx_MilestonePaymentToRegulatoryApprovals_638348706851927644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="plx_MilestonePaymentToRegulatoryApprovals_638348706851927644" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638348706851927644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638348706851927644" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" xlink:type="extended" xlink:title="40801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)">
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422969008821" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638348706851927644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422969008821" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638348706851927644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638348706851927644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638348706851927644" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638348706851927644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_638348706851927644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638348706851927644" xlink:to="us-gaap_InterestPayableCurrent_638348706851927644" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_638348706851927644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638348706851927644" xlink:to="us-gaap_AccruedVacationCurrent_638348706851927644" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638348706851927644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638348706851927644" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638348706851927644" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent_638348706851927644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638348706851927644" xlink:to="us-gaap_AccruedRoyaltiesCurrent_638348706851927644" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_638348706851927644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638348706851927644" xlink:to="us-gaap_TaxesPayableCurrent_638348706851927644" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ReserveForDeductionsFromRevenueCurrent" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_638348706851927644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638348706851927644" xlink:to="plx_ReserveForDeductionsFromRevenueCurrent_638348706851927644" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638348706851937644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638348706851927644" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638348706851937644" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638348706851937644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638348706851927644" xlink:to="us-gaap_AccountsPayableCurrent_638348706851937644" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40901 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638348706851937644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_2" xlink:to="us-gaap_SubsequentEventTable_638348706851937644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638348706851937644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638348706851937644" xlink:to="us-gaap_SubsequentEventTypeAxis_638348706851937644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638348706851937644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638348706851937644" xlink:to="us-gaap_SubsequentEventTypeDomain_638348706851937644" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638348706851937644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638348706851937644" xlink:to="us-gaap_SubsequentEventMember_638348706851937644" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638348706851937644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638348706851937644" xlink:to="us-gaap_AwardTypeAxis_638348706851937644" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638348706851937644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638348706851937644" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638348706851937644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638348706851937644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638348706851937644" xlink:to="us-gaap_EmployeeStockOptionMember_638348706851937644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638348706851937644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638348706851937644" xlink:to="srt_TitleOfIndividualAxis_638348706851937644" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638348706851937644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638348706851937644" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638348706851937644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficerMember" xlink:label="srt_OfficerMember_638348706851947642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638348706851937644" xlink:to="srt_OfficerMember_638348706851947642" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638348706851947642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638348706851937644" xlink:to="us-gaap_PlanNameAxis_638348706851947642" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638348706851947642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638348706851947642" xlink:to="us-gaap_PlanNameDomain_638348706851947642" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member_638348706851947642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638348706851947642" xlink:to="plx_EmployeeStockIncentivePlan2006Member_638348706851947642" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638348706851947642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638348706851937644" xlink:to="us-gaap_TypeOfArrangementAxis_638348706851947642" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638348706851947642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638348706851947642" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638348706851947642" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_638348706851947642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638348706851947642" xlink:to="plx_ChiesiAgreementsMember_638348706851947642" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638348706851947642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638348706851937644" xlink:to="us-gaap_SubsequentEventLineItems_638348706851947642" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638348706851947642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638348706851947642" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638348706851947642" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638348706851947642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638348706851947642" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638348706851947642" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638348706851947642" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638348706851947642" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638348706851947642" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638348706851957644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638348706851947642" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638348706851957644" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements_638348706851957644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638348706851947642" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements_638348706851957644" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOnDateOfGrant" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOnDateOfGrant_638348706851957644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638348706851947642" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOnDateOfGrant_638348706851957644" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20230930.xsd#plx_ProceedsFromSaleOfProducts" xlink:label="plx_ProceedsFromSaleOfProducts_638348706851957644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638348706851947642" xlink:to="plx_ProceedsFromSaleOfProducts_638348706851957644" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449561049152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Nov. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROTALIX BIOTHERAPEUTICS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 University Plaza<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-9345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,952,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449561181120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 20,408<span></span>
</td>
<td class="nump">$ 17,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShortTermBankDeposits', window );">Short-term bank deposits</a></td>
<td class="nump">20,567<span></span>
</td>
<td class="nump">5,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="nump">8,935<span></span>
</td>
<td class="nump">4,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">1,125<span></span>
</td>
<td class="nump">1,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">21,583<span></span>
</td>
<td class="nump">16,804<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">72,618<span></span>
</td>
<td class="nump">44,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Funds in respect of employee rights upon retirement</a></td>
<td class="nump">1,260<span></span>
</td>
<td class="nump">1,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,684<span></span>
</td>
<td class="nump">4,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income tax asset</a></td>
<td class="nump">3,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">5,915<span></span>
</td>
<td class="nump">5,087<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">87,569<span></span>
</td>
<td class="nump">55,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
<td class="nump">3,114<span></span>
</td>
<td class="nump">5,862<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">18,740<span></span>
</td>
<td class="nump">12,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,313<span></span>
</td>
<td class="nump">1,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contracts liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible notes</a></td>
<td class="nump">20,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">43,359<span></span>
</td>
<td class="nump">32,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
<td class="nump">1,461<span></span>
</td>
<td class="nump">1,642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">4,502<span></span>
</td>
<td class="nump">4,169<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
<td class="nump">5,963<span></span>
</td>
<td class="nump">33,998<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">49,322<span></span>
</td>
<td class="nump">66,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</a></td>
<td class="nump">38,247<span></span>
</td>
<td class="num">(10,640)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity (net of capital deficiency)</a></td>
<td class="nump">$ 87,569<span></span>
</td>
<td class="nump">$ 55,787<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShortTermBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShortTermBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449557798768">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10,345<span></span>
</td>
<td class="nump">$ 14,183<span></span>
</td>
<td class="nump">$ 55,008<span></span>
</td>
<td class="nump">$ 39,021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF GOODS SOLD</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(4,893)<span></span>
</td>
<td class="num">(7,074)<span></span>
</td>
<td class="num">(14,126)<span></span>
</td>
<td class="num">(17,195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(3,669)<span></span>
</td>
<td class="num">(7,386)<span></span>
</td>
<td class="num">(13,991)<span></span>
</td>
<td class="num">(23,732)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(3,670)<span></span>
</td>
<td class="num">(2,848)<span></span>
</td>
<td class="num">(10,816)<span></span>
</td>
<td class="num">(8,613)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING INCOME (LOSS)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,887)<span></span>
</td>
<td class="num">(3,125)<span></span>
</td>
<td class="nump">16,075<span></span>
</td>
<td class="num">(10,519)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">FINANCIAL EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(460)<span></span>
</td>
<td class="num">(639)<span></span>
</td>
<td class="num">(2,406)<span></span>
</td>
<td class="num">(1,879)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">FINANCIAL INCOME</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">628<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="nump">1,323<span></span>
</td>
<td class="nump">1,211<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL INCOME (EXPENSES), NET</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">168<span></span>
</td>
<td class="num">(442)<span></span>
</td>
<td class="num">(1,083)<span></span>
</td>
<td class="num">(668)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">INCOME (LOSS) BEFORE TAXES ON INCOME</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,719)<span></span>
</td>
<td class="num">(3,567)<span></span>
</td>
<td class="nump">14,992<span></span>
</td>
<td class="num">(11,187)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">TAXES ON INCOME</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(133)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(636)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME (LOSS) FOR THE PERIOD</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1,852)<span></span>
</td>
<td class="num">$ (3,567)<span></span>
</td>
<td class="nump">$ 14,356<span></span>
</td>
<td class="num">$ (11,187)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - BASIC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - DILUTED</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE- BASIC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">72,281,681<span></span>
</td>
<td class="nump">49,498,105<span></span>
</td>
<td class="nump">65,811,506<span></span>
</td>
<td class="nump">47,582,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE- DILUTED</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">83,782,679<span></span>
</td>
<td class="nump">49,498,105<span></span>
</td>
<td class="nump">81,040,281<span></span>
</td>
<td class="nump">47,582,733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10,168<span></span>
</td>
<td class="nump">$ 8,812<span></span>
</td>
<td class="nump">$ 30,309<span></span>
</td>
<td class="nump">$ 21,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 177<span></span>
</td>
<td class="nump">$ 5,371<span></span>
</td>
<td class="nump">$ 24,699<span></span>
</td>
<td class="nump">$ 17,799<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><b style="font-size:8pt;font-weight:bold;">(1) Includes share-based compensation</b></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</b></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><b style="font-size:8pt;font-weight:bold;">(3) Includes share-based compensation</b></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449557801760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 195<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 299<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">506<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 720<span></span>
</td>
<td class="nump">$ 272<span></span>
</td>
<td class="nump">$ 1,276<span></span>
</td>
<td class="nump">$ 1,213<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449557188080">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 368,852<span></span>
</td>
<td class="num">$ (374,934)<span></span>
</td>
<td class="num">$ (6,036)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">45,556,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">4,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,841,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock awards (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">759,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueWarrantsExercises', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,187)<span></span>
</td>
<td class="num">(11,187)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">374,557<span></span>
</td>
<td class="num">(386,121)<span></span>
</td>
<td class="num">(11,514)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">50,158,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">372,616<span></span>
</td>
<td class="num">(382,554)<span></span>
</td>
<td class="num">(9,889)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">48,712,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,445,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,567)<span></span>
</td>
<td class="num">(3,567)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">374,557<span></span>
</td>
<td class="num">(386,121)<span></span>
</td>
<td class="num">(11,514)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">50,158,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">379,167<span></span>
</td>
<td class="num">(389,861)<span></span>
</td>
<td class="num">(10,640)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">53,790,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">23,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">12,560,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Convertible notes conversions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">7,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Convertible notes conversions (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,691,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock awards (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,371,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueWarrantsExercises', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">538,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,356<span></span>
</td>
<td class="nump">14,356<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">413,679<span></span>
</td>
<td class="num">(375,505)<span></span>
</td>
<td class="nump">38,247<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">72,952,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">412,582<span></span>
</td>
<td class="num">(373,653)<span></span>
</td>
<td class="nump">39,001<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">71,580,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock awards (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,371,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,852)<span></span>
</td>
<td class="num">$ (1,852)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">$ 413,679<span></span>
</td>
<td class="num">$ (375,505)<span></span>
</td>
<td class="nump">$ 38,247<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">72,952,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Common stock, $0.001 par value; Authorized &#8211; as of September&#160;30, 2023 and December&#160;31, 2022 &#8211; 185,000,000 and 144,000,000 shares, respectively.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of recognized equity-based compensation during the period for restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Sales Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449557946032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jul. 25, 2023</div></th>
<th class="th"><div>Jul. 24, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (CAPITAL DEFICIENCY)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">185,000,000<span></span>
</td>
<td class="nump">185,000,000<span></span>
</td>
<td class="nump">144,000,000<span></span>
</td>
<td class="nump">144,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449560004416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 14,356<span></span>
</td>
<td class="num">$ (11,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net income (loss) to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">2,081<span></span>
</td>
<td class="nump">1,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">878<span></span>
</td>
<td class="nump">811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial income, net (mainly exchange differences)</a></td>
<td class="num">(511)<span></span>
</td>
<td class="num">(1,083)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(391)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Changes in deferred tax asset</a></td>
<td class="num">(3,092)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement', window );">Loss (gain) on amounts funded in respect of employee rights upon retirement</a></td>
<td class="num">(49)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_GainLossOnDebtConversion', window );">Gain on conversions of convertible notes</a></td>
<td class="num">(421)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Decrease in contracts liability</a></td>
<td class="num">(13,178)<span></span>
</td>
<td class="num">(5,547)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable-trade and other assets</a></td>
<td class="num">(4,188)<span></span>
</td>
<td class="num">(5,692)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ChangeInOperatingLeaseRightOfUseAssets', window );">Changes in operating lease right of use assets, net</a></td>
<td class="nump">12<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease (increase) in inventories</a></td>
<td class="num">(4,779)<span></span>
</td>
<td class="nump">3,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in accounts payable and accruals</a></td>
<td class="nump">3,820<span></span>
</td>
<td class="num">(4,438)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(4,913)<span></span>
</td>
<td class="num">(22,389)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_IncreaseDecreaseInBankDeposits', window );">Investment in bank deposits</a></td>
<td class="num">(20,420)<span></span>
</td>
<td class="num">(16,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ProceedsFromSaleOfShortTermDeposits', window );">Proceeds from sale of short-term deposits</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(899)<span></span>
</td>
<td class="num">(415)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts paid (funded) in respect of employee rights upon retirement, net</a></td>
<td class="num">(50)<span></span>
</td>
<td class="nump">427<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(16,369)<span></span>
</td>
<td class="num">(9,988)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under the Sales Agreement, net</a></td>
<td class="nump">23,954<span></span>
</td>
<td class="nump">4,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="nump">712<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">24,666<span></span>
</td>
<td class="nump">4,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(87)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">3,297<span></span>
</td>
<td class="num">(28,265)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">17,111<span></span>
</td>
<td class="nump">38,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">20,408<span></span>
</td>
<td class="nump">10,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right of use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">1,395<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Convertible notes conversions</a></td>
<td class="nump">7,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">2,743<span></span>
</td>
<td class="nump">2,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_InterestReceivedNet', window );">Interest received</a></td>
<td class="nump">$ 303<span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Change in Operating Lease Right Of use Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on amounts funded in respect of employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnDebtConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of gain (loss) on conversion of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnDebtConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseDecreaseInBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deposits held with banks.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseDecreaseInBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_InterestReceivedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash received for interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_InterestReceivedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromSaleOfShortTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of short-term deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromSaleOfShortTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449558522000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). The Company&#8217;s current focus is to facilitate the commercialization efforts of Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), the Company&#8217;s development and commercialization partner for pegunigalsidase alfa, or Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (which the Company referred to as PRX-102 during its development stage), for the treatment of Fabry disease, a rare, genetic lysosomal disorder. To date, the Company has successfully developed taliglucerase alfa (marketed under the name Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> except in Brazil where it is marketed as BioManguinhos alfataliglicerase), an enzyme replacement therapy for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s strategy is to develop proprietary recombinant proteins designed to address high, unmet needs in the rare disease space that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. Consistent with this strategy, the Company has a number of product candidates in varying stages of the clinical development process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On May&#160;5, 2023, the European Commission (&#8220;EC&#8221;) announced that it had approved the Marketing Authorization Application (&#8220;MAA&#8221;) for Elfabrio and on May&#160;9, 2023, the U.S.&#160;Food and Drug Administration (&#8220;FDA&#8221;) announced that it had approved the Biologics License Application (&#8220;BLA&#8221;) for Elfabrio, each for adult patients with Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. The European Medicines Agency (&#8220;EMA&#8221;) approval followed the February 2023 adoption of a positive opinion and recommendation of marketing authorization for Elfabrio by the EMA&#8217;s Committee for Medicinal Products for Human Use the (&#8220;CHMP&#8221;). Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with Enzyme Replacement Therapy (ERT) class labeling, and Warnings/Precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The Warnings/Precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In August and September of 2023, Elfabrio was approved in Great Britain and Switzerland, respectively, for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The Company has entered into two exclusive global licensing and supply agreements for Elfabrio with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;). On October&#160;19, 2017, Protalix Ltd., the Company&#8217;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi Ex-US Agreement&#8221;), pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the Chiesi US Agreement, with respect to the commercialization of Elfabrio in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Elfabrio, an enzyme replacement therapy, or ERT, was the subject of a phase&#160;III clinical program studying the drug as a treatment of patients with Fabry disease, a rare, genetic lysosomal disorder. The phase&#160;III clinical program included three separate studies, which are referred to as the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which subjects that participated in our phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship of the two open-label extension studies was transferred to Chiesi, which is now administering the extension studies. Over time, and as Elfabrio is approved for marketing in different jurisdictions, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">participants withdraw from the open-label extension studies. Some of the withdrawals<span style="text-decoration-line:line-through;text-decoration-style:solid;"> </span>transfer to a commercial setting, others withdraw for other reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The BLA for Elfabrio for the treatment of adult patients with Fabry disease was resubmitted to the FDA on November&#160;9, 2022. An initial BLA for Elfabrio was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, but resulted in a Complete Response Letter (&#8220;CRL&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The MAA was submitted to the EMA on February&#160;7, 2022, after the October&#160;8, 2021 meeting we held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The FDA publicly released the internal review documents for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161. These documents provide previously unavailable additional information regarding the basis for the FDA&#8217;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study (Study PB-102-F01/02) with confirmatory evidence provided by the <i style="font-style:italic;">BALANCE</i> study (also referred to as Study PB-102-F20). The FDA review team also concluded that the <i style="font-style:italic;">BALANCE</i> study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the <i style="font-style:italic;">BALANCE</i> study did not support a non-inferiority claim to the comparator product due to the lack of data to support a non-inferiority margin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has licensed the rights to commercialize taliglucerase alfa worldwide (other than Brazil) to Pfizer Inc. (&#8220;Pfizer&#8221;), and in Brazil to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;). Otherwise, except with respect to taliglucerase alfa and Elfabrio, the Company holds the worldwide commercialization rights to its other proprietary development candidates. In addition, the Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(1)</span>PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat severe gout; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(2)</span>PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</div><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On March&#160;21, 2023, the first patient was dosed in the Company&#8217;s phase&#160;I First-in-Human (&#8220;FIH&#8221;) clinical trial of PRX-115. As of September&#160;30, 2023, 32 patients have been dosed in this trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;2021 Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell, from time to time through the Agent, shares of its common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $20.0&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the 2021 Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, the Company sold a total of 13,980,060 ATM Shares for total gross proceeds of approximately $20.0&#160;million under the 2021 Sales Agreement, thereby completing the ATM program under said agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#8220;2023 Sales Agreement&#8221;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to $20.0&#160;million. As of September&#160;30, 2023, shares of Common Stock for total gross proceeds of approximately $6.4&#160;million remain available to be sold under the 2023 Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements. In addition, following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. is required to manufacture all of the Elfabrio drug substance needed under the agreements, subject to certain exceptions, and Chiesi will purchase Elfabrio drug product from Protalix, subject to certain terms and conditions. The consideration for Protalix Ltd. is based on the drug product supplied to Chiesi and the average selling price of the drug product in the relevant territory multiplied by tiered payments as described in the relevant agreement. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments for drug product purchased from Protalix of 15% to 35%, depending on the amount of annual net sales outside of the United States, and under the Chiesi US Agreement, Chiesi is required to make tiered payments for drug product purchased from Protalix of 15% to 40%, depending on the amount of annual net sales in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#8220;F/F Agreement&#8221;) and a Letter Agreement (the &#8220;Letter Agreement&#8221;), in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for PRX-102 and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide the Company with commercial fill/finish services for PRX-102, including to support the anticipated global launch of PRX-102. The F/F Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with the terms of the F/F Agreement and the term may be extended by mutual agreement for an additional period of&#160;seven years&#160;upon mutual written agreement prior to expiration of the initial term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement with Fiocruz (the &#8220;Brazil Agreement&#8221;) for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to the product candidates. Under the terms of the Company&#8217;s outstanding 7.50% Senior Secured Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;)<span style="font-family:'28mugxoulnobhnx';">, </span>the Company is required to comply with certain<span style="color:#222222;background:#ffffff;"> </span>financial covenants, including the maintenance of a minimum cash balance of at least $7.5&#160;million. As of September&#160;30, 2023, the Company is in<span style="background:#ffffff;"> compliance with all such covenants. </span>The Company believes that its cash and cash equivalents as of September&#160;30, 2023, are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2022 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2022.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Revenue recognition</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Revenues from selling products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery), at the net selling price, which reflects reserves for variable consideration, potential discounts and allowances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price is the consideration to which the Company expects to be entitled from the customer. The consideration promised in a contract with the Company&#8217;s customers may include fixed amounts and variable amounts. The Company estimates the variable consideration and includes it in the transaction price using the most likely outcome method, and only to the extent it is highly probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenues from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified two performance obligations in the Chiesi Agreements as follows: (i)&#160;the license and research and development services and (ii)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The manufacturing was contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license, research and development services. Following the regulatory approvals for Elfabrio received in May 2023, the Company started recognizing revenue from manufacturing, see also revenue from selling products above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue. Following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million (see also note 4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services was recognized over time using the cost-to-cost method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi is recognized over time using the cost-to-cost method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services was recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449558563312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at September&#160;30, 2023 and December&#160;31, 2022 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,198</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,269</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449561046016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">Based on a Level 3 measurement, as of September&#160;30, 2023, the fair value of the $20.4&#160;million aggregate principal amount of the Company&#8217;s outstanding 2024 Notes is approximately $24.5&#160;million. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449562906448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_RevenueDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">NOTE&#160;4&#160;&#8211; REVENUES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,541</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,972</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,279</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,320</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,708</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,120</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,162</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,781</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,812</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,222</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,699</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,799</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449557490208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCK TRANSACTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; STOCK TRANSACTIONS</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;">Authorized Capital</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">On June&#160;28, 2023, the Company held its 2023 Annual Meeting of Stockholders, which was adjourned and reconvened on July&#160;13, 2023 (the &#8220;Annual Meeting&#8221;). At the Annual Meeting, the Company&#8217;s stockholders, among other matters, approved an amendment to the Company&#8217;s Certificate of Incorporation, as amended, to increase the number of shares of Common Stock authorized for issuance from 144,000,000 to 185,000,000 (the &#8220;Charter Amendment&#8221;). The Charter Amendment was filed with the Secretary of State of the State of Delaware on July&#160;25, 2023.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;">At-the-Market (ATM) Offering</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">During the nine months ended September&#160;30, 2023, the Company sold, in the aggregate, 12,560,150 shares of Common Stock under the 2023 Sales Agreement. The Company generated aggregate gross proceeds equal to approximately $24.9&#160;million in connection with such sales. All such sales were completed during the quarters ended March&#160;31, 2023 and June&#160;30, 2023. No sales were completed during the three-months ended September&#160;30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;">(c)</b></span><b style="font-weight:bold;background:#ffffff;">Exercise of Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">On May&#160;8, 2023, the Company issued 301,810 shares of Common Stock in connection with the cash exercise of a warrant issued on March&#160;18, 2020, as part of the Company&#8217;s private placement of Common Stock and warrants. The Company generated net proceeds equal to $0.7&#160;million from the exercise of the warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">On May&#160;10, 2023, the Company issued 237,012 shares of Common Stock in connection with the cashless exercise of a warrant to purchase 845,000 shares of Common Stock issued on March&#160;18, 2020, as part of the Company&#8217;s private placement of Common Stock and warrants. The Company did not generate any proceeds from the cashless exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">No warrants were exercised during the three months ended September&#160;30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;">(d)</b></span><b style="font-weight:bold;background:#ffffff;">Conversion of 2024 Notes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">During the nine months ended September&#160;30, 2023, the Company issued, in the aggregate, 4,691,623 shares of Common Stock in connection with the conversions of 2024 Notes. In connection with such conversions, during the nine months ended September&#160;30, 2023, the Company paid to the converting holders $0.9&#160;million representing cash payments due to accrued but unpaid interest, make-whole interest payments and payments in lieu of fractional shares. As a result of the conversions, the total principal amount of the 2024 Notes decreased by approximately $8.3&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">No 2024 Notes were converted during the three months ended September&#160;30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(e)</b></span><b style="font-weight:bold;">Stock based compensation</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On June&#160;28, 2023, at the Annual Meeting, the Company&#8217;s stockholders, among other matters, adopted amendments to the Company&#8217;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#8220;Plan&#8221;) to increase the number of shares of Common Stock available under Plan from </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8,475,171</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12,475,171</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares and to amend certain other terms of the Plan.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On August&#160;15, 2023, the Company granted, with the approval of the Company&#8217;s compensation committee, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1,371,362</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of restricted Common Stock, in the aggregate, to certain of the Company&#8217;s officers under the Plan. Of such grants, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">200,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of restricted Common Stock vested upon grant, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">600,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of restricted Common Stock vest over a </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two-year</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> period in </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eight</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;equal quarterly increments and the remaining </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">571,362</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of restricted Common Stock vest over a </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three-year</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> period in </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;equal quarterly increments. The Company estimated the fair value of the restricted stock on the date of grant to be approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$2.7</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">On August&#160;15, 2023, the Company granted, with the approval of the Company&#8217;s compensation committee, 10-year options to purchase 1,056,315 shares of Common Stock, in the aggregate, to certain of the Company&#8217;s officers and other employees under the Plan. The options have an exercise price equal to $1.99 per share and vest over a three-year period in 12&#160;equal quarterly increments. Vesting of the options granted to executive officers is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the aggregate fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $1.5&#160;million. </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 108pt;">On September&#160;14, 2023, the Company granted, with the approval of the Company&#8217;s compensation committee, 10-year options to purchase 85,715 shares of Common Stock, in the aggregate, to the new Chairman of the Company&#8217;s Board of Directors under the Plan. The options have an exercise price equal to $1.75 per share and vest over a three-year period in 12&#160;equal quarterly increments. Vesting of the options is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the aggregate fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $0.1&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 108pt;">On September&#160;29, 2023, the Company granted, with the approval of the Company&#8217;s compensation committee, 10-year options to purchase 308,380 shares of Common Stock, in the aggregate, to the non-executive directors of the Company&#8217;s Board of Directors, other than the Chairman, under the Plan. The options have an exercise price equal to $1.66 per share and vest over a three-year period in 12&#160;equal quarterly increments. Vesting of the options is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the aggregate fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $0.4&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 108pt;"><span style="background:#ffffff;">The fair value of each option granted during the three-month period ended September&#160;30, 2023 is estimated at the date of grant using the Black-Scholes option-pricing model. The following weighted average assumptions were applied in determining the fair value of the options described in this Note&#160;5(e)(3) on their respective grant dates:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Weighted average grants date fair value (USD)</p></td><td style="vertical-align:bottom;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Exercise price (USD)</p></td><td style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 79.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected life (Years)</p></td><td style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449557943152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>EARNINGS (LOSS) PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; EARNINGS (LOSS) PER SHARE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Basic earnings (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of Common Stock outstanding during each period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Diluted earnings per share is calculated by dividing the net income by the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#8220;if-converted&#8221; method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Basic and diluted net earnings (loss) per share attributable to common stockholders were calculated as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:29.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(In&#160;thousands,&#160;except&#160;share&#160;data)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,852)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,567)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,187)</p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Add:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financial expenses of 2024 Notes*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,766)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,610)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net income (loss) for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,618)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,567)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,746</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,187)</p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares of Common Stock outstanding for basic calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72,281,681</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,498,105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65,811,506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,582,733</p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average dilutive effect of 2024 Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,500,998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,981,660</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average dilutive effect of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,247,115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares of Common Stock outstanding for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 83,782,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,498,105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81,040,281</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,582,733</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 10pt 54pt;">* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the period and inclusion of make-whole interest payments that will be incurred upon conversion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Diluted earnings (loss) per share do not include 19,429,910 and 18,399,260 shares of Common Stock underlying outstanding stock options and warrants of the Company for the three and nine months ended September&#160;30, 2023, respectively, because the effect would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Diluted earnings (loss) per share do not include 33,922,624 and 33,295,154 shares of Common Stock underlying outstanding stock options, warrants and the 2024 Notes for the three and nine months ended September&#160;30, 2022, respectively, because the effect would be anti-dilutive.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449557490208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES ON INCOME</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 7 &#8211; TAXES ON INCOME</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s taxes on income:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,728</p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,092)</p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 133</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 636</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company had an effective tax rate of 4% for the nine months ended September&#160;30, 2023, compared to an effective tax rate of 0% for the nine months ended September&#160;30, 2022. For the nine months ended September&#160;30, 2023, the difference between the Company&#8217;s effective tax rate and the U.S.&#160;federal statutory rate of 21% was the result of the provision for current taxes on income mainly derived from U.S. taxable GILTI income mainly in respect of milestone payments and Section&#160;174 of the U.S.&#160;Tax Cuts and Jobs Act, which was enacted in December 2017 (the &#8220;TCJA&#8221;), partially offset by the release of the valuation allowance on net operating losses (NOLs) in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Following the regulatory approvals for Elfabrio in May 2023, the receipt of the $20.0&#160;million milestone payment and the launch of Elfabrio in the United States, the Company released valuation allowance previously recorded on deferred tax assets in respect of its NOLs in the United States resulting in a net tax benefit of $3.1&#160;million. The Company concluded that, based upon the preponderance of positive evidence over negative evidence and the anticipated ability to use the deferred tax assets, it was more likely than not that these deferred tax assets would be realizable due to forecasted profits. The Company considered the following: (i)&#160;cumulative profits for tax over the previous 12 quarters in its U.S. operations; (ii)&#160;the impact of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Section&#160;174 of the TCJA which requires the Company to capitalize and amortize its research and development expenses over 15 years; and (iii) its forecasted profits in the United States following the regulatory approvals of Elfabrio.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449562922880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SupplementalInformationAbstract', window );"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 8 &#8211; </b><b style="font-weight:bold;background:#ffffff;">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">Balance sheets:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,239</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,216</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest Payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 719</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,471</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,404</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,249</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,478</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 781</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,257</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 530</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reserve for deductions from revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,816</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 253</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 143</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,740</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,271</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449559326416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 9 &#8211; SUBSEQUENT EVENTS</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">On October&#160;4, 2023 the Company collected approximately $6.4&#160;million from sales to Chiesi<span style="background:#ffffff;">.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">On October&#160;15, 2023, the Company granted, with the approval of the Company&#8217;s compensation committee, 10-year options to purchase 250,000 shares of Common Stock to a new officer of the Company under the Plan. The options have an exercise price equal to $1.48 per share and vest over a three-year period in 12&#160;equal quarterly increments. The Company estimated the aggregate fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $0.26&#160;million.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">3)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Because the Company's operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;In October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets while simultaneously launching extensive rocket attacks on the Israeli population and industrial centers. At the same time, clashes between Israel and Hezbollah in Lebanon have increased. In response, Israel&#8217;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#8217;s defensive measures, may result in a greater regional conflict. It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on our business, operations and financial conditions. The ongoing conflict is rapidly evolving and developing, and could disrupt certain of our business and operations, among others.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449559863552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). The Company&#8217;s current focus is to facilitate the commercialization efforts of Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), the Company&#8217;s development and commercialization partner for pegunigalsidase alfa, or Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (which the Company referred to as PRX-102 during its development stage), for the treatment of Fabry disease, a rare, genetic lysosomal disorder. To date, the Company has successfully developed taliglucerase alfa (marketed under the name Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> except in Brazil where it is marketed as BioManguinhos alfataliglicerase), an enzyme replacement therapy for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s strategy is to develop proprietary recombinant proteins designed to address high, unmet needs in the rare disease space that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. Consistent with this strategy, the Company has a number of product candidates in varying stages of the clinical development process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On May&#160;5, 2023, the European Commission (&#8220;EC&#8221;) announced that it had approved the Marketing Authorization Application (&#8220;MAA&#8221;) for Elfabrio and on May&#160;9, 2023, the U.S.&#160;Food and Drug Administration (&#8220;FDA&#8221;) announced that it had approved the Biologics License Application (&#8220;BLA&#8221;) for Elfabrio, each for adult patients with Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. The European Medicines Agency (&#8220;EMA&#8221;) approval followed the February 2023 adoption of a positive opinion and recommendation of marketing authorization for Elfabrio by the EMA&#8217;s Committee for Medicinal Products for Human Use the (&#8220;CHMP&#8221;). Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with Enzyme Replacement Therapy (ERT) class labeling, and Warnings/Precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The Warnings/Precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In August and September of 2023, Elfabrio was approved in Great Britain and Switzerland, respectively, for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The Company has entered into two exclusive global licensing and supply agreements for Elfabrio with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;). On October&#160;19, 2017, Protalix Ltd., the Company&#8217;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi Ex-US Agreement&#8221;), pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the Chiesi US Agreement, with respect to the commercialization of Elfabrio in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Elfabrio, an enzyme replacement therapy, or ERT, was the subject of a phase&#160;III clinical program studying the drug as a treatment of patients with Fabry disease, a rare, genetic lysosomal disorder. The phase&#160;III clinical program included three separate studies, which are referred to as the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which subjects that participated in our phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship of the two open-label extension studies was transferred to Chiesi, which is now administering the extension studies. Over time, and as Elfabrio is approved for marketing in different jurisdictions, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">participants withdraw from the open-label extension studies. Some of the withdrawals<span style="text-decoration-line:line-through;text-decoration-style:solid;"> </span>transfer to a commercial setting, others withdraw for other reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The BLA for Elfabrio for the treatment of adult patients with Fabry disease was resubmitted to the FDA on November&#160;9, 2022. An initial BLA for Elfabrio was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, but resulted in a Complete Response Letter (&#8220;CRL&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The MAA was submitted to the EMA on February&#160;7, 2022, after the October&#160;8, 2021 meeting we held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The FDA publicly released the internal review documents for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161. These documents provide previously unavailable additional information regarding the basis for the FDA&#8217;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study (Study PB-102-F01/02) with confirmatory evidence provided by the <i style="font-style:italic;">BALANCE</i> study (also referred to as Study PB-102-F20). The FDA review team also concluded that the <i style="font-style:italic;">BALANCE</i> study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the <i style="font-style:italic;">BALANCE</i> study did not support a non-inferiority claim to the comparator product due to the lack of data to support a non-inferiority margin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has licensed the rights to commercialize taliglucerase alfa worldwide (other than Brazil) to Pfizer Inc. (&#8220;Pfizer&#8221;), and in Brazil to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;). Otherwise, except with respect to taliglucerase alfa and Elfabrio, the Company holds the worldwide commercialization rights to its other proprietary development candidates. In addition, the Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(1)</span>PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat severe gout; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(2)</span>PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</div><div style="margin-top:11pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On March&#160;21, 2023, the first patient was dosed in the Company&#8217;s phase&#160;I First-in-Human (&#8220;FIH&#8221;) clinical trial of PRX-115. As of September&#160;30, 2023, 32 patients have been dosed in this trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;2021 Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell, from time to time through the Agent, shares of its common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $20.0&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the 2021 Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, the Company sold a total of 13,980,060 ATM Shares for total gross proceeds of approximately $20.0&#160;million under the 2021 Sales Agreement, thereby completing the ATM program under said agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#8220;2023 Sales Agreement&#8221;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to $20.0&#160;million. As of September&#160;30, 2023, shares of Common Stock for total gross proceeds of approximately $6.4&#160;million remain available to be sold under the 2023 Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements. In addition, following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. is required to manufacture all of the Elfabrio drug substance needed under the agreements, subject to certain exceptions, and Chiesi will purchase Elfabrio drug product from Protalix, subject to certain terms and conditions. The consideration for Protalix Ltd. is based on the drug product supplied to Chiesi and the average selling price of the drug product in the relevant territory multiplied by tiered payments as described in the relevant agreement. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments for drug product purchased from Protalix of 15% to 35%, depending on the amount of annual net sales outside of the United States, and under the Chiesi US Agreement, Chiesi is required to make tiered payments for drug product purchased from Protalix of 15% to 40%, depending on the amount of annual net sales in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#8220;F/F Agreement&#8221;) and a Letter Agreement (the &#8220;Letter Agreement&#8221;), in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for PRX-102 and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide the Company with commercial fill/finish services for PRX-102, including to support the anticipated global launch of PRX-102. The F/F Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with the terms of the F/F Agreement and the term may be extended by mutual agreement for an additional period of&#160;seven years&#160;upon mutual written agreement prior to expiration of the initial term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement with Fiocruz (the &#8220;Brazil Agreement&#8221;) for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to the product candidates. Under the terms of the Company&#8217;s outstanding 7.50% Senior Secured Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;)<span style="font-family:'28mugxoulnobhnx';">, </span>the Company is required to comply with certain<span style="color:#222222;background:#ffffff;"> </span>financial covenants, including the maintenance of a minimum cash balance of at least $7.5&#160;million. As of September&#160;30, 2023, the Company is in<span style="background:#ffffff;"> compliance with all such covenants. </span>The Company believes that its cash and cash equivalents as of September&#160;30, 2023, are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2022 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2022.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Revenue recognition</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Revenues from selling products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery), at the net selling price, which reflects reserves for variable consideration, potential discounts and allowances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price is the consideration to which the Company expects to be entitled from the customer. The consideration promised in a contract with the Company&#8217;s customers may include fixed amounts and variable amounts. The Company estimates the variable consideration and includes it in the transaction price using the most likely outcome method, and only to the extent it is highly probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenues from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified two performance obligations in the Chiesi Agreements as follows: (i)&#160;the license and research and development services and (ii)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The manufacturing was contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license, research and development services. Following the regulatory approvals for Elfabrio received in May 2023, the Company started recognizing revenue from manufacturing, see also revenue from selling products above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue. Following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million (see also note 4).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services was recognized over time using the cost-to-cost method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi is recognized over time using the cost-to-cost method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services was recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the services.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nature Of Operations Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449557943152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,198</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,269</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449562082320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.49</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449563115152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Company's Disaggregation of Revenues</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,304</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,541</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,972</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,279</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,320</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,708</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,120</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,162</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,544</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,781</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,812</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,222</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,699</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,799</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449559698128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Stock Option Valuation Assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Weighted average grants date fair value (USD)</p></td><td style="vertical-align:bottom;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Exercise price (USD)</p></td><td style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="vertical-align:bottom;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 79.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected life (Years)</p></td><td style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449559408192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>EARNINGS (LOSS) PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Earnings (Loss) Per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:29.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(In&#160;thousands,&#160;except&#160;share&#160;data)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,852)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,567)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,187)</p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Add:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financial expenses of 2024 Notes*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,766)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,610)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net income (loss) for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,618)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,567)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,746</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,187)</p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares of Common Stock outstanding for basic calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72,281,681</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,498,105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65,811,506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,582,733</p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average dilutive effect of 2024 Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,500,998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,981,660</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average dilutive effect of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,247,115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares of Common Stock outstanding for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 83,782,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,498,105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81,040,281</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,582,733</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 10pt 54pt;">* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the period and inclusion of make-whole interest payments that will be incurred upon conversion.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449559408192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of Income Tax Expense (Benefit)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,728</p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,092)</p></td></tr><tr><td style="vertical-align:bottom;width:63.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 133</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 636</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449559296960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SupplementalInformationAbstract', window );"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SupplementaryBalanceSheetsInformationTableTextBlock', window );">Supplemental Information, Balance Sheets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,239</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,216</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest Payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 719</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,471</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,404</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,249</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,478</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 781</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,257</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 530</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reserve for deductions from revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,816</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 253</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 143</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,740</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,271</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementaryBalanceSheetsInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure for supplemental balance sheets information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementaryBalanceSheetsInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449552044240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 27, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 29, 2022</div></th>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 13, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 23, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 19, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 21, 2023 </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NumberOfGlobalLicensingAndSupplyAgreements', window );">Number of global licensing and supply agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NumberOfPatientsDosed', window );">Number of patients dosed | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,954<span></span>
</td>
<td class="nump">$ 4,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible Debt, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember', window );">ATM Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,980,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SaleOfStockMaximumOfferingPrice', window );">Sale of stock, maximum offering price</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtmEquityOfferingSalesAgreementMember', window );">ATM Equity Offering Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,296,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,560,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MaintainOfMinimumCashBalance', window );">Maintain of Minimum Cash Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember', window );">Amended Pfizer Agreement | Protalix Bio Therapeutics Incorporation | Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Collaborative Arrangement Revenues and Expenses Sharing Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember', window );">Chiesi Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MilestonePaymentReceived', window );">Amount of milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_RevenuePerformanceObligationNumber', window );">Revenue, Performance Obligation, Number | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AgreementAmendmentPaymentReceivable', window );">Agreement Amendment Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones', window );">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_FillFinishAgreementMember', window );">Fill/Finish Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ExtendedTermOfAgreement', window );">Extended term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember', window );">Chiesi US Agreement and Chiesi Ex-US Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable', window );">Non-refundable Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount payable to entity for the achievement of regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to the entity to cover development costs under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountsPayableToCoverDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AgreementAmendmentPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement Amendment Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AgreementAmendmentPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement revenues and expense sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CollaborativeArrangementRevenuesExpensesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ExtendedTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extended term  of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ExtendedTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaintainOfMinimumCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum cash balance required to be maintained under long term debt agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaintainOfMinimumCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payment received upon achievement of certain milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NumberOfGlobalLicensingAndSupplyAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of global licensing and supply agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NumberOfGlobalLicensingAndSupplyAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NumberOfPatientsDosed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of patients that were dosed in the trial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NumberOfPatientsDosed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the payment as a percentage of future net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenuePerformanceObligationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenuePerformanceObligationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SaleOfStockMaximumOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock, maximum offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SaleOfStockMaximumOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_UpfrontNonrefundableNoncreditablePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtmEquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_AtmEquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_FillFinishAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_FillFinishAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449561021136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Schedule of Inventory) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 4,198<span></span>
</td>
<td class="nump">$ 3,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">9,116<span></span>
</td>
<td class="nump">2,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods (drug substance and drug product)</a></td>
<td class="nump">8,269<span></span>
</td>
<td class="nump">10,618<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 21,583<span></span>
</td>
<td class="nump">$ 16,804<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449557546208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details) - 2024 Notes - Level 3<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares </div>
<div>Y</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Share Price.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input | $ / shares</a></td>
<td class="nump">1.66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input | Y</a></td>
<td class="nump">0.93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">5.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">62.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">Yield</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">12.49<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449557785600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Additional Information) (Details) - Level 3 - 2024 Notes<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt Instrument Carrying Amount</a></td>
<td class="nump">$ 20,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Debt Instrument Fair Value</a></td>
<td class="nump">$ 24,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449551940528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 10,345<span></span>
</td>
<td class="nump">$ 14,183<span></span>
</td>
<td class="nump">$ 55,008<span></span>
</td>
<td class="nump">$ 39,021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">10,168<span></span>
</td>
<td class="nump">8,812<span></span>
</td>
<td class="nump">30,309<span></span>
</td>
<td class="nump">21,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods | Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">2,304<span></span>
</td>
<td class="nump">4,541<span></span>
</td>
<td class="nump">7,972<span></span>
</td>
<td class="nump">11,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods | Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">2,320<span></span>
</td>
<td class="nump">1,708<span></span>
</td>
<td class="nump">5,120<span></span>
</td>
<td class="nump">7,162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods | Chiesi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">5,544<span></span>
</td>
<td class="nump">2,563<span></span>
</td>
<td class="nump">17,217<span></span>
</td>
<td class="nump">2,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 177<span></span>
</td>
<td class="nump">$ 5,371<span></span>
</td>
<td class="nump">$ 24,699<span></span>
</td>
<td class="nump">$ 17,799<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_ChiesiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_ChiesiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449550773664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK TRANSACTIONS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 10, 2023</div></th>
<th class="th"><div>May 08, 2023</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jul. 25, 2023</div></th>
<th class="th"><div>Jul. 24, 2023</div></th>
<th class="th"><div>Jun. 28, 2023</div></th>
<th class="th"><div>Jun. 27, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,000,000<span></span>
</td>
<td class="nump">185,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,000,000<span></span>
</td>
<td class="nump">144,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="nump">237,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueWarrantsExercises', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 712<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">712<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase common stock</a></td>
<td class="nump">845,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,954<span></span>
</td>
<td class="nump">$ 4,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">2006 Employee Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance under share-based payment arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,475,171<span></span>
</td>
<td class="nump">8,475,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Converted instrument, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,691,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentsToDebtHoldersOnConversion', window );">Paid to the converting holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DebtConversionDecreaseInPrincipalAmount', window );">Decrease in principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtmEquityOfferingSalesAgreementMember', window );">ATM Equity Offering Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,296,123<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,560,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtConversionDecreaseInPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of decrease in the total principal amount of debt due to conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtConversionDecreaseInPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentsToDebtHoldersOnConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to debt holders on conversion for accrued but unpaid interest, make-whole interest payments and payments in lieu of fractional shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentsToDebtHoldersOnConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtmEquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_AtmEquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449552049184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK TRANSACTIONS - Stock based compensation (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 29, 2023 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 14, 2023 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 15, 2023 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 28, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 27, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">2006 Employee Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance under share-based payment arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,475,171<span></span>
</td>
<td class="nump">8,475,171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">2006 Employee Stock Incentive Plan | Shares of restricted Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,371,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant', window );">Estimated fair value on date of grant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">2006 Employee Stock Incentive Plan | Shares of restricted Common Stock | Upon grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">2006 Employee Stock Incentive Plan | Shares of restricted Common Stock | Over a two-year period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements', window );">Vesting in number of quarterly increments | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">2006 Employee Stock Incentive Plan | Shares of restricted Common Stock | Over a three-year period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements', window );">Vesting in number of quarterly increments | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">2006 Employee Stock Incentive Plan | Options | Officers and other employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements', window );">Vesting in number of quarterly increments | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant', window );">Estimated fair value on date of grant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,056,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">2006 Employee Stock Incentive Plan | Options | Chairman, Board of Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements', window );">Vesting in number of quarterly increments | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant', window );">Estimated fair value on date of grant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">2006 Employee Stock Incentive Plan | Options | Non-executive directors other than Chairman</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements', window );">Vesting in number of quarterly increments | item</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant', window );">Estimated fair value on date of grant | $</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options to purchase shares</a></td>
<td class="nump">308,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 1.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the vesting of awards in number of quarterly increments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated grant date fair value of awards under share-based payment arrangement granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=plx_OfficersAndOtherEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=plx_OfficersAndOtherEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=plx_NonExecutiveDirectorsOtherThanChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=plx_NonExecutiveDirectorsOtherThanChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449561082256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK TRANSACTIONS - Schedule of Weighted average assumptions (Details) - Options<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average grants date fair value (USD)</a></td>
<td class="nump">$ 1.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (USD)</a></td>
<td class="nump">$ 1.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">79.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (Years)</a></td>
<td class="text">5 years 9 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449557833008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (1,852)<span></span>
</td>
<td class="num">$ (3,567)<span></span>
</td>
<td class="nump">$ 14,356<span></span>
</td>
<td class="num">$ (11,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecurities', window );">Financial expenses of 2024 Notes</a></td>
<td class="num">(1,766)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,610)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income (loss) for diluted calculation</a></td>
<td class="num">$ (3,618)<span></span>
</td>
<td class="num">$ (3,567)<span></span>
</td>
<td class="nump">$ 12,746<span></span>
</td>
<td class="num">$ (11,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of Common Stock outstanding for basic calculation</a></td>
<td class="nump">72,281,681<span></span>
</td>
<td class="nump">49,498,105<span></span>
</td>
<td class="nump">65,811,506<span></span>
</td>
<td class="nump">47,582,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Weighted average dilutive effect of 2024 Notes</a></td>
<td class="nump">11,500,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,981,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Weighted average dilutive effect of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,247,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of Common Stock outstanding for diluted calculation</a></td>
<td class="nump">83,782,679<span></span>
</td>
<td class="nump">49,498,105<span></span>
</td>
<td class="nump">81,040,281<span></span>
</td>
<td class="nump">47,582,733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsAndWarrantsMember', window );">Outstanding Stock Options And Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">19,429,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,399,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsWarrantsAnd2024NotesMember', window );">Outstanding Stock Options Warrants And 2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,922,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,295,154<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2029-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsWarrantsAnd2024NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsWarrantsAnd2024NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449551920832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>May 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current taxes on income</a></td>
<td class="nump">$ 95<span></span>
</td>
<td class="nump">$ 3,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred taxes on income</a></td>
<td class="nump">38<span></span>
</td>
<td class="num">(3,092)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total taxes on income</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">$ 636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MilestonePaymentToRegulatoryApprovals', window );">Milestone Payments to regulatory approvals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance related to deferred tax assets</a></td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MilestonePaymentToRegulatoryApprovals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the milestone payments to regulatory approvals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MilestonePaymentToRegulatoryApprovals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449553356640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals - other:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related expenses</a></td>
<td class="nump">$ 1,239<span></span>
</td>
<td class="nump">$ 1,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest Payable</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Provision for vacation</a></td>
<td class="nump">1,471<span></span>
</td>
<td class="nump">1,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">9,249<span></span>
</td>
<td class="nump">7,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties payable</a></td>
<td class="nump">332<span></span>
</td>
<td class="nump">781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income tax payable</a></td>
<td class="nump">3,257<span></span>
</td>
<td class="nump">530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ReserveForDeductionsFromRevenueCurrent', window );">Reserve for deductions from revenue</a></td>
<td class="nump">2,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent', window );">Property and equipment suppliers</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable and accruals - other</a></td>
<td class="nump">$ 18,740<span></span>
</td>
<td class="nump">$ 12,271<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ReserveForDeductionsFromRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of reserve for deductions from revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ReserveForDeductionsFromRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140449550761648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 15, 2023 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 04, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Chiesi Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ProceedsFromSaleOfProducts', window );">Proceeds From Sale Of Products | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Stock Options | New officer | 2006 Employee Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options to purchase shares | shares</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 1.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements', window );">Vesting in number of quarterly increments | item</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOnDateOfGrant', window );">Estimated fair value on date of grant | $</a></td>
<td class="nump">$ 260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromSaleOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of proceeds from sale of products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromSaleOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the vesting of awards in number of quarterly increments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOnDateOfGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated grant date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOnDateOfGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>plx-20230930x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:plx="http://www.protalix.com/20230930"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="plx-20230930.xsd" xlink:type="simple"/>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_mfC9kUaxCUWkEdReEq0g8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtmEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MD0IJnJslU6DgpIpslYWHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nImxNodwz0S5hDYBFYIz4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_J6U7oUvVYE-mVxaE0p0afA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_U0vvCuWzP0ObL95ACk6iGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ljE3QYELHUKaEWcB1Rf2BA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jJqKna28f0aNpKm3h9LebQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DpbxB34Toka6ZMB06mjkFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZG9OKwFgA0KmxShrccpWnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_whHKsJQCKUCuIHXPg4Ju7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hThUOSh2DEu8b-5DZ4GtMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TvqjevVyaU2E1PYtpATXHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_qEv4_s2oRkuGKBh0bBdY8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RSrC8ujTNE-EKKHgIJyQfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mlxdQ7onNUCEQtHYpxTeEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6VRsvwfuMUqcCJm_5O_Dig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kSgL5r7c3k-B0VAIxyKmAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3RZ-bdtfs0CiBzoZ1x2umw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FCS-baPkIkmVTzMkLUh60g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uJvKLP-QfUi47f7FK9xAAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-2ASuQfAFkaEwmIK1OCojg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_28_2023_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_VafRBM-KXUKE9nl21SfoWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-28</instant>
        </period>
    </context>
    <context id="As_Of_6_27_2023_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_WfHmnalC9keIkorDt44VZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-27</instant>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_F7acgBp0NEaoQj7JasNEtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_n9IBOPzcQEm-_TNOT65ZwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="Duration_8_15_2023_To_8_15_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_IPgkJRT2mUmlR7n5uxuhBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-15</startDate>
            <endDate>2023-08-15</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_sVnDgezrHka5Dw8PspQs3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_ZO1PgNYXMEuC--7AWaeWEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_eB0Q82DpoUe8I_AVASAV5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_Lo8_JpbjYUCk7biQuAf2Cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_3i3mFrnEFE2XxVcL7eIj9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_nJExY4OnmUmt1WUuJLndIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_-Z5nFPVF50-Y_QNXqgvqxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_UWm8Okbu-EqlxDiNTSf2Zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_ZRFZeNwM3kOgwL_HZhzgeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_1lopoDCmBESgKQUfzzjJoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_tKo7RTZIJ0G9Lb7VY5FW9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_c26sRwH14EOOXdDcKHSfXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_54yhJyQsfUWr69wXcncDRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_isIRGT_PckWgKUstJZEmKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_FPM1y3Bjl0Gc-RAt1yp0Fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_iH38GCBvckuT-5RWJRmh4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_UZ9M3vS4pUmQfa--0rmbMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_nYCRV7igxEO8F_DL0WaJTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_r2IxwFzzbEK8WGh9RQOkuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_403rz0Wpzk6dQXNU5Z2R7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_5_8_2023_To_5_8_2023_LWrHj6ICi0aqDBWvUoRhNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2023-05-08</startDate>
            <endDate>2023-05-08</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_TBP-Nxi6xkSucxKQEfEKFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtmEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_bcEsWzSIKk6tSkX7LMh0hQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_mvxv3O6LxEaaJFEPDGVkrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtmEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Ky9hROQdhEKplEsRyyjknA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_smFmNjh_GkaF3ZVKa76X_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Pdy3Pw8g706hDOOxHjfOfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_U2kNPoY9pkW-TRdA8PGoWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_uB6aVsBg6EaCcs-hRuTW_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_bez3doxPHEy6nArxyu-5WA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_X09KFdeVa0mgHlIW0IelcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_tTdbaH9LGEq9pS4VzhrCSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_G4UyzvxD9UiRqqT-Li8wCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_h7Ke6bk0e0aU5lPXoIrMVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_kgA--Gd-2UWeFMP4kZXqwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_7_25_2023_edYzzPajLkGQMaRQZP-YaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-07-25</instant>
        </period>
    </context>
    <context id="As_Of_7_24_2023_9kwXDECmXUmLqJV4f95MAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-07-24</instant>
        </period>
    </context>
    <context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_ABTzvay3O0OZCuw98-XbeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="As_Of_5_10_2023_EgRr_kLVqEarxsyOSeb0Ng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_NdH__egkDk-gnw4KdsuuTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_WSd24FsHlEmdwHxFiK3fWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_7EmATnfMK0aTY5iMdjV79w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_3o-LEw18Kkyl1N3FcZEEcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_c1_YEps6pEOYi4wGlehl0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsWarrantsAnd2024NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_gylvzioUakSqiKwd3I9tug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsWarrantsAnd2024NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_cbS2-pmOL0Kpi-J5rXA22Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_LKZh0o6NGE2MzvbfP03xRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_ALka6XKZRUmdNKQ5DKH7HQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_QE-SblqY_067QtFhhF2IPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_86JU9iqNeUK_xkPVKBXLAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_Nmsn3P7UYUW6XcC0gH1dFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_wDkN_aLVuk6lqFu3E0NlpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_CbDm0MJU2kKR-xAL6zKx2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_sY47uYJaBUyZAjhmKmp6Ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_Xy3Mpk_8mkmNehLbu6bpWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_u97-niTANECYjZrKdF99Mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_SzhiOOTJqkimQ5q3bMRpYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_c_DS6CF9IUONf5DnuePWGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-23</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_I0f7iY_hoUWDw20FCFX8EQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="Duration_5_10_2023_To_5_10_2023_uEkJTuuYLE2tgKefXtN0Mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2023-05-10</startDate>
            <endDate>2023-05-10</endDate>
        </period>
    </context>
    <context id="Duration_5_8_2023_To_5_8_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_aZyevVDxgUeUldAkpXak_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-08</startDate>
            <endDate>2023-05-08</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hlJfBq7xHUuJTVElf5mZ9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WbDaBJULK0-Dh7pEyOjn7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4ubTKPzTYUaZJP68MFh1aA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_74hbg6s0YUGMZEgtc7zlCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EHdJ5Zm9dUSQMKgSd6xQEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PdQzi6Bi4kqkEATH0PHmyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bKsEqv1Q706_PDc9XAYvmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gbkRzHwbyku8_AQoT0Dllg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_8_15_2023_To_8_15_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_fMPAZxDZF0CjT3jIiJlVWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-15</startDate>
            <endDate>2023-08-15</endDate>
        </period>
    </context>
    <context id="Duration_10_15_2023_To_10_15_2023_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_8Dni7RhDUkWYV5S6kg5TFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-15</startDate>
            <endDate>2023-10-15</endDate>
        </period>
    </context>
    <context id="Duration_9_29_2023_To_9_29_2023_srt_TitleOfIndividualAxis_plx_NonExecutiveDirectorsOtherThanChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_Bq1ATcIXikWWLcA2fkgW1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:NonExecutiveDirectorsOtherThanChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-29</startDate>
            <endDate>2023-09-29</endDate>
        </period>
    </context>
    <context id="Duration_9_14_2023_To_9_14_2023_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_hR8IXrLXFkKqN26E-oWJTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-14</startDate>
            <endDate>2023-09-14</endDate>
        </period>
    </context>
    <context id="Duration_8_15_2023_To_8_15_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_yKs6Fnw-ukqovfuD-GaUEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-15</startDate>
            <endDate>2023-08-15</endDate>
        </period>
    </context>
    <context id="Duration_8_15_2023_To_8_15_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_dHfFwQNMk0elAnvVrjK_Aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-15</startDate>
            <endDate>2023-08-15</endDate>
        </period>
    </context>
    <context id="Duration_8_15_2023_To_8_15_2023_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member__6-TI0LU8kycGOjbjujtRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:OfficersAndOtherEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-15</startDate>
            <endDate>2023-08-15</endDate>
        </period>
    </context>
    <context id="Duration_2_27_2023_To_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_z_3UoywC8ECDn2BmWvhnnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-27</startDate>
            <endDate>2023-02-27</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_IZYUYcpDQ0W3wVn53D7jkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_FE-7EpG9IkW88m9UfwwG6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_eoOa9SWffEiVP049zeIqSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="Duration_10_4_2023_To_10_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_4Sfq-5ZsukC6Bl13MlMlcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-04</startDate>
            <endDate>2023-10-04</endDate>
        </period>
    </context>
    <context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_etzFjnmIFkqSQ8Z9LeDedg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-23</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_DKlLQr64h0q6S5laUAGccw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-23</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3JKpw53nwkGDyDlVTy2Gxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-19</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_GHWT0ykNeEuO1RlIzpZFhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-19</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="As_Of_3_21_2023_59uxaENwDEeis1uswurdAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-03-21</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2023_Qhp5my5CU0-pA3CT50IRVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_iN4jeRGThUGJ9_j3XbAknA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_ONDNURLUTUKjjQ_0xrpP0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_FillFinishAgreementMember_sD-xmdGPaE-ij5-ExlU3kQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:FillFinishAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-29</startDate>
            <endDate>2022-08-29</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_IsSkHrMXCEC808Zd6VbjIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_-xsCF2uYFkqT5zfBjQzLVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_GERNj3wXEUWT0EvS1LtJJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-13</startDate>
            <endDate>2021-05-13</endDate>
        </period>
    </context>
    <context id="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_jp1gAPcWdUq4GpRSn43eoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-13</instant>
        </period>
    </context>
    <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_rCjFnyR3fEa9cw5ekQ7pew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-23</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_WBsGH7Src0eGVZCrXqiz2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_1_2023_ZRHeL0WBLUyknbdyhuAyuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-11-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_agreement_lKNqKU4rvUupTelfJQIVSg">
        <measure>plx:agreement</measure>
    </unit>
    <unit id="Unit_Standard_item_dyUGGngOZEG007onwpOmGw">
        <measure>plx:item</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_Y_P_CRw8WyjU2VbFabIi54IQ">
        <measure>plx:Y</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      id="Hidden_79k0Fym550W0XRd-zx53gA"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      id="Hidden_xNypmcKgj0C0KYr8pGJEbg"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tc_lim12hmlr0yO4bbBAxN6vQ_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tc_6_nxbeMHhkePJf8skc3bmg_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tc_cs6Iw2Gn1ECTFQKhDW1-MA_4_1">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tc_TAxD6bvyU0i0MVQjYykgoQ_5_1">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tc_7YbUXHEyFkepLoLneQ38cQ_6_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Narr_ZpFnWfF6cE6fwGvkJfBykg">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Narr_PxlshRZarUGWC4rlaGSsLA">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Narr_w4aayxutKUaa_dqFqjJaKA">2023-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Narr_y71JFQkYw0SeIHZZA9Ev8A">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Narr_e7a2Z01ykE2UZ-bVELFYZw">001-33357</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Narr_UBL0kfTlyUeNlMe1UDV-rQ">PROTALIX BIOTHERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tc_9hwcn1E8lEagnpaOJAz-RQ_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Narr_bptRBvqH1USQD5qs_NnVyw">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Narr_wexkwzhIgk2o3ck7sGbxaw">2 University Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Narr_Y2NYpVKtm0-1zi-Ylg5otg">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Narr_flN6S65QNEeBr77E6vkwQQ">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Narr_3_UeUeHndEGhSl3qrUsSBA">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tc_-3zbPnBDv0OjViqPVWk4kA_4_1">07601</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Narr_rzuwY_6Aiki3WeS3N3OoVw">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Narr_yBsYCQRfjkyh5wBLEeHfxA">696-9345</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tc_Eqjs6imuyUK25zuvY77zLg_2_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tc_BOL-1IYTtkyLjFzAiHlL3A_2_2">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tc_L-Jv3dR0KkSdFtUP4j2hMw_2_4">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Narr_3UfJ2hItykGYRvrVgqL8mA">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Narr_qzGpodYTBkaj3you556Dqw">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tc_ZiGRgJgZME6ROfgwehHwJA_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tc_IYwtrOjOPkG9Oz9EtioTpA_2_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tc_BVdYJOZXQEuGrYnejeyOYQ_3_3">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Narr_0A1lwhLFgEmn2pUiUpo9PA">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_11_1_2023_ZRHeL0WBLUyknbdyhuAyuw"
      decimals="INF"
      id="Narr_4NzGzAX6FEqbBakMcGQg2Q"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">72952124</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_2ykBFYDYY0Cj7RqZHL8XOw_6_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">20408000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_4vvueeMnlUSeBCRN5y46Fg_6_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">17111000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <plx:ShortTermBankDeposits
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_C9nRA2sND0-0aNpLmu3Tug_7_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">20567000</plx:ShortTermBankDeposits>
    <plx:ShortTermBankDeposits
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_IyXiNlfNnUetvA2t3y6QDw_7_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">5069000</plx:ShortTermBankDeposits>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_8m_B89z5V0KDNxul0let0Q_8_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">8935000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_6blqH6z2LUqZwARX4RxTkQ_8_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">4586000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_6OH4LcU3Sk-3rcOHufNfxQ_9_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">1125000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_hWYLTKIUbUmOcDpri-9GYQ_9_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">1310000</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_MKRBUH2_SEW8dFImeooZZg_10_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">21583000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_PQdRZPT8KESgfkA7Epw85g_10_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">16804000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_l-qnNJgVoUSBCn-IV7DIiw_11_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">72618000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_EthWUNrYG02eNDfOaNmo0g_11_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">44880000</us-gaap:AssetsCurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_-Dly0AwAOEObCccrBTZMnw_14_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">1260000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_DNR9VkowU0GyYI2c9ZBWtw_14_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">1267000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_v0jSl0chxkO-vdQE106SfA_15_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">4684000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_AOX8OawzskWpC2DAN_VWww_15_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">4553000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_PdrWYQ2L20CxsVBEorLGQg_16_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">3092000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_HWWbvjMDG0Se7B7l4Y_bIw_17_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">5915000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc__qKeSUqhfkyuuE3-EOUOOA_17_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">5087000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_Q_ucWSm6ukyPn5158R1Ufg_18_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">87569000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_D7Yekxy0wUW4KAAbRdofdg_18_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">55787000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_BRws_jzyb0S4ljWdwW_JCg_24_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">3114000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_5tsyBIapXUy7EYQY8ZDtTQ_24_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">5862000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_hbzUmCqYEEy2Gm0M34vNcA_25_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">18740000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_AJ5Z2UgL3E-PErfQh7badQ_25_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">12271000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_pFxWfUN1SkuPj8tkrGbjJQ_26_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">1313000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_GOdbQ3DcqEKml7EY5nuWAw_26_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">1118000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_y7nYbOVceUWce3-ViqSW3g_27_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">13178000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_u50XKh0IxkWFJmdYdG5frQ_28_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">20192000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_NGbR8NIoDEuSETS56q8boA_29_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">43359000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_ozWhHhQJxUiE9l-f5x1oLw_29_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">32429000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_1uqgtlemMk-mmzmcVTvXoQ_32_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">28187000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_atigZGIHj0y9_MXha8aM3A_33_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">1461000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc__lrQqySaLUmo1v1ggjfbVg_33_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">1642000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_JjYJagKwD0OmbKg3OhPthA_34_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">4502000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_nmWg4ugYT0-wDSNUUJb4hQ_34_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">4169000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_cKLgcak4VkCOhLGzvioSpg_35_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">5963000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_lHUuVvvLgEaKrz1Fb261-A_35_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">33998000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_CjiTkpv1pkGfOLy4zejncw_36_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">49322000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_nCZR-v2gakChsBSHHb0yBQ_36_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">66427000</us-gaap:Liabilities>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_DDCo6UdOGUeSBLdXOcXzHA_40_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">38247000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_jeu12nV8UEydE6MaoVAx-A_40_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-10640000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_JFk7VA_SCkGH-TB-sUbaNQ_41_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">87569000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_JFx0IpEpW0qmzFjGTT7QLw_41_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">55787000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_ZRFZeNwM3kOgwL_HZhzgeQ"
      decimals="-3"
      id="Tc_bkPXmefXuEibjQiEZoWjcA_3_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">30309000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_r2IxwFzzbEK8WGh9RQOkuQ"
      decimals="-3"
      id="Tc_pIxvtS6LZUes6JQYgAQtEQ_3_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">21222000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_Lo8_JpbjYUCk7biQuAf2Cw"
      decimals="-3"
      id="Tc_vLjTt5XNGUC0NExGjiHqmw_3_9"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">10168000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_isIRGT_PckWgKUstJZEmKA"
      decimals="-3"
      id="Tc_8WTby3rt4EOvbWwvWMIuog_3_12"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">8812000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_1lopoDCmBESgKQUfzzjJoA"
      decimals="-3"
      id="Tc_uDbIPMNj70GW20WBBZ17Iw_4_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">24699000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_403rz0Wpzk6dQXNU5Z2R7w"
      decimals="-3"
      id="Tc_MCeYHn4n0kavf-QBOhUjUg_4_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">17799000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_3i3mFrnEFE2XxVcL7eIj9g"
      decimals="-3"
      id="Tc_izVWE8fcH0qNEeFs30ErKw_4_9"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">177000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_FPM1y3Bjl0Gc-RAt1yp0Fw"
      decimals="-3"
      id="Tc_rpk0b4maj0eeNd56iFXorA_4_12"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">5371000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_-5uDFLQTIECA0c63b4m1Kg_5_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">55008000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_qciJ_4R0HEK0Btde43MdUg_5_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">39021000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"
      decimals="-3"
      id="Tc_N26z-awyA0Ollv4aZSFSGg_5_9"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">10345000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q"
      decimals="-3"
      id="Tc_NET1dlW5xkSITkc0ZqafXw_5_12"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">14183000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_G0ODR8Y4jkmKMtpr632bPA_6_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">14126000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_8wtWJciV8kmbYLH3-slgtA_6_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">17195000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"
      decimals="-3"
      id="Tc_-7kbwyUL10qShnyaYOvqvg_6_9"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">4893000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q"
      decimals="-3"
      id="Tc_c34c36I-G0S88s1ziCq9og_6_12"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">7074000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_y6Oll5Og3kOBM7CsL9ePzg_7_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">13991000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_vtrKcBIMm0S36Zv8et0UtA_7_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">23732000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"
      decimals="-3"
      id="Tc_T8ohq58km0y3V14t17cmZA_7_9"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">3669000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q"
      decimals="-3"
      id="Tc_Wb3u-4rnKkun54FaHGKbGg_7_12"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">7386000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_JDDF75sBRkyjOTbTIkA6qg_8_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">10816000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_ohkn7emcLUW77GJO-hPiMA_8_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">8613000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"
      decimals="-3"
      id="Tc_myGHGQWRZEKv8Cpthrqxyw_8_9"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">3670000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q"
      decimals="-3"
      id="Tc_LFDGdqGoaEmMTMxTxEiR8w_8_12"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">2848000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_ibHFDZ5hskqP9bA8KMo8lA_9_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">16075000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_D-27XZ_2DEe_G3QD11YhVw_9_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-10519000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"
      decimals="-3"
      id="Tc_O6ufI-r1_Um_mVWb_qY27Q_9_9"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-1887000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q"
      decimals="-3"
      id="Tc_sZVTuhY8gkK6xNUvqrxfvw_9_12"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-3125000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_RWJw44NyR0qKrh_qKBYy6Q_10_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">2406000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_r3F_3UfQYEuZmgz10bThJA_10_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">1879000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"
      decimals="-3"
      id="Tc_bg9LZkm_rUeyFb3QwmXADg_10_9"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">460000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q"
      decimals="-3"
      id="Tc_o6UHZ1vdZkqgVeJ3CPUHMA_10_12"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">639000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_RXONl4hfYk2ObVYDxL-VvQ_11_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">1323000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_rDEFPKo-I0-uz8LnhIYLQw_11_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">1211000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"
      decimals="-3"
      id="Tc_xuIZVA0EhESMs9n3NV5nRg_11_9"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">628000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q"
      decimals="-3"
      id="Tc_DSKLidnI60eucOiC1LU9Cw_11_12"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">197000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_MwfvH9US70Wwuz8kd79f9w_12_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-1083000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_WzFZl7moP06BeP76Qe5xXw_12_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-668000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"
      decimals="-3"
      id="Tc_OQCSqqUkxkqiEF5rTkQPow_12_9"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">168000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q"
      decimals="-3"
      id="Tc_Stth-RilaUGmClT3HyEh-A_12_12"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-442000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_HOW3csPwEEmWfUaiEzb22Q_13_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">14992000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_CndD8q-t7kiH1HMepnQj-A_13_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-11187000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"
      decimals="-3"
      id="Tc_SvLvsUAIjUmKWyDRIlc1Dw_13_9"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-1719000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q"
      decimals="-3"
      id="Tc_ZAgw8_ol2E-31x5Xq8wYiw_13_12"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-3567000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_wnkALPTav0ul7UySDGs4Mw_14_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">636000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"
      decimals="-3"
      id="Tc_4td0wPqyP0WhnzaP3Upjrg_14_9"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">133000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_uua0KxnzZ0CEXmrKHABvew_15_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">14356000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_hSyc2IPGEUKfPBzV_dI4KA_15_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-11187000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"
      decimals="-3"
      id="Tc_DyarZOSjvkuh_QYVAqCHNQ_15_9"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-1852000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q"
      decimals="-3"
      id="Tc_80BADIf6lE29QeBL1YZBDw_15_12"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-3567000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="2"
      id="Tc_VE_wjBhubUOmOGIL9RCPAA_17_3"
      unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg">0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="2"
      id="Tc_GXzedqLkR0yuinujo6eyhA_17_6"
      unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"
      decimals="2"
      id="Tc_tcIalq7EYEylMJLta1Dqmg_17_9"
      unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q"
      decimals="2"
      id="Tc_d-onVhQFc0KqE1JEHtBHFg_17_12"
      unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg">-0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="2"
      id="Tc_k3ctnbG_FkSWV9wSrHzsFg_18_3"
      unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg">0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="2"
      id="Tc_ynYXQAGJC0-en-6mU2yk9Q_18_6"
      unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"
      decimals="2"
      id="Tc_87mD3-06cEyDrT0l-A7NDw_18_9"
      unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q"
      decimals="2"
      id="Tc_yWMpeoT8fESx5QTvCf_43w_18_12"
      unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg">-0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="0"
      id="Tc_88836MAH30WSJ6HwR20hLQ_21_3"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">65811506</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="0"
      id="Tc_EJzKW6sNaUSgvqTxgNNLRw_21_6"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">47582733</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"
      decimals="0"
      id="Tc_qTGAKch9EEywniE1goMfhg_21_9"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">72281681</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q"
      decimals="0"
      id="Tc_hZYkntesxU-_dOni6gudhw_21_12"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">49498105</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="0"
      id="Tc_GnpiwWUZUkWR76IdMa-OFw_22_3"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">81040281</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="0"
      id="Tc_P1iFhxdNHk6v3gnjVqdJeA_22_6"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">47582733</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"
      decimals="0"
      id="Tc_P2jcjZ1BZUWCa1Jh_V-z0g_22_9"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">83782679</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q"
      decimals="0"
      id="Tc_60r4bbq0dkOkN6Y4f1bpLA_22_12"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">49498105</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_Nmsn3P7UYUW6XcC0gH1dFw"
      decimals="-3"
      id="Tc_aNBMHY7EskGcS2Na-VKyww_23_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">299000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_SzhiOOTJqkimQ5q3bMRpYg"
      decimals="-3"
      id="Tc_4C-eO2ELpE2-Cd5TPfc2DA_23_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">58000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_ALka6XKZRUmdNKQ5DKH7HQ"
      decimals="-3"
      id="Tc_VTgwaxq8_0CappJBI9NjIA_23_9"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">195000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_sY47uYJaBUyZAjhmKmp6Ug"
      decimals="-3"
      id="Tc_UUplnK6KOkq9Ru4zV7_ZHg_23_12"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">36000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_86JU9iqNeUK_xkPVKBXLAQ"
      decimals="-3"
      id="Tc_qvxW8X5DL0CaLdzFflIEOQ_24_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">506000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_u97-niTANECYjZrKdF99Mw"
      decimals="-3"
      id="Tc_quwWFSbGYEug0PlB4BcKwA_24_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">275000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_LKZh0o6NGE2MzvbfP03xRg"
      decimals="-3"
      id="Tc_sOQN3ZK-U0iig1vu1IqHxA_24_9"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">182000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_CbDm0MJU2kKR-xAL6zKx2A"
      decimals="-3"
      id="Tc_StRVhKVrBUyqDvPDioOXjg_24_12"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">114000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_QE-SblqY_067QtFhhF2IPw"
      decimals="-3"
      id="Tc_nWwC0MMkc0aCPQt4dTDo3A_25_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">1276000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_Xy3Mpk_8mkmNehLbu6bpWg"
      decimals="-3"
      id="Tc_vObSNit_qUeZYZkSTYJSEg_25_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">1213000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_cbS2-pmOL0Kpi-J5rXA22Q"
      decimals="-3"
      id="Tc_TzWL1ozZVUuXQrPL9AtF7Q_25_9"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">720000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_wDkN_aLVuk6lqFu3E0NlpA"
      decimals="-3"
      id="Tc_BUV-PafmpE6_lr8al_b1uw_25_12"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">272000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-2ASuQfAFkaEwmIK1OCojg"
      decimals="INF"
      id="Tc_J0Q06cNZT0aJQvKE4KrnZg_6_2"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">45556647</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-2ASuQfAFkaEwmIK1OCojg"
      decimals="-3"
      id="Tc_35s4mwejOkuxbATc6E_lPg_6_5"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mlxdQ7onNUCEQtHYpxTeEw"
      decimals="-3"
      id="Tc_U4bjFrxj-UaBT5DjPYWZNg_6_8"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">368852000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RSrC8ujTNE-EKKHgIJyQfQ"
      decimals="-3"
      id="Tc_i-KyUgoPFUikcLYKrbDovg_6_11"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-374934000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_WSd24FsHlEmdwHxFiK3fWQ"
      decimals="-3"
      id="Tc_no3FLywtk0yZZrY0k19pWA_6_14"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-6036000</us-gaap:StockholdersEquity>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WbDaBJULK0-Dh7pEyOjn7g"
      decimals="INF"
      id="Tc_Xmtr-8UVh0W8zZUKbrcCNg_8_2"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">3841479</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WbDaBJULK0-Dh7pEyOjn7g"
      decimals="-3"
      id="Tc_LvcEcxjT4UeMFGeymTdmgQ_8_5"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">4000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gbkRzHwbyku8_AQoT0Dllg"
      decimals="-3"
      id="Tc_FpTSStsomEupyKyGaH4WnQ_8_8"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">4157000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_xeB_wNXVwEWwFrr9kIpPZA_8_14"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">4161000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gbkRzHwbyku8_AQoT0Dllg"
      decimals="-3"
      id="Tc_BZJwvzWAREi4tmnXqGWW8A_9_8"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">592000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_e5xgTP8wTEilVk0lVT0_CA_9_14"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">592000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WbDaBJULK0-Dh7pEyOjn7g"
      decimals="INF"
      id="Tc_3ak7Ebjw5kG6Kyjj5L8Eqg_10_2"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">759482</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gbkRzHwbyku8_AQoT0Dllg"
      decimals="-3"
      id="Tc_I7LAvUaQBkK23jCVLjmuOw_10_8"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">954000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_Z8Bz7x11a0OFJbV3nXQ3qA_10_14"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">954000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WbDaBJULK0-Dh7pEyOjn7g"
      decimals="INF"
      id="Tc_70Fh3FgfJ0i1a7pZPnjd4Q_11_2"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">1000</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gbkRzHwbyku8_AQoT0Dllg"
      decimals="-3"
      id="Tc_F26x8WeRPkGIOY6N2IgpLA_11_8"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">2000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_HtijywFhD0OfpPFozYJAow_11_14"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">2000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_U2kNPoY9pkW-TRdA8PGoWw"
      decimals="-3"
      id="Tc_3DyKCgbPCUOVY8UTEeLQBA_12_11"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-11187000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_NIMHf3M2aECaMjeSv2WYWA_12_14"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-11187000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FCS-baPkIkmVTzMkLUh60g"
      decimals="INF"
      id="Tc_XGzOlH__60G7j3Mh5UicPQ_13_2"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">50158608</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FCS-baPkIkmVTzMkLUh60g"
      decimals="-3"
      id="Tc_aBwuRKQFPUOf_heS0d6X8w_13_5"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">50000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_whHKsJQCKUCuIHXPg4Ju7Q"
      decimals="-3"
      id="Tc_0TWqUbcwhUm7hhuUo_X7zA_13_8"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">374557000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZG9OKwFgA0KmxShrccpWnA"
      decimals="-3"
      id="Tc_9vZm-_rbvEypHNB-i80mug_13_11"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-386121000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_NdH__egkDk-gnw4KdsuuTw"
      decimals="-3"
      id="Tc_upNsvEL-HEaqocD4Lwnakw_13_14"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-11514000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3RZ-bdtfs0CiBzoZ1x2umw"
      decimals="INF"
      id="Tc_1eTA6uTMHkyR3m-Xxn97EQ_14_2"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">53790167</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3RZ-bdtfs0CiBzoZ1x2umw"
      decimals="-3"
      id="Tc_fP9tdGw5v0eerzTPJEF1Kg_14_5"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">54000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DpbxB34Toka6ZMB06mjkFw"
      decimals="-3"
      id="Tc_CBJGpSbQP0Sgg3lfqm4gfA_14_8"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">379167000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jJqKna28f0aNpKm3h9LebQ"
      decimals="-3"
      id="Tc_eelVxSZJtkW_B1F0RaSBWA_14_11"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-389861000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_eObqsVs3EEm6SEgGzsrHhA_14_14"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-10640000</us-gaap:StockholdersEquity>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EHdJ5Zm9dUSQMKgSd6xQEQ"
      decimals="INF"
      id="Tc_UwQx0fb9LkSfPmBHKpezKQ_16_2"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">12560150</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EHdJ5Zm9dUSQMKgSd6xQEQ"
      decimals="-3"
      id="Tc_F0XKuP22REebgjnMSc4pzQ_16_5"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">13000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PdQzi6Bi4kqkEATH0PHmyQ"
      decimals="-3"
      id="Tc_D7_pNsjF90qa4tE3ox6wbA_16_8"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">23941000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_cPCBqzzwTEKMA0ojPpz4ow_16_14"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">23954000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EHdJ5Zm9dUSQMKgSd6xQEQ"
      decimals="INF"
      id="Tc_zHYnQE3siUSd8cZtbB4jMQ_17_2"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">4691623</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EHdJ5Zm9dUSQMKgSd6xQEQ"
      decimals="-3"
      id="Tc_cO6bR__IRU-bvMAoYnDczg_17_5"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">5000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PdQzi6Bi4kqkEATH0PHmyQ"
      decimals="-3"
      id="Tc_CJH7qSiYFU6x8x1itIalbw_17_8"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">7778000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_giP-OWbc6UCQAi7g5ZHftw_17_14"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">7783000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PdQzi6Bi4kqkEATH0PHmyQ"
      decimals="-3"
      id="Tc_3-M9PsR6OEa7fSG3BVAF-w_18_8"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">1195000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_iIQR50Z9xUa_mMqkfVEzDA_18_14"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">1195000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EHdJ5Zm9dUSQMKgSd6xQEQ"
      decimals="INF"
      id="Tc_9yhZrR-b-EGqxOFYn_g5Nw_19_2"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">1371362</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EHdJ5Zm9dUSQMKgSd6xQEQ"
      decimals="-3"
      id="Tc_A-OywiQSm0SYADlahtz2Rg_19_5"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">1000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PdQzi6Bi4kqkEATH0PHmyQ"
      decimals="-3"
      id="Tc_S9FmsJvGgEC8MI5XO3sJUw_19_8"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">886000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_6ouDkmIGiUCAN6nj2YvdVA_19_14"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">887000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_EHdJ5Zm9dUSQMKgSd6xQEQ"
      decimals="INF"
      id="Tc_b7Y7BJIK3UedTfkl07xmNQ_20_2"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">538822</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PdQzi6Bi4kqkEATH0PHmyQ"
      decimals="-3"
      id="Tc_FnhUFhjo60WdAvXPeKRpOQ_20_8"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">712000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_earkpNbLQEWV0SKNpZsfqA_20_14"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">712000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_smFmNjh_GkaF3ZVKa76X_A"
      decimals="-3"
      id="Tc_rwe9wrnP_UmLLu7Q_Qnf0Q_21_11"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">14356000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_SOMWVQXGWEqPJMn_qiDKEw_21_14"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">14356000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6VRsvwfuMUqcCJm_5O_Dig"
      decimals="INF"
      id="Tc_UnYL-Dklw0Oi5ZpVIu_wxw_22_2"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">72952124</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6VRsvwfuMUqcCJm_5O_Dig"
      decimals="-3"
      id="Tc_REaFJNl8YkKyEZeUOwtvUw_22_5"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">73000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nImxNodwz0S5hDYBFYIz4A"
      decimals="-3"
      id="Tc_MmlChRLf_0mzxj_YPlJvfQ_22_8"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">413679000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MD0IJnJslU6DgpIpslYWHw"
      decimals="-3"
      id="Tc_idWd9dITdU6O85KFl3JDzA_22_11"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-375505000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_gt8BScB2fEiq7Iu4e7A9vQ_22_14"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">38247000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uJvKLP-QfUi47f7FK9xAAQ"
      decimals="INF"
      id="Tc_Bvi01VlUckODSjGL09xVuQ_23_2"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">48712952</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uJvKLP-QfUi47f7FK9xAAQ"
      decimals="-3"
      id="Tc_urvyISw19Ei6qHCMYZk3ZQ_23_5"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">49000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TvqjevVyaU2E1PYtpATXHQ"
      decimals="-3"
      id="Tc_TsLmszYby0C9TA1bVRPwvg_23_8"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">372616000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hThUOSh2DEu8b-5DZ4GtMg"
      decimals="-3"
      id="Tc_qC0vCn4mTESY_Lf0wWMk8Q_23_11"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-382554000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_qEv4_s2oRkuGKBh0bBdY8w"
      decimals="-3"
      id="Tc_gOzXNbH78E2mWZmVK2EcBA_23_14"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-9889000</us-gaap:StockholdersEquity>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hlJfBq7xHUuJTVElf5mZ9Q"
      decimals="INF"
      id="Tc_yK0f7kNti0uhUFBdgENL7A_25_2"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">1445656</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hlJfBq7xHUuJTVElf5mZ9Q"
      decimals="-3"
      id="Tc_pcWSisSGPUqqaF5R5OhJ6Q_25_5"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">1000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bKsEqv1Q706_PDc9XAYvmA"
      decimals="-3"
      id="Tc_BQGCaYNgU0CYb28e1rJ8qQ_25_8"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">1519000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q"
      decimals="-3"
      id="Tc_hycE_oRgNk-dEzFvv311oA_25_14"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">1520000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bKsEqv1Q706_PDc9XAYvmA"
      decimals="-3"
      id="Tc_kEpLpHWqD06wb6hcaiv0-A_26_8"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">298000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q"
      decimals="-3"
      id="Tc_CLLgtBGNbEOq7Dj-ZAx79w_26_14"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">298000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bKsEqv1Q706_PDc9XAYvmA"
      decimals="-3"
      id="Tc_YVpeLJWZuky7cOT2_0mEcA_27_8"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">124000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q"
      decimals="-3"
      id="Tc_ndFMKZBjEkSZRnJx2rGc4w_27_14"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">124000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Pdy3Pw8g706hDOOxHjfOfQ"
      decimals="-3"
      id="Tc_r7B1Tym6_kStcgHryYRK1A_28_11"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-3567000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q"
      decimals="-3"
      id="Tc_IP3_GuLFX0Cie-UG04-qqg_28_14"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-3567000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FCS-baPkIkmVTzMkLUh60g"
      decimals="INF"
      id="Tc_xBU_amZ-LkuBgXXAAuDnEA_29_2"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">50158608</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FCS-baPkIkmVTzMkLUh60g"
      decimals="-3"
      id="Tc_qSqcxtDrHkKfWEvkmPfmWg_29_5"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">50000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_whHKsJQCKUCuIHXPg4Ju7Q"
      decimals="-3"
      id="Tc_hE1P2g-NuEehQEzhTBAmzQ_29_8"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">374557000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZG9OKwFgA0KmxShrccpWnA"
      decimals="-3"
      id="Tc_7dBF6GM240uzNQrlBuQj7A_29_11"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-386121000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_NdH__egkDk-gnw4KdsuuTw"
      decimals="-3"
      id="Tc_wLc8Z-iY_EudddgDsODZkg_29_14"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-11514000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kSgL5r7c3k-B0VAIxyKmAQ"
      decimals="INF"
      id="Tc_5JtCaCayY02Yie7S2mhEPw_30_2"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">71580762</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_kSgL5r7c3k-B0VAIxyKmAQ"
      decimals="-3"
      id="Tc_J0Gw3XqvY0OgZ6OaDq61Sg_30_5"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">72000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_U0vvCuWzP0ObL95ACk6iGQ"
      decimals="-3"
      id="Tc_ZiDns9xcokqMkYVDz7qQuQ_30_8"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">412582000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_J6U7oUvVYE-mVxaE0p0afA"
      decimals="-3"
      id="Tc_0UEUaHb3Q0uwua4AARLPag_30_11"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-373653000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_ljE3QYELHUKaEWcB1Rf2BA"
      decimals="-3"
      id="Tc_xMz58Y8KiUOJxdxv8TMbzA_30_14"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">39001000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_74hbg6s0YUGMZEgtc7zlCQ"
      decimals="-3"
      id="Tc_CqIIQgfw-k2mmHOByJTqkQ_32_8"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">383000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"
      decimals="-3"
      id="Tc_HsCkhrXJeEy2fu3A2HhMXw_32_14"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">383000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4ubTKPzTYUaZJP68MFh1aA"
      decimals="INF"
      id="Tc_GQwKI1DfuUWngKk4EwwxsA_33_2"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">1371362</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4ubTKPzTYUaZJP68MFh1aA"
      decimals="-3"
      id="Tc_tmeK12uDsUW-E0RJNtXvyg_33_5"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">1000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_74hbg6s0YUGMZEgtc7zlCQ"
      decimals="-3"
      id="Tc_Mldx4XwReEKiqUooo-V2tQ_33_8"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">714000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"
      decimals="-3"
      id="Tc_HCmkBA_NwUaon6zmV_ceyw_33_14"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">715000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Ky9hROQdhEKplEsRyyjknA"
      decimals="-3"
      id="Tc_gJ3Iug9Cz0qKn9iLHd9BGw_34_11"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-1852000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"
      decimals="-3"
      id="Tc_oRVv8wBuok6RTz3KL5f_4g_34_14"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-1852000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6VRsvwfuMUqcCJm_5O_Dig"
      decimals="INF"
      id="Tc_xfcNdFkJBECaKEusvGlF7g_35_2"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">72952124</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6VRsvwfuMUqcCJm_5O_Dig"
      decimals="-3"
      id="Tc_2FFhYJkWFkGIetyz_ajSEw_35_5"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">73000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nImxNodwz0S5hDYBFYIz4A"
      decimals="-3"
      id="Tc_ypFLMrev30-EuSiUyyko2A_35_8"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">413679000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MD0IJnJslU6DgpIpslYWHw"
      decimals="-3"
      id="Tc_7H5TdEdB_UeQ2X9_jmW5Aw_35_11"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-375505000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_4cSjhTe-KEWWpUpU3kX9YA_35_14"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">38247000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="INF"
      id="Narr_OGXS2XbVUkCIfbX2ptcq9A"
      unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="INF"
      id="Narr_L4e8_3m_yUCGXoXAx7KX4Q"
      unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="INF"
      id="Narr_grZI2TAWWkuMvo3WLpaE7A"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">185000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="INF"
      id="Narr_Vf02-JriJ0ekFDrg3kEQ9A"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">144000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_h_L9bTiiHEaPxk09coh3bA_4_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">14356000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_hGnYxGnloUyTLcj79pP_lw_4_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-11187000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_3GYKW74_2UyS0xwDb_MqHA_6_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">2081000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_ZXFrhoQupkuPq3uuLiEB-g_6_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">1546000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_9sahu4Cc10mFigecvux4aQ_7_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">878000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc__gwDNQGNRk6Jt6wRI45-ng_7_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">811000</us-gaap:Depreciation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_bGp8oClmfk6j6-x-lgfQXQ_8_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">511000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_c7UQfHza6EGFmqWay5_awg_8_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">1083000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_268lZaPBBkKN_DQy-IbuyA_9_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-50000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_EkmnzPCICE2A4lH8nsHihQ_9_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-391000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_M9j0JtMNJ0iw_Dqol6ORdQ_10_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-3092000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_ECfgfUt-hUmikVfduqVPGA_11_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">49000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_PYT5Pt_sFEOpMBdvNkpKYg_11_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-6000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <plx:GainLossOnDebtConversion
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_8OD9BkaT3EulWRvhQst_lg_12_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">421000</plx:GainLossOnDebtConversion>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_871zzaIuU0y8f-52y866pw_13_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">208000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_I_qv9YGjcUq9kccBtJasNg_13_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">224000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_FXeM-aOlk06stbQlnEYzAg_15_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-13178000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_qTqbDjE09EONqsfxoQyo9w_15_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-5547000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_YrWQvzihdkCBHMmul282YA_16_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">4188000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_Zfnnncw9M0aFKjpAouAxVw_16_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">5692000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_SxDDrL3Aq0G2Gk86Af0YBg_17_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-12000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_5AtoUuTO-Uq_GTbiULXFYw_17_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">30000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_9fbyMby1xkePenkc76R6Ng_18_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">4779000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_u1Xrsvlm7EiCjBm6y8CKZQ_18_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-3392000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_OmJ3JIH0KUGyPYpD8GGfug_19_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">3820000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_ryFZqzfrn0eHo8x1vBWp6w_19_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-4438000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_5zvuRkC4CkGtBFEtIjpMUA_20_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-4913000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_vKvyT6-xE0ixRYbc5SdTgQ_20_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-22389000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <plx:IncreaseDecreaseInBankDeposits
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_0ZgjW9orZU2fZspHWsbsfA_23_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">20420000</plx:IncreaseDecreaseInBankDeposits>
    <plx:IncreaseDecreaseInBankDeposits
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_ridz6eWHyUKYE9NIIScSrg_23_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">16000000</plx:IncreaseDecreaseInBankDeposits>
    <plx:ProceedsFromSaleOfShortTermDeposits
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_SyBX_UkOw0CoqXsoPPz8ZQ_24_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">5000000</plx:ProceedsFromSaleOfShortTermDeposits>
    <plx:ProceedsFromSaleOfShortTermDeposits
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_jqCrhOWvsEiLq6tqljhOQA_24_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">6000000</plx:ProceedsFromSaleOfShortTermDeposits>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_AVSnifNGAUST56VNakcqmg_25_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">899000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_HWGIfPkaCUaGO94D0nCgxQ_25_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">415000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_MdGZwb2U6Ua8JR_tiLqkbA_26_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">50000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_YpmYhapJsEWTbLp-xcq74g_26_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-427000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_R3jBzLYOxkOq-Ausx6QO8Q_27_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-16369000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_Tw47nGHztUO1N4iyKJWp8g_27_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-9988000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_vNFbsAikpEa8BrtGTwdhag_30_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">23954000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_q_Hs48OCU0ecHEd1v-Kb2g_30_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">4161000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_mnpH3xv7GU2F0ezKe50idQ_31_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">712000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_MnTjso8-JkCGxC1kSbjjJw_31_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">2000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_Vh4z3v1_N0eE4nf21c1ncw_32_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">24666000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_YKUzwGVtTUq4Fv1bq_Vn0w_32_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">4163000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_rsCP1423wEC4pJ2EeIo6Cw_33_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-87000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_AZyoh7NAaEWCZlCX3WTvkQ_33_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-51000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_tqvuCwmHo0WGQWpdVs5Bgg_34_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">3297000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_uGNAyKYQrEu5iWER6Qljkg_34_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-28265000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_m8-MRPTBKESqWZF19ZTlQw_35_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">17111000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_WSd24FsHlEmdwHxFiK3fWQ"
      decimals="-3"
      id="Tc_QF4TmIiaikO_iGZ8lvOA2Q_35_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">38985000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_sdwgUAfZRUmhLL9KEg_e8A_36_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">20408000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2022_NdH__egkDk-gnw4KdsuuTw"
      decimals="-3"
      id="Tc_o0EDyXRDgUOyMcHKLJnOag_36_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">10720000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_W6jmPjiCW0KY4RRKFal4IA_4_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">253000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_uimbCBfijEilhaUv7sz8Pg_4_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">205000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_eOp7k9eFdkSgwIvD2VH-EA_5_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">1395000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_9HTBNbjIDUG2K4SbSOnIgg_5_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">396000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_2Mbz_Gitj0i5ctQ0PEnsYw_6_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">7783000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_5uS7-1VejUeyG4XxA32Aeg_8_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">2743000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_hl6PlX6GCUCTDQkbHHNEFg_8_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">2198000</us-gaap:InterestPaidNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_S0rp3jEZW0SQL02A7oFPqA_9_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">303000</plx:InterestReceivedNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_nk7RaPMNwk--yoEZQEG_qw_9_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">136000</plx:InterestReceivedNet>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tb_0LHuygT7JUiPOYYUewHgSQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). The Company&#x2019;s current focus is to facilitate the commercialization efforts of Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;), the Company&#x2019;s development and commercialization partner for pegunigalsidase alfa, or Elfabrio&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (which the Company referred to as PRX-102 during its development stage), for the treatment of Fabry disease, a rare, genetic lysosomal disorder. To date, the Company has successfully developed taliglucerase alfa (marketed under the name Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; except in Brazil where it is marketed as BioManguinhos alfataliglicerase), an enzyme replacement therapy for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company&#x2019;s strategy is to develop proprietary recombinant proteins designed to address high, unmet needs in the rare disease space that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. Consistent with this strategy, the Company has a number of product candidates in varying stages of the clinical development process.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On May&#160;5, 2023, the European Commission (&#x201c;EC&#x201d;) announced that it had approved the Marketing Authorization Application (&#x201c;MAA&#x201d;) for Elfabrio and on May&#160;9, 2023, the U.S.&#160;Food and Drug Administration (&#x201c;FDA&#x201d;) announced that it had approved the Biologics License Application (&#x201c;BLA&#x201d;) for Elfabrio, each for adult patients with Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. The European Medicines Agency (&#x201c;EMA&#x201d;) approval followed the February 2023 adoption of a positive opinion and recommendation of marketing authorization for Elfabrio by the EMA&#x2019;s Committee for Medicinal Products for Human Use the (&#x201c;CHMP&#x201d;). Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with Enzyme Replacement Therapy (ERT) class labeling, and Warnings/Precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The Warnings/Precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In August and September of 2023, Elfabrio was approved in Great Britain and Switzerland, respectively, for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The Company has entered into two exclusive global licensing and supply agreements for Elfabrio with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;). On October&#160;19, 2017, Protalix Ltd., the Company&#x2019;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi Ex-US Agreement&#x201d;), pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the Chiesi US Agreement, with respect to the commercialization of Elfabrio in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;Elfabrio, an enzyme replacement therapy, or ERT, was the subject of a phase&#160;III clinical program studying the drug as a treatment of patients with Fabry disease, a rare, genetic lysosomal disorder. The phase&#160;III clinical program included three separate studies, which are referred to as the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study, the &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; study and the &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; study. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which subjects that participated in our phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship of the two open-label extension studies was transferred to Chiesi, which is now administering the extension studies. Over time, and as Elfabrio is approved for marketing in different jurisdictions, &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;participants withdraw from the open-label extension studies. Some of the withdrawals&lt;span style="text-decoration-line:line-through;text-decoration-style:solid;"&gt; &lt;/span&gt;transfer to a commercial setting, others withdraw for other reasons.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The BLA for Elfabrio for the treatment of adult patients with Fabry disease was resubmitted to the FDA on November&#160;9, 2022. An initial BLA for Elfabrio was submitted to the FDA on May&#160;27, 2020 under the FDA&#x2019;s Accelerated Approval pathway, but resulted in a Complete Response Letter (&#x201c;CRL&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The MAA was submitted to the EMA on February&#160;7, 2022, after the October&#160;8, 2021 meeting we held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The FDA publicly released the internal review documents for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161. These documents provide previously unavailable additional information regarding the basis for the FDA&#x2019;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study (Study PB-102-F01/02) with confirmatory evidence provided by the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study (also referred to as Study PB-102-F20). The FDA review team also concluded that the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study did not support a non-inferiority claim to the comparator product due to the lack of data to support a non-inferiority margin.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company has licensed the rights to commercialize taliglucerase alfa worldwide (other than Brazil) to Pfizer Inc. (&#x201c;Pfizer&#x201d;), and in Brazil to Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;). Otherwise, except with respect to taliglucerase alfa and Elfabrio, the Company holds the worldwide commercialization rights to its other proprietary development candidates. In addition, the Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;white-space:nowrap;"&gt;(1)&lt;/span&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat severe gout; and&lt;/div&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;white-space:nowrap;"&gt;(2)&lt;/span&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.&lt;/div&gt;&lt;div style="margin-top:11pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On March&#160;21, 2023, the first patient was dosed in the Company&#x2019;s phase&#160;I First-in-Human (&#x201c;FIH&#x201d;) clinical trial of PRX-115. As of September&#160;30, 2023, 32 patients have been dosed in this trial.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;2021 Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell, from time to time through the Agent, shares of its common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), having an aggregate offering price of up to $20.0&#160;million (the &#x201c;ATM Shares&#x201d;). Upon execution of the 2021 Sales Agreement, the Company terminated the ATM Equity Offering&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#x201c;BofA Securities&#x201d;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, the Company sold a total of 13,980,060 ATM Shares for total gross proceeds of approximately $20.0&#160;million under the 2021 Sales Agreement, thereby completing the ATM program under said agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#x201c;2023 Sales Agreement&#x201d;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to $20.0&#160;million. As of September&#160;30, 2023, shares of Common Stock for total gross proceeds of approximately $6.4&#160;million remain available to be sold under the 2023 Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#x201c;Chiesi Agreements&#x201d;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements. In addition, following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under the terms of both of the Chiesi Agreements, Protalix Ltd. is required to manufacture all of the Elfabrio drug substance needed under the agreements, subject to certain exceptions, and Chiesi will purchase Elfabrio drug product from Protalix, subject to certain terms and conditions. The consideration for Protalix Ltd. is based on the drug product supplied to Chiesi and the average selling price of the drug product in the relevant territory multiplied by tiered payments as described in the relevant agreement. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments for drug product purchased from Protalix of 15% to 35%, depending on the amount of annual net sales outside of the United States, and under the Chiesi US Agreement, Chiesi is required to make tiered payments for drug product purchased from Protalix of 15% to 40%, depending on the amount of annual net sales in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#x201c;F/F Agreement&#x201d;) and a Letter Agreement (the &#x201c;Letter Agreement&#x201d;), in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for PRX-102 and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide the Company with commercial fill/finish services for PRX-102, including to support the anticipated global launch of PRX-102. The F/F Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with the terms of the F/F Agreement and the term may be extended by mutual agreement for an additional period of&#160;seven years&#160;upon mutual written agreement prior to expiration of the initial term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement with Fiocruz (the &#x201c;Brazil Agreement&#x201d;) for taliglucerase alfa. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to the product candidates. Under the terms of the Company&#x2019;s outstanding 7.50% Senior Secured Convertible Notes due 2024 (the &#x201c;2024 Notes&#x201d;)&lt;span style="font-family:'28mugxoulnobhnx';"&gt;, &lt;/span&gt;the Company is required to comply with certain&lt;span style="color:#222222;background:#ffffff;"&gt; &lt;/span&gt;financial covenants, including the maintenance of a minimum cash balance of at least $7.5&#160;million. As of September&#160;30, 2023, the Company is in&lt;span style="background:#ffffff;"&gt; compliance with all such covenants. &lt;/span&gt;The Company believes that its cash and cash equivalents as of September&#160;30, 2023, are sufficient to satisfy the Company&#x2019;s capital needs for at least 12&#160;months from the date that these financial statements are issued.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#x201c;Commission&#x201d;). The comparative balance sheet at December&#160;31, 2022 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2022.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Revenue recognition&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Revenues from selling products&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 72pt;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery), at the net selling price, which reflects reserves for variable consideration, potential discounts and allowances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price is the consideration to which the Company expects to be entitled from the customer. The consideration promised in a contract with the Company&#x2019;s customers may include fixed amounts and variable amounts. The Company estimates the variable consideration and includes it in the transaction price using the most likely outcome method, and only to the extent it is highly probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;2.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenues from Chiesi Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company has identified two performance obligations in the Chiesi Agreements as follows: (i)&#160;the license and research and development services and (ii)&#160;the contingent performance obligation regarding future manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The manufacturing was contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license, research and development services. Following the regulatory approvals for Elfabrio received in May 2023, the Company started recognizing revenue from manufacturing, see also revenue from selling products above.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue. Following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million (see also note 4).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services was recognized over time using the cost-to-cost method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from additional research and development services ordered by Chiesi is recognized over time using the cost-to-cost method.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;3.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from the research and development services was recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <plx:NatureOfOperationsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tb_-o45tTp75Ui0www99M_qdg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). The Company&#x2019;s current focus is to facilitate the commercialization efforts of Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;), the Company&#x2019;s development and commercialization partner for pegunigalsidase alfa, or Elfabrio&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (which the Company referred to as PRX-102 during its development stage), for the treatment of Fabry disease, a rare, genetic lysosomal disorder. To date, the Company has successfully developed taliglucerase alfa (marketed under the name Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; except in Brazil where it is marketed as BioManguinhos alfataliglicerase), an enzyme replacement therapy for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company&#x2019;s strategy is to develop proprietary recombinant proteins designed to address high, unmet needs in the rare disease space that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. Consistent with this strategy, the Company has a number of product candidates in varying stages of the clinical development process.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On May&#160;5, 2023, the European Commission (&#x201c;EC&#x201d;) announced that it had approved the Marketing Authorization Application (&#x201c;MAA&#x201d;) for Elfabrio and on May&#160;9, 2023, the U.S.&#160;Food and Drug Administration (&#x201c;FDA&#x201d;) announced that it had approved the Biologics License Application (&#x201c;BLA&#x201d;) for Elfabrio, each for adult patients with Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. The European Medicines Agency (&#x201c;EMA&#x201d;) approval followed the February 2023 adoption of a positive opinion and recommendation of marketing authorization for Elfabrio by the EMA&#x2019;s Committee for Medicinal Products for Human Use the (&#x201c;CHMP&#x201d;). Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with Enzyme Replacement Therapy (ERT) class labeling, and Warnings/Precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The Warnings/Precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In August and September of 2023, Elfabrio was approved in Great Britain and Switzerland, respectively, for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The Company has entered into two exclusive global licensing and supply agreements for Elfabrio with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;). On October&#160;19, 2017, Protalix Ltd., the Company&#x2019;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi Ex-US Agreement&#x201d;), pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the Chiesi US Agreement, with respect to the commercialization of Elfabrio in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;Elfabrio, an enzyme replacement therapy, or ERT, was the subject of a phase&#160;III clinical program studying the drug as a treatment of patients with Fabry disease, a rare, genetic lysosomal disorder. The phase&#160;III clinical program included three separate studies, which are referred to as the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study, the &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; study and the &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; study. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which subjects that participated in our phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102. As of March&#160;1, 2023, sponsorship of the two open-label extension studies was transferred to Chiesi, which is now administering the extension studies. Over time, and as Elfabrio is approved for marketing in different jurisdictions, &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;participants withdraw from the open-label extension studies. Some of the withdrawals&lt;span style="text-decoration-line:line-through;text-decoration-style:solid;"&gt; &lt;/span&gt;transfer to a commercial setting, others withdraw for other reasons.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The BLA for Elfabrio for the treatment of adult patients with Fabry disease was resubmitted to the FDA on November&#160;9, 2022. An initial BLA for Elfabrio was submitted to the FDA on May&#160;27, 2020 under the FDA&#x2019;s Accelerated Approval pathway, but resulted in a Complete Response Letter (&#x201c;CRL&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The MAA was submitted to the EMA on February&#160;7, 2022, after the October&#160;8, 2021 meeting we held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The FDA publicly released the internal review documents for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161. These documents provide previously unavailable additional information regarding the basis for the FDA&#x2019;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study (Study PB-102-F01/02) with confirmatory evidence provided by the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study (also referred to as Study PB-102-F20). The FDA review team also concluded that the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study did not support a non-inferiority claim to the comparator product due to the lack of data to support a non-inferiority margin.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company has licensed the rights to commercialize taliglucerase alfa worldwide (other than Brazil) to Pfizer Inc. (&#x201c;Pfizer&#x201d;), and in Brazil to Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;). Otherwise, except with respect to taliglucerase alfa and Elfabrio, the Company holds the worldwide commercialization rights to its other proprietary development candidates. In addition, the Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;white-space:nowrap;"&gt;(1)&lt;/span&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat severe gout; and&lt;/div&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;white-space:nowrap;"&gt;(2)&lt;/span&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.&lt;/div&gt;&lt;div style="margin-top:11pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On March&#160;21, 2023, the first patient was dosed in the Company&#x2019;s phase&#160;I First-in-Human (&#x201c;FIH&#x201d;) clinical trial of PRX-115. As of September&#160;30, 2023, 32 patients have been dosed in this trial.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;2021 Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell, from time to time through the Agent, shares of its common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), having an aggregate offering price of up to $20.0&#160;million (the &#x201c;ATM Shares&#x201d;). Upon execution of the 2021 Sales Agreement, the Company terminated the ATM Equity Offering&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#x201c;BofA Securities&#x201d;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of Common Stock for total gross proceeds of approximately $13.8&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, the Company sold a total of 13,980,060 ATM Shares for total gross proceeds of approximately $20.0&#160;million under the 2021 Sales Agreement, thereby completing the ATM program under said agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#x201c;2023 Sales Agreement&#x201d;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to $20.0&#160;million. As of September&#160;30, 2023, shares of Common Stock for total gross proceeds of approximately $6.4&#160;million remain available to be sold under the 2023 Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#x201c;Chiesi Agreements&#x201d;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements. In addition, following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under the terms of both of the Chiesi Agreements, Protalix Ltd. is required to manufacture all of the Elfabrio drug substance needed under the agreements, subject to certain exceptions, and Chiesi will purchase Elfabrio drug product from Protalix, subject to certain terms and conditions. The consideration for Protalix Ltd. is based on the drug product supplied to Chiesi and the average selling price of the drug product in the relevant territory multiplied by tiered payments as described in the relevant agreement. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments for drug product purchased from Protalix of 15% to 35%, depending on the amount of annual net sales outside of the United States, and under the Chiesi US Agreement, Chiesi is required to make tiered payments for drug product purchased from Protalix of 15% to 40%, depending on the amount of annual net sales in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#x201c;F/F Agreement&#x201d;) and a Letter Agreement (the &#x201c;Letter Agreement&#x201d;), in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for PRX-102 and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide the Company with commercial fill/finish services for PRX-102, including to support the anticipated global launch of PRX-102. The F/F Agreement shall continue in force until December&#160;31, 2025, unless terminated earlier in accordance with the terms of the F/F Agreement and the term may be extended by mutual agreement for an additional period of&#160;seven years&#160;upon mutual written agreement prior to expiration of the initial term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement with Fiocruz (the &#x201c;Brazil Agreement&#x201d;) for taliglucerase alfa. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to the product candidates. Under the terms of the Company&#x2019;s outstanding 7.50% Senior Secured Convertible Notes due 2024 (the &#x201c;2024 Notes&#x201d;)&lt;span style="font-family:'28mugxoulnobhnx';"&gt;, &lt;/span&gt;the Company is required to comply with certain&lt;span style="color:#222222;background:#ffffff;"&gt; &lt;/span&gt;financial covenants, including the maintenance of a minimum cash balance of at least $7.5&#160;million. As of September&#160;30, 2023, the Company is in&lt;span style="background:#ffffff;"&gt; compliance with all such covenants. &lt;/span&gt;The Company believes that its cash and cash equivalents as of September&#160;30, 2023, are sufficient to satisfy the Company&#x2019;s capital needs for at least 12&#160;months from the date that these financial statements are issued.&lt;/p&gt;</plx:NatureOfOperationsPolicyTextBlock>
    <plx:NumberOfGlobalLicensingAndSupplyAgreements
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="INF"
      id="Narr_BPbFGo0yRkCDGUyp0wcJ7w"
      unitRef="Unit_Standard_agreement_lKNqKU4rvUupTelfJQIVSg">2</plx:NumberOfGlobalLicensingAndSupplyAgreements>
    <plx:NumberOfPatientsDosed
      contextRef="As_Of_3_21_2023_59uxaENwDEeis1uswurdAQ"
      decimals="INF"
      id="Narr_HY07nkL-zk-MXaB_6kBcTA"
      unitRef="Unit_Standard_item_dyUGGngOZEG007onwpOmGw">32</plx:NumberOfPatientsDosed>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_ABTzvay3O0OZCuw98-XbeQ"
      decimals="INF"
      id="Narr_BzhCttsxX0W08dI9OJtzKg"
      unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_FE-7EpG9IkW88m9UfwwG6w"
      decimals="-5"
      id="Narr_eBVVMKPpikGhmbS8IOKcWA"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">20000000.0</plx:SaleOfStockMaximumOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_mvxv3O6LxEaaJFEPDGVkrA"
      decimals="INF"
      id="Narr_jD4eYDzKPEW6F8nb1FRh6A"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">3296123</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_mvxv3O6LxEaaJFEPDGVkrA"
      decimals="-5"
      id="Narr_9-PDJWvxYEmUotkb0D--fA"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">13800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_bcEsWzSIKk6tSkX7LMh0hQ"
      decimals="INF"
      id="Narr_5Yl222-uy0Cn-x3KEjq13Q"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">13980060</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_bcEsWzSIKk6tSkX7LMh0hQ"
      decimals="-5"
      id="Narr_P3EE_7wPwE6HhAJxCo4Ing"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">20000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="Duration_2_27_2023_To_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_z_3UoywC8ECDn2BmWvhnnw"
      decimals="-5"
      id="Narr_fl84Zaa9nU2wujrUE3NU5A"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">20000000.0</plx:SaleOfStockMaximumOfferingPrice>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_IZYUYcpDQ0W3wVn53D7jkQ"
      decimals="-5"
      id="Narr_FEV3dBDXMkStUmpmiN_BpQ"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">6400000</plx:SaleOfStockMaximumOfferingPrice>
    <plx:UpfrontNonrefundableNoncreditablePaymentReceivable
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_I0f7iY_hoUWDw20FCFX8EQ"
      decimals="-5"
      id="Narr_JRpPKU2PfUmMavjgZxVAkg"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">25000000.0</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
    <plx:UpfrontNonrefundableNoncreditablePaymentReceivable
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_c_DS6CF9IUONf5DnuePWGg"
      decimals="-5"
      id="Narr_fg_FgWo83EmbroF0qd8yQw"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">25000000.0</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_WBsGH7Src0eGVZCrXqiz2A"
      decimals="-5"
      id="Narr_gE-AujAEkkaGxYQ6AIyGWw"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">25000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_WBsGH7Src0eGVZCrXqiz2A"
      decimals="-5"
      id="Narr_aawHMbp25ESpZAvMtjF4mg"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">320000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_rCjFnyR3fEa9cw5ekQ7pew"
      decimals="-5"
      id="Narr_jL0dGnJ0j02kwmHbPhL1Hg"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">20000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_rCjFnyR3fEa9cw5ekQ7pew"
      decimals="-5"
      id="Narr_3YyC-cT5iUy5qGw1YrSyrQ"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">760000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:MilestonePaymentReceived
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_iN4jeRGThUGJ9_j3XbAknA"
      decimals="-5"
      id="Narr_J_N3VfrKFkWjFr-v8QSmbw"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">20000000.0</plx:MilestonePaymentReceived>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3JKpw53nwkGDyDlVTy2Gxw"
      decimals="INF"
      id="Narr_FbZktYaQ706B1z6skG28ug"
      unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_GHWT0ykNeEuO1RlIzpZFhg"
      decimals="INF"
      id="Narr_LBWGsG0nS02ynHXJV8deqw"
      unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw">0.35</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_etzFjnmIFkqSQ8Z9LeDedg"
      decimals="INF"
      id="Narr_BRcufVO2tUadI8EDETHYZg"
      unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_DKlLQr64h0q6S5laUAGccw"
      decimals="INF"
      id="Narr_VZlAbnPoM0GYRv2fNp20eQ"
      unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw">0.40</plx:PaymentOnNetSalesPercentage>
    <plx:ExtendedTermOfAgreement
      contextRef="Duration_8_29_2022_To_8_29_2022_us-gaap_TypeOfArrangementAxis_plx_FillFinishAgreementMember_sD-xmdGPaE-ij5-ExlU3kQ"
      id="Narr_Ctajezos-0Gy33CDwq-mag">P7Y</plx:ExtendedTermOfAgreement>
    <plx:AgreementAmendmentPaymentReceivable
      contextRef="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_jp1gAPcWdUq4GpRSn43eoQ"
      decimals="-5"
      id="Narr_7HN7MFaTa0WtPVcCIFWS-Q"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">10000000.0</plx:AgreementAmendmentPaymentReceivable>
    <plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_GERNj3wXEUWT0EvS1LtJJA"
      decimals="-5"
      id="Narr_pmtKhrRKpU6IIJsIaxoa5A"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">25000000.0</plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:CollaborativeArrangementRevenuesExpensesSharingPercentage
      contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_-xsCF2uYFkqT5zfBjQzLVw"
      decimals="2"
      id="Narr_4VXmwTLIHkekUvihR2wxpw"
      unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw">1</plx:CollaborativeArrangementRevenuesExpensesSharingPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_ONDNURLUTUKjjQ_0xrpP0w"
      decimals="4"
      id="Narr_A1I0iWOevEaCy0eqUqHorg"
      unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <plx:MaintainOfMinimumCashBalance
      contextRef="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_ONDNURLUTUKjjQ_0xrpP0w"
      decimals="-5"
      id="Narr_ICwgvzGix0-O3RcRDU_IcA"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">7500000</plx:MaintainOfMinimumCashBalance>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tb_RlegqHN8xkeHe5dTWx_gRA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#x201c;Commission&#x201d;). The comparative balance sheet at December&#160;31, 2022 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2022.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tb_HFsrOjleAU2xinF68td5DA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Revenue recognition&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Revenues from selling products&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 72pt;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery), at the net selling price, which reflects reserves for variable consideration, potential discounts and allowances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price is the consideration to which the Company expects to be entitled from the customer. The consideration promised in a contract with the Company&#x2019;s customers may include fixed amounts and variable amounts. The Company estimates the variable consideration and includes it in the transaction price using the most likely outcome method, and only to the extent it is highly probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;2.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenues from Chiesi Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company has identified two performance obligations in the Chiesi Agreements as follows: (i)&#160;the license and research and development services and (ii)&#160;the contingent performance obligation regarding future manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The manufacturing was contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license, research and development services. Following the regulatory approvals for Elfabrio received in May 2023, the Company started recognizing revenue from manufacturing, see also revenue from selling products above.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue. Following the approval of Elfabrio by the FDA, the Company received a milestone payment equal to $20.0&#160;million (see also note 4).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services was recognized over time using the cost-to-cost method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from additional research and development services ordered by Chiesi is recognized over time using the cost-to-cost method.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;3.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from the research and development services was recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the services.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <plx:RevenuePerformanceObligationNumber
      contextRef="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_eoOa9SWffEiVP049zeIqSA"
      decimals="INF"
      id="Narr_nQq2Rh8QoUSsmNWG7M6zMw"
      unitRef="Unit_Standard_agreement_lKNqKU4rvUupTelfJQIVSg">2</plx:RevenuePerformanceObligationNumber>
    <plx:MilestonePaymentReceived
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_iN4jeRGThUGJ9_j3XbAknA"
      decimals="-5"
      id="Narr_XuN7DFGPd06u6sKZbJ7Nwg"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">20000000.0</plx:MilestonePaymentReceived>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tb_Jpcm8yTCkkqdd0RLi0JX4Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;2&#160;- INVENTORIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Inventories at September&#160;30, 2023 and December&#160;31, 2022 consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,198&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,508&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,116&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,678&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,269&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,618&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,583&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,804&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tb_GdCkTKd880GcI55VBwBGDA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,198&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,508&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,116&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,678&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,269&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,618&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,583&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,804&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_30Pjrj068kO_qkyIsJ8EGQ_3_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">4198000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_pW_aKbDRdkKScvqrbdTp4Q_3_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">3508000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_TKIhhqbbRkiLc0oHumd2xA_4_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">9116000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_iqV61xDeNk6a945z3F3pdQ_4_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">2678000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_JIrRKoTdWkiBdWwAd9sFyg_5_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">8269000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_tDMpT7mhhUOAychbtYG7bw_5_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">10618000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_ng4uO8OeEkmVSyJb7rEySg_6_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">21583000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_fRUp5v-MYkOVsPafqdtAZw_6_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">16804000</us-gaap:InventoryNet>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tb_NP2USvyA9EatKNAI5J9ghg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;3&#160;&#x2013; FAIR VALUE MEASUREMENT&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;"&gt;Based on a Level 3 measurement, as of September&#160;30, 2023, the fair value of the $20.4&#160;million aggregate principal amount of the Company&#x2019;s outstanding 2024 Notes is approximately $24.5&#160;million. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 62.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.49&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_kgA--Gd-2UWeFMP4kZXqwA"
      decimals="-4"
      id="Narr_TnY_-SFdbESZEKHIRv746w"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">20400000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_kgA--Gd-2UWeFMP4kZXqwA"
      decimals="-5"
      id="Narr__L3MZoch7E2EkZZrT4AkMQ"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">24500000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_IsSkHrMXCEC808Zd6VbjIQ"
      id="Tb_EUdlsbm8Y0OiA2eMvR07RQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 62.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.49&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_uB6aVsBg6EaCcs-hRuTW_A"
      decimals="2"
      id="Tc_Ix7qqpwHNE6ArUbPsr7GFQ_2_5"
      unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg">1.66</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_tTdbaH9LGEq9pS4VzhrCSw"
      decimals="2"
      id="Tc_M5DGdhXbfUebMCfrB0Qp9Q_3_5"
      unitRef="Unit_Standard_Y_P_CRw8WyjU2VbFabIi54IQ">0.93</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_bez3doxPHEy6nArxyu-5WA"
      decimals="2"
      id="Tc_CMz7LUJ_1UCsG_m-9fVkwg_4_5"
      unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw">5.34</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_X09KFdeVa0mgHlIW0IelcQ"
      decimals="2"
      id="Tc_2XdPeY5fr0y9GXtOWRrl3A_5_5"
      unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw">62.84</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_G4UyzvxD9UiRqqT-Li8wCA"
      decimals="2"
      id="Tc_9hYrT8X4ZE6Bjn9083lG_g_6_5"
      unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw">12.49</us-gaap:DebtInstrumentMeasurementInput>
    <plx:RevenueDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tb_tXB_CAklzUqDf54ruIJc4w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;NOTE&#160;4&#160;&#x2013; REVENUES&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="background:#ffffff;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,304&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,541&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,972&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,279&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,320&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,708&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,120&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,162&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chiesi&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,544&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,563&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,217&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,781&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,168&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,812&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,309&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,222&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,371&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,699&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,799&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</plx:RevenueDisclosureTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tb_gCQZKczj-EWNQaqHKSu4VQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,304&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,541&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,972&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,279&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,320&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,708&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,120&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,162&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chiesi&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,544&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,563&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,217&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,781&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,168&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,812&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,309&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,222&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,371&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,699&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,799&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="color:#212529;font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_sVnDgezrHka5Dw8PspQs3w"
      decimals="-3"
      id="Tc_0A3xcGB9A0moGME3M1EGVw_3_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">2304000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_tKo7RTZIJ0G9Lb7VY5FW9Q"
      decimals="-3"
      id="Tc_wlxHhHivz0KOeE_VAf6bjg_3_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">4541000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_nJExY4OnmUmt1WUuJLndIQ"
      decimals="-3"
      id="Tc_eZe8q4cbMUSa2xTQmzWMLg_3_9"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">7972000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_iH38GCBvckuT-5RWJRmh4g"
      decimals="-3"
      id="Tc_yX9rb1lMR0CVck3eX_QQpA_3_12"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">11279000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_eB0Q82DpoUe8I_AVASAV5g"
      decimals="-3"
      id="Tc_yF9zO5dljU29010NJxxj3g_4_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">2320000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_54yhJyQsfUWr69wXcncDRw"
      decimals="-3"
      id="Tc_cvKD_JVKg0ORlhb5i5lDHQ_4_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">1708000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_UWm8Okbu-EqlxDiNTSf2Zg"
      decimals="-3"
      id="Tc_myoC_KTvNk2l72U86a2DQw_4_9"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">5120000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_nYCRV7igxEO8F_DL0WaJTQ"
      decimals="-3"
      id="Tc_9mFzwE1EOUiqjwQhN8iGXA_4_12"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">7162000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_ZO1PgNYXMEuC--7AWaeWEQ"
      decimals="-3"
      id="Tc_aod4aOXFEUOVY94NYe3c8A_5_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">5544000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_c26sRwH14EOOXdDcKHSfXg"
      decimals="-3"
      id="Tc_LFYEjG-J8E6scpBuWz7lUw_5_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">2563000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_-Z5nFPVF50-Y_QNXqgvqxg"
      decimals="-3"
      id="Tc_SmmxSZBX6U2M6o6Pq9yazQ_5_9"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">17217000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_UZ9M3vS4pUmQfa--0rmbMg"
      decimals="-3"
      id="Tc_AsBJMVUz80qaxcjLwjRCVA_5_12"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">2781000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_Lo8_JpbjYUCk7biQuAf2Cw"
      decimals="-3"
      id="Tc_byrBSPcDdUuuG9_iziMWng_6_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">10168000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_isIRGT_PckWgKUstJZEmKA"
      decimals="-3"
      id="Tc_bNfrnuDhLUqjp7woTXweow_6_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">8812000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_ZRFZeNwM3kOgwL_HZhzgeQ"
      decimals="-3"
      id="Tc_vGpZzAZBKUO8Kst0rTD8kA_6_9"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">30309000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_r2IxwFzzbEK8WGh9RQOkuQ"
      decimals="-3"
      id="Tc_5aBgsEtzakGsvsCSY8cDJQ_6_12"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">21222000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_3i3mFrnEFE2XxVcL7eIj9g"
      decimals="-3"
      id="Tc_nrBK5BVeZki4gvMTopoukg_7_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">177000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_FPM1y3Bjl0Gc-RAt1yp0Fw"
      decimals="-3"
      id="Tc_YBvGLjAE-0mUzo4Rax8nAA_7_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">5371000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_1lopoDCmBESgKQUfzzjJoA"
      decimals="-3"
      id="Tc_GAHH9qIPQkqkoTcyBC1gRA_7_9"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">24699000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_403rz0Wpzk6dQXNU5Z2R7w"
      decimals="-3"
      id="Tc_yzp0jOFASUaV0w2t68NDww_7_12"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">17799000</us-gaap:Revenues>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tb_NBGPSGpc_UOCCkwkuibhqQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 5 &#x2013; STOCK TRANSACTIONS&lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(a)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;"&gt;Authorized Capital&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;"&gt;On June&#160;28, 2023, the Company held its 2023 Annual Meeting of Stockholders, which was adjourned and reconvened on July&#160;13, 2023 (the &#x201c;Annual Meeting&#x201d;). At the Annual Meeting, the Company&#x2019;s stockholders, among other matters, approved an amendment to the Company&#x2019;s Certificate of Incorporation, as amended, to increase the number of shares of Common Stock authorized for issuance from 144,000,000 to 185,000,000 (the &#x201c;Charter Amendment&#x201d;). The Charter Amendment was filed with the Secretary of State of the State of Delaware on July&#160;25, 2023.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(b)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;"&gt;At-the-Market (ATM) Offering&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;"&gt;During the nine months ended September&#160;30, 2023, the Company sold, in the aggregate, 12,560,150 shares of Common Stock under the 2023 Sales Agreement. The Company generated aggregate gross proceeds equal to approximately $24.9&#160;million in connection with such sales. All such sales were completed during the quarters ended March&#160;31, 2023 and June&#160;30, 2023. No sales were completed during the three-months ended September&#160;30, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;"&gt;(c)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;Exercise of Warrants&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;"&gt;On May&#160;8, 2023, the Company issued 301,810 shares of Common Stock in connection with the cash exercise of a warrant issued on March&#160;18, 2020, as part of the Company&#x2019;s private placement of Common Stock and warrants. The Company generated net proceeds equal to $0.7&#160;million from the exercise of the warrant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;"&gt;On May&#160;10, 2023, the Company issued 237,012 shares of Common Stock in connection with the cashless exercise of a warrant to purchase 845,000 shares of Common Stock issued on March&#160;18, 2020, as part of the Company&#x2019;s private placement of Common Stock and warrants. The Company did not generate any proceeds from the cashless exercise.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;"&gt;No warrants were exercised during the three months ended September&#160;30, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;background:#ffffff;"&gt;(d)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;Conversion of 2024 Notes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;"&gt;During the nine months ended September&#160;30, 2023, the Company issued, in the aggregate, 4,691,623 shares of Common Stock in connection with the conversions of 2024 Notes. In connection with such conversions, during the nine months ended September&#160;30, 2023, the Company paid to the converting holders $0.9&#160;million representing cash payments due to accrued but unpaid interest, make-whole interest payments and payments in lieu of fractional shares. As a result of the conversions, the total principal amount of the 2024 Notes decreased by approximately $8.3&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;"&gt;No 2024 Notes were converted during the three months ended September&#160;30, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;(e)&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Stock based compensation&lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;On June&#160;28, 2023, at the Annual Meeting, the Company&#x2019;s stockholders, among other matters, adopted amendments to the Company&#x2019;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#x201c;Plan&#x201d;) to increase the number of shares of Common Stock available under Plan from &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;8,475,171&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;12,475,171&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares and to amend certain other terms of the Plan.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;On August&#160;15, 2023, the Company granted, with the approval of the Company&#x2019;s compensation committee, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1,371,362&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares of restricted Common Stock, in the aggregate, to certain of the Company&#x2019;s officers under the Plan. Of such grants, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;200,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares of restricted Common Stock vested upon grant, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;600,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares of restricted Common Stock vest over a &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two-year&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; period in &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;eight&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;equal quarterly increments and the remaining &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;571,362&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares of restricted Common Stock vest over a &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three-year&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; period in &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;12&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;equal quarterly increments. The Company estimated the fair value of the restricted stock on the date of grant to be approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$2.7&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:72pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;3)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;On August&#160;15, 2023, the Company granted, with the approval of the Company&#x2019;s compensation committee, 10-year options to purchase 1,056,315 shares of Common Stock, in the aggregate, to certain of the Company&#x2019;s officers and other employees under the Plan. The options have an exercise price equal to $1.99 per share and vest over a three-year period in 12&#160;equal quarterly increments. Vesting of the options granted to executive officers is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the aggregate fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $1.5&#160;million. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 108pt;"&gt;On September&#160;14, 2023, the Company granted, with the approval of the Company&#x2019;s compensation committee, 10-year options to purchase 85,715 shares of Common Stock, in the aggregate, to the new Chairman of the Company&#x2019;s Board of Directors under the Plan. The options have an exercise price equal to $1.75 per share and vest over a three-year period in 12&#160;equal quarterly increments. Vesting of the options is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the aggregate fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $0.1&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 108pt;"&gt;On September&#160;29, 2023, the Company granted, with the approval of the Company&#x2019;s compensation committee, 10-year options to purchase 308,380 shares of Common Stock, in the aggregate, to the non-executive directors of the Company&#x2019;s Board of Directors, other than the Chairman, under the Plan. The options have an exercise price equal to $1.66 per share and vest over a three-year period in 12&#160;equal quarterly increments. Vesting of the options is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the aggregate fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $0.4&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 108pt;"&gt;&lt;span style="background:#ffffff;"&gt;The fair value of each option granted during the three-month period ended September&#160;30, 2023 is estimated at the date of grant using the Black-Scholes option-pricing model. The following weighted average assumptions were applied in determining the fair value of the options described in this Note&#160;5(e)(3) on their respective grant dates:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average grants date fair value (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 79.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected life (Years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_7_24_2023_9kwXDECmXUmLqJV4f95MAw"
      decimals="INF"
      id="Narr_cSaJe3XCL0iXDwv4IgloXA"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">144000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_7_25_2023_edYzzPajLkGQMaRQZP-YaA"
      decimals="INF"
      id="Narr_hXCHF1w8bUqBua6YXXMbuQ"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">185000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_TBP-Nxi6xkSucxKQEfEKFA"
      decimals="INF"
      id="Narr_V3z3EWQhHkC-hTfBz71r6w"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">12560150</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_TBP-Nxi6xkSucxKQEfEKFA"
      decimals="-5"
      id="Narr_cXpKDKZwZkyixmGzy330Fw"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">24900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtmEquityOfferingSalesAgreementMember_mfC9kUaxCUWkEdReEq0g8g"
      decimals="INF"
      id="Narr_5jQm3oD3Fk-paHce4yRUcQ"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_5_8_2023_To_5_8_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_aZyevVDxgUeUldAkpXak_A"
      decimals="INF"
      id="Narr_CpyWGwzdM0aGySefqBYPqw"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">301810</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_5_8_2023_To_5_8_2023_LWrHj6ICi0aqDBWvUoRhNQ"
      decimals="-5"
      id="Narr_-pT0noy5X0mURxa5LrHDbw"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">700000</us-gaap:ProceedsFromWarrantExercises>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_5_10_2023_To_5_10_2023_uEkJTuuYLE2tgKefXtN0Mg"
      decimals="INF"
      id="Narr_tus0EOuDYEelJ9uBLorz0Q"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">237012</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_5_10_2023_EgRr_kLVqEarxsyOSeb0Ng"
      decimals="INF"
      id="Narr_wZ5BUnLBOkaWmdAAwvYqJQ"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">845000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"
      decimals="INF"
      id="Narr_2TleHd53xk-AyRKt5x6xQw"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">0</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_IsSkHrMXCEC808Zd6VbjIQ"
      decimals="INF"
      id="Narr_x3Jn4tjUb0Orl3R6m6hhVQ"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">4691623</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <plx:PaymentsToDebtHoldersOnConversion
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_IsSkHrMXCEC808Zd6VbjIQ"
      decimals="-5"
      id="Narr_BVPeA3vrp0OfmdJg3At2tw"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">900000</plx:PaymentsToDebtHoldersOnConversion>
    <plx:DebtConversionDecreaseInPrincipalAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_IsSkHrMXCEC808Zd6VbjIQ"
      decimals="-5"
      id="Narr_ajmio51OUkyv5xJpC5dJDA"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">8300000</plx:DebtConversionDecreaseInPrincipalAmount>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_h7Ke6bk0e0aU5lPXoIrMVA"
      decimals="INF"
      id="Narr_YH0NSp1OqECNNqElwXmxig"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">0</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_6_27_2023_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_WfHmnalC9keIkorDt44VZg"
      decimals="INF"
      id="Narr_-v-RLvbezEehBIU8VW1MMQ"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">8475171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_6_28_2023_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_VafRBM-KXUKE9nl21SfoWg"
      decimals="INF"
      id="Narr_olkQbyxRDkqjnYdZwommdw"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">12475171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_8_15_2023_To_8_15_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_fMPAZxDZF0CjT3jIiJlVWg"
      decimals="INF"
      id="Narr_VDJgeFMmlkuwmzUpyNKC6g"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">1371362</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_8_15_2023_To_8_15_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_IPgkJRT2mUmlR7n5uxuhBQ"
      decimals="INF"
      id="Narr_6A3XaJ-qU0upF7iJyHmAtQ"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_8_15_2023_To_8_15_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_yKs6Fnw-ukqovfuD-GaUEw"
      decimals="INF"
      id="Narr_H0xkdG2Djk6BTd9I9FECMA"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_8_15_2023_To_8_15_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_yKs6Fnw-ukqovfuD-GaUEw"
      id="Narr_uhWbUe_S_0GEE5jBJXWUUw">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements
      contextRef="Duration_8_15_2023_To_8_15_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_yKs6Fnw-ukqovfuD-GaUEw"
      decimals="INF"
      id="Narr_tVftvRyu9Umd-LRY2pL8SQ"
      unitRef="Unit_Standard_item_dyUGGngOZEG007onwpOmGw">8</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_8_15_2023_To_8_15_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_dHfFwQNMk0elAnvVrjK_Aw"
      decimals="INF"
      id="Narr_QSBRnYjnBUKu3vpZX31yLw"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">571362</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_8_15_2023_To_8_15_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_dHfFwQNMk0elAnvVrjK_Aw"
      id="Narr_HOPWrCxFzEyJBgs1O3cXGQ">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements
      contextRef="Duration_8_15_2023_To_8_15_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_dHfFwQNMk0elAnvVrjK_Aw"
      decimals="INF"
      id="Narr_oA7V78vnmUqEhU1pe2OhcQ"
      unitRef="Unit_Standard_item_dyUGGngOZEG007onwpOmGw">12</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant
      contextRef="Duration_8_15_2023_To_8_15_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_fMPAZxDZF0CjT3jIiJlVWg"
      decimals="-5"
      id="Narr_iOI2nOX7y0Sknt536iWChA"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">2700000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_8_15_2023_To_8_15_2023_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member__6-TI0LU8kycGOjbjujtRw"
      id="Narr_01eOZXisHEWZnRFWzx0U2A">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_8_15_2023_To_8_15_2023_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member__6-TI0LU8kycGOjbjujtRw"
      decimals="INF"
      id="Narr_uH504OlqlEyT3sxDs50krQ"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">1056315</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_8_15_2023_To_8_15_2023_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member__6-TI0LU8kycGOjbjujtRw"
      decimals="2"
      id="Narr_Lwf959kMNUC3KTsfoAXfZA"
      unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg">1.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_8_15_2023_To_8_15_2023_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member__6-TI0LU8kycGOjbjujtRw"
      id="Narr_3ap6OD14y02-Q4D1A285Pg">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements
      contextRef="Duration_8_15_2023_To_8_15_2023_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member__6-TI0LU8kycGOjbjujtRw"
      decimals="INF"
      id="Narr_LhhOjSuXGEmNTWJK4ZLpYg"
      unitRef="Unit_Standard_item_dyUGGngOZEG007onwpOmGw">12</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant
      contextRef="Duration_8_15_2023_To_8_15_2023_srt_TitleOfIndividualAxis_plx_OfficersAndOtherEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member__6-TI0LU8kycGOjbjujtRw"
      decimals="-5"
      id="Narr_A7WWa1yR_kKKY75350_TTA"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">1500000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_9_14_2023_To_9_14_2023_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_hR8IXrLXFkKqN26E-oWJTg"
      id="Narr_ly_ciIdI9EyELBLzU6zksg">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_9_14_2023_To_9_14_2023_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_hR8IXrLXFkKqN26E-oWJTg"
      decimals="INF"
      id="Narr_vQTomEGbK0i02qa0xBMDjA"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">85715</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_9_14_2023_To_9_14_2023_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_hR8IXrLXFkKqN26E-oWJTg"
      decimals="2"
      id="Narr_fu-GpIOnokKs5b6dvwhS2w"
      unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg">1.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_9_14_2023_To_9_14_2023_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_hR8IXrLXFkKqN26E-oWJTg"
      id="Narr_4Cp3GAeXbEGeozmQ69w70A">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements
      contextRef="Duration_9_14_2023_To_9_14_2023_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_hR8IXrLXFkKqN26E-oWJTg"
      decimals="INF"
      id="Narr_VuABQEWHOkC9u0QPyuBYig"
      unitRef="Unit_Standard_item_dyUGGngOZEG007onwpOmGw">12</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant
      contextRef="Duration_9_14_2023_To_9_14_2023_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_hR8IXrLXFkKqN26E-oWJTg"
      decimals="-5"
      id="Narr_dBFZfW6EfkexMQ0hnjaAbg"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">100000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_9_29_2023_To_9_29_2023_srt_TitleOfIndividualAxis_plx_NonExecutiveDirectorsOtherThanChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_Bq1ATcIXikWWLcA2fkgW1Q"
      id="Narr_RyasA4daR0en530R8HrwSA">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_9_29_2023_To_9_29_2023_srt_TitleOfIndividualAxis_plx_NonExecutiveDirectorsOtherThanChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_Bq1ATcIXikWWLcA2fkgW1Q"
      decimals="INF"
      id="Narr_ohljFngQ6UiVkWJ3ImhuGQ"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">308380</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_9_29_2023_To_9_29_2023_srt_TitleOfIndividualAxis_plx_NonExecutiveDirectorsOtherThanChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_Bq1ATcIXikWWLcA2fkgW1Q"
      decimals="2"
      id="Narr_9_Y1_xdwj0SdTRk7RUYuGA"
      unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg">1.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_9_29_2023_To_9_29_2023_srt_TitleOfIndividualAxis_plx_NonExecutiveDirectorsOtherThanChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_Bq1ATcIXikWWLcA2fkgW1Q"
      id="Narr_BFjenqRABEKOOOPHf3CQNQ">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements
      contextRef="Duration_9_29_2023_To_9_29_2023_srt_TitleOfIndividualAxis_plx_NonExecutiveDirectorsOtherThanChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_Bq1ATcIXikWWLcA2fkgW1Q"
      decimals="INF"
      id="Narr_QTzI_Zx83k2Vci6CoHxKfA"
      unitRef="Unit_Standard_item_dyUGGngOZEG007onwpOmGw">12</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant
      contextRef="Duration_9_29_2023_To_9_29_2023_srt_TitleOfIndividualAxis_plx_NonExecutiveDirectorsOtherThanChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_Bq1ATcIXikWWLcA2fkgW1Q"
      decimals="-5"
      id="Narr_PopcxVCJOEWdZGIcQqJMOA"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">400000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tb_1qUgChpJWkmJaywcyqoDYw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average grants date fair value (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 79.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected life (Years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_F7acgBp0NEaoQj7JasNEtg"
      decimals="2"
      id="Tc_L9UOE5pXlkqbAZens8zAdw_1_2"
      unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg">1.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_n9IBOPzcQEm-_TNOT65ZwQ"
      decimals="2"
      id="Tc_DlcIQ0gAyUqZZ3cgj8R-3Q_2_2"
      unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg">1.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_F7acgBp0NEaoQj7JasNEtg"
      decimals="4"
      id="Tc_Kes3hrwrBEee_x5agdNO8Q_3_2"
      unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw">0.0440</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_F7acgBp0NEaoQj7JasNEtg"
      decimals="4"
      id="Tc_2NydLLgeA0208YywzRykGg_4_2"
      unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw">0.7940</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_F7acgBp0NEaoQj7JasNEtg"
      decimals="2"
      id="Tc_Xh-UeIXOSE-9QyW2nkQtyA_5_2"
      unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_F7acgBp0NEaoQj7JasNEtg"
      id="Tc_Ww33gYu8C0a9qQPArzaEpA_6_2">P5Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tb_Gb4nUA7FFkOqDAZ0pkPsMQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 6 &#x2013; EARNINGS (LOSS) PER SHARE&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Basic earnings (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of Common Stock outstanding during each period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Diluted earnings per share is calculated by dividing the net income by the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#x201c;if-converted&#x201d; method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Basic and diluted net earnings (loss) per share attributable to common stockholders were calculated as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:29.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(In&#160;thousands,&#160;except&#160;share&#160;data)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net income (loss)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,852)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,567)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,356&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,187)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Add:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Financial expenses of 2024 Notes*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,766)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,610)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net income (loss) for diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,618)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,567)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,746&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,187)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average shares of Common Stock outstanding for basic calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 72,281,681&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 49,498,105&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 65,811,506&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47,582,733&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average dilutive effect of 2024 Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,500,998&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,981,660&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average dilutive effect of stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,247,115&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average shares of Common Stock outstanding for diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 83,782,679&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 49,498,105&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 81,040,281&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47,582,733&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 10pt 54pt;"&gt;* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the period and inclusion of make-whole interest payments that will be incurred upon conversion.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Diluted earnings (loss) per share do not include 19,429,910 and 18,399,260 shares of Common Stock underlying outstanding stock options and warrants of the Company for the three and nine months ended September&#160;30, 2023, respectively, because the effect would be anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Diluted earnings (loss) per share do not include 33,922,624 and 33,295,154 shares of Common Stock underlying outstanding stock options, warrants and the 2024 Notes for the three and nine months ended September&#160;30, 2022, respectively, because the effect would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tb_lO56xroqA0KP4RLvYbWGeg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:29.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(In&#160;thousands,&#160;except&#160;share&#160;data)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net income (loss)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,852)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,567)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,356&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,187)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Add:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Financial expenses of 2024 Notes*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,766)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,610)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net income (loss) for diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,618)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,567)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,746&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,187)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average shares of Common Stock outstanding for basic calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 72,281,681&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 49,498,105&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 65,811,506&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47,582,733&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average dilutive effect of 2024 Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,500,998&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,981,660&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average dilutive effect of stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,247,115&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average shares of Common Stock outstanding for diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 83,782,679&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 49,498,105&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 81,040,281&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47,582,733&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 10pt 54pt;"&gt;* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the period and inclusion of make-whole interest payments that will be incurred upon conversion.&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"
      decimals="-3"
      id="Tc_q9ViZB5T80CftMJMH0SBUA_4_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-1852000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q"
      decimals="-3"
      id="Tc_izvHNV5vMUuk1JFoiCGgYQ_4_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-3567000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_ZbsOCAmFR0ewDjDpQZ-R6w_4_9"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">14356000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_0jFIzkXizUORZaTWdUWTTw_4_12"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-11187000</us-gaap:NetIncomeLoss>
    <us-gaap:DilutiveSecurities
      contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"
      decimals="-3"
      id="Tc_xvqlqRK4I0uqP0htPPsG7A_6_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-1766000</us-gaap:DilutiveSecurities>
    <us-gaap:DilutiveSecurities
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_b1IAf62yDU23p_yCDd16HQ_6_9"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-1610000</us-gaap:DilutiveSecurities>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"
      decimals="-3"
      id="Tc_-HGYh6gqb0KzSbPYiKAL3g_7_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-3618000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q"
      decimals="-3"
      id="Tc_Pd32DO4k1kGfiiCDlok7KQ_7_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-3567000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_JkgILYQrwUWiLyX53-NoxA_7_9"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">12746000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="-3"
      id="Tc_-bR-rl07n0uyAL_k3EDWDg_7_12"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-11187000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"
      decimals="0"
      id="Tc_9J_QAB3F6Em8Y2migqHapQ_9_3"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">72281681</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q"
      decimals="0"
      id="Tc_7uXqG6ogZ0uL-fJEIkyBtA_9_6"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">49498105</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="0"
      id="Tc_BFl-FqOWCEmG5PZNlfIhsw_9_9"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">65811506</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="0"
      id="Tc_v9NmF0MmmEi70Rz5Rn2uGQ_9_12"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">47582733</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"
      decimals="0"
      id="Tc_JxE4BShAhkaBMCPwldlEBQ_10_3"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">11500998</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="0"
      id="Tc_LY9PwIsDKkWqjDq3xhXZRw_10_9"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">13981660</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="0"
      id="Tc_2NcZYlB3SkiOAej-hvgtCw_11_9"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">1247115</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"
      decimals="0"
      id="Tc_F_gr67VSVE2udycTl4uALQ_12_3"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">83782679</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2022_To_9_30_2022_3TUtAAwn-0yoLgfjZmT78Q"
      decimals="0"
      id="Tc_KWfFtnhRDU2irafuq_X_TQ_12_6"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">49498105</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="0"
      id="Tc_LRBkAwPl40enZLrLwkVJeQ_12_9"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">81040281</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="0"
      id="Tc_txr5qlmml0OSJ1RMP4HQ1A_12_12"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">47582733</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_7EmATnfMK0aTY5iMdjV79w"
      decimals="INF"
      id="Narr_6fPkzvvsdUqFqU1vSHmWvg"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">19429910</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_3o-LEw18Kkyl1N3FcZEEcQ"
      decimals="INF"
      id="Narr_U85CfE2We0uFXV-6_27SVg"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">18399260</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_c1_YEps6pEOYi4wGlehl0Q"
      decimals="INF"
      id="Narr_QRcvyvcEiE6Q4fQwuL9eVw"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">33922624</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_gylvzioUakSqiKwd3I9tug"
      decimals="INF"
      id="Narr_Fz1OD9jbFEyqYgUtCqbW3Q"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">33295154</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tb_m8_Mfv_erUaiHI4p2moL1Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 7 &#x2013; TAXES ON INCOME&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="background:#ffffff;"&gt;The following table summarizes the Company&#x2019;s taxes on income:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,728&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,092)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 133&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 636&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company had an effective tax rate of 4% for the nine months ended September&#160;30, 2023, compared to an effective tax rate of 0% for the nine months ended September&#160;30, 2022. For the nine months ended September&#160;30, 2023, the difference between the Company&#x2019;s effective tax rate and the U.S.&#160;federal statutory rate of 21% was the result of the provision for current taxes on income mainly derived from U.S. taxable GILTI income mainly in respect of milestone payments and Section&#160;174 of the U.S.&#160;Tax Cuts and Jobs Act, which was enacted in December 2017 (the &#x201c;TCJA&#x201d;), partially offset by the release of the valuation allowance on net operating losses (NOLs) in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;Following the regulatory approvals for Elfabrio in May 2023, the receipt of the $20.0&#160;million milestone payment and the launch of Elfabrio in the United States, the Company released valuation allowance previously recorded on deferred tax assets in respect of its NOLs in the United States resulting in a net tax benefit of $3.1&#160;million. The Company concluded that, based upon the preponderance of positive evidence over negative evidence and the anticipated ability to use the deferred tax assets, it was more likely than not that these deferred tax assets would be realizable due to forecasted profits. The Company considered the following: (i)&#160;cumulative profits for tax over the previous 12 quarters in its U.S. operations; (ii)&#160;the impact of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Section&#160;174 of the TCJA which requires the Company to capitalize and amortize its research and development expenses over 15 years; and (iii) its forecasted profits in the United States following the regulatory approvals of Elfabrio.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tb_DMTK64XJjU6I1WvGvCXtMA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,728&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,092)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 133&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 636&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"
      decimals="-3"
      id="Tc_F0x2LiEvH0ydmUCUsH9yiw_3_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">95000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_8HyMpj0XuEK45nPhfsyaZw_3_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">3728000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"
      decimals="-3"
      id="Tc_dKQvw0c-YkeYCmAgmME8JA_4_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">38000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_MMfJi-GKOESaij2Bdq7PVw_4_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">-3092000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"
      decimals="-3"
      id="Tc_DrJQmC76DUKmrFhh4a8mzQ_5_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">133000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="-3"
      id="Tc_8xqaOvlHBEizwW1a7psdbg_5_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">636000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="2"
      id="Narr_miufEYLb7E2Gjp_juFgMTw"
      unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw">0.04</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2022_To_9_30_2022_0tW5xt0yD06xLrx5mXpkbA"
      decimals="2"
      id="Narr_USexgcvYlUeVC6R_b2Zx2w"
      unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      decimals="INF"
      id="Narr_F4QXr__5oUSD694JJo303Q"
      unitRef="Unit_Standard_pure_XT4a4orCSkyydmsUoH4dNw">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <plx:MilestonePaymentToRegulatoryApprovals
      contextRef="As_Of_5_31_2023_Qhp5my5CU0-pA3CT50IRVw"
      decimals="-5"
      id="Narr_iDyUBQPXXkmqBrD1KITbMw"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">20000000.0</plx:MilestonePaymentToRegulatoryApprovals>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg"
      decimals="-5"
      id="Narr_LNO4RHzIeUq7vOUcy9wF2A"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">3100000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tb_h0OZ6P5AF0qSzt2GBfeKWw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 8 &#x2013; &lt;/b&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance sheets:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts payable and accruals &#x2013; other:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,239&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,216&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest Payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 123&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 719&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Provision for vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,471&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,404&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,249&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,478&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Royalties payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 332&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 781&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,257&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Reserve for deductions from revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,816&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment suppliers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 253&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 143&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,740&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,271&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <plx:SupplementaryBalanceSheetsInformationTableTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tb_0DIj7WFHHUyrSY7QQzfdTQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts payable and accruals &#x2013; other:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,239&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,216&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest Payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 123&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 719&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Provision for vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,471&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,404&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,249&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,478&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Royalties payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 332&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 781&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,257&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Reserve for deductions from revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,816&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment suppliers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 253&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 143&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,740&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,271&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</plx:SupplementaryBalanceSheetsInformationTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_vm6jQw2Tc0mELJz7dMGJQw_4_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">1239000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_5KnRVTwEsUmgILN-XEk2fA_4_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">1216000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_Zf7vD-bRqUKEDDBXxuGkJQ_5_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">123000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_kOmreecsTkev10Mdpz29wQ_5_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">719000</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_oyGkpDZhUUmJonry3mhegQ_6_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">1471000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_-dKofppgSkCcjUWVPpPwIQ_6_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">1404000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_SKNi1zQ2hU6fAWb5BR9g2w_7_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">9249000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_r0RFVHZcgUKqo-Z7XRW5cQ_7_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">7478000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_mAU9MyrxAUWI6AdFXMS_qw_8_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">332000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_vt41thqyPk2HEytHaw1vMg_8_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">781000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_RWERPmXhTkGStmK0susRcw_9_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">3257000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_k7FNdnM6I0WSUi2ZfShdTA_9_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">530000</us-gaap:TaxesPayableCurrent>
    <plx:ReserveForDeductionsFromRevenueCurrent
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_tPsJp1hSVkePldqPxmg0Og_10_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">2816000</plx:ReserveForDeductionsFromRevenueCurrent>
    <plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_BVqnVllCW0eXxM6Gvf9oKA_11_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">253000</plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent>
    <plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_cQb5TGiFLkatqnPoqtooPA_11_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">143000</plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ"
      decimals="-3"
      id="Tc_zITyN_3P-UW3eXbV8VJFLg_12_3"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">18740000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022_pOaLmvV2RkyS9WE64DFbaQ"
      decimals="-3"
      id="Tc_GycKLvvrSUCmKcjQxeBGHg_12_6"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">12271000</us-gaap:AccountsPayableCurrent>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug"
      id="Tb_cll6vfPrGUibToooafizcg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 9 &#x2013; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;1)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;On October&#160;4, 2023 the Company collected approximately $6.4&#160;million from sales to Chiesi&lt;span style="background:#ffffff;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;2)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;On October&#160;15, 2023, the Company granted, with the approval of the Company&#x2019;s compensation committee, 10-year options to purchase 250,000 shares of Common Stock to a new officer of the Company under the Plan. The options have an exercise price equal to $1.48 per share and vest over a three-year period in 12&#160;equal quarterly increments. The Company estimated the aggregate fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $0.26&#160;million.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;3)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;Because the Company's operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;In October 2023, Hamas terrorists infiltrated Israel&#x2019;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#x2019;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets while simultaneously launching extensive rocket attacks on the Israeli population and industrial centers. At the same time, clashes between Israel and Hezbollah in Lebanon have increased. In response, Israel&#x2019;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#x2019;s defensive measures, may result in a greater regional conflict. It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on our business, operations and financial conditions. The ongoing conflict is rapidly evolving and developing, and could disrupt certain of our business and operations, among others.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <plx:ProceedsFromSaleOfProducts
      contextRef="Duration_10_4_2023_To_10_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_4Sfq-5ZsukC6Bl13MlMlcw"
      decimals="-5"
      id="Narr_Irsi69UX_ECKTts5OXJedw"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">6400000</plx:ProceedsFromSaleOfProducts>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_10_15_2023_To_10_15_2023_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_8Dni7RhDUkWYV5S6kg5TFg"
      id="Narr_GFpf3Pl4dkqTCy1DhGrrcg">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_10_15_2023_To_10_15_2023_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_8Dni7RhDUkWYV5S6kg5TFg"
      decimals="INF"
      id="Narr_Rtqm2hUnRk-hnA01NLlWMA"
      unitRef="Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_10_15_2023_To_10_15_2023_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_8Dni7RhDUkWYV5S6kg5TFg"
      decimals="2"
      id="Narr_spC05Pmfl0ODXHG0DGyJgw"
      unitRef="Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg">1.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_10_15_2023_To_10_15_2023_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_8Dni7RhDUkWYV5S6kg5TFg"
      id="Narr_7sm6n3l5LkCmiUUJzZMjSQ">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements
      contextRef="Duration_10_15_2023_To_10_15_2023_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_8Dni7RhDUkWYV5S6kg5TFg"
      decimals="INF"
      id="Narr_tWWz6j_Y1EqSqTU51IhRFw"
      unitRef="Unit_Standard_item_dyUGGngOZEG007onwpOmGw">12</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOnDateOfGrant
      contextRef="Duration_10_15_2023_To_10_15_2023_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_8Dni7RhDUkWYV5S6kg5TFg"
      decimals="-4"
      id="Narr_1mAj0T8rBE2cNOxFT_xt6w"
      unitRef="Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw">260000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOnDateOfGrant>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Tc_3ak7Ebjw5kG6Kyjj5L8Eqg_10_2"
          xlink:label="Tc_3ak7Ebjw5kG6Kyjj5L8Eqg_10_2"
          xlink:type="locator"/>
        <link:footnote id="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" xlink:label="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; Authorized &#x2013; as of September&#160;30, 2023 and December&#160;31, 2022 &#x2013; 185,000,000 and 144,000,000 shares, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_3ak7Ebjw5kG6Kyjj5L8Eqg_10_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_9yhZrR-b-EGqxOFYn_g5Nw_19_2"
          xlink:label="Tc_9yhZrR-b-EGqxOFYn_g5Nw_19_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_9yhZrR-b-EGqxOFYn_g5Nw_19_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_GQwKI1DfuUWngKk4EwwxsA_33_2"
          xlink:label="Tc_GQwKI1DfuUWngKk4EwwxsA_33_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_GQwKI1DfuUWngKk4EwwxsA_33_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_Xmtr-8UVh0W8zZUKbrcCNg_8_2"
          xlink:label="Tc_Xmtr-8UVh0W8zZUKbrcCNg_8_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Xmtr-8UVh0W8zZUKbrcCNg_8_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_yK0f7kNti0uhUFBdgENL7A_25_2"
          xlink:label="Tc_yK0f7kNti0uhUFBdgENL7A_25_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_yK0f7kNti0uhUFBdgENL7A_25_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_UwQx0fb9LkSfPmBHKpezKQ_16_2"
          xlink:label="Tc_UwQx0fb9LkSfPmBHKpezKQ_16_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_UwQx0fb9LkSfPmBHKpezKQ_16_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_70Fh3FgfJ0i1a7pZPnjd4Q_11_2"
          xlink:label="Tc_70Fh3FgfJ0i1a7pZPnjd4Q_11_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_70Fh3FgfJ0i1a7pZPnjd4Q_11_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_b7Y7BJIK3UedTfkl07xmNQ_20_2"
          xlink:label="Tc_b7Y7BJIK3UedTfkl07xmNQ_20_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_b7Y7BJIK3UedTfkl07xmNQ_20_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_J0Q06cNZT0aJQvKE4KrnZg_6_2"
          xlink:label="Tc_J0Q06cNZT0aJQvKE4KrnZg_6_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_J0Q06cNZT0aJQvKE4KrnZg_6_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_Bvi01VlUckODSjGL09xVuQ_23_2"
          xlink:label="Tc_Bvi01VlUckODSjGL09xVuQ_23_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Bvi01VlUckODSjGL09xVuQ_23_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_xBU_amZ-LkuBgXXAAuDnEA_29_2"
          xlink:label="Tc_xBU_amZ-LkuBgXXAAuDnEA_29_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_xBU_amZ-LkuBgXXAAuDnEA_29_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_XGzOlH__60G7j3Mh5UicPQ_13_2"
          xlink:label="Tc_XGzOlH__60G7j3Mh5UicPQ_13_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_XGzOlH__60G7j3Mh5UicPQ_13_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_1eTA6uTMHkyR3m-Xxn97EQ_14_2"
          xlink:label="Tc_1eTA6uTMHkyR3m-Xxn97EQ_14_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_1eTA6uTMHkyR3m-Xxn97EQ_14_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_5JtCaCayY02Yie7S2mhEPw_30_2"
          xlink:label="Tc_5JtCaCayY02Yie7S2mhEPw_30_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_5JtCaCayY02Yie7S2mhEPw_30_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_xfcNdFkJBECaKEusvGlF7g_35_2"
          xlink:label="Tc_xfcNdFkJBECaKEusvGlF7g_35_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_xfcNdFkJBECaKEusvGlF7g_35_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_UnYL-Dklw0Oi5ZpVIu_wxw_22_2"
          xlink:label="Tc_UnYL-Dklw0Oi5ZpVIu_wxw_22_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_UnYL-Dklw0Oi5ZpVIu_wxw_22_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_zHYnQE3siUSd8cZtbB4jMQ_17_2"
          xlink:label="Tc_zHYnQE3siUSd8cZtbB4jMQ_17_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_zHYnQE3siUSd8cZtbB4jMQ_17_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_8wtWJciV8kmbYLH3-slgtA_6_6"
          xlink:label="Tc_8wtWJciV8kmbYLH3-slgtA_6_6"
          xlink:type="locator"/>
        <link:footnote id="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" xlink:label="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:b style="font-size:8pt;font-weight:bold;">(1) Includes share-based compensation</xhtml:b></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_8wtWJciV8kmbYLH3-slgtA_6_6"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_c34c36I-G0S88s1ziCq9og_6_12"
          xlink:label="Tc_c34c36I-G0S88s1ziCq9og_6_12"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_c34c36I-G0S88s1ziCq9og_6_12"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_G0ODR8Y4jkmKMtpr632bPA_6_3"
          xlink:label="Tc_G0ODR8Y4jkmKMtpr632bPA_6_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_G0ODR8Y4jkmKMtpr632bPA_6_3"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_-7kbwyUL10qShnyaYOvqvg_6_9"
          xlink:label="Tc_-7kbwyUL10qShnyaYOvqvg_6_9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_-7kbwyUL10qShnyaYOvqvg_6_9"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_vtrKcBIMm0S36Zv8et0UtA_7_6"
          xlink:label="Tc_vtrKcBIMm0S36Zv8et0UtA_7_6"
          xlink:type="locator"/>
        <link:footnote id="_8530ca94_6c84_4f48_984f_7cc5a2959400" xlink:label="_8530ca94_6c84_4f48_984f_7cc5a2959400" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</xhtml:b></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_vtrKcBIMm0S36Zv8et0UtA_7_6"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_Wb3u-4rnKkun54FaHGKbGg_7_12"
          xlink:label="Tc_Wb3u-4rnKkun54FaHGKbGg_7_12"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Wb3u-4rnKkun54FaHGKbGg_7_12"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_y6Oll5Og3kOBM7CsL9ePzg_7_3"
          xlink:label="Tc_y6Oll5Og3kOBM7CsL9ePzg_7_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_y6Oll5Og3kOBM7CsL9ePzg_7_3"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_T8ohq58km0y3V14t17cmZA_7_9"
          xlink:label="Tc_T8ohq58km0y3V14t17cmZA_7_9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_T8ohq58km0y3V14t17cmZA_7_9"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_ohkn7emcLUW77GJO-hPiMA_8_6"
          xlink:label="Tc_ohkn7emcLUW77GJO-hPiMA_8_6"
          xlink:type="locator"/>
        <link:footnote id="_64475d15_2bf5_4e75_bed3_14deb6a39d55" xlink:label="_64475d15_2bf5_4e75_bed3_14deb6a39d55" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:b style="font-size:8pt;font-weight:bold;">(3) Includes share-based compensation</xhtml:b></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_ohkn7emcLUW77GJO-hPiMA_8_6"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_LFDGdqGoaEmMTMxTxEiR8w_8_12"
          xlink:label="Tc_LFDGdqGoaEmMTMxTxEiR8w_8_12"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_LFDGdqGoaEmMTMxTxEiR8w_8_12"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_JDDF75sBRkyjOTbTIkA6qg_8_3"
          xlink:label="Tc_JDDF75sBRkyjOTbTIkA6qg_8_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_JDDF75sBRkyjOTbTIkA6qg_8_3"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_myGHGQWRZEKv8Cpthrqxyw_8_9"
          xlink:label="Tc_myGHGQWRZEKv8Cpthrqxyw_8_9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_myGHGQWRZEKv8Cpthrqxyw_8_9"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>51
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M3GT%I#(RFJ9LI26H?LD___4Z'\6KU(5FF48J-]S%SG7$7J2-@H/-*B54Q=X
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MMEGSL=R\46X_3VB^I,P,_Q0;^^[)[$ DK6G*W T&!;DN[&_YQ?$A&O!\LF?
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MGM+TA@X>B#M08Q#M(3 W&@D]M*V(9JFZ UJ5KF6<2/K."%$4#CQ-3X8*$NX
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MI0TPZRLA],ZP&]3/S?@W4$L#!!0    ( %@^9E>&$AVT5@4  -D,   9
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M#!\?M:4+C90#=:4G%RHK,Z25\-3"M<HA1>KW#*E=<UA:4P8I)Q2"61)R8V,
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MVVF%[RM($X#KA1#Z8I@-^A=[]2]02P,$%     @ 6#YF5QKMHTO%"   31X
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M_R1>_4;RB>HYASP0; :J_O&PWR&Z^MVA>K"J<-_Z4V6MRMUMQBBPB +P?J:
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MGOL T_6U66J#NR"^@Z0"PY-%:>=IDJ?=ZHL/M5IFF#J*PJ7XZ;LJJX%"8I%
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M'H4)T.]7G*N#83:H_S4,_@=02P,$%     @ 6#YF5UW^"IV>!0  G P  !D
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MJ-.TK:1B<K+&02LTF]8A_<G[ /28^X'"+X=@1&]\7.%$#2GCZC&D7 F<K0@
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M(\1!O-IJ/R-!ZOKI=L3LY<C2SOZDM6V07Y*WNKR\[&(##!I2R#E&,*+DQ($
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M\/F\A$6X?VB!\"UTK_\'4$L#!!0    ( %@^9E=#]@YUE0(  "0&   9
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M6HA4*-/VT I!VST;<DBL.G%F.Z7MKY^=0.IHE.UM+[;/[3O?\>5XO&/\660
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M5]+0]*BV*8UK5-:![A,IS=ZP 9H/0/@;4$L#!!0    ( %@^9E>&0O@)0 ,
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MN%3%IM7JP64#S5"BFHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ$:6UJTN3O-1.WO9
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M1&GMFRPVZ=6^,K:VG@+Y=J,^75^M'+K=HYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ
M:B&J1936KB9-2+6OO>DD2!\-K:*:@6HFJEFH9J.:@VHNJGFHYJ-:@&HAJD64
MUBXS>E-FU!'8R\DDJ4<M\50\S8<4XCK^&=<W;_F:B5'V6 UDC&K ,\WFRXF1
M459T']M1]W-PO4%SL:AFHIK5WTYN=HS';;13!]5<5/-0S4>U -5"5(LHK5U(
M7MQC_I4 [68A>:XC5I97>S#5X.CQ*6/R^4Y\D?>+:5QF^4]QF4Y$?65EF8^3
MJFVXGHKM+C+LK>C9>]&S-Z-G[T:_?17/TY.N*L/>:9Z]U3Q[KWGV9O/LW>;9
MV\VS]YM_BX!LOPG(]I7)N*XY%O%K?>Y.9\4@<WLC5#-0S40U"]5L5'-0S44U
M#]5\5 M0+42UB-+:=:5)Q/:';SO;@F9?4<U -1/5+%2S4<U!-1?5/%3S42U
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M]/\)"K- /U]QW9:*P+3,\H\G_ M02P,$%     @ 6#YF5T;,\AH4 @  +P0
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M*O-%GJ1A[YF-<#\9T$-8H;0(2F-0&D?1[&08P1JZ!>M13W*DWF$V)N[2SI&
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M S$F9,W4@F^_XCZ>GN&+.)/V%[;[LYX#T5HJGNW!VD%&\_)+WO9Y. +XO1,
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MK@W4^PUC\G6@6Y6F-4W^!5!+ P04    " !8/F97@D$)1%D$  #&%0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6RMF-MNVS@0AE]EH"T6+5!$!Q^2
M9FT#2>2B ;9)6B?9B\5>,-+8)B*)"DG9"9"'7U*29<N5B1K@C2W2G)^<SQQJ
MAJ,UX\]BB2CA-4TR,7:64N;GKBNB):9$G+ <,_7+G/&42-7D"U?D'$E<&J6)
M&WC>T$T)S9S)J.R[XY,1*V1",[SC((HT)?SM$A.V'CN^L^GX21=+J3O<R2@G
M"YRA?,CON&JYC4I,4\P$91EPG(^="_\\](?:H!SQ2'$M=IY!N_+$V+-N7,=C
MQ],KP@0CJ26(^EKA%2:)5E+K>*E%G69.;;C[O%'_6CJOG'DB J]8\@^-Y7+L
MG#D0XYP4B?S)UM^P=FB@]2*6B/(3UO58SX&H$)*EM;%:04JSZIN\UB!V#/J#
M P9!;1#L&03! 8->;=#;-S@T0[\VZ)=D*E=*#B&19#+B; U<CU9J^J&$65HK
M]VFF__>9Y.I7JNSD9/9P.9O^>)C>W,/T47W.X&.(DM!$?((/X()8$HX": 8/
M&97BL^I4S_=+5@B2Q6+D2K4(+>5&]81A-6%P8,(>?&>97 J89C'&;7M7+;[Q
M(-AX<!D8!6\C>0+^X#,$7M"#AUD('S]\ BHQW76@^NI8[M5OJ'O]MGJ7UV:9
M&>8GT/-JF>VZ#/[WFG^P5TKW#TE+%CW#;:[#J,O!2Z.Y/E?.14XB'#OJX!#(
M5^A,_OS#'WI_==&R*19:$FMAZS?8^J5Z[Q"VXDG@2X&9A.E*?_[[MQH!UVK?
MB/^Z,/9M8K0I%EH2:V$<-!@'QMTW?44>48&0<QHAO!_<VQ5$H]BQ$&V*A978
M:2FF7Y:KB7_2ZX_<50><80-G: [-_3WV#E=+BH+"Q8(CJM>G[*1D5#V6DDVQ
MT))8B^9I0_/4;L2>VL1H4RRT)-;">-9@/#-NRCO.(L18P%?.4IB1!.%V#JHW
M+B(I= 1WL31J'LNR$AONQ-JP[WE-K%6,+,W88O2E8?3EV,!MO695^T:EM&P^
M5X<>5RV=9L,TS1/VAEB/O<XB9:JR6KA+2-8%U;B(8Z':% LMB;7@^]XV)_7L
M1GJM9XFD5;70EEJ;Y4Y^[QNW\CWR5&U4(&O"XTYV9GO?@S<DO#-U-IL>#<J2
M6AM4L 45&!V]*=(G%<L*%:N#7#+("QXM55FY*2/>#;E-K3_8.=:"@>?M'VQ7
MYG4<3<V26IO:MOCPS=7'D?E?K=9.L_IG^X2L5AFVU-J$MG6&;\R_)X\H),T6
MD".GK#L"S0(]0P!:K2-LJ;5!;2L)WUQ*;$#1#+(F%E\*PB7RY$UU1[Q*F=4N
MT^5])\K!+S'H!_N[RVK=8$NM#6U;8?CF$F.JF*5$8@QS0CFL2%(@L QBU:?Y
M+3@ITY?.I*[6WDW$@N$OQY75 L*66H7+W;GX2I$OR@M$ 1$K,EG=@36]S27E
M17DUYVZ'5S><WPE?4'7H)SA7IM[)J?I?>75I6#4DR\MKM"<F)4O+QR62&+D>
MH'Z?,R8W#3U!<W4[^1]02P,$%     @ 6#YF5V"9I"8X P  [!,   T   !X
M;"]S='EL97,N>&ULW5A=;]HP%/TKD;M.K30U0-:4K("T(56:M$V5VH>]588X
M8,FQ,\=TL%\_WS@)'_5%K \;+*C$OL?GW&/[IG$[*,U*L(<Y8R98YD*60S(W
MIO@0AN5TSG):7JF"28MD2N?4V*Z>A66A&4U+(.4B['4Z<9A3+LEH(!?Y76[*
M8*H6T@Q)W(8"=_N<#DDW?D\")S=6*1N2IXNW/Q;*W+X)W/WLW=E9Y^GR=C=^
M40&7)/2*7A\@>M7!=2V&2<>'2>_51L5OML6;\>=6K"6?8^2^A[QFHK3DH GM
MF4XE'-:[/1ID2JXW/2(N8#/3G 7/5 S)F H^T1Q8&<VY6+EP#P)3)90.C*TV
M:Z4+D?*7@[NN!X58Z^1<*EWE=AG<]Z0>O@,T/3#(A6@-]H@+C 8%-89I>6<[
MU> J^ (*ZO;CJK .9YJNNKUKLB94-YMDHG3*=)NF2YK0:"!8!G8TG\WA;E01
M FB,RFTCY72F)*T\-(RZ866G3(@'>$J_9UO:RVQC3SNPH[)M6D-UT\FX#NAO
MJCGM3=GH5;I!P9^5^;2PTY%5'VJ%W6N6\6757V:M 4R]BZO3HA"KCX+/9,[<
MY ]..!K0AA?,E>:_;#8HE:D-,$V"9Z8-GVY&?FI:/+*E:<IIF>&>>R?H^>^N
M\XQ)IJG8-&UK_YA7^=6.HYM_9;GZK;)KV.NQ?O4>N\GK4S 9GX+)DZC)_O&;
MC)+C]U@?ZX[.9%@?,C9.,EOGF#8:P'EQ2+[!R52LDP:3!1>&R[HWYVG*Y(OC
MC)4W=&+_E-G2M^-3EM&%,(\M."3K]E>6\D6>M*/N82'J4>OV%YA>-VX/JS87
MERE;LG1<=_5L4C4#V[!9ZPL(N\A==?D1C.,P/P(8E@=S@'$<"\OS/\VGC\['
M89BWOA?IHYP^RG$L'S*N/E@>/R>QEW^F21)%<8RMZ'CL=3#&UBV.X<>OAGD#
M!I8',OW96N.[C5?(_CK ]G1?A6 SQ2L1FRF^UH#XUPT82>+?;2P/,+!=P&H'
M\OOS0$WY.5$$NXIYPYY@'$D2#(%:]-=H'".K$\/'OS_84Q)%2>)' /,[B"(,
M@:<11S 'X %#HJAZ#^Z\C\+F/16N_[\W^@U02P,$%     @ 6#YF5Y>*NQS
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MW@J^HYGKB:. :\U;W\J8D"5TQ9K RUOL?%T*3%0]$F%GWT%FT!6K <RZG9.
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M%.@MJ+>\4V\?'J7S8\]SC?N_D^K0O^O&[8?E\^;D&Q]PMG#FN_\%4$L#!!0
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 6#YF5PG;AQSN    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
M6#YF5YE<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " !8/F97)B];R.T%  #D'P  &
M    @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
M6#YF5],D(1;4!0  NQ@  !@              ("!, X  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( %@^9E?:&3T,4 8  -P;   8
M          " @3H4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    " !8/F97"P#TT\D#  ![$@  &               @(' &@  >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 6#YF5S9&><A\"0  C40
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M965T.2YX;6Q02P$"% ,4    " !8/F97AA(=M%8%  #9#   &0
M    @(%D4   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M %@^9E=VH>U/"P,  +T'   9              " @?%5  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ 6#YF5QKMHTO%"   31X  !D
M             ("!,UD  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " !8/F97]\&/9;0%   ($@  &0              @($O8@  >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( %@^9E>!#?,4, 4
M -,,   9              " @1IH  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ 6#YF5\K\R[,S P  00@  !D              ("!
M@6T  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !8/F97
M7?X*G9X%  "<#   &0              @('K<   >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( %@^9E?.7%@_:1D  )%.   9
M      " @<!V  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ 6#YF5T/V#G65 @  ) 8  !D              ("!8)   'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " !8/F97@V*)7G,"  #\!0
M&0              @($LDP  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( %@^9E<HQ@S>]P(  '\'   9              " @=:5  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ 6#YF5W]8!%F.
M @  Q 4  !D              ("!!)D  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " !8/F97+S#]MO(#  #M"P  &0
M@(')FP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( %@^
M9E=EQ@($B (   P&   9              " @?*?  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ 6#YF5X9"^ E  P  ^ <  !D
M         ("!L:(  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    " !8/F97\;08UQD0  "M]   &0              @($HI@  >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( %@^9E<GVNK;I (  .X&
M   9              " @7BV  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ 6#YF5SW4-4'- @  _0@  !D              ("!4[D
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " !8/F971LSR
M&A0"   O!   &0              @(%7O   >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    ( %@^9E=\!-5AO0,  "\2   9
M  " @:*^  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
M6#YF5^MWIW3@!P  !%8  !D              ("!EL(  'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    " !8/F97FKIJF&4)  "3:P  &0
M            @(&MR@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( %@^9E>F;F:PVP(  %D'   9              " @4G4  !X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ 6#YF5T8AZ&+]!
M/AH  !D              ("!6]<  'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    " !8/F97=^%3-J<#   5$   &0              @(&/
MW   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( %@^9E<L
M@O!$:0,  *8*   9              " @6W@  !X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ 6#YF5X)!"419!   QA4  !D
M     ("!#>0  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
M" !8/F978)FD)C@#  #L$P  #0              @ &=Z   >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( %@^9E>7BKL<P    !,"   +              "
M 0#L  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( %@^9E?ZL^GB;@,  %X8   /
M              "  >GL  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !8
M/F97UOKYL7@!   #%@  &@              @ &$\   >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !8/F97ZXBZY94!  ""%@  $P
M            @ $T\@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     +  L
+ .L+  #Z\P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>129</ContextCount>
  <ElementCount>193</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>43</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurement</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenues</Role>
      <ShortName>REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - STOCK TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactions</Role>
      <ShortName>STOCK TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - EARNINGS (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureEarningsLossPerShare</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - TAXES ON INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncome</Role>
      <ShortName>TAXES ON INCOME</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>30203 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventories</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurement</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>30403 - Disclosure - REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesTables</Role>
      <ShortName>REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRevenues</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30501 - Disclosure - STOCK TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactionsTables</Role>
      <ShortName>STOCK TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureStockTransactions</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30603 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureEarningsLossPerShareTables</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureEarningsLossPerShare</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30703 - Disclosure - TAXES ON INCOME (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeTables</Role>
      <ShortName>TAXES ON INCOME (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncome</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30803 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails</Role>
      <ShortName>INVENTORIES (Schedule of Inventory) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventoriesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40401 - Disclosure - REVENUES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesDetails</Role>
      <ShortName>REVENUES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRevenuesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40501 - Disclosure - STOCK TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactionsDetails</Role>
      <ShortName>STOCK TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureStockTransactionsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40502 - Disclosure - STOCK TRANSACTIONS - Stock based compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails</Role>
      <ShortName>STOCK TRANSACTIONS - Stock based compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40503 - Disclosure - STOCK TRANSACTIONS - Schedule of Weighted average assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactionsScheduleOfWeightedAverageAssumptionsDetails</Role>
      <ShortName>STOCK TRANSACTIONS - Schedule of Weighted average assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40601 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureEarningsLossPerShareTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40701 - Disclosure - TAXES ON INCOME (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails</Role>
      <ShortName>TAXES ON INCOME (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncomeTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="plx-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40901 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>36</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>plx-20230930.xsd</File>
    <File>plx-20230930_cal.xml</File>
    <File>plx-20230930_def.xml</File>
    <File>plx-20230930_lab.xml</File>
    <File>plx-20230930_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="plx-20230930x10q.htm">plx-20230930x10q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>plx-20230930x10q005.jpg</File>
    <File>plx-20230930x10q006.jpg</File>
    <File>plx-20230930x10q007.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="381">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>57
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "plx-20230930x10q.htm": {
   "nsprefix": "plx",
   "nsuri": "http://www.protalix.com/20230930",
   "dts": {
    "schema": {
     "local": [
      "plx-20230930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "plx-20230930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "plx-20230930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20230930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20230930_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "plx-20230930x10q.htm"
     ]
    }
   },
   "keyStandard": 154,
   "keyCustom": 39,
   "axisStandard": 17,
   "axisCustom": 0,
   "memberStandard": 25,
   "memberCustom": 18,
   "hidden": {
    "total": 7,
    "http://xbrl.sec.gov/dei/2022": 5,
    "http://fasb.org/us-gaap/2022": 2
   },
   "contextCount": 129,
   "entityCount": 1,
   "segmentCount": 43,
   "elementCount": 313,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 381,
    "http://xbrl.sec.gov/dei/2022": 30
   },
   "report": {
    "R1": {
     "role": "http://www.protalix.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
     "longName": "00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
     "longName": "00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical",
     "longName": "00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_ALka6XKZRUmdNKQ5DKH7HQ",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_ALka6XKZRUmdNKQ5DKH7HQ",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
     "longName": "00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-2ASuQfAFkaEwmIK1OCojg",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-2ASuQfAFkaEwmIK1OCojg",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical",
     "longName": "00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "longName": "00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies",
     "longName": "10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.protalix.com/role/DisclosureInventories",
     "longName": "10201 - Disclosure - INVENTORIES",
     "shortName": "INVENTORIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurement",
     "longName": "10301 - Disclosure - FAIR VALUE MEASUREMENT",
     "shortName": "FAIR VALUE MEASUREMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.protalix.com/role/DisclosureRevenues",
     "longName": "10401 - Disclosure - REVENUES",
     "shortName": "REVENUES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "plx:RevenueDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "plx:RevenueDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.protalix.com/role/DisclosureStockTransactions",
     "longName": "10501 - Disclosure - STOCK TRANSACTIONS",
     "shortName": "STOCK TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.protalix.com/role/DisclosureEarningsLossPerShare",
     "longName": "10601 - Disclosure - EARNINGS (LOSS) PER SHARE",
     "shortName": "EARNINGS (LOSS) PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncome",
     "longName": "10701 - Disclosure - TAXES ON INCOME",
     "shortName": "TAXES ON INCOME",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation",
     "longName": "10801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.protalix.com/role/DisclosureSubsequentEvents",
     "longName": "10901 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "longName": "20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.protalix.com/role/DisclosureInventoriesTables",
     "longName": "30203 - Disclosure - INVENTORIES (Tables)",
     "shortName": "INVENTORIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
     "longName": "30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)",
     "shortName": "FAIR VALUE MEASUREMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_IsSkHrMXCEC808Zd6VbjIQ",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_IsSkHrMXCEC808Zd6VbjIQ",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.protalix.com/role/DisclosureRevenuesTables",
     "longName": "30403 - Disclosure - REVENUES (Tables)",
     "shortName": "REVENUES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.protalix.com/role/DisclosureStockTransactionsTables",
     "longName": "30501 - Disclosure - STOCK TRANSACTIONS (Tables)",
     "shortName": "STOCK TRANSACTIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.protalix.com/role/DisclosureEarningsLossPerShareTables",
     "longName": "30603 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)",
     "shortName": "EARNINGS (LOSS) PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeTables",
     "longName": "30703 - Disclosure - TAXES ON INCOME (Tables)",
     "shortName": "TAXES ON INCOME (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables",
     "longName": "30803 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023_1cgPvKT-vE-QPO-DyuVcug",
      "name": "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
     "longName": "40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ",
      "name": "plx:NumberOfGlobalLicensingAndSupplyAgreements",
      "unitRef": "Unit_Standard_agreement_lKNqKU4rvUupTelfJQIVSg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "plx:NatureOfOperationsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_21_2023_59uxaENwDEeis1uswurdAQ",
      "name": "plx:NumberOfPatientsDosed",
      "unitRef": "Unit_Standard_item_dyUGGngOZEG007onwpOmGw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails",
     "longName": "40201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)",
     "shortName": "INVENTORIES (Schedule of Inventory) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
     "longName": "40301 - Disclosure - FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)",
     "shortName": "FAIR VALUE MEASUREMENT (Schedule of Fair Value Assumptions) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_uB6aVsBg6EaCcs-hRuTW_A",
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "unitRef": "Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_uB6aVsBg6EaCcs-hRuTW_A",
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "unitRef": "Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
     "longName": "40302 - Disclosure - FAIR VALUE MEASUREMENT (Additional Information) (Details)",
     "shortName": "FAIR VALUE MEASUREMENT (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_kgA--Gd-2UWeFMP4kZXqwA",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_kgA--Gd-2UWeFMP4kZXqwA",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.protalix.com/role/DisclosureRevenuesDetails",
     "longName": "40401 - Disclosure - REVENUES (Details)",
     "shortName": "REVENUES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_sVnDgezrHka5Dw8PspQs3w",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
     "longName": "40501 - Disclosure - STOCK TRANSACTIONS (Details)",
     "shortName": "STOCK TRANSACTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_5_10_2023_To_5_10_2023_uEkJTuuYLE2tgKefXtN0Mg",
      "name": "plx:StockIssuedDuringPeriodSharesWarrantsExercises",
      "unitRef": "Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails",
     "longName": "40502 - Disclosure - STOCK TRANSACTIONS - Stock based compensation (Details)",
     "shortName": "STOCK TRANSACTIONS - Stock based compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_F7acgBp0NEaoQj7JasNEtg",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "unitRef": "Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_8_15_2023_To_8_15_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_fMPAZxDZF0CjT3jIiJlVWg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Unit_Standard_shares_5fsAx7kYmE24ahi41e2xzg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.protalix.com/role/DisclosureStockTransactionsScheduleOfWeightedAverageAssumptionsDetails",
     "longName": "40503 - Disclosure - STOCK TRANSACTIONS - Schedule of Weighted average assumptions (Details)",
     "shortName": "STOCK TRANSACTIONS - Schedule of Weighted average assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_F7acgBp0NEaoQj7JasNEtg",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "unitRef": "Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_n9IBOPzcQEm-_TNOT65ZwQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "unitRef": "Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails",
     "longName": "40601 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)",
     "shortName": "EARNINGS (LOSS) PER SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg",
      "name": "us-gaap:DilutiveSecurities",
      "unitRef": "Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails",
     "longName": "40701 - Disclosure - TAXES ON INCOME (Details)",
     "shortName": "TAXES ON INCOME (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_4dpONjWdSESPgPD_gRAOTg",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails",
     "longName": "40801 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_cNw3kmoFyEKRPQe28MY3kQ",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
     "longName": "40901 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_F7acgBp0NEaoQj7JasNEtg",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "unitRef": "Unit_Divide_USD_shares_YFwPPMiQREGSlwX7DB77wg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_4_2023_To_10_4_2023_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_4Sfq-5ZsukC6Bl13MlMlcw",
      "name": "plx:ProceedsFromSaleOfProducts",
      "unitRef": "Unit_Standard_USD_eABQy_fFtUalfWR9DdIfgw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20230930x10q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY (CAPITAL DEFICIENCY)"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsEstimatedFairValueOnDateOfGrant",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated grant date fair value of awards under share-based payment arrangement granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Estimated Fair Value on Date of Grant",
        "terseLabel": "Estimated fair value on date of grant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of goods sold",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock under the Sales Agreement, net",
        "verboseLabel": "Stock issuance proceeds",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "plx_StockIssuedDuringPeriodSharesWarrantsExercises": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercises",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during period for exercise of warrants.",
        "label": "Stock Issued During Period, Shares, Warrants Exercises",
        "terseLabel": "Exercise of warrants (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ConvertibleNotesDue2021And2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "ConvertibleNotesDue2021And2024Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to convertible notes due 2021 and 2024.",
        "label": "Notes 2021 and 2024"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ConvertibleDebtFairValueDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "Debt Instrument Fair Value",
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "FINANCIAL INCOME (EXPENSES), NET",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Valuation Assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Gross",
        "verboseLabel": "Debt Instrument Carrying Amount",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r81",
      "r86",
      "r215"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "plx_NumberOfGlobalLicensingAndSupplyAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "NumberOfGlobalLicensingAndSupplyAgreements",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of global licensing and supply agreements.",
        "label": "Number Of Global Licensing And Supply Agreements",
        "terseLabel": "Number of global licensing and supply agreements"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "verboseLabel": "Schedule of Fair Value Assumptions",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "plx_OutstandingStockOptionsWarrantsAnd2024NotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "OutstandingStockOptionsWarrantsAnd2024NotesMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding stock options and warrants and 2024 notes.",
        "label": "Outstanding Stock Options Warrants And 2024 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r118",
      "r119"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Weighted average dilutive effect of stock options",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r154",
      "r249"
     ]
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DebtInstrumentMeasurementInput",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Measurement Input",
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ConvertibleDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt, Current",
        "verboseLabel": "Convertible notes",
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock",
        "terseLabel": "Shares of restricted Common Stock",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ConvertibleDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible notes",
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes Payable, Current",
        "terseLabel": "Income tax payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r312",
      "r335",
      "r373",
      "r374",
      "r380",
      "r381",
      "r382"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "verboseLabel": "Convertible notes conversions (in shares)",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r56",
      "r57",
      "r63",
      "r209"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsScheduleOfWeightedAverageAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangements and Non-arrangement Transactions [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "terseLabel": "Weighted average dilutive effect of 2024 Notes",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r154"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Increase (decrease) in accounts payable and accruals",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Number of shares issued (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r56",
      "r63"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Increase in accounts receivable-trade and other assets",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "negatedLabel": "RESEARCH AND DEVELOPMENT EXPENSES",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r94",
      "r468"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r99",
      "r361"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Interest rate (as a percent)",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r200"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r80",
      "r81",
      "r86",
      "r124",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r325",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r408"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "EARNINGS (LOSS) PER SHARE OF COMMON STOCK - BASIC",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r138",
      "r140",
      "r152",
      "r153",
      "r154",
      "r158",
      "r310",
      "r311",
      "r340",
      "r343",
      "r369"
     ]
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Net Earnings (Loss) Per Share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsScheduleOfWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "verboseLabel": "Exercise price (USD)",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORIES"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "plx_ReserveForDeductionsFromRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "ReserveForDeductionsFromRevenueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of reserve for deductions from revenue.",
        "label": "Reserve For Deductions From Revenue Current",
        "terseLabel": "Reserve for deductions from revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r312",
      "r333",
      "r334",
      "r335",
      "r373",
      "r374",
      "r380",
      "r381",
      "r382"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Schedule of Inventory",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r15",
      "r16",
      "r17"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r189",
      "r247",
      "r337",
      "r345",
      "r359",
      "r360",
      "r377",
      "r383",
      "r393",
      "r422",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "verboseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of components of Income Tax Expense (Benefit)",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "EARNINGS (LOSS) PER SHARE OF COMMON STOCK - DILUTED",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r140",
      "r152",
      "r153",
      "r154",
      "r158",
      "r310",
      "r311",
      "r340",
      "r343",
      "r369"
     ]
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsScheduleOfWeightedAverageAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average grants date fair value (USD)",
        "verboseLabel": "Exercise price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "plx_MilestonePaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "MilestonePaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of milestone payment received upon achievement of certain milestone.",
        "label": "Milestone Payment Received",
        "terseLabel": "Amount of milestone payment received"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r189",
      "r247",
      "r337",
      "r345",
      "r359",
      "r360",
      "r377",
      "r383",
      "r393",
      "r422",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r88",
      "r100",
      "r121",
      "r165",
      "r168",
      "r172",
      "r181",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r302",
      "r306",
      "r316",
      "r390",
      "r420",
      "r421",
      "r460"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r331"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r189",
      "r240",
      "r247",
      "r272",
      "r273",
      "r274",
      "r336",
      "r337",
      "r345",
      "r359",
      "r360",
      "r377",
      "r383",
      "r393",
      "r417",
      "r422",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Decrease in contracts liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r405"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "RangeMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r189",
      "r240",
      "r247",
      "r272",
      "r273",
      "r274",
      "r336",
      "r337",
      "r345",
      "r359",
      "r360",
      "r377",
      "r383",
      "r393",
      "r417",
      "r422",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467"
     ]
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of recognized equity-based compensation during the period for restricted stock awards.",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures",
        "terseLabel": "Share-based compensation related to restricted stock awards"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods (drug substance and drug product)",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r364"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price.",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r366"
     ]
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "terseLabel": "Share-based compensation related to restricted stock awards (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in progress",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r365"
     ]
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs and debt discount",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r324",
      "r375",
      "r376",
      "r406"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r331"
     ]
    },
    "plx_EmployeeStockIncentivePlan2006Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "EmployeeStockIncentivePlan2006Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represent the employee stock incentive plan for the particular period.",
        "label": "2006 Employee Stock Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent",
        "terseLabel": "Liability for employee rights upon retirement",
        "documentation": "Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r66",
      "r67",
      "r68"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk free rate",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "plx_SupplementaryBalanceSheetsInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "SupplementaryBalanceSheetsInformationTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure for supplemental balance sheets information.",
        "label": "Supplementary Balance Sheets Information [Table Text Block]",
        "verboseLabel": "Supplemental Information, Balance Sheets"
       }
      }
     },
     "auth_ref": []
    },
    "plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "AccountsPayablePropertyAndEquipmentSuppliersCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Property And Equipment Suppliers, Current",
        "terseLabel": "Property and equipment suppliers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Expense",
        "negatedLabel": "FINANCIAL EXPENSES",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY (NET OF CAPITAL DEFICIENCY)"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ChiesiUsAgreementAndChiesiExUsAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "ChiesiUsAgreementAndChiesiExUsAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Chiesi US Agreement and Chiesi Ex-US Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accounts payable and accruals:",
        "verboseLabel": "Accounts payable and accruals - other:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Decrease (increase) in inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "plx_ShortTermBankDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "ShortTermBankDeposits",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.",
        "label": "Short-term Bank Deposits",
        "terseLabel": "Short-term bank deposits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD",
        "periodStartLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r41",
      "r45"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "PensionAndOtherPostretirementBenefitExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)",
        "terseLabel": "Changes in accrued liability for employee rights upon retirement",
        "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits."
       }
      }
     },
     "auth_ref": []
    },
    "plx_ChiesiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "ChiesiMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except Brazil and Italy",
        "label": "Chiesi"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r379",
      "r392",
      "r423"
     ]
    },
    "plx_OfficersAndOtherEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "OfficersAndOtherEmployeesMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to officers and other employees.",
        "label": "Officers and Other Employees [Member]",
        "terseLabel": "Officers and other employees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "TAXES ON INCOME"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SupplementalInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "SupplementalInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "plx_MaintainOfMinimumCashBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "MaintainOfMinimumCashBalance",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum cash balance required to be maintained under long term debt agreements.",
        "label": "Maintain of Minimum Cash Balance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "totalLabel": "Accounts payable and accruals - other",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r390"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate (as a percent)",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on amounts funded in respect of employee rights upon retirement.",
        "label": "Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement",
        "negatedLabel": "Loss (gain) on amounts funded in respect of employee rights upon retirement"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ChangeInOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "ChangeInOperatingLeaseRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Change in Operating Lease Right Of use Assets.",
        "label": "Change in Operating Lease Right Of use Assets",
        "negatedLabel": "Changes in operating lease right of use assets, net"
       }
      }
     },
     "auth_ref": []
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "BoardOfDirectorsChairmanMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chairman, Board of Directors"
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "plx_RevenueDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "RevenueDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenues"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure pertaining to revenue.",
        "label": "Revenue Disclosure [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r76"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable - Trade",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "SignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies [Table].",
        "label": "Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Other, Current",
        "terseLabel": "Other",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "plx_NatureOfOperationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "NatureOfOperationsPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature Of Operations Policy",
        "label": "Nature Of Operations [Policy Text Block]",
        "verboseLabel": "General"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r40"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "plx_AmendedPfizerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "AmendedPfizerAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Pfizer Agreement [Member]",
        "label": "Amended Pfizer Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "plx_NonExecutiveDirectorsOtherThanChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "NonExecutiveDirectorsOtherThanChairmanMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to non-executive directors other than Chairman.",
        "label": "Non-Executive Directors Other Than Chairman [Member]",
        "terseLabel": "Non-executive directors other than Chairman"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "INCOME (LOSS) BEFORE TAXES ON INCOME",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r77",
      "r84",
      "r93",
      "r165",
      "r167",
      "r171",
      "r173",
      "r341",
      "r371"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "TAXES ON INCOME",
        "totalLabel": "Total taxes on income",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r136",
      "r137",
      "r164",
      "r282",
      "r292",
      "r297",
      "r344"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "plx_ChiesiUSAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "ChiesiUSAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chiesi US Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contracts liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235",
      "r236"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity (net of capital deficiency)",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r82",
      "r89",
      "r390",
      "r409",
      "r416",
      "r455"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r331"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants issued to purchase common stock",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Valuation allowance related to deferred tax assets",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "plx_ChiesiExUSAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "ChiesiExUSAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chiesi Ex-US Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r121",
      "r181",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r303",
      "r306",
      "r307",
      "r316",
      "r370",
      "r420",
      "r460",
      "r461"
     ]
    },
    "plx_PfizerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "PfizerMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except for Brazil",
        "label": "Pfizer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "SignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r106",
      "r121",
      "r181",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r302",
      "r306",
      "r316",
      "r390",
      "r420",
      "r421",
      "r460"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Payable, Current",
        "verboseLabel": "Interest Payable",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "plx_ProtalixBioTherapeuticsIncorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "ProtalixBioTherapeuticsIncorporationMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Protalix Bio Therapeutics Incorporation [Member].",
        "label": "Protalix Bio Therapeutics Incorporation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r18"
     ]
    },
    "plx_CollaborativeArrangementRevenuesExpensesSharingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "CollaborativeArrangementRevenuesExpensesSharingPercentage",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement revenues and expense sharing percentage.",
        "label": "Collaborative Arrangement Revenues Expenses Sharing Percentage",
        "verboseLabel": "Collaborative Arrangement Revenues and Expenses Sharing Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r332"
     ]
    },
    "plx_UpfrontNonrefundableNoncreditablePaymentReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "UpfrontNonrefundableNoncreditablePaymentReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.",
        "label": "Upfront Nonrefundable Non creditable Payment Receivable",
        "terseLabel": "Non-refundable Payment Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r331"
     ]
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Amounts paid (funded) in respect of employee rights upon retirement, net",
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403"
     ]
    },
    "plx_AdditionalAmountsPayableToCoverDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "AdditionalAmountsPayableToCoverDevelopmentCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount payable to the entity to cover development costs under agreement.",
        "label": "Additional Amounts Payable To Cover Development Costs"
       }
      }
     },
     "auth_ref": []
    },
    "plx_PaymentOnNetSalesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "PaymentOnNetSalesPercentage",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the payment as a percentage of future net sales.",
        "label": "Payment On Net Sales Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ProceedsFromSaleOfProducts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "ProceedsFromSaleOfProducts",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of proceeds from sale of products.",
        "label": "Proceeds From Sale Of Products"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412",
      "r453"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Over a three-year period",
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE- DILUTED",
        "totalLabel": "Weighted average shares of Common Stock outstanding for diluted calculation",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r154"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r159"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "plx_OutstandingStockOptionsAndWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "OutstandingStockOptionsAndWarrantsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding stock options and warrants.",
        "label": "Outstanding Stock Options And Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DilutiveSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DilutiveSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share",
        "terseLabel": "Financial expenses of 2024 Notes",
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long term liabilities",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r7",
      "r8",
      "r121",
      "r181",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r303",
      "r306",
      "r307",
      "r316",
      "r420",
      "r460",
      "r461"
     ]
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r124",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r325",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r408"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r90",
      "r342",
      "r390"
     ]
    },
    "plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOnDateOfGrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedFairValueOnDateOfGrant",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated grant date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Estimated Fair Value on Date of Grant",
        "terseLabel": "Estimated fair value on date of grant"
       }
      }
     },
     "auth_ref": []
    },
    "plx_GainLossOnDebtConversion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "GainLossOnDebtConversion",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of gain (loss) on conversion of convertible debt.",
        "label": "Gain (Loss) On Debt Conversion",
        "negatedLabel": "Gain on conversions of convertible notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net income (loss)",
        "totalLabel": "NET INCOME (LOSS) FOR THE PERIOD",
        "verboseLabel": "Net income (loss) for the period",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r40",
      "r85",
      "r92",
      "r96",
      "r107",
      "r108",
      "r111",
      "r121",
      "r128",
      "r130",
      "r131",
      "r132",
      "r133",
      "r136",
      "r137",
      "r150",
      "r165",
      "r167",
      "r171",
      "r173",
      "r181",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r311",
      "r316",
      "r371",
      "r420"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "LONG TERM LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Relationship to Entity [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues.",
        "terseLabel": "TOTAL REVENUE",
        "verboseLabel": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r121",
      "r162",
      "r163",
      "r166",
      "r169",
      "r170",
      "r174",
      "r175",
      "r177",
      "r181",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r316",
      "r341",
      "r420"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE- BASIC",
        "verboseLabel": "Weighted average shares of Common Stock outstanding for basic calculation",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r154"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Upon grant",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r415",
      "r459"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to seven point five percentage senior secured convertible notes due 2024.",
        "label": "2024 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_LicenseAndServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "LicenseAndServiceMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License and R&amp;D Services",
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "auth_ref": []
    },
    "plx_PaymentsToDebtHoldersOnConversion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "PaymentsToDebtHoldersOnConversion",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to debt holders on conversion for accrued but unpaid interest, make-whole interest payments and payments in lieu of fractional shares.",
        "label": "Payments To Debt Holders On Conversion",
        "terseLabel": "Paid to the converting holders"
       }
      }
     },
     "auth_ref": []
    },
    "plx_NumberOfPatientsDosed": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "NumberOfPatientsDosed",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of patients that were dosed in the trial.",
        "label": "Number Of Patients Dosed",
        "terseLabel": "Number of patients dosed"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingNumberOfQuarterlyIncrements",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the vesting of awards in number of quarterly increments.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting, Number of Quarterly Increments",
        "terseLabel": "Vesting in number of quarterly increments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "INVENTORIES",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "verboseLabel": "Purchase of property and equipment",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r44"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r174",
      "r339",
      "r378",
      "r391",
      "r418",
      "r419",
      "r423",
      "r469"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related expenses",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r107",
      "r108",
      "r116",
      "r121",
      "r128",
      "r136",
      "r137",
      "r165",
      "r167",
      "r171",
      "r173",
      "r181",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r301",
      "r304",
      "r305",
      "r311",
      "r316",
      "r341",
      "r371",
      "r387",
      "r388",
      "r401",
      "r420"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income",
        "terseLabel": "FINANCIAL INCOME",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of options to purchase shares",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income (loss) for diluted calculation",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r144",
      "r145",
      "r146",
      "r147",
      "r151",
      "r154"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Financial income, net (mainly exchange differences)",
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r456",
      "r457"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "plx_DebtConversionDecreaseInPrincipalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "DebtConversionDecreaseInPrincipalAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of decrease in the total principal amount of debt due to conversion.",
        "label": "Debt Conversion, Decrease In Principal Amount",
        "terseLabel": "Decrease in principal amount"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments required to reconcile net income (loss) to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Over a two-year period",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r283",
      "r295"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r98",
      "r121",
      "r181",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r303",
      "r306",
      "r307",
      "r316",
      "r390",
      "r420",
      "r460",
      "r461"
     ]
    },
    "plx_MilestonePaymentToRegulatoryApprovals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "MilestonePaymentToRegulatoryApprovals",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the milestone payments to regulatory approvals.",
        "label": "Milestone Payment To Regulatory Approvals",
        "terseLabel": "Milestone Payments to regulatory approvals"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "country_BR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "localname": "BR",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Brazil"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "verboseLabel": "Convertible notes conversions",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r56",
      "r63"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r56",
      "r95",
      "r109",
      "r110",
      "r111",
      "r125",
      "r126",
      "r127",
      "r129",
      "r135",
      "r137",
      "r160",
      "r182",
      "r233",
      "r277",
      "r278",
      "r279",
      "r289",
      "r290",
      "r309",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r329",
      "r346",
      "r347",
      "r348"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table Text Block]",
        "verboseLabel": "Schedule of Company's Disaggregation of Revenues",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "TAXES ON INCOME",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r284",
      "r285",
      "r286",
      "r291",
      "r296",
      "r298",
      "r299",
      "r300"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r362",
      "r390"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "verboseLabel": "STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)",
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r49",
      "r390",
      "r409",
      "r416",
      "r455"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit",
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r125",
      "r126",
      "r127",
      "r129",
      "r135",
      "r137",
      "r182",
      "r277",
      "r278",
      "r279",
      "r289",
      "r290",
      "r309",
      "r346",
      "r348"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Share-based compensation related to stock options",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71",
      "r248"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Funds in respect of employee rights upon retirement",
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r87",
      "r237",
      "r238",
      "r239",
      "r382"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r174",
      "r339",
      "r378",
      "r391",
      "r418",
      "r419",
      "r423",
      "r469"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r379",
      "r392",
      "r423"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income tax asset",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r281"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Current taxes on income",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r287",
      "r294",
      "r410"
     ]
    },
    "plx_ExtendedTermOfAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "ExtendedTermOfAgreement",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extended term  of agreement.",
        "label": "Extended Term Of Agreement",
        "terseLabel": "Extended term of agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StatementTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r160",
      "r339"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCK TRANSACTIONS",
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r120",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r233",
      "r308"
     ]
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsScheduleOfWeightedAverageAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r55",
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r62",
      "r63",
      "r101",
      "r102",
      "r103",
      "r161",
      "r216",
      "r217",
      "r218",
      "r220",
      "r224",
      "r229",
      "r231",
      "r377",
      "r400",
      "r407"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition, Policy [Policy Text Block]",
        "verboseLabel": "Revenue recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Number of shares granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "verboseLabel": "Term of award",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right of use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "plx_FillFinishAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "FillFinishAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fill/Finish Agreement [Member]",
        "label": "Fill/Finish Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r333",
      "r334",
      "r335",
      "r373",
      "r374",
      "r380",
      "r381",
      "r382"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "verboseLabel": "Converted instrument, shares issued",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r44"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation",
        "terseLabel": "Share-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsScheduleOfWeightedAverageAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r95",
      "r109",
      "r110",
      "r111",
      "r125",
      "r126",
      "r127",
      "r129",
      "r135",
      "r137",
      "r160",
      "r182",
      "r233",
      "r277",
      "r278",
      "r279",
      "r289",
      "r290",
      "r309",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r329",
      "r346",
      "r347",
      "r348"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "verboseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r51"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Amount",
        "verboseLabel": "Convertible notes conversions",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r44"
     ]
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK TRANSACTIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsScheduleOfWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected life (Years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r271"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right of use assets obtained in exchange for new operating lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r389"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "plx_IncreaseDecreaseInBankDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "IncreaseDecreaseInBankDeposits",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deposits held with banks.",
        "label": "Increase (Decrease) in Bank Deposits",
        "negatedLabel": "Investment in bank deposits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsScheduleOfWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "OPERATING INCOME (LOSS)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r167",
      "r171",
      "r173",
      "r371"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r411",
      "r412",
      "r413",
      "r453"
     ]
    },
    "plx_ChiesiAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "ChiesiAgreementsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chiesi Agreements [Member]",
        "label": "Chiesi Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsScheduleOfWeightedAverageAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options",
        "verboseLabel": "Options",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedVacationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AccruedVacationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Vacation, Current",
        "terseLabel": "Provision for vacation",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r65"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsScheduleOfWeightedAverageAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Award [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AccruedRoyaltiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Royalties, Current",
        "terseLabel": "Royalties payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r363"
     ]
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "FAIR VALUE MEASUREMENT",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450"
     ]
    },
    "plx_MeasurementInputYieldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "MeasurementInputYieldMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yield",
        "label": "Yield"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450"
     ]
    },
    "plx_SaleOfStockMaximumOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "SaleOfStockMaximumOfferingPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock, maximum offering price.",
        "label": "Sale Of Stock Maximum Offering Price",
        "terseLabel": "Sale of stock, maximum offering price"
       }
      }
     },
     "auth_ref": []
    },
    "plx_AtmEquityOfferingSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "AtmEquityOfferingSalesAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to ATM Equity Offering Sales Agreement.",
        "label": "ATM Equity Offering Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Revenue",
        "negatedLabel": "COST OF GOODS SOLD",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r121",
      "r181",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r316",
      "r420"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "COMMITMENTS",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r83",
      "r91"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "SUPPLEMENTARY DISCLOSURE ON CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Share-based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ProductMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goods",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "plx_AtMarketEquityOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "AtMarketEquityOfferingMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to At The Market equity offering.",
        "label": "ATM Shares"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2022",
     "localname": "OfficerMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officer [Member]",
        "terseLabel": "New officer"
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative expenses",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "plx_InterestReceivedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "InterestReceivedNet",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash received for interest.",
        "label": "Interest Received, Net",
        "terseLabel": "Interest received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized for issuance under share-based payment arrangement",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "plx_StockIssuedDuringPeriodSharesSalesAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "StockIssuedDuringPeriodSharesSalesAgreement",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Sales Agreement",
        "label": "Stock Issued During Period, Shares, Sales Agreement",
        "terseLabel": "Issuance of common stock under the Sales Agreement, net (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount payable to entity for the achievement of regulatory and commercial milestones.",
        "label": "Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "plx_StockIssuedDuringPeriodValueWarrantsExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercises",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued during period for exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercises",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsScheduleOfWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentType",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsScheduleOfWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk free rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "plx_StockIssuedDuringPeriodValueSalesAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "StockIssuedDuringPeriodValueSalesAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.",
        "label": "Stock Issued During Period, Value, Sales Agreement",
        "terseLabel": "Issuance of common stock under the Sales Agreement, net"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ProceedsFromSaleOfShortTermDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "ProceedsFromSaleOfShortTermDeposits",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of short-term deposits.",
        "label": "Proceeds from Sale of Short-term Deposits",
        "terseLabel": "Proceeds from sale of short-term deposits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Changes in deferred tax asset",
        "verboseLabel": "Deferred taxes on income",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r74",
      "r288",
      "r293",
      "r294",
      "r410"
     ]
    },
    "plx_AgreementAmendmentPaymentReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "AgreementAmendmentPaymentReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Amendment Payment Receivable",
        "label": "Agreement Amendment Payment Receivable",
        "terseLabel": "Agreement Amendment Payment Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones",
        "label": "Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "plx_RevenuePerformanceObligationNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.protalix.com/20230930",
     "localname": "RevenuePerformanceObligationNumber",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Number",
        "label": "Revenue, Performance Obligation, Number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expense",
        "negatedLabel": "SELLING, GENERAL AND ADMINISTRATIVE EXPENSES",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Current",
        "terseLabel": "Other assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r390"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "24",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "28",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "310",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "330",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "3",
   "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "3",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "730",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "230",
   "Section": "45",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "940",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "220",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "220",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(16))",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "220",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "220",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(8))",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "105",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "7",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "24",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "24",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "22",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "28A",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "42",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2029-109256"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "7",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "15",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "272",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "272",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "42",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "310",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "310",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "310",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "9",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "323",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "326",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "13",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "3",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "80",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "35",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "14",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "270",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "19",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "17",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "842",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "842",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "842",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "848",
   "SubTopic": "10",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "855",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "855",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "910",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "912",
   "SubTopic": "310",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "924",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "220",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "235",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "360",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "220",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "220",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "948",
   "SubTopic": "310",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "970",
   "SubTopic": "360",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "970",
   "SubTopic": "360",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "970",
   "SubTopic": "360",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "970",
   "SubTopic": "360",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "970",
   "SubTopic": "360",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "970",
   "SubTopic": "360",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "970",
   "SubTopic": "360",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "970",
   "SubTopic": "360",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "970",
   "SubTopic": "360",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "976",
   "SubTopic": "310",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "978",
   "SubTopic": "310",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "69B",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "69C",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "69E",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "69F",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "80",
   "Section": "55",
   "Paragraph": "8",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "842",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "53",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "852",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "10",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "55",
   "Paragraph": "29F",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "272",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "3",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r401": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r402": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r403": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r404": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r405": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r406": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r407": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r408": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r409": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r410": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "235",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r411": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r412": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "24",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r413": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r414": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r415": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "310",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r416": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "323",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r417": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "410",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r418": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r419": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r420": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r421": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r422": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r423": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r424": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r425": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r426": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r427": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r428": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r429": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r430": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r431": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r432": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r433": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r434": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r435": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r436": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r437": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r438": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r439": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r441": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r442": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r443": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r444": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r445": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r446": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r447": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r448": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r449": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r450": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r451": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r452": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r453": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r454": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r455": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r456": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r457": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r458": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "230",
   "Section": "45",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r459": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r460": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "852",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r461": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "852",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r462": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r463": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r464": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r465": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r466": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r467": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "860",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r468": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "912",
   "SubTopic": "730",
   "Section": "25",
   "Paragraph": "1",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r469": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Publisher": "FASB",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "4H",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>58
<FILENAME>0001558370-23-017664-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-017664-xbrl.zip
M4$L#!!0    ( %@^9E=M%AZ9:0\  *>-   0    <&QX+3(P,C,P.3,P+GAS
M9.U=2W/;.!*^;]7^!ZXNFSG8LN0D,W'%,T7KD:A6%C62G$E.4S )2:A0) .
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M<'Z7GT%3&'@Q.8C">X:U0Q)531/9IF_7J+CC++]>^#0"[3@L8>2X]-4]U['
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MD[*!+!JE6KE6J5S6&[5&HU(KG1):,@K]M' G$0=5-@FCA@M8OB8GNG6A:;>
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MG 5IHBMV@GX? +"20EIB5ZG? :\Q0#7LKVM3YJ)V#S_%+K$$4FO(ZL[+(^G
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M[P3<Y7KMEN_4M+N1!Z:KPZ^#((BVNWABG$Q:BZ&ZI7?@NI".9WMC?X7P-C8
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MS8"VCX]U2^!L?/A'!(*8(4M"]3U!^W>.R'L:^WQN@GMBB+Y]YP*N?;B"#CF
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M[_(>W#=8QD?NA->-7;M4\CG'2CZ<1XQD-.;;+N;3?\D>(POS<!XGZEQ_^J_
MPU2?&48. &Y 0S 7-KTS(=^XD<,T'2)@$RJ6R I-1,=)(:8_72>L(O_0,]??
M_A]02P,$%     @ 6#YF5Y)B1"093   C=<# !0   !P;'@M,C R,S Y,S!?
M;&%B+GAM;-U]?X_C-K+@_P?<=^#E@-L)X,YDDG<+)+?['MS=[HGQ>NS>MF>R
M>X.'0"W1;5UDR2O)/>W]],<B]5LD1=DR2Q-@-].VJXI59%61+!:+?_F/UUU
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M*M[:>6JE,:B D)6IQJI4;3@$GH)4FF\?A.9 Y#,'^R_<8;_W0SIG?S:7%SI
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MXQ6-7WR73E_]YB9&#6975[K8!251P5C3#CT#LJ(\ ,J]3 9-/@/\@ \MF6D
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MG0C)J"2B/O:;1PKWO9AB\QMO27JA%[H[XRIG"W[#33#AU4Y<-X:\@,!WGOP
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MXT].<* ERUUK;CT*C@F8B%$U 1V\=1/H9J:E-G?3^2/Y-+W_.",?9E,([T'
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M"EC[)4"TC+2K2DP?X3+>BKRY7ZY6W\*-/++Z9?HX&X7"=+EA#?PX5$;K9I7
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MI4>JC_W$&46^\*396Z2)(%LQ3MLE*"XI?O7YKIQB_@QK0C*:&BN^=%H;4@^
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M'U)Q_%,0)"5%\IG3Q*G+7?32];'X\Q>?QDQ+M\=[N.JEJ>INBHQL/4:B2>U
MBXFGT09LZ72SP.$JN9A^PBP,7TA2L9BD+9ZV1GQ/&LCJV$=0J5::$,!33G/N
M>NKHX&\UG:*EPI=S8_M16I?;" -9 ]5"2/6M#8ZG72I>)(]),Q#R(XJV5$R
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M.UOD>5=B]!5TG"R*T^5J9G^74@UW>W[C_XO&RE5"_6>$^_$2]HH+\97?<&[
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M7G&.*>]!=?OC$D)2&DKZNO& CS6 Q7Q$74LZB%M1<NQUJ /P&@#' M;NMS#
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M@4\\*77!CAFEPT13H&8G\2TJMS:!Q$)!-^R1+-5&)UE07@/4:+>Z77E1EAD
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M6!=?Q P$!GYQ-XV?X#B<2(4[B:B$J-JX$;+2,EW[Q+*=!%)<4NJ%MK;F&;A
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M89K?,7H-E:0!VD*95T\;WJA&G;!B+J0+31^-EEH,Q7F8$HVR"4,N_(98(J&
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MG0 &6^+$5* %;3@A!RR'$ 5D;ITIF"R7T 0><<K(_3TK\@42^4PCF O E24
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M=*/?X!N,)"-)+]PEIDA*J>C^IBV7 ^U?'V-PT/]@7\1__7]02P,$%     @
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M_MC5% UZG1W)  VUX]FRSJTU5X1 B9QG\G!)\H*&"I\,;5$XR.4F#@ A 6O
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M]O=YA5&["*I8/U,5 MT:*\'4YP(_=OEW_- IO5C^'9<GS66EBRYYM-5LH+G
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M-0V:FQ!\\AJ@[Z;LZ8*&%A,+R!Y.>3@KFZ-0=-+7 +T]U2T6F')5Z+-LH=Q
MITVMQHFI1X+/4!1+*V'+IK%*BQ1@:7$,%!*Z= H8,Q*95FCZ4Z"OYG,%95&P
M)=ZL=6OK[IK7VJE5V%Z*N ;PR[E<GJ7=3%L/9HWNN%O2.681IG?(:X#># K%
M0JO?'O&592H[]Z;.8AV$Q$^?%_KM)Z[M.S)PMV^G0%*B32!%6_[[-_R#N%X0
M(F1*:W2E*=[T#L>P__EK+BF*9DU0 ZC>'7V;2CU\Y&B3Z?UGMAM=&;%[\!+\
M]>/)K,Y$LU#/GM\1^"TS]_XZ> 8<.M\/5&T+DDLR-2.X^V]7,X&+U,$*:=NF
M9/WW9OL)_-<%CJ;^]Z]HM*MM )P(SAGN(J&2H4VLN[#@%CA_;9][%WX)G^+.
M)6O_H*7F:F/-T+S@;JHI"K#@@/_[GQ2!D7_]_3,<"&DS/Q=@OPW&$9MD TC.
MW=CVIG\]Y=@1*TQ(^2F(N)6^);8PW.,UCB0'A3-YMHE&']Y9M@7^^F6$X0/V
M(K*=-<)[_U$H OAC7D6"]-<.D/![\A;^ G%M0U.0_V#1?T](.'[$EM46N;%M
M*/#+AO/WS_$3[CV+Y<-3SX([=AKY]PCF8TH>X;?3I-WD>,C.]XKRY7'&3^+\
MB EW^*M,_EBJ?)CE>?@I?6\:?@5R*=K-$R5*9>@QFQ)3<HH5J31)B1*+I42"
M(=040P"65>AP59 ^"M>7=%.HE[I\#NETN2[?.5;33X.KPV>%=JE;XCL(5\\A
M_"!;Y.H%'LDV:K52IU-JU,\';.HW8>U+<%6W)IYMW2"YV^PM0F TE?Y@8EY"
MH ^6MU^F[2UV!$+TR<,2B-_B:6">6"8?>R0'P(PE69\XMF\IJ&P;MG.W-U?[
M&4,#>#1=N)!AMPQ\U'9B@KZ%,V]MX-;B[BF*2+YGA\_<KO+;O]?+QM^'G/E-
M#<DWVK7_^Q^<P?Z*M *ZNY#>41F&)B.[:B/H7?]J719B26'557C&)F?+T=&O
ML%CS1V2/ZY+CB*-YWNJK>4;F&7556.IE-1/HDU>@QC&TM=7B1P G6IUH]9O#
MB=CH<.H(S)=$_X^P*232L,"?9U[&KH!2C_SG*,S&[ST$S0KK->]0_)B<CXV:
M:CNFY/WS0X,_<H$,Z6H;8\DP;&]LKW]<QN:U?,F!)L0(VF!N.]Z!^6NN#7?:
M'DF.4.AG*<>0"AVWRAW)P)Y8'3"Q 2*4D$Y@0H'X[[%['U(^S5+,7R?MXTN2
MM5T&#O^V!*[=Y=O5(=+FFXUV%VD*[8[ U;M(MX% /[ +G;WM2)Q$&FT$I_]0
M_MQ^T,@CW2*/'#B+]XXBE^TB\&L<NM_?5(0?X$3V_T=B>\3V>_MP:N6VM\'[
M:32WTR%[V-\^K3<%R&(OKLBV_!B)CH<B)SR$ V6Z4\)CK'#"J2(% 9 <8%U(
MFYH14/RV4OI EU:4) 5KWZL(DB0JB_QB5I8JQ[KT$O8=,/>B<R!;*2:Q&R0$
M[L*^QA7([>]&8HWV)^EZLC:]YH\[DK5UW8X6IX#%R_F6/EQA'5 JCD9<FE^F
MSK X4>=8G+IMKMXIA4M0LCI=QA5]97$Z6HZ0<.WP[L5IOWB$^SC;M>/YWT=J
MH@!YUU;A29CQ]%M#L\ =C$;@$@5?'7V]S=1&Z=*3DO-9?U^AP1Y4Q+./%O9O
M09\=^A^YIQ0;S7M3SN&"V9EM\Y.\9@ X/?1_#E8!P$K$",,#G2>$$3KN\=7\
M<+1ZEUN%83A*DB3-7LZ1^ET'Y8^L;9J:&QXL1E1(!L2*Z'#N*#M)*WVKM%*L
M\L 7-Q]M,-'<T 'PPINQ#DR(D*EBNMHU @'4C1K A5P/=5JO:&2SW>ARU=(
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MJ4YVA?HO572&1^CL\%M;UF^0_X/=8AB.S"4'64J&#^ZU]#=J6K_Q,GXIDWA
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M?X0X\/QAPC_5RS=I4 \_7Z6_/YPI8"B8A.M-PO-G/<B+L:9@7JXT+]!7\L6
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MV>?UZ/4(J3Z%-]K46AM#O8FR7:G>R5;?5/,AT/<MOB" Z]8[?/<!7#_EG4,
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ME/.Y*>?>5+K+<LZS+C[K:A5J70I)RZS#]8Z^<GO+U,5'LS [N A?+,<18!_
M/H!]<B(.7HE]Q$U[$TA,8RDYK=&NTF_8*ER)4_;)$JR1%TO.""+V /D \LF)
M-GDE\IDR1DS)GHUP)13>XN,U%4_,C'P.&=IPXGVN#PC] Z%_MQ?Z=S9U,U^3
MFP\I\WKG73>STH(CP8]5.9/E].$DL*R[^MP\I5#&KL6TNP-E T4V*>W$2BW
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MQA5XJ5/F^NF]LNR"F?CK#;,"B(P#Y37NO;Q&?D.J0=P' !0 %  4 %1^!@4
M"H06 4 !0%W^%EWN#07$VN1 ?LBKUB")7*70X%,YH2L-&GRM\&Q>&Y#'!MR_
M!O>O0;X.@ N "X +@ N B^MOW3^U50!<?&)<@*/]6^_P9SS:!WELP*W07T?Q
MO_X#)J!_?]JKH7]<_.DA# Z?!\R6M"8.AV#*PL1@'=GNSWTI!GI#&-PHLWI=
M8Y+I4PR=CYR9[@OS+"0N$*(P2#N0C/!S*6XHBD*)#E-'H9'8).IQ'X$6[9Z,
MP%G9;KQ(P7 1AT")J*N?!UT;58!4<D4J;[YK\Y&DPC7WK1$1\(HD&IOU8&OP
M?+L?IZ1"?/F.D46<0HKDB0K&@%0 J0!2N0*I_.G%G8\DE?6@QK34!<UQN]@U
M.=CP.O.%D9(*_>4[B101"BX2%'P94@&1*X!4 *G\$:F\^1;01Y+*8CJQDE</
MME))U@37)(Q(6V2>2GHE"*.+&$T580A_#ZN \!T0OG,7X3L@5<[GNAU[]L42
MK(Q7%P8?KLD>+9"G\M>Z*S,>25/)&O5)HJ%UE))03=9&))4&$V<;PJ#4Z0:Y
M=  [ ':X#X7O#>S0A<WJ8JOQ=8O8H(:['*ZUILZD[/!!&A]@AVLC!K##YY+J
MWL(.R%)=3N'R5!JQ"MQ<R,/2'C)2=J 3WP$MD@D[$"1].;$.L,.U$0/8X7-I
M;F]@!P+RL=EL#6F68/'$!)O#LU4[\QTNHKKEBPM R-[9];3KQ>>],!P(=OB.
MQ(3GGA>Z7J@7MH[]S59<XW^_Z&Y)$@^ D!.<S><XKLHS8@[+V R;R[2*J0EV
M9W,546"=IO4C:>YY]>K+][_@OPL-5[4C+>E'1B.EF1+H6L(9SDIW@XPK#C+>
MD[>[]3#!QP%_@]!W>%#)UN=A]H9Y.CB#DU4L\&Q3R\."_9'%)#Z\XQ=9O=/<
M>3I3[NWD>364%'L^ZM,5K3$WXC>)@@^+KIS V7/TY.FA[NANV/;4[%\Q6S/X
MT8;U@E"8B\EB&W3T=%&6>2=PT2XI3:01,599R*C#6C5^NO"7T#>L_(QMI]_[
ML,B74TIAGS *MTU_U7\L^.B/!5_ARYWZA.0"JZ:*"*^4AJU=',M)_] OWQ'Z
M0ON 7+%3KK8&N8,@X)X\<,\OVX;W<8^X7YB",&BN+=/IX6MTUNFO)L;'<P_&
MEG0!X=HK#BFQ&C[H)CY5A4FYA_CR':< ]0#J =1S/>HYK6>^CWJ8MJ40X]:T
M+SD:W^KAE5:=K/<^GGJ& R-6MFM*AEAEM6J6&S2_;&340W_Y#M/OTC= K"+@
M'L ]9^&>L[H]P00CHTE3*4N[*;-<."UG14A7<'LD:66[+:(E6&NZ'V'[(2E/
MZT;*/:G&BK[K1E<>(QJ?57\^3._)88CCQ0?ESS3:O NR%(Y"JD)C,J%2F(S-
M,4JF*6PNDZJ**PB-TQ@$O4V013Y0D,V9J>53??T<ZSY8Y,^AJ_;U0%=\=<&X
M6D7?Z+:W2IL^++T/RSY%-"7:7/.ZU)*W5G?8*H_;S!6V'.O-=D2-\4H[V7*T
MM7UU;C<XH2<C6*JT7O0B-]A? %+Y;*3RCIW#:T@EHLF2:PX8GF,GRZG?TJHT
MW;G"\<TZBD=5<5:;<)$!=>TR5E9;,9.2"O'E.T)>2,< I )(Y5.1RONET->0
M2KLU74 >P=<XI+/?S.9="-WVKR!0!$*/1Z>MD@29I@%O(KBQKF\S4DG%40H!
ML:& 5 "IY$#C? VIL+.* W6:$F*U^J4MTR;VK2W"?#RIB&%_N&@-_;*T6U<V
MW8KI">.ED9)*JGK"\'&IUUL**<V3QGFG(_!I@DX)#"-Q#<9E9#;'94PG<7FF
M:Z@,8YH^(Q24UG#\;1HG"H).<R][YNX@$)R YD''>,>60]1M.QF;FN[JOF(G
M/@*C.:9K!F'Z#1O]8:E^/!WM<25Q9J\G,D20O;"Z6%211O<*BH8[BEFHT[%4
M2&&[O1#3!A4/338?>"J3PD6$!!DO 3,!9KH^,[UCW_(V9AKOT,[*DBG'<GA]
MT9Y%Q&PUNH(LLA%F(I^,W%K2IY.I)0XF39$S4F8B,F:"0=I,P$R F:ZOJ'R8
MSZ3.1*2T<H0VU%J9I2;NCQD$N<+1\F _:L/>?CJ4HG'/[[9I)JR2O929L@2<
M$(AF!;P$>.GJO/1A'E-<L7A9:0\CB[#7U0CE(-Y>74'S+4O#4E>9.RN.D&V?
M4FQY!D=QRDNIYHN0[SI) J&N(-3UB3+\/Z$RL_7S]^37-W]XT4="0U[_KF>O
MPJ4F;*'[OXYZ^DJOR1DZ6.@%14TE8,7=):902$7?H) @O)#TUDP>;2144U@I
M?ECPYH4P:9Z0FY9"/56.W8S'4U8HS$U7<54S:1P\DECP]4<NTDM/R&LM13,W
MW_]?\N/QWZFVKO@I;A;__N><HNF7/*YKT'^>#QXO35WR+>B3]\Q^_M__\_1]
M?^*YI'JVYW][7$*?=&1QF&$D [BAEV:^KE@E99Y\US?%CI5=\- QBOJ*8(_G
ML-]^+,-IUPO9P4GAYZ_I !R-GJ-L2T_&Z(%.#O@]_*O'C[)U]_$S+S!3GO_F
MZW:V<*7/_L=3LXD(O=7E9N$7N*#03[@HA86?+MS_,1#8D\YD^GNR7B7KIOV/
MTX.'CQ)0I224PH5-_8 $!S],4'F-&?YS3$\-EG(X(T(IDL#H.2[CA$[*&$UI
M,D7-5!G!4)W09C"B:NJ7P[>>9]2.".0WQMSM"P.FW1@7R@UA4.?Z3)>3!@U6
M+!X23#5X]FLV'H?^L )?X7B1JR2_B$*[46$&7$4<)#\['#\0A2I;9_@:)UZU
M2S]>LO#T+0L_7[,@5 L/+UIH\&<DO[>^J9C8;ZLNM"M<7TRI$";_7>!Z4F,P
M*?S%,MU&,C.%"E=ML V.9R=_?]#JE)Y$2E_%KP7-LVW%#Y(U)EE5O"A(W.J@
M6-"WJIY ,3N?+"0+B_*A[^4JD99L;K0/_-(SN14/C(##,VBN(*2L080B8Q@)
MR12FX3($HS-ZCB0_->H!/LJC?VZ08\8L\4;+$FI[?.RN2X+3-Y+-"OEK2PS6
M-R2"(ZB%E)&-@%H=6ULQ,B(CO[9<[)OQRC4@!EIOV:EN#V ,A1*?7\9^;1G5
M]INQOV]NI1'6:34GT PRI%[2\NC;J;;$Q5@)"S@V7@:"QJT03$N_'89^;=JJ
M^GS'0[>$Y AH,QR90H..&!D]?E&FTV47^ZI.00Z'RVVU7J_6O+3ET8LJS6$T
M-W"3EHA.=T#XV[&)4T;2\NA%Z1Y/U5QU*$A$92=OZ)VU';72EL<O.O6MM8U"
M0XHSD>9RZ$QT$=JF7P^COS:MH,HZ)(9&V2I1HD4XE%FM=V,9.^Y3L]F3H%U_
MX%@BC6B-VKS6F=5[,G[<LMP9#\:T;?*0,H)UVJ-D!D69I.51[YV2%:!^9ZMP
MD;]V:ET!L;WDVPGYJ$N;I=>J2EJO+8V<1ENS<(1>E)FDY=$S612-$*/'49 R
MKZ!<:U<;\(U>TO)H1&O.8L9W=,* HGFDL\[:9TD_;7D\HN4*6BZ;6\65=N&D
M)XX;\_J&S9H>C2BS7>][L*;J7,U93C1^1DL3I)?LTX\>RLI4/UH-:S5+89WM
M<J-!G?7&D*GCE@P\XBALV&>D4<>#]S6^1BX61K+?/VKIC=LKUMW5AI(0V#I4
M7UE#=Q$G/3INV@SH5@.6--5"HM)V&7HU$NH9:5/\UZ:N$=@KFL,\")D3R@;'
MMHLZUY-A^/BIQ+@*S9IN4["$'EGQW+;0PGDC;7KT5-T=5^&=6H\@Q2F3B!S"
M3GF:/!4Y?FJ](8WY6G^E2$2]7^J:S2:^@I*GHL=-)X97W93'JQ'70E8$'[23
M!=5FTJ9'IM)62U%91*.ZM,;Y5KR>(IB^RYH>V4H)BIG&!.-X:>?&E&+7PG(I
MS%[@V%C<2;!W0Q7"H-:4ELJ3-L:X>O;88VLIMX@-R>R;C#4J*5U>GO4-7$[&
M #ONF+9PH]Y2TJ9<3??;DB5-W3!!==+TJ&.EG;LE-[VI);6TYFKMM.7-AL^>
M>M2Q,1P[M" LYY")CO<+BQUM]9&1-CWN6&PAI(/1C8!3:,@IB[P?!:/L#8X[
M9E.CT@PK*U7)J9&50&N6EW,R>07\N&-09^JUN1CM0WHG#CP^7%6,A-G@$S1@
M+Y<-:54JU[F13G4' W$QKI%)TQ/H@D<;/89"&Y&<$5=;Z&L/)O0$"2?@-0DH
M51J9>Q(:];4*T^?G75A(GGH"7S34G0=HL\Y+2,^6V@ZRK;4C0T9.X(N?F]&
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MYZ7(1J2K3M#<U R.I3H-?"R@05/*O!SJRW>*(@#= +JY#[JY594RIU8"XM]
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MZ6ED>YZV%YS: /JQ3L>^VY4EI]V.R)[<<^=03T:2'L)?OL-8$<5!).0E]2/
M0&\6DP #?="UU=^1ARAT1L/>N#;BUMUFQY779J7%Q1EY8*\@CSL(_7K1RRTK
M=E:[5@D+HKX*,WX_>+XH5#S\DL[:F=Q@$"YVLO?_9 LT80O-B])Z&7FDBQ?'
MZP+!9DP@"_,S1I<1PWZPB>=11UJK;-.1<4&NF,8["CMD71&B,$@[ETS-J4JV
M[J1=JEAV# DF/ET-&Y$<;Q,20M(@,A(ITCA2A)%355]N%G:WMW(_>QI];7C^
M,7O]Z])I:ZX],A]/7*]U@CZ>M=Z>5W:1=%WW@\.;G'"=^IQ2;?(V-;%:.VZJ
M2T(<;J2,M?"$M4XEB@5L!=@*L-5G8ZN7 __<AK/E/2W>0R*^J$S*U4ECC_VY
M6/0JYNHX-KOHM^<RY.RW2WG2M9N;>2]E+NK+=PQ&BP1) _H"] 7HZTST];:A
M*OR5*_YZ1N7N5*!&TVT&MD14C%5C%=B343T^+W$E@YD\YE1J-&VDT5ICH$F$
M0.&MJHTV*WLF9;!4\T9)O(A#Q\G1_@8<]J$<]DQTY;61F@,.>R:B\MHC<SLN
MF,K'J.5XU1W7ZG=[.D)U)JCUSMI<OW.;C) JBVH9F7/FFFQ$F$XR]"9SFU*M
M'*6*"';JFO13D[FU@,O7BN/-R-6/=7'DK'R;4W+]I"6+KZ-S$P\$@+Q;,8J:
MFU:[6^K-)1,CYV2U16\9YCT%C%^A<Y<W)@0/;4FUA(JXK+4A>CN,$@)!LYK$
M5)&$,ZW[LENOSPRCBZ<NRHE[D;?D9U=P%3Z2*<[O:D3^9M<08YCF3&)=9SN3
MJ85.,Z; $Z:XL#@#& (P!&"(/]1S!YOU4M\,=XJ$<'!W$JZ8P;A^8;88!&TG
MV$]F.XBE!PP\&_:[\<9(V8)*Q1"D2,"G@G@ 90#*N!W*R(6&^J><\8R&NA@L
M)$%<(!4NHF8EO#+%:F'GS,?6SVJH:Q;:L"[F##AQ(K?G4#SJ6%3F8V0:*H44
M<?PXYN:\&NKGYHT+YX?,"6]<.>5CSGACS6TP.4"\OA756N4%-"MK$^JCCDT,
M83_F9W62XA!G-'6&+813RTP&>>S+=[I(4<=;B[_/H&#>4$@KNU!<(_DF+;N+
MGUTQ#Q>^KI>276&X>+AN7M!=3==>"@E&OGW2LZ8/E$/!H !+ 3F4;CJ'4KY-
M!^ )X G@"> )X G@*8^F _ $4OJ=-P MIZ/TED&YM1"K-/5?%D;ES=.ZMXZ7
MCD%:VS:9%_V0XTY4[.3;&,/7,Z6Y6'#U$$BP=QE6=<ER%.0AX0#R-.' ^\,C
M%G9S7EZ3V[H4-0=#SI[CSI2^1#F*# 4_0' BO&K7@N:DQ8<F%"VD:EDS.+Y-
M,C*"'XK>8AA>)$ JE!L]!,W]"%S]@/3#2MI>BT?.DE+W&1;Y>4:R4D>B&8BU
MKK1>*U6\CPN+)M%+6014L 7L\7G8XV)YC\Y!'R_'8,U: ;?>P#T2(N1N1:7'
MS&3CO/U.[;NII-RKL<J$-R2(G<P02H?])K7.J(1*'1(</A7(">@$T$G^Z00D
M3+T]H\AU05I0?_8C5EET((4,$[LE:.>UC?ERZ@Q(Z@I.]F*G<K+7-WBKI''[
MZF:#PK"7;=6SM(-%'('N.^M@)FF49FGYWE3U^U&_M^#K=N( :870>Y !O57Z
M^:U6H\T])8!0(F IX*@6'-4"/ $\ 3S=AA>;0ZWH,1Z?T991$*;O% R\9[XY
M\_TRUX]]XOGU]:0306(%HNYO3%4_N--]7?4,-WM*YEF?\*4M;M5>U4?K"D3$
M,V*A*N8&*B6^-)&J3 A-@7JM@- ^.:'=@.D /(%8KIN)Y<J[@W FF>N*BSK;
M;AMAN<;/.&%-5I:E*;,EZ3A=U%.![.55_=8BX%ZCA?EZ$/JFFO[I((LI<6(O
MYU/%<DHI]Q$%E_L1 #:0ZR/3:SJJ.1T2  L BSN%1=Z=RQRJ3]EY;.I%E8\=
MT$>_*3NO93*OB==#85[U_+ENAE'B69WP/R?#E=YNCJ:1M2-588#(D,.IC(R0
M6>C2R5I,@&X W=P@W=R 40!8Y#APZ9JJSR=>A<\9R736E=/5JIW6M+SD+'':
M=YM;Q*^I6)RNG%EHTXM+Y^N5F^?L(H^Q3LF@%6PO"-+9R.XS'I(H =G\@R.:
M;K10-3B R=V!YHU:4LX./&]T% $> 1X!'O,SB@"/ (\ CU=.*GSVO,%G%:&?
M23_>U79H-Z8,$B(6%4'8UI=S8?[G81+)/J_AJIZCMY/-WDMIB'VR# ]V#B%;
M8J@:=7\WZ;=@1D:H0^;Q(DX<UU'[&Y#85<LT A([1TE'0&(7#--Z-?\TNJA<
MB]K5,<2:>DFJ05AIO38R_L%>P3^W%E_UVB*.+Z4S!U4?SJO.?;I"KV\N]7B^
MS$)55BS-E*[5L)SA8-^QVM*"@(S+EGK<EB59<::EMA65C?&88:**RR4N#IWF
M(L.A(HQ310(Z%<4)<';.O1DH-9UMKCX=W?Q97>F/X)KSEW];BVMU&U;\NM6:
MC[B-Y73GSLA(N09/N09P#. 8P#$WRS$O!Q#&BWHK:/;8EL1&C?JX:V#-B+QP
MN<D%!W<1H\1'G+[H<?O%H,PX^U[*-UFY2:R(X\?[)T Z@'0^%^F\;5PN5'CN
MS(KQM$8+K;AJ,%#+V8H+7U57(_?/;\N_K7H=J96K1*V#8%"TYWN^78YZ2S+;
M4QT*5A)%&#E.T H*5IY9*0;,DTF]@'E>RSR\5I=EW; J5LEP8ZRE!5$T^*B2
MEW%;I:8E<R)SD:9I1B40*E,KVQQEX9AI%M;?%KF]@WQSK]6 FY&K'\N_*"AF
M>5\9Z&Y$ WXLFXN^6Y>Q1*.-^Z2*6J4R-&0:VUW+8?Z@2L5;-&"\&;(*J^PF
M$#(Q=5)$G 77C;,N??E.)LQ#04620"Z[50)@NWJ.GIQX+3>01^P*LLQ'4LSY
MI9@F5(O1\7HS@01C2@A*94W HI%V"4\H!E +H!9 +3='+2\KOA*TV;#1:-^%
MA%F;QAG6(LS:A6EF:E;<@-ZJGK7N6)-A94^N>U$O[1[UY3L&(XDK [@&<,TG
MY9I<R"U_2C;/"+U-0B(]:3.<<"5GN%4X: 4I\X\2>B&)DY3Z#.U!41PI&,/T
MVUTE\VHRH9=$BP2.7ECH!81S]5R,.2&<&TBO>%7GQEYR:&_"M>M22^%&:AGN
MSY'RF:GB5X;8=O8X-:%:IB0TM]IV0PTZLSV3,40:P4L7(>A4J;YWB[IYM79V
MH;A&\DU:5HDENV0?+GQ=+R5[U'#Q<.&^H+N:KKT4YHM^ X=E(*DBR%OS&=(Y
M@>Q-  4 !0 %  4 !0 %  4@D]]]).[[J!&X@Z H4(0S)Z  13B!I>3WX"OW
M@P)*:@'X /C<%'QREUX9?9J:Y;P1*R2VF!E$ $VD6F?*&:%*[FWVMJIQK1N-
MGC&/2Q;B.'6AO&L.UE9/1I'LQB-U?!8-^ OPUUWS5^X'!< G)U$<N1^4FXCP
M^.#E']-6 K\<:2(G=HUN13;ZC##X\S0F5UBRZP%K+?QQ4^=VR#Q"&:2^Z(SC
M=,G.(D1>7+-O+30$%-#,@WQUBW3QAAMY9]TP'-^>P:+9H-7=#R:2,FUV":I3
M7< *\_8+>N\LZ'*XUW?B,E^M%[<:<&4>22/7:%D8%\?;@)%1-+W,!Q=1,OG_
MY%T^@"]P=IK_L].WAYSF6([X$W:Y4K6HQ"EJP4A4":11B8/Z33X<;W9&2BMX
M0BN 3@"=? XZ ?+F^;FE8VM;;!SW=:YEKB7/\TI#).REW$*E^0= #5? +K?)
M+KD? 8 "$.CU^2JT7D9#//^Z6&<=J\S(?"PIGDOLG:&LZKLX71=3:9"$<5"A
M%51H!15:<S9HP)+><AX.+.FV"L[E?M  _ #\ /P _/(U* !^=P&__%4J?)=>
M_$Q.I=:.7O2%GK;@6BN;"_J[W=)Z1_+\5Y<[-)IH(S)H=@^M6RYMMNL:7:XE
M^UTL2Z<$%RG\^-P:E%L%Y5;S,VB@NNKU8_A>33=>?[BAXG+D641_L$=;;7PN
M8T9&-]@KZ.;6@N_.4%WUO.GU/S-1@.JJ;ZRN^O[0&F+8#S;Q/.I(:Y5M.C(N
MR!7STM55YRJO5:UFF6.5%A<%FYI=)1.*P;/,^DB1QI$BC)PZX 8X T7(/E,1
MLCRDBOQ(KCE_JDFD6EU,FM:H:M4:>KC;R\I2Y.*4:](4^Z>N$0". 1P#..8V
M..;ET#ZWX6QY3XOWD(@O*I-R==+88Q=.;;M;5=L=7]^@4(F+1%/:[2P/85*^
MR7+MHT6"I 'I -+YY*3SMG&Y<(W#,PG$G0K4:+K-P):(BK%JK )[,JI_5*%$
MLHX/-$XKRY+>0\:TO'1&.)/Y.8>D^W@1AXXCHT!UU3,+PX!Y\EY=-5_NCLK'
MJ.5XU1W7ZG=[.D)U)JAUX7) F"HN%P.]U.)&HY6TDE!K3$\R%^5PM[J(8+\K
M )^IO/\3*LF<GA_<SZ,9_M'NQYD!\GJ 7_H]\_MF3X]>YME_28O_[NLK7P_2
MU:V0-%6<Y._#@KZ.%#N]<6[K05 (%\G?_ O^>AO#J&06+BN(#J$$ALL(@:$R
M!A.43".$)L.H#F%S90Y#E))\Y_\H%UJ7TE=^X):_X+\/QP0IC<P]+W2]4"]L
M'?N;K;C&_W[1W9(D'H I$U#RUAJIR22)SV0,Q0E90;6Y/)_IB$*H,VHV)[]\
M/Z@JA2P)0+'PKY?IJ6)N3$W/R.E!8IY4XVZW8_;Z7$VTXS%9*9-D_!N)^?<<
M]3:)^(DPU%5\P<^<+BW+!-'5_4Q _E4TYA7?EX7:6$3&LZ%DL8WY;)R,LKJF
MF=_=97W/&,"(C,*'*M@K06D[FR'2MW8B/>((K%*=*5<8A#:F4S+JR#N)K8V]
M,;,E6V.L]^5[LJ2=K)GRRP>%E>(7-NFW_+O 1.'"\Q,KU@HIF&#XWP4E*'CS
M$V==A=00$I;0"A5=??I7</97R(\'7/[ XX+6>#B[^#DL)R? \*<-9,",1E;4
MV7CHJ+U2.#*Q0IC"BXEKD_Y_/.KIR%UJ:#[&2%\U-L,YA)2:OMF$=*M:\0W4
MXGHI0F$,>WYL#ATNIBE.5GKRV4:W=U^S9H^$><YUYXEKJ"9+G^Z_P-XO>H:#
MA5Y0U#1?B^+NTJH]Z9LF*ZFOIZNIF3S:\).5-,%;F&(JO9:1S%VR=AW2O+A9
MI$.6WF5NNHJKFDGCX''[&7S]X6]=>KE][>Y(,S??_U_RX_'?J;:N^.E^8/&+
M2X:F7_*P*8*@_SS?]N^EJ4N^!7ORGMG/__M_GK[O3Q^HI'JVYW][W(L\Z<CB
M,,-(MBTQ]-+,UQ6KI,R3[_JFV+&R"QX/JJFOR(^3ZF\_]C-IUPOX5XKZS\+/
M7],!.!H]1]F6GHS1PR:H9.OS\-OA7SU^E&U@'C_S@DSN_)9E!DJ0DC[['T_-
M)B+T5I>;A5_@@D(_X:(4%G[*2_\Q$-B3/GSZ>P+^A'WL?S^%U,-'":C2'44*
M%S:EN00'/TQ0>8T9_G-,3PW6HXN(0B1,X) ,P7-*Q@B$D&<SA4HV0!B):*JN
MTW/JK"[B$8'\QIB[?6' M!OC0KDA#.I<G^ERTJ#!B@]1)PV>_?K$Y64%OL+Q
M(E=)?A&%=J/"#+B*.$A^=CA^( I5EA'KU;9PU2[]>,G"T[<L_'S-@E MI"]:
M2-YT)'X0YZ=.NO15_%K0/-M6_"!A[H2KO2A(EN/@[X]\"5>)-#-9#S[P2\^[
M[TJV+S,(P1,440HI8S.%D&E-UV551Q52TQ!RAN,/%J@\:A%TFUT3@VK8DW;J
MLH9Y%C]%YTP:$/=KRT8KXM$!27F2P$:6V>LU5K%AR,AQRR$['L*]?J4JL1..
M)>?3J%RKI2V/OKW3;6GVI(HI7&2M27HU]&UC8,BH#/W:LM3E!I:^,'U.J,F-
M;BEN0ZK-R-AQRVW%KN,3NF59+60[\311UZMRG+0\>D]Z2"IMJ2NWH:B$ULQ:
MC1YCL_291^]9XBN-F.<676EG+_A-R 8UM\G(^/&W^Z+%<XS#MR%%%^'>G.OT
MT%Y/)HY;1B92I6=.6;)J+HTVZX-Y5VK',GG<$@^;\]6TNG>MM4"-X>H,AZ)D
MCJCCEG9%X1O8UNY*"(-O&T2C*_3W<>*\'[4<$!MFH;KSNK269BVBS<R&!F_(
M,'3<U% ';106J 57HPFK@L?[T@)ETJ;$KTU1!I+73."YDM,4Y:';[YHQECP5
M/GYJ,-\BLH89/K3;]>=1J"SK@X:1.M/'<P_[8V$<-+J6:,GHRF 9.6[$:=.C
M%R!\O6MCT6#(*9TQC<\A'MG(R;N>L*B1T QHAI'KG%#J#4=E0T*Y?B]9@8Z;
M4CN9,9;>&(;8-56UG!K.BVCRKB?FGY?BD.R1LB^MFXC&"/W)O"DG3SUA  L(
MH]69%.K6&D&8EL:IJQ*2//6$!8QJ=-<;-[B))/3@,LD[*+D:)T\]80*;ZLJ8
M6AM[9REH8\C[,UPOIT\]80.,B/1: W9G6V*C')7PV0[90@E.3]@ RS-$S^DN
MQQP;,%25V@XG0O("2=,C5"TBSG;7FMRSS+V&63VU21!6]M0C6$W+7F-:CLM+
M;M>RFI[>;2AI773DA TP0J"N&_Y:LH2PKZR[;'-0EY*F)R9V'-2M@*\V'6NT
M['=WT[&GS20F;7KTKGN!&V'\/N8D?1*'\S);HRD[3IL>$^5$\N'29L5(-3$8
M-)M[T=[22=,3YN)8;7J#<)V&I0@;=J7/H*T^3T;@A+G4_)T<#SJ:)B4.D.4:
MT!#'W.2I)\Q%W&&>VE:[>\FT1QZV,=SA.&75$^;2AH2V9'BS*<2B^X'1WC"D
MCV1-CT; M=?BI$;5MURK7 ^W#%L92@DHDJ9'(V!&&]K >B@.B8IJ1[.67L'I
M9 I.6):\8[325#5,3A^S&]N5J[,5$:<2PE'3?20,-9?9=ZT=U>9QH;)DAZNL
MZ=&[MN!U>9W,E6"MEYL)+;(FWS"RID?O.D:K#M9%K 7$RIU>H]DK2;@0I_OT
MHQ>8)DSF1] \L0&CQ$%#(MY5AT::Z?1X8NM=*X3+>YYKM1==A)[NQRB2Y3$_
M>M=NF6D[XJQ.<BVL.[/=>-%$Y.RI1^_JQR1OD'  2>QJ..ZMD&&E-LQRF!V]
M@-6:5-=;31M 4<.J$+/1IFRB\4,6Q5\6X05189N,7Y)&2\93PTTS=-J]A\QH
MOTP!BY'>8*%@$$O0S1'66RP]/HLX/\:6L#+WFP!J0[JVPY=<>ZJ*^RQR]*AI
MHX_WD^52<3C"Q%AMZHXZ+,'(Z G3'F.MH!:UIF-)Y!8=,82Y;B6-1R6.NR5$
M-:A-;#!48B-E5UVR;%A+*"-I^MBM[%#DQZ;S<!"FIK[E*M"_/?[RU$\C$D?K
M8>.9[F#4P\[GGUO")P=E#QO"X^U=Z#]^Z\/3X(./][I ?(+X"M$O'>$^V7,]
M>;Z7/'-N>_&C?_CXYU)Z)OCML'^.DT'X[=;UP>W,OOBQJ3(+/#L*]8_8Q[[F
M,!E^PV'R3QGBG2>JR%?XQ:-U,"_7F1?X*_IBUF P+U>:%_0K!(.)R=_$ "++
MY[P (LOIO"!?"0"8/$X, ,PEY^6--XA_NW&Y_]C3WZVL5QV!HV.B-PY)LF5.
M/_S?+_B7/QP>%/J*'5TKOF:R@=.!!Z\/2N5-5R]TDL\708%S-5TKG"V,^V5F
MNUU#NBM2>2^D<LHR[PI@/YR+'_\\0L8//D'^E$]@["MZ%.1^RWSR ;DM@/'\
ME"?HSV(\"%B6+K(LY2TGUTOF\3.@IU#M"YV"T.7ZS*#!UPH,.V@,&X,&)WX[
M*\GD;'0>F>1,*,A9[_XHE/0<^NX5QN%-]UG_N8P TP:F_6K%[Y.9]GU-_BUM
M-+,8ST/Y"#/+#5CX*RTC<8[DH3F3I#[H"OBUW=1_G6]]O2;C?%SI&_ADZDU8
M-;J;UJ"TX4J]KE"J[**A&OUYGJJN[\W-\"'OYJ^7L1=RFYX-3+/.*=VM!=&J
MMT"S(& TO3951''B$G7> #QO%IZ_.Q6\@D-PN=2X#_A$GN(3D:%PA&]#:%>!
MB&W;W^+.>&7-_CROTS_P^6R"E47-G6QKKNU)NT%;79+TJBO;:5P_D0 5+L+4
M<<Z$\V3AOK;5?K KE!M'\,$[8K1E%(39I<R"KZ\CT]>U-#^"KR<6JYJV7G!_
M]9_2OTX_5)5@48C2^YZF6_!6>FK4KE%(K6-CAJ8>?+O7G>&UV#UGPW"^/=)M
MB!X?/^W ^C^#]=^&+@*F_=-))UE6C-),.>1T^%G;%&S1;M39/?>*#624L\DH
MIZL(G]BIH;5):T1B,B+M1&@;5V9R9UUG9"*55) B1)U*DP3@^LGA>GU9Y</A
M>EE5Y=5PG8ZK_L+K12LKZJ[1*&J;7+ED)'!-A94BCEU$ +V^Z7YR6:62)I]4
MS?-Z2[GI)-@0?!X5Y,[<K*? /,'6=* L(HQ58<BIFH:N;J(MIO1D,G6N*)*Z
MG&N5,Z,&V/X,&L^=^62_P;9LQ!6^5^/[%M$,B;C?P/"2:R383CPQ"K[(MBF7
M1OV9%*SJC^2CAR.L8G9R]9>CF*Z]*^A;=:&XAE[0S/E<]W57U4%XT,UN.>Y)
MW#KJW,6#$"[K=E4]7T\ZRD9^BK+=P%>2'7/6CUH"Q30X07)]/1F,I[F7?U+W
MK+:B/-9VYA:Q)$K;DFW,>^.>3*5N&7Z"N@&( 8BO+WE]/(@OZU^]$\0J*?7F
M];U"<+6JLQXI.UQ68B,!<::$0=1QM4H0870'4AB;N5A9YF%%5?U(UPJVJ1S&
M(+6]@NZL;&^GZX4,0$$A6B7 \/70]+-D\6"+#;;8MRN?W9LCU]7=(/DRQM6$
M<*'[72\(?T*UK+OZW RY;7H@HK\4;HH0E#U5NN6RU>+E2F]7:LRB'9.^=N+0
M'5?1.)\_ES/K!R3P&72V>W,$ST0"G.6X^R[;8#F$P>PZY09U<]%+7CMQ"%'Z
M,KNZ7)K_9U+DGKB#FC[7_2S>7-D6E"#0S^?KW>1L?L8]#A#I\N/;51[PV,BD
M\H&R?>#P!T9_B<H[]!)JAAV^"9FQ7%E[-B'TM5Y:Q2)QZ- B1"- HP-@OV4Q
M[_BL-"L*B9PO1\!-3NE]:%2I=EGXRU!,]^^"]U@L."C,HRS]H.D^5F],:[<!
MN0KL5(%<E7.79F5OOST>2@@N<\!S-8-SP^T?P"S,N0<H]S,D2PF0^S]P?&J_
MRLZ-N126%I)C6L.Y%JV'W1J3UM]*G!R,!JH5X()[4JWN)#KL+%3P[,:G.QG@
MW5 .JIRPZI2U#6^M6I.L)A_QY?L%8_MS!H7/I&"EQI1ZB8DI)Z^:"J%96?G#
M'T,SK8^5%<L&^]O/MAD"8E;>/+^*/@O9'S@]P=^44*'+EC) N<@>]3>+7A#*
M=E8H-?7I$!!:!F -9*O[F]+[D*T29S9YYWW&JJD+HB5L5S"#(%)<54^X-PB#
M0D+2A\\U,U!3WQ=L2N]Z4PI25M_EO<6G4!?F#]=:7(--,<ZX6N4!W*=R<%(D
MO-\KC4B"=M2\A",[BB!6<5JU/<T8 8%+C8 A/F7F[SO1M\[ $ UYO:$GM:4J
MK6E+5<MA4PEX(V4((F$(! ,RUAW*6$\"L9XD[TRCL Y.XV.0_ED3>=[DY-[P
M!NFN[T1>*Q\G,.);->+KZS%@0C^S;$.M#LFA5%]7 CU=>E-_,?6J@I^7XL#V
MZZZW7R""Z*:$EX9[ .LC:!LN^P#9D1DNV"A(YDCWVX_@?2E6H#K6.R5%L"V(
M",)9SW:YR9Y)MEEX5@T%+<(G$DR!&"+ !C>LL7P\&UQ69#DC&ZP'ZUEER4$T
M)_#K8+[U>CN/CE,V(+Y\QXLX=LF**SE#P>?070[>WZ,)/21$.$2:^[JJFQME
M9NNEQ)HT/5-@O/1RY8,D S:O-[K7N6L%YNY\.^8!D/T?>#S!W!-_U-OLS85F
ML>5ZQXELA$(FC QG*=BQ(DQ=THT#^+U5_.90?+H[;^Q5^)W.7==58[H#*=76
M<L5X$;,=QBE^,\^+N-!EU>O;\B?7W4Z>>-F9+Y9!)0VABI(_'#RN+%4HV'V#
MW??M:G%W$@.5AG0?L-MPA4?@ME/<9K=UA+D4Z$R&V9?VV^*V4O';*+.&:DC-
MH@AF#DW*A@QGN=WA8\K__^R]:7/B2-,N_/U$G/^@Z&=YNR/ (\3><Y^.$" 6
MFWVU_840D@"!D$ +VZ]_*ZLD(8&\=1N#W9J(F;&Q4%5EY7)E5E9F*/JAZ(>!
MMTM#O3?)_K'()UE3ZUG=1K2W&I:Z([E7O2\^;$#DH<+4><K,726S_TWQ-?=T
M];MLNP<_ /')ZEI234V7PXMYG]9_"6-IUP?.GO;%*P>)"^JT,Q[M:J-=;#N7
MFI(Z%]*I=@IR3C,DB)9.G[.>0BBXGU5P+Q]$^V)IXR_)[9/^E!6[UXVULDAS
M<GZ66Z1VF?S=8PL$&,!5)!X01?L2O/R7!]'<X\OOHN2!5^Y)YI+?0=@5'V#B
M>N^()4-7^NRN]$C314F/DN__C"VWE*$ILDC]%XW_^2+:_\DHVZ67?U4&XU*'
MIDTB^JPJLJ310_5PA23 @#06M_';2IF^ZY5VS8=E(5,JC2V$ +.D9BB2G# F
M%RJ2#X[977KYU^4R7NKX]@5-\B0FU7?%Q]5^K*NT5-8RV]@Z-UBF-J!24N!4
M)N+GR<P(8WX7B_G%;Y)XE+ID4@)O3.$ 5SRZTX@V>HU9)XP?_ E[7[%A^.]W
M!)>A ?@P*(F$-H]DMJEK:UF4Q-RN9T!11O><AW4E]SFEG]ROK?8\G\C/2V:N
MR)F5V;+68]&$220Q&SM/8[E0$WQ936"CPU 3?!@4?!]-L+Y;[[JIZ):CY6W[
M820D.V)WT@)-@.M81.*9\QPJA$')3PIUPRA"Z/A\ZNR_ZZ)#*!6A5%Q#8MR5
MT>%+L<-GB@[90XQ\0VPD --HEHH(=P+83IDJ5AN##E5L-VI4I=[G.MU*O42Q
M^6ZE7^E6N,[/__PS"JL'?59H_*63QL(26"$3?[8$JG!#_V*'W2X^"3EFA@G-
M=>"L9L2K<TJ4EIHAOV.E@ZM9<P@\SW14\[=?N3G?=;O3H_D<DM&"+:(!H5?Z
M<3(;9#7]L<>,'XUE>6",C#$[9.PBXY%$0#9/6-LJ%/7K#2)<EZB?[W;=FT5=
ME\5]2AJ4=[V[!RY;KU0Z0D>?@*BGOOV*I2(T'=ZL^UIQ%!NT-74-$5PTJ+&N
M+2@#L0543#"FFFY&34E?O#^$^Y0[^S=Z)9\YJ/)%\K-!ESL26D0"VD'RV1AW
M0#J[2#B?4>B=7>Y^V)LW-G1>6]T;6K.YSSRVADP"L%LR4)^'$AY*^.>).'V1
M*WN_+^&S55Z?-@9K@Y.KJY2Y4F;31HL%"8<NQ>>2\$_,[5\CRM:T=&$*=_40
M3%OJD!%M[O#%/&EER4N(OH4>^)?VP/^F5)CK\M?/FSC=Y'<@O4978P4DRKK4
MM*6[J?"JR:HBYPAX@#%@^QU5'M=+;*_33:;Z=7XNK!;(?\=EZ#/9<]9=",4C
MU!)A5.^CDJK_2$N4!Z7*N#GG\SV^U,@F"K2:GVQ;H"7@*ETL&8;XOF*(CUTX
M51QDD?H^1EL@B;B^@RX92TG )5*EQ5+1=I)=--6@K*4&?S<1@P$OO6_=U$^Y
M\5_X?LV[UW((+]E\.&HL:KHWC-" -A,D(>/XILVQ4:B)I<?-B.FE>GSFMCTT
MY>H*&:@A@RO?)\]YPAOJ@:^J!Z[_LMT7"1_^OAIX\L+=PW+Q,.67MP8WZ(ZJ
MR^A66*43$] ' !*9TPY&853Q\T<53THMR [3G*/4PM6L_NI"!I=6F9?+\KOT
MRO\FT/C$S>PW&HIV?);;5Q\:VWEC%64M8YMJ-3*M(4.*[Z<B\508=@QUR$>F
M#UYZY=>E0RY2W>&-.J2[2:354GEO]AJQ>D+>W=T.EID)Z! $-K.1[)G:KH4Q
MR0O')'UK)4]&%6ELXBF$=]["5*6OE(QX!50(N?TO6?/E$_.N@0J?=^<_>3C)
M'N(MU1F*E3I;SY^S.L.U4>=Z7,6_C R?(X\MK/$4BLD58(A03+XV?WS"J('_
MLJ)L&!:O"C@37M 6"PW(H ES"C*<=,J<2A3<IC H=J)+81K3I\?4[WC^]%=E
M'IPY <F3;E"Q);(QSF-Y[( X!M7TK1='!BO/EQR?R>EFJ;L1I_P$9@B%)>*1
M;#(1WDX,Q?:JPAI?+6'H-\1V-2P;B4PCWZ,EH<R)L77T;L1@L<6=6&*I6)@;
M])6".3;JXK:2+LCDQN&&UW5>#0MZ_>7'^-<4N[DTG:[*:'P<UAL03> HAZ#,
M\H6Z+,>WZW2IQQ1I:7\G)6E9; WC,8!YZ=A9>LF&6B74*E\]E>@+0]%7:)6:
MVIT96B9Z.\^7MOG8O#.:S6XWH%6@(<SY$.A7T2F?,.[G9J<O[6PS:K2CQK**
MG):P&>!?<37I+VD&^,7PXA,YHD5'<I^]E]B?)O;Q=6Q8IR4NH8Z9F!!3!:3G
M&1PD3$12J508) SE/[R5>+W([H_D_^&NM]^4^F:WMTH4U['1:MA7:2S_=K3Q
MM 5H&&W\Q-%&^N74,:Y8Y/)=JE&DN/M\F:V7.*K-=CF*_-RA&G4*9Y>Q]0+Y
M@6OU*GVVRM6[G3"C[*^/+X07& ]VY7-?8.3&8TDP&V-N*TQY=2*U>5-JJ&!K
MX%\H@;1&UD0UC;9DF+HLF)((?V!5T?^!Y\F**B@6[$I!-I::P2LEM+U+] WT
M.RQ45BU)M'O7:NJSEYIT(]^,)9CXALLGEK<,)U6T5!Y9+MPW(7-Z@3Z\%!GJ
MI;\SDOGQ>NF\@/>Z]1+[N-.FZ3K+<X/\HY*_CP^ZZWD+]!)"U,G3P_OPIN5G
MCIV^ D_7N2Y5J>?;'-OAJ.\%COST WWV03CZ4S+!)_8MOU+?S"\6*_TC(]%$
MU-/$TZX_MNGPFB-BH@*L@[E:6_G-HJS1@U)KL!3[1C(WF0SCN&-$/,)DSU+Y
M*=0#GUL/7#XQ\ZMAR ]7!$_B1:M49W=W#RV=LY+R@&NG6LILCC4"G+1G(DSJ
MG!6#/Z5.^/HQV!Q;9>MY#H*P3V)$BNU2.:Y4J=?A6B]ZLLFU*XU"&(+]ZT,=
M[UYJ^/J6?U',RAK#QG@88R ="ANG98.O+M9]ICW?=;(#+I4H%$=\ZS+&*2A%
M-!.MM9O=W!W760T>B['L8U=I;89QW+<BEH[$8F>Y4Q"JD%"%?-*0Z4>KD-AP
MT!&91-$H*]Q"W)2W1?DN/AY<CPII%1/=147FY7EC*)<>,\JZP3(M4"$(I<8S
MD6SF%*6&@<VO'=A\+4CET.?G@:>?D@O>-8$LCM2FJ%DC1;H*LW&V#-(+K/,*
M[,,A#BK4-_'Y0BONN+MVLR4QF=I#?'X]YL$0-Y,>.WYL]Q;3:C5[QTV&4H8=
MQG%["X:.).C3$J.A%@BUP!OS2/]N+< ,ZV)Y.)0F\\(\.E$WB3O1L*SNYFJT
M@$9SA=U]NS#I-78UH7Q7O54;4'$"-[6(T9$T$W;+#4"$_Y@\XNCWG^?QQ#P/
MNL^Y[A?< 7KES,\]STO/S"/R N)T23_>>YC2:P!R=RI1O"!H"S3!'=RA4C43
MS837T<?0_,.4)CJO4$M>Q^WAH)82DGZT.F@/@G["_C"/1,^YAH4>-DST >Y"
M<^-"Z7-OR&LY6I37O_Z#_N-\3U D7@?QG1YQ6QP&L867IO_G+-KZ9.O0*$G/
M//%__^__\<[WX&=&!4W1])^.D?$L9$IVF,%J9B)%1[K$SZ/\&(WUDU<V_,ZP
M%Y;)W#"NH?[I&BI8.I6\R63^ASK\" 0XH=Z"WT8]-+*5&BG@3;[E?(0-D_,9
M=#)'BO6G+BF\*:\E>+?OK7@C3&UYOETX$I<X?1 7GIKJ8-G^J]O(!ZHG^!FI
M=V3!E'^](F5_A(0*E"6(2QX,):Z28;,@_QHV]-,TB%CO0X,3=? ":S;;C2Y;
MK=Q3N4JC6^;:;)/K=2OY3H1$XBKU_,T[ROI;9Y=OU M<O<,A![]1[S2JE0+;
M1;]TNNA_->SG.T$ 7'/V@Y0QFMCWWDWG!F%"1>%U UHJF5/-,A#,,GY\J$4X
ML/CWGLI;(H(JXGO.P+_HO).2^(-P!RCC6.Q?BKER^\QCI#A,I/@D'1]GAR/T
MZ# 1SR2&O!23ANELG!$$(<XD^=0W(M"\@RVKCWT$?(U&D5L)M7*I7=J:JC&!
M5('C)Y7=>%1-:JUT+W5_RRGWFUF[6)T,F=,G^\5:9YA_4$1.2M82C]%[61=[
M&_1D\OC)S5K:I[/[96Q>ZO9:++OF.B4:^;=#^OC)-;^;S:S-(\_Q24/7HNF!
MN43O3)P^F7E(#Q<M]D[I#;@[/3:0A]RMWD)/GLRS4*G<=4>99:VW&/<&%2TF
M2\DD/'DR3V-B/JJ/ W[ I7K)X;PW7E6-?6N8/!W]X:&;?TP\ZK-YGFEK=74P
MUT;:!#UY,OI]L4UWZ6Z6Z:V42J6VL6ZU?1>>/!F]-&17ZCC7;_0:O77J=L3'
MX]/%9I@Z';V4'\\T55:%.;.>L%E&'R86$Q8]>3)ZHEEJ,=%Q^9XK)5?C6*>H
MIV6NA9X\&5WN,%;L_G:SY59FI9P<U#:E16(RQ,Z'_\D\/U2:DZ1X2Z]6R[O5
M;2P6+2 JI4_GN<WG&\N6V=*YQ6(RK7:'56,PF0PSIT_V"LMHOSA6\KV&+A=S
MFS[3J299].3)BEKCK%JR[G>M.5.3<WHN9JE3NH6>/%E1:W=?'C<[?966%G,K
MVQ^J-5F9('_P9/1$:K-(,VVZ-^>CW):+E;-6E]F@)T]&UZM%L]86&_UYJ971
MXJF$=3M[:*$GG=&Q,^(B(N)^"Z!?EX;TT_G!JRQ22/YM5 3F52!FV4%\&*[P
MEJDY'Q"P@C_Q01J/XV8_<PI/3-V9F#U@C&BGU\73T[$;^MEPD0<S>-ZOH7>.
M%6WC:#;G]RBXH#\)_ML@.KT(O6R%B0=V'N5'".1;IO01..QIE]7O&;X)[MO_
M_4,'/IT)]^4:]R49[LLU[@M]$^[+->Y+J,>N=%]2SUZC"/?E8GHLG0XWYOHV
MAG[AOD&X+W^T+V_, WK1;[D8$3)O(,)9+>M%*7 23'TC29!3#1_^OV_);[^;
M!Y&Z2:8N6G0I\YHHZ1ONS,JJ1-70YU.#XE2H1?A.>6,O:;;/RTBA4KDZI9)Y
MB0#/B8 3V3_^[XD@N.J#^5WU$6-NXIFOI#XZTM*4%B-))R2+T_8I&J32O9,B
M"9GG+V0>)K1"9[%"UY;@_RQ[])K-*C[T9ML/5*5>;+1K;+?2J$-AO$J]SW6Z
MN,UJO1#8=)6J-Z <2+]1[<,?#F?F[]6-E2BF:Z/H!=)DDR$9G%!Q2(90* Z!
MT) ,).[XU].!OE0+VFNX77=1!]AIM6KIPI0G3;^6NK9$T]U1O"I2TLJ2EY#E
M^QD\E2OD;-OZ7_KRR-DOR1#K?NEE_E4%Q):RR2O<=BFIHFQ:N@2U(RU=E\2<
M9=8U\T$RF[PL!MR.&:1FB^9,S@_HNX=$NWU7Y)5$A1WBRE],\DQUUO]&T4]=
MP^W1#Q!]C&$NO<ZKDOUSUPS[;=FWY,4HGQO+,TY6IGQOG3;VF>9D2&I\T6<I
MG7!E,::_*(AD@SN[7+ ZH10H#T=A\0"D9Z%?>,.03(/21B8OJY((-Q<DNVP<
M,"2EHCEH1R]09!Y3\'U:<(4N\?-QHHMKU@\"CU>X\JNR*>?%DVU87V/<,R06
M-$+#U@<5U2DB6=1T5Y%400U4;2VP"S S4F.9GF>EHCCO3#:5=8'IEZ,<.R1U
MOB+Q[)EJ](2*Y+G8VL7%Z:.@Z!4N_:HTR7G1Z?MJDFRYFZN/9I5"K\3<)3JC
M3D.M3.#2%Y3[RIZE)V 8C;QP-#*OJ7B*(*"D4H& /S&@Y448C0@#D6$@\GJ
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M-,X'"GY;$A%S=(Z98Y S2N5T1Q=HJ=1_S.OW*WG/O#W<"<S!ND0@?<T-Q S
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M ^QVF/$_L&G_X+T^U]U[QH_'(+"!!1.LB.6 >9P12\K-0RXLM*/!J#)0XOP
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ME@1MHN*XRU. I%PT],9,D=@>LY758BICBLD">QIE"7[.Z?46PI>7\ 'HH%.
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M;S#GQ+;$K>A)9O*<V$<-20 FV"!3:TCJ.\I]<M9:Q+5"O#B/+OFR("5V[9Z
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M@F!]SC*6QH3*(UZ@T"V1,//Y0Q0;*R"C>*Z%RN$#3^09&[MR ^X2RUYD3Z
MJBMS7)W3LG"YQ^S$:N8"YS8:%$>7=9*+3^RQ6.N-M)-^/.?*+C4HGO,+VF0,
MJ$5,"B!J.H[Y"@ /"'7AJJJ-JD[7<P%0%+0ZQNR(XT:$D3(DT2D E@1?+AZ
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MZ3[==_J/XLAOFFSY5-[?M]_Q'YN:9^]L.=L.6/^Y^HVMU%NZB^7R%1-03-=
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MZ4;L#U&T@[C-J&9Q4C1MJ@5+.C+H7&F>AR'=M_OYP?CD:C@Z4>93=7YO%6Z
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MQ_0A. WKA?(0--A11YNWRV6S7[LMED4Q;9G3<6U4?L(:.N#)WTA#M+S>!&,
MZK"N6N_"4VR7V,8<]FTSMK21F[A75P^IN\Z-5+QOWK?:2:DR:)20FZQ7@#)5
MG0FK>__Q@%;^\YFL\^4@+F=$QPE0Q;T/)FL?/@H]1<<F>X9'?,GI2T?+I!\U
MO I^HMJ_X#FP*?K]D0'V8+2I#BPT&=E-412@>,'(T@@5H5VR10_  ><WXWPT
M\=XHST5IT4>R$F#5)2)5S2S YUJ/"MF-'@MIE+L36QG[J"BKY[59J=69N2G
M>#$FKR?Q+KDL8@>GPR-6OKC)R(_ORN>P<35'1%4\4+F7W ;Q["]D)821M".@
MG@3$CNXNHK'YD03T?LZ1*HZM$(/Y*+K(F(CC4+4J](21,D<>I.DV45U@/TJO
MQ_R276")\&AKI*L186QAUQ" 9$3H$ROX1!\VPC" 8L_I0G3V5%@)>WF,(60E
M\)]PM\FQ,E+ ]B6V;=FZX^(=/=UP;<J V:V!D\2Q/)R_9@H,(YDC#O=45AX4
MV*VMC^E"%@>A"'CLS!A27!?X,.76*O V0P=[9FG9\$^?H#1@:P*&8 F&XIGJ
M@#8[<X'*@2,)-O GXH8?QY:IP^&,/8.Y</#!.JS"<7&6D< F\CF"8:ET8XIA
M >]?V1[?5> S6MD5'"4=/X>PAN7A99OAS)>&T@4,/BI6\<<G-RT )2(KT$>>
M 8*%6)X#.,!VCP]Z:ONXA!<?04S(N?0.1\'J9R".B* :BC, ('6).R7$#+8!
M#S@F#UWD0P/<_AGI*L#CF#5*Q3=RUY@ 2 4VY1CP#1ZVBC-$]6S=!:14NH#W
M+C)[ TY0$X ;@W17=--A"^)0Q[%_(516@." 986O1%KT\56P[+YBZ@^<B-!S
M1T!V46B-%5LQ#";=X3;0'E <ZR;VSO-/$=[&GN4?:$RH6C9!2X>1JW_.0(6+
M!0:G$J$?5[:LD1Z'U0@.R(.CB5#JAC\ N+@R!704 CACPW=]6#B"QS)[AJZZ
M<)IP">R$15H!"4S+!; ZCHZR IU4<'AP(5-YN$X!QP G#8O&D_:U([-O(>KX
M3\9K=, T0AD+Q1S+LP-^%%EB9["KGFXJIJJSM7%^PKT2JT^&]8+HT#58+9E8
MQH2B/CQ"@R49UA@^1CAC\ SX5G=L;^P"1MJN@E356UK("F.$.T=(K)3VG,<D
MZ=M( RYBH@;IN4P$4DD)5 2@^!FEWZQF-6"4/[4>J@T].>3(I@\67QZV/6SK
M;;=%(\&;]O6'&WGO! "V:'%S+M%:!/NUIP^$.#:4.>Z _'K=B@T@U>B O?NU
M2Z8;Q1__= /_@FWT^S_PC_]8U2"*C?E"@Q6%+HZO\9,!Q7_>)>EG;=HO!L)3
MH872?__[O\(+7D0H4=^W[)]^LE)H)_QT98KI?1+M@L@81I4>O.RG8DR5N<-W
MELG$Y""=\V>0\(1[%Y*Q3.8?8?$GM0U6CV^DS**A0UJB*W:7_Q5-</*_LQPJ
M%'[2Z7\@[O#92T\-%.EW \,*VL5#:*<( QO-[O]IU?(;L1#_!M0'8]-8PD3^
MU;??+6J=43<^0-ATG0 'E9?@X?*9;CHLA=J6'3&9RLAJ0NH  G0[B6Y:[60R
MJMI14FHB*?>DI)A1OK&WLCLJ+AG)5<54N-NXH#NJY^ @ A"=.= FYH[N6+T2
MO^G=F=)3.36X5K\XJOO4I6%3%%2<*#5&O_V68X*PV&J@8RVV3-4%?],(K5*@
MM^1]O85>TZ#J%[VD%F@704K/^[.%5QU;/M=N56KGN<:-T&SE6L4J9B$UBN5<
MHU Y+PNE6N,*_HR>U6JG^#FXIOG,*>-K;>'?W\]>ECLO"(U*\U0HY?*M6J,I
M--O5*BSGC0_LB>/1-Y K& 6@<,*O-Y8G. .J3@);9*["'JCDUA1U3VT9.Y00
M=J"FN4&SY6-, PP)Z<*N!0;:P#<,E^]WT/*C-,A,B0'U M#R&6IG/GFE/S45
M%'R"=K=J>!I:NH9#IO ^PMP(L.P2<"10-?PBPR</1A*C%X&Y"FO-F2:Z71MD
M;-DNZORO?-@I;2N!R\40@4!,7&*!J-2C]]+GQ"6:I0&TW,2>6]Q T4WFZF,I
M%R;: K[O!#;]" PC:-:YN@I6+CJ1*4S0^"1H$5ETRZ#3<!/&H7Z,_ISN8<W&
M\,^? PF-% X$!V] ;V'4L"QJR(? %S+\P;XSX5>*,4W"O,1R.N=OL,EL7_1_
MY%1F; 972<4-5Q5GZ@ =F/1R^%G*QA-@_\!R1_3@(P*'1?A"?]4KRT2ON:TQ
MWP&>CF]-=8FADYZ#=Z%08PYTVS\JG>V=T9/G@O$:$ZX&Q!0\)P0;FV(3,Y"!
MR8T<FC,IB[\4>*"JC^%)$?J-],O_A;YVLO:U[^Q?^YZN>?5;53'7ON(F_?KW
MP!M6OZ1;7OL6;//5KQ"%UKZSZ'DIQMH/S"!?_]JZV[ 'QK56OYWJQMISIWBA
M_QTB#PT8(K#& UMQF%?-T8'Q F'J(P82=.8-R)PCMT\2*H^M<#(8!0(U0CV7
M[%PPXF*!@H&[[,V?( % "?\>>)D"F&T83U%,EPB.U[WC),J<3STP'Q2[BYOQ
MIR@Y/D74;7V"BP]1QAG\7Y^QB@9!MK$@D6R2>B4<\M02<)>6"0R# ROP<H".
MB/F?]%@F.IDZ>()\'32@1$\3;Q\I&EGC-XQ&!#()./N"Y8,(H0S.5 ES?TP)
M2_)PE2$!KB]87</?%#S*&[, %CJ%X$#@'A,;^EAX&\O_H-Y?E3IXZ,6X1_]R
M[F-Y FSX#G^W?+UPLZK;JC>"BV"5L &T+D+!-!/]DBISARX>I#OL,)!/+)Y)
M?4XJ\UNIE,E[YH(?:/R=$6!'*@$IKP0N;QO;*:!'D&7 *%@1J5+=VU"F,118
M3T$UA%DCW+^M.T,&"<_D'B:*0111F0.*^?,1XHKJHG3T!3\\0]-[/8(4 @<!
M0 2,H5YN>K(,UO[%P*+@3V2+%B4_X&_46<]4D<?7#/_U78%(O^BU@R7T8"F6
M[0@H4I\2IAMS6Q<"P!U8L#6'N+@$0%5VI)RA-.!HA!)[D<]7N)H01'TW: K/
MY];Z"CXSCUZ[>JJR^$*'QX>YHG'BF60;2XB+/#6<:TY4RNWZ3)Y#!9K3K&]'
M&R_.%,!P$K#&QZB,*U"@9G@N)4_T7AL@HV@\WXHL*^H_Z=I#!O1;Y@^+&_R3
M*\&]L+]PDU?0=Y#I)O5W=;&BY=<('A *DH:?0=T<ZR%51(9L*IWUL8$=GJ]^
M<I%(0Q<V"@X>S<"C+AH]I6OK<&Z46]$D9KAES!+K Z)Q,9I 63/&V31D+<!S
M]4!=!:+OVG-4J3%B\VO=<?'ESIWR2BLXW\"O  NE<2$59123W#0UW*568@1N
MUD==SW:8(&0*1!\C;A:<+PO].V&%?(7;TP"P-6/1+Y/'4,*&#Q%*A=PB6]T&
M0TM'B/N0YI _@- G':[=KI .VH@FU@APL+)I&W-Z0Y<&G6@0%KD6?EB&*I[U
M@O!\:YU&8*F:P50B3F  8;!**:H@</JV,G)XK"LZ5N:A[X 9>BXLXX%H7Q9\
M%(7]6":/ W)6AX ,>5TTC_B<$0/%0=08%*SG(LSK0>7-X>(@&X!3WB+>S\34
MDT'H4&2<QBNIAVCQ'F0%$V:Z4.^%/2):$"]]AD$LGPM+= O.!1,)>-PTS'D\
M4/SLQ?M"5_&C#1J516C)FP*6%_5#^Z0"W\/2<)X<AJM5@#K-*V&Y PX %KZ%
MA<%GD.RHJ%(<]QQ .+CYE_"5,=K0A\30!Y;%S6'.QB-"L9JC)C=+&UG8-0.B
M&-2.W A ] 7XLAZ3_N%:8IL,6II%TQHQ;0!XU1*K^K),9:,Z%3Y;7YHRMNS+
M"B )D/).X!5F4/)5*[S6_UN%#]2ABZ*]%ZAA7_; >XINH"5,^PW#\WT&ZF??
M,$V4>9T,$F;P8#$'K,5Q@0-R?K7,;^"8F8SE#@)JKU/6OV(MAQCI3\$!FX(Z
M+VB=S)@ESZ%3DT+8%]>P -O3J;+\"VP7("#B8,X3>J1 ANB.XQ%@9QI!OZ9N
M!IHX)SS_=TPIQJ]9,@U0)O4J:R"(4*=;W@T:V2$%!%-5';8!0!-XTPCX.O6^
M@K%D BAZF'9O\ZL#G1^Q4QGK9.EQ<,B>B?P"7FMR7!ZA@PM>KIM8M($.)I]=
MH^S27<]E&4?H-@+<[%H*>A71ET7-,J91^3N E[L6"(S53<":=1>==[Z9H6B8
MWTT3I_DI8$X5<R?YU@GU8OX+W_NGYWB8TTSAT@/[EROES(-&EA?"C_*KDARE
M,\<GM$4U*T# =TL#0.]X= &M0'/N2QRF.$S![L84PR"]<5U"/2V6_!C*,I\,
M\\:%(K1N:3&>3#%NC(7BSM>%)?>=.(X%8@B95  2$R@=@Y(V$.A$MSW'-]EI
MX"=?NZP4HE(6G0$NS09AI5D*D ;UK"Z8IJ(!GW20&'507;E[>Y'I]T(V_"N<
MP++?^3;I0[[-(=_FN7R; Z>AG*9O6-VEK-YPKBX+4H!J/$#3E%J-8  /T)*$
M?PV#F'UD]3Q^SU+-T48F)C LRPS<8B["5J!V)G>J10(=Q-<CN#3K*B8-DO!D
M]?DK&-E*RG)(0;$5+)-&,N+J3A#EIRH\7NPL(D]4<ID\ELV=?SS=VOOJ@BID
M6*%2 9JJZ7!/)RH5""6F!?OP''M=4#NH;L(#N7C, !:&!\X"/"HHM"ZK8/>5
MOD60#4A;':RB9LBQ@A4P)K4&*#0UV*].]6BTD]$ ,!TNUJ:631&,O^X ST K
M0VHB6%.Y*!D9>[8#T*+J.<\)40,GT4 ??UUR\.->"R=/.&%LW5AACAP,@"$;
MQ0 BU]U]-Y!J*/J(97$PZQ-(AJ!%I*AS[G=67&XWKVK;BX?3W #J-R0.969!
M@8?-+L+*UA41@&%AN)B5'^H:"=_#-'C/#&QHX/M8U4C0L:FK7Q?^F\DG;!33
MM!KZ+;L*6"10S")Q<.%YI<Z+)7\J-:9]5VS@UF"!U-4@:KT'IV=3%&'MKPXP
M"?O^E!'VK&09@+Z'@:7-4" H#A,K] \43<  4>LY'.+CB#T$/H%UF)Z!X6=6
M3QTD X"8-S'+![MK16B)&O4) L>@74/,1:)0R+,#-BR&S:C3AV7 HL,(<]0H
M_\$== &FYL%3$ 8,2_ND*A0]8'V$!S[&MS*%BR"?H!HYB F%)2^MRB4J5J88
M6S MC\+#9DJ;,S@<]9+'BGJP=8JSW;E0TBW5]AX8/\=2RJ!?V"*3S^$I5T',
MC4MRH@Y,R[#Z7('&'#/%;\88-GAXII^??^8;0+Z*C6TH'!Z\GK,2Z459J9^.
M&W);,T/.?]&7AB[+ENV;.BI8)MJF4U1TG>7\:7C?P#(0@D:0<NK#1V<%QG"R
M_+ -O8=\$<4+H8%HD.1?]HP1XS4RQL0]RE/,< (L2XS4;2V*2LZ<)?UJ6))/
M<R#MB:YR8XT'JI? @@0'\H+I0!PDJR%J_HPO>_S,(X-U(QCE>C0]+U23+6BV
MU\=J"1>AY(1#GH%H=^=C0D6%34)W?NU#YHZHWI)? C,N6*(8ZSK$8G5^P"M@
M__A=U]=Q6%:^_H61=F,Z%Q>;>, 407V4A)^9X?-ECVL1Z_,= J"<<#6='B7S
ML;)3I8Q59;%8/SHK&(BR]#?_T'73\6S*HE6+=1+\LL>[R$[CT?4>^KCQ %DO
MEY  "[+/L+;!##M.4"VG+<4]!B8V-9(&<A:E?PNNS,Q2FI.(+_$?1V%!H^@+
M[T_ H3%Z&DA+FL/2\[!2@6 Z@^K?]?1"@DPV?TLTLP >^:[ WU_8/VYJ@<QD
M@7$5A2!JC1'!]@SBUP_U><.=(#J/[>& L&A7((H8045G;%,L,-B]Q"-I[)KW
MSN@O8](*;Z>SI"1$A/FBN)8VGS'@W-"L\6C-*C.'+/_>I\K$\KZ "T(# P7T
M095XBZY57=T*&4=^PR+">]ZB_X:@4S.LN3O$[=*F/)C'JTT4VO"'II4@E%WT
MP:TE%&'U$<]'"5$;6,>T=$H@BHW9D5R9#/RZRQ9U3Z?N"I8*02VKE=?$!&QW
MAP&FGC*QF'O59>T5F3D.%@0+6M"ZTTVV.:9N+,F]2) 5#B_%="5,1'TD10-M
M0H08BV!1AXJ?1LB#+Y21+=)":$H(S:Q25F$#-R^#QJ\A]%/1PXN,;:<D_*F"
M]0;!Q("@BV0A%,X,:M;?F*FMLC 6K4_$XNM<S0_HAX7@&J?;6 GT&N8G9?Z,
M^=5,(>?U@?!6F^HS[W+@* KEM[9/A2HFFF$@EO?$"GAD(*\:"S3-]:D/]GOU
MN)'[ ;2M^4WZPXC)4)EG9X=S6Y'2RYA&)AP!JF,P&G_%)FY1='B Y'N8CY [
M45[%JAVI#CYG/&*](D:AV=@ZS<O6=*5O6G[[B'"I3.SC9,!D#ADPAPR8)S-@
MD$_X():SL52"+?O %!]EBDV0HK31!>>+DL\7FU/=<6BB+1//S.&*&LT2"^/^
M+'1-.6%9S80H"E#NR^4INP'C!*8%KW#!UC7@]\@2 UX>9A+FD*%;MLP?WPJ'
M7@+]$ 52K!)")+@;M)!]M C%5 )(6:!5^QZBH@$:E=#0,:*N82VQXV*?R?H@
M5HAA/E)^H.CH+_5#E4>8FXT?"K0K+(:)@X1SWJ=@=2U\QE5,N"5D M(2@$@,
MS:^[!7#:2V^IVQ86$\\">Y:]T@:!;/LJ:KB!!*(5X+/#,\@5A]8[KBXJZ"^*
MJ0K[9/0\J4'"6>3!8B[.?@HUV#*.:P9#A%: X3$1H)0BJ_E'VF[. 7BCK;5#
M"A:'-@1W"@3+\WVXK$L+[1&*C(3P0)'I8;D!2ZL"0'8Q"NO2U'[8$X8#@<#Z
M ]HW![MR&D:4SMOQ.QSXMJWC.9A4A?VLA<5RL-\1;1Q,+1?$$YL,>/]3[$.
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MA<T< 9N4)"JA0:[SG+FI%5H!@Q C[[6W\[9BE,G&A&6L#C-?9X%A8\N8$W<
M!VW2DE[0QREI BX#M:N+HBS'QVI>YK_.S+!I-UX%CU@D.1G8.!R];:#?P#D
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M6Q<=>:\1KH4M3\<#Y5?U>*WUT@9X\BC1Q[S)))>'-%741R2\D,;OT5FC4_N
MSWS/!<=R1O,[_+GO;'N6YQJ\@P\[0"WJC=''BGM1:#CL13[XD/M_'!SPBH)
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MKRDA_*85'*;5:6MQ'<4>@;B@CV!$B?.#Z PUUAR4NC301TM[4"*UXA 0K,(
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M2T"L"!7+\;7U:@[WX&_)6IVC+9ID09HH0+@^G#EM6&/ #!=VQ#JOG[  4'!
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M%_B7@$4E)>K2=]E<D=$-$>APS)K50,P/> \W%,$<G'WZE!SJ@[);$^4.&[;
M+P(=*8(SNKZ(8[ G&Q:(:OC" C,6 >RSS,/ VC3(O/ /T0S\+_#6( @!L_#O
M'"=,BGF&1^4D0]9MY#,JIPW-&] GX&+&012!^ +-EI.9\7BX^U(Q('HM*7'<
MZ=L#HQRB07>.;@[;0M6+OAI-R"AUS9(UK1_@FZ4/%^,8&.G@0*!ZXA@OJUB1
M.$$&[N8ICI<1*VS=JN]OAZK..4$C2R<HM*4-R24GS$8>2-^?H!(0ROKM9*5
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M@/<8WHC:;4-5D8[9TI)Y3? %GZXG^N*%])GT?[K4N-&E_"1 '-!Z\WDU7A@
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M3'M#6D>.[U&.-T>,>&0?OLL2$]_5_=2IF2%P1'P,GED9KD#S0E5EUEP$TV:
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MV 0W$B6@E- 6*14HO@;)&5 &R7+N4_3C/]SADIWRTU2NE#3HZ#R%"+N^D7D
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M')\;6I-C'1-FX)P"5L<8YXQ#%""YLC$\A9^K*+ L_(\P(XMJF^!U1_!YJ0L
M>_:UD]&-J$:;4F-4C;:?YKY=>71TK,?D/>> "544>0"Y<CAAI<\X"\DXNA8!
MI321NY/=@*3GJ62W/+=B[7CAM0&J6PI7.795*JVOZAG;+<<:%Q0[,/VP8RYP
M-Y*J< O\/6ZEK/>] TTX3JF"E [[2B7&OPDRU%(XI^F!VW#<T"U<O7YJOGX2
M90!+P76N64Y6>;(E(;#Z14P QUGP2+9C=I+D1L]4BJ.;O^,O,GYA-,T%"I!X
MKYSPD\KM$550D^L\/B.+<J77GT/ C'IYIEBYBP'MX^Y%)$^/-Q^FT^9+F5MU
M/O>\U#HQN,_C80TS80)[&"$K:ZH,KX1V8?) 65=%5>DWU5>%Z]J&/ Z<RV(8
M&S1QP.'%W'==+R1A/FRW.L=F<W%A^>[//UQTG-'4[;9:%RUO)"ZZCFA?C(?#
MP45GVA^XHML7PW;_!];8^!MG<.C./[#TUD])$8/SPJ^!_.VUGV")>A;++SUV
MLLN-6(5[54,YQC<]:BI&8+4U234"*\2V+/.H=+?&82U]6B3],3:$>B?B+X W
MG_SDRR.SNCO"0/-!5<Z_W;UA>KSF=7EDFOO\3J(P6H!2X85?_3@*5?8R)ZJ5
MV@WQ6(T0-1RTKA/=RHHOV$6-)K:M=S+JP;Q2!OGQVBB2#KI B/-WU1.%#MPJ
M#%C,!>9D2Y4V)QN*8<44O5"V,A*%'&%N^Z3>D8?_Y\! :&J!3L.&=<I' &EQ
M3GF_%-"A/ZG3@BJDTH(42!O(X+T4H0D8O$BT3T&.%>''4!BQUX  8*S,&;<+
MD':4 9PE.BU6UHSKS'O,76!))*/'14:9QT?#*&R6-E5Z"RPP]Q/,O9\0N,W.
MAGK4"KM!9,NQ=<M0[!2L'3&[<<>&> 2$\B,WQS+XVS6GD5!K>R"=,,?7%)A_
M$K!!@2T1*0M%YF[S9LP9+I0[HBI>BP+ZT3C_24&C['9^RG72I)CKG&=5%) ^
MPO"^9^1PB!*>OS\[QYR\J00#_.4LB847D$I-@I/R8*22,E6:E()W&;UU6+)$
MWGI=>-FT^ILN12XY,PF[W\E>[G)C,J</MDOY,Q0SEQH_D3Z?$)EVGD2#ML4-
M&Z$^[+K-'K:K^DFQ,'@-OT*JDK@(50"-O2DQ&G&%B7"4\DLTY_S$I4(%;#<[
M\A6.:AZ&:T^BL-P"E PR(#Y7M897G2IX^PU*AA.HL6)_P.3%+BD?&SAN^*WH
M))'^/'0,3=BAI'PQY&@361JI/[";C?Y2<,:UC(9;_$SN6!NR7RV-U;[D^QSI
MN]$ND))WA5U#<I'NT.ZW?S(!5'*8&&X'8WV,ST_AEA30U.^DB+Q@Q^4E@.E6
MGZ'AI]*/BC$8D%GJ/;(#L=(=Q ^B2^INB&$X?,N>IYO [MB=?@WU+4)]G2-Q
M8(\Z]47LP$4X]K!77\0.7 101,V:=N$B:AFQ(Q=1RX@=N0B0$35%[,)% $4,
MZHO8@8NHM:9=N0C';M>\Z0%O@G(?BODGW^3'V-ZIAQN<^N$\!CM]ODD4X!]_
M_J'SPYW..K '/96+I)-&EU>86."[EDJ=>T1@X!EOR?B[,8CUF8+:[SB6?8JQ
M;!W >ERC8+MHL'+R1\.+M?  5!GL-:J\QZR'1\&4FU6#_<*41Y+*>P2$6B!^
MEP+Q)L:WWS)R-1_)2'W9%TEY&P!JV;G7*+0-$?IT*/1-0G6/T68EV[$*:VIY
M^XSD[;<X_O<8T3&_=U]XX;>>E6EX]=\'.C^'1?<;%]JU:E5SBVUQB\?%D-WG
M%ONM63\HM_B^)<?^Z\NKR' _Y=AL>#V9>%YQ3.SCZY,G9N8]9E5S<OW]-.&G
M/LQ]TI@?1,!M_]R;: )K*J.LCCWH]A[0"":F]M0XH/C40VFW^WJUW5;[(:^V
M)N\]Q(%^M_.@Y+T#./"0Y#W8XZOM.#7GODV[W-N[[;?V,=3Y"55(D4H-LNF%
M]]0BOPN9LA^8.&QW'YK+["=+N:T"9)<NK?>P4K\FR9VZW8<FR6W?[@,K</MQ
M:0],DOO+1[>4??9 M^:,JO4PU7]N1YC?8W=]^AQ1:Y!\'"(VP?+"F9AQ>XFY
MY\ZH5P2VVN"I1SP#BAN>Z-& V&V";@,;GT9YBXZJ[_,@!W/:BY]09X1\R*AW
MM:2V/3SUI="#2W;RN%NC!D%M05+5K8%Z/,!+98^2I&'-HTL/\)SG\]%P&Q=G
MF%&[CF4<I;(/&6U#M_P2+@YV4ETU]* I?(F_ &23C396>G+89F>GL3L93MU)
M^Z+=&@TONFY'7(PF@\G%H#?MC$=M=S1INX SQ<Y.76S5&4=!(D+W(W:N<_$8
M%\-^KZW[0#UIH[!O;>G4M2U+G9$:H.2GW%IKNIL[Z!4ZCN0-IIY\U[^;_9=H
M6*6YT;P)#(XDDB..J-&0AZV1JJ?UN/GI)N;IEOITLN<:K4[=:LPF/C360O4_
M\1/LS!4#!0%E??*644P]\]Y$L<07I]7\A^S!DN\<>Z3DI\I;0B;9$EOZ)6J8
MAIY22*.&:6*3/ < 57"#.+/;#IX.VTI.K=,KZO<,G.\#M=J):3W^[(WF1_(S
MV[SPM2"YX3.&MIQS TPH"D':7&.SU"R6DW]\;"V]X/V;8W'&GKH/.2V;.F@M
M:8;7U \*X-&]Q$XF<&R>9)7<]1(:V,\*6R?%+@X8I-WCU!Y<: 'X1_V4>)HC
M+B ;O$JVG/H+=?^)A4U _:F?MU]ZA<U$$[PU/78BS@+9Z@B/G=P9PC0][ [@
MI,.;,(7#B<DD6V G>7D0;!":X0R55,X(XTE5%7BCVI%NB#<-!#]U%UW&/LU-
MBW#N:G1)\,*NJP HGK:(4QQI:&Q^^3D9/EJ?JI>JB5%:H+_&?0F%=0FX/YI'
MYM)5-!Z8633NRJ.H-YQF?C03E!N\Y3B#LY9O;7A-K8N>NO%ZMVZ\+F^B;KR^
MMO'Z8^L:Q& %=T'<4&29HDG+KX<7.++G6BYPU# W:C8M]?CBO@.>_:XG#X(F
M'U[+$20\B1 36$A&)-DX\5V?.BAB3T=@)5_ %J8N=P\L.%BA 6&%K'"U4>+E
MW&.X\N_^1,,4A>38HQ$5-.?"<W>@C_!9./=H.N1;?T%-6FG <&B=EE53I4UO
M37W^L%;FWU,$-BPW@KV1/2V;R"/RW5%FR1EN-%22&HKR<Q9*2<-.YLNFT;K8
M[7 9RQ'UV(V1;%><[N[%<<1;Q=^FL<A<;)ZHEDRN$S#:&MA@&6@!37@PBD%H
MTE!#J5_EY@&2Y43H'JEP><&U(4<;;$3+4OR&5>(4<BZR\5ZM"$;C_S *)*HY
M))CI*5L$TDC!%NVEKUN++$$^,@T8PA[-7-0O0T61&H'*GJ](Q6F,/5B3?+KC
M&+!NZJ=RUKB\#UIWS-_ X:$T )8YK+3U_5@-LWV3Q?BN!C:T%%FBW1&^PO;
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MNOW>R!FU!MU^JWV4+IQ1N]]OMUQGNT[QSW,_K@5W[2??C5/LOY^\V)G?&9'
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MC6_%V N26B[6<K&6B[5<W(73[I-<[!7DXL=/I[LO%WO/6"ZN.=M]Y.+'V$L
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M@*C8#/#8-PQ@"XI*OI%2#O4$]SQ'*6, ^8T8P)D5O/!?).CE>;,C*#U/KL^
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MZC*=@T#8TS_^!)=6D_):\ N?93/+#-5FS6_??PG&6">.I*7*YR(A%K&7E<C
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M#-?Q-SB8HDH_YT,P@?[Y4XB$1Q_^/G'!30UVC8AKTB Y@6):"DBY3J#O-+E
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M:M7RO= (-=MHSK>U+W DUQ@\<H/"#,/2I4BB]"[;AD\GJJ2LDJMY1':+'7G
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M# #;"A7]W^&^V>]G8O\_=-Z%_]%B5OX3JO<NGP"EA"ILNQ?[/Z+=<PS@ 0;
M>P)$$8%/>?Y[O'.(9VD2^-^(_HWHWXC^/T?T'DQ:;P8E00HH3XI\$MI.J^WB
M55G"P?I#$2@0P'PG";Y:B-EP.][=FW92B9>>3)A0#UE@P\, \"C (I<!7AB
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MK&]I4W2 Z("^8T@4$G1-$S_<5D;CMR(8&/@GOEP$BAP>R[[_VJR?/\2:A@%
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M4!\;M[WYJ6'R#QDHRX7Y3_,=@ @R/X#Q?:8W/ 7"V'DT"?!:*+WT],*5/.@
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MS!ATF,WK"&4"0H-@E[\-4I,[9@0S]C("*R^^3#BRY"+ZDI86\E_K%H3FKE]
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M?IA#+_CE+G9\P4XJ:HZ"U"T["!C9<T3'ZH/K+-_]HX+Z*2FP55WN"QY.'3T
M,%%Q.92=-%FCA8@G<'N*?<6F4^.8K.;$Q6K^P=<YX(\?M@,YD^FVHF<%QY>1
MG)UHUJ1N ];BWY5E&YR<ONZ1/;MWX@H.!URDQ$1)Y_1W!8O%;)G1NE/)(Z V
M I0(W/CSG9+FY&9]\QLF;XD^68[8R(T/A-AJ^$0&;"<KG@^ 8/07(H\QV ,
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MOW<."U]#DZA\%!_"JIY,_%#\O8=8YIJ;U"^M6ROH+SF3@Q;=W%2M>JW]]7]
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MAS1'0JG(-E3?'D#&/G_2+A95&SH3\G^U""1LP%I22WFIS?:'6<3TX_E2Z -
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M 2T)=\<B6S'%5@G^5Y G(Y7_^!:S!.$C.W<67\TQU%(=A+>*J<=\7C>D \N
M)[ ;- :O!UJY;0PQ?IMRIRF<TOF-NW :-X&);TG"+/K/TP@/C<#,;-? =K8G
MO[^9<$U)*/&4I C<A*DT@L03N[[ID\N^M"[I(@3M5$6(J<#"P&KP"K:/M7%J
MDZ'%&T/)-5"9^ B:2Y%ZC78V3&;W'LG:%5JEF68EAUF/%!\M?X%SE"S6VW(+
M/4% [_E3P V# R[;]ETW(IWIA/,Q.*U1\]OYL,O:G']QI<W(*YQSTB]H[BXR
MO/ (C1U6PV3:,.F/-\#N1H>DR@/BCCPY1]?3V]T>&DV#PE_8O?K" [OASF=4
M8X.TCH.J2A5VR+.NKNQGB.WA6^]QJ*0L"]30$6_5$-J"DO4(:'3E(5R#O\(P
M.L:*_?;QZMP#17HONP<!HKG]PZ;(-#'C"?F.@!_^-PEO=W*0[,<G2"OAQ1ZU
MJYFJEYM(BZJ11\*E'^EUMN<Z8XB MWUH6R]^8WIE:8;M7+Z8]   #YAFF-:\
M.$,S?6JYRMDVL6A;G3R3?&:X/RG&&VZF@-#MIE;O^/4I&*GM1R' W=+\\7UU
MX_X*#GGI9IET'=ADYE6_*3_6TSC'E+\5I(=7&O66+CS\,D<!H/;NGONO)_:0
MBP(?P;: BBT?HH#U%/B5<!H1\J)>4[<8+]#$!?TV;&,L K+!F/)R3JP]2*&#
MS8PWVGDM\IHW% &Q1TH9ZRT]4^C]^7H+_ZF#[JUNF!>L<TZLJH_QF=)]MA6N
M.8AIQ7ZT/9\MI[.UD\S<:] P1^3(.%/=E.#)$+P%E3*Q,E"RZ/UK"1A,S!7,
M?-UQ4=$6S&>"/-;V4U/-%K5?5.,>*8U\ \>RU^Y':]U5A:571:&9]VFROD\8
M=%SE""OO:H)[VY__(FQ_?AO7*::;4"23A&63+..AO4AU]WQA*,-<:#FG(YOQ
M6P)>*0" #9H5!)&$YP=(EF5.' 6\=*M<4OW.968>::.GLARZ3_P.:Z>Z ,K@
MH,;:B/>'7W&9A)/G0P,:JOM"U?U^@0Y?1VOV]VYL,E30E+>M0N>MM5"&G"*G
M'L9>G$\0$*"U]7S5U\Q7VYN[3PK*_734X9$/!&M.L?W]Z<E92GT;>48 6K^8
M19L%:[1X]B\:O/<WN+:I0&X&ZUU[G.$,[*E/?+@A[1:CR-T8H_=R7]=GJ:]M
M) DX"5+=WETK=%N\REHW="0W]4I$WWJ;0Z%?KZ1,>O5T66 ^^+O%A3Y"?9U[
ME1).CZRA=(!??CNOSKU?HX_ZHG\$/(=@^IRABK".N^+/[\OSCJBWH!.EN]-T
M^AS'J<#^KBE_PKIE&JSV>X^F-(:'RZ+U^Q*T#"?R'<XR@%"F5VP*3638[2\(
MULA6Q:/Z8EK:@4[>9'P"5N$."W?S9>+L3X_.DX^!@7.:>W67@@./3&8V)#WL
M,;L91!J5261YPP^Y"8GI<#&?B.Y--NQ-N!4L';L-_DZ'-H=+,<M+;[!\RKFQ
MBLKY6H$6ZN0.-LZ3I:%F3O2:(5=BCF\G&I[+!2M$QY%^MWL /+LGL 6_':\0
MM.>YZS5H? #D[<6APV@OLC=QOC'\LM#M_\HN5E^J5-26>U'+=GB* /DR,<%G
MAG.()+A_H=Z%%R^R<?ZVG62RYJ_N5)0,T+@A,HBZ2FO,GGT =$PN#4Y\2OC8
M_\])MM.%,QCA4.8-5R/O*5V3_NGIMFH7[?>IJOT"DPK%";LOI/6[_JXK$>4=
MAPXVB2S)>MZ<P5SQ[\O D$%BRE'=V*NIG4RY*VCRY,&=POS'<D]LO?%=Z<_&
MBL$B"PZ.V<!0O_? ,F=G=M&[U2]+E^M;=[/8D<%WKW%=@^\+G<<FWTCWYEA8
MA*G-;IGI*+34FJW>63/=Z.;@U@\ ^_=+R5D&=::YDRN%,I_(-K['I=HDT?'_
MG6&?AUF\T/  :"VSUFR@%*%)[E>7/^O>I?_+B%*Q!,GX97F VPT#<Y#$%8XG
M-EOFW!7[TE??:XB1 IW/,6BSSJ2/TA\ ,08-D^@9!&?71,*9[->_,!16HK0Z
M^P. @<1PC!#)+VA\DR(;'8O=7^9SBV&]V720_QTH29 FX"0P4%4"G30)"ZB[
M&Y-LG8X9+2P934RT:#Q_LEDJR7F5<:5HY;@ :V=!7U\YC4+6;%%*<4\ZBO 2
M:?T/[Y[?P^X35"%68X"<V[ 'P.&1$16;SPSU7*3.=S6]I$)S6U/GUM"Z_VG9
M5F5W3J#"A);]XT=T+N12NO<_/Q-__)^[14:[$5*OD+Z=8J-1A;:WB?JF!_QI
M7*^\EF]&Q2V>X*">1>9H(UHC\KSBE,<='2<)3+4)[8X^\MF\QZ_NQ\+W35#<
MJ&[06V4_;8%%U8X=W@T<?ZVQPOY6L?6,S>0?BJ[T&)O3+!-_QD]</4KK;^0^
M^<_7\21Y<)R0OG?;=-CTXH$RI HDLB1*-"'R&-I*,CBR:K]=010ZMX5U&2S3
MRA"7."[A[59/^=X=S'$':BEX^=#+2!$/?&U9<RB0L9U0;5QCA^*?5&30X)GD
M^TG:M!3M6&W\O&_9;(#;_(!!OW#LXO\KA[QW$M!O94"P9L KQ(]NM?N;:L\9
M&-]R\HY&:X=2879@J6-GD6G3QKCTSFD8XO)\/AK!7*[XNUWP;3I@F,Q%\0/C
M9QG*DA*NRLVVVM"=5QQ]'#@:@BJD 9#F6$SVJY<O/H]C*)"I_S>>O(A7^EB8
M]^UJE7'2WNU B-W>(9"8;T"J('LK,]%O__*_S;G/D^Y1W!X]CH)W:2?<^ED4
MWS)<$LNU Z2&"_S),%S^5]KC2.ZM,;<I7=B;,E:@OX?W7UT=KDE$IJW*7-"F
MLBW[C#_EA#S;NVKE;49PX$K7'A^]_AN?>B-1O_#32=)E-WTQ+SX>@WG].69%
M3U[IGD%+2H-%:KK?L&=*I;[.?R\L*.VX>AG76?GXU>19<%[B/33I>-5EEL&6
M_EX*,;1GI$/G"YTM_T@(5B:1K(QCGN"WWZEBA2V5*;?!WG^7N$P\;R6(./]N
M2G.\Y.JC#V!;+,^/>*%G@4U-&XAS)OF&_*1DGU- [='<OVUOLU-!;BQM4Y^^
M'A.7XRO,N;@H$BI)D!JXX?^/XJ.[X30VQWT3CY>D/NE.=734D"H<DC24D)#!
MU##(*P333V^+$%QY?O*IKK61XGQ?E]&R]GTY>,$C9:G]W8;R0#N\]M^>XT';
M/CVD2FW\35$_7-!:])6BZK@R*HRUNC:'VD9LMDHX&>3,=O6#8L($"!)JCN]/
M^*"OD286;9'O/!>K +"?T'N,X^B+'+P.3ZDRB3J/V0BZQ&7)VJ*7]%=O",G*
MZ%>T2!1E7S[AT)?0+NS@XE-SLK?(/CE\6S&MAIMM7UC7UTR XJ2K5,38#9:A
MF=90 )#];QBN!_]+#A/R (A;>  <Y&O(,(I#.I2M@)"%$5:7^CC#6OM*?MH(
MJ<^752,Y@:_?M/+US^YM=S@S9M% W/AWR6^5'@!/.50> #5!/"+6AK6;:$P6
M?QLP:>H0LH_FQ369PD7G7 ;O=4G6!!K3ORUW"?4Q0 $AK0X.,EE17#Z_!F57
M:UYQ4I^X4)Y7YL M\T6Z#X*Q[%FZ4PY"%%@RMH\B'2(V1-#S4&AS8Q!U/VCL
M+]>OP??!TYBH@\%L&G>$L"'H)O\W^:9JR)J%CU(8KX.$T*E81U9SDZ$GKWC)
MLD3N*YSB.:$A\'OVC;*#'/(>OB:;H]=_INP/7=G-NGX22I:U(&U_YQ"Y+>$U
MY#?!FA(VDXV^Z!M58S(F*Y_"*9IGW"6Y]O[*$>:PI=1\R-#XX_0D2)+S8+O@
MLY2O-[]TL(94BPW7Y!Y,)QMXM.(2(A]&K\4P<WA%X_JD&,/OMY^T"@6B!$#T
MQ5 X!?+N7?DD_;'^5#DB>,^8I9JOEV^V1'\QI*,'U/-B88I<ON6YJV4&6X6V
MUX!H!5M4TI'&C2#^KW%LL@G'.(,)BEV&'Q=U8[: 09#Q2MO'"J%LM8]KPKN5
M'+CVKC)TAW5Z8^3)OE]5O2I[@>JZ">FCC36[\1PT[';>.U#\E+IS0>>;<K+X
M@#.U0K IW!A/$R'5 M\KGCQVFYD6G EE/\[GR(VZ'U5BUEUM# D@B&D8 1_<
MR2/5>J680XW%96"!<+XP??HK_OJ79W[O2N>MA_VQIK]"PF_QV0F&'6U\Z5N[
M,;3UA&D]P<Y]LZW!IPHMT42;M#&*,Y9*B)#&;H'@9J:G4DC6YMU.*6($=A3B
M"3U0)W1R$0[J1R$U9#E&0IA]@H/[]](OX\(P56<K46J%2B4*-MXV<,R2Y1X7
M;Z\I)A=?\PJ08,9X6FN!"<LI="R\V9*^]CEF"KZEY LG%S6H%C(9C@<:XB0B
MVJ/[M@@4Q)A#&P[RM<I=,J/=B7H=H\5,@R34I$/LX;[Z/':)WE 9?B27(N "
M0'</(O'C\7(S]*T?-UY0'=WSM//LBWY%6WWM.F9PP]49_:_T7=FYR<F%5-Q3
M32$ZA\O8<+AC!7!_T>:?!'07O31@W'=$A*=6@30FMK:O76E;J=0Y9F(M*X@N
MD_\:T>B:Y"J"U%6^4^JV1HB$JCOY#['3;4J_K31@+^<VE?<8N]_)&=X0]".1
MW:!EQY79U6AF 0*<MPV)$*@> :5)!QXWR8\4%OAS*1MX;W%>6:_?N?9-3Z?P
MI37S%C%M.T/ ([46.8GSD(_^6:RI%%$^K/I9)L>\.>]>?D^Z99QM<%,IGJ =
M$*X]ENYFH$@<%"\D-90O9TH0^8"]#0B.]ASU*E<! D$!D0XZ[[*)R7%W@XB8
MH':VZ1>>!A+<YACL%%\=)>42Y4B;$&-[^HOAE*%*W\;[$UYQ 8S<F'.^&+X_
M3U0WG-],;:(=&NY#GG,EVK013@<4K/:'T2-#&W/H#ZY7&>-ZYIP^_:M>,)2C
M,SNEGW\"865,MD"!_R1^0-,,X9MUP@X3D_=27KQX /SR3RY$&/142;!4IBVD
M #,ROBE.I+#9QO_R9'/\>$>E.&32-RIJ^W.G;>E,"!KYX8_Q@%/@*)*22;1]
M;P#>9B=M0;!V.L)(! LA=!O_H!%XO03UYP5S3+IE>797/P!L5][$]F/1N'>\
M;=[02J*I7A?VI?/1/2H^'"G7 ST ,,#DD,+VJT7P+* +/PJ:(/>V@S'$\F-4
MT?+/@@-?-;<+[_]I36NEFAQ3ZM=[2[,G("3XO\0FQ060?F&B7+15I3I.)EAF
M OUZ#25SZCX7 HWB),);&NXSA-;+6&2)/WTGV?*L8S<[^=^%QOL)/8;*W0#T
MA %!7SC8=4/<EYR@5,X<XFZ9/?>"0YD1+?'+7VAX #[?[+@9AP66T7P F-4W
M9>-QL>I_#9V(+B L^/DIF!Y5;:JB5KA@M&:X.F*-!4O92*$-B_B4@'W7H1<=
M?=UG4$49>A%.,6 ^69YO2&$-Q7,(,*RQ=HZ+^Y&9F1"]-:G[<6VN:N772@:Z
MK>)2RN6T+1Q:ID:&$IBFU<IA8-4WL:B?V6KP[?_$,BN'#2YI"PMO[W@W4.)/
M,52"W-]L]Q"K:ZD8L'?=R#B(Z*;)/*V=Y)[7]G WZPYP(O1K=#9]_^@1*/9\
M8\G1G(TLAMX=Y9BN$?LO9 Z3F=L#VE@PMNSF]*9BI*'"I,G*H5L4G@@LXE=(
MQ5$"OD:-@X41(5GV!SK2D<^PW1LAI+!J6^K.SW/3("A3N2V$H%FCPG3-R-;9
MRUH[X9ABWZ@M@>.I.959Y?S^LYM8@4Q\EK;PRQ$FHU/)\9E*)D?B^=4A05<0
MR?*0.U6=M3(X#US_YWW.2F"0\XC?ZU:"T]N^8D5!24'6S!T@"T4"?";690(?
M_'WKK'[?MC+G=+/3YU.BLOF&'\7(UH_1(\?B+FJ;9QQ&\<W56$$^Z^F:CY6*
M= _L%LWHSEK[:,6VRC8))(,QL-<@JZ*UL.K ZEDKH_X^QLOIG3#W@73G73X=
M+!BFJ,2Z]3ORE?ULCAE>:4OL.:OIW;H91GG]'(T(5,.+/_P;87)K0@?"_A03
M;M=$H (]PW=U%(:Y=?)2,LSA]8Q.)!],,K,Y17I:,?\@1 ).4)S/5#C5&NN$
M!^O^E.CI3JB;F2]FKDP!JVX&T"J\\4K*O6J%;6^J1D3.)71[Q))W0Q1SK3>.
M()_;:IM/[6>+O04;OZ<2.(JE=9/FUY!2)[FM<<07#_5C8M>ZJ0@.P2'82)#&
M[&6:VV.<$ Z4"<:4+3/#8+\ZJ;R7K@/"@3>V[>#NA$"3MEPOG*Y6^HGBR4,W
M2>'%T6UG3S(*Y]Y4)0>\#[^^1-"[ID/+D4KO$12I%#]__VOT*"[JUNJS]@;1
MC>>:-GTWD^ES>%>TV)HSUW-C;(CB=(A/LN$].$1[>%Y"I)^>6K65>$T930CR
M$H-T)[YA3WU.&3S#VZU+TO!R>,'$S66I7R</-*,35A9]\E<*'T2RMYC3N03R
M,]FXB&J*(V9JR P_7M 3M+Q9/ H8%CA6\KF5TST-#:[:<]IK+(HHMC5P8S'@
M%&_ZL!WR_'ZRI#U R8Z0 Z\-@/SZ )!7H=GM2E?IC4_T'BH>,B<U+-L5_V[I
M$9RHZIRNO'2[YN?GCL*>>0!4-,=AG*9&G#1_*4.Z*K7,GBQU+18U53"GZER?
MR9]+L+V58=4A+(LY)'\V.NPV K(58TVR1F@N[JK..5XJ<Z$X2Z@<EG13-.E9
MM!<_MLYR9IH%N6"(FA'XJO0%2@AYYBGGJVT<<?@QZ)Z;JB4.LL(\1SVI!H_8
M)';)F9"\79.LV7&_]F(;7?[J<^KW*OQ.7NR4DI+1BO?8C.6@:51VTT'1M UN
MF^JL^:)%8,.G:J'IW]%"D_"X[M57TX?PJ68^<S][+I_,NN&>/%;#5$LSBRY\
M^KO46"4APP[/]+%N4,: A&S9 <59\7=[QQ1.SIL*0.9-?<:+Y)OPY\[CN_&@
MM1,4YD:,SI(JK.5T)\G;L=A>6,-(KWL/!#N^D:DDI:):BM:)N^+)N6HX;NVR
MORJ%$P.E$YNVHJV?C40G4TLPB II2Z)!-K[H1C3G\<7?L";0C7_.-O(>S0:/
MH]J?:ZN&(V.-=7PEO]IC+^X8?UQ!E;Y8LMK#H"=BGI9Z@\!%NKO"B0ZS(%K-
MDVT;U$D:V=N5,0<=HG9*_-2X>/4DSO&9%H"G/JFQ_G0V:'ZD:XF7,'VZ<(:[
M';>Z?F>NF8PL!K$9@"]:IRAF_0BG:U9$V,<JJMAF%J:0#J<%?H K+X12-99@
M1!RK&91"V3\"*_YKD_7G5X/6Y[T' .8M&GH3W-MX'0ZF98N\F(>",J@+3RUG
M\TZ5*L9\N00JA0?IEZXMMC:M)OYQ-L]<[ ;==:'I:J?=#0-Y?MQ6')B 8!3[
MJL34GSI0HT12!O'!S/ 6D[Z-G."+(;::FM.B,!LK1+.*(W;6<\7^!X#?QY .
M@L"$M1:CV6;JC0< "7?Z_BU%QF_N)!PH99WS\,LOXT7K'@F!_3ULOV&7<V>-
M=XTV7TQO'P PR,#]O0]J\W3,>$:*>1',%:PS!V4_.K&[U'"YHCSKN,K%[WEM
MY6;6]SQ_9U0-;CL7"%4!J4Y*T8!PC![)+_#S=%7M78*W+U.?(-_/66:^7:MU
M)K4<VCA1-J$+E9R0"WLQ/1;H)!=W84#_>+-P?PQU NR#5F#O#G.=6%(2D"A4
MT->K?#-*N3I2G)T&I 5\K/WM4BP X()CNX0@%[]O#G<0@S_5YW$!ER=D((I6
MPMG*2AK.%@?$KVF+5)-T[4QZ^ ?S6NUN;@:^Y$5=1RZ?6=.@UK5BI&=[.N$/
MF*>829E[V9 [Y=7%59S@A)%8'\U(BL6Z /G[!@[E7=%;C[F.Q:>A+:Z5AM]\
M[%NA+L)CI0HV-,N#[S8*,%T)<3XOEBVC)$^AVS&7R7VAM=Z')[MW*BO-*2\$
M/4F=[P;(*NGK&?D&X*&/JSXU557R:$Q3R#\OR9@K&-P3Z5NXWS@S7YMC.EU!
M?]&BZFYSE!>KQB/*9ASZOL">ZQV+:R)H$LUKO+P@'53K=5Q97AL#U %R'J3Q
M&+#+^QLFJPD2#S7,Z+[<S6X06BT.JRT)S2;]5"-;C+"B6,%9:#5N:]K<VHQ+
MI7/6M%V4#&TK'OE2.K]D*RQ \'=QI?MOS\L+2S-91@/:I1GP%>J096X"5?7?
M7>V!6V+=.A/(I@XT,0S!FNN\4?93Z&ECEKNU0$;)K !]OA$G+C9F_Q+045R4
M#;O^7D1K&J6T283S3P#46)[^8LZ]C&H7UIHHT@*-)#8G>DT\!H6]L=O=/DB_
MWFLFV&B*(V(-Y V[*'5C!O"D7&ED:&/^>F&_*,T!HPP33"/,_CIYF"_F9/F7
MW2'XL+URDFESJW_]J(].T\3G 6"(S@[VM;EW1'O>,$KN29\F(%,5:J:.+G=;
MC,4-9K@AU<?N$7;'E\]>VRG5;= .FU/(2KK6.PA17L6F5B W-UJ;)P_>0HL2
MRN,N*MXK_9# 9B#LQ>,A/%Y[A^GAQ'>2GA,@P5=A,VES&Q8F&'6'RRK""W(U
M)TL0+-CJU_X1U'W>1%U&R4 R?IP[E9NC,+43I>*>V"O*;6X)-7M+\U*I7V:=
MO(<&]0!8-WBLA%?#"E%0U(GY+B\1,L-@"NQ]"I?]/<J$D"R\@+U5*P.ZLPR#
M[";[V,-S>.C>FEZ:N3.E0[X?N].JL&U0%"WN5#\BDOA2EO1G2H/H2>;3^_2-
M]F>&SP8GBNAE',32K^_%-^9"!'WCI+JZ:(2BT:Y&-W6+8 U8^J!V0;^Z)[F5
MYHI3MV?9A)>Y8BBWU)N+#*K-J>4AJRB[ $-1+(IH\RUF ?S*=^8'6D?W/BW2
MM*25;;,M8]+WZ6Y#]@(;"D&&$J,,\"U8EBMS]POQ6+SJ/H"35,L!#$$(_6VC
M*=_H'\)368EK%;O!-.\GY0#U!8[7KN ;$8BHUD[U#!=YHX>>].ST^S398[HR
M?AXQ*5A9Z?CF+=W-&Y'-?WH2RMHZU4PN;LI<S?56:-C%+S<J<!O0O%T3?;7O
MA9V#0._#[ZY B):>E7P]8^ O(XFZ\HWA3U]%C;N"XS1,RK2AW,)3^G_JJ]N@
M0;>#&_BNAD:]S+%:$N26+X.(<DMM$<['1J9</YH8^<#*#=.M#'LT]RD)E;9[
M]'V!E4+8WI>XEFX-T8"_O?H1X6=>GP@SM=O"#: SUT'^;+;I<1%"W$0:X[7_
M>M-F&S-3-L@KDE/>1[:+*[^R''KBM8G=&M9V6A?U^^3.(>&+=^M*!>T11?_=
M+\FOHHQ.UR;9,YU>U^OVQ=W<BCK3#D?,4Y91AVCY1BT2(\-N1>J7]2\%9<-,
M<+<VR37!:])=.@\ MJ]?CL]:UV*C4!D2429_LTPW*2->S0B)2W[^.%G.<V0R
M>?5!ZU-=1K!8&08;4_QZM'7DI5K,8EWN ^"Y"6V3X5V6V-6.L:3!SJA.I,(Y
M:[0P%5UTJ- _Z\Y&3EE?/!MA7O(+$,&B9./;!@7C7(O^FW:3MPOP\M5_5S3)
MD0O&\TO&^J6:=>?R550<LD;L5.L!2D5/A:?\=4T?0<K[A0K+ZMB9SAWT;BP'
M99 .C8MU5R,TD+R^DDK*Z_.S9D:S9D\J>-K@)S5'ZQ<]>Q]3^3&P5Y3<5'Z:
M1\(8GMC*CC#>_E[MQ3&D^:WV2!'T 7PTY=B@?8/;2Q;?A</D)*';>K!*/ [6
MLE>%YMDL-D APFM'5PEC6VW724[B:O65GAI(N5\@"#$;0K7"TKKLPZRZ?H^-
MGPW= $:DDGL"'F;H#:+OD];^A3_D1]N(W]+5Y%V;VJCT%OH!T#: DBP%H7D1
MNF%L,XY""LUQ[0>_Z<7P&BHVTP^!(9[RE@,23EZ[6%HI-+.YA4CSC>L(P2RK
M!X N@K6%9VE)^:0@A3-G1319GOE'W-"7N 1=JHX1/VS!LE<E,3+Z2U$(RH6>
MN1^MCJF9ARO11V/O1@6TW!X .-]H5&L\R^;_^=AG5W@^ !A%KJX2"LXA;2]I
M,Q""2ZV+D"X8LBCI@G5M;H"WHVBN]+RQL.)RKL//Q]CCZOHQ-RJF[%"?K&IY
M/VUNM9J/(H\;,H=MX<WAL%;8, A-ZV[ .A\ (H:-]IKG/:RS9M>?++-T]&'R
MJ.T #-G/1R8G1 $2O(X5RN4*&RVON0V4Y4_\4_AP%V6>$5K@U=?A4H]Z"_)V
M/0#PBJIYREMI)RFU4[2S@1M?B+.V3!NWKXZY^)U<$U1O45.H6A1&A90.ZA*E
MQH'TXS* ?9_J26^+$*)5(S$R,EEJJ4TO8^;E^$EF6-%@'U"BKCA#=+:5#=V%
MX!T=@34>@6K%M3L]!HKR?_ZG@42I= #K[PON"0%Q3FR_'%ZLY)L;G,A;;PG2
MC?G+A4OHN"!TUH&X1SB/:Y.2Y!45QZ3]LB)@/;W4_72LD[(3PW5#A61=AND%
MKML_PZ&%)JOE*EK/.KXIY[[/G^]]OLWF^#T RF(.[KV+;PUOJ\_9(B4T*KV"
MNTQ8:%I6AE).1Z.<[+=<:X9!"QCQ;#+#OQM>NO;8[L^NG29[E7TP?L1E]>27
MR"CN G%W:OA9OK!F?!FT5U0CVFT ,_3E/:_OACVE9B(<V/*Z<Q\8/DF=[6OA
MRL'DH/!5Z95>(L8Z:8*&B9= UVU(84_%;%C1\I*1*D]1*.C="G,:L7QT@5G]
M2W!?]E/M.:''3!\A/: G)G0/EFC++DY BAC."C'2[[5BYJ@WVS0+>#I#2I8%
MATUVEK ,..M<.J*;_OC<T,TUS@EMY&!#OARDC]:X>_!>2G[*:^Y\0?SA\^MW
M[5BG_-YLB6H?]VQ,Y1LO+REU[R$&RV_R(N6>O\D+^/]SB%[^KQ^X[Q\ ?8</
M@,N)DE]$SQX 0<$VJ315CP^V#>69DX5 -ORC)25/!LY)/NREHX:0*ALW@CF1
M;XV470EZ;SQVL)<Q^JZ;TN\I_KM1VL@OX\J*(&!A]@A[TDN:*_FFZE1S!Q1'
MMW<FX+]A@?'^?OGZ=7TA&>*YL6HAIX;SL2];SP. =MF+W:'2#?G:]UJ6:HF8
MY:]8$X,,?5D?Q'KH2$D#V6+C7:DB>9SK8>0]Q?>2H 7C9,]8Y(A)JHTQO'^J
M]KIQ2H<,%*;X'.,?OXKK P [OSFL#TTWO?)B4O(.'BO3*Q&+:88PB68:FAH^
MS\PZ]*,^-5<&K3WCIV ZO/TQBGL48= RN*2ZXI7(@2K/C>B#>IUT^.;RQ+D3
M%' [[]CRYW_?'!I*5+XBOV#-^ H.]^HE>UY7WH%%D?6N @A2IW).3U^=HMID
MK;4_.E-\^DR78G6>1%PG'-8YG7)ZA"DQ$QJ=<*3%6FGM37T[Z9>6O99LHO='
ME$VTF,O+X:E*>]X?.I>W.#X)+Y>=9,N".'QZDC+-R0**KXRL)_,2YS"I*M28
M(LU[$B8#^!FFF #:P P2=83A$8'\[*_@=)E8_K/NCP F_)8#3)T)S6V]OP3M
M_LEKJS9W$1QO03SP*1]B1:(6WM<3YZFQ*&($2(>FEBF-SI%@O,@;U3@7[L4Z
M\ M1U=UB[+ P^^Y8R[":5M<U9"6NM[4,V8-=]65CDR?9+#4WDWF9Y%]Q8Z#I
M6Y30:6KD6(S0_7L_&B">8J*\>W/XC6=\PQ9CL<'HB"2@X[Y(< LZ6^M(?!_A
M<"PU;#_TMI_6D/.69K.5%JR:JF@8F%2TV$',UX=G;I[2&;CDH'80><D;E9X:
MAE(N7[3Q25Z[XO+X-;0CF$:2LBP<H&2?4^'-V;>^AOM_L/?607%]S[[H)"0!
M@@5W=W>W$((,!">X!0U,!H([! CN$"!!@T-P'=S=G>#N-H,., R7[^^<<T_5
MO56WZMZZ]>K5>^>/^6/6ZE[=>^WN_G3OVJMWP1_.<M0PS'V%!;=3W")2AC>2
MGM=_7"CU%@U=R(H.AO9/+.#1MILX>'\S=!7JA.GT-HB3S3KIB[\.Z7$/K?'S
M#I+>EK0^9']Q"9=0R1XLLN,NE'!3V<'%^1F=(KH2%#^A&V%KW6T$>Y7HF2</
MLWT$V$$^1FRQJ1,;%4OUQX&F'@&@8,=-:ARTI&WK6JNNJ"TNQ[LH/\%M-1P6
MK6+4XB.M'M:/WY-#>6T="I1M0,_A@:,]#A)!-ZJ-J^I/&%'NJB-)UQFWU%MJ
MJ-IFZUL4Y1S<?S&^8R144^(;@>;B\J:R7KWL:Q#'F)^UZ/4*!'I3]+L]<V%3
MD81Q.$H65\1:9-13D*<,,D@.R=[G4 ***ENTMT_G3-?23*V6Y@W]*4K'OZG,
ME8[V,'U*NH1U;]1M[WQ+%@XVW^,=,QIH8C_S@U,E'452910=9-FDRC>V*N"-
M5.-5$/R\=1)W9895,,TC^%T_E<J?R\^K2_SQF9 T;/76^\#V^T=^XY9NCQAD
MY^^U:4SJIQ1-N-F;A@66^"2_,T0-1>SX15D6GG$O>*/D^@7'VB)/K1/)39+K
M.QF RT'4?>H@?,W3U6*S/;2*/CN\$SNJ<<OIFT)#K^WJ6VZ$J,\](@72IH]R
MMM1P;":=X96V/\95'.<!T9ML8USLN[L.29YOTS,]D>0<<9(2;\(-V9M/?=!_
MB"MKZ[\7])'^)E&-=CD1L'M_C%*/7M%?&ZL5LC[NN)G['#\>4R7NI5^/WZ#6
M0^'U5RA!UF=0Z^+7A_LK_XQ& 6<I.?)H'Y7,DO_I4(OZY__5F1:R1T /)_\F
M:E I@CM;_U"*I.E7BD%K!HRQVHU]X&1<-K&?$C2Y;U 2-/FW3"K?%N3J !:<
MX5E>3J - 3YOR</,^)V>CNU1(KCM3\SD[1 NC5,073](?1U48I%-M!VQW8(.
M0^FMO^/N:G70GM^;QXG@^+GZM[64MZ^4<R0@]V] $!Z/4P\%%%6)J+AM#>H_
M +9+N7JP\WWF6FR@!W2@')T1.C>23GH]3*/%OB6NC3_8(?&ZQI3?]%!LM=T!
M&ME'%M/,N3[KRM JII"(U_OL,X-5#-T?:C81\85JF8.I6A\LF%H?V02TH%G
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M%JZM9LCOTCNR\AD1Z7 WNVT,%7>(;.6+-#]E4*86CX!X_V^I3<IW]Z:[48^
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M4]E/J.,!0=%%&^5-%/UM[2.,8ZUTPO7]<EQ)=^XI4QE&1?3J>7_U[$#\:39
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M%&#LOWZF?R?\+THX\Y\30FX2_M6+)F#R_<S[&1[IE-O>+..;Y.LIEY3@.U&
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M)-NNLG;,/2CKJX7+'C.9\Q 6Z<]J<Q)S4KU'MHY8C;T<!?6Z+"^2^(2./9W
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M5SIS<=W4?![T3:Y@^%?)Z^'2ZU"Y,X*E'\9%<_J@[K_$9#FQ='DE,?E'3Z4
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MHVBEF6G#P1 )Y-+Z*)4&_YT"@@759#*:4<FLB,95T-G\>4)3VUMA+E>/<=Z
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MXIQEO0F-YE#^N1-W8%^0E($/?<9>\.E?\FNZ7:AD_[;F6[DY/!;L/> '^=*
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M7NO@^$R3Y0+7]V%X)']&O>JLHZX0X?W0IR]\NY)>,:M#KT_%#9LF]%R(]AX
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M'/N!W[W]W+[$R0[:#S5..RECQZGU;"FXK>=V$6Y;C/^#Y:CJQ+F^2F?(C80
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M^ZQMY?1O&XD/@-C:Q-!^W^^V\99)MZ1'.46G#JW3XUZN;KI+7"KI+LWW=SQ
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MG[WWX0SU#?J)%5I*L,U?JS^<T?7SHCP?R;=Z9\YK/)4_28;+;;',J39HG:5
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MDG^DEC!%D9Q>Y(JKF%H^L*A,4TI7-MM*DR"$^N<N&Q('=S$A]"3N>:.KH;_
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M#]ZL>G^W;:GXR#=Y9/JS\YS\KL^:MQV8VQMA5M"01:V ]*&;!W/X4U5V"N'
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M32*B5,5!&^IO>Z$:[%Q3PHMQ&J!JKOD$%LB$,_F;!EN&VJ,K@@2Y[[18-97
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M?N&&AO7VS(ER9KV_7H3KB82"E@>X#CI&BQNC)5?V)+'--6D[(X1.FX7 U(X
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M,ZOD&3E8^JG%:N.<9C*M9M\>B<6+LPLQ+K[2?0+X\$*#\\00=$9%3HW0ZF#
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M%42 2S2QDAZ*63X[ZMR,OOO,P3<R=B0-9A*Z6-_'%$_/H'M)STLK*8#K[K9
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M3>J_<;Q;!YRV>[H^+NJ++5?I<SUY$NS3+L]N/S/]J$:KLI;M?NROZ 67'*<
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M(H.5;(BEA@37\M<EUD0Y*0F[M4^:/M;^]V#U#'\ NZ;-<E@5'NBS-(QK'(1
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MQO1W*]<Q;BR5^@0SF^F]XPZQZ=!N&+,ML.C3^NE#Q86YDBL19_03J%G>:V0
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M*!.5G>B$B4^_3U8K['-*B)+D=$D''>>4D#R/*LN_*A+T;J2]+&K1TR0FAP^
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MA7O%2;\F,&9U&ZKD;VXWVE^;[K#NONC/8L+-)B*KKSD_2Z!<S;[]3:PY7G>
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MUTB< I<J2$V53MGN*[>,J6D=MHVER_GB)JDG(F4\\YF42R++K0/K;GM\I;M
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MY53V+FAE=G<S5B2L]6-V0ZH>&;BQ,IHCOC _0Q8GEI6AB5LZ31/;=7R2/ '
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MV;*$UL2%^6OW'"&F/+<&]84L(E;(-QO>5P/55UVR %3:8#YU*K/3]C7QE]"
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MP4*5E6SSP .=8V,/N;FN2"Z4=U](]$^R/"P#J_DXH??. .*DEK2"PK;TTS.
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MYJ"G9P##R7<-WO0L+P'/L7]./L=?51B6COZ(N*SLFGVSG>C#D/X<'[=:"LD
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M*O^+NO^*:NH+WT;1*"HJO7>"%%%IBA2EBDJ-B""]147%$"&BE "!(%VJH("
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M?['].-DLED=9EY=QHUL)^"QK*1\!HER1C*')PBW:0'G:L&S+%FF5XK1N_48
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M28:CF>:<\+G*>M3BUIM'QV$#QS-M%(N>QMN4"#1EV5C9NSA#NHC91$'"1/-
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MG<G$+E'93@C<PZ)QD7C:8L(-[,E(G!MGH*BNS23:Q(4O2L&N#C46"3@<^$]
MD:>N(6W$(W/)Z(N-?,*KN5*!$W(/:"4)8#NZ .Z1\XZHM;J%3R0*BLCA/&"1
MFX;=72S/V*]$'TX*V^UM=9T$6*_R 1([WI( V_K7+JPM_;&EJQY9E %B' 3&
M+P>;O@H_.Z49M.72C@4Q.@L4Q)=.3XD((,X4<);>DW7O!,UE!9NI"C@Z.GQ1
M1%M4:;JY_9\3+0-'GDM?MS%[J-X7H?VL^4(@7?_*>V_HDJ;"_4KI=R,2>\SH
M+!5DJQ>>"A-K%:'$;7*0)Y0S_P04QAU!8]][@CN?_6,X@T6:]9(_YHZ4NA6>
M![@V]I:\]G\#!_C_RA@V$9RMM^Q) (X *O=<Q\=52P_$;'WCTFZ[MI]SKK8(
M1@((LO@8S*DIWFSU@@2@!LU 01!'_%DPY2,(9?%!456%(^(?H -B/DO],KM9
M#%9GC$\>9IYS?.!&0SB"Z .+3 F9V-%@&#1,B;=YS'./OVK*R3PO+Y9M_,<I
MQ<SG)_]151FA1CP3"< ;U4X"X.C"2( 7%8Q-T&#(H7$S%PGP_C'D6!!P604E
MOZR$K*M- O>NU+,MU/_?WF?3?/_]'SSYOSV]% _&H'7QB:O// ;)'RD<9*[$
M)= ?:)00R3"<Q5A*R[ WDX^$A]R%NP+BQ;SX6K?Q(,RR)MX!=3QY?$PE]+Y"
MU#C@"%B,.[ZBSQ7T+8<EBC$1CQA16H9:RB^]:'GOCXK]4O#_=<1PC6IQG36P
M#"ZCIPX&TZ4D7*F4; X-_L\":5YY#J7S*K[6[E0;^8.-LBLNVVM33U8BMX*$
M(/W26/Y+GT$2('OVJX]_CY)XY40K+=ZN QE2'CY]O$/8;(*;&'A]43G']K<I
MG%:DZ5L8-RF"SS6(8;R.Q!X'J8+TBU]&Q#^!*I+C"UV' WOL]A(C6P :7?M0
M^X-'&A\\$V38DL;6:7>I @K6:!A])KNR;BGQV#<NE8.D\U 7RS7#_E0EV8UA
ML=*Q](>RG#^NA [!% OIU*' \W<6E]WV5'P]NT^A5S?Q#7WW3E05(VTGIXM&
MN2&=KJF&18NBB/]ECT1/C^AAU.N1"_M)&/P@4+D4)!?TU0%7_AJWK%/WY_Y(
M8Y*U5F]V_P.;29%FY4)+1[>=F?.8LO-O[R+R8;&V#N]HU 2IGRO!#F=:L&*F
M^##,TW>L^\VE_M:E"QUP-U,V<&WABLI?H,?%G>UL['.,43>":Z]03/X"V%'Y
MY]:5-M7_0K&E/FVNWY!90@)\T3EAFJ7_9<X8NW!6E[4>R*\:D()9QGW'QA:L
M9O#"GKJ6[/C%*SDU;O<L"K>SW.#C"O#JKT!T*#W!EV-9*@*TLI<=Q+<K'47L
MTQBZKKVIRGO_<_C+@(M[)._78@H'240IQ$*A]VZ@8"1&Z\P3>4J$'2H2+)\[
MQU2F/74I8>^N!U/NQ=87EVY:4<WC2Y9Q\=C%B;U*'B]<_*@KS;S^63P]W[/V
MOT:Q_M-[Z&A+P:\XOSKLZ^4>*?C4Q-PHS@?S=N1>3'WO(CHRJU2F+Y<H:D5(
M_Y IHJHU(/+X*&#*8/[8]FWCK,<"Q^M1[88ID7(T6B8P;<8DR3;=?O"3KML<
M^R\/: 91)N CUBA40=GW9MRJ/)4T&YO-#Q,56US_ ?/G5XG<M'%^WWT*(6P!
M;_ L%>8]5>:6R&6-1]EM5.O?7<\,5"@%>*6/O4F "3.K[T71WVP?JSHBAOG/
MLIZ#EO@F%(0^BIYDZ(YJP$0JM?SE.KZ=VX:SE+1R8I=#"6:25?9^Q-0R3;J#
M>&'1M9_9)P\UNGW%]GWC\"\\WLQ#'&CVC2%C^,M3H'NF;(5W>]#-::FLJ"#.
MV6-TF !FX<V$]<_%E9Y"M!^#P0(S8.5\HN@%7?ZNQD+0(ATD9C^[] /_G:41
MP7/^V5)08>3,;N!3U0 49GG5+LY3C H4]'3F),HLANRUC,!E%D>:<$T2CX H
MH(TBFKJV+XB'\!K3FH1:9@,U)J?_]@&;-(:R2(8[&7!.\SXS-*$05L\YR=NM
MWMQHW#EM22D&,]$W-%A9-3B?S@<2U2?TC49.,\7PJ:NCX4&2$P&RT#F'M*#O
MQ<)JF_V\0:ESS]"[[N:S$4!'&EJ9K\W\5-FL7@W%+5W>*<DX*Y#XSU?DO4QJ
MB_''FS]<:C(:3)O@J]!S\JH?J.&AM->[EZ(9<:6.;.E]PDFLJ_8K1JZLJ<R/
MA?VN96Y-M%KIQ!&?9JT0:WX'X,XWLP*IFF5.62$)HM9>%SU\Y&3')1!F27!X
M-:2C.<40:_$C!>XW(05/+"HIKXW^G,.-_T)8RVS@3')M'\Q0<],T"[I-+'3K
M5=5S_V8VCIBTPC,I5><V\Q,9>^!74K)+27Q"P:18/>A3F>&%]J_G\;Z?H^FO
M/1]5:H"^QEOYEB_YD+UJQ8ITC)::=^(B4JV-.T+/DEP [ +7&S8T.A1.)W5Z
M2( DF%R.Y=,47MCL!BC(>VRZ"1L4\KY<.>_/GC3C>2W^L,RV037SS3'RVSKQ
M.FQOA01@]]EZ/MNLL0IAJ:LAY^29A-DCJLOG8W'PZ)6U:/?(4R@#00\K%AU@
M@ )2^S 29S6<S-X09]+?-7S6IE-8>:#7+MNGN%=HK/&XO7SI=-YA^"SH\7JL
MM*B[CBT,[G=(]#I[.G]\"7DS?5"Q7^;)9C88)7-X\.&+K7<(HG&%O1@G%=2J
MA&FM61.CZ,2J&\.;X!9V.M-Y:21 ?["I;!X7Y%H-/#I3:,8#&L6:%:W$O5P1
MX7L=;Z4QMM;28,+@U>\JF!)C^N+V6WKWR C4+\^H1MCRGZPU?V[C#XD!U5KR
M\Y 50X),D'KM.RM^O!4N& LA"$.HYRU!,Z9+&646EYF:9EI &^FV7U2)*TR/
M:D]HPA'T4CIXXQ2D85/1_$XK,\*5W=TXKU_B,7GWKW\ LOWD1S-AWWX%\27
M2 #Z)M]$=B?9  &XO\??Y:#^+,U!7_*GW7<3U1(ULT2E_V'!SI*U:%D).#*U
M"F'A/> PUI9,&+A0Z[>#B"MKND'\>PM$BZ7?P5]_/25!XABG& 8>X>D? ^R2
M\YX[WNN&6[!.].X_G&Q(=E-24_I:Q "BX'_<+N4-2<I  &>G4F*_1)<\:S4
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MF<QKTZ!JD2>JK<XYW;E([-_<>I.NP2DSE:C*E(N;U9;>M@X^=98]JY[?6>
M;=\14*$U9'3U]_.8IO8QE;JO:W;6.D.(8\3R_YUEA*\&6NO#L-HY!:9[M+[>
M,RXO8C9_63\<?>!/,P+ST EVW3X/^URQ8)K@A<DWNI>;[H)PH"NV# *GL)P.
M^Q70"ZN^_*&W0$@CI"N?.&IK&TZ?G^H<O5H+X@N0C5M5C$UUXCTRIA2:0Y,)
MFYTFR2Y,62O!YN*3N*<^)$=V]]<?*B)&B<R++P2U RU2%B%'=C=6(-^\+.]A
M5$F 4&?1=/V:EF0'7KMH-5=N.C4)/[MR-U;@W[$ZO]!4SH+5?4UCS%+*LX:J
ML:T8PV<9VD:BU,;4/H]:JB.GC7[GKV="SXFI/RJ/"Q,2D"3 U8?B7[#>#"?2
MXJ.ZN9@# EV=2AV)M'7UAQ/R<T[N#!,0NI@YBET:AC^.5C5!/P)D40LB3(;-
M8S"G6TVFCIC?OC+ \XX!;>K=DW/!I4<%N8FP<KP01--:*J3(5U;H2 ;?1 +H
MN/>+*@$HE\-..3F:L5*7)XO3?[Q36#,FSJ(/RG\).G?$_0/R7XWK*,#'YS@8
MNNX>;<\B+::\O>!C+SD27I*3U<9GML*6QDTN'%.T+^0)QR0 #^BOP&']@EKY
MH9(3/FM%'AT!H6\6RK^**)OQ 1+ 'O]EE484N<M98!#<R8Z#9GL."YQ8W+S0
MKJN_(/MCUGQ;KA M)!0='/\K$*06R6\P0OMUW@K[1W^[Q#U)M0G^IT[AJ).+
MC""#(@'(55$[94Y23/=JW:R&[3,_1?NU^CX@2O4I7XAS -4P!%/O*+3'OMU+
MB5Y0J8IS$R',J8?OQ=PSGI4MQ.M30<'6*@,9(31TB_@I)31W-6\P=_+P:L@\
MFKJZAD'(1)JIP*L^SIX1)].SOYKWO>_=E:B7?4!8+I!!;;5Q<+<IW9Q5D!3C
M0\09.2A<%%J)/@]Y44*ML\BA!-O5UQ^ :5C(M"2>?=*WUXN*T@3!CI;1"MPO
M+E/,U!LQ?R=\!LY/)(5@]=7PA&E&R>=!F]?Z@?OW\48FMAA3-D7N7D-N R].
M@?H$;\@#FIJ#M_5DWL/1_D8%XP8*JAJ+&B2 D<[1BU#6)'FW\A9_J3-I7[X<
MS*V!5IH4':S(2,IO'R^:&MXIP]VE #OT]7Q" P&4.0VQO>5Y;97-6,'JM\GV
M>4M_BYS?\Q!=-V7AX5_U:P=89,MA9$%$2<8DH;&)Z'?FP8MZ#'.V7#P7"C+U
M/5$RP[>C(+0^>JO4<<7;YU;AZW5FY#6-4P0I0'WR^N.>GG!,%MIF!M$Q^MD=
M9'4++#E*J^J=:VFQ1^>(>]/%EO["A?LC"0 B^QX(VD8*$F%2.O'@Y2W(T."N
M"^[7_LY"X55<"XP1R?N="D!/0$%B,U(+EZ\?WFZ18+XKJ'30K?=9'>I7OK(\
M?ZY%V6-HR3VK8.2_ZM^B])0A8=3Y^]D#C)M^PA;'L-\E0\J,H$43>F?G\(PM
MT# I 026V8-"?KY391CQ_,_*M?\;,YJ2W+,P'0!I+O@<E'_4K5:1"#7D_,9:
MI0H(T+Q0AK0K?/+$-<P0V8?2/"\^JH]7L-T;\"/NDP"?+SAE=X56H,QX+DL\
MI'PXWR?J=>.$U*V(FVR_!QA9>C8460)O]4E=9)D7=7&%M#+A"_*E,U:=6!?T
MX0_V';XS19^7>NH=/";#$",OHM9H"/?!;R<)>U=>B"Q:0/6#_PXKU_51Y-;O
M'2M<S/8N/<'[K^H K&!9X1YFPWR>S[J[;,B.%:D [E/_?>YH,8"2!$CHOF+K
MB]LJ)$".$:7%;!OB3-B2A@2H_ $\9P $S<U^"9H#'G([9)V<D0#5LRW_]GZ,
MHD__?TR7AJ<AA-M0GX&=?R8DYP_Z%1J+;RD.>D"S"607CU2YDCQ72SL%=C\Y
M:3-M#T\1F;-I,INY5S) O7+?J\<_\;:DQ/S]NA[M5^-!MF>E3Q"Z_.F!N,/L
M27-/PA&9AOKV(&B3FP2H8<6)4'8BP:&?Z 8UJT-[IN74K]_@LI2?B0%(T5JK
MZK\MR;OVO.UZQG\PVV)@87B\@[1=G--YTGY?H_:7'=FS4H/45<@9DY3..2Z1
M!%"6DO"*LJ\7ZN?SD4Z]T, O[76\Q;>NH;I *)4CC4!P*4^"H#/26/WSOW:Q
MP!&QDO(Z-"9[1N<%A4E%%FH)ZE*$O3N$S@=7"G>S%8QGP; ".0G\8Q4G0":?
MD-KTF&&^$(X9X3[J((OZ;=<T)+[  =5"L<8?=K]G9CR+;,'!B>IG4W0_B+V3
M;(N9.YMYU \'FLC=;7PR7HAK[7<JG3[GO,D*\U0V^GV09K;@-=,HP@CW5DSO
MX91CE?F&FCFV+G(<UQ(&L2?LBBN3E;([TU4A T-]2\^S8@. 5X-@M7K97MK'
M1%>WG+S(@\-G@UL73>&+L[" 5(5W-*%!XNEJD:\4N,3"5YP$6%X7#G?R7MMN
MV#$,DIJS?^*S>XX[>E<9NZLE^@S9VV4:A"]@\Y&>B#5H/&XOFV&5>0=)1MSQ
M(FAEBCK(\K1>*O%5M!YLS<I5( KM37U;IV!L%DI]_Z2G%R<_Z_$+&'J>.VLY
M"?9 [,L'OI@)E'> P'HE:LW4]9K9K;'0& 5_D:6&%41("A.M.@I"4T;#1@(X
MF,'V:^]27_-(Y"D&6'LYE*(NZI7(\(U:,H:)YN.\TT[YOXP=-B?$!,Q]"WDI
MV%XMC%'_(.:7EY6AP83T%,M,_\03W'HY9879&4$!:64E E?ZWH2?+QK&4G1F
M<HUG]II53>?%I[^M;39A?)0?D^>LO+,KJ!.SS.*D1+,M/<OW6 RFV3_#!F)Q
M3J8Z4V@2W\YK\F!A@=*-'01<\\22 &W5/G1+2"%(];-ZT+/F^D%_C,1281,$
MN?9R\H2*JWW2?%[957RVO/RTG]EZHT$^D1^O?5,]0!=WST! N>CC2>M%K;XK
M ^_KVDFCR,:Z4I3.^9$B4 ,?5=2-TN(VQ$KADE#ST%43<MW==Y(FW,\TW&&]
M]>57"9G!OM&@I:#[ &KM<&.!')[L_T,U-;SOEL99!&?2D7>D2  ;"AW#VFQU
M3]@I#W/HX**:J^Y^<\]^2I3EG>OG^1USS6UP"9ZF+2WPF(X$^&?)9TXDIJ5/
M5MKIER@-)M.AE_).N>3?C!8I?[^*_$$F.8'N^?JBO=P6W/RQTO"D9Q,56(OI
MW':_->]CV]_,&8,$Z5YSB02AKEJQ6"Y:@O5E#C LB!6YZ^=9OEX'<7!R?J8I
M(4TSL,*E,]*2I3GF@::R1\R?&_Q@#8Q^O2"R/_9(U/<96;"5%($*;Q"XNBAC
M-OT VQLAR9QHT:CWOM#"UT6:G3VI5^\7:\\W!QD9D:1R_]-#Z2[M:OTUCD4T
MR.M(L505G^0-P0IN=1CYF9IJ@(MZ?7DZ M>?4NLQ]W(V5&3I8$._ECHF[M3)
MS63Y_FXGUDU0YOM:DP"^U_H(H(YF$P8L?GPM_'AB'T("W)JX%7FYN@#)\.GM
M4+PNE,6 9U_ IXTHNK&-2IA1BMSE_>/#/V06$4S^I2G43!'DZ&-O&)FTG_NO
M(N6AH0:N[MEG3L/0A'GU22/W_1 L/,QRX!#KN2A5+IPUV/#+HK?Z)G&OSJ5H
M;O9I.4$[Z\TL3!/D;Z%TI T;6Y]>K==Z_52RP$\L0>+B%@F0_+/7\6QRE8.8
M20(PH6%F9O+%!$#:-Z$*!?Y+3K,"H#]'FR*H'OL#8TYPQ+Z9&8*"^3_SV\\K
M[>C^L5Y@R)J>B$SQ6"[(@^"%!GH&Z39DJ(?%S :6,5P9HV9X;ZSU*VQK6)Z.
MU'Y(:,WOA?*VB:"9\B?D7GJAW,OT]EQT;";XI%4P9;]-,F9[3.59TY&;S?*O
M#=<>\3TK7H?>=CCD;@"+ VI0/V[U84M(5.=ML\2C@+]6+ *QOU:;EL/O[4[Z
MI*SI^QG'P\CR3:X_'%EMN-P$KLB7^M7;J[G512TM]Y<'2A&H'8T;1FA;H8L+
M(Z<ZHRH[+6S=C5SAFYD<0B:54QN?]Y.$#W0-H\^?Z+KB9V6P_JO1P#L$12>_
M3_E3:+1SPL#(B#3EYL!\F[ ?M=SL, 10*V^'3T<UQ3SMPLFDW%M@K(=-'"L[
MP<2/> Y%)9;-9V'$26\Y5A]U[3HL7X1WL?TI4TFUE4D_[!C7WK5XNX?2D.$)
MML#T7LODF>>1=$%DAN/]C+*)2:CF\?[E(W3G:/1Y7+B"-? ;00]5A^D-9Z2I
M[;[SI[S+K3=Z7>ZTUQ'] 9L9+%V'E/3;_'7>>#A#Z<GR*U!/'O'Z+ 6U'"DE
M)!9.A4+?\NFXZ%7B2-=)RO1OLY&.I?_[=OUNX T[@D 6*@8:6JL)OF^L*=;%
M?*([*5*K+48@ 9[L?WS_Q7KGUR]_P\E.-=U&PW%[:*"94<VTT_*FM0[3XY[A
MHM)IF!.=5^/XTF5*SHEVZ1J8QE[NFZ%<<E/ASFF-]6!=8U.L+)?BDS)EJ>#?
M :_\Q:),K;X:=O-$GFHG7.QG@H5@=?L+L>Y[:6?\:VK%17OGI[%]M9.UY6I+
MGQZWUB5L$M? 6+6A5Q&0Q3;HNXGUAGI\T@HC['N_S])-B$#[>NMT[][;RH$G
M,>K3BL#]F?&\[@$#7FU%UEGB<K35UJ5S(!53M"3+2?($]TSMF93-Q8R01ZCK
MR9N#2\$EV&\.?O76UEL\TF,*[;=[]DNTG^*-VHCW,&?-4Y*_"[ BY7$1:L59
ME=VYX"G:SBVQ)YT,I_P,)ZTPF:[T2SO#R2R-<9J0 GC:XX,)[PNSCX^8-D8D
MS.(*[,([2C3<!O,.D0O>+<-/YGI-==)8+7S1@1>?= H"3%)T\3+ 6.JT^$&.
MLA3@A_MT1<X^RW'@UU.8WFXJ;@-,5MB)D^EYY\N&Z?V@28:"8:3 @[MUBW/"
M@%U7*Z5M!$, ,)\XRIKR%>T<@XBD6P+Q3B"ECS+Z'[J(CTU;A;-ZQ>68!]RI
MQ7K^EC-GE*#LX]4=*!J,)G364[ P-'6J#O?,:)OZN?7O+-O\4^46(R6_^'NW
M^2P7MM^D5#GN>?FTRRL+-.')IJ4]RQNP)YNL/UJH'V^TMP6=W_ H;N7#K^YU
M/ D/8'O4\^#P7C[5DXMNBC?6$ZTA%7>FIF5YFO@KSD\5[S!8V->=2]?.+Y3<
M>9Q;*??BO]C;>Q=-Z_.ELR.-XP!:/.1T?/%LJ.;U[Q$#=3V8,O_V#5=3IEX2
M@&+O/#3#CCVM^^NN<-7\<*F]S,P]\Z=W2_)K.L*'%C_+*I9 XE))@!"9U<7Z
M11Q3CY]=Y$HM-+15'!^&TB'O70TT>QGW?%(KN?"[@W1"_F'S0TLI[_BY:]^?
MUEYWU<VH6!I8=F\A 1YJOBQO0J! 07:M[ZQN^Y"UGTNG8XQ0K<6N3NLFH+1.
MY56.YW8>&(I$&W>@E=@S9@67&V)=?0J*[RL<Y413/6805-98QM [\Z]4R^B:
MA_B,(S'9%7_VRV4#-[@D$0Q$ZY3&_ L^$@#8JU-_45VL4MJN5.I:5.;]R(?;
MA&4)J1H>.G*]S\B:4_:.!KO-W4A\V&IL5+YJ&<B2$].@BJ%T/']^(15% N3R
M#B8?&2JX2#1I7NO1*!>+]M-?NH[EBI&,N]5.'94G4A=&A7Q94=EI?^K,)USU
M?>$6O]<$]<140DOS(N(&(AGAE5='U "V+* O/93:L-Y1'J-DVS*L/5!YL[GG
M^@J1T>N,_^2%D)\\@N5^UZ)[A?#\_/Y8"DL12^3<P;528+_9Z6$RB-^_FPQ?
M!J,6-&Z4UV:Z#/>.')0,%5$P[PQ;X*?=41P@=>P0(RMG=(K<S0A6I"-KQJ#\
MRR4]"3;FX#/QX"-^PQX__?[?[?TDP.O.R,V$R"L!0488A=E#HY18"9+C1"E\
M3;==UQ/1TL"K7+CT8P;^-&.3)6V:YF=1C1W[2<4%SA_+6( 5ZYZQ-M1( %\S
MUB@P/RL-YMVK:UN;O=?C2P(4PDI#\E=.K9(1)9J;T?KH&U(U\*4)+X+5G]$"
M>VA<JY"/_&LLL L2<^J74=F8KCU>MEDCVGO)J7SOT4OBGG\L2-QV@LCHJ,0Y
M_;ZV"11HAMK?P-5P?!OFZ,D1C'+CR.>22;WHN7;^&?2XJ;1UEL!# N!F\6Q2
M'Q.(K0PD #R( OG#J$V)QY^*J7N/,P24N^WBJ$3?G+ [^^)7G^T_V:5O5O:]
M6?:B9Y5+\+H+[8W@SRC,=$YM$U8L6.K][\LL>?0ZXRMLJGS-387[?2,"@XM1
M*38D #6$J(ZE-Y+,XR0!4J[PJS^(8D%&AA9I-J@PPAW)*WK@]YB,9X8B..BA
M/8).LEA*Y*9F:=2-[SUP)L:G"SSY[(S1 U&;8A2;YG%^9SJ&T\=6C',$C@FE
M<:>2&V-BC =3\0^8Z\BH%=WD6 M6A,0HVC&GJ*S0(DQ=HMMIFL%F$??ND:^<
M%^I1SL>H@T'Q,Y<@C,$G@P&%"DU_>;$4F1TZ;E%;)MCT\LARJ=)BF3HV-CE3
M/*IC\R-Q+J'_Y!I-\MRAP?3MQ>C +78[*:QZ1U.I%>TV@D82PFC>[;X"WN<P
M9+%._6F2HO[^KE/SY9C2MK4%9\N5++S.'X=>Z*@T6WZ(X2QG3/7DEJQNWD5)
M=Z&/Z$I&LLDZ$B@8Z$X]=]# 1A$"S,K5P6IQSZ/UC)=H-W^BAC;Z,OJNNCI!
M/CD-#4G&FFGP@&IMT/'Z)?[.W(HU5FQ[K0*5TY(Z7W%>?M^\F=[:>V?9QPI(
MC,<[10-S1JV'/\3=M"?>QX,Q R2 9G7LQ(4^IA J=3) LV1>7\6K"3?D=B53
MO,$ ]"H\W2 $B1%?_K1TICQ#4"&&+CHB\<D+S[FNFA?BE_5-!#EI.2-IEN/K
M2OT&7B9R*O83$OVU;_1U5@?2[LM?@L,%<-G>^\X2WQ1OII9Y[T.)/YHXV;LQ
M+G*IY-^"F^*O6@CE;UX+S$  .U_H0SEMD5?C'/%H7TYH$Q'C9_<-!D6JM^,L
M)7S87@?2;20O8;%@H;!G2S04'#5+S37MF<QP['(7\/J.Z11-V38C%A]U\8CR
M;Z.&$SMN[Z9*X(:NF;/_C5YEX^XCLTWB'E'.'M$W 4JRFL1>*HPV;$,C)*,"
M^091O6&>"[=-E$2D8>P2?=%!?WJ'.U^L07\P17.E,,P$R, PY?,SS<JKH"J:
M+GRS.N1&68*Y@K?-EXZENP)_WHOOR^OTC_A-*XIMD #(_>55IA,2H "\@%*"
MYK8^PK_/L7*L([+/'B@8H3(HN@YW@3NS0F 7SZC0)>]V@:-;#V)E+?)@%IB,
MNJ25+/H=Y\D=O^-S6/=E<Y#(6$5^U#NM0>Z4EBB>OOLWU)X#2E;>3G^=/%\F
MQ-4^AH9[\">B=I[@_29?SUZ]5<'29527)4=C/$_&-,O7I<[Z ^OY])P=PU8.
MO#'DHX^[80T6'JH@ZQJ8/^+)(NGO'_Q[Z> SVC_7YE,_VP;\R8B*=3F5_3(8
M#USG2/QO0]:QTE1NJP'^&F/ZE:>&(]42J6+C?R\Z,DK$0_'..UW>=YK13=^J
M+E'$(_<TZ(7J,MZ_*X@;.YTT$E6H56*?IO I+;3%;7^CB5LN_9E[)[7$SM2:
MHJ"CTLO,"R(3"2!:Q\XD#YK$PL^R3/1E4ER-3;7<Y3^%TCMP5&K3WTT,WK>B
M)4AA"I.P,J;3%<V:U_? X)52C=4+/2:#% HZ "3<RSDWI=U]1TEQ0L06G^.-
M*S4.N&WKFJ_Q^Y57ZIT!OC0)O^$DY:R6SX(E_#=$KQI41P*L>]&S9HG9_=]'
M/Q-HJ@E"J^5/>Y W,F%YYFPMTON:G>(QB2[]7)Z?N;_[1<Y ^2Y_=($N@#Z2
M+[IS&,.L972;%LB)#'M2!<:_M=]9L-P+&/C[.#>RK_+_;:7JOUM9'!U>Y24V
M)LIDS\^@L/A3)Z?%E#+VF#\>;]A"?^TPJPN"Y[?K7&9DJ5  NGJC0#W]E$SH
M;(K+#F6NT^F WK5E/#^DBP2@E$S8[K=>C3+@B:L:X?XAUJ@!S[+E0^@^SJ;I
M1# 0GF"]@].45VGN[C:^R$':--<D/!L=#V\G4+DS7(PJUAH][A?6$'S2;O16
MF:'=)P47A'==W7*0LKJQ/>M.&R=;-J9! @1>2P,0#"KV5JP(R6(4),#<:Z[+
M.P@-6-8<TPJN7&B0,\3U/3=D%/:W)&^[J1(H6) =U :A#A!?=7IJ-EDX_:"A
M,M4NAJIGXZ->_*\QBDF&E:PZ&D(XTNXR"/(7AO;L)6CB;8L(;R?VRZ38(O91
M7ZPD?<FO]S*W]V73C/H)_?T)M(FC4+OE"RW@SY%8XTIRVD'4R'SVV+SKD=(
M/@?+UQ,BN@$!,F;G3)TD )U/ZIA#&L<E$JY!=W,>7_<$*'<QJXYW104"2AW.
MJ;,<U_!K\+?+F4*Y^OK,!G<40P !WBC(/'>W7['Z=!%L/ ?H:T*8=_W+Q'WT
MJ"6E@ZL:_4U!VCKYA'>F(B5CEN*3+^X=D:\E-!)07K13EV90O3!OI@JZ?AQ+
M?P?XT-#^O_AC!)3;%QV;DQ1ZI[+O488J0-G6VJEP@;>EH-FP;N?T0\CU1Y>
M%3TI#L%!HZ_]B!IX2YCLX<$C$R;@"RK3W(S% R$AX\)SZ4R<@,V,]/#'G_/.
M[_58UPJ9F)E_G]#0[/@A4G#[TB.G@RBE\>L:\)WOKJ;T[[SKW4I-N\W*10?.
M)__"I;^;FZYQOJD2XK\\5!/X9U)XOZRUERJ?UO0?Z/?X8$Z:=[5W#=(>-\T)
MPY\Z*4CES6G0)R,-8IKC[0;MR\=?VU7<8C=(7Y2>U#6>.9AA*XCI"N>/?F;(
MP6SCHEYNDAO5<L"HJ4D/XV#2GF%@)';,G+S=4!T2>F!5J-PMY\37@W*:,9/W
M-5S\VL')^XB/XPZVG3.W?%P52?GP5E^OXY=!'=ADGOV^2 Y,_</?RIY[C(H:
M9 TGI?2Z+.8.,Z4^LQ^0M%Z#546T<4^@.<[UOT5J.21&#C6; N4F*!N>^:X%
M&RSLMME,GPLL1O9E2W*(?\JO8?7,KOV>[.]Z_>R3CJX1LV2>RN3+D)XL1_9.
MG-O2ZZT!XJ;K:6"CP>[C)DINN>5./ZV"+KWV@GD5!<UJ66NXJ@WGY^#O@AT.
M=?'FPV[)E05=;<(UPO\H?/:XZYJ(G[[JIO<VD=*LG.D%&CS)IH'EOQ(.T> [
M.9!BLK0:=Q#57YH;7>*CE-&2;K]MWV\K[^F.JRZ0)\SE%6Z;.D>R.YQ[%H1#
M6G#VC(K+%MEZ1IWGIKLW+ST6E /\_H0S#9, K55I8__J45$#D/%H5N>YQ?!0
MRE.'.K<_KYHXC8)9Y@-O<_/XZW_?1@8VCPTSQ-2Z=7(ET4?<"8T!-A:QT[PW
M>IS[U\LB\G;V3OSNS3.//=561>>7=WB &.&/T'%5)DJ>CQJH#$X0NJX_?ZYE
MTQT76J?"%^AM+37D,XJR0$037%%@6AW?C8K0CR2 BCU9>5O\B^\:"M:<H4TE
M@GFRRL7\\-WR,UI!UU_F-K40S :(2GKT]=>^:MB7$?:M07CTHZWM&R:YD<GH
M!@>SE_3O5!^&_!=S^[06IIW^8!ZF>[T*=%10^A(68[][/I+;J%CFY,?CUC'/
M#529 =2?:5[GK7+=,_8Q4FV>ALF'U%761O<+E\]!8GSVP_85WU]I["BUA(XU
MM3$]U?H94:BGOQ<\25>BR43MU6/]JE%+ 2$9\-[+Y?6??_<A>QX(?7]F##&Y
M\=WDS?2/DA.WI#^0'[Y2B*]AOA2*QIZV!W+WI/&%Y2,+*B**=M):*DIQ()#D
M8<&A#;7U8^G/;,S\F2U4[^)PD9CZNDQ0DX75FWDG7%]>:[5XRQ#@LTVXW>:[
M[SK:0D9=7&P!_*C4E5CBV9A685T)SZO3QY_I 0GR5?$O8M<GYXNV(&FS&/@*
M;T74>6M6R<5(VFR'*4?2-R_I<^FL&S_<;NLBA8QGI"#H&V2 B^EB#Q!EA"A/
M<@]20]2:5AM])U'P+LIX;9,]DZ;<ERF:!' 0$N'N8.T^R"A<- 75W;[;J3GK
MA%Q<$N"YQ0/@-$H<\3><J;IX@;?N/&6ZM\B7XY),J\Y7Y&_K:%LW>0J !)R=
M^<BBN^7--;5BEP;;D3?3BT;?.^3LU-4])0'*Z[Y,2$;JG/ZXR]63F]B6R9IF
M;YO8V:@W>#=(7WOF'6.,>$R)%^:)#ME,O98>[B<F-+5BM]$XSJ#%Z;':Z:RA
ME]HKD;5X%>'HE<L_3S;S9A&.-#>V9?SRWTC);]?6/VQL::RJD>@DI_MB:/CI
M<HA:Q]'R4]"KXY_-0+O"3B!.JR SU0-[*]F^7!] __X:973(&ADWILPJ3.F:
MU76'V550[92GQ>M]*!B:!S\DG_C.]%!&>HSA>8^6>YKW/LO*Q5;K?0W_0A'8
M3X2)V'ZTIJNS-N.KAK-@18%$XCCQ_N1QH-G;*=2T!^3O'G"?103\=\A]T*E>
M+)W5;M.\FNAQ8@2&GYR!=M;9YL7VSA%KFWZ2:7P9DG!=C?>.AQ:/-</L]5-_
MN)#]"NB<FS1[/C&?:UV(9(R\#V9Y(JK+'=WS#*5-P?&,87WIP66A9#J$"I0B
M]S&I% *:-X;8FYE8F3 /#ZD'"U(M2]@A&)#V0+I/RRB#N!BIL7.1/&/>C5GD
MY/LXP=MGOBN9F0WT=5JM61A(?\C!A 5D!9(F51Y AHKB70"CAOD673IIC;OR
MJ$X;Q8*(L%Q)"UF;VN_&IA$B]WJ=5QF&!-7NY/0.W +\XV?T8P]1VQKS'M7B
M>+C\:GIM^E.9*9%*FCC4R3MDO/J294-1"X2G6.6/4%#&6"A807(N\TPRAZ$B
MQ^G,EGPI@G<>4 ^YZ6#MR-TCI6H"$5<4F$A=[$T"!!/M_Y81[J,6E;S29I4G
M10H_#-F$CDA^>-7.$[*K;FJ&N.D#>0N#U36.U2ZD@U32?3[6Q$S<W_T<+8:R
ME*D@^&+M.BW4V,#,]GZ>:Y8.$U8+[7GR^?'T/1]2?-]GNM;_\[%\D3@.1Q=:
M+"BC9'.PPKKF:C,T@2S&"?(>J05'TJC*:O[^Z,1XC2;5P=Q+#@3-WHL?YFD6
M) "*!+#:R82)?:V]?;Q5F:(R:5/I+2%5BE3[\%'1N$(\R^^[CY6:B; -J^IG
M?P8A^X[YI\ZWVFE_!63'O3'D3%TK=7J*BLF*#%#QJ,.4)YC_&7H.H)-MX[P,
M<9<SVA="4:D8-TZ*)NJ/B^Y[],[P6A@.M=THJ8:F_LHLZ*$(<D1N),89G$/:
M$'TC8FF"(+MS$J SKZD. PP3WO!U(@ +VH42AK#S:F5=T72O+-?*32'4#A+*
M8$H'+RVJ9B=Z\70/(=8GG8+1+K=6@J>,LKB0,AUUYUXYOK^52W:NCPQ#N^1"
M4B,UPRE,'ID3.@HP6_M4*. ]<P4=W"4[Q$ZZG#ZMO#A85(2);2,ZP5OPP)P$
M:!8,0%0@UHF;5EDGDX39I=A-=&<R$V.\*D,M8[59SSARF%Z@<9:;)8Z;$F^4
M@M?#^0<*]:09A<-:W":-LS0D6K)KQO.J$C0L7J<Z<U@T;]UY17Z#2_S9)JP<
M: ^FU**?,.\L<0BO@_I>0]2(!U;0L]B%9?VTSISF3+U0V38=B; NGK=OY:Z/
M>]MI\CS-VA>N 7?UZ?%]*Y>@*N5QUD@"9)  *Y=++[=G!8I6P5^1=E%!O Y*
M0E-#3)5SQH.VEZF>]C7J?$<9ZU4K<6^,;!DCBE2DRJKF3'M%RCX^YGC_=BRG
MQX!:Z:W+,\XOS7I&E[^=1#V!%+VH2_YW+;73L-N?H#+S\2(U:M3K0DUAY&Z*
M0NYO+G,EU<8]YGDU6^P,6_UK.$*C/J#%DLC1]U]9?^Q[JW]=8_TXQX%#FIBU
M2[14\=^[]+BD>177@10V;7(LSC?F^_U':G?AP:]+*S:$*4U(K5X9E?$.(X4!
MF7VK=/_6VF203!!L*P52B_B:EZ[^I=]3\>.>(3QA=69!JT:B[P6[7'Q\*,5O
MJ7D?NU7&F-7EFS3T#I,:?#^YDY;=G!*>LKQ_)(&S%6R+>Z=Q48*V86R"NQ&4
MZ,;V3^RF'XW7XF$R%[/%(.;45F@TL38YB&;,X_*UA=KLR\ERV&WW38M.!];7
M9WLI9/Q TZ,K=4"<(-)@]9-O+DII:EH\!\Y!Q3X-O36O_F)"6S/H.E&Z30+
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MY6WT_W1-#]3$7+?]SAKYC(,6S$WCOA SMR]-$.4GD"=A\W:;WZ7+;,X =&>
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M,B:#%F:M='A,5L.JIC.4C0YO31EX28AZ2V['/=<3.1D_D;E(#C"J']F2\H0
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MAVU3-CVC;W8D.Y!_X!%G@(:63[%?\K>UC6U,FC5D>K]9C7[/S?T<J,G_Y@S
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MW_FO_WRG[(=,+J[KF34S]YI9LV96G@0WB9L'?M-4U5 %" @!@ #_!^"0@#)
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M)A;5PH4]"L4DQ?JD7G*ZL@Q4VAC$*095.9%IJ(BQ6:O82!DR$7O3;0)\65$
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M-E,LG9GU%F&NOG1T+"^G*GED>!)!HSYKO-!</,2)\5_XZ$E=J_;%B'LMA?<
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MER'V4]?8+.?)%--\U(VXZ#WPK8_O_,$MOWRH.Y)-&C:_V24]V-14NJ%-^(F
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MV5#]R4OC6G&]J1^- 77887C2M'(>\D;-ZS8*QFZKZ"/==;D"I/,6;#S\' =
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MXC[DKZO(K*]KJM =8WB@@O$NG)DT[;=W2_7J<W)9$A")\].>,K4WF]SE*R=
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M<;X";_]TC($W2EQB8*ABNB<DL-JNRRGX'KZ;#>-P?GO^#387@5\ %2H ^#S
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MSCG^;!:IUL@0!!%X?J^2XT[3S^!X=3*N VU_:/&IUSY\$";<RHTMSQE[.=L
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MB-,8:FO?#'X#FL##W+'9KUT\TNI,F83LOT7<R(D,'%#_/63!G(RPV)?5)Y+
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MP GP^ X]4]]!M%#'Z6B T(^&YKRU*Z.#1FFAO!GCL2>.ZT@*) >LNC'2D09
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MWO-Y+L:JMXBX.F-%703#[%9E])>GMY+C7/"OQ'<K?^(ZN+J@J%;4.?\@OR+
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M=-OB)RCX$#ED8M7COR&"C[[.0DY?=J0!OETH7.L2F7[=GF<3R>1- ^1]=M&
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M]JHW3\1AI!7N!R&*U<&[".MQ/W2#_@$/_[YJ-VJY9#Q%X2^%3W/A-Z:@D9-
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M[ZC,&:9%WO,P$2O@!9G-AF#LP^73,A>!Q<7$;RN[ OO$#$,5R-TH$',)"@9
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M"&\M#HKZCT%$(Q1J!;G=?P%02P,$%     @ 6#YF5RU*A5YE"   O28  !<
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ME\)REN1<&V'?['R>O N.(&&E+<3)<;C\ZV5CE2Y.CE,Y8\8N"O%FI^1Z*JO
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M_>J;J]7#OZA:=0?X=.F,O=OH(S+H.L1M(!*DCTAA]VJ/E6H<]8=5VJRRAFO
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M;)1JZQE\4=%^UZ/Z\,\QR_A,,"UF4LS!$C:3AOU1<PW<\@7:*Z4MN(.]4[K
M4L&_F$K9I586"-^P4ZDFF="\$K65L>FP<1EW1UMBDZ#7[1TXN^P_VBZGW#C.
M9,6"79=JG@NP:\>;IS%*HK"34H&6H3*7)>/E@M6EU;7 UL&YCK-A+<X*/&D)
M#TIYC";-5"$ML\K+W1$H12R,X7I!(@6_%EBW-:=!6P)EL&1.YX76((%8:@0*
MB"%T&&B2",WFF8PS9FKZ6(^?"RV:26@#A30@-+*S#RU:F$K$3D&:MX)J*L$V
M9QB6L&C1-L/V@3UX.K %2V4)<Q(R:_-U@#3$T:U;_;),<40XD3^^QWF=8$Y
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MZFSU\&_*5ET!GRR=L;,^?40&;8=8'T2"]!$A[$[NL5*-(_^P2IM5U' -F+)
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MK^U;HTDCN)M*8BS)M69[1C]\N.Q,1.)_#)ZFRVU_-?V)^6-@[FEEDN#K@/\
M)I]A%0_A AWVH8TZ:KJHQJ"O%3C?247]_IT"W7?PL9&[)=S_C*C\Z41K6+MY
MMD4F*._ 'J.@.XD]FI.]RMLY7WR)SSYEFC87,"51'QJ ']>OYHKG,9UJ;DW^
MEQ-_6 =]4\,^^W#^@[O*LRU[UY5\+^KM-$K9]HP0D^3M2LFZH/?NR':N4O<)
M;1-JRJBY+7/:=W_OM--<U^X==_:&MG?#)5DQIVE728H'F)#<2DY;MX_'[F"T
M+3;-F&^ODYL[9WN)??PW4$L! A0#%     @ 6#YF5VT6'IEI#P  IXT  !
M             ( !     '!L>"TR,#(S,#DS,"YX<V102P$"% ,4    " !8
M/F97QT$%]S8-  "%J   %               @ &7#P  <&QX+3(P,C,P.3,P
M7V-A;"YX;6Q02P$"% ,4    " !8/F97"NP#(ZXC  #O, ( %
M    @ '_'   <&QX+3(P,C,P.3,P7V1E9BYX;6Q02P$"% ,4    " !8/F97
MDF)$)!E,  "-UP, %               @ '?0   <&QX+3(P,C,P.3,P7VQA
M8BYX;6Q02P$"% ,4    " !8/F97P$^OF.4U  !8@@, %
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M-BYJ<&=02P$"% ,4    " !8/F97^DJX<Y&8  #-T@  %P
M@ %?B04 <&QX+3(P,C,P.3,P>#$P<3 P-RYJ<&=02P$"% ,4    " !8/F97
M+4J%7F4(  "])@  %P              @ $E(@8 <&QX+3(P,C,P.3,P>&5X
M,S%D,2YH=&U02P$"% ,4    " !8/F97.]_KAG@(   E*   %P
M    @ &_*@8 <&QX+3(P,C,P.3,P>&5X,S%D,BYH=&U02P$"% ,4    " !8
M/F979F3&JH\%  !_%P  %P              @ %L,P8 <&QX+3(P,C,P.3,P
M>&5X,S)D,2YH=&U02P$"% ,4    " !8/F973Q64@)(%  "9%P  %P
M        @ $P.08 <&QX+3(P,C,P.3,P>&5X,S)D,BYH=&U02P4&      T
,#0!K P  ]SX&

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
